data_9pcy_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 9pcy _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.4 tm-20 . . . . . 0 CA--C 1.533 0.291 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 25.8 t -109.72 128.92 65.43 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.293 0 C-N-CA 125.891 1.676 . . . . 0.0 109.193 179.63 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 62.4 mt -94.6 126.69 40.05 Favored 'General case' 0 C--O 1.233 0.222 0 N-CA-C 108.307 -0.998 . . . . 0.0 108.307 177.455 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 55.2 mt -86.55 99.03 11.4 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 105.942 -1.873 . . . . 0.0 105.942 177.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 101.17 134.0 8.34 Favored Glycine 0 CA--C 1.525 0.706 0 C-N-CA 125.539 1.542 . . . . 0.0 109.583 -178.495 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 22.3 p -82.87 42.86 0.81 Allowed 'General case' 0 N--CA 1.462 0.157 0 O-C-N 120.944 -1.327 . . . . 0.0 112.875 -178.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.24 -53.46 1.08 Allowed Glycine 0 CA--C 1.527 0.784 0 C-N-CA 126.18 1.848 . . . . 0.0 112.691 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -73.1 36.27 0.08 Allowed 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 125.837 1.655 . . . . 0.0 113.675 -177.539 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 70.39 -19.83 0.63 Allowed Glycine 0 CA--C 1.53 1.003 0 C-N-CA 124.808 1.194 . . . . 0.0 115.08 177.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 32.9 t -56.66 129.21 40.08 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-N 118.515 1.157 . . . . 0.0 110.916 -178.146 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 55.5 mt -77.31 65.87 2.97 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 126.378 1.871 . . . . 0.0 112.071 -175.492 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 29.6 m -130.32 144.24 38.58 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.213 0 C-N-CA 123.174 0.59 . . . . 0.0 111.475 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 37.7 m-85 -84.76 129.21 34.86 Favored 'General case' 0 N--CA 1.456 -0.138 0 N-CA-C 104.764 -2.31 . . . . 0.0 104.764 175.723 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.9 t -117.56 102.8 51.61 Favored Pre-proline 0 CA--C 1.534 0.334 0 CA-C-O 117.986 -1.007 . . . . 0.0 108.992 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -76.89 166.83 81.62 Favored 'Cis proline' 0 CA--C 1.535 0.554 0 CA-C-N 120.373 1.169 . . . . 0.0 111.23 -1.375 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 29.2 t -103.14 -60.42 1.55 Allowed 'General case' 0 CA--C 1.531 0.216 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 178.023 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 4.3 tm-20 -102.3 125.78 49.11 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 106.11 -1.811 . . . . 0.0 106.11 178.457 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.1 p90 -161.65 -176.69 5.44 Favored 'General case' 0 CA--C 1.535 0.372 0 CA-C-N 119.118 0.872 . . . . 0.0 112.757 -179.362 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.0 m -130.14 147.03 51.83 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 126.284 1.834 . . . . 0.0 108.605 179.686 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.0 m -145.25 152.17 49.85 Favored Pre-proline 0 CA--C 1.528 0.134 0 C-N-CA 125.086 1.354 . . . . 0.0 108.28 178.465 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -73.7 158.02 47.52 Favored 'Trans proline' 0 N--CA 1.453 -0.905 0 C-N-CA 121.931 1.754 . . . . 0.0 110.514 176.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 50.2 m -56.3 126.13 24.91 Favored 'General case' 0 CA--C 1.529 0.149 0 C-N-CA 123.221 0.608 . . . . 0.0 109.98 177.441 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 89.82 6.5 69.79 Favored Glycine 0 CA--C 1.526 0.73 0 CA-C-O 118.887 -0.952 . . . . 0.0 112.598 -179.621 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -61.8 138.14 58.31 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 119.315 1.557 . . . . 0.0 110.854 178.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 15.3 ptpt -93.49 95.85 9.52 Favored 'General case' 0 N--CA 1.444 -0.736 0 C-N-CA 126.394 1.878 . . . . 0.0 106.534 177.384 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 39.6 mt -83.04 136.14 23.41 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 -179.716 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 90.8 t -118.92 132.95 67.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 105.032 -2.21 . . . . 0.0 105.032 179.012 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 94.9 m-85 -121.44 123.57 42.38 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 106.33 -1.73 . . . . 0.0 106.33 178.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 7.7 ttpm? -120.15 136.57 54.57 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 118.812 0.733 . . . . 0.0 112.875 -178.369 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 6.6 m-20 -67.72 99.6 0.82 Allowed 'General case' 0 C--O 1.232 0.161 0 C-N-CA 124.108 0.963 . . . . 0.0 109.279 177.095 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 57.8 t30 -87.17 -59.75 2.17 Favored 'General case' 0 N--CA 1.455 -0.192 0 N-CA-C 109.443 -0.576 . . . . 0.0 109.443 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -161.08 167.51 26.17 Favored 'General case' 0 C--O 1.226 -0.179 0 C-N-CA 123.617 0.767 . . . . 0.0 109.841 -179.293 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 68.89 20.37 74.4 Favored Glycine 0 CA--C 1.533 1.177 0 O-C-N 121.834 -0.541 . . . . 0.0 113.181 179.308 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 18.6 p90 -68.61 166.66 24.43 Favored Pre-proline 0 CA--C 1.546 0.797 0 N-CA-C 106.53 -1.656 . . . . 0.0 106.53 177.043 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -69.97 156.34 93.41 Favored 'Cis proline' 0 N--CA 1.449 -1.136 0 CA-C-N 120.446 1.195 . . . . 0.0 114.488 4.215 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 87.9 m-70 -147.61 168.95 20.69 Favored 'General case' 0 N--CA 1.449 -0.498 0 O-C-N 121.638 -0.664 . . . . 0.0 111.49 -179.197 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 51.6 p30 -163.82 174.01 12.07 Favored 'General case' 0 N--CA 1.451 -0.416 0 N-CA-C 104.948 -2.242 . . . . 0.0 104.948 176.48 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 22.9 t -133.81 103.92 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.323 0 N-CA-C 107.062 -1.459 . . . . 0.0 107.062 -179.507 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.2 t -110.92 135.86 48.74 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 N-CA-C 105.896 -1.89 . . . . 0.0 105.896 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 53.5 m-85 -95.81 139.42 32.06 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 -179.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -72.02 111.09 6.97 Favored 'General case' 0 N--CA 1.45 -0.444 0 N-CA-C 107.7 -1.222 . . . . 0.0 107.7 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -46.16 -31.3 2.33 Favored 'General case' 0 CA--C 1.532 0.274 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -178.218 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -81.99 -50.92 8.58 Favored 'General case' 0 CA--C 1.531 0.25 0 CA-C-N 118.392 0.542 . . . . 0.0 109.662 178.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 40.3 mt-10 -80.45 56.65 2.61 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 124.143 0.977 . . . . 0.0 112.713 -177.066 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 26.4 pt -151.53 149.71 24.89 Favored Pre-proline 0 CA--C 1.534 0.329 0 C-N-CA 126.06 1.744 . . . . 0.0 107.715 175.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -69.11 116.26 4.4 Favored 'Trans proline' 0 N--CA 1.45 -1.068 0 C-N-CA 121.692 1.595 . . . . 0.0 108.706 176.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -33.65 -40.61 0.08 Allowed 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 127.741 2.416 . . . . 0.0 115.192 -177.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -50.98 -35.58 32.81 Favored Glycine 0 CA--C 1.533 1.16 0 C-N-CA 123.532 0.587 . . . . 0.0 112.805 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 48.2 t -103.53 103.77 15.65 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.209 0 CA-C-N 117.862 0.831 . . . . 0.0 108.945 -179.577 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -63.39 135.23 56.82 Favored 'General case' 0 CA--C 1.535 0.402 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 177.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -43.24 -41.26 3.79 Favored 'General case' 0 C--O 1.231 0.104 0 C-N-CA 126.182 1.793 . . . . 0.0 114.212 -179.504 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 85.8 t -56.88 -27.99 27.53 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 C-N-CA 123.03 0.532 . . . . 0.0 110.767 -179.459 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 34.5 mmtp -76.27 -19.11 58.62 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-O 118.438 -0.791 . . . . 0.0 112.539 -179.198 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -117.11 -23.37 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 N-CA-C 113.491 0.923 . . . . 0.0 113.491 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 31.3 m -84.09 129.82 34.89 Favored 'General case' 0 N--CA 1.453 -0.308 0 N-CA-C 113.892 1.071 . . . . 0.0 113.892 -177.207 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 15.0 tpt . . . . . 0 CA--C 1.54 0.559 0 N-CA-C 104.824 -2.287 . . . . 0.0 104.824 173.85 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.449 -0.483 0 CA-C-O 121.79 0.805 . . . . 0.0 111.247 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 50.9 mt -76.81 96.27 4.24 Favored 'General case' 0 N--CA 1.444 -0.743 0 N-CA-C 103.278 -2.86 . . . . 0.0 103.278 177.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 4.0 p30 -88.0 -40.42 13.89 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 126.228 1.811 . . . . 0.0 113.515 -175.207 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -95.63 156.44 37.44 Favored Pre-proline 0 CA--C 1.535 0.374 0 C-N-CA 123.823 0.849 . . . . 0.0 110.142 -178.448 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -64.69 161.42 35.82 Favored 'Trans proline' 0 N--CA 1.457 -0.664 0 C-N-CA 122.245 1.964 . . . . 0.0 109.545 176.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 78.54 -34.5 1.81 Allowed Glycine 0 CA--C 1.529 0.931 0 CA-C-O 118.59 -1.117 . . . . 0.0 114.182 177.205 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 50.6 mt-10 -48.46 140.98 7.26 Favored 'General case' 0 CA--C 1.533 0.324 0 CA-C-N 119.062 1.431 . . . . 0.0 111.056 179.17 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 2.5 p -120.14 161.44 21.02 Favored 'General case' 0 N--CA 1.453 -0.316 0 C-N-CA 124.732 1.213 . . . . 0.0 111.84 -177.028 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 47.4 t80 -137.1 147.83 46.32 Favored 'General case' 0 N--CA 1.456 -0.13 0 N-CA-C 104.608 -2.367 . . . . 0.0 104.608 173.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 25.9 t -136.21 145.03 31.49 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.097 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 -178.46 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.8 p -152.62 138.13 11.17 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 178.739 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 33.8 m -105.6 112.25 25.26 Favored 'General case' 0 CA--C 1.528 0.129 0 C-N-CA 123.927 0.891 . . . . 0.0 108.801 -179.183 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 27.6 mt -93.19 88.5 6.07 Favored 'General case' 0 CA--C 1.529 0.167 0 CA-C-O 121.247 0.546 . . . . 0.0 110.84 -178.541 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -60.9 -69.12 0.25 Allowed 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 124.747 1.219 . . . . 0.0 114.052 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 2.8 m -73.2 138.82 45.88 Favored 'General case' 0 N--CA 1.452 -0.354 0 C-N-CA 124.098 0.959 . . . . 0.0 113.459 -172.174 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -62.72 154.17 30.37 Favored 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 123.711 0.804 . . . . 0.0 110.189 177.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 145.31 -170.3 26.71 Favored Glycine 0 C--N 1.334 0.456 0 N-CA-C 111.194 -0.763 . . . . 0.0 111.194 178.333 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 24.0 m -112.24 120.44 41.76 Favored 'General case' 0 N--CA 1.453 -0.304 0 N-CA-C 106.451 -1.685 . . . . 0.0 106.451 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 34.7 m-85 -117.28 107.32 14.26 Favored 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 124.046 0.938 . . . . 0.0 109.327 -178.232 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -92.5 139.58 30.44 Favored 'General case' 0 C--O 1.232 0.171 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 177.601 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 32.9 p90 -137.27 167.45 21.56 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 121.387 0.613 . . . . 0.0 111.613 -178.389 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 44.8 p90 -155.84 161.03 40.68 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 114.933 -1.03 . . . . 0.0 112.379 -178.461 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.4 t -101.72 103.77 14.55 Favored 'General case' 0 CA--C 1.519 -0.241 0 N-CA-C 105.308 -2.108 . . . . 0.0 105.308 176.674 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.344 77.7 p -45.48 -58.25 6.26 Favored Pre-proline 0 CA--C 1.537 0.452 0 N-CA-C 115.723 1.749 . . . . 0.0 115.723 -173.258 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -60.3 -7.79 7.38 Favored 'Trans proline' 0 N--CA 1.458 -0.57 0 C-N-CA 121.994 1.796 . . . . 0.0 114.527 -179.414 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 35.1 m80 -132.78 18.96 4.2 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 119.843 1.201 . . . . 0.0 111.427 179.064 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 31.8 tt0 -58.07 -49.86 75.45 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 178.133 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -55.96 -32.04 59.06 Favored Glycine 0 CA--C 1.531 1.046 0 C-N-CA 123.798 0.713 . . . . 0.0 112.005 178.61 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -82.32 4.12 25.05 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 117.497 0.648 . . . . 0.0 111.56 179.277 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 83.11 16.01 70.7 Favored Glycine 0 CA--C 1.526 0.727 0 CA-C-O 119.019 -0.878 . . . . 0.0 112.967 178.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 20.5 ttt -78.76 77.96 5.22 Favored 'General case' 0 C--O 1.237 0.398 0 CA-C-N 119.322 1.561 . . . . 0.0 108.569 178.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 8.1 m -128.0 174.65 11.16 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 C-N-CA 125.984 1.714 . . . . 0.0 110.993 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -166.66 174.08 42.06 Favored Glycine 0 CA--C 1.526 0.766 0 N-CA-C 111.053 -0.819 . . . . 0.0 111.053 177.461 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 23.6 ttmm -149.01 110.88 4.57 Favored 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 124.389 1.076 . . . . 0.0 110.057 -177.128 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.1 p -106.53 128.87 60.78 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.356 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 179.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.0 m -100.99 110.2 22.2 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 124.73 1.212 . . . . 0.0 110.354 -177.36 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 24.0 t -83.92 101.32 8.35 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.768 0 N-CA-C 105.799 -1.926 . . . . 0.0 105.799 179.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 2.7 m-80 . . . . . 0 N--CA 1.451 -0.402 0 C-N-CA 125.749 1.62 . . . . 0.0 108.922 -177.892 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 14.6 tp10 . . . . . 0 N--CA 1.452 -0.367 0 N-CA-C 104.756 -2.313 . . . . 0.0 104.756 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 41.6 t -118.14 130.9 72.32 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 -178.827 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 68.8 mt -94.54 126.24 39.7 Favored 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 178.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 82.3 mt -90.13 98.94 12.06 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 105.835 -1.913 . . . . 0.0 105.835 177.046 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 110.57 -161.27 12.93 Favored Glycine 0 N--CA 1.447 -0.606 0 N-CA-C 109.095 -1.602 . . . . 0.0 109.095 -178.563 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 19.9 p -155.9 158.35 37.84 Favored 'General case' 0 N--CA 1.447 -0.591 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 -179.551 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.55 -39.99 31.16 Favored Glycine 0 CA--C 1.53 1.015 0 C-N-CA 123.538 0.59 . . . . 0.0 112.27 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -79.21 11.38 2.89 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 124.124 0.97 . . . . 0.0 112.642 179.218 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 70.12 14.02 70.62 Favored Glycine 0 CA--C 1.527 0.832 0 C-N-CA 124.605 1.098 . . . . 0.0 114.35 178.037 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 47.3 t -77.39 135.22 38.31 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 119.417 1.609 . . . . 0.0 108.82 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -73.57 67.98 1.14 Allowed 'General case' 0 N--CA 1.443 -0.793 0 C-N-CA 126.011 1.724 . . . . 0.0 111.179 -178.249 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 20.9 m -129.76 153.16 38.41 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 C-N-CA 123.477 0.711 . . . . 0.0 110.4 179.498 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 39.5 m-85 -93.33 131.44 38.48 Favored 'General case' 0 C--N 1.332 -0.169 0 N-CA-C 104.132 -2.544 . . . . 0.0 104.132 175.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.3 t -125.03 109.66 27.43 Favored Pre-proline 0 CA--C 1.534 0.362 0 CA-C-N 119.161 0.891 . . . . 0.0 108.906 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_endo -72.04 150.77 95.08 Favored 'Cis proline' 0 N--CA 1.459 -0.533 0 CA-C-N 120.209 1.11 . . . . 0.0 110.987 -1.478 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.2 m -77.17 -48.08 18.62 Favored 'General case' 0 N--CA 1.456 -0.133 0 C-N-CA 123.036 0.534 . . . . 0.0 110.258 179.444 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -124.68 134.28 52.92 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 179.475 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 39.0 p90 -158.67 -176.83 6.11 Favored 'General case' 0 C--O 1.233 0.215 0 O-C-N 123.181 0.301 . . . . 0.0 110.7 -178.701 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 16.0 m -133.95 149.77 51.27 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 125.036 1.334 . . . . 0.0 107.925 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.7 p -144.98 138.99 14.73 Favored Pre-proline 0 CA--C 1.537 0.445 0 C-N-CA 123.796 0.839 . . . . 0.0 109.962 -177.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_exo -65.3 140.54 64.64 Favored 'Trans proline' 0 N--CA 1.455 -0.743 0 CA-C-N 120.746 1.302 . . . . 0.0 110.241 176.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 52.2 m -52.42 122.35 8.64 Favored 'General case' 0 N--CA 1.455 -0.193 0 C-N-CA 124.161 0.984 . . . . 0.0 110.857 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 102.56 -19.13 48.86 Favored Glycine 0 CA--C 1.528 0.877 0 CA-C-O 118.82 -0.989 . . . . 0.0 113.051 179.446 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -73.19 143.78 47.07 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-N 119.658 1.729 . . . . 0.0 110.25 179.312 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 18.3 ptmt -81.16 144.2 31.83 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 124.424 1.09 . . . . 0.0 111.58 -178.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 35.9 mt -113.2 130.48 67.04 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 178.424 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 59.7 t -114.25 102.63 14.15 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.245 0 C-N-CA 125.135 1.374 . . . . 0.0 108.017 -179.258 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -90.92 98.5 11.82 Favored 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 178.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 27.0 ttpp -91.75 132.38 36.44 Favored 'General case' 0 CA--C 1.528 0.132 0 C-N-CA 123.581 0.752 . . . . 0.0 112.724 -177.608 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 54.5 t-20 -66.21 110.25 2.95 Favored 'General case' 0 CA--C 1.53 0.21 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 176.395 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 -87.34 -72.96 0.49 Allowed 'General case' 0 C--N 1.338 0.078 0 CA-C-N 118.31 0.504 . . . . 0.0 110.843 -179.11 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -163.46 175.43 10.76 Favored 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 125.131 1.372 . . . . 0.0 107.732 -177.747 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 65.36 24.11 70.53 Favored Glycine 0 CA--C 1.534 1.272 0 CA-C-N 118.694 0.679 . . . . 0.0 111.594 -178.8 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 17.1 p90 -74.72 169.05 21.7 Favored Pre-proline 0 CA--C 1.542 0.668 0 N-CA-C 107.108 -1.442 . . . . 0.0 107.108 178.411 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -69.53 158.3 90.45 Favored 'Cis proline' 0 N--CA 1.448 -1.201 0 CA-C-O 123.115 1.215 . . . . 0.0 114.994 3.731 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 88.2 m-70 -149.55 172.94 14.2 Favored 'General case' 0 N--CA 1.445 -0.711 0 CA-C-N 114.693 -1.14 . . . . 0.0 109.356 179.542 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 48.0 p30 -169.77 173.11 6.38 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 104.435 -2.432 . . . . 0.0 104.435 176.514 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 37.6 t -130.14 110.51 19.4 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.222 0 N-CA-C 107.767 -1.197 . . . . 0.0 107.767 -178.54 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.9 t -113.03 129.12 69.27 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.606 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 -179.737 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 62.2 m-85 -91.04 133.17 35.52 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 178.658 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -68.61 110.57 4.3 Favored 'General case' 0 N--CA 1.452 -0.352 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 -179.751 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -41.75 -35.0 0.7 Allowed 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 126.154 1.782 . . . . 0.0 115.747 -177.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -85.14 -50.01 7.77 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 118.5 0.591 . . . . 0.0 110.879 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -79.67 56.56 2.27 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 124.271 1.028 . . . . 0.0 112.412 -176.362 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 31.8 pt -153.35 156.57 32.57 Favored Pre-proline 0 CA--C 1.533 0.304 0 C-N-CA 126.689 1.996 . . . . 0.0 107.473 176.673 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_exo -53.62 109.5 0.38 Allowed 'Trans proline' 0 N--CA 1.456 -0.681 0 C-N-CA 122.819 2.346 . . . . 0.0 111.141 177.001 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -52.28 106.42 0.15 Allowed 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 124.203 1.001 . . . . 0.0 110.107 -179.772 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 142.29 -35.57 1.73 Allowed Glycine 0 CA--C 1.526 0.756 0 N-CA-C 109.005 -1.638 . . . . 0.0 109.005 -177.699 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 47.2 t -77.08 108.19 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 179.285 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 45.2 t0 -59.11 109.11 0.78 Allowed 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 123.039 0.535 . . . . 0.0 110.566 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.34 -40.42 17.21 Favored 'General case' 0 N--CA 1.453 -0.313 0 C-N-CA 125.079 1.351 . . . . 0.0 111.531 179.274 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 54.4 t -58.33 -28.77 36.3 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 C-N-CA 123.491 0.717 . . . . 0.0 111.925 -179.088 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 2.6 mmmp? -82.34 -40.66 21.1 Favored 'General case' 0 N--CA 1.461 0.122 0 CA-C-N 118.709 0.686 . . . . 0.0 110.909 -178.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 33.1 pt -78.14 -30.26 15.84 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.209 0 N-CA-C 112.191 0.441 . . . . 0.0 112.191 -179.842 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 35.5 m -90.7 146.74 23.76 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 114.667 1.358 . . . . 0.0 114.667 -176.792 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 48.2 mmm . . . . . 0 N--CA 1.448 -0.556 0 N-CA-C 102.066 -3.309 . . . . 0.0 102.066 169.005 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 92.3 mt . . . . . 0 N--CA 1.45 -0.442 0 CA-C-O 120.755 0.312 . . . . 0.0 110.446 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 84.4 mt -86.23 99.85 11.83 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 104.421 -2.437 . . . . 0.0 104.421 175.245 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 33.0 p-10 -86.57 -51.4 6.19 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 124.189 0.996 . . . . 0.0 111.736 -177.556 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.91 143.49 66.51 Favored Pre-proline 0 CA--C 1.533 0.322 0 O-C-N 121.932 -0.48 . . . . 0.0 110.468 -177.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -64.91 152.4 82.4 Favored 'Trans proline' 0 N--CA 1.453 -0.872 0 C-N-CA 122.522 2.148 . . . . 0.0 109.513 178.322 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 86.14 -24.52 7.97 Favored Glycine 0 CA--C 1.527 0.822 0 CA-C-O 118.41 -1.217 . . . . 0.0 114.09 177.125 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 66.1 mt-10 -51.8 127.43 20.83 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-N 119.465 1.633 . . . . 0.0 110.522 179.11 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 11.8 p -105.63 120.7 42.32 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 124.772 1.229 . . . . 0.0 112.334 -178.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 25.1 t80 -95.01 107.54 19.58 Favored 'General case' 0 N--CA 1.452 -0.372 0 N-CA-C 104.743 -2.317 . . . . 0.0 104.743 173.576 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 22.6 t -95.63 138.13 22.0 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 -178.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 10.9 p -145.85 168.81 7.06 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.17 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 177.548 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 29.1 m -147.02 130.39 16.66 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 64.6 mt -114.31 116.85 29.62 Favored 'General case' 0 CA--C 1.531 0.224 0 C-N-CA 123.636 0.774 . . . . 0.0 109.766 -177.601 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -91.3 -46.37 8.08 Favored 'General case' 0 CA--C 1.531 0.239 0 C-N-CA 124.195 0.998 . . . . 0.0 111.716 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.7 m -73.22 121.03 19.66 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 122.792 0.437 . . . . 0.0 110.712 -177.069 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 23.4 pttm -64.77 153.17 40.69 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 122.918 0.487 . . . . 0.0 111.462 178.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 139.18 174.28 13.45 Favored Glycine 0 CA--C 1.529 0.911 0 C-N-CA 125.552 1.548 . . . . 0.0 110.467 179.426 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 99.0 m -99.01 116.95 32.42 Favored 'General case' 0 N--CA 1.456 -0.128 0 C-N-CA 124.296 1.038 . . . . 0.0 108.646 179.457 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 10.7 m-85 -103.82 134.31 47.34 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 125.368 1.467 . . . . 0.0 108.05 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 20.2 m -104.3 139.51 39.19 Favored 'General case' 0 C--O 1.232 0.173 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 176.333 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 15.6 p90 -138.13 166.37 24.3 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-O 121.474 0.654 . . . . 0.0 111.946 -179.421 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 43.7 p90 -152.22 162.45 41.11 Favored 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 124.393 1.077 . . . . 0.0 112.294 -178.697 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.6 t -101.57 106.68 17.79 Favored 'General case' 0 CA--C 1.52 -0.174 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 176.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 4.9 t -38.82 -64.21 0.51 Allowed Pre-proline 0 CA--C 1.542 0.645 0 N-CA-C 115.349 1.611 . . . . 0.0 115.349 -175.413 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -64.09 -4.31 7.44 Favored 'Trans proline' 0 C--N 1.348 0.537 0 C-N-CA 122.467 2.111 . . . . 0.0 114.533 -177.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 37.0 m80 -130.42 20.81 5.2 Favored 'General case' 0 N--CA 1.455 -0.216 0 CA-C-N 119.461 1.028 . . . . 0.0 110.698 179.041 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 4.6 tp60 -58.43 -51.97 67.58 Favored 'General case' 0 CA--C 1.533 0.296 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 177.093 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.13 -33.55 61.19 Favored Glycine 0 CA--C 1.532 1.129 0 C-N-CA 123.526 0.584 . . . . 0.0 111.866 178.276 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -81.54 1.57 33.01 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 123.284 0.634 . . . . 0.0 111.953 179.265 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 77.14 23.82 67.74 Favored Glycine 0 CA--C 1.526 0.757 0 CA-C-O 119.231 -0.76 . . . . 0.0 113.512 178.711 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 26.1 ttt -79.27 80.47 5.63 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-N 119.207 1.504 . . . . 0.0 107.406 177.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 16.5 m -121.65 169.49 12.91 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.191 0 C-N-CA 125.943 1.697 . . . . 0.0 110.878 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -170.93 179.47 42.81 Favored Glycine 0 CA--C 1.526 0.733 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 178.139 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 49.6 mttp -148.17 161.4 41.53 Favored 'General case' 0 CA--C 1.528 0.132 0 CA-C-N 117.985 0.893 . . . . 0.0 110.581 -179.474 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 3.8 p -145.04 124.01 5.84 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 C-N-CA 123.488 0.715 . . . . 0.0 110.201 178.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 99.1 m -98.32 98.22 9.49 Favored 'General case' 0 C--O 1.236 0.359 0 C-N-CA 124.641 1.176 . . . . 0.0 111.214 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 30.2 t -75.88 120.35 25.6 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.631 0 N-CA-C 104.617 -2.364 . . . . 0.0 104.617 179.184 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 5.5 p30 . . . . . 0 N--CA 1.464 0.238 0 N-CA-C 112.634 0.605 . . . . 0.0 112.634 -174.034 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 . . . . . 0 N--CA 1.456 -0.172 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 33.5 t -91.97 138.27 20.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 C-N-CA 125.39 1.476 . . . . 0.0 109.076 -179.503 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 72.3 mt -99.76 125.44 45.67 Favored 'General case' 0 N--CA 1.45 -0.43 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 177.816 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 59.0 mt -86.46 101.93 13.61 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 105.855 -1.906 . . . . 0.0 105.855 178.196 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 95.87 157.88 32.01 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 108.347 -1.901 . . . . 0.0 108.347 -178.196 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 53.9 p -107.57 159.71 16.23 Favored 'General case' 0 N--CA 1.445 -0.718 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 -179.833 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.91 -34.62 61.81 Favored Glycine 0 CA--C 1.529 0.937 0 C-N-CA 124.183 0.897 . . . . 0.0 111.262 178.689 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -75.66 -2.9 31.64 Favored 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 123.519 0.728 . . . . 0.0 112.243 178.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 96.36 -17.86 58.51 Favored Glycine 0 CA--C 1.526 0.764 0 CA-C-O 118.903 -0.943 . . . . 0.0 113.556 178.671 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 32.8 t -57.27 132.35 52.76 Favored 'General case' 0 C--O 1.238 0.487 0 CA-C-N 119.4 1.6 . . . . 0.0 110.487 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 47.8 mt -77.59 67.39 3.49 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 126.818 2.047 . . . . 0.0 110.384 -177.087 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.6 m -128.2 153.76 38.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 C-N-CA 123.264 0.626 . . . . 0.0 110.611 179.862 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -87.43 130.64 34.6 Favored 'General case' 0 N--CA 1.453 -0.311 0 N-CA-C 104.153 -2.536 . . . . 0.0 104.153 175.259 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 35.3 t -120.45 108.96 37.06 Favored Pre-proline 0 CA--C 1.535 0.385 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_endo -73.3 157.2 99.31 Favored 'Cis proline' 0 N--CA 1.459 -0.552 0 CA-C-N 120.332 1.154 . . . . 0.0 110.48 -1.566 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.5 m -79.16 -43.33 24.19 Favored 'General case' 0 C--N 1.332 -0.153 0 C-N-CA 123.054 0.542 . . . . 0.0 110.884 -179.598 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -129.08 145.18 51.34 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 106.669 -1.604 . . . . 0.0 106.669 178.192 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 19.2 p90 -166.52 -179.62 5.01 Favored 'General case' 0 C--O 1.235 0.342 0 C-N-CA 123.213 0.605 . . . . 0.0 110.186 -177.665 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 37.1 p -139.71 136.29 34.06 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 124.422 1.089 . . . . 0.0 108.684 -178.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 33.7 m -130.09 146.27 60.76 Favored Pre-proline 0 CA--C 1.533 0.298 0 C-N-CA 124.177 0.991 . . . . 0.0 110.185 179.606 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_exo -57.67 144.34 93.09 Favored 'Trans proline' 0 N--CA 1.455 -0.742 0 C-N-CA 122.591 2.194 . . . . 0.0 110.845 174.785 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 16.3 m -51.26 119.58 4.19 Favored 'General case' 0 CA--C 1.529 0.149 0 C-N-CA 122.608 0.363 . . . . 0.0 110.955 177.846 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 96.72 -7.48 65.44 Favored Glycine 0 CA--C 1.525 0.68 0 CA-C-O 118.426 -1.208 . . . . 0.0 113.618 178.526 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -69.18 152.96 44.46 Favored 'General case' 0 CA--C 1.531 0.224 0 CA-C-N 119.953 1.877 . . . . 0.0 110.494 178.28 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 64.4 mttp -83.36 142.0 31.35 Favored 'General case' 0 N--CA 1.446 -0.666 0 C-N-CA 124.172 0.989 . . . . 0.0 109.882 -178.502 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 37.8 mt -120.56 130.08 74.89 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 105.963 -1.866 . . . . 0.0 105.963 178.386 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 84.9 t -121.88 131.42 73.16 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.428 0 N-CA-C 106.459 -1.682 . . . . 0.0 106.459 -179.242 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -118.19 103.47 9.88 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 178.799 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 38.0 ttpt -100.76 131.3 46.72 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 123.886 0.874 . . . . 0.0 113.296 -175.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 6.2 m-20 -64.96 107.81 1.61 Allowed 'General case' 0 C--O 1.232 0.137 0 C-N-CA 124.124 0.969 . . . . 0.0 109.975 177.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 7.0 t30 -87.67 -64.42 1.15 Allowed 'General case' 0 N--CA 1.456 -0.148 0 CA-C-O 121.496 0.665 . . . . 0.0 110.089 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -163.1 172.8 14.36 Favored 'General case' 0 C--N 1.331 -0.213 0 C-N-CA 125.54 1.536 . . . . 0.0 107.191 -178.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 66.2 20.28 69.05 Favored Glycine 0 CA--C 1.534 1.219 0 CA-C-N 118.291 0.496 . . . . 0.0 112.839 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 23.4 p90 -69.96 166.94 27.89 Favored Pre-proline 0 CA--C 1.549 0.905 0 N-CA-C 106.444 -1.688 . . . . 0.0 106.444 177.177 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -69.94 156.43 93.27 Favored 'Cis proline' 0 N--CA 1.444 -1.386 0 N-CA-C 115.712 1.389 . . . . 0.0 115.712 4.719 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 86.9 m-70 -147.81 164.86 32.34 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.83 -179.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 56.0 p30 -162.36 177.62 9.39 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 104.986 -2.228 . . . . 0.0 104.986 177.259 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 33.6 t -135.66 111.01 11.88 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 -179.547 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 93.9 t -115.19 130.47 69.68 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.586 0 N-CA-C 106.394 -1.706 . . . . 0.0 106.394 179.568 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 54.4 m-85 -87.59 136.31 33.0 Favored 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 123.4 0.68 . . . . 0.0 109.755 -179.394 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 43.7 t0 -73.11 103.89 4.01 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -47.54 -32.46 5.37 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 124.139 0.976 . . . . 0.0 113.555 179.207 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -77.3 -17.19 58.53 Favored 'General case' 0 CA--C 1.535 0.386 0 N-CA-C 112.983 0.734 . . . . 0.0 112.983 -179.78 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 81.5 mm-40 -132.91 65.9 1.58 Allowed 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.112 0.965 . . . . 0.0 111.801 -177.17 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 29.3 pt -153.3 153.49 29.44 Favored Pre-proline 0 CA--C 1.533 0.326 0 C-N-CA 127.542 2.337 . . . . 0.0 105.851 175.784 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -60.47 113.47 1.7 Allowed 'Trans proline' 0 N--CA 1.452 -0.964 0 C-N-CA 121.972 1.781 . . . . 0.0 110.556 178.293 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -51.5 108.37 0.26 Allowed 'General case' 0 N--CA 1.453 -0.276 0 C-N-CA 125.111 1.364 . . . . 0.0 110.397 -179.248 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 143.61 -37.51 1.45 Allowed Glycine 0 CA--C 1.524 0.617 0 N-CA-C 109.019 -1.632 . . . . 0.0 109.019 -178.428 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 45.8 t -77.58 113.82 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.239 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 41.9 t0 -60.94 111.65 1.75 Allowed 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 122.769 0.428 . . . . 0.0 110.114 179.543 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.4 -41.47 20.0 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 124.685 1.194 . . . . 0.0 111.149 178.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 48.6 t -59.7 -29.16 42.19 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.395 0 C-N-CA 123.283 0.633 . . . . 0.0 112.048 -179.053 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 64.3 mttp -78.71 -40.93 32.31 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-N 119.055 0.843 . . . . 0.0 110.772 -179.173 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 23.1 pt -77.6 -33.36 19.12 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 N-CA-C 111.917 0.34 . . . . 0.0 111.917 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 49.1 m -82.55 138.97 34.11 Favored 'General case' 0 N--CA 1.452 -0.341 0 N-CA-C 113.935 1.087 . . . . 0.0 113.935 -177.602 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 15.7 tpt . . . . . 0 N--CA 1.449 -0.498 0 N-CA-C 101.956 -3.35 . . . . 0.0 101.956 170.813 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.445 -0.68 0 CA-C-O 120.962 0.41 . . . . 0.0 110.971 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 73.8 mt -77.86 112.39 14.68 Favored 'General case' 0 N--CA 1.448 -0.575 0 N-CA-C 105.059 -2.2 . . . . 0.0 105.059 178.199 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 63.7 t30 -115.54 46.69 1.45 Allowed 'General case' 0 N--CA 1.464 0.247 0 C-N-CA 124.2 1.0 . . . . 0.0 112.491 -177.03 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -160.5 155.39 20.74 Favored Pre-proline 0 CA--C 1.531 0.22 0 N-CA-C 107.08 -1.452 . . . . 0.0 107.08 178.204 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -73.02 162.64 40.42 Favored 'Trans proline' 0 N--CA 1.454 -0.833 0 C-N-CA 122.013 1.808 . . . . 0.0 109.332 178.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 77.42 -35.94 1.56 Allowed Glycine 0 CA--C 1.529 0.938 0 CA-C-O 118.798 -1.001 . . . . 0.0 114.709 176.256 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 74.5 mm-40 -47.0 134.45 10.39 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 118.783 1.291 . . . . 0.0 111.387 179.165 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 21.8 p -119.53 132.56 55.78 Favored 'General case' 0 N--CA 1.456 -0.134 0 N-CA-C 113.83 1.048 . . . . 0.0 113.83 -177.436 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 31.9 t80 -100.91 140.38 35.28 Favored 'General case' 0 CA--C 1.529 0.166 0 N-CA-C 103.801 -2.666 . . . . 0.0 103.801 170.746 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 22.0 t -128.89 145.45 35.71 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.109 0 CA-C-N 119.007 0.821 . . . . 0.0 109.74 -177.647 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 12.5 p -152.23 169.23 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.197 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 178.367 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 83.6 m -149.06 133.62 17.68 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 106.264 -1.754 . . . . 0.0 106.264 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 79.2 mt -121.25 112.14 18.25 Favored 'General case' 0 CA--C 1.53 0.189 0 C-N-CA 123.234 0.614 . . . . 0.0 110.52 -177.305 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -93.86 -39.86 10.48 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 124.427 1.091 . . . . 0.0 110.543 178.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 6.4 m -70.19 122.11 18.85 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 123.594 0.758 . . . . 0.0 110.091 -178.162 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 20.8 mmtm -59.24 160.29 6.66 Favored 'General case' 0 CA--C 1.529 0.14 0 C-N-CA 124.186 0.995 . . . . 0.0 110.988 -179.692 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 134.96 -170.29 22.91 Favored Glycine 0 CA--C 1.524 0.6 0 C-N-CA 123.604 0.621 . . . . 0.0 111.822 177.703 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 25.3 m -121.26 130.34 53.62 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 105.503 -2.036 . . . . 0.0 105.503 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 16.5 m-85 -124.05 135.01 53.29 Favored 'General case' 0 N--CA 1.448 -0.525 0 C-N-CA 124.106 0.962 . . . . 0.0 109.818 -176.595 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 19.2 m -108.81 143.6 37.77 Favored 'General case' 0 C--O 1.233 0.199 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 175.644 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 11.8 p90 -143.89 171.31 14.41 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-O 121.15 0.5 . . . . 0.0 111.167 -179.308 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 34.4 p90 -157.76 167.38 30.21 Favored 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 123.805 0.842 . . . . 0.0 111.917 -179.176 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.3 t -102.99 109.31 20.8 Favored 'General case' 0 N--CA 1.463 0.181 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 177.494 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -40.92 -61.09 1.37 Allowed Pre-proline 0 CA--C 1.535 0.395 0 N-CA-C 115.659 1.725 . . . . 0.0 115.659 -173.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 63.6 Cg_endo -65.96 -4.2 9.71 Favored 'Trans proline' 0 N--CA 1.457 -0.638 0 C-N-CA 121.885 1.723 . . . . 0.0 114.87 -177.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 34.9 m80 -135.21 4.78 3.22 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-N 120.183 1.356 . . . . 0.0 113.185 -179.395 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 16.2 pt20 -55.7 -44.38 77.33 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 119.652 1.115 . . . . 0.0 109.975 178.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -59.17 -28.15 63.71 Favored Glycine 0 CA--C 1.531 1.037 0 N-CA-C 111.454 -0.659 . . . . 0.0 111.454 177.598 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.83 10.09 24.96 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 123.875 0.87 . . . . 0.0 110.843 178.771 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 87.31 10.22 71.47 Favored Glycine 0 CA--C 1.527 0.819 0 CA-C-O 118.558 -1.135 . . . . 0.0 113.789 178.29 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 18.4 ttt -78.96 76.54 5.45 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 119.791 1.796 . . . . 0.0 109.17 179.006 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 9.5 m -123.36 169.72 14.42 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 C-N-CA 126.388 1.875 . . . . 0.0 109.664 179.172 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -170.02 -179.8 41.85 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 110.211 -1.156 . . . . 0.0 110.211 178.156 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 54.1 mtmt -145.44 163.18 35.45 Favored 'General case' 0 N--CA 1.455 -0.224 0 C-N-CA 124.218 1.007 . . . . 0.0 110.29 -178.294 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.4 p -152.93 136.14 7.54 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 C-N-CA 123.898 0.879 . . . . 0.0 108.975 177.34 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -107.26 130.43 54.75 Favored 'General case' 0 C--N 1.332 -0.167 0 C-N-CA 124.441 1.096 . . . . 0.0 109.167 -179.633 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 43.4 t -99.8 97.81 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 N-CA-C 106.078 -1.823 . . . . 0.0 106.078 179.252 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 17.4 m-20 . . . . . 0 C--O 1.236 0.377 0 C-N-CA 123.604 0.762 . . . . 0.0 109.551 -176.728 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 69.2 tt0 . . . . . 0 N--CA 1.453 -0.279 0 N-CA-C 105.142 -2.17 . . . . 0.0 105.142 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 38.4 t -78.56 111.31 15.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 -176.713 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 57.8 mt -79.59 123.53 27.69 Favored 'General case' 0 N--CA 1.451 -0.416 0 N-CA-C 108.377 -0.971 . . . . 0.0 108.377 179.814 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 79.4 mt -84.23 107.41 16.52 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 178.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 86.56 130.48 2.79 Favored Glycine 0 C--N 1.337 0.599 0 N-CA-C 108.536 -1.826 . . . . 0.0 108.536 -179.014 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 5.0 p -78.99 157.46 28.13 Favored 'General case' 0 N--CA 1.441 -0.883 0 CA-C-N 118.461 1.131 . . . . 0.0 108.623 -178.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -43.94 -37.85 4.35 Favored Glycine 0 CA--C 1.531 1.06 0 C-N-CA 125.871 1.701 . . . . 0.0 113.76 -179.292 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -75.67 2.26 12.44 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 123.952 0.901 . . . . 0.0 113.253 -179.473 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 91.19 -10.33 75.22 Favored Glycine 0 CA--C 1.528 0.862 0 CA-C-O 118.828 -0.985 . . . . 0.0 113.188 -179.563 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.2 t -61.35 134.3 56.78 Favored 'General case' 0 C--N 1.343 0.293 0 CA-C-N 119.447 1.623 . . . . 0.0 110.518 -179.046 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 56.2 mt -76.63 66.06 2.53 Favored 'General case' 0 N--CA 1.447 -0.59 0 C-N-CA 126.079 1.751 . . . . 0.0 111.292 -176.312 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 29.4 m -131.13 148.65 32.94 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 C-N-CA 123.767 0.827 . . . . 0.0 110.361 179.437 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 49.9 m-85 -82.0 138.74 34.84 Favored 'General case' 0 N--CA 1.455 -0.204 0 N-CA-C 104.485 -2.413 . . . . 0.0 104.485 175.525 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.4 t -123.78 107.09 31.46 Favored Pre-proline 0 CA--C 1.533 0.302 0 CA-C-O 118.33 -0.843 . . . . 0.0 108.755 179.422 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_exo -70.45 154.69 95.22 Favored 'Cis proline' 0 C--N 1.346 0.429 0 CA-C-N 119.877 0.992 . . . . 0.0 112.015 -0.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.6 m -80.24 -45.44 17.97 Favored 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 177.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -126.98 142.5 51.54 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 105.84 -1.911 . . . . 0.0 105.84 177.642 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 33.8 p90 -166.88 175.62 7.59 Favored 'General case' 0 N--CA 1.455 -0.202 0 C-N-CA 123.637 0.775 . . . . 0.0 109.319 -178.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 16.4 m -134.8 143.16 46.92 Favored 'General case' 0 N--CA 1.45 -0.439 0 C-N-CA 124.499 1.12 . . . . 0.0 108.187 -179.652 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 32.7 m -137.73 149.51 64.9 Favored Pre-proline 0 CA--C 1.53 0.192 0 C-N-CA 124.632 1.173 . . . . 0.0 108.675 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -71.66 148.66 53.51 Favored 'Trans proline' 0 N--CA 1.448 -1.163 0 C-N-CA 121.76 1.64 . . . . 0.0 108.902 176.426 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 52.3 m -49.01 121.75 5.11 Favored 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 123.434 0.694 . . . . 0.0 110.961 178.572 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 99.51 -10.42 61.12 Favored Glycine 0 CA--C 1.526 0.766 0 CA-C-O 118.452 -1.193 . . . . 0.0 113.513 178.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -65.6 144.54 56.9 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 119.982 1.891 . . . . 0.0 108.969 178.394 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.2 ptmt -89.36 140.85 29.09 Favored 'General case' 0 N--CA 1.443 -0.825 0 N-CA-C 108.606 -0.886 . . . . 0.0 108.606 178.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 35.8 mt -112.61 131.94 62.74 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.386 0 N-CA-C 105.305 -2.109 . . . . 0.0 105.305 179.066 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 95.2 t -119.01 101.07 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.351 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 -179.071 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -86.27 132.66 33.94 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 106.228 -1.768 . . . . 0.0 106.228 177.357 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 61.1 tttp -131.27 130.54 42.96 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 119.237 0.926 . . . . 0.0 112.629 -176.699 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 4.1 m-20 -64.18 105.95 0.99 Allowed 'General case' 0 C--O 1.232 0.153 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 176.796 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 36.0 t30 -97.44 -69.72 0.75 Allowed 'General case' 0 N--CA 1.456 -0.162 0 CA-C-O 121.121 0.486 . . . . 0.0 110.521 -179.58 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -143.46 170.42 15.84 Favored 'General case' 0 C--O 1.224 -0.271 0 C-N-CA 124.102 0.961 . . . . 0.0 109.15 -178.56 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 57.75 19.68 36.81 Favored Glycine 0 CA--C 1.536 1.393 0 CA-C-N 118.748 0.703 . . . . 0.0 114.094 179.56 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 27.0 p90 -71.25 167.02 33.12 Favored Pre-proline 0 CA--C 1.542 0.662 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 178.026 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -70.49 160.42 90.25 Favored 'Cis proline' 0 N--CA 1.448 -1.153 0 N-CA-C 115.571 1.335 . . . . 0.0 115.571 4.336 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 86.7 m-70 -151.87 173.16 15.12 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.672 -178.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 57.2 p30 -163.14 178.25 8.41 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 105.035 -2.209 . . . . 0.0 105.035 176.397 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 24.0 t -135.39 110.23 11.51 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.307 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 -179.207 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 53.7 t -112.93 131.02 65.69 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 N-CA-C 106.552 -1.647 . . . . 0.0 106.552 179.545 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -92.02 132.64 36.4 Favored 'General case' 0 N--CA 1.45 -0.43 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 178.411 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -71.74 101.2 2.52 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 -178.881 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -37.61 -36.68 0.18 Allowed 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 126.676 1.99 . . . . 0.0 115.681 179.48 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 72.6 m-20 -77.94 -43.71 29.04 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-N 118.747 0.703 . . . . 0.0 110.343 179.755 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -93.32 57.58 2.68 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 124.487 1.115 . . . . 0.0 113.028 -176.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 37.5 pt -154.98 157.86 32.0 Favored Pre-proline 0 CA--C 1.533 0.306 0 C-N-CA 126.392 1.877 . . . . 0.0 106.879 176.238 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -57.85 108.15 0.36 Allowed 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 122.09 1.86 . . . . 0.0 108.245 173.812 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -35.08 -43.4 0.2 Allowed 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 126.829 2.052 . . . . 0.0 115.433 -177.084 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -57.68 -31.59 64.09 Favored Glycine 0 CA--C 1.533 1.218 0 C-N-CA 123.114 0.387 . . . . 0.0 113.341 -179.208 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 41.8 t -83.54 99.94 6.61 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 CA-C-N 117.945 0.873 . . . . 0.0 109.186 -178.595 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 17.4 t0 -53.6 113.29 1.12 Allowed 'General case' 0 CA--C 1.536 0.405 0 C-N-CA 123.321 0.648 . . . . 0.0 110.306 178.149 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -46.67 -39.91 12.23 Favored 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 125.778 1.631 . . . . 0.0 112.295 -179.874 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 54.0 t -59.11 -27.72 36.92 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 C-N-CA 123.101 0.561 . . . . 0.0 111.706 -178.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 2.9 mmmp? -77.91 -42.94 31.5 Favored 'General case' 0 CA--C 1.529 0.16 0 CA-C-N 118.675 0.671 . . . . 0.0 110.837 -179.096 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 26.4 pt -78.78 -33.44 16.49 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.339 0 N-CA-C 112.284 0.475 . . . . 0.0 112.284 -179.037 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 44.4 m -80.52 141.69 34.9 Favored 'General case' 0 C--N 1.333 -0.112 0 N-CA-C 114.96 1.467 . . . . 0.0 114.96 -176.599 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 CA--C 1.539 0.528 0 N-CA-C 103.031 -2.951 . . . . 0.0 103.031 172.008 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 2.2 pp . . . . . 0 N--CA 1.448 -0.547 0 CA-C-O 121.419 0.628 . . . . 0.0 112.072 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 72.9 mt -86.82 109.12 19.06 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 104.166 -2.531 . . . . 0.0 104.166 177.075 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 34.6 p-10 -81.14 -55.45 4.74 Favored 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 123.936 0.895 . . . . 0.0 113.282 -176.658 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.32 156.76 78.59 Favored Pre-proline 0 CA--C 1.535 0.373 0 C-N-CA 123.918 0.887 . . . . 0.0 112.302 -176.426 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -67.04 163.39 34.14 Favored 'Trans proline' 0 N--CA 1.455 -0.74 0 C-N-CA 122.364 2.043 . . . . 0.0 108.967 175.109 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 79.1 -36.48 1.94 Allowed Glycine 0 CA--C 1.528 0.897 0 CA-C-O 119.041 -0.866 . . . . 0.0 113.62 177.336 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 50.7 mm-40 -42.26 129.14 3.81 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 124.606 1.162 . . . . 0.0 110.683 178.564 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -111.83 159.76 18.01 Favored 'General case' 0 N--CA 1.452 -0.354 0 C-N-CA 124.665 1.186 . . . . 0.0 112.393 -177.07 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 75.8 t80 -138.24 111.58 8.03 Favored 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 105.136 -2.172 . . . . 0.0 105.136 174.623 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 37.4 t -101.71 142.2 16.69 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 C-N-CA 123.686 0.794 . . . . 0.0 109.657 -177.635 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 12.1 p -149.51 168.0 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 177.648 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 28.7 m -147.46 129.61 15.54 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 107.367 -1.346 . . . . 0.0 107.367 -179.858 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 62.3 mt -113.26 107.45 15.91 Favored 'General case' 0 CA--C 1.53 0.183 0 C-N-CA 123.461 0.704 . . . . 0.0 110.319 -177.394 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -86.99 -45.03 11.15 Favored 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 123.65 0.78 . . . . 0.0 111.347 179.397 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.7 m -71.88 122.34 20.61 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 123.05 0.54 . . . . 0.0 110.742 -177.063 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 55.6 mttp -59.9 160.85 7.2 Favored 'General case' 0 N--CA 1.456 -0.17 0 C-N-CA 124.835 1.254 . . . . 0.0 112.342 179.482 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 136.94 -142.82 13.98 Favored Glycine 0 C--N 1.334 0.469 0 N-CA-C 110.209 -1.156 . . . . 0.0 110.209 177.285 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 85.2 m -146.14 135.2 22.65 Favored 'General case' 0 N--CA 1.444 -0.75 0 N-CA-C 105.221 -2.14 . . . . 0.0 105.221 178.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 10.6 m-85 -124.7 130.08 51.74 Favored 'General case' 0 N--CA 1.446 -0.672 0 C-N-CA 123.937 0.895 . . . . 0.0 108.669 -176.456 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 17.7 m -100.32 141.52 33.05 Favored 'General case' 0 C--O 1.233 0.191 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 176.425 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 20.3 p90 -140.0 168.98 18.56 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-O 121.293 0.568 . . . . 0.0 111.275 -179.443 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 52.2 p90 -158.34 166.53 32.08 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 115.52 -0.764 . . . . 0.0 111.788 -179.264 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.3 t -105.49 107.63 18.72 Favored 'General case' 0 CA--C 1.519 -0.247 0 N-CA-C 105.817 -1.92 . . . . 0.0 105.817 177.346 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.305 0.3 OUTLIER -49.37 -56.15 17.93 Favored Pre-proline 0 CA--C 1.532 0.273 0 CA-C-N 119.119 0.872 . . . . 0.0 113.057 -174.667 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_exo -46.29 -19.49 0.65 Allowed 'Trans proline' 0 N--CA 1.457 -0.654 0 C-N-CA 123.741 2.961 . . . . 0.0 115.883 177.422 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 38.0 m80 -136.63 18.27 3.09 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 119.829 1.195 . . . . 0.0 112.16 179.764 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 15.2 pt20 -60.57 -41.69 95.14 Favored 'General case' 0 N--CA 1.455 -0.204 0 CA-C-N 119.16 0.891 . . . . 0.0 109.58 179.491 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -58.33 -28.99 62.57 Favored Glycine 0 CA--C 1.532 1.136 0 N-CA-C 111.334 -0.707 . . . . 0.0 111.334 177.203 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -90.44 11.42 21.67 Favored 'General case' 0 CA--C 1.534 0.327 0 C-N-CA 123.781 0.832 . . . . 0.0 110.954 178.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 78.64 19.11 74.22 Favored Glycine 0 CA--C 1.527 0.819 0 CA-C-O 118.604 -1.109 . . . . 0.0 113.575 178.657 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 22.5 ttt -78.69 76.58 5.18 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-N 119.775 1.788 . . . . 0.0 108.756 178.147 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 10.2 m -120.86 172.54 7.76 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 C-N-CA 126.191 1.796 . . . . 0.0 109.787 179.566 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -170.52 177.34 43.73 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 177.672 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 58.6 mttp -146.63 157.26 43.68 Favored 'General case' 0 CA--C 1.526 0.047 0 CA-C-N 117.53 0.665 . . . . 0.0 110.623 -178.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 5.5 p -143.82 126.14 11.47 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.289 0 C-N-CA 123.152 0.581 . . . . 0.0 110.48 177.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.28 124.06 34.06 Favored 'General case' 0 CA--C 1.53 0.179 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 177.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 40.7 t -100.28 95.04 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.209 0 N-CA-C 103.161 -2.903 . . . . 0.0 103.161 177.302 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 . . . . . 0 N--CA 1.453 -0.297 0 C-N-CA 125.019 1.328 . . . . 0.0 113.108 -173.945 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 . . . . . 0 N--CA 1.453 -0.298 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 40.6 t -87.77 121.52 38.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 C-N-CA 124.51 1.124 . . . . 0.0 108.527 -179.463 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 70.0 mt -85.07 122.48 29.34 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 108.588 -0.894 . . . . 0.0 108.588 179.065 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 72.2 mt -86.84 99.88 12.14 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 106.103 -1.814 . . . . 0.0 106.103 177.783 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 100.9 151.29 25.04 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 108.713 -1.755 . . . . 0.0 108.713 -178.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 96.5 p -86.73 172.94 9.79 Favored 'General case' 0 N--CA 1.445 -0.711 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 177.378 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -54.08 -43.25 73.03 Favored Glycine 0 CA--C 1.53 0.971 0 N-CA-C 110.4 -1.08 . . . . 0.0 110.4 178.219 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -81.29 13.78 2.74 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 123.313 0.645 . . . . 0.0 112.221 178.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 74.48 16.98 79.8 Favored Glycine 0 CA--C 1.526 0.737 0 CA-C-O 118.849 -0.973 . . . . 0.0 114.156 178.2 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 22.8 t -71.33 140.13 50.13 Favored 'General case' 0 C--N 1.34 0.161 0 CA-C-N 119.443 1.622 . . . . 0.0 107.119 178.293 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 67.6 mt -76.52 67.65 2.71 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 125.136 1.374 . . . . 0.0 111.954 -175.411 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 26.0 m -135.17 150.17 29.4 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.21 0 C-N-CA 123.593 0.757 . . . . 0.0 110.498 179.654 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 45.3 m-85 -89.58 129.44 36.04 Favored 'General case' 0 N--CA 1.457 -0.099 0 N-CA-C 104.809 -2.293 . . . . 0.0 104.809 175.757 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 37.0 t -122.5 107.74 34.07 Favored Pre-proline 0 CA--C 1.537 0.467 0 CA-C-O 118.496 -0.764 . . . . 0.0 109.162 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -71.69 161.5 91.04 Favored 'Cis proline' 0 N--CA 1.457 -0.635 0 CA-C-N 120.227 1.117 . . . . 0.0 111.044 -1.355 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 6.2 p -86.21 -64.71 1.11 Allowed 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 178.345 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 64.9 tt0 -102.6 127.15 49.82 Favored 'General case' 0 N--CA 1.454 -0.275 0 C-N-CA 125.819 1.648 . . . . 0.0 107.577 178.47 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 33.9 p90 -150.34 -171.51 3.93 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-O 121.578 0.704 . . . . 0.0 111.998 178.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 7.0 m -141.63 146.8 36.63 Favored 'General case' 0 N--CA 1.45 -0.431 0 C-N-CA 124.655 1.182 . . . . 0.0 108.229 -178.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.0 p -148.85 137.89 12.21 Favored Pre-proline 0 CA--C 1.539 0.552 0 C-N-CA 123.28 0.632 . . . . 0.0 110.501 -177.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_exo -66.59 139.7 54.25 Favored 'Trans proline' 0 N--CA 1.455 -0.736 0 C-N-CA 121.424 1.416 . . . . 0.0 111.013 176.585 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 63.1 m -46.7 127.63 9.82 Favored 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 123.708 0.803 . . . . 0.0 110.978 177.125 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 94.96 -23.82 31.37 Favored Glycine 0 CA--C 1.529 0.946 0 CA-C-O 119.188 -0.784 . . . . 0.0 113.338 178.673 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 74.9 mm-40 -74.15 96.1 2.69 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 119.469 1.634 . . . . 0.0 109.318 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -41.42 126.5 2.84 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 125.734 1.614 . . . . 0.0 114.119 179.499 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 60.3 mt -90.06 136.77 22.98 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.314 0 N-CA-C 105.943 -1.873 . . . . 0.0 105.943 178.036 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 66.6 t -117.76 119.39 61.46 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.33 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 179.532 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 95.3 m-85 -106.16 109.38 21.3 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 178.338 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 62.5 tttp -105.16 129.31 53.58 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 124.489 1.115 . . . . 0.0 113.322 -175.159 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 3.6 m-20 -65.58 110.54 2.77 Favored 'General case' 0 C--O 1.23 0.07 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 176.834 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 51.1 t-20 -84.33 -72.08 0.48 Allowed 'General case' 0 N--CA 1.456 -0.166 0 N-CA-C 111.738 0.273 . . . . 0.0 111.738 -178.653 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -146.24 -53.54 0.25 Allowed 'General case' 0 C--O 1.225 -0.199 0 N-CA-C 114.359 1.244 . . . . 0.0 114.359 -175.82 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -69.69 33.88 0.37 Allowed Glycine 0 CA--C 1.538 1.494 0 N-CA-C 116.24 1.256 . . . . 0.0 116.24 -176.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 18.9 p90 -73.34 165.71 50.45 Favored Pre-proline 0 CA--C 1.543 0.705 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 179.783 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -62.27 149.38 60.03 Favored 'Cis proline' 0 N--CA 1.451 -0.992 0 N-CA-C 116.425 1.663 . . . . 0.0 116.425 2.446 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 91.8 m-70 -145.95 172.6 13.13 Favored 'General case' 0 N--CA 1.447 -0.59 0 O-C-N 121.715 -0.616 . . . . 0.0 110.157 179.19 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 22.9 p-10 -169.42 175.85 5.33 Favored 'General case' 0 N--CA 1.447 -0.583 0 N-CA-C 104.048 -2.575 . . . . 0.0 104.048 176.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 46.5 t -137.99 114.67 11.4 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.332 0 N-CA-C 107.225 -1.398 . . . . 0.0 107.225 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 62.0 t -119.46 135.97 58.12 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 106.335 -1.728 . . . . 0.0 106.335 179.427 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 57.2 m-85 -89.23 135.5 33.54 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 123.219 0.608 . . . . 0.0 109.682 -178.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 7.3 t0 -74.85 99.46 3.79 Favored 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 124.315 1.046 . . . . 0.0 109.721 -179.06 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -44.21 -34.33 1.84 Allowed 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 124.687 1.195 . . . . 0.0 113.59 178.714 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -66.96 -25.58 66.41 Favored 'General case' 0 CA--C 1.536 0.419 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 179.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -135.36 76.23 1.61 Allowed 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 123.683 0.793 . . . . 0.0 111.136 -177.312 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 25.8 pt -153.66 149.94 22.16 Favored Pre-proline 0 CA--C 1.535 0.382 0 C-N-CA 127.372 2.269 . . . . 0.0 105.354 175.228 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -64.56 131.68 30.49 Favored 'Trans proline' 0 N--CA 1.453 -0.886 0 C-N-CA 121.746 1.631 . . . . 0.0 109.773 178.886 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -51.72 143.23 13.2 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 124.027 0.931 . . . . 0.0 112.061 -178.532 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 105.13 -41.35 2.18 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 110.365 -1.094 . . . . 0.0 110.365 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 19.7 t -79.25 93.23 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 CA-C-N 117.45 0.625 . . . . 0.0 109.337 -179.286 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 18.3 t0 -55.85 118.57 4.71 Favored 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 123.09 0.556 . . . . 0.0 110.494 178.606 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -44.31 -46.25 9.12 Favored 'General case' 0 CA--C 1.529 0.135 0 C-N-CA 125.662 1.585 . . . . 0.0 111.532 179.02 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 48.4 t -56.68 -31.03 33.77 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.471 0 C-N-CA 122.786 0.434 . . . . 0.0 111.926 -178.633 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 65.6 mttp -75.71 -39.46 57.31 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-N 118.678 0.672 . . . . 0.0 111.008 -178.834 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 20.6 pt -81.15 -28.27 10.85 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.271 0 N-CA-C 112.428 0.529 . . . . 0.0 112.428 -179.521 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 63.2 m -74.95 144.86 43.03 Favored 'General case' 0 N--CA 1.455 -0.224 0 O-C-N 121.778 -0.576 . . . . 0.0 112.534 -178.313 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 7.7 tmm? . . . . . 0 CA--C 1.537 0.463 0 N-CA-C 106.185 -1.783 . . . . 0.0 106.185 177.239 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 88.4 mt . . . . . 0 N--CA 1.454 -0.24 0 N-CA-C 106.407 -1.701 . . . . 0.0 106.407 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 67.8 mt -83.91 96.68 8.89 Favored 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 104.722 -2.325 . . . . 0.0 104.722 176.492 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -105.59 34.08 3.44 Favored 'General case' 0 CA--C 1.536 0.434 0 C-N-CA 124.499 1.12 . . . . 0.0 113.878 -177.45 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -151.43 156.49 34.86 Favored Pre-proline 0 CA--C 1.531 0.22 0 N-CA-C 108.106 -1.072 . . . . 0.0 108.106 179.639 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -72.79 163.54 38.13 Favored 'Trans proline' 0 N--CA 1.455 -0.782 0 C-N-CA 121.885 1.724 . . . . 0.0 109.816 179.324 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 78.07 -44.71 2.41 Favored Glycine 0 CA--C 1.526 0.771 0 CA-C-O 118.557 -1.135 . . . . 0.0 114.523 175.687 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 55.2 mm-40 -38.33 122.82 1.11 Allowed 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 124.82 1.248 . . . . 0.0 113.058 -178.809 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 17.9 p -109.13 134.03 52.24 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 125.316 1.446 . . . . 0.0 112.95 -178.104 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 17.5 t80 -107.55 143.27 36.2 Favored 'General case' 0 CA--C 1.528 0.097 0 N-CA-C 104.591 -2.374 . . . . 0.0 104.591 171.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 20.4 t -128.57 140.13 50.05 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.16 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 -179.057 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 12.8 p -146.01 144.9 20.55 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.134 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 178.301 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 7.6 m -115.25 106.65 14.29 Favored 'General case' 0 N--CA 1.454 -0.23 0 C-N-CA 124.356 1.062 . . . . 0.0 109.849 -178.6 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 50.5 mt -95.06 129.18 42.25 Favored 'General case' 0 CA--C 1.531 0.217 0 N-CA-C 107.52 -1.289 . . . . 0.0 107.52 177.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 13.9 m-20 -113.85 -46.53 3.02 Favored 'General case' 0 CA--C 1.527 0.08 0 C-N-CA 123.988 0.915 . . . . 0.0 111.24 -178.638 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 4.5 m -66.22 118.98 10.71 Favored 'General case' 0 N--CA 1.452 -0.362 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 -178.67 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 64.4 mttm -63.79 152.64 38.9 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 123.337 0.655 . . . . 0.0 110.306 -179.282 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 145.41 -157.81 27.46 Favored Glycine 0 CA--C 1.522 0.469 0 N-CA-C 109.328 -1.509 . . . . 0.0 109.328 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 15.3 m -123.59 132.33 53.85 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 106.535 -1.654 . . . . 0.0 106.535 -179.627 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 19.6 m-85 -125.02 119.93 30.1 Favored 'General case' 0 N--CA 1.447 -0.624 0 C-N-CA 123.681 0.793 . . . . 0.0 108.906 -178.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 70.2 m -91.51 144.88 25.1 Favored 'General case' 0 C--O 1.233 0.213 0 N-CA-C 107.699 -1.223 . . . . 0.0 107.699 175.612 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 17.4 p90 -141.22 164.14 31.07 Favored 'General case' 0 N--CA 1.455 -0.222 0 CA-C-O 121.237 0.541 . . . . 0.0 110.771 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 53.3 p90 -150.7 160.16 44.03 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-N 115.061 -0.972 . . . . 0.0 112.713 -177.424 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 11.6 t -99.41 106.16 18.19 Favored 'General case' 0 CA--C 1.522 -0.104 0 N-CA-C 105.877 -1.898 . . . . 0.0 105.877 176.453 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 4.5 m -38.83 -60.03 1.23 Allowed Pre-proline 0 CA--C 1.536 0.44 0 N-CA-C 115.976 1.843 . . . . 0.0 115.976 -174.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 89.3 Cg_endo -72.06 -2.53 11.7 Favored 'Trans proline' 0 N--CA 1.458 -0.612 0 C-N-CA 122.056 1.837 . . . . 0.0 114.602 -178.576 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 32.9 m170 -132.96 3.86 3.77 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 120.35 1.432 . . . . 0.0 113.723 -178.152 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 15.1 pt20 -52.72 -42.81 65.2 Favored 'General case' 0 CA--C 1.534 0.355 0 CA-C-N 119.009 0.822 . . . . 0.0 110.196 178.002 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -58.52 -28.77 62.8 Favored Glycine 0 CA--C 1.53 1.021 0 C-N-CA 123.951 0.786 . . . . 0.0 111.763 178.167 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -90.74 11.94 20.74 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 123.83 0.852 . . . . 0.0 110.505 178.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 82.97 13.0 78.64 Favored Glycine 0 CA--C 1.527 0.825 0 CA-C-O 118.632 -1.094 . . . . 0.0 113.227 178.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 20.5 ttt -77.66 79.82 4.14 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 119.708 1.754 . . . . 0.0 109.473 178.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 11.0 m -131.36 169.66 21.29 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.199 0 C-N-CA 126.158 1.783 . . . . 0.0 110.298 179.1 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -168.02 179.73 41.07 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 109.321 -1.511 . . . . 0.0 109.321 178.017 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 33.8 mtmm -148.32 150.5 33.73 Favored 'General case' 0 N--CA 1.456 -0.159 0 C-N-CA 123.944 0.898 . . . . 0.0 110.439 -178.429 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.0 p -135.33 131.17 51.62 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.252 0 C-N-CA 122.973 0.509 . . . . 0.0 109.948 178.76 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.0 m -98.27 100.87 12.2 Favored 'General case' 0 CA--C 1.534 0.361 0 C-N-CA 125.212 1.405 . . . . 0.0 109.396 -179.64 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 43.6 t -79.92 114.9 21.46 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.388 0 N-CA-C 105.277 -2.119 . . . . 0.0 105.277 -179.553 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 6.6 p30 . . . . . 0 C--N 1.333 -0.133 0 C-N-CA 123.426 0.691 . . . . 0.0 111.946 -174.673 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 . . . . . 0 N--CA 1.449 -0.5 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 58.6 t -132.99 117.56 29.8 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.683 0 N-CA-C 106.217 -1.772 . . . . 0.0 106.217 178.585 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 38.7 mt -84.89 119.22 25.1 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 179.427 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 49.0 mt -82.52 83.07 7.68 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 104.372 -2.455 . . . . 0.0 104.372 176.534 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 121.38 152.1 8.68 Favored Glycine 0 CA--C 1.527 0.812 0 C-N-CA 125.708 1.623 . . . . 0.0 109.616 -176.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 50.5 p -114.8 44.65 1.73 Allowed 'General case' 0 CA--C 1.522 -0.121 0 C-N-CA 124.28 1.032 . . . . 0.0 111.799 -179.394 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 74.87 -56.81 2.65 Favored Glycine 0 CA--C 1.523 0.542 0 C-N-CA 126.023 1.773 . . . . 0.0 111.401 179.294 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -73.72 34.37 0.08 Allowed 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 125.406 1.482 . . . . 0.0 113.625 -177.697 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 58.94 4.39 2.24 Favored Glycine 0 CA--C 1.532 1.102 0 C-N-CA 124.828 1.204 . . . . 0.0 115.837 178.743 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.3 t -64.97 138.6 58.46 Favored 'General case' 0 N--CA 1.456 -0.146 0 CA-C-N 119.528 1.664 . . . . 0.0 110.12 -179.009 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 71.0 mt -79.98 64.69 4.9 Favored 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 124.807 1.243 . . . . 0.0 110.604 -177.098 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 28.0 m -133.68 145.13 34.02 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.223 0 C-N-CA 123.253 0.621 . . . . 0.0 112.421 -178.467 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 68.8 m-85 -89.21 125.96 35.29 Favored 'General case' 0 N--CA 1.455 -0.224 0 N-CA-C 104.037 -2.579 . . . . 0.0 104.037 175.536 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 22.4 t -118.02 110.17 40.17 Favored Pre-proline 0 CA--C 1.532 0.267 0 CA-C-N 119.529 1.059 . . . . 0.0 109.218 179.25 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -74.81 153.64 99.27 Favored 'Cis proline' 0 CA--C 1.535 0.57 0 CA-C-N 120.392 1.176 . . . . 0.0 111.164 -1.375 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.2 m -80.87 -45.55 16.66 Favored 'General case' 0 CA--C 1.528 0.127 0 C-N-CA 123.324 0.65 . . . . 0.0 110.805 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -123.58 130.96 53.45 Favored 'General case' 0 N--CA 1.451 -0.396 0 N-CA-C 104.657 -2.349 . . . . 0.0 104.657 178.46 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 42.1 p90 -157.96 -177.54 6.64 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 118.435 0.562 . . . . 0.0 111.175 -177.765 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.9 p -126.09 151.26 47.44 Favored 'General case' 0 N--CA 1.448 -0.569 0 C-N-CA 125.809 1.644 . . . . 0.0 108.758 178.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.8 p -145.53 134.36 11.05 Favored Pre-proline 0 CA--C 1.539 0.52 0 C-N-CA 123.893 0.877 . . . . 0.0 109.136 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -64.64 136.88 51.9 Favored 'Trans proline' 0 N--CA 1.455 -0.782 0 C-N-CA 121.536 1.491 . . . . 0.0 110.096 175.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 48.6 m -49.69 122.1 6.0 Favored 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 123.796 0.838 . . . . 0.0 111.131 179.325 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.46 -17.25 58.74 Favored Glycine 0 CA--C 1.529 0.938 0 CA-C-O 118.816 -0.991 . . . . 0.0 113.554 179.006 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 71.1 mm-40 -70.25 167.05 18.78 Favored 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 119.623 1.712 . . . . 0.0 111.428 179.679 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -92.95 146.88 23.29 Favored 'General case' 0 N--CA 1.45 -0.434 0 C-N-CA 125.029 1.331 . . . . 0.0 111.017 -179.213 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 32.1 mt -125.23 126.41 70.8 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.424 0 N-CA-C 103.682 -2.71 . . . . 0.0 103.682 176.349 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 57.2 t -112.39 96.61 4.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 C-N-CA 125.081 1.352 . . . . 0.0 108.896 -178.259 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -81.69 97.13 7.77 Favored 'General case' 0 CA--C 1.531 0.239 0 N-CA-C 106.862 -1.533 . . . . 0.0 106.862 178.305 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 63.5 tttp -93.98 127.81 39.97 Favored 'General case' 0 CA--C 1.53 0.187 0 C-N-CA 124.884 1.274 . . . . 0.0 113.557 -174.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -67.7 93.51 0.38 Allowed 'General case' 0 CA--C 1.533 0.324 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 176.78 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 14.0 t-20 -80.69 -67.25 0.79 Allowed 'General case' 0 N--CA 1.455 -0.221 0 C-N-CA 123.342 0.657 . . . . 0.0 110.654 -179.354 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -161.05 167.93 25.43 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.258 -176.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 68.87 17.5 71.51 Favored Glycine 0 CA--C 1.533 1.199 0 O-C-N 121.587 -0.695 . . . . 0.0 112.144 -179.236 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 32.8 p90 -70.12 165.95 38.38 Favored Pre-proline 0 CA--C 1.545 0.771 0 N-CA-C 106.325 -1.732 . . . . 0.0 106.325 177.351 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -68.97 155.53 91.03 Favored 'Cis proline' 0 N--CA 1.446 -1.274 0 N-CA-C 115.525 1.317 . . . . 0.0 115.525 4.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 90.1 m-70 -147.72 170.32 17.82 Favored 'General case' 0 N--CA 1.449 -0.478 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.464 -179.683 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 40.4 p-10 -160.55 175.37 12.79 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 104.423 -2.436 . . . . 0.0 104.423 176.639 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 21.9 t -136.15 106.52 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.314 0 N-CA-C 106.787 -1.56 . . . . 0.0 106.787 -179.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 55.5 t -113.17 133.95 57.4 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 106.422 -1.696 . . . . 0.0 106.422 179.229 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 56.9 m-85 -96.18 140.82 30.33 Favored 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 123.544 0.738 . . . . 0.0 109.647 -179.711 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -74.08 108.13 6.7 Favored 'General case' 0 N--CA 1.453 -0.308 0 N-CA-C 107.078 -1.453 . . . . 0.0 107.078 178.204 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -44.25 -30.61 0.83 Allowed 'General case' 0 CA--C 1.535 0.386 0 N-CA-C 115.916 1.821 . . . . 0.0 115.916 -177.765 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -86.17 -49.19 7.93 Favored 'General case' 0 CA--C 1.53 0.196 0 CA-C-N 118.703 0.683 . . . . 0.0 110.48 179.153 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -80.66 57.48 2.96 Favored 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 124.109 0.964 . . . . 0.0 112.257 -176.609 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 36.2 pt -153.35 156.63 32.61 Favored Pre-proline 0 CA--C 1.534 0.348 0 C-N-CA 127.634 2.374 . . . . 0.0 106.217 176.649 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -53.07 115.53 2.34 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 C-N-CA 122.51 2.14 . . . . 0.0 111.384 178.065 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -52.88 107.88 0.26 Allowed 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 123.992 0.917 . . . . 0.0 110.083 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 136.46 -30.42 2.7 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 109.835 -1.306 . . . . 0.0 109.835 -178.069 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 69.9 t -75.62 121.89 28.35 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 CA-C-N 117.861 0.831 . . . . 0.0 109.059 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 14.8 t0 -66.35 105.46 1.45 Allowed 'General case' 0 N--CA 1.453 -0.3 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 178.752 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.49 -39.03 21.73 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 124.168 0.987 . . . . 0.0 111.463 178.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 41.4 t -61.68 -29.3 45.9 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.429 0 C-N-CA 122.821 0.448 . . . . 0.0 111.574 -179.359 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.53 -34.03 58.57 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 119.224 0.92 . . . . 0.0 110.979 -178.593 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 25.0 pt -85.74 -32.35 7.0 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.21 0 C-N-CA 123.266 0.626 . . . . 0.0 111.899 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 39.7 m -85.87 136.43 33.3 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 114.273 1.212 . . . . 0.0 114.273 -177.208 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 69.2 mmm . . . . . 0 N--CA 1.452 -0.348 0 N-CA-C 103.822 -2.659 . . . . 0.0 103.822 170.936 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.446 -0.634 0 CA-C-O 121.393 0.616 . . . . 0.0 111.833 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 43.5 mt -76.85 99.94 5.35 Favored 'General case' 0 N--CA 1.446 -0.631 0 N-CA-C 104.176 -2.527 . . . . 0.0 104.176 177.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -96.47 -22.33 17.19 Favored 'General case' 0 N--CA 1.462 0.171 0 N-CA-C 113.993 1.108 . . . . 0.0 113.993 -176.623 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -93.97 152.94 40.89 Favored Pre-proline 0 CA--C 1.533 0.305 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -66.43 161.99 38.5 Favored 'Trans proline' 0 N--CA 1.453 -0.908 0 C-N-CA 121.773 1.649 . . . . 0.0 110.195 178.207 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 80.14 -53.93 4.45 Favored Glycine 0 CA--C 1.523 0.568 0 CA-C-O 118.228 -1.318 . . . . 0.0 113.404 176.4 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -18.53 111.07 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.399 0 C-N-CA 126.444 1.898 . . . . 0.0 114.388 -177.011 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 14.5 p -100.71 119.07 38.05 Favored 'General case' 0 N--CA 1.446 -0.633 0 C-N-CA 124.619 1.168 . . . . 0.0 112.225 -178.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 10.8 t80 -97.13 105.61 17.79 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 105.06 -2.2 . . . . 0.0 105.06 174.624 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.9 t -94.98 134.46 32.29 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.283 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 -178.686 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.1 p -151.16 161.22 3.52 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 178.485 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.1 m -133.62 142.29 48.03 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 125.501 1.52 . . . . 0.0 107.9 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 62.4 mt -118.82 120.52 37.59 Favored 'General case' 0 N--CA 1.453 -0.31 0 N-CA-C 107.567 -1.272 . . . . 0.0 107.567 179.288 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 9.0 p-10 -95.02 -41.07 9.32 Favored 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 124.178 0.991 . . . . 0.0 112.395 -178.43 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 25.0 m -77.14 125.77 29.86 Favored 'General case' 0 N--CA 1.452 -0.328 0 C-N-CA 123.428 0.691 . . . . 0.0 109.933 -176.564 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 66.3 mttm -65.47 156.02 33.75 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 124.017 0.927 . . . . 0.0 111.477 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 127.23 177.33 14.82 Favored Glycine 0 CA--C 1.526 0.743 0 C-N-CA 123.92 0.771 . . . . 0.0 112.201 177.445 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 7.3 m -94.57 127.73 40.71 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 125.15 1.38 . . . . 0.0 108.914 -179.063 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 15.6 m-85 -115.95 135.81 53.63 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 125.755 1.622 . . . . 0.0 108.643 179.066 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 16.9 m -108.81 136.23 48.71 Favored 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 123.362 0.665 . . . . 0.0 109.419 176.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 20.3 p90 -137.83 168.53 19.5 Favored 'General case' 0 C--O 1.232 0.142 0 CA-C-O 121.77 0.795 . . . . 0.0 111.818 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -156.37 160.62 39.83 Favored 'General case' 0 N--CA 1.453 -0.278 0 CA-C-N 115.322 -0.854 . . . . 0.0 112.532 -178.756 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.4 t -99.74 102.37 13.81 Favored 'General case' 0 CA--C 1.519 -0.226 0 N-CA-C 106.396 -1.705 . . . . 0.0 106.396 176.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -48.24 -55.07 20.19 Favored Pre-proline 0 CA--C 1.532 0.263 0 CA-C-O 118.593 -0.717 . . . . 0.0 112.51 -175.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_exo -50.59 -15.7 1.78 Allowed 'Trans proline' 0 N--CA 1.458 -0.572 0 C-N-CA 123.387 2.725 . . . . 0.0 115.566 178.259 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 39.3 m80 -137.69 31.5 2.52 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 119.757 1.162 . . . . 0.0 110.999 -179.765 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 1.5 pm0 -60.73 -45.64 93.48 Favored 'General case' 0 CA--C 1.534 0.333 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 178.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.99 -35.06 67.09 Favored Glycine 0 CA--C 1.527 0.816 0 C-N-CA 124.272 0.939 . . . . 0.0 111.661 179.1 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -80.96 4.97 17.71 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-N 117.209 0.504 . . . . 0.0 111.465 179.006 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 73.94 25.2 72.15 Favored Glycine 0 CA--C 1.524 0.651 0 CA-C-O 119.147 -0.807 . . . . 0.0 112.573 179.229 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 24.5 ttt -78.96 78.24 5.41 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 119.092 1.446 . . . . 0.0 107.831 177.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 13.5 m -121.25 169.09 12.99 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.245 0 C-N-CA 126.181 1.792 . . . . 0.0 109.915 179.56 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -168.87 177.97 42.43 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.108 -1.197 . . . . 0.0 110.108 178.489 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 58.6 mttm -147.57 161.22 41.57 Favored 'General case' 0 N--CA 1.455 -0.21 0 C-N-CA 123.772 0.829 . . . . 0.0 109.621 -179.48 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 4.2 p -144.88 132.63 16.59 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.246 0 C-N-CA 123.62 0.768 . . . . 0.0 109.1 178.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.3 m -103.41 106.88 17.51 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.965 1.306 . . . . 0.0 109.665 -178.44 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 32.6 t -82.55 106.97 13.95 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.574 0 N-CA-C 105.905 -1.887 . . . . 0.0 105.905 178.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 25.6 m120 . . . . . 0 C--O 1.231 0.127 0 C-N-CA 124.279 1.032 . . . . 0.0 111.042 -176.637 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 45.9 tt0 . . . . . 0 N--CA 1.452 -0.343 0 N-CA-C 105.546 -2.02 . . . . 0.0 105.546 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 38.7 t -99.35 118.66 46.28 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.455 0 C-N-CA 123.813 0.845 . . . . 0.0 108.833 -177.645 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 59.1 mt -81.98 122.05 27.3 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 179.297 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 70.4 mt -87.39 89.93 8.18 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 105.321 -2.103 . . . . 0.0 105.321 177.128 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 118.25 166.36 13.7 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 109.098 -1.601 . . . . 0.0 109.098 -177.408 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 5.4 p -136.26 48.56 2.15 Favored 'General case' 0 N--CA 1.461 0.102 0 CA-C-O 122.798 1.285 . . . . 0.0 113.259 -178.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.44 -62.13 0.62 Allowed Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 128.238 2.828 . . . . 0.0 113.364 176.636 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.402 ' C ' ' H ' ' A' ' 11' ' ' SER . 7.5 p-10 -78.31 42.97 0.44 Allowed 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 123.981 0.913 . . . . 0.0 112.268 -175.578 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 75.55 -31.22 1.21 Allowed Glycine 0 CA--C 1.528 0.891 0 C-N-CA 124.934 1.254 . . . . 0.0 113.388 178.305 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.402 ' H ' ' C ' ' A' ' 9' ' ' ASP . 7.4 t -40.44 106.27 0.05 Allowed 'General case' 0 C--O 1.237 0.443 0 C-N-CA 126.178 1.791 . . . . 0.0 112.141 -178.522 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 48.9 mt -75.2 69.96 2.11 Favored 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 128.196 2.598 . . . . 0.0 111.551 -176.399 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.6 m -136.49 153.38 30.78 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 C-N-CA 122.86 0.464 . . . . 0.0 110.233 179.034 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 61.5 m-85 -88.57 127.27 35.55 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 105.096 -2.187 . . . . 0.0 105.096 176.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 38.8 t -120.79 114.42 32.61 Favored Pre-proline 0 CA--C 1.533 0.313 0 CA-C-O 118.175 -0.916 . . . . 0.0 108.688 178.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -73.06 147.91 90.88 Favored 'Cis proline' 0 CA--C 1.535 0.574 0 CA-C-N 120.49 1.211 . . . . 0.0 111.423 -0.455 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.4 m -78.77 -33.02 46.76 Favored 'General case' 0 CA--C 1.529 0.148 0 C-N-CA 123.715 0.806 . . . . 0.0 111.809 179.826 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -138.75 141.25 38.85 Favored 'General case' 0 N--CA 1.454 -0.241 0 N-CA-C 105.288 -2.115 . . . . 0.0 105.288 178.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 13.3 p90 -168.1 172.44 8.74 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 123.904 0.882 . . . . 0.0 108.739 -178.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 14.9 m -133.26 137.7 46.16 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 123.918 0.887 . . . . 0.0 108.685 -179.09 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.3 m -139.9 155.02 71.2 Favored Pre-proline 0 CA--C 1.531 0.234 0 C-N-CA 124.26 1.024 . . . . 0.0 110.145 -178.61 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -77.11 151.21 30.22 Favored 'Trans proline' 0 N--CA 1.451 -0.992 0 C-N-CA 121.845 1.697 . . . . 0.0 110.64 177.638 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 14.7 m -49.79 126.55 14.19 Favored 'General case' 0 N--CA 1.457 -0.112 0 C-N-CA 123.328 0.651 . . . . 0.0 109.993 175.579 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 103.21 -6.64 50.81 Favored Glycine 0 CA--C 1.526 0.752 0 CA-C-O 119.082 -0.844 . . . . 0.0 111.678 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -61.65 136.87 58.17 Favored 'General case' 0 CA--C 1.534 0.329 0 CA-C-N 119.117 1.458 . . . . 0.0 110.43 178.567 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 61.0 mttp -94.93 98.56 10.79 Favored 'General case' 0 N--CA 1.446 -0.657 0 C-N-CA 127.244 2.218 . . . . 0.0 107.436 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 56.3 mt -81.45 137.4 21.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 -179.247 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 60.4 t -120.53 102.51 12.54 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.187 0 C-N-CA 125.017 1.327 . . . . 0.0 108.703 -178.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -88.46 107.03 18.65 Favored 'General case' 0 CA--C 1.53 0.183 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 178.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 64.6 tttm -103.35 128.45 50.43 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 124.49 1.116 . . . . 0.0 113.379 -175.556 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -62.27 108.69 1.14 Allowed 'General case' 0 N--CA 1.464 0.26 0 N-CA-C 109.155 -0.684 . . . . 0.0 109.155 176.654 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 20.2 t-20 -94.05 -69.93 0.73 Allowed 'General case' 0 C--N 1.339 0.152 0 C-N-CA 123.434 0.693 . . . . 0.0 110.71 -179.403 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -154.89 166.0 34.9 Favored 'General case' 0 C--N 1.331 -0.213 0 C-N-CA 123.899 0.88 . . . . 0.0 109.586 -177.722 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 64.51 23.04 68.31 Favored Glycine 0 CA--C 1.534 1.234 0 N-CA-C 111.938 -0.465 . . . . 0.0 111.938 -178.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 15.3 p90 -71.94 166.84 36.72 Favored Pre-proline 0 CA--C 1.543 0.697 0 N-CA-C 106.177 -1.786 . . . . 0.0 106.177 177.231 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -70.38 161.31 88.25 Favored 'Cis proline' 0 N--CA 1.448 -1.201 0 CA-C-N 120.227 1.117 . . . . 0.0 114.928 3.708 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 -150.69 168.28 24.84 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.207 -178.606 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -159.19 177.48 11.01 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 104.029 -2.582 . . . . 0.0 104.029 175.243 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 41.6 t -132.19 119.35 39.8 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 -179.625 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 25.6 t -114.57 122.24 68.29 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.679 0 N-CA-C 105.602 -1.999 . . . . 0.0 105.602 177.501 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 59.5 m-85 -86.32 125.56 33.7 Favored 'General case' 0 N--CA 1.446 -0.668 0 N-CA-C 105.868 -1.901 . . . . 0.0 105.868 177.046 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 12.1 t0 -64.28 103.48 0.64 Allowed 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 123.059 0.543 . . . . 0.0 110.612 -177.616 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.7 pm0 -45.02 -35.47 2.97 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 125.235 1.414 . . . . 0.0 112.994 177.703 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -70.34 -20.73 62.96 Favored 'General case' 0 CA--C 1.536 0.438 0 N-CA-C 113.277 0.843 . . . . 0.0 113.277 -179.545 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -139.81 74.76 1.48 Allowed 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 123.68 0.792 . . . . 0.0 111.659 -177.732 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 30.5 pt -157.25 157.35 30.32 Favored Pre-proline 0 CA--C 1.532 0.253 0 C-N-CA 128.562 2.745 . . . . 0.0 105.67 175.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -58.67 108.98 0.45 Allowed 'Trans proline' 0 N--CA 1.455 -0.738 0 C-N-CA 122.02 1.813 . . . . 0.0 107.996 173.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -35.08 -43.03 0.19 Allowed 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 126.676 1.99 . . . . 0.0 115.605 -177.01 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -58.21 -29.33 62.69 Favored Glycine 0 CA--C 1.533 1.19 0 CA-C-O 119.893 -0.393 . . . . 0.0 113.538 -179.122 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 42.6 t -84.72 108.11 16.45 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.295 0 CA-C-N 118.21 1.005 . . . . 0.0 109.751 -178.451 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -58.27 114.11 2.26 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 122.955 0.502 . . . . 0.0 109.784 177.716 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.76 -40.82 21.76 Favored 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 124.205 1.002 . . . . 0.0 111.499 179.183 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 48.4 t -60.65 -30.06 46.15 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.398 0 C-N-CA 123.123 0.569 . . . . 0.0 111.768 -179.133 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 37.7 mmtm -76.56 -40.98 48.15 Favored 'General case' 0 CA--C 1.528 0.112 0 CA-C-N 118.715 0.688 . . . . 0.0 110.414 -179.084 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 23.1 pt -78.84 -33.65 16.52 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 N-CA-C 112.223 0.453 . . . . 0.0 112.223 -179.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 41.1 m -79.47 162.35 25.51 Favored 'General case' 0 C--N 1.331 -0.203 0 N-CA-C 113.454 0.909 . . . . 0.0 113.454 -178.089 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 2.7 tmm? . . . . . 0 CA--C 1.54 0.576 0 N-CA-C 104.522 -2.399 . . . . 0.0 104.522 175.368 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.443 -0.81 0 CA-C-O 121.241 0.543 . . . . 0.0 110.426 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 81.7 mt -78.5 106.06 10.2 Favored 'General case' 0 N--CA 1.446 -0.629 0 N-CA-C 104.488 -2.412 . . . . 0.0 104.488 177.121 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 13.2 t30 -77.0 -62.2 1.73 Allowed 'General case' 0 CA--C 1.528 0.133 0 N-CA-C 114.932 1.456 . . . . 0.0 114.932 -175.034 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.88 157.02 76.95 Favored Pre-proline 0 CA--C 1.533 0.295 0 C-N-CA 123.056 0.542 . . . . 0.0 111.601 -175.534 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -63.66 164.16 22.09 Favored 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 122.2 1.933 . . . . 0.0 109.433 175.335 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 80.92 -37.61 2.34 Favored Glycine 0 CA--C 1.527 0.783 0 CA-C-O 118.231 -1.316 . . . . 0.0 114.305 176.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 66.7 mt-10 -41.69 126.03 2.91 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 119.079 1.44 . . . . 0.0 112.144 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 16.9 p -109.22 127.61 54.38 Favored 'General case' 0 N--CA 1.455 -0.219 0 C-N-CA 125.481 1.512 . . . . 0.0 112.693 -178.552 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 35.5 t80 -106.45 114.02 27.89 Favored 'General case' 0 N--CA 1.456 -0.159 0 N-CA-C 106.05 -1.833 . . . . 0.0 106.05 174.034 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 15.4 t -100.52 141.23 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.236 0 C-N-CA 123.189 0.596 . . . . 0.0 110.464 -177.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 10.7 p -150.45 141.52 16.6 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.208 0 N-CA-C 108.774 -0.825 . . . . 0.0 108.774 177.308 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 23.7 m -108.46 123.57 49.08 Favored 'General case' 0 CA--C 1.528 0.113 0 C-N-CA 123.752 0.821 . . . . 0.0 108.966 -178.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 36.9 mt -104.56 104.15 13.94 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 118.33 0.514 . . . . 0.0 109.798 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -87.19 -53.52 4.81 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 123.974 0.909 . . . . 0.0 111.602 -179.443 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 4.7 m -66.2 128.41 36.0 Favored 'General case' 0 N--CA 1.455 -0.223 0 O-C-N 121.822 -0.549 . . . . 0.0 111.402 -175.571 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 24.9 mtpp -65.89 161.52 21.01 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 124.787 1.235 . . . . 0.0 110.871 179.648 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 132.66 -137.33 9.32 Favored Glycine 0 C--N 1.335 0.503 0 N-CA-C 110.039 -1.225 . . . . 0.0 110.039 177.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 58.8 m -147.79 141.81 25.95 Favored 'General case' 0 N--CA 1.443 -0.824 0 N-CA-C 105.717 -1.957 . . . . 0.0 105.717 179.65 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 12.1 m-85 -129.61 126.43 38.43 Favored 'General case' 0 N--CA 1.446 -0.675 0 C-N-CA 124.302 1.041 . . . . 0.0 108.821 -177.054 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 74.5 m -95.4 145.67 24.97 Favored 'General case' 0 C--N 1.331 -0.201 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 175.668 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 11.7 p90 -143.49 164.5 30.16 Favored 'General case' 0 N--CA 1.455 -0.191 0 CA-C-O 121.435 0.636 . . . . 0.0 112.369 -179.538 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 53.1 p90 -155.32 160.33 40.66 Favored 'General case' 0 N--CA 1.454 -0.256 0 CA-C-N 115.228 -0.896 . . . . 0.0 112.678 -179.714 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 4.3 t -102.44 100.92 11.08 Favored 'General case' 0 CA--C 1.516 -0.341 0 N-CA-C 105.991 -1.855 . . . . 0.0 105.991 176.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.252 0.0 OUTLIER -38.7 -63.07 0.63 Allowed Pre-proline 0 CA--C 1.538 0.511 0 N-CA-C 114.346 1.239 . . . . 0.0 114.346 -175.019 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_exo -50.53 -18.27 3.67 Favored 'Trans proline' 0 CA--C 1.534 0.501 0 C-N-CA 123.635 2.89 . . . . 0.0 115.748 179.111 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 36.6 m80 -131.63 20.19 4.68 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 119.132 0.878 . . . . 0.0 111.293 -179.044 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 66.2 tt0 -60.07 -49.06 79.13 Favored 'General case' 0 CA--C 1.528 0.13 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.226 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.8 -32.22 61.74 Favored Glycine 0 CA--C 1.531 1.073 0 N-CA-C 111.475 -0.65 . . . . 0.0 111.475 178.066 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -81.79 4.12 23.29 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 123.334 0.654 . . . . 0.0 111.718 179.105 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 84.66 16.01 66.9 Favored Glycine 0 CA--C 1.527 0.798 0 CA-C-O 118.851 -0.972 . . . . 0.0 113.509 178.384 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 19.6 ttt -78.48 78.22 4.95 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 119.509 1.655 . . . . 0.0 108.332 178.491 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 5.9 m -128.43 171.71 16.08 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 C-N-CA 125.802 1.641 . . . . 0.0 110.607 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -175.99 -174.7 42.75 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 109.155 -1.578 . . . . 0.0 109.155 177.618 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 52.2 mttp -151.63 169.77 21.33 Favored 'General case' 0 N--CA 1.453 -0.323 0 C-N-CA 124.064 0.946 . . . . 0.0 109.343 179.8 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.3 p -150.37 139.5 15.27 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.382 0 C-N-CA 123.744 0.818 . . . . 0.0 108.972 177.267 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -100.44 133.51 44.76 Favored 'General case' 0 CA--C 1.529 0.168 0 C-N-CA 124.615 1.166 . . . . 0.0 107.89 179.792 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 31.7 t -115.33 109.72 29.35 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.18 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 178.784 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 48.0 p30 . . . . . 0 C--O 1.231 0.117 0 C-N-CA 124.385 1.074 . . . . 0.0 111.878 -177.0 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 . . . . . 0 N--CA 1.452 -0.339 0 N-CA-C 105.687 -1.968 . . . . 0.0 105.687 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 41.0 t -99.88 125.28 53.59 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.374 0 C-N-CA 124.251 1.02 . . . . 0.0 109.368 -177.273 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 74.8 mt -88.54 119.05 28.63 Favored 'General case' 0 N--CA 1.446 -0.658 0 N-CA-C 108.015 -1.105 . . . . 0.0 108.015 178.264 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 19.8 mt -83.75 101.98 11.96 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 104.841 -2.281 . . . . 0.0 104.841 176.26 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 101.83 -161.34 17.68 Favored Glycine 0 N--CA 1.447 -0.573 0 N-CA-C 108.043 -2.023 . . . . 0.0 108.043 -178.016 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 54.8 p -153.32 150.34 28.81 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 106.665 -1.606 . . . . 0.0 106.665 179.545 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -50.63 -34.79 28.82 Favored Glycine 0 CA--C 1.531 1.069 0 C-N-CA 123.293 0.473 . . . . 0.0 113.09 -179.809 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -74.29 -4.99 39.48 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 123.668 0.787 . . . . 0.0 112.75 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 97.29 -17.3 59.34 Favored Glycine 0 CA--C 1.527 0.839 0 C-N-CA 124.181 0.896 . . . . 0.0 114.091 178.597 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 33.0 t -56.94 135.03 56.06 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 119.217 1.509 . . . . 0.0 111.739 -178.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 91.6 mt -80.09 78.24 6.75 Favored 'General case' 0 N--CA 1.446 -0.655 0 C-N-CA 125.713 1.605 . . . . 0.0 109.819 -178.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.7 p -138.6 159.1 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.303 0 C-N-CA 123.616 0.767 . . . . 0.0 109.524 178.713 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 30.7 m-85 -97.98 124.49 42.48 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 103.521 -2.77 . . . . 0.0 103.521 175.893 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 43.4 t -120.21 109.32 37.18 Favored Pre-proline 0 CA--C 1.537 0.456 0 CA-C-N 119.337 0.972 . . . . 0.0 109.717 -179.34 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -71.01 157.39 95.59 Favored 'Cis proline' 0 N--CA 1.456 -0.679 0 CA-C-N 120.325 1.152 . . . . 0.0 110.732 -1.448 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.4 p -84.11 -62.67 1.51 Allowed 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 107.577 -1.268 . . . . 0.0 107.577 179.253 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 51.1 mt-10 -107.31 127.98 54.04 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 125.367 1.467 . . . . 0.0 107.925 178.345 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 39.1 p90 -151.5 -177.21 5.95 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.875 0.369 . . . . 0.0 111.607 179.749 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 15.1 m -139.54 145.92 39.26 Favored 'General case' 0 N--CA 1.452 -0.362 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 -179.481 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.6 p -156.34 139.61 11.01 Favored Pre-proline 0 CA--C 1.54 0.576 0 CA-C-N 118.914 0.779 . . . . 0.0 109.977 -178.163 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -55.96 146.85 66.44 Favored 'Trans proline' 0 N--CA 1.458 -0.612 0 C-N-CA 122.558 2.172 . . . . 0.0 113.597 177.432 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 21.6 m -56.87 139.76 50.44 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 123.244 0.618 . . . . 0.0 110.464 177.057 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 89.41 -13.91 62.52 Favored Glycine 0 CA--C 1.529 0.922 0 CA-C-O 119.099 -0.834 . . . . 0.0 113.928 177.46 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 72.7 mm-40 -71.56 149.66 45.48 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 119.218 1.509 . . . . 0.0 110.356 178.716 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 1.7 mptm? -90.26 114.89 27.01 Favored 'General case' 0 N--CA 1.453 -0.323 0 C-N-CA 124.3 1.04 . . . . 0.0 109.274 -179.036 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 69.2 mt -86.54 137.13 21.45 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.267 0 N-CA-C 105.403 -2.073 . . . . 0.0 105.403 177.017 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 62.5 t -120.81 107.14 19.88 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.136 0 C-N-CA 124.515 1.126 . . . . 0.0 108.986 -178.021 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -94.31 101.64 13.6 Favored 'General case' 0 CA--C 1.532 0.279 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 178.441 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -97.85 125.81 42.91 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 125.597 1.559 . . . . 0.0 113.11 -176.134 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 8.0 m-20 -63.3 102.61 0.41 Allowed 'General case' 0 N--CA 1.466 0.36 0 C-N-CA 123.306 0.642 . . . . 0.0 110.092 176.55 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -80.01 -57.44 3.64 Favored 'General case' 0 CA--C 1.519 -0.216 0 C-N-CA 123.075 0.55 . . . . 0.0 110.921 -179.364 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -174.44 178.25 2.02 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 126.561 1.944 . . . . 0.0 106.275 -177.414 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 64.38 19.0 63.91 Favored Glycine 0 CA--C 1.536 1.35 0 CA-C-N 119.098 0.863 . . . . 0.0 112.597 -179.555 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 9.0 p90 -74.07 168.8 22.86 Favored Pre-proline 0 CA--C 1.538 0.517 0 N-CA-C 106.233 -1.765 . . . . 0.0 106.233 177.353 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo -63.94 156.82 71.53 Favored 'Cis proline' 0 N--CA 1.454 -0.838 0 N-CA-C 116.507 1.695 . . . . 0.0 116.507 1.568 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -148.97 171.91 15.58 Favored 'General case' 0 C--O 1.221 -0.445 0 O-C-N 121.691 -0.63 . . . . 0.0 111.166 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 31.1 p-10 -166.47 -179.91 5.19 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 104.704 -2.332 . . . . 0.0 104.704 176.452 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 60.9 t -138.7 115.6 10.99 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.229 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 178.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 67.5 t -119.8 132.02 70.69 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.658 0 N-CA-C 105.618 -1.993 . . . . 0.0 105.618 178.326 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 52.9 m-85 -88.01 130.86 34.84 Favored 'General case' 0 N--CA 1.446 -0.633 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 -179.261 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -73.34 100.86 3.28 Favored 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 122.774 0.429 . . . . 0.0 109.861 -178.302 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -40.71 -38.7 0.95 Allowed 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 125.801 1.64 . . . . 0.0 113.639 178.225 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 36.8 t70 -68.26 -26.11 65.51 Favored 'General case' 0 CA--C 1.535 0.398 0 N-CA-C 113.487 0.921 . . . . 0.0 113.487 -179.055 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 40.2 mt-10 -129.49 61.64 1.55 Allowed 'General case' 0 CA--C 1.535 0.38 0 C-N-CA 124.018 0.927 . . . . 0.0 112.384 -176.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 40.5 pt -153.27 157.31 32.9 Favored Pre-proline 0 CA--C 1.531 0.24 0 C-N-CA 127.603 2.361 . . . . 0.0 105.509 174.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_exo -58.88 104.81 0.2 Allowed 'Trans proline' 0 N--CA 1.455 -0.788 0 C-N-CA 121.828 1.685 . . . . 0.0 108.334 173.703 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -35.15 -43.94 0.23 Allowed 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 126.993 2.117 . . . . 0.0 115.368 -176.752 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -55.21 -33.38 57.88 Favored Glycine 0 CA--C 1.533 1.175 0 C-N-CA 123.178 0.418 . . . . 0.0 112.97 -179.619 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 40.4 t -82.12 95.73 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.386 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 -179.244 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 25.2 t0 -49.03 112.48 0.63 Allowed 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 124.24 1.016 . . . . 0.0 110.679 178.819 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -44.73 -44.71 9.42 Favored 'General case' 0 N--CA 1.454 -0.228 0 C-N-CA 125.748 1.619 . . . . 0.0 111.496 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 59.4 t -54.64 -30.56 22.36 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 C-N-CA 123.544 0.738 . . . . 0.0 112.144 -179.085 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -77.53 -34.95 53.77 Favored 'General case' 0 CA--C 1.531 0.22 0 CA-C-N 118.732 0.696 . . . . 0.0 111.788 -178.464 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 25.1 pt -89.02 -26.14 5.57 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 C-N-CA 123.33 0.652 . . . . 0.0 112.375 -179.083 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 49.4 m -88.16 146.59 25.32 Favored 'General case' 0 N--CA 1.454 -0.232 0 N-CA-C 114.132 1.16 . . . . 0.0 114.132 -177.1 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 42.6 mmm . . . . . 0 N--CA 1.451 -0.425 0 N-CA-C 103.713 -2.699 . . . . 0.0 103.713 170.947 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.451 -0.399 0 CA-C-O 121.467 0.651 . . . . 0.0 111.879 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 42.7 mt -82.53 96.12 7.95 Favored 'General case' 0 N--CA 1.447 -0.617 0 C-N-CA 126.548 1.939 . . . . 0.0 106.065 178.242 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 11.9 t30 -79.01 -51.87 9.0 Favored 'General case' 0 C--O 1.225 -0.221 0 N-CA-C 113.204 0.816 . . . . 0.0 113.204 -178.457 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.96 157.73 78.53 Favored Pre-proline 0 CA--C 1.536 0.436 0 C-N-CA 123.475 0.71 . . . . 0.0 112.252 -175.809 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -65.54 165.73 21.92 Favored 'Trans proline' 0 N--CA 1.457 -0.656 0 C-N-CA 122.518 2.145 . . . . 0.0 109.954 175.663 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 79.31 -50.6 3.78 Favored Glycine 0 CA--C 1.526 0.742 0 CA-C-O 118.871 -0.961 . . . . 0.0 113.016 177.076 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 43.3 mm-40 -26.24 118.41 0.07 Allowed 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 126.79 2.036 . . . . 0.0 113.403 -179.424 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 13.3 p -106.54 123.49 48.18 Favored 'General case' 0 N--CA 1.453 -0.292 0 C-N-CA 125.605 1.562 . . . . 0.0 112.827 -178.239 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 19.8 t80 -101.81 115.32 30.29 Favored 'General case' 0 C--O 1.232 0.169 0 N-CA-C 105.835 -1.913 . . . . 0.0 105.835 173.477 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.8 t -100.81 136.88 30.34 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.295 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 -179.606 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.6 p -147.35 150.92 14.19 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.078 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 178.705 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 25.5 m -121.06 130.3 53.71 Favored 'General case' 0 N--CA 1.457 -0.081 0 C-N-CA 124.316 1.046 . . . . 0.0 108.408 -178.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 74.7 mt -113.11 121.32 44.21 Favored 'General case' 0 CA--C 1.53 0.21 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 179.418 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -92.35 -63.22 1.26 Allowed 'General case' 0 CA--C 1.529 0.149 0 C-N-CA 124.152 0.981 . . . . 0.0 112.458 -178.038 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.1 m -65.21 135.1 55.02 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 122.986 0.515 . . . . 0.0 110.318 -174.879 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 61.1 mttp -71.52 156.59 39.25 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 122.998 0.519 . . . . 0.0 111.259 -178.368 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 139.55 175.76 14.41 Favored Glycine 0 CA--C 1.525 0.696 0 C-N-CA 123.558 0.599 . . . . 0.0 111.662 177.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 18.3 m -94.47 112.18 23.95 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 107.51 -1.292 . . . . 0.0 107.51 179.072 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 18.8 m-85 -104.93 125.43 50.93 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 123.686 0.795 . . . . 0.0 109.263 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 7.3 m -98.39 142.12 30.41 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 177.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 12.0 p90 -139.55 163.6 32.13 Favored 'General case' 0 N--CA 1.455 -0.198 0 CA-C-O 121.502 0.668 . . . . 0.0 111.719 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 49.5 p90 -148.99 161.66 41.46 Favored 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 124.855 1.262 . . . . 0.0 111.784 -178.195 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.8 t -105.32 107.48 18.49 Favored 'General case' 0 CA--C 1.522 -0.126 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 177.279 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 1.3 m -41.51 -61.55 1.38 Allowed Pre-proline 0 CA--C 1.535 0.378 0 N-CA-C 115.06 1.504 . . . . 0.0 115.06 -175.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -60.19 -4.84 3.35 Favored 'Trans proline' 0 CA--C 1.536 0.624 0 C-N-CA 121.859 1.706 . . . . 0.0 114.792 -179.042 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 38.7 m80 -134.34 19.67 3.67 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-N 119.73 1.15 . . . . 0.0 110.556 177.443 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 19.6 pt20 -63.35 -42.46 98.9 Favored 'General case' 0 N--CA 1.452 -0.33 0 O-C-N 121.693 -0.629 . . . . 0.0 109.531 179.192 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -61.13 -40.98 99.3 Favored Glycine 0 CA--C 1.529 0.964 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 177.557 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -66.32 -34.14 77.32 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 122.713 0.405 . . . . 0.0 110.117 178.536 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 108.33 31.19 3.59 Favored Glycine 0 CA--C 1.525 0.715 0 C-N-CA 124.287 0.946 . . . . 0.0 112.513 178.072 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -80.18 91.08 5.52 Favored 'General case' 0 C--O 1.237 0.41 0 N-CA-C 106.609 -1.626 . . . . 0.0 106.609 178.122 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 20.1 m -131.12 171.6 17.64 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.246 0 C-N-CA 125.128 1.371 . . . . 0.0 112.15 -177.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -171.27 -179.89 42.66 Favored Glycine 0 CA--C 1.529 0.956 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 177.507 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 81.3 mttt -147.75 155.09 41.33 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-N 117.77 0.785 . . . . 0.0 110.435 -179.657 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 4.3 p -137.75 127.96 36.73 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 C-N-CA 123.938 0.895 . . . . 0.0 109.637 179.197 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -91.99 103.92 16.39 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 107.135 -1.431 . . . . 0.0 107.135 178.736 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 40.0 t -81.37 112.28 19.11 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 N-CA-C 105.386 -2.079 . . . . 0.0 105.386 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 31.1 m120 . . . . . 0 N--CA 1.456 -0.173 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 -178.596 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 . . . . . 0 N--CA 1.455 -0.199 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 43.8 t -118.22 121.83 68.14 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.355 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 179.478 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 36.9 mt -89.62 127.88 35.97 Favored 'General case' 0 N--CA 1.454 -0.262 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 179.247 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 44.1 mt -86.64 96.87 10.26 Favored 'General case' 0 N--CA 1.452 -0.326 0 N-CA-C 106.656 -1.609 . . . . 0.0 106.656 177.822 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 105.39 132.41 7.31 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 -178.679 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 23.9 p -83.0 43.88 0.89 Allowed 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 119.07 1.435 . . . . 0.0 112.802 -178.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.58 -55.14 1.25 Allowed Glycine 0 CA--C 1.527 0.815 0 C-N-CA 126.197 1.856 . . . . 0.0 112.278 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -72.85 34.47 0.07 Allowed 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 126.163 1.785 . . . . 0.0 113.633 -177.554 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 68.08 -13.27 0.74 Allowed Glycine 0 CA--C 1.53 0.996 0 C-N-CA 124.505 1.05 . . . . 0.0 115.035 178.428 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 20.3 t -61.55 129.15 39.72 Favored 'General case' 0 C--N 1.339 0.126 0 CA-C-N 119.328 1.564 . . . . 0.0 109.768 -178.464 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 59.4 mt -75.11 66.76 1.69 Allowed 'General case' 0 N--CA 1.448 -0.534 0 C-N-CA 126.113 1.765 . . . . 0.0 111.857 -175.538 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.8 m -135.06 149.55 29.15 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.182 0 C-N-CA 123.446 0.698 . . . . 0.0 110.856 179.368 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 74.7 m-85 -88.09 135.46 33.41 Favored 'General case' 0 N--CA 1.456 -0.144 0 N-CA-C 105.477 -2.046 . . . . 0.0 105.477 176.549 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 48.4 t -122.67 110.73 31.69 Favored Pre-proline 0 CA--C 1.533 0.305 0 CA-C-O 118.026 -0.987 . . . . 0.0 108.851 178.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -72.87 151.62 97.13 Favored 'Cis proline' 0 N--CA 1.458 -0.565 0 CA-C-N 120.408 1.181 . . . . 0.0 111.175 -0.773 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.2 m -80.66 -48.92 11.92 Favored 'General case' 0 CA--C 1.529 0.161 0 C-N-CA 123.351 0.661 . . . . 0.0 110.799 179.811 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -119.97 129.47 54.32 Favored 'General case' 0 N--CA 1.454 -0.251 0 N-CA-C 105.904 -1.887 . . . . 0.0 105.904 179.821 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 38.2 p90 -157.4 -175.78 5.59 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-N 118.828 0.74 . . . . 0.0 111.963 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 32.9 m -133.97 147.9 51.09 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 125.601 1.561 . . . . 0.0 107.092 178.37 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.4 p -145.71 139.01 14.36 Favored Pre-proline 0 N--CA 1.449 -0.509 0 C-N-CA 123.568 0.747 . . . . 0.0 109.308 -178.156 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 70.7 Cg_exo -53.66 137.26 66.57 Favored 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 122.359 2.039 . . . . 0.0 111.436 177.327 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.6 m -60.13 117.23 4.88 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 179.476 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 109.35 -17.21 31.54 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-O 118.729 -1.039 . . . . 0.0 112.181 -178.119 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -72.17 157.45 37.73 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 119.534 1.667 . . . . 0.0 110.698 179.226 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 57.1 pttt -93.76 135.09 35.42 Favored 'General case' 0 N--CA 1.444 -0.76 0 C-N-CA 124.764 1.226 . . . . 0.0 110.826 -179.695 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 45.6 mt -102.36 130.71 51.81 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.358 0 N-CA-C 104.804 -2.295 . . . . 0.0 104.804 177.055 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 80.6 t -115.27 99.54 8.71 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 C-N-CA 124.819 1.247 . . . . 0.0 108.705 -178.104 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -86.13 103.0 14.37 Favored 'General case' 0 N--CA 1.456 -0.169 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 178.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 60.9 tttp -98.39 128.8 44.95 Favored 'General case' 0 CA--C 1.528 0.131 0 C-N-CA 124.315 1.046 . . . . 0.0 112.27 -177.216 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 38.8 t30 -64.43 110.36 2.25 Favored 'General case' 0 N--CA 1.456 -0.15 0 C-N-CA 123.608 0.763 . . . . 0.0 109.86 177.57 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 59.9 t30 -102.59 -64.74 1.04 Allowed 'General case' 0 C--N 1.339 0.134 0 CA-C-N 118.495 0.589 . . . . 0.0 111.312 -179.207 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -157.17 168.4 27.55 Favored 'General case' 0 C--O 1.226 -0.18 0 C-N-CA 122.869 0.468 . . . . 0.0 111.284 -177.762 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 66.23 24.86 72.19 Favored Glycine 0 CA--C 1.532 1.144 0 O-C-N 121.868 -0.52 . . . . 0.0 112.269 -179.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 10.3 p90 -74.68 169.53 19.42 Favored Pre-proline 0 CA--C 1.543 0.7 0 C-N-CA 125.457 1.503 . . . . 0.0 107.768 179.023 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 95.7 Cg_endo -70.32 162.21 86.17 Favored 'Cis proline' 0 N--CA 1.448 -1.19 0 CA-C-N 120.189 1.103 . . . . 0.0 114.314 2.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 89.9 m-70 -148.9 174.86 11.8 Favored 'General case' 0 C--O 1.22 -0.476 0 O-C-N 121.545 -0.722 . . . . 0.0 111.276 -178.634 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 25.4 p-10 -163.87 179.08 7.3 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 103.858 -2.645 . . . . 0.0 103.858 175.707 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 45.1 t -138.52 117.44 13.81 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.377 0 N-CA-C 107.358 -1.349 . . . . 0.0 107.358 178.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 91.8 t -121.55 138.18 52.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 106.737 -1.579 . . . . 0.0 106.737 178.409 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 76.2 m-85 -97.09 131.82 43.49 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -63.19 116.26 5.26 Favored 'General case' 0 N--CA 1.454 -0.242 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 -178.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.1 pm0 -48.45 -29.57 4.22 Favored 'General case' 0 CA--C 1.533 0.299 0 N-CA-C 115.682 1.734 . . . . 0.0 115.682 -177.719 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 18.0 m-20 -90.07 -52.18 5.08 Favored 'General case' 0 CA--C 1.53 0.178 0 CA-C-N 118.752 0.706 . . . . 0.0 110.101 -179.593 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 80.0 mt-10 -79.92 58.82 3.0 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 124.402 1.081 . . . . 0.0 112.169 -176.721 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 19.2 pt -150.58 151.29 30.45 Favored Pre-proline 0 CA--C 1.532 0.261 0 C-N-CA 127.025 2.13 . . . . 0.0 107.1 176.199 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 21.0 Cg_endo -61.89 117.58 4.43 Favored 'Trans proline' 0 N--CA 1.452 -0.948 0 C-N-CA 121.925 1.75 . . . . 0.0 110.466 178.746 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -46.98 120.91 3.3 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 125.02 1.328 . . . . 0.0 110.963 -179.398 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 126.31 -39.51 1.99 Allowed Glycine 0 CA--C 1.525 0.676 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -178.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 21.7 t -78.28 95.06 1.65 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 53.5 t0 -54.47 114.82 1.81 Allowed 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 123.213 0.605 . . . . 0.0 110.535 179.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -45.44 -43.67 11.59 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 125.554 1.541 . . . . 0.0 111.887 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 55.0 t -57.61 -28.85 32.92 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.344 0 C-N-CA 123.274 0.63 . . . . 0.0 111.805 -178.258 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 28.8 mtpp -79.05 -36.01 41.68 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 118.556 0.616 . . . . 0.0 111.229 -178.723 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 26.2 pt -86.78 -26.11 6.12 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.408 0 C-N-CA 123.201 0.6 . . . . 0.0 112.482 -179.564 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 46.0 m -90.25 148.6 22.8 Favored 'General case' 0 C--N 1.331 -0.2 0 N-CA-C 114.455 1.28 . . . . 0.0 114.455 -176.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 69.5 mmm . . . . . 0 CA--C 1.534 0.358 0 N-CA-C 105.749 -1.945 . . . . 0.0 105.749 173.583 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 2.5 pp . . . . . 0 N--CA 1.451 -0.415 0 CA-C-O 121.198 0.523 . . . . 0.0 111.279 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 37.4 mt -102.51 134.13 46.35 Favored 'General case' 0 N--CA 1.446 -0.662 0 C-N-CA 128.049 2.54 . . . . 0.0 104.598 177.53 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 30.0 t30 -138.77 -46.12 0.49 Allowed 'General case' 0 C--O 1.227 -0.111 0 C-N-CA 122.812 0.445 . . . . 0.0 111.833 -178.029 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -69.95 131.18 89.29 Favored Pre-proline 0 C--O 1.237 0.424 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 -178.575 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -48.56 130.22 21.56 Favored 'Trans proline' 0 N--CA 1.454 -0.823 0 C-N-CA 123.047 2.498 . . . . 0.0 111.538 -179.392 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 99.31 -23.3 36.83 Favored Glycine 0 CA--C 1.525 0.693 0 CA-C-O 117.662 -1.632 . . . . 0.0 114.462 177.627 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 52.4 mt-10 -50.86 125.41 13.36 Favored 'General case' 0 CA--C 1.536 0.438 0 CA-C-N 120.116 1.958 . . . . 0.0 110.849 179.719 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 2.3 p -104.27 140.73 37.44 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 125.514 1.526 . . . . 0.0 112.184 -178.163 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 20.8 t80 -117.79 115.22 24.57 Favored 'General case' 0 C--O 1.232 0.176 0 N-CA-C 104.789 -2.3 . . . . 0.0 104.789 172.259 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.4 t -103.56 139.41 24.57 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.388 0 C-N-CA 123.183 0.593 . . . . 0.0 109.526 -178.497 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.5 p -143.48 156.11 16.61 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 N-CA-C 106.6 -1.63 . . . . 0.0 106.6 176.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 12.5 m -132.29 123.66 27.33 Favored 'General case' 0 C--N 1.333 -0.139 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 -179.286 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 68.1 mt -111.56 102.09 10.45 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 123.254 0.622 . . . . 0.0 109.698 -177.531 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -82.46 -42.73 18.14 Favored 'General case' 0 CA--C 1.529 0.165 0 C-N-CA 124.069 0.947 . . . . 0.0 110.676 178.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 4.4 m -73.21 112.42 9.25 Favored 'General case' 0 N--CA 1.45 -0.458 0 C-N-CA 123.083 0.553 . . . . 0.0 109.87 -177.745 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 25.8 pttm -60.21 152.17 25.35 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 123.077 0.551 . . . . 0.0 111.299 178.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 150.96 -167.94 30.61 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.106 -1.198 . . . . 0.0 110.106 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 23.3 m -113.97 124.71 52.82 Favored 'General case' 0 N--CA 1.454 -0.271 0 N-CA-C 106.435 -1.691 . . . . 0.0 106.435 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -121.01 114.9 22.18 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 124.059 0.944 . . . . 0.0 110.045 -178.164 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 48.7 m -90.51 139.62 30.52 Favored 'General case' 0 C--O 1.233 0.197 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 175.788 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 22.5 p90 -136.41 165.44 25.81 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-O 121.419 0.628 . . . . 0.0 112.071 -179.312 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 49.4 p90 -153.33 161.12 42.69 Favored 'General case' 0 N--CA 1.453 -0.323 0 C-N-CA 124.277 1.031 . . . . 0.0 112.179 -178.498 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 3.7 t -103.1 102.62 12.64 Favored 'General case' 0 CA--C 1.519 -0.239 0 N-CA-C 106.254 -1.758 . . . . 0.0 106.254 176.638 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.263 0.7 OUTLIER -44.67 -56.36 8.67 Favored Pre-proline 0 CA--C 1.535 0.402 0 N-CA-C 113.985 1.106 . . . . 0.0 113.985 -175.131 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_exo -50.93 -18.16 4.07 Favored 'Trans proline' 0 CA--C 1.534 0.514 0 C-N-CA 123.187 2.591 . . . . 0.0 115.042 177.772 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 38.2 m80 -133.85 25.73 3.98 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 123.783 0.833 . . . . 0.0 110.862 -179.599 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 65.7 tt0 -61.61 -50.27 73.27 Favored 'General case' 0 N--CA 1.457 -0.093 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 179.214 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.56 -33.3 62.27 Favored Glycine 0 CA--C 1.532 1.098 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 177.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -79.92 2.17 24.44 Favored 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 123.403 0.681 . . . . 0.0 112.037 179.082 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 79.9 21.84 64.99 Favored Glycine 0 CA--C 1.527 0.832 0 CA-C-O 118.978 -0.901 . . . . 0.0 113.706 178.42 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 22.1 ttt -78.65 80.78 5.0 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 119.321 1.56 . . . . 0.0 107.928 177.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 12.6 m -124.2 170.3 14.54 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.188 0 C-N-CA 125.975 1.71 . . . . 0.0 111.07 -179.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -170.02 178.56 42.8 Favored Glycine 0 CA--C 1.527 0.84 0 N-CA-C 108.848 -1.701 . . . . 0.0 108.848 177.611 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 33.8 mtmm -148.42 149.75 32.28 Favored 'General case' 0 N--CA 1.455 -0.199 0 CA-C-N 118.091 0.946 . . . . 0.0 110.463 -178.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.2 p -135.26 132.17 52.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 C-N-CA 123.121 0.569 . . . . 0.0 109.813 178.132 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.2 m -98.87 103.49 15.45 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 125.05 1.34 . . . . 0.0 107.848 179.341 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 47.0 t -82.59 102.24 8.31 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.753 0 N-CA-C 105.026 -2.213 . . . . 0.0 105.026 -179.189 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 45.5 p-10 . . . . . 0 C--N 1.332 -0.167 0 C-N-CA 124.984 1.314 . . . . 0.0 109.599 -178.059 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 . . . . . 0 N--CA 1.45 -0.466 0 N-CA-C 106.869 -1.53 . . . . 0.0 106.869 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 60.2 t -129.34 126.59 63.98 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 39.7 mt -87.98 122.53 31.7 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 178.763 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 88.9 mt -81.11 100.01 8.81 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 106.248 -1.76 . . . . 0.0 106.248 177.35 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 95.84 137.96 9.5 Favored Glycine 0 C--N 1.336 0.532 0 N-CA-C 107.402 -2.279 . . . . 0.0 107.402 -177.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 80.8 p -78.97 157.97 28.06 Favored 'General case' 0 N--CA 1.438 -1.037 0 CA-C-O 121.985 0.898 . . . . 0.0 109.21 -179.212 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.4 -34.55 59.69 Favored Glycine 0 CA--C 1.531 1.04 0 CA-C-N 114.608 -1.178 . . . . 0.0 111.085 178.162 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -76.03 -3.77 37.65 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 123.573 0.749 . . . . 0.0 112.256 179.074 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 99.76 -21.14 46.39 Favored Glycine 0 CA--C 1.528 0.847 0 CA-C-O 119.007 -0.885 . . . . 0.0 113.451 178.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 33.4 t -56.81 131.99 51.0 Favored 'General case' 0 C--O 1.237 0.442 0 CA-C-N 119.249 1.524 . . . . 0.0 110.426 -179.641 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 56.4 mt -74.06 68.3 1.38 Allowed 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 126.489 1.916 . . . . 0.0 111.114 -176.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.5 m -134.38 152.94 34.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 C-N-CA 123.739 0.816 . . . . 0.0 109.533 178.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 -82.45 135.95 35.02 Favored 'General case' 0 N--CA 1.454 -0.245 0 N-CA-C 105.529 -2.026 . . . . 0.0 105.529 176.625 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 48.0 t -123.92 110.46 29.44 Favored Pre-proline 0 CA--C 1.535 0.397 0 CA-C-O 118.158 -0.925 . . . . 0.0 108.79 179.296 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -70.43 152.28 93.89 Favored 'Cis proline' 0 N--CA 1.459 -0.524 0 CA-C-N 120.361 1.164 . . . . 0.0 111.543 -0.79 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.4 m -82.3 -44.09 16.67 Favored 'General case' 0 CA--C 1.529 0.145 0 C-N-CA 123.784 0.833 . . . . 0.0 111.019 179.721 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 37.8 tt0 -129.68 133.98 47.4 Favored 'General case' 0 N--CA 1.452 -0.33 0 N-CA-C 106.354 -1.721 . . . . 0.0 106.354 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 30.2 p90 -163.23 -179.26 6.49 Favored 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 122.944 0.498 . . . . 0.0 110.251 -179.177 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 17.7 m -128.69 148.43 50.83 Favored 'General case' 0 N--CA 1.455 -0.191 0 N-CA-C 106.932 -1.507 . . . . 0.0 106.932 177.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.8 p -141.61 127.73 11.13 Favored Pre-proline 0 CA--C 1.538 0.496 0 C-N-CA 123.16 0.584 . . . . 0.0 111.35 -177.211 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -55.57 132.21 50.79 Favored 'Trans proline' 0 N--CA 1.452 -0.921 0 C-N-CA 122.327 2.018 . . . . 0.0 110.55 175.336 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 38.2 m -47.73 127.19 11.34 Favored 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 123.118 0.567 . . . . 0.0 110.042 178.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 99.03 -25.98 26.1 Favored Glycine 0 CA--C 1.531 1.054 0 CA-C-O 118.809 -0.995 . . . . 0.0 113.011 -179.591 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 75.4 mt-10 -74.73 100.91 4.13 Favored 'General case' 0 N--CA 1.454 -0.253 0 CA-C-N 119.742 1.771 . . . . 0.0 108.586 178.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 21.5 pttp -51.66 139.56 20.64 Favored 'General case' 0 N--CA 1.45 -0.44 0 C-N-CA 124.795 1.238 . . . . 0.0 113.926 -178.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 38.1 mt -93.54 133.39 34.82 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.405 0 N-CA-C 105.199 -2.149 . . . . 0.0 105.199 176.784 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 60.7 t -119.21 94.76 3.22 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.202 0 C-N-CA 124.453 1.101 . . . . 0.0 108.49 -178.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -83.27 98.94 9.68 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 122.857 0.463 . . . . 0.0 109.948 -179.384 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 24.3 ttmm -88.35 128.47 35.5 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 125.055 1.342 . . . . 0.0 112.114 -177.653 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 4.8 t30 -67.01 93.82 0.3 Allowed 'General case' 0 CA--C 1.534 0.363 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 177.019 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 42.5 t30 -85.39 -75.77 0.35 Allowed 'General case' 0 C--O 1.228 -0.074 0 N-CA-C 113.162 0.801 . . . . 0.0 113.162 -175.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -143.98 163.67 32.82 Favored 'General case' 0 C--O 1.224 -0.277 0 C-N-CA 123.67 0.788 . . . . 0.0 109.79 -176.456 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 63.65 19.59 62.91 Favored Glycine 0 CA--C 1.535 1.297 0 O-C-N 121.906 -0.496 . . . . 0.0 112.697 -179.591 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 16.2 p90 -72.24 166.53 40.53 Favored Pre-proline 0 CA--C 1.546 0.799 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 177.483 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -68.31 158.06 86.79 Favored 'Cis proline' 0 N--CA 1.447 -1.222 0 N-CA-C 115.754 1.405 . . . . 0.0 115.754 4.246 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 88.9 m-70 -150.74 171.32 17.37 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 114.643 -1.162 . . . . 0.0 109.459 -179.422 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 34.9 p-10 -159.61 173.2 16.46 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 104.663 -2.347 . . . . 0.0 104.663 175.423 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 36.8 t -129.19 111.55 23.03 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.245 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 -178.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.9 t -113.36 131.46 65.03 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.579 0 N-CA-C 106.547 -1.649 . . . . 0.0 106.547 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 -97.01 131.56 43.7 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 179.243 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -71.76 109.17 5.47 Favored 'General case' 0 N--CA 1.454 -0.26 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 -179.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -46.27 -31.97 2.82 Favored 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 115.279 1.585 . . . . 0.0 115.279 -178.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 20.0 m-20 -84.31 -17.96 37.85 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-N 118.518 0.599 . . . . 0.0 111.839 -179.356 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -118.91 59.36 0.83 Allowed 'General case' 0 CA--C 1.532 0.259 0 C-N-CA 124.657 1.183 . . . . 0.0 111.087 -177.078 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 25.0 pt -152.68 151.4 26.71 Favored Pre-proline 0 CA--C 1.531 0.24 0 C-N-CA 126.165 1.786 . . . . 0.0 106.224 176.746 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_endo -57.7 118.2 5.03 Favored 'Trans proline' 0 N--CA 1.453 -0.873 0 C-N-CA 122.316 2.01 . . . . 0.0 111.125 179.43 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -47.85 117.72 2.0 Allowed 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 124.996 1.318 . . . . 0.0 110.695 -179.611 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 128.54 -35.98 2.55 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 -178.504 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 34.7 t -77.4 109.27 11.77 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 46.2 t0 -64.29 112.09 2.91 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 122.676 0.39 . . . . 0.0 110.512 179.634 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.1 -40.05 14.54 Favored 'General case' 0 CA--C 1.528 0.106 0 C-N-CA 125.057 1.343 . . . . 0.0 111.626 178.644 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 55.4 t -61.3 -31.13 49.43 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.349 0 C-N-CA 123.348 0.659 . . . . 0.0 111.641 -179.027 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -78.62 -40.72 33.56 Favored 'General case' 0 C--O 1.227 -0.113 0 CA-C-N 118.515 0.598 . . . . 0.0 110.469 -178.7 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 35.4 pt -78.02 -33.74 18.55 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.252 0 N-CA-C 112.566 0.58 . . . . 0.0 112.566 -178.804 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 50.7 m -78.17 139.92 38.98 Favored 'General case' 0 N--CA 1.455 -0.201 0 N-CA-C 112.774 0.657 . . . . 0.0 112.774 -177.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.2 tmt? . . . . . 0 CA--C 1.538 0.513 0 N-CA-C 105.559 -2.015 . . . . 0.0 105.559 176.017 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 96.1 mt . . . . . 0 N--CA 1.454 -0.253 0 N-CA-C 106.588 -1.634 . . . . 0.0 106.588 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 74.8 mt -78.59 102.05 7.75 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 106.114 -1.81 . . . . 0.0 106.114 177.373 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 31.8 p-10 -83.26 -55.46 4.32 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 124.291 1.037 . . . . 0.0 112.311 -177.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.94 149.57 77.1 Favored Pre-proline 0 CA--C 1.533 0.289 0 C-N-CA 123.203 0.601 . . . . 0.0 111.185 -177.59 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -66.87 164.02 31.25 Favored 'Trans proline' 0 N--CA 1.454 -0.799 0 C-N-CA 122.406 2.071 . . . . 0.0 109.804 177.513 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 79.42 -38.77 2.08 Favored Glycine 0 CA--C 1.528 0.862 0 CA-C-O 118.55 -1.139 . . . . 0.0 113.947 176.295 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -39.86 123.91 1.67 Allowed 'General case' 0 CA--C 1.536 0.437 0 CA-C-N 118.495 1.147 . . . . 0.0 111.696 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 18.0 p -105.03 121.04 42.95 Favored 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 124.662 1.185 . . . . 0.0 112.647 -177.701 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 62.3 t80 -95.13 111.4 23.24 Favored 'General case' 0 N--CA 1.454 -0.239 0 N-CA-C 105.367 -2.086 . . . . 0.0 105.367 174.081 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -100.11 139.92 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 C-N-CA 123.219 0.608 . . . . 0.0 110.54 -177.448 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 11.6 p -146.67 139.28 19.64 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.174 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 176.626 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 14.2 m -126.61 99.01 5.62 Favored 'General case' 0 C--N 1.34 0.187 0 C-N-CA 122.918 0.487 . . . . 0.0 112.286 -176.067 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -87.05 130.54 34.44 Favored 'General case' 0 N--CA 1.439 -0.984 0 C-N-CA 123.057 0.543 . . . . 0.0 111.666 178.329 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -100.9 -45.1 5.54 Favored 'General case' 0 N--CA 1.454 -0.227 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 174.549 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 4.6 m -65.52 115.64 5.96 Favored 'General case' 0 N--CA 1.446 -0.652 0 C-N-CA 124.808 1.243 . . . . 0.0 110.192 -178.231 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 25.9 pttm -63.93 153.59 36.53 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-N 115.159 -0.928 . . . . 0.0 110.896 178.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 147.08 -177.51 25.33 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.401 -1.08 . . . . 0.0 110.401 178.392 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 28.7 m -106.49 121.94 45.29 Favored 'General case' 0 N--CA 1.452 -0.327 0 N-CA-C 106.941 -1.503 . . . . 0.0 106.941 -179.024 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 16.4 m-85 -115.07 122.44 46.16 Favored 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 124.594 1.158 . . . . 0.0 109.735 -178.358 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 41.4 m -98.3 132.86 43.44 Favored 'General case' 0 C--O 1.234 0.248 0 N-CA-C 107.635 -1.246 . . . . 0.0 107.635 175.366 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 21.0 p90 -132.62 165.68 23.88 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-O 121.638 0.732 . . . . 0.0 111.842 -179.438 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 52.4 p90 -156.56 161.92 39.94 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 115.226 -0.897 . . . . 0.0 112.561 -178.601 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.7 t -103.36 99.97 9.83 Favored 'General case' 0 CA--C 1.516 -0.333 0 N-CA-C 106.454 -1.684 . . . . 0.0 106.454 177.177 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.281 13.1 p -35.84 -64.31 0.35 Allowed Pre-proline 0 CA--C 1.541 0.63 0 N-CA-C 115.861 1.8 . . . . 0.0 115.861 -175.654 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -60.68 -7.25 6.99 Favored 'Trans proline' 0 C--N 1.348 0.506 0 C-N-CA 122.663 2.242 . . . . 0.0 115.221 -177.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 36.2 m80 -132.09 15.83 4.65 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 119.674 1.125 . . . . 0.0 110.814 178.22 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 65.6 tt0 -59.5 -46.57 88.45 Favored 'General case' 0 CA--C 1.529 0.163 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 178.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -57.07 -30.45 60.63 Favored Glycine 0 CA--C 1.531 1.082 0 C-N-CA 123.588 0.613 . . . . 0.0 111.579 177.613 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -86.08 8.15 21.91 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 123.599 0.759 . . . . 0.0 111.347 178.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 81.67 16.33 73.44 Favored Glycine 0 CA--C 1.527 0.839 0 CA-C-O 118.762 -1.021 . . . . 0.0 113.371 178.722 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 20.0 ttt -78.25 77.12 4.75 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 119.525 1.663 . . . . 0.0 108.925 178.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.7 m -125.8 170.81 15.33 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.314 0 C-N-CA 125.901 1.68 . . . . 0.0 110.052 179.43 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -170.07 177.27 43.5 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 109.262 -1.535 . . . . 0.0 109.262 177.804 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 59.4 mttp -145.98 157.53 43.88 Favored 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 123.401 0.68 . . . . 0.0 109.677 -178.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.2 p -147.25 130.6 8.77 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 C-N-CA 122.689 0.396 . . . . 0.0 110.417 178.007 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 99.1 m -98.49 102.65 14.46 Favored 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 124.171 0.988 . . . . 0.0 108.85 178.579 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 48.8 t -83.2 132.29 31.75 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.444 0 N-CA-C 105.797 -1.927 . . . . 0.0 105.797 178.686 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.334 -0.106 0 CA-C-N 118.395 0.543 . . . . 0.0 111.416 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 . . . . . 0 N--CA 1.452 -0.326 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 28.1 t -110.88 112.25 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.238 0 C-N-CA 123.695 0.798 . . . . 0.0 110.305 -177.505 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 53.6 mt -80.29 123.78 28.27 Favored 'General case' 0 N--CA 1.451 -0.403 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 178.427 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 64.9 mt -87.08 110.73 20.3 Favored 'General case' 0 N--CA 1.447 -0.575 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 178.566 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 84.61 126.37 1.45 Allowed Glycine 0 C--N 1.337 0.594 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.709 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 6.1 p -77.64 161.43 27.81 Favored 'General case' 0 N--CA 1.442 -0.827 0 O-C-N 121.48 -1.012 . . . . 0.0 108.689 -179.099 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -44.32 -38.66 5.18 Favored Glycine 0 CA--C 1.531 1.085 0 C-N-CA 125.777 1.656 . . . . 0.0 113.822 -178.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -76.31 4.08 9.6 Favored 'General case' 0 CA--C 1.537 0.48 0 N-CA-C 113.267 0.84 . . . . 0.0 113.267 -179.647 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 86.73 -6.16 83.33 Favored Glycine 0 CA--C 1.529 0.965 0 CA-C-O 118.92 -0.933 . . . . 0.0 113.105 -179.626 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 20.7 t -61.67 135.81 57.76 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-N 119.233 1.517 . . . . 0.0 110.457 -179.108 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 58.1 mt -75.94 65.93 2.09 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 126.064 1.746 . . . . 0.0 111.465 -176.556 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 28.7 m -130.94 152.5 37.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 C-N-CA 123.772 0.829 . . . . 0.0 110.436 179.547 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 73.3 m-85 -89.34 138.07 31.77 Favored 'General case' 0 N--CA 1.455 -0.222 0 N-CA-C 104.973 -2.232 . . . . 0.0 104.973 176.102 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 52.5 t -125.65 105.64 26.91 Favored Pre-proline 0 CA--C 1.537 0.457 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 179.009 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -68.23 158.44 86.05 Favored 'Cis proline' 0 C--N 1.347 0.466 0 CA-C-N 120.031 1.047 . . . . 0.0 111.799 -1.023 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.7 p -84.77 -63.65 1.3 Allowed 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 125.039 1.336 . . . . 0.0 108.907 179.672 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -117.8 135.66 53.92 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 125.102 1.361 . . . . 0.0 107.435 178.541 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 43.4 p90 -158.59 175.34 13.78 Favored 'General case' 0 C--N 1.333 -0.127 0 CA-C-O 121.22 0.533 . . . . 0.0 111.724 -178.455 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 24.0 p -128.33 147.18 50.61 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 107.19 -1.411 . . . . 0.0 107.19 178.358 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.0 p -149.93 140.46 14.06 Favored Pre-proline 0 CA--C 1.537 0.456 0 CA-C-N 118.843 0.747 . . . . 0.0 110.662 -178.08 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -52.87 138.79 60.76 Favored 'Trans proline' 0 CA--C 1.538 0.706 0 C-N-CA 122.609 2.206 . . . . 0.0 112.44 176.378 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 23.5 m -57.96 131.85 51.66 Favored 'General case' 0 CA--C 1.53 0.191 0 C-N-CA 122.875 0.47 . . . . 0.0 111.125 179.601 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 101.52 -18.1 54.0 Favored Glycine 0 CA--C 1.526 0.774 0 CA-C-O 119.156 -0.802 . . . . 0.0 112.92 179.57 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 81.5 mm-40 -68.7 156.5 38.12 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-N 119.075 1.438 . . . . 0.0 112.823 -179.198 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 24.0 ttmm -91.49 142.05 28.08 Favored 'General case' 0 N--CA 1.452 -0.372 0 C-N-CA 125.965 1.706 . . . . 0.0 110.14 -179.786 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 40.6 mt -120.88 134.42 64.35 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.343 0 N-CA-C 105.929 -1.878 . . . . 0.0 105.929 178.307 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 97.6 t -124.15 101.53 9.25 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 C-N-CA 125.236 1.414 . . . . 0.0 108.571 -177.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -86.25 136.19 33.26 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 106.115 -1.809 . . . . 0.0 106.115 176.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 12.1 tmtt? -135.27 132.46 37.81 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 118.986 0.812 . . . . 0.0 112.4 -177.369 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 6.2 m-20 -66.47 101.4 0.76 Allowed 'General case' 0 C--N 1.341 0.203 0 C-N-CA 123.69 0.796 . . . . 0.0 108.886 177.77 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 38.7 t30 -92.38 -61.84 1.53 Allowed 'General case' 0 N--CA 1.455 -0.224 0 CA-C-O 121.34 0.59 . . . . 0.0 109.951 -179.663 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -150.77 -179.47 7.29 Favored 'General case' 0 C--O 1.223 -0.299 0 C-N-CA 124.065 0.946 . . . . 0.0 108.898 -179.029 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 52.72 17.12 4.41 Favored Glycine 0 CA--C 1.538 1.503 0 N-CA-C 115.534 0.973 . . . . 0.0 115.534 178.574 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 14.5 p90 -73.85 167.62 33.61 Favored Pre-proline 0 CA--C 1.539 0.531 0 N-CA-C 106.921 -1.511 . . . . 0.0 106.921 178.535 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo -63.4 157.87 67.55 Favored 'Cis proline' 0 N--CA 1.454 -0.82 0 N-CA-C 117.407 2.041 . . . . 0.0 117.407 2.638 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 90.8 m-70 -152.47 169.0 23.67 Favored 'General case' 0 N--CA 1.453 -0.3 0 O-C-N 121.598 -0.689 . . . . 0.0 111.638 179.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 51.4 p30 -162.15 178.64 8.59 Favored 'General case' 0 N--CA 1.452 -0.332 0 N-CA-C 104.606 -2.368 . . . . 0.0 104.606 174.707 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 34.8 t -135.46 123.4 37.7 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 71.1 t -123.07 139.27 50.35 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.58 0 N-CA-C 105.558 -2.016 . . . . 0.0 105.558 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -103.99 135.37 45.63 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 108.165 -1.05 . . . . 0.0 108.165 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -66.44 122.08 16.73 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 -179.482 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -74.43 50.2 0.4 Allowed 'General case' 0 CA--C 1.538 0.511 0 N-CA-C 113.956 1.095 . . . . 0.0 113.956 -178.509 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -161.7 -64.79 0.05 Allowed 'General case' 0 N--CA 1.456 -0.129 0 C-N-CA 125.19 1.396 . . . . 0.0 108.987 177.3 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -83.0 63.81 7.28 Favored 'General case' 0 CA--C 1.538 0.496 0 CA-C-O 122.069 0.938 . . . . 0.0 110.274 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 26.8 pt -145.3 153.63 52.54 Favored Pre-proline 0 CA--C 1.536 0.408 0 C-N-CA 129.763 3.225 . . . . 0.0 105.523 177.019 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo -57.92 114.81 2.12 Favored 'Trans proline' 0 N--CA 1.455 -0.79 0 C-N-CA 121.628 1.552 . . . . 0.0 111.699 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -48.11 112.07 0.53 Allowed 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 125.384 1.474 . . . . 0.0 110.735 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 131.12 -34.08 2.69 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 109.721 -1.351 . . . . 0.0 109.721 -178.822 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 42.8 t -77.32 111.48 14.17 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.23 0 CA-C-N 117.565 0.683 . . . . 0.0 109.214 -179.863 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 40.7 t0 -64.23 109.86 2.01 Favored 'General case' 0 CA--C 1.532 0.277 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 178.734 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.51 -38.79 14.68 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 125.131 1.372 . . . . 0.0 111.97 179.508 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 60.0 t -60.63 -28.9 43.73 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.311 0 C-N-CA 123.331 0.653 . . . . 0.0 111.789 -179.109 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 47.1 mmtm -75.84 -40.99 53.73 Favored 'General case' 0 CA--C 1.53 0.197 0 CA-C-N 118.571 0.623 . . . . 0.0 110.688 -178.408 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 21.5 pt -80.68 -38.75 17.67 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.289 0 N-CA-C 112.576 0.584 . . . . 0.0 112.576 -179.463 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 31.5 m -76.9 135.5 38.81 Favored 'General case' 0 N--CA 1.454 -0.252 0 N-CA-C 114.0 1.111 . . . . 0.0 114.0 -176.085 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 84.7 mtp . . . . . 0 N--CA 1.449 -0.524 0 N-CA-C 104.721 -2.326 . . . . 0.0 104.721 173.218 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.444 -0.725 0 CA-C-O 121.463 0.649 . . . . 0.0 110.934 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 47.3 mt -80.69 106.12 12.45 Favored 'General case' 0 N--CA 1.441 -0.885 0 N-CA-C 103.561 -2.755 . . . . 0.0 103.561 177.671 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 29.0 p-10 -89.19 -38.19 14.46 Favored 'General case' 0 C--N 1.332 -0.16 0 C-N-CA 124.803 1.241 . . . . 0.0 113.153 -176.732 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.68 155.89 45.38 Favored Pre-proline 0 CA--C 1.534 0.344 0 C-N-CA 123.895 0.878 . . . . 0.0 110.882 -178.054 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -66.11 164.68 26.78 Favored 'Trans proline' 0 N--CA 1.456 -0.702 0 C-N-CA 122.419 2.079 . . . . 0.0 109.753 176.629 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 79.73 -44.03 2.69 Favored Glycine 0 CA--C 1.528 0.86 0 CA-C-O 118.78 -1.011 . . . . 0.0 113.59 176.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 53.7 mt-10 -41.19 134.03 2.2 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 124.959 1.304 . . . . 0.0 111.686 -179.399 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 69.0 p -114.18 167.71 10.45 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 123.826 0.85 . . . . 0.0 113.268 -177.147 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 3.7 t80 -140.65 114.41 8.9 Favored 'General case' 0 N--CA 1.455 -0.213 0 N-CA-C 103.849 -2.649 . . . . 0.0 103.849 174.717 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 41.3 t -106.82 144.78 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.296 0 C-N-CA 123.703 0.801 . . . . 0.0 109.638 -177.4 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 13.7 p -152.02 167.25 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.204 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 177.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 57.2 m -145.88 122.72 11.28 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 105.765 -1.939 . . . . 0.0 105.765 179.49 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 66.3 mt -107.08 99.56 9.1 Favored 'General case' 0 N--CA 1.455 -0.192 0 CA-C-O 121.303 0.573 . . . . 0.0 111.389 -175.168 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -77.14 -47.14 21.2 Favored 'General case' 0 N--CA 1.455 -0.217 0 C-N-CA 123.835 0.854 . . . . 0.0 110.539 178.143 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.7 m -72.48 122.82 21.93 Favored 'General case' 0 N--CA 1.451 -0.382 0 C-N-CA 123.012 0.525 . . . . 0.0 110.599 -177.664 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 50.6 tttm -67.02 155.18 39.32 Favored 'General case' 0 N--CA 1.436 -1.168 0 C-N-CA 126.906 2.082 . . . . 0.0 110.316 179.177 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 132.8 178.24 15.42 Favored Glycine 0 CA--C 1.526 0.761 0 C-N-CA 124.798 1.19 . . . . 0.0 111.378 178.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 74.7 m -102.13 119.83 39.44 Favored 'General case' 0 CA--C 1.52 -0.201 0 C-N-CA 124.119 0.968 . . . . 0.0 108.756 -179.283 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 37.2 m-85 -105.92 112.65 25.79 Favored 'General case' 0 N--CA 1.445 -0.681 0 C-N-CA 125.794 1.638 . . . . 0.0 109.833 -179.035 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 4.1 m -85.87 128.7 34.88 Favored 'General case' 0 C--O 1.234 0.28 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 177.368 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 35.4 p90 -132.19 167.65 19.42 Favored 'General case' 0 N--CA 1.457 -0.1 0 CA-C-O 121.822 0.82 . . . . 0.0 112.562 -179.142 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 50.5 p90 -159.96 162.48 34.41 Favored 'General case' 0 N--CA 1.452 -0.372 0 CA-C-N 114.977 -1.01 . . . . 0.0 111.569 -179.37 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.2 t -99.6 102.9 14.55 Favored 'General case' 0 CA--C 1.518 -0.279 0 N-CA-C 106.575 -1.639 . . . . 0.0 106.575 177.52 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.312 16.9 p -40.44 -61.2 1.25 Allowed Pre-proline 0 CA--C 1.538 0.518 0 N-CA-C 115.795 1.776 . . . . 0.0 115.795 -174.489 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -60.12 -6.09 4.66 Favored 'Trans proline' 0 CA--C 1.537 0.638 0 C-N-CA 122.208 1.939 . . . . 0.0 114.924 -178.751 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 35.8 m80 -134.43 14.24 3.78 Favored 'General case' 0 CA--C 1.532 0.254 0 CA-C-N 119.694 1.134 . . . . 0.0 111.355 178.671 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 16.6 pt20 -60.66 -42.83 97.82 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 119.147 0.885 . . . . 0.0 109.217 179.259 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -58.48 -31.39 66.61 Favored Glycine 0 CA--C 1.531 1.071 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 177.18 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -85.12 5.25 30.61 Favored 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 123.556 0.743 . . . . 0.0 111.333 178.91 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 83.89 17.24 65.89 Favored Glycine 0 CA--C 1.528 0.849 0 CA-C-O 118.795 -1.003 . . . . 0.0 113.591 178.726 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 21.8 ttt -78.72 77.16 5.21 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 119.593 1.696 . . . . 0.0 108.494 178.144 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 11.6 m -120.24 169.95 10.69 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 C-N-CA 125.984 1.714 . . . . 0.0 110.404 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -169.45 174.19 43.79 Favored Glycine 0 CA--C 1.527 0.83 0 N-CA-C 109.108 -1.597 . . . . 0.0 109.108 178.112 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 54.2 mttp -149.4 139.04 21.71 Favored 'General case' 0 C--O 1.231 0.083 0 CA-C-N 118.173 0.986 . . . . 0.0 109.756 -178.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 6.0 p -125.66 120.17 56.83 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.139 0 CA-C-O 120.921 0.391 . . . . 0.0 110.519 178.798 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 48.6 m -94.22 100.58 12.63 Favored 'General case' 0 N--CA 1.455 -0.203 0 C-N-CA 124.68 1.192 . . . . 0.0 109.342 178.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 44.7 t -79.69 107.09 11.73 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.012 0 N-CA-C 104.397 -2.445 . . . . 0.0 104.397 179.536 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 51.1 p-10 . . . . . 0 N--CA 1.456 -0.16 0 C-N-CA 125.157 1.383 . . . . 0.0 110.291 -177.034 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 . . . . . 0 N--CA 1.453 -0.294 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 47.1 t -112.24 111.0 34.28 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 105.855 -1.906 . . . . 0.0 105.855 178.517 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 31.7 mt -90.46 120.4 31.54 Favored 'General case' 0 N--CA 1.45 -0.462 0 O-C-N 121.822 -0.549 . . . . 0.0 109.706 -178.68 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -79.47 106.88 11.82 Favored 'General case' 0 N--CA 1.444 -0.738 0 N-CA-C 105.909 -1.886 . . . . 0.0 105.909 174.378 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 97.03 132.8 7.54 Favored Glycine 0 CA--C 1.523 0.586 0 C-N-CA 125.871 1.701 . . . . 0.0 112.329 178.666 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.6 p -82.78 47.87 1.26 Allowed 'General case' 0 N--CA 1.456 -0.135 0 C-N-CA 124.43 1.092 . . . . 0.0 111.197 179.325 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 70.74 -52.2 0.91 Allowed Glycine 0 CA--C 1.527 0.781 0 C-N-CA 126.598 2.047 . . . . 0.0 113.078 -179.668 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -72.1 38.07 0.07 Allowed 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 126.05 1.74 . . . . 0.0 113.851 -177.298 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 59.17 3.04 1.62 Allowed Glycine 0 CA--C 1.531 1.075 0 N-CA-C 115.911 1.124 . . . . 0.0 115.911 178.569 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 27.7 t -64.31 145.45 56.0 Favored 'General case' 0 N--CA 1.455 -0.181 0 CA-C-N 119.131 1.465 . . . . 0.0 110.87 -178.661 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 93.0 mt -86.43 73.26 10.16 Favored 'General case' 0 N--CA 1.447 -0.58 0 C-N-CA 124.044 0.938 . . . . 0.0 109.482 -178.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.9 m -137.01 143.97 33.4 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.217 0 C-N-CA 123.05 0.54 . . . . 0.0 111.204 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -90.27 122.84 33.55 Favored 'General case' 0 N--CA 1.46 0.051 0 N-CA-C 103.695 -2.706 . . . . 0.0 103.695 174.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.8 t -113.94 100.56 52.62 Favored Pre-proline 0 CA--C 1.536 0.422 0 CA-C-O 118.237 -0.887 . . . . 0.0 109.984 -179.271 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -81.01 164.24 78.26 Favored 'Cis proline' 0 N--CA 1.46 -0.463 0 CA-C-N 120.605 1.252 . . . . 0.0 111.257 -1.618 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 15.7 p -92.61 -62.86 1.31 Allowed 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 107.576 -1.268 . . . . 0.0 107.576 177.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 10.8 mp0 -98.21 126.85 43.85 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 125.835 1.654 . . . . 0.0 107.532 178.428 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.9 p90 -160.55 -175.57 5.08 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-O 121.541 0.686 . . . . 0.0 111.847 179.631 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 35.3 m -135.97 146.07 46.85 Favored 'General case' 0 N--CA 1.45 -0.426 0 N-CA-C 106.204 -1.776 . . . . 0.0 106.204 178.245 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 1.4 p -147.21 140.56 15.02 Favored Pre-proline 0 N--CA 1.449 -0.496 0 CA-C-O 118.367 -0.825 . . . . 0.0 109.631 -178.343 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_exo -60.71 144.13 99.5 Favored 'Trans proline' 0 N--CA 1.456 -0.689 0 C-N-CA 121.671 1.58 . . . . 0.0 112.678 179.411 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.2 m -56.35 128.0 33.7 Favored 'General case' 0 N--CA 1.454 -0.233 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 176.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.76 -3.57 78.1 Favored Glycine 0 CA--C 1.526 0.719 0 CA-C-O 119.012 -0.882 . . . . 0.0 112.198 179.35 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -70.64 149.3 47.17 Favored 'General case' 0 CA--C 1.534 0.361 0 CA-C-N 119.033 1.417 . . . . 0.0 109.124 178.025 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -90.44 105.09 17.58 Favored 'General case' 0 N--CA 1.447 -0.582 0 C-N-CA 124.868 1.267 . . . . 0.0 108.585 -178.563 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 34.6 mt -81.09 130.7 35.43 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.343 0 N-CA-C 105.381 -2.081 . . . . 0.0 105.381 177.364 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 67.9 t -117.69 97.58 5.58 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 C-N-CA 124.904 1.281 . . . . 0.0 108.665 -178.439 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -84.47 97.16 9.38 Favored 'General case' 0 N--CA 1.456 -0.158 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 178.011 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 28.4 ttpp -99.3 129.29 45.5 Favored 'General case' 0 CA--C 1.528 0.126 0 C-N-CA 123.746 0.818 . . . . 0.0 112.691 -176.444 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 5.2 m-20 -69.63 105.3 2.64 Favored 'General case' 0 N--CA 1.455 -0.2 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 177.456 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 51.5 t30 -89.17 -57.42 2.9 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 178.466 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -164.37 175.28 10.14 Favored 'General case' 0 CA--C 1.529 0.167 0 C-N-CA 124.095 0.958 . . . . 0.0 109.328 179.802 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 71.09 16.07 74.78 Favored Glycine 0 CA--C 1.531 1.084 0 O-C-N 121.753 -0.592 . . . . 0.0 113.095 179.19 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 21.5 p90 -67.77 166.4 23.24 Favored Pre-proline 0 CA--C 1.545 0.785 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 178.178 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -69.7 151.4 91.26 Favored 'Cis proline' 0 N--CA 1.447 -1.23 0 N-CA-C 116.395 1.652 . . . . 0.0 116.395 5.161 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 88.8 m-70 -144.93 156.92 44.24 Favored 'General case' 0 N--CA 1.451 -0.387 0 O-C-N 121.695 -0.628 . . . . 0.0 111.093 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 56.6 p30 -158.18 175.52 13.66 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 103.966 -2.605 . . . . 0.0 103.966 175.287 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 42.0 t -137.98 121.08 20.12 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.36 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 -179.027 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 95.9 t -117.33 131.9 68.69 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.621 0 N-CA-C 105.83 -1.915 . . . . 0.0 105.83 178.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -96.91 131.2 43.92 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 107.24 -1.393 . . . . 0.0 107.24 179.425 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 35.6 t0 -67.21 108.74 2.81 Favored 'General case' 0 N--CA 1.451 -0.393 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 -179.131 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -47.82 -31.33 4.84 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.028 0.931 . . . . 0.0 113.45 178.865 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 34.4 t70 -75.74 -22.38 56.57 Favored 'General case' 0 CA--C 1.536 0.426 0 N-CA-C 112.741 0.645 . . . . 0.0 112.741 179.563 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -128.39 68.07 1.37 Allowed 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 124.453 1.101 . . . . 0.0 111.791 -177.042 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 31.8 pt -153.67 157.34 32.66 Favored Pre-proline 0 CA--C 1.535 0.371 0 C-N-CA 127.884 2.474 . . . . 0.0 105.79 175.825 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_exo -56.33 115.62 2.6 Favored 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.559 2.173 . . . . 0.0 111.07 178.391 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.34 107.33 0.27 Allowed 'General case' 0 N--CA 1.455 -0.178 0 C-N-CA 123.608 0.763 . . . . 0.0 109.676 179.569 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 137.79 -32.29 2.39 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 -177.805 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 57.3 t -76.84 107.37 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.262 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 179.354 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 45.0 t0 -57.99 108.15 0.56 Allowed 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 123.252 0.621 . . . . 0.0 110.777 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.63 -38.6 32.77 Favored 'General case' 0 C--O 1.223 -0.295 0 C-N-CA 123.73 0.812 . . . . 0.0 111.228 178.883 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 46.7 t -58.67 -27.22 33.76 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 CA-C-N 118.071 0.396 . . . . 0.0 111.863 -179.44 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 44.0 mmtm -82.55 -41.93 18.98 Favored 'General case' 0 CA--C 1.529 0.172 0 CA-C-N 118.611 0.641 . . . . 0.0 110.839 -179.392 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 24.6 pt -78.03 -46.9 25.83 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.29 0 N-CA-C 112.005 0.372 . . . . 0.0 112.005 -179.29 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 60.7 m -73.22 128.41 35.4 Favored 'General case' 0 N--CA 1.451 -0.422 0 C-N-CA 124.224 1.01 . . . . 0.0 113.01 -176.018 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 88.4 mmm . . . . . 0 N--CA 1.451 -0.422 0 N-CA-C 105.401 -2.074 . . . . 0.0 105.401 174.661 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.448 -0.555 0 CA-C-O 121.713 0.768 . . . . 0.0 112.292 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 63.0 mt -79.02 106.03 10.77 Favored 'General case' 0 N--CA 1.444 -0.749 0 N-CA-C 104.862 -2.273 . . . . 0.0 104.862 178.151 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 65.6 t30 -112.29 42.14 1.86 Allowed 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 124.259 1.024 . . . . 0.0 112.747 -177.732 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -158.0 158.26 29.97 Favored Pre-proline 0 C--O 1.233 0.186 0 N-CA-C 107.045 -1.465 . . . . 0.0 107.045 178.366 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 96.8 Cg_endo -73.92 167.78 26.39 Favored 'Trans proline' 0 N--CA 1.451 -0.999 0 C-N-CA 121.542 1.495 . . . . 0.0 109.313 178.242 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 78.63 -42.65 2.26 Favored Glycine 0 CA--C 1.527 0.84 0 CA-C-O 118.74 -1.033 . . . . 0.0 114.411 175.756 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 47.7 mt-10 -42.4 131.57 3.69 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 118.494 1.147 . . . . 0.0 112.442 -179.609 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 20.8 p -118.33 127.4 53.66 Favored 'General case' 0 N--CA 1.457 -0.122 0 N-CA-C 113.675 0.991 . . . . 0.0 113.675 -178.554 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 2.4 t80 -100.15 107.16 18.97 Favored 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 103.682 -2.71 . . . . 0.0 103.682 172.367 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 38.8 t -100.08 140.11 19.99 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.162 0 C-N-CA 123.415 0.686 . . . . 0.0 109.674 -178.026 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.2 p -150.31 135.03 9.69 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.254 0 C-N-CA 122.766 0.426 . . . . 0.0 110.319 177.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 19.7 m -103.57 100.4 10.24 Favored 'General case' 0 CA--C 1.53 0.207 0 C-N-CA 124.59 1.156 . . . . 0.0 109.0 -179.595 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 59.5 mt -90.19 99.73 12.69 Favored 'General case' 0 CA--C 1.53 0.192 0 CA-C-O 121.074 0.464 . . . . 0.0 109.82 -179.555 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -79.13 -55.34 5.18 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 123.216 0.606 . . . . 0.0 111.27 178.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.5 m -64.58 119.48 10.56 Favored 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 123.386 0.674 . . . . 0.0 110.388 -176.119 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.86 161.5 20.98 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 123.449 0.7 . . . . 0.0 112.373 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 133.87 178.77 15.83 Favored Glycine 0 CA--C 1.525 0.718 0 C-N-CA 125.565 1.555 . . . . 0.0 110.74 178.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 7.4 m -96.29 114.55 26.24 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 124.417 1.087 . . . . 0.0 109.336 -178.531 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 29.8 m-85 -105.09 111.05 23.67 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 124.684 1.193 . . . . 0.0 109.217 179.73 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 18.3 m -88.01 137.58 32.21 Favored 'General case' 0 C--O 1.232 0.172 0 N-CA-C 107.517 -1.29 . . . . 0.0 107.517 177.379 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 28.5 p90 -140.95 167.24 22.67 Favored 'General case' 0 C--N 1.339 0.124 0 CA-C-N 119.06 0.845 . . . . 0.0 113.266 -178.177 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 53.7 p90 -154.31 160.49 41.77 Favored 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 114.924 -1.034 . . . . 0.0 112.202 -179.658 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.6 t -104.24 99.31 9.03 Favored 'General case' 0 CA--C 1.519 -0.241 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 177.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -33.79 -62.99 0.33 Allowed Pre-proline 0 CA--C 1.537 0.45 0 N-CA-C 115.927 1.825 . . . . 0.0 115.927 -176.296 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -60.4 -7.04 6.19 Favored 'Trans proline' 0 C--N 1.348 0.546 0 C-N-CA 122.307 2.005 . . . . 0.0 114.92 -177.558 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 36.3 m80 -135.62 14.65 3.42 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 119.416 1.007 . . . . 0.0 111.124 178.505 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 14.6 pt20 -61.04 -41.24 96.2 Favored 'General case' 0 N--CA 1.454 -0.262 0 O-C-N 121.442 -0.786 . . . . 0.0 109.489 179.531 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -58.46 -29.45 63.59 Favored Glycine 0 CA--C 1.532 1.119 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 177.039 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.91 11.86 19.13 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 123.804 0.842 . . . . 0.0 110.864 178.798 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 74.47 21.87 78.18 Favored Glycine 0 CA--C 1.527 0.8 0 CA-C-O 119.112 -0.826 . . . . 0.0 113.171 178.877 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -78.86 80.55 5.2 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 119.255 1.528 . . . . 0.0 107.464 178.156 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 12.4 m -123.49 171.76 11.94 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 C-N-CA 125.579 1.552 . . . . 0.0 111.691 -178.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -167.12 178.79 41.15 Favored Glycine 0 CA--C 1.529 0.948 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 178.18 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 39.1 ttpt -158.48 130.57 6.82 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 -178.518 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.7 p -119.25 128.27 75.83 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 CA-C-O 121.391 0.615 . . . . 0.0 110.346 -178.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.4 m -94.37 98.78 11.13 Favored 'General case' 0 N--CA 1.452 -0.336 0 N-CA-C 107.514 -1.291 . . . . 0.0 107.514 179.151 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 45.2 t -80.31 114.28 20.97 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.587 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 -178.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 77.7 m-20 . . . . . 0 C--O 1.233 0.212 0 C-N-CA 123.664 0.785 . . . . 0.0 109.085 -178.112 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 36.4 mt-10 . . . . . 0 N--CA 1.451 -0.378 0 N-CA-C 105.612 -1.996 . . . . 0.0 105.612 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 28.3 t -87.22 119.29 34.69 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.454 0 CA-C-N 114.968 -1.015 . . . . 0.0 108.923 -176.757 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 58.1 mt -88.27 121.47 30.7 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 179.189 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -78.01 103.18 7.78 Favored 'General case' 0 N--CA 1.445 -0.685 0 N-CA-C 105.815 -1.92 . . . . 0.0 105.815 173.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 97.1 152.31 28.6 Favored Glycine 0 N--CA 1.446 -0.675 0 C-N-CA 123.91 0.766 . . . . 0.0 111.331 179.083 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 78.9 p -85.59 173.46 10.15 Favored 'General case' 0 N--CA 1.44 -0.938 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 177.783 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -52.51 -43.94 58.97 Favored Glycine 0 CA--C 1.531 1.07 0 N-CA-C 111.265 -0.734 . . . . 0.0 111.265 178.679 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -79.81 11.78 3.05 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 123.362 0.665 . . . . 0.0 112.316 178.76 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 69.44 27.46 73.51 Favored Glycine 0 CA--C 1.524 0.639 0 CA-C-O 119.07 -0.85 . . . . 0.0 114.009 178.712 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 27.1 t -73.42 145.21 45.98 Favored 'General case' 0 C--N 1.34 0.155 0 N-CA-C 106.084 -1.821 . . . . 0.0 106.084 176.899 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 76.1 mt -76.12 64.75 2.01 Favored 'General case' 0 N--CA 1.449 -0.482 0 C-N-CA 124.363 1.065 . . . . 0.0 111.798 -176.102 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.2 m -132.89 139.45 49.6 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.215 0 C-N-CA 124.069 0.948 . . . . 0.0 111.268 -179.124 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 36.2 m-85 -82.83 129.52 35.01 Favored 'General case' 0 C--O 1.232 0.171 0 N-CA-C 104.314 -2.476 . . . . 0.0 104.314 175.201 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 25.2 t -117.84 105.2 47.93 Favored Pre-proline 0 CA--C 1.535 0.368 0 CA-C-O 118.168 -0.92 . . . . 0.0 108.963 179.561 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -75.13 164.81 87.47 Favored 'Cis proline' 0 C--N 1.348 0.518 0 CA-C-N 120.482 1.208 . . . . 0.0 111.505 -1.332 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 7.0 p -90.4 -62.29 1.49 Allowed 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 125.352 1.461 . . . . 0.0 108.655 179.207 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -106.42 137.48 44.32 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 126.313 1.845 . . . . 0.0 106.366 177.174 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 18.0 p90 -163.63 -174.73 3.82 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 118.38 0.536 . . . . 0.0 110.871 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 24.2 m -140.1 149.19 42.77 Favored 'General case' 0 N--CA 1.455 -0.212 0 C-N-CA 124.783 1.233 . . . . 0.0 108.813 -178.636 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 29.0 m -148.88 151.68 35.45 Favored Pre-proline 0 N--CA 1.463 0.2 0 C-N-CA 123.585 0.754 . . . . 0.0 110.332 -179.695 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -70.94 150.19 60.63 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 C-N-CA 121.778 1.652 . . . . 0.0 110.135 176.309 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 60.0 m -55.04 118.84 4.66 Favored 'General case' 0 CA--C 1.53 0.187 0 C-N-CA 123.308 0.643 . . . . 0.0 109.329 177.754 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 106.01 -5.6 39.51 Favored Glycine 0 CA--C 1.528 0.894 0 CA-C-O 118.877 -0.957 . . . . 0.0 112.802 -179.159 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -59.58 136.3 57.94 Favored 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 119.41 1.605 . . . . 0.0 110.623 179.374 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -90.98 93.15 9.07 Favored 'General case' 0 N--CA 1.445 -0.7 0 N-CA-C 106.013 -1.847 . . . . 0.0 106.013 177.457 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 63.4 mt -75.2 137.84 22.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 -178.616 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 67.9 t -115.75 102.41 13.67 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.296 0 C-N-CA 124.659 1.184 . . . . 0.0 108.479 -178.239 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -90.16 101.62 14.33 Favored 'General case' 0 CA--C 1.53 0.177 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 177.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 26.7 ttpp -99.99 129.54 46.07 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 124.774 1.229 . . . . 0.0 112.633 -176.596 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 39.6 t30 -66.82 115.35 6.5 Favored 'General case' 0 CA--C 1.528 0.098 0 CA-C-O 118.805 -0.617 . . . . 0.0 110.342 177.856 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 43.6 t30 -97.04 -73.82 0.59 Allowed 'General case' 0 N--CA 1.457 -0.114 0 CA-C-O 121.111 0.481 . . . . 0.0 110.664 179.835 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -157.95 170.97 21.12 Favored 'General case' 0 C--N 1.332 -0.183 0 C-N-CA 124.783 1.233 . . . . 0.0 108.16 -177.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 71.59 17.57 76.54 Favored Glycine 0 CA--C 1.534 1.263 0 O-C-N 121.487 -0.758 . . . . 0.0 112.252 -178.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 7.4 p90 -72.09 170.49 12.39 Favored Pre-proline 0 CA--C 1.54 0.559 0 C-N-CA 125.946 1.698 . . . . 0.0 107.77 178.59 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_exo -64.99 152.07 76.22 Favored 'Cis proline' 0 N--CA 1.451 -0.982 0 N-CA-C 115.581 1.339 . . . . 0.0 115.581 2.19 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 87.6 m-70 -141.74 170.11 16.34 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 123.311 0.645 . . . . 0.0 109.485 179.235 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 46.7 p30 -168.71 177.4 5.14 Favored 'General case' 0 N--CA 1.451 -0.423 0 N-CA-C 104.109 -2.552 . . . . 0.0 104.109 175.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 39.6 t -135.95 112.43 13.09 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.274 0 N-CA-C 107.262 -1.384 . . . . 0.0 107.262 -179.063 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 48.4 t -116.96 133.35 63.96 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 N-CA-C 105.98 -1.859 . . . . 0.0 105.98 -179.141 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 55.0 m-85 -93.69 142.69 27.07 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -179.138 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -74.62 97.95 3.29 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.749 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -39.89 -35.97 0.41 Allowed 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 125.842 1.657 . . . . 0.0 115.324 -179.234 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -82.77 -27.64 30.88 Favored 'General case' 0 CA--C 1.535 0.375 0 N-CA-C 112.607 0.595 . . . . 0.0 112.607 -179.715 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 47.5 tt0 -112.22 61.28 0.63 Allowed 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 124.62 1.168 . . . . 0.0 111.438 -176.475 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 36.8 pt -157.01 158.3 31.12 Favored Pre-proline 0 CA--C 1.535 0.374 0 C-N-CA 128.468 2.707 . . . . 0.0 105.721 176.817 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -55.4 111.94 0.9 Allowed 'Trans proline' 0 N--CA 1.456 -0.717 0 C-N-CA 122.498 2.132 . . . . 0.0 109.59 175.537 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -33.08 -48.47 0.22 Allowed 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 126.855 2.062 . . . . 0.0 115.619 -177.517 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -58.87 -29.12 64.28 Favored Glycine 0 CA--C 1.533 1.182 0 O-C-N 122.131 -0.356 . . . . 0.0 113.78 -178.457 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 43.1 t -82.19 96.28 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 CA-C-N 118.154 0.977 . . . . 0.0 109.759 -178.193 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 6.7 t0 -52.77 116.71 2.46 Favored 'General case' 0 CA--C 1.535 0.392 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 176.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -46.77 -38.51 10.18 Favored 'General case' 0 N--CA 1.456 -0.17 0 C-N-CA 126.085 1.754 . . . . 0.0 112.552 -178.734 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 59.9 t -59.54 -28.17 39.31 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 C-N-CA 123.006 0.522 . . . . 0.0 111.443 -179.276 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 41.7 mtmt -74.28 -45.57 46.86 Favored 'General case' 0 CA--C 1.528 0.125 0 O-C-N 121.666 -0.646 . . . . 0.0 110.602 -179.111 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 25.6 pt -79.59 -32.81 14.72 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 N-CA-C 113.008 0.744 . . . . 0.0 113.008 -177.766 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 47.1 m -77.39 130.54 37.23 Favored 'General case' 0 N--CA 1.452 -0.327 0 C-N-CA 123.148 0.579 . . . . 0.0 112.035 -178.034 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.5 tmt? . . . . . 0 N--CA 1.449 -0.508 0 N-CA-C 104.869 -2.271 . . . . 0.0 104.869 175.738 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 5.1 mp . . . . . 0 N--CA 1.451 -0.397 0 CA-C-O 121.378 0.609 . . . . 0.0 110.745 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 59.9 mt -80.67 93.42 6.15 Favored 'General case' 0 N--CA 1.444 -0.735 0 N-CA-C 103.046 -2.946 . . . . 0.0 103.046 174.01 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -109.65 -42.2 4.36 Favored 'General case' 0 C--N 1.333 -0.116 0 C-N-CA 124.273 1.029 . . . . 0.0 111.22 -176.736 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.27 134.61 73.63 Favored Pre-proline 0 C--O 1.236 0.356 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 -178.694 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_exo -50.7 132.51 36.56 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 C-N-CA 122.571 2.181 . . . . 0.0 110.903 179.776 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 92.73 -15.09 63.42 Favored Glycine 0 CA--C 1.527 0.821 0 CA-C-O 117.325 -1.82 . . . . 0.0 115.782 176.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -52.76 125.54 17.12 Favored 'General case' 0 CA--C 1.537 0.457 0 CA-C-N 121.045 2.423 . . . . 0.0 110.923 179.302 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 12.1 p -105.26 122.46 45.98 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 125.827 1.651 . . . . 0.0 112.395 -178.725 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 54.3 t80 -103.85 108.35 19.64 Favored 'General case' 0 N--CA 1.454 -0.235 0 N-CA-C 105.984 -1.858 . . . . 0.0 105.984 174.301 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 15.8 t -96.65 136.93 25.84 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 -178.609 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.5 p -145.51 127.06 8.29 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.404 0 CA-C-N 118.428 0.558 . . . . 0.0 110.97 178.628 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 7.9 m -88.73 101.97 14.53 Favored 'General case' 0 CA--C 1.53 0.174 0 C-N-CA 125.45 1.5 . . . . 0.0 110.239 -179.489 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 22.4 mt -87.33 87.45 7.43 Favored 'General case' 0 N--CA 1.462 0.151 0 CA-C-N 118.585 0.63 . . . . 0.0 109.357 179.394 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -69.5 -46.74 65.86 Favored 'General case' 0 CA--C 1.532 0.281 0 N-CA-C 113.399 0.889 . . . . 0.0 113.399 -179.703 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 2.0 m -78.83 127.47 32.09 Favored 'General case' 0 N--CA 1.454 -0.268 0 O-C-N 121.866 -0.521 . . . . 0.0 112.113 -175.23 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.1 155.38 37.0 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 122.987 0.515 . . . . 0.0 110.599 176.784 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 138.91 175.35 13.95 Favored Glycine 0 CA--C 1.525 0.67 0 C-N-CA 125.137 1.351 . . . . 0.0 109.984 179.445 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -100.0 116.04 31.12 Favored 'General case' 0 N--CA 1.451 -0.396 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 17.9 m-85 -107.83 131.33 54.59 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 124.379 1.071 . . . . 0.0 109.806 -178.101 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 18.2 m -102.31 139.27 38.14 Favored 'General case' 0 C--O 1.233 0.233 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 176.099 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 26.1 p90 -140.81 169.52 17.48 Favored 'General case' 0 CA--C 1.521 -0.151 0 CA-C-O 121.586 0.708 . . . . 0.0 111.204 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 43.4 p90 -157.57 160.61 38.32 Favored 'General case' 0 N--CA 1.45 -0.462 0 CA-C-N 115.601 -0.727 . . . . 0.0 112.016 -178.81 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 t -97.63 99.88 11.26 Favored 'General case' 0 CA--C 1.512 -0.485 0 N-CA-C 105.68 -1.97 . . . . 0.0 105.68 177.334 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.371 4.9 p -43.43 -56.5 6.77 Favored Pre-proline 0 CA--C 1.54 0.572 0 N-CA-C 114.323 1.231 . . . . 0.0 114.323 -175.175 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_exo -47.27 -20.04 1.26 Allowed 'Trans proline' 0 CA--C 1.534 0.518 0 C-N-CA 123.6 2.867 . . . . 0.0 116.103 177.248 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 38.5 m80 -136.13 18.37 3.2 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-N 119.15 0.887 . . . . 0.0 111.806 -178.298 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 16.8 pt20 -60.88 -41.97 97.04 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-N 119.047 0.84 . . . . 0.0 109.539 179.533 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -58.39 -29.48 63.41 Favored Glycine 0 CA--C 1.532 1.155 0 N-CA-C 111.209 -0.756 . . . . 0.0 111.209 177.145 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.34 10.6 21.81 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 123.718 0.807 . . . . 0.0 111.084 178.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 79.33 17.1 76.98 Favored Glycine 0 CA--C 1.526 0.772 0 CA-C-O 118.758 -1.023 . . . . 0.0 113.801 178.484 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 22.9 ttt -79.26 77.35 5.79 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 119.703 1.751 . . . . 0.0 108.265 178.213 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 14.3 m -117.87 170.58 7.11 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.319 0 C-N-CA 125.909 1.684 . . . . 0.0 110.198 179.809 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -164.86 176.54 40.64 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 178.092 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 53.8 tttp -154.68 154.48 32.99 Favored 'General case' 0 N--CA 1.454 -0.253 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 -176.074 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.4 p -145.53 134.2 17.0 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.159 0 O-C-N 121.987 -0.445 . . . . 0.0 110.988 -178.773 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.7 m -100.15 94.51 6.27 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 125.65 1.58 . . . . 0.0 110.852 -178.002 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 21.4 t -80.17 120.28 31.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 105.459 -2.052 . . . . 0.0 105.459 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 5.8 p30 . . . . . 0 C--N 1.332 -0.157 0 C-N-CA 123.483 0.713 . . . . 0.0 111.652 -174.914 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 . . . . . 0 N--CA 1.453 -0.308 0 CA-C-O 120.171 0.034 . . . . 0.0 110.997 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 39.0 t -113.23 118.24 57.55 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.332 0 N-CA-C 107.364 -1.347 . . . . 0.0 107.364 178.386 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 64.3 mt -89.1 120.86 30.88 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 -179.77 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -78.76 111.22 14.65 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 106.799 -1.556 . . . . 0.0 106.799 175.158 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 93.61 138.75 9.12 Favored Glycine 0 N--CA 1.446 -0.649 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.168 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 68.4 p -81.8 158.34 24.14 Favored 'General case' 0 N--CA 1.437 -1.11 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 178.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.0 -33.87 57.58 Favored Glycine 0 CA--C 1.53 1.025 0 CA-C-N 115.252 -0.885 . . . . 0.0 111.512 178.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -75.8 -3.71 36.57 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 123.597 0.759 . . . . 0.0 112.292 178.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 99.51 -20.85 47.98 Favored Glycine 0 CA--C 1.527 0.794 0 CA-C-O 118.892 -0.949 . . . . 0.0 113.486 178.782 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 22.7 t -57.31 131.63 50.62 Favored 'General case' 0 C--O 1.239 0.516 0 CA-C-N 119.336 1.568 . . . . 0.0 110.682 -179.228 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 56.8 mt -73.03 65.63 0.77 Allowed 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 127.085 2.154 . . . . 0.0 112.412 -176.222 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 2.4 t -123.2 151.36 27.55 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.442 0 C-N-CA 124.247 1.019 . . . . 0.0 108.785 178.859 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 33.2 m-85 -86.17 129.74 34.75 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 104.125 -2.546 . . . . 0.0 104.125 175.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 48.8 t -118.44 104.62 47.49 Favored Pre-proline 0 CA--C 1.537 0.445 0 CA-C-O 118.324 -0.846 . . . . 0.0 108.877 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -75.05 161.78 94.14 Favored 'Cis proline' 0 C--N 1.347 0.499 0 CA-C-N 120.338 1.157 . . . . 0.0 111.597 -1.073 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 6.2 p -91.89 -60.47 1.85 Allowed 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 125.502 1.521 . . . . 0.0 108.609 179.212 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -105.4 127.01 52.75 Favored 'General case' 0 N--CA 1.453 -0.282 0 C-N-CA 126.238 1.815 . . . . 0.0 106.616 177.69 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 14.6 p90 -160.03 -175.36 5.05 Favored 'General case' 0 C--O 1.232 0.18 0 CA-C-O 121.08 0.467 . . . . 0.0 110.792 179.867 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 66.1 p -147.02 156.84 43.35 Favored 'General case' 0 N--CA 1.451 -0.403 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 18.1 m -152.75 151.28 26.35 Favored Pre-proline 0 CA--C 1.531 0.245 0 C-N-CA 123.61 0.764 . . . . 0.0 109.539 -178.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -73.17 148.52 44.4 Favored 'Trans proline' 0 N--CA 1.451 -1.0 0 C-N-CA 121.781 1.654 . . . . 0.0 110.761 177.812 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 64.7 m -48.93 121.24 4.52 Favored 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 122.996 0.518 . . . . 0.0 110.55 176.048 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 106.39 -9.72 42.14 Favored Glycine 0 CA--C 1.529 0.961 0 C-N-CA 124.165 0.888 . . . . 0.0 112.642 179.431 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -63.3 135.81 57.28 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-N 118.813 1.307 . . . . 0.0 109.979 179.242 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 52.9 mtpt -91.54 106.03 18.19 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 125.409 1.483 . . . . 0.0 108.659 179.386 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 40.4 mt -85.21 135.12 25.53 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 -179.672 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 64.7 t -119.73 100.3 9.27 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.34 0 C-N-CA 126.134 1.774 . . . . 0.0 108.152 -178.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -87.06 107.18 18.32 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 178.025 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 62.9 tttp -105.91 131.97 52.58 Favored 'General case' 0 CA--C 1.531 0.243 0 C-N-CA 125.266 1.426 . . . . 0.0 112.78 -176.408 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 8.1 m-20 -68.56 112.53 5.41 Favored 'General case' 0 C--O 1.232 0.132 0 C-N-CA 123.149 0.579 . . . . 0.0 110.021 177.538 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 24.5 t30 -97.46 -72.22 0.65 Allowed 'General case' 0 N--CA 1.456 -0.171 0 CA-C-O 121.052 0.453 . . . . 0.0 109.851 178.727 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -143.2 167.41 22.18 Favored 'General case' 0 C--N 1.331 -0.219 0 C-N-CA 123.972 0.909 . . . . 0.0 109.521 -178.028 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 62.65 23.78 65.5 Favored Glycine 0 CA--C 1.535 1.295 0 O-C-N 121.839 -0.538 . . . . 0.0 113.774 179.407 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 10.5 p90 -74.74 167.54 35.42 Favored Pre-proline 0 CA--C 1.537 0.463 0 N-CA-C 106.671 -1.603 . . . . 0.0 106.671 176.756 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -62.66 159.91 58.31 Favored 'Cis proline' 0 N--CA 1.456 -0.698 0 N-CA-C 116.99 1.881 . . . . 0.0 116.99 1.072 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 93.3 m-70 -149.67 170.14 19.39 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.809 -179.464 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 37.3 p-10 -163.98 177.04 8.83 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 104.32 -2.474 . . . . 0.0 104.32 176.298 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 39.3 t -138.25 112.17 8.07 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.389 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 179.291 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 64.8 t -116.83 133.69 62.72 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.604 0 N-CA-C 106.052 -1.833 . . . . 0.0 106.052 179.525 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 64.6 m-85 -93.33 140.65 29.32 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 -179.306 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 53.1 t0 -70.76 104.48 2.89 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 179.42 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -48.02 -32.29 6.43 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 124.168 0.987 . . . . 0.0 113.293 178.211 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -92.04 6.39 46.6 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 123.494 0.717 . . . . 0.0 112.871 -178.839 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 20.7 tt0 -150.44 63.36 0.95 Allowed 'General case' 0 CA--C 1.538 0.506 0 CA-C-O 122.108 0.956 . . . . 0.0 110.71 -179.283 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 28.0 pt -155.59 158.2 31.77 Favored Pre-proline 0 CA--C 1.532 0.263 0 C-N-CA 128.573 2.749 . . . . 0.0 105.771 177.459 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_exo -55.93 109.5 0.44 Allowed 'Trans proline' 0 CA--C 1.538 0.692 0 C-N-CA 122.306 2.004 . . . . 0.0 108.585 174.127 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -33.65 -44.21 0.15 Allowed 'General case' 0 N--CA 1.465 0.322 0 C-N-CA 126.789 2.036 . . . . 0.0 115.77 -177.195 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -58.34 -29.84 63.77 Favored Glycine 0 CA--C 1.534 1.221 0 CA-C-O 119.856 -0.413 . . . . 0.0 113.766 -178.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 37.4 t -84.69 107.54 15.86 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.316 0 CA-C-N 118.179 0.99 . . . . 0.0 110.318 -177.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 19.7 t0 -59.29 116.15 3.71 Favored 'General case' 0 CA--C 1.534 0.364 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 177.333 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -46.79 -40.33 13.45 Favored 'General case' 0 N--CA 1.457 -0.113 0 C-N-CA 125.223 1.409 . . . . 0.0 112.012 179.671 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 53.1 t -60.23 -28.88 42.77 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 C-N-CA 122.994 0.518 . . . . 0.0 111.784 -178.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -76.56 -42.11 44.01 Favored 'General case' 0 N--CA 1.462 0.128 0 CA-C-N 118.617 0.644 . . . . 0.0 110.594 -179.006 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 22.7 pt -79.09 -32.84 15.45 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 N-CA-C 112.582 0.586 . . . . 0.0 112.582 -178.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 49.1 m -78.05 141.65 38.71 Favored 'General case' 0 N--CA 1.454 -0.255 0 N-CA-C 112.531 0.567 . . . . 0.0 112.531 -178.261 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 12.8 tpt . . . . . 0 CA--C 1.535 0.401 0 N-CA-C 105.583 -2.006 . . . . 0.0 105.583 174.914 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 4.8 mp . . . . . 0 N--CA 1.452 -0.332 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 71.9 mt -79.33 96.34 5.96 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 104.391 -2.448 . . . . 0.0 104.391 177.275 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 36.9 p-10 -80.32 -58.2 3.25 Favored 'General case' 0 CA--C 1.529 0.162 0 C-N-CA 124.156 0.982 . . . . 0.0 113.303 -177.17 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -79.75 160.45 69.32 Favored Pre-proline 0 CA--C 1.535 0.403 0 C-N-CA 124.318 1.047 . . . . 0.0 111.902 -176.75 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -64.59 161.89 33.49 Favored 'Trans proline' 0 N--CA 1.458 -0.614 0 C-N-CA 122.29 1.993 . . . . 0.0 109.172 175.081 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 78.74 -39.57 1.99 Allowed Glycine 0 CA--C 1.528 0.853 0 CA-C-O 118.656 -1.08 . . . . 0.0 113.829 177.293 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 79.5 mm-40 -42.03 130.32 3.54 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 124.476 1.111 . . . . 0.0 111.669 179.827 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 6.7 p -110.88 150.4 29.24 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 125.412 1.485 . . . . 0.0 112.424 -177.856 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 30.5 t80 -126.43 113.14 16.46 Favored 'General case' 0 N--CA 1.455 -0.177 0 N-CA-C 105.082 -2.192 . . . . 0.0 105.082 172.466 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 19.6 t -100.41 136.89 29.84 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.398 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 -178.543 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.2 p -150.07 140.88 16.66 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.121 0 N-CA-C 108.275 -1.009 . . . . 0.0 108.275 178.253 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 25.1 m -112.07 127.44 55.91 Favored 'General case' 0 N--CA 1.456 -0.126 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 -178.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 55.5 mt -110.67 124.63 52.29 Favored 'General case' 0 CA--C 1.529 0.137 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 179.713 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -108.48 -47.96 3.41 Favored 'General case' 0 CA--C 1.528 0.126 0 C-N-CA 124.286 1.034 . . . . 0.0 112.096 -178.296 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 5.0 m -66.4 128.69 37.16 Favored 'General case' 0 N--CA 1.454 -0.25 0 O-C-N 121.707 -0.621 . . . . 0.0 109.661 -177.51 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 61.8 mtpt -69.04 155.46 40.33 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 123.02 0.528 . . . . 0.0 110.441 -179.155 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 128.37 175.44 14.07 Favored Glycine 0 CA--C 1.527 0.832 0 C-N-CA 124.389 0.995 . . . . 0.0 111.409 179.023 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 89.3 m -95.25 127.22 41.12 Favored 'General case' 0 N--CA 1.451 -0.405 0 C-N-CA 124.871 1.269 . . . . 0.0 109.288 -179.828 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 25.2 m-85 -115.75 120.69 40.15 Favored 'General case' 0 N--CA 1.447 -0.601 0 C-N-CA 126.051 1.74 . . . . 0.0 108.615 179.398 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 64.1 m -92.37 140.16 29.87 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 177.023 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 22.8 p90 -139.39 165.48 27.1 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-O 121.555 0.693 . . . . 0.0 112.307 -179.52 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -152.66 157.31 40.76 Favored 'General case' 0 N--CA 1.452 -0.342 0 C-N-CA 124.205 1.002 . . . . 0.0 112.64 -178.334 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.4 t -99.68 102.04 13.41 Favored 'General case' 0 CA--C 1.519 -0.234 0 N-CA-C 105.483 -2.043 . . . . 0.0 105.483 176.84 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.28 0.8 OUTLIER -43.12 -57.69 4.92 Favored Pre-proline 0 CA--C 1.535 0.384 0 N-CA-C 114.446 1.276 . . . . 0.0 114.446 -173.692 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -52.17 -20.12 10.31 Favored 'Trans proline' 0 C--N 1.347 0.494 0 C-N-CA 123.146 2.564 . . . . 0.0 115.183 178.833 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 37.1 m80 -130.61 19.01 5.19 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-N 118.697 0.68 . . . . 0.0 111.446 -178.44 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -60.01 -51.17 70.81 Favored 'General case' 0 C--N 1.339 0.128 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 179.707 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.12 -30.26 57.35 Favored Glycine 0 CA--C 1.533 1.177 0 N-CA-C 111.717 -0.553 . . . . 0.0 111.717 177.863 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -84.04 5.83 24.38 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 123.51 0.724 . . . . 0.0 111.72 179.187 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 83.56 15.35 71.25 Favored Glycine 0 CA--C 1.527 0.827 0 CA-C-O 118.991 -0.894 . . . . 0.0 113.71 178.347 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 19.2 ttt -78.44 79.65 4.86 Favored 'General case' 0 C--O 1.236 0.377 0 CA-C-N 119.527 1.664 . . . . 0.0 108.595 178.657 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 10.7 m -126.56 169.46 17.96 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.207 0 C-N-CA 125.917 1.687 . . . . 0.0 110.813 179.842 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -169.03 179.45 41.74 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 109.276 -1.53 . . . . 0.0 109.276 178.343 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 58.7 mttm -149.64 149.46 30.67 Favored 'General case' 0 N--CA 1.455 -0.203 0 CA-C-N 117.66 0.73 . . . . 0.0 109.588 -179.014 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 6.6 p -135.72 127.29 45.04 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.3 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 178.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 71.6 m -102.09 106.46 17.34 Favored 'General case' 0 C--N 1.333 -0.143 0 C-N-CA 123.772 0.829 . . . . 0.0 110.436 179.487 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 44.6 t -79.69 122.99 35.97 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.633 0 N-CA-C 106.643 -1.614 . . . . 0.0 106.643 179.021 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 48.7 p30 . . . . . 0 C--N 1.333 -0.122 0 C-N-CA 124.895 1.278 . . . . 0.0 111.034 -177.605 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 78.4 tt0 . . . . . 0 N--CA 1.452 -0.348 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 48.1 t -106.05 122.48 59.75 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 -179.361 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 40.8 mt -86.03 120.82 27.83 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 177.886 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 5.1 tp -78.19 98.53 5.88 Favored 'General case' 0 N--CA 1.429 -1.489 0 C-N-CA 125.424 1.49 . . . . 0.0 107.525 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 91.72 145.34 15.07 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 108.7 -1.76 . . . . 0.0 108.7 -178.393 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 78.0 p -78.86 154.94 29.37 Favored 'General case' 0 N--CA 1.44 -0.948 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 179.574 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -53.16 -35.39 49.41 Favored Glycine 0 CA--C 1.529 0.942 0 CA-C-N 114.979 -1.01 . . . . 0.0 111.697 178.808 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -74.82 -4.42 37.66 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 123.53 0.732 . . . . 0.0 112.506 179.404 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 101.08 -20.75 46.25 Favored Glycine 0 CA--C 1.527 0.782 0 CA-C-O 118.763 -1.021 . . . . 0.0 113.292 178.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 28.6 t -56.81 132.13 51.4 Favored 'General case' 0 C--O 1.239 0.536 0 CA-C-N 119.391 1.595 . . . . 0.0 110.603 -179.332 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -71.55 69.28 0.61 Allowed 'General case' 0 N--CA 1.44 -0.935 0 C-N-CA 126.806 2.042 . . . . 0.0 111.676 -177.457 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.5 m -135.06 141.74 42.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 C-N-CA 123.708 0.803 . . . . 0.0 109.403 178.383 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 88.2 m-85 -79.16 135.2 36.75 Favored 'General case' 0 N--CA 1.455 -0.186 0 N-CA-C 105.291 -2.115 . . . . 0.0 105.291 176.81 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.8 t -120.09 104.35 43.92 Favored Pre-proline 0 CA--C 1.534 0.339 0 CA-C-O 118.25 -0.881 . . . . 0.0 109.094 179.567 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -73.85 164.16 88.15 Favored 'Cis proline' 0 C--N 1.348 0.524 0 CA-C-N 120.301 1.143 . . . . 0.0 112.179 -1.412 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 10.5 p -97.59 -62.28 1.27 Allowed 'General case' 0 N--CA 1.452 -0.331 0 C-N-CA 125.681 1.592 . . . . 0.0 109.236 179.32 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 -103.54 123.96 47.89 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 126.106 1.763 . . . . 0.0 106.857 178.345 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -158.06 174.3 15.43 Favored 'General case' 0 CA--C 1.528 0.118 0 CA-C-N 118.9 0.773 . . . . 0.0 112.013 179.486 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.4 p -116.67 147.83 41.59 Favored 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 125.478 1.511 . . . . 0.0 107.555 178.461 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.8 p -141.79 136.25 15.18 Favored Pre-proline 0 CA--C 1.536 0.428 0 CA-C-O 118.443 -0.789 . . . . 0.0 109.036 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_exo -63.03 142.73 88.86 Favored 'Trans proline' 0 N--CA 1.456 -0.693 0 C-N-CA 122.043 1.828 . . . . 0.0 111.363 177.091 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.8 m -45.8 121.61 3.25 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 124.265 1.026 . . . . 0.0 111.778 177.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 84.96 -5.79 81.39 Favored Glycine 0 CA--C 1.525 0.69 0 CA-C-O 118.502 -1.166 . . . . 0.0 114.411 177.407 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -74.97 147.77 40.55 Favored 'General case' 0 CA--C 1.537 0.444 0 CA-C-N 119.954 1.877 . . . . 0.0 108.084 177.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 2.7 ptpp? -92.79 138.88 31.11 Favored 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 124.007 0.923 . . . . 0.0 112.499 -177.844 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 48.8 mt -105.05 136.76 37.42 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 C-N-CA 126.292 1.837 . . . . 0.0 106.06 179.166 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 58.4 t -117.92 100.29 9.81 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 C-N-CA 125.355 1.462 . . . . 0.0 108.832 -178.7 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -84.5 100.06 11.11 Favored 'General case' 0 C--N 1.334 -0.073 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 178.418 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 64.4 tttm -92.07 125.0 36.58 Favored 'General case' 0 C--O 1.231 0.127 0 C-N-CA 123.73 0.812 . . . . 0.0 110.621 -178.622 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 49.3 t30 -63.19 111.11 2.09 Favored 'General case' 0 CA--C 1.528 0.119 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 177.367 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 36.2 t30 -99.65 -76.45 0.55 Allowed 'General case' 0 N--CA 1.457 -0.079 0 C-N-CA 122.94 0.496 . . . . 0.0 112.256 -177.036 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -151.08 174.92 12.62 Favored 'General case' 0 C--O 1.224 -0.26 0 C-N-CA 124.012 0.925 . . . . 0.0 109.383 -176.807 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 62.3 17.96 57.22 Favored Glycine 0 CA--C 1.535 1.294 0 O-C-N 121.679 -0.638 . . . . 0.0 112.519 -179.119 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 3.9 p90 -78.25 169.5 20.56 Favored Pre-proline 0 CA--C 1.538 0.509 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 179.153 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_exo -64.45 160.25 68.42 Favored 'Cis proline' 0 N--CA 1.449 -1.098 0 N-CA-C 116.07 1.527 . . . . 0.0 116.07 1.605 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 90.7 m-70 -152.29 177.69 10.29 Favored 'General case' 0 N--CA 1.45 -0.467 0 CA-C-N 115.118 -0.946 . . . . 0.0 109.769 179.578 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 53.4 p30 -162.94 169.78 19.14 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 105.064 -2.198 . . . . 0.0 105.064 173.556 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 44.3 t -123.93 104.55 14.22 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.333 0 N-CA-C 106.62 -1.622 . . . . 0.0 106.62 -177.522 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 38.8 t -116.33 135.26 57.13 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.366 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 -179.316 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 55.7 m-85 -100.65 138.19 38.04 Favored 'General case' 0 N--CA 1.454 -0.272 0 C-N-CA 123.267 0.627 . . . . 0.0 109.68 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -70.14 114.1 7.97 Favored 'General case' 0 N--CA 1.454 -0.26 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 -179.81 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -47.85 -30.57 4.17 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 115.825 1.787 . . . . 0.0 115.825 -178.471 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 23.5 t70 -88.61 -50.15 6.45 Favored 'General case' 0 CA--C 1.53 0.204 0 CA-C-N 118.52 0.6 . . . . 0.0 110.649 179.88 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -80.22 57.07 2.63 Favored 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 124.087 0.955 . . . . 0.0 112.413 -176.397 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 20.2 pt -150.14 149.0 26.11 Favored Pre-proline 0 CA--C 1.534 0.36 0 C-N-CA 127.376 2.27 . . . . 0.0 106.537 176.805 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -65.6 124.63 13.08 Favored 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 122.096 1.864 . . . . 0.0 110.504 179.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -52.0 109.95 0.43 Allowed 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 124.802 1.241 . . . . 0.0 111.228 -179.456 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 153.09 -56.77 0.43 Allowed Glycine 0 CA--C 1.522 0.517 0 N-CA-C 108.249 -1.94 . . . . 0.0 108.249 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 41.8 t -83.21 93.09 2.87 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.429 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 179.285 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -58.96 134.33 56.86 Favored 'General case' 0 CA--C 1.532 0.251 0 N-CA-C 109.319 -0.622 . . . . 0.0 109.319 177.807 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -39.56 -43.82 1.36 Allowed 'General case' 0 C--N 1.331 -0.196 0 C-N-CA 127.389 2.275 . . . . 0.0 113.963 179.52 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 98.9 t -55.62 -30.41 26.68 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.333 0 CA-C-N 118.119 0.418 . . . . 0.0 110.918 -179.378 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 33.1 mtmm -75.85 -18.83 59.3 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-O 118.451 -0.785 . . . . 0.0 112.868 -179.278 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -115.32 -20.91 5.59 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-N 119.196 0.907 . . . . 0.0 113.065 179.642 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 35.6 m -84.13 127.46 33.93 Favored 'General case' 0 N--CA 1.451 -0.386 0 C-N-CA 123.869 0.868 . . . . 0.0 112.038 -178.577 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 7.2 tmm? . . . . . 0 CA--C 1.536 0.432 0 N-CA-C 103.801 -2.666 . . . . 0.0 103.801 175.071 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 4.8 mp . . . . . 0 N--CA 1.45 -0.469 0 CA-C-O 121.036 0.446 . . . . 0.0 110.503 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 44.1 mt -78.1 105.68 9.49 Favored 'General case' 0 N--CA 1.445 -0.68 0 N-CA-C 103.778 -2.675 . . . . 0.0 103.778 175.295 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 34.3 p-10 -101.25 -52.98 3.12 Favored 'General case' 0 N--CA 1.455 -0.183 0 C-N-CA 124.796 1.238 . . . . 0.0 111.733 -177.151 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -71.85 136.65 82.65 Favored Pre-proline 0 CA--C 1.531 0.245 0 CA-C-N 118.723 0.692 . . . . 0.0 110.069 -177.477 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -63.61 149.73 90.22 Favored 'Trans proline' 0 N--CA 1.451 -1.009 0 C-N-CA 122.142 1.895 . . . . 0.0 109.659 179.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 97.54 -34.98 4.76 Favored Glycine 0 CA--C 1.523 0.591 0 CA-C-O 118.623 -1.098 . . . . 0.0 112.777 177.855 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 76.9 mt-10 -45.28 118.72 1.81 Allowed 'General case' 0 CA--C 1.536 0.419 0 CA-C-N 118.537 1.169 . . . . 0.0 111.665 -179.696 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 11.0 p -101.88 120.46 40.42 Favored 'General case' 0 N--CA 1.452 -0.356 0 C-N-CA 124.992 1.317 . . . . 0.0 111.551 -179.485 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 38.4 t80 -101.34 108.06 19.58 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 106.422 -1.695 . . . . 0.0 106.422 175.124 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 14.6 t -93.91 139.86 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.301 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 -179.263 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 9.9 p -148.61 142.64 18.79 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.153 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 177.778 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 7.8 m -117.21 124.44 49.09 Favored 'General case' 0 CA--C 1.527 0.072 0 C-N-CA 124.318 1.047 . . . . 0.0 109.495 -177.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 44.3 mt -105.55 98.51 8.19 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 123.156 0.583 . . . . 0.0 109.777 -179.394 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -74.67 -58.36 3.34 Favored 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 123.782 0.833 . . . . 0.0 112.709 -179.38 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 4.1 m -70.42 128.87 37.68 Favored 'General case' 0 N--CA 1.453 -0.325 0 C-N-CA 123.495 0.718 . . . . 0.0 111.465 -175.116 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 57.5 mtmt -65.35 156.04 33.43 Favored 'General case' 0 N--CA 1.455 -0.194 0 C-N-CA 123.438 0.695 . . . . 0.0 110.8 179.115 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 142.44 -166.46 26.45 Favored Glycine 0 CA--C 1.521 0.446 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 179.33 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 88.5 m -117.44 123.83 47.35 Favored 'General case' 0 N--CA 1.454 -0.245 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 179.612 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -114.81 124.3 51.39 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 124.348 1.059 . . . . 0.0 108.58 -178.553 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 13.2 m -99.81 134.29 42.92 Favored 'General case' 0 C--O 1.233 0.205 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 177.868 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 40.3 p90 -133.67 166.96 21.39 Favored 'General case' 0 CA--C 1.521 -0.161 0 CA-C-O 121.588 0.708 . . . . 0.0 111.625 -179.552 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 46.6 p90 -159.01 165.09 34.82 Favored 'General case' 0 N--CA 1.45 -0.43 0 CA-C-N 115.453 -0.794 . . . . 0.0 112.322 -177.76 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.5 t -106.09 97.18 7.03 Favored 'General case' 0 CA--C 1.519 -0.243 0 N-CA-C 106.638 -1.615 . . . . 0.0 106.638 177.377 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.304 16.1 p -31.1 -64.56 0.21 Allowed Pre-proline 0 CA--C 1.544 0.721 0 N-CA-C 117.138 2.273 . . . . 0.0 117.138 -174.474 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -61.89 -16.49 49.76 Favored 'Trans proline' 0 C--N 1.347 0.468 0 C-N-CA 122.576 2.184 . . . . 0.0 114.294 -177.338 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 34.7 m170 -119.08 9.26 11.76 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 123.322 0.649 . . . . 0.0 110.747 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 66.4 tt0 -58.34 -49.69 76.28 Favored 'General case' 0 CA--C 1.529 0.144 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 179.228 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -57.45 -30.32 61.67 Favored Glycine 0 CA--C 1.531 1.067 0 N-CA-C 111.475 -0.65 . . . . 0.0 111.475 177.45 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -84.8 5.45 28.54 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 123.774 0.83 . . . . 0.0 111.577 179.091 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 87.37 11.39 69.21 Favored Glycine 0 CA--C 1.527 0.823 0 CA-C-O 118.608 -1.107 . . . . 0.0 113.833 178.263 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 22.2 ttt -78.9 77.26 5.38 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 119.812 1.806 . . . . 0.0 108.614 178.334 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 10.8 m -122.94 169.13 14.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 C-N-CA 126.042 1.737 . . . . 0.0 108.96 178.568 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -162.42 172.34 38.49 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 108.491 -1.843 . . . . 0.0 108.491 178.51 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 6.9 ttpm? -151.4 141.33 22.02 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 -176.765 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 6.0 p -132.97 126.43 53.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 CA-C-O 121.057 0.456 . . . . 0.0 110.697 -179.025 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 21.0 m -97.17 105.84 18.06 Favored 'General case' 0 C--O 1.235 0.324 0 C-N-CA 124.724 1.21 . . . . 0.0 109.222 179.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 40.8 t -79.91 103.02 6.36 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.621 0 N-CA-C 106.484 -1.673 . . . . 0.0 106.484 -179.743 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 . . . . . 0 C--O 1.235 0.313 0 C-N-CA 125.205 1.402 . . . . 0.0 109.487 -177.206 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 . . . . . 0 N--CA 1.453 -0.32 0 CA-C-O 120.267 0.08 . . . . 0.0 110.895 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 44.2 t -120.55 123.94 71.45 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 N-CA-C 106.112 -1.81 . . . . 0.0 106.112 177.492 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 32.5 mt -96.65 122.91 40.09 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 118.383 0.538 . . . . 0.0 110.206 -179.478 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.2 mm? -79.68 101.9 8.65 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 106.316 -1.735 . . . . 0.0 106.316 174.111 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 108.84 127.69 5.58 Favored Glycine 0 CA--C 1.522 0.522 0 C-N-CA 124.788 1.185 . . . . 0.0 111.576 179.688 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 14.9 p -84.34 46.84 1.26 Allowed 'General case' 0 N--CA 1.457 -0.092 0 O-C-N 121.434 -1.039 . . . . 0.0 111.314 179.279 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 72.07 -55.73 1.45 Allowed Glycine 0 CA--C 1.527 0.83 0 C-N-CA 126.071 1.796 . . . . 0.0 111.991 -179.26 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -73.17 33.69 0.07 Allowed 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 126.038 1.735 . . . . 0.0 113.743 -177.519 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 57.33 8.42 3.56 Favored Glycine 0 CA--C 1.531 1.069 0 C-N-CA 124.875 1.226 . . . . 0.0 115.848 179.207 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 22.8 t -68.63 141.43 55.39 Favored 'General case' 0 N--CA 1.457 -0.107 0 CA-C-N 119.532 1.666 . . . . 0.0 109.502 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 68.9 mt -78.1 66.57 3.74 Favored 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 124.411 1.084 . . . . 0.0 111.781 -176.048 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.6 p -138.44 150.08 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.217 0 CA-C-O 121.788 0.804 . . . . 0.0 111.715 -179.494 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 58.7 m-85 -92.38 126.33 37.42 Favored 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 105.185 -2.154 . . . . 0.0 105.185 177.78 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 48.8 t -115.39 107.47 49.17 Favored Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 119.629 1.104 . . . . 0.0 109.448 179.609 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -77.27 155.84 96.66 Favored 'Cis proline' 0 CA--C 1.536 0.613 0 CA-C-N 120.706 1.288 . . . . 0.0 111.729 -1.3 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.5 m -84.83 -55.1 4.26 Favored 'General case' 0 CA--C 1.527 0.096 0 C-N-CA 123.357 0.663 . . . . 0.0 110.302 179.232 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 58.9 mt-10 -114.0 131.87 56.19 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 -179.471 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 53.0 p90 -161.13 -178.41 6.73 Favored 'General case' 0 C--O 1.234 0.255 0 CA-C-O 121.372 0.606 . . . . 0.0 112.081 -178.114 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 35.2 p -140.02 140.26 36.18 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 124.948 1.299 . . . . 0.0 109.257 -179.249 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.4 m -145.47 152.19 49.05 Favored Pre-proline 0 CA--C 1.532 0.257 0 C-N-CA 124.553 1.141 . . . . 0.0 108.136 178.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo -71.67 151.44 58.03 Favored 'Trans proline' 0 N--CA 1.451 -0.998 0 C-N-CA 121.78 1.653 . . . . 0.0 111.16 179.842 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 56.7 m -49.31 127.15 14.42 Favored 'General case' 0 C--N 1.332 -0.18 0 C-N-CA 124.343 1.057 . . . . 0.0 111.508 178.479 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 92.9 -10.74 73.44 Favored Glycine 0 CA--C 1.527 0.817 0 CA-C-O 118.911 -0.938 . . . . 0.0 112.829 178.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -70.47 141.96 51.98 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 119.392 1.596 . . . . 0.0 108.43 178.601 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 20.4 pttp -82.01 160.45 23.27 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 123.928 0.891 . . . . 0.0 111.131 -179.018 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 15.8 mt -131.44 129.05 61.84 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 N-CA-C 105.355 -2.091 . . . . 0.0 105.355 177.775 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 75.3 t -116.37 98.06 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.202 0 C-N-CA 125.851 1.66 . . . . 0.0 107.928 -177.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -86.5 96.57 10.1 Favored 'General case' 0 CA--C 1.529 0.17 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.773 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -90.52 128.98 36.72 Favored 'General case' 0 CA--C 1.531 0.212 0 C-N-CA 125.027 1.331 . . . . 0.0 112.046 -177.6 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 45.6 t30 -69.15 116.66 9.85 Favored 'General case' 0 N--CA 1.457 -0.119 0 CA-C-O 118.393 -0.813 . . . . 0.0 109.947 177.938 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 50.2 t30 -103.4 -66.23 0.96 Allowed 'General case' 0 C--N 1.339 0.135 0 CA-C-N 118.702 0.683 . . . . 0.0 110.551 179.474 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -160.17 169.25 23.67 Favored 'General case' 0 C--O 1.225 -0.196 0 C-N-CA 123.254 0.622 . . . . 0.0 110.452 -177.684 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 71.66 18.91 77.61 Favored Glycine 0 CA--C 1.532 1.094 0 O-C-N 121.823 -0.548 . . . . 0.0 111.878 -179.512 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 10.4 p90 -71.37 168.92 17.64 Favored Pre-proline 0 CA--C 1.54 0.568 0 C-N-CA 126.001 1.72 . . . . 0.0 108.598 -179.815 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 75.8 Cg_endo -70.93 158.44 94.52 Favored 'Cis proline' 0 N--CA 1.449 -1.104 0 N-CA-C 115.042 1.131 . . . . 0.0 115.042 3.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 90.3 m-70 -146.8 160.83 41.78 Favored 'General case' 0 C--O 1.222 -0.391 0 O-C-N 121.59 -0.694 . . . . 0.0 112.72 -177.808 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 52.1 p30 -157.53 177.69 11.13 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 106.39 -1.707 . . . . 0.0 106.39 176.437 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 23.4 t -132.55 113.95 21.91 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 -179.27 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 25.5 t -118.98 132.11 69.82 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 N-CA-C 105.601 -2.0 . . . . 0.0 105.601 178.522 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -93.99 136.78 33.91 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -71.02 104.75 3.08 Favored 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 -178.66 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -35.26 -37.34 0.08 Allowed 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 127.416 2.287 . . . . 0.0 115.401 178.275 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 24.9 m-20 -85.47 -53.24 5.32 Favored 'General case' 0 CA--C 1.53 0.188 0 CA-C-N 118.545 0.611 . . . . 0.0 110.301 179.43 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 38.3 mm-40 -80.91 58.28 3.34 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 124.031 0.933 . . . . 0.0 112.906 -176.706 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 36.1 pt -152.31 159.15 33.16 Favored Pre-proline 0 CA--C 1.534 0.336 0 C-N-CA 128.452 2.701 . . . . 0.0 105.633 175.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -53.12 110.84 0.53 Allowed 'Trans proline' 0 N--CA 1.456 -0.684 0 C-N-CA 122.365 2.044 . . . . 0.0 111.162 177.22 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -51.77 108.23 0.26 Allowed 'General case' 0 CA--C 1.529 0.156 0 C-N-CA 124.119 0.968 . . . . 0.0 110.284 -179.507 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 133.83 -29.42 3.1 Favored Glycine 0 CA--C 1.527 0.795 0 N-CA-C 109.958 -1.257 . . . . 0.0 109.958 -178.133 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 88.5 t -74.94 117.91 19.91 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.279 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 179.763 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -63.13 102.81 0.41 Allowed 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 122.953 0.501 . . . . 0.0 110.335 179.454 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.71 -40.5 20.38 Favored 'General case' 0 N--CA 1.456 -0.168 0 C-N-CA 124.424 1.09 . . . . 0.0 111.381 179.094 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 44.6 t -58.94 -28.62 38.9 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 C-N-CA 123.03 0.532 . . . . 0.0 111.844 -179.132 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 33.3 pttt -75.7 -31.96 59.9 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 119.497 1.044 . . . . 0.0 111.571 -178.622 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 26.4 pt -91.78 -31.45 4.89 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.36 0 C-N-CA 123.728 0.811 . . . . 0.0 111.925 -178.79 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 35.5 m -87.74 142.95 27.42 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 124.73 1.212 . . . . 0.0 114.196 -176.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 87.2 mtp . . . . . 0 N--CA 1.45 -0.428 0 N-CA-C 104.656 -2.35 . . . . 0.0 104.656 171.213 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.449 -0.475 0 N-CA-C 113.339 0.866 . . . . 0.0 113.339 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 63.9 mt -82.32 127.65 33.43 Favored 'General case' 0 N--CA 1.446 -0.644 0 N-CA-C 106.041 -1.837 . . . . 0.0 106.041 176.353 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 23.8 t30 -118.21 -47.89 2.55 Favored 'General case' 0 C--O 1.225 -0.189 0 C-N-CA 123.267 0.627 . . . . 0.0 110.469 178.617 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -67.07 136.9 94.25 Favored Pre-proline 0 CA--C 1.533 0.322 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -178.666 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -64.68 145.04 86.06 Favored 'Trans proline' 0 N--CA 1.452 -0.954 0 C-N-CA 122.462 2.108 . . . . 0.0 109.949 -178.511 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.23 -30.21 8.98 Favored Glycine 0 CA--C 1.523 0.563 0 CA-C-O 118.729 -1.04 . . . . 0.0 113.678 177.042 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 65.9 mm-40 -52.97 135.68 36.3 Favored 'General case' 0 CA--C 1.535 0.381 0 CA-C-N 118.859 1.329 . . . . 0.0 110.655 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 17.3 p -114.31 123.91 50.69 Favored 'General case' 0 N--CA 1.454 -0.251 0 C-N-CA 124.863 1.265 . . . . 0.0 113.515 -177.235 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 43.0 t80 -94.7 108.89 20.87 Favored 'General case' 0 C--O 1.233 0.194 0 N-CA-C 105.069 -2.197 . . . . 0.0 105.069 172.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.8 t -96.28 137.99 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.356 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 -179.21 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 13.5 p -147.55 168.5 4.54 Favored 'Isoleucine or valine' 0 C--O 1.232 0.142 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 177.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 40.9 m -149.51 136.72 19.85 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 67.5 mt -118.52 112.87 20.46 Favored 'General case' 0 CA--C 1.53 0.202 0 C-N-CA 123.681 0.792 . . . . 0.0 109.786 -177.752 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -88.23 -42.84 12.02 Favored 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 123.68 0.792 . . . . 0.0 111.473 179.692 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -71.52 127.97 34.3 Favored 'General case' 0 N--CA 1.453 -0.324 0 C-N-CA 124.095 0.958 . . . . 0.0 109.878 -177.432 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.7 mttp -66.84 160.18 26.58 Favored 'General case' 0 CA--C 1.53 0.175 0 C-N-CA 123.386 0.674 . . . . 0.0 111.683 178.87 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 129.64 177.39 14.85 Favored Glycine 0 CA--C 1.525 0.716 0 C-N-CA 124.33 0.967 . . . . 0.0 112.591 176.756 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 14.7 m -95.32 112.46 24.17 Favored 'General case' 0 N--CA 1.453 -0.277 0 C-N-CA 124.769 1.227 . . . . 0.0 108.192 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 26.2 m-85 -104.04 111.72 24.41 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 124.01 0.924 . . . . 0.0 109.47 -179.626 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 20.1 m -86.14 138.38 31.96 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 107.985 -1.116 . . . . 0.0 107.985 177.163 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 34.3 p90 -135.83 164.66 27.41 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 123.099 0.56 . . . . 0.0 111.241 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 56.0 p90 -155.31 164.22 39.06 Favored 'General case' 0 N--CA 1.45 -0.462 0 CA-C-N 114.934 -1.03 . . . . 0.0 112.089 -177.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 6.3 t -105.11 106.97 17.71 Favored 'General case' 0 CA--C 1.523 -0.064 0 N-CA-C 106.212 -1.774 . . . . 0.0 106.212 177.229 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.304 52.3 p -43.42 -60.25 2.67 Favored Pre-proline 0 CA--C 1.539 0.554 0 N-CA-C 115.776 1.769 . . . . 0.0 115.776 -173.124 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -61.38 -7.56 8.82 Favored 'Trans proline' 0 C--N 1.348 0.52 0 C-N-CA 122.21 1.94 . . . . 0.0 114.365 -178.526 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 34.7 m80 -131.34 16.84 4.96 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 119.504 1.047 . . . . 0.0 111.039 179.644 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 65.6 tt0 -60.22 -49.54 77.22 Favored 'General case' 0 C--N 1.34 0.164 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 179.048 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.77 -32.12 61.54 Favored Glycine 0 CA--C 1.53 0.976 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 177.832 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -81.49 3.89 23.12 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 123.326 0.65 . . . . 0.0 111.711 179.117 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 81.92 17.82 69.11 Favored Glycine 0 CA--C 1.526 0.775 0 CA-C-O 118.944 -0.92 . . . . 0.0 113.259 178.836 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 21.5 ttt -78.58 80.03 4.98 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-N 119.369 1.584 . . . . 0.0 107.997 178.317 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 6.8 m -127.39 170.61 16.99 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.249 0 C-N-CA 126.196 1.798 . . . . 0.0 110.949 -179.853 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -166.65 175.11 42.06 Favored Glycine 0 CA--C 1.528 0.855 0 N-CA-C 109.134 -1.587 . . . . 0.0 109.134 178.251 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 58.9 mttm -147.27 126.35 12.88 Favored 'General case' 0 N--CA 1.461 0.095 0 CA-C-N 118.037 0.919 . . . . 0.0 110.947 -178.627 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 6.8 p -113.17 124.77 70.13 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.167 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 178.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.7 m -94.14 104.23 16.25 Favored 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 124.111 0.965 . . . . 0.0 109.06 -179.648 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 21.9 t -81.89 98.6 4.47 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 N-CA-C 103.98 -2.6 . . . . 0.0 103.98 178.651 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 37.2 t-20 . . . . . 0 N--CA 1.454 -0.256 0 C-N-CA 124.898 1.279 . . . . 0.0 112.925 -175.008 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 8.9 tt . . . . . 0 CA--C 1.532 0.255 0 N-CA-C 110.26 -0.274 . . . . 0.0 110.26 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.4 tm-20 -94.7 119.43 33.31 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 123.84 0.856 . . . . 0.0 109.374 -179.3 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 25.8 t -109.72 128.92 65.43 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.293 0 C-N-CA 125.891 1.676 . . . . 0.0 109.193 179.63 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 62.4 mt -94.6 126.69 40.05 Favored 'General case' 0 C--O 1.233 0.222 0 N-CA-C 108.307 -0.998 . . . . 0.0 108.307 177.455 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 55.2 mt -86.55 99.03 11.4 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 105.942 -1.873 . . . . 0.0 105.942 177.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 101.17 134.0 8.34 Favored Glycine 0 CA--C 1.525 0.706 0 C-N-CA 125.539 1.542 . . . . 0.0 109.583 -178.495 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 22.3 p -82.87 42.86 0.81 Allowed 'General case' 0 N--CA 1.462 0.157 0 O-C-N 120.944 -1.327 . . . . 0.0 112.875 -178.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.24 -53.46 1.08 Allowed Glycine 0 CA--C 1.527 0.784 0 C-N-CA 126.18 1.848 . . . . 0.0 112.691 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -73.1 36.27 0.08 Allowed 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 125.837 1.655 . . . . 0.0 113.675 -177.539 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 70.39 -19.83 0.63 Allowed Glycine 0 CA--C 1.53 1.003 0 C-N-CA 124.808 1.194 . . . . 0.0 115.08 177.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 32.9 t -56.66 129.21 40.08 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-N 118.515 1.157 . . . . 0.0 110.916 -178.146 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 55.5 mt -77.31 65.87 2.97 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 126.378 1.871 . . . . 0.0 112.071 -175.492 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 29.6 m -130.32 144.24 38.58 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.213 0 C-N-CA 123.174 0.59 . . . . 0.0 111.475 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 37.7 m-85 -84.76 129.21 34.86 Favored 'General case' 0 N--CA 1.456 -0.138 0 N-CA-C 104.764 -2.31 . . . . 0.0 104.764 175.723 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.9 t -117.56 102.8 51.61 Favored Pre-proline 0 CA--C 1.534 0.334 0 CA-C-O 117.986 -1.007 . . . . 0.0 108.992 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -76.89 166.83 81.62 Favored 'Cis proline' 0 CA--C 1.535 0.554 0 CA-C-N 120.373 1.169 . . . . 0.0 111.23 -1.375 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 29.2 t -103.14 -60.42 1.55 Allowed 'General case' 0 CA--C 1.531 0.216 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 178.023 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 4.3 tm-20 -102.3 125.78 49.11 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 106.11 -1.811 . . . . 0.0 106.11 178.457 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.1 p90 -161.65 -176.69 5.44 Favored 'General case' 0 CA--C 1.535 0.372 0 CA-C-N 119.118 0.872 . . . . 0.0 112.757 -179.362 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.0 m -130.14 147.03 51.83 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 126.284 1.834 . . . . 0.0 108.605 179.686 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.0 m -145.25 152.17 49.85 Favored Pre-proline 0 CA--C 1.528 0.134 0 C-N-CA 125.086 1.354 . . . . 0.0 108.28 178.465 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -73.7 158.02 47.52 Favored 'Trans proline' 0 N--CA 1.453 -0.905 0 C-N-CA 121.931 1.754 . . . . 0.0 110.514 176.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 50.2 m -56.3 126.13 24.91 Favored 'General case' 0 CA--C 1.529 0.149 0 C-N-CA 123.221 0.608 . . . . 0.0 109.98 177.441 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 89.82 6.5 69.79 Favored Glycine 0 CA--C 1.526 0.73 0 CA-C-O 118.887 -0.952 . . . . 0.0 112.598 -179.621 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -61.8 138.14 58.31 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 119.315 1.557 . . . . 0.0 110.854 178.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 15.3 ptpt -93.49 95.85 9.52 Favored 'General case' 0 N--CA 1.444 -0.736 0 C-N-CA 126.394 1.878 . . . . 0.0 106.534 177.384 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 39.6 mt -83.04 136.14 23.41 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 -179.716 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 90.8 t -118.92 132.95 67.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 105.032 -2.21 . . . . 0.0 105.032 179.012 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 94.9 m-85 -121.44 123.57 42.38 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 106.33 -1.73 . . . . 0.0 106.33 178.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 7.7 ttpm? -120.15 136.57 54.57 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 118.812 0.733 . . . . 0.0 112.875 -178.369 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 6.6 m-20 -67.72 99.6 0.82 Allowed 'General case' 0 C--O 1.232 0.161 0 C-N-CA 124.108 0.963 . . . . 0.0 109.279 177.095 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 57.8 t30 -87.17 -59.75 2.17 Favored 'General case' 0 N--CA 1.455 -0.192 0 N-CA-C 109.443 -0.576 . . . . 0.0 109.443 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -161.08 167.51 26.17 Favored 'General case' 0 C--O 1.226 -0.179 0 C-N-CA 123.617 0.767 . . . . 0.0 109.841 -179.293 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 68.89 20.37 74.4 Favored Glycine 0 CA--C 1.533 1.177 0 O-C-N 121.834 -0.541 . . . . 0.0 113.181 179.308 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 18.6 p90 -68.61 166.66 24.43 Favored Pre-proline 0 CA--C 1.546 0.797 0 N-CA-C 106.53 -1.656 . . . . 0.0 106.53 177.043 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -69.97 156.34 93.41 Favored 'Cis proline' 0 N--CA 1.449 -1.136 0 CA-C-N 120.446 1.195 . . . . 0.0 114.488 4.215 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 87.9 m-70 -147.61 168.95 20.69 Favored 'General case' 0 N--CA 1.449 -0.498 0 O-C-N 121.638 -0.664 . . . . 0.0 111.49 -179.197 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 51.6 p30 -163.82 174.01 12.07 Favored 'General case' 0 N--CA 1.451 -0.416 0 N-CA-C 104.948 -2.242 . . . . 0.0 104.948 176.48 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 22.9 t -133.81 103.92 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.323 0 N-CA-C 107.062 -1.459 . . . . 0.0 107.062 -179.507 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.2 t -110.92 135.86 48.74 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 N-CA-C 105.896 -1.89 . . . . 0.0 105.896 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 53.5 m-85 -95.81 139.42 32.06 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 -179.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -72.02 111.09 6.97 Favored 'General case' 0 N--CA 1.45 -0.444 0 N-CA-C 107.7 -1.222 . . . . 0.0 107.7 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -46.16 -31.3 2.33 Favored 'General case' 0 CA--C 1.532 0.274 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -178.218 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -81.99 -50.92 8.58 Favored 'General case' 0 CA--C 1.531 0.25 0 CA-C-N 118.392 0.542 . . . . 0.0 109.662 178.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 40.3 mt-10 -80.45 56.65 2.61 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 124.143 0.977 . . . . 0.0 112.713 -177.066 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 26.4 pt -151.53 149.71 24.89 Favored Pre-proline 0 CA--C 1.534 0.329 0 C-N-CA 126.06 1.744 . . . . 0.0 107.715 175.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -69.11 116.26 4.4 Favored 'Trans proline' 0 N--CA 1.45 -1.068 0 C-N-CA 121.692 1.595 . . . . 0.0 108.706 176.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -33.65 -40.61 0.08 Allowed 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 127.741 2.416 . . . . 0.0 115.192 -177.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -50.98 -35.58 32.81 Favored Glycine 0 CA--C 1.533 1.16 0 C-N-CA 123.532 0.587 . . . . 0.0 112.805 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 48.2 t -103.53 103.77 15.65 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.209 0 CA-C-N 117.862 0.831 . . . . 0.0 108.945 -179.577 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -63.39 135.23 56.82 Favored 'General case' 0 CA--C 1.535 0.402 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 177.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -43.24 -41.26 3.79 Favored 'General case' 0 C--O 1.231 0.104 0 C-N-CA 126.182 1.793 . . . . 0.0 114.212 -179.504 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 85.8 t -56.88 -27.99 27.53 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 C-N-CA 123.03 0.532 . . . . 0.0 110.767 -179.459 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 34.5 mmtp -76.27 -19.11 58.62 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-O 118.438 -0.791 . . . . 0.0 112.539 -179.198 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -117.11 -23.37 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 N-CA-C 113.491 0.923 . . . . 0.0 113.491 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 31.3 m -84.09 129.82 34.89 Favored 'General case' 0 N--CA 1.453 -0.308 0 N-CA-C 113.892 1.071 . . . . 0.0 113.892 -177.207 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 15.0 tpt -66.18 121.57 77.08 Favored Pre-proline 0 CA--C 1.54 0.559 0 N-CA-C 104.824 -2.287 . . . . 0.0 104.824 173.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 90.5 Cg_exo -47.99 121.58 6.12 Favored 'Trans proline' 0 N--CA 1.457 -0.636 0 C-N-CA 123.0 2.467 . . . . 0.0 112.902 -178.094 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 21.2 mm-40 -42.51 -38.23 1.88 Allowed 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 126.009 1.724 . . . . 0.0 113.372 179.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 43.0 tt0 -54.63 -36.01 64.06 Favored 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 124.821 1.248 . . . . 0.0 111.562 179.54 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 49.9 mt-10 -105.02 157.1 17.46 Favored 'General case' 0 N--CA 1.445 -0.693 0 C-N-CA 125.736 1.615 . . . . 0.0 110.734 -177.621 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -161.17 151.81 18.08 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-O 121.79 0.805 . . . . 0.0 111.247 177.558 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 50.9 mt -76.81 96.27 4.24 Favored 'General case' 0 N--CA 1.444 -0.743 0 N-CA-C 103.278 -2.86 . . . . 0.0 103.278 177.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 4.0 p30 -88.0 -40.42 13.89 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 126.228 1.811 . . . . 0.0 113.515 -175.207 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -95.63 156.44 37.44 Favored Pre-proline 0 CA--C 1.535 0.374 0 C-N-CA 123.823 0.849 . . . . 0.0 110.142 -178.448 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -64.69 161.42 35.82 Favored 'Trans proline' 0 N--CA 1.457 -0.664 0 C-N-CA 122.245 1.964 . . . . 0.0 109.545 176.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 78.54 -34.5 1.81 Allowed Glycine 0 CA--C 1.529 0.931 0 CA-C-O 118.59 -1.117 . . . . 0.0 114.182 177.205 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 50.6 mt-10 -48.46 140.98 7.26 Favored 'General case' 0 CA--C 1.533 0.324 0 CA-C-N 119.062 1.431 . . . . 0.0 111.056 179.17 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 2.5 p -120.14 161.44 21.02 Favored 'General case' 0 N--CA 1.453 -0.316 0 C-N-CA 124.732 1.213 . . . . 0.0 111.84 -177.028 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 47.4 t80 -137.1 147.83 46.32 Favored 'General case' 0 N--CA 1.456 -0.13 0 N-CA-C 104.608 -2.367 . . . . 0.0 104.608 173.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 25.9 t -136.21 145.03 31.49 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.097 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 -178.46 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.8 p -152.62 138.13 11.17 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 178.739 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 33.8 m -105.6 112.25 25.26 Favored 'General case' 0 CA--C 1.528 0.129 0 C-N-CA 123.927 0.891 . . . . 0.0 108.801 -179.183 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 27.6 mt -93.19 88.5 6.07 Favored 'General case' 0 CA--C 1.529 0.167 0 CA-C-O 121.247 0.546 . . . . 0.0 110.84 -178.541 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -60.9 -69.12 0.25 Allowed 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 124.747 1.219 . . . . 0.0 114.052 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 2.8 m -73.2 138.82 45.88 Favored 'General case' 0 N--CA 1.452 -0.354 0 C-N-CA 124.098 0.959 . . . . 0.0 113.459 -172.174 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -62.72 154.17 30.37 Favored 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 123.711 0.804 . . . . 0.0 110.189 177.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 145.31 -170.3 26.71 Favored Glycine 0 C--N 1.334 0.456 0 N-CA-C 111.194 -0.763 . . . . 0.0 111.194 178.333 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 24.0 m -112.24 120.44 41.76 Favored 'General case' 0 N--CA 1.453 -0.304 0 N-CA-C 106.451 -1.685 . . . . 0.0 106.451 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 34.7 m-85 -117.28 107.32 14.26 Favored 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 124.046 0.938 . . . . 0.0 109.327 -178.232 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -92.5 139.58 30.44 Favored 'General case' 0 C--O 1.232 0.171 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 177.601 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 32.9 p90 -137.27 167.45 21.56 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 121.387 0.613 . . . . 0.0 111.613 -178.389 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 44.8 p90 -155.84 161.03 40.68 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 114.933 -1.03 . . . . 0.0 112.379 -178.461 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.4 t -101.72 103.77 14.55 Favored 'General case' 0 CA--C 1.519 -0.241 0 N-CA-C 105.308 -2.108 . . . . 0.0 105.308 176.674 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.344 77.7 p -45.48 -58.25 6.26 Favored Pre-proline 0 CA--C 1.537 0.452 0 N-CA-C 115.723 1.749 . . . . 0.0 115.723 -173.258 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -60.3 -7.79 7.38 Favored 'Trans proline' 0 N--CA 1.458 -0.57 0 C-N-CA 121.994 1.796 . . . . 0.0 114.527 -179.414 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 35.1 m80 -132.78 18.96 4.2 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 119.843 1.201 . . . . 0.0 111.427 179.064 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 31.8 tt0 -58.07 -49.86 75.45 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 178.133 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -55.96 -32.04 59.06 Favored Glycine 0 CA--C 1.531 1.046 0 C-N-CA 123.798 0.713 . . . . 0.0 112.005 178.61 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -82.32 4.12 25.05 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 117.497 0.648 . . . . 0.0 111.56 179.277 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 83.11 16.01 70.7 Favored Glycine 0 CA--C 1.526 0.727 0 CA-C-O 119.019 -0.878 . . . . 0.0 112.967 178.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 20.5 ttt -78.76 77.96 5.22 Favored 'General case' 0 C--O 1.237 0.398 0 CA-C-N 119.322 1.561 . . . . 0.0 108.569 178.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 8.1 m -128.0 174.65 11.16 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 C-N-CA 125.984 1.714 . . . . 0.0 110.993 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -166.66 174.08 42.06 Favored Glycine 0 CA--C 1.526 0.766 0 N-CA-C 111.053 -0.819 . . . . 0.0 111.053 177.461 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 23.6 ttmm -149.01 110.88 4.57 Favored 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 124.389 1.076 . . . . 0.0 110.057 -177.128 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.1 p -106.53 128.87 60.78 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.356 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 179.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.0 m -100.99 110.2 22.2 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 124.73 1.212 . . . . 0.0 110.354 -177.36 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 24.0 t -83.92 101.32 8.35 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.768 0 N-CA-C 105.799 -1.926 . . . . 0.0 105.799 179.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 2.7 m-80 . . . . . 0 N--CA 1.451 -0.402 0 C-N-CA 125.749 1.62 . . . . 0.0 108.922 -177.892 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 4.0 mm? . . . . . 0 N--CA 1.455 -0.208 0 CA-C-O 121.396 0.617 . . . . 0.0 111.705 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 14.6 tp10 -113.77 118.48 34.4 Favored 'General case' 0 N--CA 1.452 -0.367 0 N-CA-C 104.756 -2.313 . . . . 0.0 104.756 177.101 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 41.6 t -118.14 130.9 72.32 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 -178.827 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 68.8 mt -94.54 126.24 39.7 Favored 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 178.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 82.3 mt -90.13 98.94 12.06 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 105.835 -1.913 . . . . 0.0 105.835 177.046 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 110.57 -161.27 12.93 Favored Glycine 0 N--CA 1.447 -0.606 0 N-CA-C 109.095 -1.602 . . . . 0.0 109.095 -178.563 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 19.9 p -155.9 158.35 37.84 Favored 'General case' 0 N--CA 1.447 -0.591 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 -179.551 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.55 -39.99 31.16 Favored Glycine 0 CA--C 1.53 1.015 0 C-N-CA 123.538 0.59 . . . . 0.0 112.27 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -79.21 11.38 2.89 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 124.124 0.97 . . . . 0.0 112.642 179.218 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 70.12 14.02 70.62 Favored Glycine 0 CA--C 1.527 0.832 0 C-N-CA 124.605 1.098 . . . . 0.0 114.35 178.037 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 47.3 t -77.39 135.22 38.31 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 119.417 1.609 . . . . 0.0 108.82 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -73.57 67.98 1.14 Allowed 'General case' 0 N--CA 1.443 -0.793 0 C-N-CA 126.011 1.724 . . . . 0.0 111.179 -178.249 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 20.9 m -129.76 153.16 38.41 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 C-N-CA 123.477 0.711 . . . . 0.0 110.4 179.498 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 39.5 m-85 -93.33 131.44 38.48 Favored 'General case' 0 C--N 1.332 -0.169 0 N-CA-C 104.132 -2.544 . . . . 0.0 104.132 175.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.3 t -125.03 109.66 27.43 Favored Pre-proline 0 CA--C 1.534 0.362 0 CA-C-N 119.161 0.891 . . . . 0.0 108.906 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_endo -72.04 150.77 95.08 Favored 'Cis proline' 0 N--CA 1.459 -0.533 0 CA-C-N 120.209 1.11 . . . . 0.0 110.987 -1.478 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.2 m -77.17 -48.08 18.62 Favored 'General case' 0 N--CA 1.456 -0.133 0 C-N-CA 123.036 0.534 . . . . 0.0 110.258 179.444 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -124.68 134.28 52.92 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 179.475 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 39.0 p90 -158.67 -176.83 6.11 Favored 'General case' 0 C--O 1.233 0.215 0 O-C-N 123.181 0.301 . . . . 0.0 110.7 -178.701 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 16.0 m -133.95 149.77 51.27 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 125.036 1.334 . . . . 0.0 107.925 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.7 p -144.98 138.99 14.73 Favored Pre-proline 0 CA--C 1.537 0.445 0 C-N-CA 123.796 0.839 . . . . 0.0 109.962 -177.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_exo -65.3 140.54 64.64 Favored 'Trans proline' 0 N--CA 1.455 -0.743 0 CA-C-N 120.746 1.302 . . . . 0.0 110.241 176.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 52.2 m -52.42 122.35 8.64 Favored 'General case' 0 N--CA 1.455 -0.193 0 C-N-CA 124.161 0.984 . . . . 0.0 110.857 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 102.56 -19.13 48.86 Favored Glycine 0 CA--C 1.528 0.877 0 CA-C-O 118.82 -0.989 . . . . 0.0 113.051 179.446 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -73.19 143.78 47.07 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-N 119.658 1.729 . . . . 0.0 110.25 179.312 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 18.3 ptmt -81.16 144.2 31.83 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 124.424 1.09 . . . . 0.0 111.58 -178.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 35.9 mt -113.2 130.48 67.04 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 178.424 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 59.7 t -114.25 102.63 14.15 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.245 0 C-N-CA 125.135 1.374 . . . . 0.0 108.017 -179.258 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -90.92 98.5 11.82 Favored 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 178.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 27.0 ttpp -91.75 132.38 36.44 Favored 'General case' 0 CA--C 1.528 0.132 0 C-N-CA 123.581 0.752 . . . . 0.0 112.724 -177.608 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 54.5 t-20 -66.21 110.25 2.95 Favored 'General case' 0 CA--C 1.53 0.21 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 176.395 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 -87.34 -72.96 0.49 Allowed 'General case' 0 C--N 1.338 0.078 0 CA-C-N 118.31 0.504 . . . . 0.0 110.843 -179.11 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -163.46 175.43 10.76 Favored 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 125.131 1.372 . . . . 0.0 107.732 -177.747 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 65.36 24.11 70.53 Favored Glycine 0 CA--C 1.534 1.272 0 CA-C-N 118.694 0.679 . . . . 0.0 111.594 -178.8 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 17.1 p90 -74.72 169.05 21.7 Favored Pre-proline 0 CA--C 1.542 0.668 0 N-CA-C 107.108 -1.442 . . . . 0.0 107.108 178.411 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -69.53 158.3 90.45 Favored 'Cis proline' 0 N--CA 1.448 -1.201 0 CA-C-O 123.115 1.215 . . . . 0.0 114.994 3.731 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 88.2 m-70 -149.55 172.94 14.2 Favored 'General case' 0 N--CA 1.445 -0.711 0 CA-C-N 114.693 -1.14 . . . . 0.0 109.356 179.542 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 48.0 p30 -169.77 173.11 6.38 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 104.435 -2.432 . . . . 0.0 104.435 176.514 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 37.6 t -130.14 110.51 19.4 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.222 0 N-CA-C 107.767 -1.197 . . . . 0.0 107.767 -178.54 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.9 t -113.03 129.12 69.27 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.606 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 -179.737 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 62.2 m-85 -91.04 133.17 35.52 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 178.658 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -68.61 110.57 4.3 Favored 'General case' 0 N--CA 1.452 -0.352 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 -179.751 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -41.75 -35.0 0.7 Allowed 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 126.154 1.782 . . . . 0.0 115.747 -177.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -85.14 -50.01 7.77 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 118.5 0.591 . . . . 0.0 110.879 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -79.67 56.56 2.27 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 124.271 1.028 . . . . 0.0 112.412 -176.362 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 31.8 pt -153.35 156.57 32.57 Favored Pre-proline 0 CA--C 1.533 0.304 0 C-N-CA 126.689 1.996 . . . . 0.0 107.473 176.673 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_exo -53.62 109.5 0.38 Allowed 'Trans proline' 0 N--CA 1.456 -0.681 0 C-N-CA 122.819 2.346 . . . . 0.0 111.141 177.001 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -52.28 106.42 0.15 Allowed 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 124.203 1.001 . . . . 0.0 110.107 -179.772 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 142.29 -35.57 1.73 Allowed Glycine 0 CA--C 1.526 0.756 0 N-CA-C 109.005 -1.638 . . . . 0.0 109.005 -177.699 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 47.2 t -77.08 108.19 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 179.285 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 45.2 t0 -59.11 109.11 0.78 Allowed 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 123.039 0.535 . . . . 0.0 110.566 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.34 -40.42 17.21 Favored 'General case' 0 N--CA 1.453 -0.313 0 C-N-CA 125.079 1.351 . . . . 0.0 111.531 179.274 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 54.4 t -58.33 -28.77 36.3 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 C-N-CA 123.491 0.717 . . . . 0.0 111.925 -179.088 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 2.6 mmmp? -82.34 -40.66 21.1 Favored 'General case' 0 N--CA 1.461 0.122 0 CA-C-N 118.709 0.686 . . . . 0.0 110.909 -178.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 33.1 pt -78.14 -30.26 15.84 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.209 0 N-CA-C 112.191 0.441 . . . . 0.0 112.191 -179.842 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 35.5 m -90.7 146.74 23.76 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 114.667 1.358 . . . . 0.0 114.667 -176.792 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 48.2 mmm -74.67 128.05 86.18 Favored Pre-proline 0 N--CA 1.448 -0.556 0 N-CA-C 102.066 -3.309 . . . . 0.0 102.066 169.005 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -61.33 133.44 46.33 Favored 'Trans proline' 0 N--CA 1.453 -0.878 0 N-CA-C 107.213 -1.88 . . . . 0.0 107.213 178.609 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -43.32 -35.18 1.41 Allowed 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 124.506 1.122 . . . . 0.0 113.812 -176.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -55.0 -41.64 71.49 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 124.999 1.319 . . . . 0.0 111.414 178.399 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 74.9 mm-40 -85.3 144.41 28.1 Favored 'General case' 0 N--CA 1.444 -0.737 0 C-N-CA 124.186 0.994 . . . . 0.0 111.122 -177.904 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 92.3 mt -143.49 145.25 32.43 Favored 'General case' 0 N--CA 1.45 -0.442 0 C-N-CA 124.729 1.212 . . . . 0.0 110.446 -177.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 84.4 mt -86.23 99.85 11.83 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 104.421 -2.437 . . . . 0.0 104.421 175.245 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 33.0 p-10 -86.57 -51.4 6.19 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 124.189 0.996 . . . . 0.0 111.736 -177.556 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.91 143.49 66.51 Favored Pre-proline 0 CA--C 1.533 0.322 0 O-C-N 121.932 -0.48 . . . . 0.0 110.468 -177.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -64.91 152.4 82.4 Favored 'Trans proline' 0 N--CA 1.453 -0.872 0 C-N-CA 122.522 2.148 . . . . 0.0 109.513 178.322 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 86.14 -24.52 7.97 Favored Glycine 0 CA--C 1.527 0.822 0 CA-C-O 118.41 -1.217 . . . . 0.0 114.09 177.125 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 66.1 mt-10 -51.8 127.43 20.83 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-N 119.465 1.633 . . . . 0.0 110.522 179.11 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 11.8 p -105.63 120.7 42.32 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 124.772 1.229 . . . . 0.0 112.334 -178.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 25.1 t80 -95.01 107.54 19.58 Favored 'General case' 0 N--CA 1.452 -0.372 0 N-CA-C 104.743 -2.317 . . . . 0.0 104.743 173.576 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 22.6 t -95.63 138.13 22.0 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 -178.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 10.9 p -145.85 168.81 7.06 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.17 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 177.548 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 29.1 m -147.02 130.39 16.66 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 64.6 mt -114.31 116.85 29.62 Favored 'General case' 0 CA--C 1.531 0.224 0 C-N-CA 123.636 0.774 . . . . 0.0 109.766 -177.601 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -91.3 -46.37 8.08 Favored 'General case' 0 CA--C 1.531 0.239 0 C-N-CA 124.195 0.998 . . . . 0.0 111.716 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.7 m -73.22 121.03 19.66 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 122.792 0.437 . . . . 0.0 110.712 -177.069 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 23.4 pttm -64.77 153.17 40.69 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 122.918 0.487 . . . . 0.0 111.462 178.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 139.18 174.28 13.45 Favored Glycine 0 CA--C 1.529 0.911 0 C-N-CA 125.552 1.548 . . . . 0.0 110.467 179.426 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 99.0 m -99.01 116.95 32.42 Favored 'General case' 0 N--CA 1.456 -0.128 0 C-N-CA 124.296 1.038 . . . . 0.0 108.646 179.457 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 10.7 m-85 -103.82 134.31 47.34 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 125.368 1.467 . . . . 0.0 108.05 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 20.2 m -104.3 139.51 39.19 Favored 'General case' 0 C--O 1.232 0.173 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 176.333 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 15.6 p90 -138.13 166.37 24.3 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-O 121.474 0.654 . . . . 0.0 111.946 -179.421 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 43.7 p90 -152.22 162.45 41.11 Favored 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 124.393 1.077 . . . . 0.0 112.294 -178.697 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.6 t -101.57 106.68 17.79 Favored 'General case' 0 CA--C 1.52 -0.174 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 176.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 4.9 t -38.82 -64.21 0.51 Allowed Pre-proline 0 CA--C 1.542 0.645 0 N-CA-C 115.349 1.611 . . . . 0.0 115.349 -175.413 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -64.09 -4.31 7.44 Favored 'Trans proline' 0 C--N 1.348 0.537 0 C-N-CA 122.467 2.111 . . . . 0.0 114.533 -177.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 37.0 m80 -130.42 20.81 5.2 Favored 'General case' 0 N--CA 1.455 -0.216 0 CA-C-N 119.461 1.028 . . . . 0.0 110.698 179.041 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 4.6 tp60 -58.43 -51.97 67.58 Favored 'General case' 0 CA--C 1.533 0.296 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 177.093 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.13 -33.55 61.19 Favored Glycine 0 CA--C 1.532 1.129 0 C-N-CA 123.526 0.584 . . . . 0.0 111.866 178.276 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -81.54 1.57 33.01 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 123.284 0.634 . . . . 0.0 111.953 179.265 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 77.14 23.82 67.74 Favored Glycine 0 CA--C 1.526 0.757 0 CA-C-O 119.231 -0.76 . . . . 0.0 113.512 178.711 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 26.1 ttt -79.27 80.47 5.63 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-N 119.207 1.504 . . . . 0.0 107.406 177.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 16.5 m -121.65 169.49 12.91 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.191 0 C-N-CA 125.943 1.697 . . . . 0.0 110.878 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -170.93 179.47 42.81 Favored Glycine 0 CA--C 1.526 0.733 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 178.139 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 49.6 mttp -148.17 161.4 41.53 Favored 'General case' 0 CA--C 1.528 0.132 0 CA-C-N 117.985 0.893 . . . . 0.0 110.581 -179.474 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 3.8 p -145.04 124.01 5.84 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 C-N-CA 123.488 0.715 . . . . 0.0 110.201 178.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 99.1 m -98.32 98.22 9.49 Favored 'General case' 0 C--O 1.236 0.359 0 C-N-CA 124.641 1.176 . . . . 0.0 111.214 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 30.2 t -75.88 120.35 25.6 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.631 0 N-CA-C 104.617 -2.364 . . . . 0.0 104.617 179.184 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 5.5 p30 . . . . . 0 N--CA 1.464 0.238 0 N-CA-C 112.634 0.605 . . . . 0.0 112.634 -174.034 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 6.0 tp . . . . . 0 CA--C 1.533 0.298 0 CA-C-O 121.024 0.44 . . . . 0.0 111.274 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 -93.08 95.76 9.63 Favored 'General case' 0 N--CA 1.456 -0.172 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 177.228 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 33.5 t -91.97 138.27 20.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 C-N-CA 125.39 1.476 . . . . 0.0 109.076 -179.503 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 72.3 mt -99.76 125.44 45.67 Favored 'General case' 0 N--CA 1.45 -0.43 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 177.816 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 59.0 mt -86.46 101.93 13.61 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 105.855 -1.906 . . . . 0.0 105.855 178.196 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 95.87 157.88 32.01 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 108.347 -1.901 . . . . 0.0 108.347 -178.196 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 53.9 p -107.57 159.71 16.23 Favored 'General case' 0 N--CA 1.445 -0.718 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 -179.833 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.91 -34.62 61.81 Favored Glycine 0 CA--C 1.529 0.937 0 C-N-CA 124.183 0.897 . . . . 0.0 111.262 178.689 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -75.66 -2.9 31.64 Favored 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 123.519 0.728 . . . . 0.0 112.243 178.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 96.36 -17.86 58.51 Favored Glycine 0 CA--C 1.526 0.764 0 CA-C-O 118.903 -0.943 . . . . 0.0 113.556 178.671 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 32.8 t -57.27 132.35 52.76 Favored 'General case' 0 C--O 1.238 0.487 0 CA-C-N 119.4 1.6 . . . . 0.0 110.487 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 47.8 mt -77.59 67.39 3.49 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 126.818 2.047 . . . . 0.0 110.384 -177.087 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.6 m -128.2 153.76 38.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 C-N-CA 123.264 0.626 . . . . 0.0 110.611 179.862 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -87.43 130.64 34.6 Favored 'General case' 0 N--CA 1.453 -0.311 0 N-CA-C 104.153 -2.536 . . . . 0.0 104.153 175.259 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 35.3 t -120.45 108.96 37.06 Favored Pre-proline 0 CA--C 1.535 0.385 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_endo -73.3 157.2 99.31 Favored 'Cis proline' 0 N--CA 1.459 -0.552 0 CA-C-N 120.332 1.154 . . . . 0.0 110.48 -1.566 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.5 m -79.16 -43.33 24.19 Favored 'General case' 0 C--N 1.332 -0.153 0 C-N-CA 123.054 0.542 . . . . 0.0 110.884 -179.598 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -129.08 145.18 51.34 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 106.669 -1.604 . . . . 0.0 106.669 178.192 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 19.2 p90 -166.52 -179.62 5.01 Favored 'General case' 0 C--O 1.235 0.342 0 C-N-CA 123.213 0.605 . . . . 0.0 110.186 -177.665 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 37.1 p -139.71 136.29 34.06 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 124.422 1.089 . . . . 0.0 108.684 -178.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 33.7 m -130.09 146.27 60.76 Favored Pre-proline 0 CA--C 1.533 0.298 0 C-N-CA 124.177 0.991 . . . . 0.0 110.185 179.606 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_exo -57.67 144.34 93.09 Favored 'Trans proline' 0 N--CA 1.455 -0.742 0 C-N-CA 122.591 2.194 . . . . 0.0 110.845 174.785 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 16.3 m -51.26 119.58 4.19 Favored 'General case' 0 CA--C 1.529 0.149 0 C-N-CA 122.608 0.363 . . . . 0.0 110.955 177.846 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 96.72 -7.48 65.44 Favored Glycine 0 CA--C 1.525 0.68 0 CA-C-O 118.426 -1.208 . . . . 0.0 113.618 178.526 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -69.18 152.96 44.46 Favored 'General case' 0 CA--C 1.531 0.224 0 CA-C-N 119.953 1.877 . . . . 0.0 110.494 178.28 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 64.4 mttp -83.36 142.0 31.35 Favored 'General case' 0 N--CA 1.446 -0.666 0 C-N-CA 124.172 0.989 . . . . 0.0 109.882 -178.502 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 37.8 mt -120.56 130.08 74.89 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 105.963 -1.866 . . . . 0.0 105.963 178.386 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 84.9 t -121.88 131.42 73.16 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.428 0 N-CA-C 106.459 -1.682 . . . . 0.0 106.459 -179.242 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -118.19 103.47 9.88 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 178.799 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 38.0 ttpt -100.76 131.3 46.72 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 123.886 0.874 . . . . 0.0 113.296 -175.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 6.2 m-20 -64.96 107.81 1.61 Allowed 'General case' 0 C--O 1.232 0.137 0 C-N-CA 124.124 0.969 . . . . 0.0 109.975 177.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 7.0 t30 -87.67 -64.42 1.15 Allowed 'General case' 0 N--CA 1.456 -0.148 0 CA-C-O 121.496 0.665 . . . . 0.0 110.089 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -163.1 172.8 14.36 Favored 'General case' 0 C--N 1.331 -0.213 0 C-N-CA 125.54 1.536 . . . . 0.0 107.191 -178.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 66.2 20.28 69.05 Favored Glycine 0 CA--C 1.534 1.219 0 CA-C-N 118.291 0.496 . . . . 0.0 112.839 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 23.4 p90 -69.96 166.94 27.89 Favored Pre-proline 0 CA--C 1.549 0.905 0 N-CA-C 106.444 -1.688 . . . . 0.0 106.444 177.177 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -69.94 156.43 93.27 Favored 'Cis proline' 0 N--CA 1.444 -1.386 0 N-CA-C 115.712 1.389 . . . . 0.0 115.712 4.719 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 86.9 m-70 -147.81 164.86 32.34 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.83 -179.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 56.0 p30 -162.36 177.62 9.39 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 104.986 -2.228 . . . . 0.0 104.986 177.259 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 33.6 t -135.66 111.01 11.88 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 -179.547 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 93.9 t -115.19 130.47 69.68 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.586 0 N-CA-C 106.394 -1.706 . . . . 0.0 106.394 179.568 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 54.4 m-85 -87.59 136.31 33.0 Favored 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 123.4 0.68 . . . . 0.0 109.755 -179.394 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 43.7 t0 -73.11 103.89 4.01 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -47.54 -32.46 5.37 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 124.139 0.976 . . . . 0.0 113.555 179.207 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -77.3 -17.19 58.53 Favored 'General case' 0 CA--C 1.535 0.386 0 N-CA-C 112.983 0.734 . . . . 0.0 112.983 -179.78 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 81.5 mm-40 -132.91 65.9 1.58 Allowed 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.112 0.965 . . . . 0.0 111.801 -177.17 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 29.3 pt -153.3 153.49 29.44 Favored Pre-proline 0 CA--C 1.533 0.326 0 C-N-CA 127.542 2.337 . . . . 0.0 105.851 175.784 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -60.47 113.47 1.7 Allowed 'Trans proline' 0 N--CA 1.452 -0.964 0 C-N-CA 121.972 1.781 . . . . 0.0 110.556 178.293 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -51.5 108.37 0.26 Allowed 'General case' 0 N--CA 1.453 -0.276 0 C-N-CA 125.111 1.364 . . . . 0.0 110.397 -179.248 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 143.61 -37.51 1.45 Allowed Glycine 0 CA--C 1.524 0.617 0 N-CA-C 109.019 -1.632 . . . . 0.0 109.019 -178.428 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 45.8 t -77.58 113.82 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.239 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 41.9 t0 -60.94 111.65 1.75 Allowed 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 122.769 0.428 . . . . 0.0 110.114 179.543 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.4 -41.47 20.0 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 124.685 1.194 . . . . 0.0 111.149 178.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 48.6 t -59.7 -29.16 42.19 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.395 0 C-N-CA 123.283 0.633 . . . . 0.0 112.048 -179.053 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 64.3 mttp -78.71 -40.93 32.31 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-N 119.055 0.843 . . . . 0.0 110.772 -179.173 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 23.1 pt -77.6 -33.36 19.12 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 N-CA-C 111.917 0.34 . . . . 0.0 111.917 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 49.1 m -82.55 138.97 34.11 Favored 'General case' 0 N--CA 1.452 -0.341 0 N-CA-C 113.935 1.087 . . . . 0.0 113.935 -177.602 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 15.7 tpt -70.85 126.16 92.11 Favored Pre-proline 0 N--CA 1.449 -0.498 0 N-CA-C 101.956 -3.35 . . . . 0.0 101.956 170.813 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 76.2 Cg_exo -43.91 119.27 1.88 Allowed 'Trans proline' 0 N--CA 1.457 -0.66 0 C-N-CA 122.929 2.419 . . . . 0.0 111.51 -178.457 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -47.0 -34.97 6.08 Favored 'General case' 0 CA--C 1.532 0.255 0 C-N-CA 125.162 1.385 . . . . 0.0 113.708 -177.465 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 31.0 tp10 -61.61 -34.51 75.77 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.325 1.05 . . . . 0.0 110.729 179.009 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 63.0 mt-10 -91.68 154.61 18.88 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 124.911 1.284 . . . . 0.0 110.508 -178.61 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -160.97 139.75 10.09 Favored 'General case' 0 N--CA 1.445 -0.68 0 CA-C-N 115.015 -0.993 . . . . 0.0 110.971 179.867 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 73.8 mt -77.86 112.39 14.68 Favored 'General case' 0 N--CA 1.448 -0.575 0 N-CA-C 105.059 -2.2 . . . . 0.0 105.059 178.199 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 63.7 t30 -115.54 46.69 1.45 Allowed 'General case' 0 N--CA 1.464 0.247 0 C-N-CA 124.2 1.0 . . . . 0.0 112.491 -177.03 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -160.5 155.39 20.74 Favored Pre-proline 0 CA--C 1.531 0.22 0 N-CA-C 107.08 -1.452 . . . . 0.0 107.08 178.204 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -73.02 162.64 40.42 Favored 'Trans proline' 0 N--CA 1.454 -0.833 0 C-N-CA 122.013 1.808 . . . . 0.0 109.332 178.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 77.42 -35.94 1.56 Allowed Glycine 0 CA--C 1.529 0.938 0 CA-C-O 118.798 -1.001 . . . . 0.0 114.709 176.256 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 74.5 mm-40 -47.0 134.45 10.39 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 118.783 1.291 . . . . 0.0 111.387 179.165 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 21.8 p -119.53 132.56 55.78 Favored 'General case' 0 N--CA 1.456 -0.134 0 N-CA-C 113.83 1.048 . . . . 0.0 113.83 -177.436 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 31.9 t80 -100.91 140.38 35.28 Favored 'General case' 0 CA--C 1.529 0.166 0 N-CA-C 103.801 -2.666 . . . . 0.0 103.801 170.746 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 22.0 t -128.89 145.45 35.71 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.109 0 CA-C-N 119.007 0.821 . . . . 0.0 109.74 -177.647 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 12.5 p -152.23 169.23 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.197 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 178.367 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 83.6 m -149.06 133.62 17.68 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 106.264 -1.754 . . . . 0.0 106.264 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 79.2 mt -121.25 112.14 18.25 Favored 'General case' 0 CA--C 1.53 0.189 0 C-N-CA 123.234 0.614 . . . . 0.0 110.52 -177.305 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -93.86 -39.86 10.48 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 124.427 1.091 . . . . 0.0 110.543 178.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 6.4 m -70.19 122.11 18.85 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 123.594 0.758 . . . . 0.0 110.091 -178.162 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 20.8 mmtm -59.24 160.29 6.66 Favored 'General case' 0 CA--C 1.529 0.14 0 C-N-CA 124.186 0.995 . . . . 0.0 110.988 -179.692 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 134.96 -170.29 22.91 Favored Glycine 0 CA--C 1.524 0.6 0 C-N-CA 123.604 0.621 . . . . 0.0 111.822 177.703 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 25.3 m -121.26 130.34 53.62 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 105.503 -2.036 . . . . 0.0 105.503 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 16.5 m-85 -124.05 135.01 53.29 Favored 'General case' 0 N--CA 1.448 -0.525 0 C-N-CA 124.106 0.962 . . . . 0.0 109.818 -176.595 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 19.2 m -108.81 143.6 37.77 Favored 'General case' 0 C--O 1.233 0.199 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 175.644 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 11.8 p90 -143.89 171.31 14.41 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-O 121.15 0.5 . . . . 0.0 111.167 -179.308 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 34.4 p90 -157.76 167.38 30.21 Favored 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 123.805 0.842 . . . . 0.0 111.917 -179.176 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.3 t -102.99 109.31 20.8 Favored 'General case' 0 N--CA 1.463 0.181 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 177.494 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -40.92 -61.09 1.37 Allowed Pre-proline 0 CA--C 1.535 0.395 0 N-CA-C 115.659 1.725 . . . . 0.0 115.659 -173.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 63.6 Cg_endo -65.96 -4.2 9.71 Favored 'Trans proline' 0 N--CA 1.457 -0.638 0 C-N-CA 121.885 1.723 . . . . 0.0 114.87 -177.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 34.9 m80 -135.21 4.78 3.22 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-N 120.183 1.356 . . . . 0.0 113.185 -179.395 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 16.2 pt20 -55.7 -44.38 77.33 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 119.652 1.115 . . . . 0.0 109.975 178.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -59.17 -28.15 63.71 Favored Glycine 0 CA--C 1.531 1.037 0 N-CA-C 111.454 -0.659 . . . . 0.0 111.454 177.598 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.83 10.09 24.96 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 123.875 0.87 . . . . 0.0 110.843 178.771 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 87.31 10.22 71.47 Favored Glycine 0 CA--C 1.527 0.819 0 CA-C-O 118.558 -1.135 . . . . 0.0 113.789 178.29 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 18.4 ttt -78.96 76.54 5.45 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 119.791 1.796 . . . . 0.0 109.17 179.006 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 9.5 m -123.36 169.72 14.42 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 C-N-CA 126.388 1.875 . . . . 0.0 109.664 179.172 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -170.02 -179.8 41.85 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 110.211 -1.156 . . . . 0.0 110.211 178.156 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 54.1 mtmt -145.44 163.18 35.45 Favored 'General case' 0 N--CA 1.455 -0.224 0 C-N-CA 124.218 1.007 . . . . 0.0 110.29 -178.294 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.4 p -152.93 136.14 7.54 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 C-N-CA 123.898 0.879 . . . . 0.0 108.975 177.34 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -107.26 130.43 54.75 Favored 'General case' 0 C--N 1.332 -0.167 0 C-N-CA 124.441 1.096 . . . . 0.0 109.167 -179.633 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 43.4 t -99.8 97.81 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 N-CA-C 106.078 -1.823 . . . . 0.0 106.078 179.252 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 17.4 m-20 . . . . . 0 C--O 1.236 0.377 0 C-N-CA 123.604 0.762 . . . . 0.0 109.551 -176.728 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.451 -0.416 0 N-CA-C 105.976 -1.861 . . . . 0.0 105.976 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 69.2 tt0 -83.12 85.24 7.23 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 105.142 -2.17 . . . . 0.0 105.142 174.744 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 38.4 t -78.56 111.31 15.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 -176.713 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 57.8 mt -79.59 123.53 27.69 Favored 'General case' 0 N--CA 1.451 -0.416 0 N-CA-C 108.377 -0.971 . . . . 0.0 108.377 179.814 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 79.4 mt -84.23 107.41 16.52 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 178.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 86.56 130.48 2.79 Favored Glycine 0 C--N 1.337 0.599 0 N-CA-C 108.536 -1.826 . . . . 0.0 108.536 -179.014 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 5.0 p -78.99 157.46 28.13 Favored 'General case' 0 N--CA 1.441 -0.883 0 CA-C-N 118.461 1.131 . . . . 0.0 108.623 -178.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -43.94 -37.85 4.35 Favored Glycine 0 CA--C 1.531 1.06 0 C-N-CA 125.871 1.701 . . . . 0.0 113.76 -179.292 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -75.67 2.26 12.44 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 123.952 0.901 . . . . 0.0 113.253 -179.473 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 91.19 -10.33 75.22 Favored Glycine 0 CA--C 1.528 0.862 0 CA-C-O 118.828 -0.985 . . . . 0.0 113.188 -179.563 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.2 t -61.35 134.3 56.78 Favored 'General case' 0 C--N 1.343 0.293 0 CA-C-N 119.447 1.623 . . . . 0.0 110.518 -179.046 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 56.2 mt -76.63 66.06 2.53 Favored 'General case' 0 N--CA 1.447 -0.59 0 C-N-CA 126.079 1.751 . . . . 0.0 111.292 -176.312 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 29.4 m -131.13 148.65 32.94 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 C-N-CA 123.767 0.827 . . . . 0.0 110.361 179.437 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 49.9 m-85 -82.0 138.74 34.84 Favored 'General case' 0 N--CA 1.455 -0.204 0 N-CA-C 104.485 -2.413 . . . . 0.0 104.485 175.525 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.4 t -123.78 107.09 31.46 Favored Pre-proline 0 CA--C 1.533 0.302 0 CA-C-O 118.33 -0.843 . . . . 0.0 108.755 179.422 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_exo -70.45 154.69 95.22 Favored 'Cis proline' 0 C--N 1.346 0.429 0 CA-C-N 119.877 0.992 . . . . 0.0 112.015 -0.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.6 m -80.24 -45.44 17.97 Favored 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 177.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -126.98 142.5 51.54 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 105.84 -1.911 . . . . 0.0 105.84 177.642 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 33.8 p90 -166.88 175.62 7.59 Favored 'General case' 0 N--CA 1.455 -0.202 0 C-N-CA 123.637 0.775 . . . . 0.0 109.319 -178.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 16.4 m -134.8 143.16 46.92 Favored 'General case' 0 N--CA 1.45 -0.439 0 C-N-CA 124.499 1.12 . . . . 0.0 108.187 -179.652 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 32.7 m -137.73 149.51 64.9 Favored Pre-proline 0 CA--C 1.53 0.192 0 C-N-CA 124.632 1.173 . . . . 0.0 108.675 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -71.66 148.66 53.51 Favored 'Trans proline' 0 N--CA 1.448 -1.163 0 C-N-CA 121.76 1.64 . . . . 0.0 108.902 176.426 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 52.3 m -49.01 121.75 5.11 Favored 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 123.434 0.694 . . . . 0.0 110.961 178.572 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 99.51 -10.42 61.12 Favored Glycine 0 CA--C 1.526 0.766 0 CA-C-O 118.452 -1.193 . . . . 0.0 113.513 178.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -65.6 144.54 56.9 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 119.982 1.891 . . . . 0.0 108.969 178.394 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.2 ptmt -89.36 140.85 29.09 Favored 'General case' 0 N--CA 1.443 -0.825 0 N-CA-C 108.606 -0.886 . . . . 0.0 108.606 178.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 35.8 mt -112.61 131.94 62.74 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.386 0 N-CA-C 105.305 -2.109 . . . . 0.0 105.305 179.066 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 95.2 t -119.01 101.07 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.351 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 -179.071 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -86.27 132.66 33.94 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 106.228 -1.768 . . . . 0.0 106.228 177.357 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 61.1 tttp -131.27 130.54 42.96 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 119.237 0.926 . . . . 0.0 112.629 -176.699 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 4.1 m-20 -64.18 105.95 0.99 Allowed 'General case' 0 C--O 1.232 0.153 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 176.796 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 36.0 t30 -97.44 -69.72 0.75 Allowed 'General case' 0 N--CA 1.456 -0.162 0 CA-C-O 121.121 0.486 . . . . 0.0 110.521 -179.58 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -143.46 170.42 15.84 Favored 'General case' 0 C--O 1.224 -0.271 0 C-N-CA 124.102 0.961 . . . . 0.0 109.15 -178.56 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 57.75 19.68 36.81 Favored Glycine 0 CA--C 1.536 1.393 0 CA-C-N 118.748 0.703 . . . . 0.0 114.094 179.56 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 27.0 p90 -71.25 167.02 33.12 Favored Pre-proline 0 CA--C 1.542 0.662 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 178.026 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -70.49 160.42 90.25 Favored 'Cis proline' 0 N--CA 1.448 -1.153 0 N-CA-C 115.571 1.335 . . . . 0.0 115.571 4.336 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 86.7 m-70 -151.87 173.16 15.12 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.672 -178.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 57.2 p30 -163.14 178.25 8.41 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 105.035 -2.209 . . . . 0.0 105.035 176.397 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 24.0 t -135.39 110.23 11.51 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.307 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 -179.207 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 53.7 t -112.93 131.02 65.69 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 N-CA-C 106.552 -1.647 . . . . 0.0 106.552 179.545 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -92.02 132.64 36.4 Favored 'General case' 0 N--CA 1.45 -0.43 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 178.411 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -71.74 101.2 2.52 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 -178.881 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -37.61 -36.68 0.18 Allowed 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 126.676 1.99 . . . . 0.0 115.681 179.48 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 72.6 m-20 -77.94 -43.71 29.04 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-N 118.747 0.703 . . . . 0.0 110.343 179.755 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -93.32 57.58 2.68 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 124.487 1.115 . . . . 0.0 113.028 -176.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 37.5 pt -154.98 157.86 32.0 Favored Pre-proline 0 CA--C 1.533 0.306 0 C-N-CA 126.392 1.877 . . . . 0.0 106.879 176.238 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -57.85 108.15 0.36 Allowed 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 122.09 1.86 . . . . 0.0 108.245 173.812 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -35.08 -43.4 0.2 Allowed 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 126.829 2.052 . . . . 0.0 115.433 -177.084 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -57.68 -31.59 64.09 Favored Glycine 0 CA--C 1.533 1.218 0 C-N-CA 123.114 0.387 . . . . 0.0 113.341 -179.208 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 41.8 t -83.54 99.94 6.61 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 CA-C-N 117.945 0.873 . . . . 0.0 109.186 -178.595 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 17.4 t0 -53.6 113.29 1.12 Allowed 'General case' 0 CA--C 1.536 0.405 0 C-N-CA 123.321 0.648 . . . . 0.0 110.306 178.149 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -46.67 -39.91 12.23 Favored 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 125.778 1.631 . . . . 0.0 112.295 -179.874 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 54.0 t -59.11 -27.72 36.92 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 C-N-CA 123.101 0.561 . . . . 0.0 111.706 -178.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 2.9 mmmp? -77.91 -42.94 31.5 Favored 'General case' 0 CA--C 1.529 0.16 0 CA-C-N 118.675 0.671 . . . . 0.0 110.837 -179.096 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 26.4 pt -78.78 -33.44 16.49 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.339 0 N-CA-C 112.284 0.475 . . . . 0.0 112.284 -179.037 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 44.4 m -80.52 141.69 34.9 Favored 'General case' 0 C--N 1.333 -0.112 0 N-CA-C 114.96 1.467 . . . . 0.0 114.96 -176.599 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -73.69 137.85 77.1 Favored Pre-proline 0 CA--C 1.539 0.528 0 N-CA-C 103.031 -2.951 . . . . 0.0 103.031 172.008 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_endo -48.97 107.31 0.14 Allowed 'Trans proline' 0 CA--C 1.535 0.568 0 C-N-CA 122.768 2.312 . . . . 0.0 112.173 -178.565 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -35.91 -43.55 0.32 Allowed 'General case' 0 C--O 1.233 0.204 0 C-N-CA 128.283 2.633 . . . . 0.0 116.598 -176.334 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 13.8 tm-20 -73.81 -32.39 63.71 Favored 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 124.576 1.15 . . . . 0.0 111.637 -178.363 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 51.8 mt-10 -84.93 165.45 17.62 Favored 'General case' 0 N--CA 1.446 -0.647 0 C-N-CA 124.118 0.967 . . . . 0.0 109.426 -177.435 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 2.2 pp -157.65 160.72 38.31 Favored 'General case' 0 N--CA 1.448 -0.547 0 CA-C-O 121.419 0.628 . . . . 0.0 112.072 -178.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 72.9 mt -86.82 109.12 19.06 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 104.166 -2.531 . . . . 0.0 104.166 177.075 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 34.6 p-10 -81.14 -55.45 4.74 Favored 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 123.936 0.895 . . . . 0.0 113.282 -176.658 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.32 156.76 78.59 Favored Pre-proline 0 CA--C 1.535 0.373 0 C-N-CA 123.918 0.887 . . . . 0.0 112.302 -176.426 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -67.04 163.39 34.14 Favored 'Trans proline' 0 N--CA 1.455 -0.74 0 C-N-CA 122.364 2.043 . . . . 0.0 108.967 175.109 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 79.1 -36.48 1.94 Allowed Glycine 0 CA--C 1.528 0.897 0 CA-C-O 119.041 -0.866 . . . . 0.0 113.62 177.336 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 50.7 mm-40 -42.26 129.14 3.81 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 124.606 1.162 . . . . 0.0 110.683 178.564 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -111.83 159.76 18.01 Favored 'General case' 0 N--CA 1.452 -0.354 0 C-N-CA 124.665 1.186 . . . . 0.0 112.393 -177.07 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 75.8 t80 -138.24 111.58 8.03 Favored 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 105.136 -2.172 . . . . 0.0 105.136 174.623 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 37.4 t -101.71 142.2 16.69 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 C-N-CA 123.686 0.794 . . . . 0.0 109.657 -177.635 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 12.1 p -149.51 168.0 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 177.648 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 28.7 m -147.46 129.61 15.54 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 107.367 -1.346 . . . . 0.0 107.367 -179.858 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 62.3 mt -113.26 107.45 15.91 Favored 'General case' 0 CA--C 1.53 0.183 0 C-N-CA 123.461 0.704 . . . . 0.0 110.319 -177.394 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -86.99 -45.03 11.15 Favored 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 123.65 0.78 . . . . 0.0 111.347 179.397 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.7 m -71.88 122.34 20.61 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 123.05 0.54 . . . . 0.0 110.742 -177.063 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 55.6 mttp -59.9 160.85 7.2 Favored 'General case' 0 N--CA 1.456 -0.17 0 C-N-CA 124.835 1.254 . . . . 0.0 112.342 179.482 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 136.94 -142.82 13.98 Favored Glycine 0 C--N 1.334 0.469 0 N-CA-C 110.209 -1.156 . . . . 0.0 110.209 177.285 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 85.2 m -146.14 135.2 22.65 Favored 'General case' 0 N--CA 1.444 -0.75 0 N-CA-C 105.221 -2.14 . . . . 0.0 105.221 178.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 10.6 m-85 -124.7 130.08 51.74 Favored 'General case' 0 N--CA 1.446 -0.672 0 C-N-CA 123.937 0.895 . . . . 0.0 108.669 -176.456 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 17.7 m -100.32 141.52 33.05 Favored 'General case' 0 C--O 1.233 0.191 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 176.425 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 20.3 p90 -140.0 168.98 18.56 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-O 121.293 0.568 . . . . 0.0 111.275 -179.443 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 52.2 p90 -158.34 166.53 32.08 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 115.52 -0.764 . . . . 0.0 111.788 -179.264 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.3 t -105.49 107.63 18.72 Favored 'General case' 0 CA--C 1.519 -0.247 0 N-CA-C 105.817 -1.92 . . . . 0.0 105.817 177.346 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.305 0.3 OUTLIER -49.37 -56.15 17.93 Favored Pre-proline 0 CA--C 1.532 0.273 0 CA-C-N 119.119 0.872 . . . . 0.0 113.057 -174.667 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_exo -46.29 -19.49 0.65 Allowed 'Trans proline' 0 N--CA 1.457 -0.654 0 C-N-CA 123.741 2.961 . . . . 0.0 115.883 177.422 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 38.0 m80 -136.63 18.27 3.09 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 119.829 1.195 . . . . 0.0 112.16 179.764 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 15.2 pt20 -60.57 -41.69 95.14 Favored 'General case' 0 N--CA 1.455 -0.204 0 CA-C-N 119.16 0.891 . . . . 0.0 109.58 179.491 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -58.33 -28.99 62.57 Favored Glycine 0 CA--C 1.532 1.136 0 N-CA-C 111.334 -0.707 . . . . 0.0 111.334 177.203 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -90.44 11.42 21.67 Favored 'General case' 0 CA--C 1.534 0.327 0 C-N-CA 123.781 0.832 . . . . 0.0 110.954 178.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 78.64 19.11 74.22 Favored Glycine 0 CA--C 1.527 0.819 0 CA-C-O 118.604 -1.109 . . . . 0.0 113.575 178.657 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 22.5 ttt -78.69 76.58 5.18 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-N 119.775 1.788 . . . . 0.0 108.756 178.147 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 10.2 m -120.86 172.54 7.76 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 C-N-CA 126.191 1.796 . . . . 0.0 109.787 179.566 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -170.52 177.34 43.73 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 177.672 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 58.6 mttp -146.63 157.26 43.68 Favored 'General case' 0 CA--C 1.526 0.047 0 CA-C-N 117.53 0.665 . . . . 0.0 110.623 -178.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 5.5 p -143.82 126.14 11.47 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.289 0 C-N-CA 123.152 0.581 . . . . 0.0 110.48 177.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.28 124.06 34.06 Favored 'General case' 0 CA--C 1.53 0.179 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 177.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 40.7 t -100.28 95.04 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.209 0 N-CA-C 103.161 -2.903 . . . . 0.0 103.161 177.302 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 . . . . . 0 N--CA 1.453 -0.297 0 C-N-CA 125.019 1.328 . . . . 0.0 113.108 -173.945 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 8.2 mp . . . . . 0 N--CA 1.451 -0.387 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -98.79 97.61 8.81 Favored 'General case' 0 N--CA 1.453 -0.298 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 178.24 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 40.6 t -87.77 121.52 38.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 C-N-CA 124.51 1.124 . . . . 0.0 108.527 -179.463 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 70.0 mt -85.07 122.48 29.34 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 108.588 -0.894 . . . . 0.0 108.588 179.065 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 72.2 mt -86.84 99.88 12.14 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 106.103 -1.814 . . . . 0.0 106.103 177.783 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 100.9 151.29 25.04 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 108.713 -1.755 . . . . 0.0 108.713 -178.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 96.5 p -86.73 172.94 9.79 Favored 'General case' 0 N--CA 1.445 -0.711 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 177.378 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -54.08 -43.25 73.03 Favored Glycine 0 CA--C 1.53 0.971 0 N-CA-C 110.4 -1.08 . . . . 0.0 110.4 178.219 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -81.29 13.78 2.74 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 123.313 0.645 . . . . 0.0 112.221 178.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 74.48 16.98 79.8 Favored Glycine 0 CA--C 1.526 0.737 0 CA-C-O 118.849 -0.973 . . . . 0.0 114.156 178.2 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 22.8 t -71.33 140.13 50.13 Favored 'General case' 0 C--N 1.34 0.161 0 CA-C-N 119.443 1.622 . . . . 0.0 107.119 178.293 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 67.6 mt -76.52 67.65 2.71 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 125.136 1.374 . . . . 0.0 111.954 -175.411 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 26.0 m -135.17 150.17 29.4 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.21 0 C-N-CA 123.593 0.757 . . . . 0.0 110.498 179.654 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 45.3 m-85 -89.58 129.44 36.04 Favored 'General case' 0 N--CA 1.457 -0.099 0 N-CA-C 104.809 -2.293 . . . . 0.0 104.809 175.757 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 37.0 t -122.5 107.74 34.07 Favored Pre-proline 0 CA--C 1.537 0.467 0 CA-C-O 118.496 -0.764 . . . . 0.0 109.162 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -71.69 161.5 91.04 Favored 'Cis proline' 0 N--CA 1.457 -0.635 0 CA-C-N 120.227 1.117 . . . . 0.0 111.044 -1.355 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 6.2 p -86.21 -64.71 1.11 Allowed 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 178.345 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 64.9 tt0 -102.6 127.15 49.82 Favored 'General case' 0 N--CA 1.454 -0.275 0 C-N-CA 125.819 1.648 . . . . 0.0 107.577 178.47 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 33.9 p90 -150.34 -171.51 3.93 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-O 121.578 0.704 . . . . 0.0 111.998 178.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 7.0 m -141.63 146.8 36.63 Favored 'General case' 0 N--CA 1.45 -0.431 0 C-N-CA 124.655 1.182 . . . . 0.0 108.229 -178.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.0 p -148.85 137.89 12.21 Favored Pre-proline 0 CA--C 1.539 0.552 0 C-N-CA 123.28 0.632 . . . . 0.0 110.501 -177.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_exo -66.59 139.7 54.25 Favored 'Trans proline' 0 N--CA 1.455 -0.736 0 C-N-CA 121.424 1.416 . . . . 0.0 111.013 176.585 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 63.1 m -46.7 127.63 9.82 Favored 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 123.708 0.803 . . . . 0.0 110.978 177.125 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 94.96 -23.82 31.37 Favored Glycine 0 CA--C 1.529 0.946 0 CA-C-O 119.188 -0.784 . . . . 0.0 113.338 178.673 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 74.9 mm-40 -74.15 96.1 2.69 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 119.469 1.634 . . . . 0.0 109.318 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -41.42 126.5 2.84 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 125.734 1.614 . . . . 0.0 114.119 179.499 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 60.3 mt -90.06 136.77 22.98 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.314 0 N-CA-C 105.943 -1.873 . . . . 0.0 105.943 178.036 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 66.6 t -117.76 119.39 61.46 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.33 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 179.532 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 95.3 m-85 -106.16 109.38 21.3 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 178.338 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 62.5 tttp -105.16 129.31 53.58 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 124.489 1.115 . . . . 0.0 113.322 -175.159 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 3.6 m-20 -65.58 110.54 2.77 Favored 'General case' 0 C--O 1.23 0.07 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 176.834 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 51.1 t-20 -84.33 -72.08 0.48 Allowed 'General case' 0 N--CA 1.456 -0.166 0 N-CA-C 111.738 0.273 . . . . 0.0 111.738 -178.653 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -146.24 -53.54 0.25 Allowed 'General case' 0 C--O 1.225 -0.199 0 N-CA-C 114.359 1.244 . . . . 0.0 114.359 -175.82 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -69.69 33.88 0.37 Allowed Glycine 0 CA--C 1.538 1.494 0 N-CA-C 116.24 1.256 . . . . 0.0 116.24 -176.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 18.9 p90 -73.34 165.71 50.45 Favored Pre-proline 0 CA--C 1.543 0.705 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 179.783 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -62.27 149.38 60.03 Favored 'Cis proline' 0 N--CA 1.451 -0.992 0 N-CA-C 116.425 1.663 . . . . 0.0 116.425 2.446 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 91.8 m-70 -145.95 172.6 13.13 Favored 'General case' 0 N--CA 1.447 -0.59 0 O-C-N 121.715 -0.616 . . . . 0.0 110.157 179.19 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 22.9 p-10 -169.42 175.85 5.33 Favored 'General case' 0 N--CA 1.447 -0.583 0 N-CA-C 104.048 -2.575 . . . . 0.0 104.048 176.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 46.5 t -137.99 114.67 11.4 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.332 0 N-CA-C 107.225 -1.398 . . . . 0.0 107.225 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 62.0 t -119.46 135.97 58.12 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 106.335 -1.728 . . . . 0.0 106.335 179.427 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 57.2 m-85 -89.23 135.5 33.54 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 123.219 0.608 . . . . 0.0 109.682 -178.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 7.3 t0 -74.85 99.46 3.79 Favored 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 124.315 1.046 . . . . 0.0 109.721 -179.06 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -44.21 -34.33 1.84 Allowed 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 124.687 1.195 . . . . 0.0 113.59 178.714 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -66.96 -25.58 66.41 Favored 'General case' 0 CA--C 1.536 0.419 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 179.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -135.36 76.23 1.61 Allowed 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 123.683 0.793 . . . . 0.0 111.136 -177.312 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 25.8 pt -153.66 149.94 22.16 Favored Pre-proline 0 CA--C 1.535 0.382 0 C-N-CA 127.372 2.269 . . . . 0.0 105.354 175.228 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -64.56 131.68 30.49 Favored 'Trans proline' 0 N--CA 1.453 -0.886 0 C-N-CA 121.746 1.631 . . . . 0.0 109.773 178.886 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -51.72 143.23 13.2 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 124.027 0.931 . . . . 0.0 112.061 -178.532 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 105.13 -41.35 2.18 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 110.365 -1.094 . . . . 0.0 110.365 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 19.7 t -79.25 93.23 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 CA-C-N 117.45 0.625 . . . . 0.0 109.337 -179.286 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 18.3 t0 -55.85 118.57 4.71 Favored 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 123.09 0.556 . . . . 0.0 110.494 178.606 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -44.31 -46.25 9.12 Favored 'General case' 0 CA--C 1.529 0.135 0 C-N-CA 125.662 1.585 . . . . 0.0 111.532 179.02 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 48.4 t -56.68 -31.03 33.77 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.471 0 C-N-CA 122.786 0.434 . . . . 0.0 111.926 -178.633 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 65.6 mttp -75.71 -39.46 57.31 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-N 118.678 0.672 . . . . 0.0 111.008 -178.834 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 20.6 pt -81.15 -28.27 10.85 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.271 0 N-CA-C 112.428 0.529 . . . . 0.0 112.428 -179.521 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 63.2 m -74.95 144.86 43.03 Favored 'General case' 0 N--CA 1.455 -0.224 0 O-C-N 121.778 -0.576 . . . . 0.0 112.534 -178.313 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 7.7 tmm? -65.7 126.87 92.48 Favored Pre-proline 0 CA--C 1.537 0.463 0 N-CA-C 106.185 -1.783 . . . . 0.0 106.185 177.239 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_exo -33.54 99.28 0.02 OUTLIER 'Trans proline' 0 N--CA 1.459 -0.541 0 C-N-CA 125.195 3.93 . . . . 0.0 114.16 179.519 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 59.0 mp0 -50.58 -27.19 6.3 Favored 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 126.918 2.087 . . . . 0.0 113.894 -177.081 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.7 tm-20 -63.22 -30.75 71.83 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 122.702 0.401 . . . . 0.0 110.208 178.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 48.1 mt-10 -104.49 172.06 7.0 Favored 'General case' 0 N--CA 1.446 -0.655 0 C-N-CA 125.579 1.551 . . . . 0.0 109.896 -178.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 88.4 mt -151.4 145.83 25.53 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 106.407 -1.701 . . . . 0.0 106.407 177.385 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 67.8 mt -83.91 96.68 8.89 Favored 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 104.722 -2.325 . . . . 0.0 104.722 176.492 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -105.59 34.08 3.44 Favored 'General case' 0 CA--C 1.536 0.434 0 C-N-CA 124.499 1.12 . . . . 0.0 113.878 -177.45 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -151.43 156.49 34.86 Favored Pre-proline 0 CA--C 1.531 0.22 0 N-CA-C 108.106 -1.072 . . . . 0.0 108.106 179.639 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -72.79 163.54 38.13 Favored 'Trans proline' 0 N--CA 1.455 -0.782 0 C-N-CA 121.885 1.724 . . . . 0.0 109.816 179.324 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 78.07 -44.71 2.41 Favored Glycine 0 CA--C 1.526 0.771 0 CA-C-O 118.557 -1.135 . . . . 0.0 114.523 175.687 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 55.2 mm-40 -38.33 122.82 1.11 Allowed 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 124.82 1.248 . . . . 0.0 113.058 -178.809 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 17.9 p -109.13 134.03 52.24 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 125.316 1.446 . . . . 0.0 112.95 -178.104 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 17.5 t80 -107.55 143.27 36.2 Favored 'General case' 0 CA--C 1.528 0.097 0 N-CA-C 104.591 -2.374 . . . . 0.0 104.591 171.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 20.4 t -128.57 140.13 50.05 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.16 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 -179.057 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 12.8 p -146.01 144.9 20.55 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.134 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 178.301 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 7.6 m -115.25 106.65 14.29 Favored 'General case' 0 N--CA 1.454 -0.23 0 C-N-CA 124.356 1.062 . . . . 0.0 109.849 -178.6 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 50.5 mt -95.06 129.18 42.25 Favored 'General case' 0 CA--C 1.531 0.217 0 N-CA-C 107.52 -1.289 . . . . 0.0 107.52 177.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 13.9 m-20 -113.85 -46.53 3.02 Favored 'General case' 0 CA--C 1.527 0.08 0 C-N-CA 123.988 0.915 . . . . 0.0 111.24 -178.638 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 4.5 m -66.22 118.98 10.71 Favored 'General case' 0 N--CA 1.452 -0.362 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 -178.67 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 64.4 mttm -63.79 152.64 38.9 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 123.337 0.655 . . . . 0.0 110.306 -179.282 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 145.41 -157.81 27.46 Favored Glycine 0 CA--C 1.522 0.469 0 N-CA-C 109.328 -1.509 . . . . 0.0 109.328 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 15.3 m -123.59 132.33 53.85 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 106.535 -1.654 . . . . 0.0 106.535 -179.627 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 19.6 m-85 -125.02 119.93 30.1 Favored 'General case' 0 N--CA 1.447 -0.624 0 C-N-CA 123.681 0.793 . . . . 0.0 108.906 -178.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 70.2 m -91.51 144.88 25.1 Favored 'General case' 0 C--O 1.233 0.213 0 N-CA-C 107.699 -1.223 . . . . 0.0 107.699 175.612 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 17.4 p90 -141.22 164.14 31.07 Favored 'General case' 0 N--CA 1.455 -0.222 0 CA-C-O 121.237 0.541 . . . . 0.0 110.771 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 53.3 p90 -150.7 160.16 44.03 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-N 115.061 -0.972 . . . . 0.0 112.713 -177.424 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 11.6 t -99.41 106.16 18.19 Favored 'General case' 0 CA--C 1.522 -0.104 0 N-CA-C 105.877 -1.898 . . . . 0.0 105.877 176.453 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 4.5 m -38.83 -60.03 1.23 Allowed Pre-proline 0 CA--C 1.536 0.44 0 N-CA-C 115.976 1.843 . . . . 0.0 115.976 -174.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 89.3 Cg_endo -72.06 -2.53 11.7 Favored 'Trans proline' 0 N--CA 1.458 -0.612 0 C-N-CA 122.056 1.837 . . . . 0.0 114.602 -178.576 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 32.9 m170 -132.96 3.86 3.77 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 120.35 1.432 . . . . 0.0 113.723 -178.152 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 15.1 pt20 -52.72 -42.81 65.2 Favored 'General case' 0 CA--C 1.534 0.355 0 CA-C-N 119.009 0.822 . . . . 0.0 110.196 178.002 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -58.52 -28.77 62.8 Favored Glycine 0 CA--C 1.53 1.021 0 C-N-CA 123.951 0.786 . . . . 0.0 111.763 178.167 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -90.74 11.94 20.74 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 123.83 0.852 . . . . 0.0 110.505 178.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 82.97 13.0 78.64 Favored Glycine 0 CA--C 1.527 0.825 0 CA-C-O 118.632 -1.094 . . . . 0.0 113.227 178.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 20.5 ttt -77.66 79.82 4.14 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 119.708 1.754 . . . . 0.0 109.473 178.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 11.0 m -131.36 169.66 21.29 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.199 0 C-N-CA 126.158 1.783 . . . . 0.0 110.298 179.1 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -168.02 179.73 41.07 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 109.321 -1.511 . . . . 0.0 109.321 178.017 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 33.8 mtmm -148.32 150.5 33.73 Favored 'General case' 0 N--CA 1.456 -0.159 0 C-N-CA 123.944 0.898 . . . . 0.0 110.439 -178.429 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.0 p -135.33 131.17 51.62 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.252 0 C-N-CA 122.973 0.509 . . . . 0.0 109.948 178.76 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.0 m -98.27 100.87 12.2 Favored 'General case' 0 CA--C 1.534 0.361 0 C-N-CA 125.212 1.405 . . . . 0.0 109.396 -179.64 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 43.6 t -79.92 114.9 21.46 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.388 0 N-CA-C 105.277 -2.119 . . . . 0.0 105.277 -179.553 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 6.6 p30 . . . . . 0 C--N 1.333 -0.133 0 C-N-CA 123.426 0.691 . . . . 0.0 111.946 -174.673 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 62.6 tp . . . . . 0 N--CA 1.45 -0.433 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -150.39 163.38 38.52 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 123.791 0.836 . . . . 0.0 109.652 -178.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 58.6 t -132.99 117.56 29.8 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.683 0 N-CA-C 106.217 -1.772 . . . . 0.0 106.217 178.585 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 38.7 mt -84.89 119.22 25.1 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 179.427 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 49.0 mt -82.52 83.07 7.68 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 104.372 -2.455 . . . . 0.0 104.372 176.534 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 121.38 152.1 8.68 Favored Glycine 0 CA--C 1.527 0.812 0 C-N-CA 125.708 1.623 . . . . 0.0 109.616 -176.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 50.5 p -114.8 44.65 1.73 Allowed 'General case' 0 CA--C 1.522 -0.121 0 C-N-CA 124.28 1.032 . . . . 0.0 111.799 -179.394 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 74.87 -56.81 2.65 Favored Glycine 0 CA--C 1.523 0.542 0 C-N-CA 126.023 1.773 . . . . 0.0 111.401 179.294 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -73.72 34.37 0.08 Allowed 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 125.406 1.482 . . . . 0.0 113.625 -177.697 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 58.94 4.39 2.24 Favored Glycine 0 CA--C 1.532 1.102 0 C-N-CA 124.828 1.204 . . . . 0.0 115.837 178.743 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.3 t -64.97 138.6 58.46 Favored 'General case' 0 N--CA 1.456 -0.146 0 CA-C-N 119.528 1.664 . . . . 0.0 110.12 -179.009 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 71.0 mt -79.98 64.69 4.9 Favored 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 124.807 1.243 . . . . 0.0 110.604 -177.098 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 28.0 m -133.68 145.13 34.02 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.223 0 C-N-CA 123.253 0.621 . . . . 0.0 112.421 -178.467 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 68.8 m-85 -89.21 125.96 35.29 Favored 'General case' 0 N--CA 1.455 -0.224 0 N-CA-C 104.037 -2.579 . . . . 0.0 104.037 175.536 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 22.4 t -118.02 110.17 40.17 Favored Pre-proline 0 CA--C 1.532 0.267 0 CA-C-N 119.529 1.059 . . . . 0.0 109.218 179.25 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -74.81 153.64 99.27 Favored 'Cis proline' 0 CA--C 1.535 0.57 0 CA-C-N 120.392 1.176 . . . . 0.0 111.164 -1.375 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.2 m -80.87 -45.55 16.66 Favored 'General case' 0 CA--C 1.528 0.127 0 C-N-CA 123.324 0.65 . . . . 0.0 110.805 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -123.58 130.96 53.45 Favored 'General case' 0 N--CA 1.451 -0.396 0 N-CA-C 104.657 -2.349 . . . . 0.0 104.657 178.46 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 42.1 p90 -157.96 -177.54 6.64 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 118.435 0.562 . . . . 0.0 111.175 -177.765 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.9 p -126.09 151.26 47.44 Favored 'General case' 0 N--CA 1.448 -0.569 0 C-N-CA 125.809 1.644 . . . . 0.0 108.758 178.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.8 p -145.53 134.36 11.05 Favored Pre-proline 0 CA--C 1.539 0.52 0 C-N-CA 123.893 0.877 . . . . 0.0 109.136 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -64.64 136.88 51.9 Favored 'Trans proline' 0 N--CA 1.455 -0.782 0 C-N-CA 121.536 1.491 . . . . 0.0 110.096 175.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 48.6 m -49.69 122.1 6.0 Favored 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 123.796 0.838 . . . . 0.0 111.131 179.325 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.46 -17.25 58.74 Favored Glycine 0 CA--C 1.529 0.938 0 CA-C-O 118.816 -0.991 . . . . 0.0 113.554 179.006 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 71.1 mm-40 -70.25 167.05 18.78 Favored 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 119.623 1.712 . . . . 0.0 111.428 179.679 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -92.95 146.88 23.29 Favored 'General case' 0 N--CA 1.45 -0.434 0 C-N-CA 125.029 1.331 . . . . 0.0 111.017 -179.213 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 32.1 mt -125.23 126.41 70.8 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.424 0 N-CA-C 103.682 -2.71 . . . . 0.0 103.682 176.349 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 57.2 t -112.39 96.61 4.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 C-N-CA 125.081 1.352 . . . . 0.0 108.896 -178.259 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -81.69 97.13 7.77 Favored 'General case' 0 CA--C 1.531 0.239 0 N-CA-C 106.862 -1.533 . . . . 0.0 106.862 178.305 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 63.5 tttp -93.98 127.81 39.97 Favored 'General case' 0 CA--C 1.53 0.187 0 C-N-CA 124.884 1.274 . . . . 0.0 113.557 -174.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -67.7 93.51 0.38 Allowed 'General case' 0 CA--C 1.533 0.324 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 176.78 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 14.0 t-20 -80.69 -67.25 0.79 Allowed 'General case' 0 N--CA 1.455 -0.221 0 C-N-CA 123.342 0.657 . . . . 0.0 110.654 -179.354 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -161.05 167.93 25.43 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.258 -176.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 68.87 17.5 71.51 Favored Glycine 0 CA--C 1.533 1.199 0 O-C-N 121.587 -0.695 . . . . 0.0 112.144 -179.236 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 32.8 p90 -70.12 165.95 38.38 Favored Pre-proline 0 CA--C 1.545 0.771 0 N-CA-C 106.325 -1.732 . . . . 0.0 106.325 177.351 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -68.97 155.53 91.03 Favored 'Cis proline' 0 N--CA 1.446 -1.274 0 N-CA-C 115.525 1.317 . . . . 0.0 115.525 4.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 90.1 m-70 -147.72 170.32 17.82 Favored 'General case' 0 N--CA 1.449 -0.478 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.464 -179.683 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 40.4 p-10 -160.55 175.37 12.79 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 104.423 -2.436 . . . . 0.0 104.423 176.639 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 21.9 t -136.15 106.52 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.314 0 N-CA-C 106.787 -1.56 . . . . 0.0 106.787 -179.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 55.5 t -113.17 133.95 57.4 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 106.422 -1.696 . . . . 0.0 106.422 179.229 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 56.9 m-85 -96.18 140.82 30.33 Favored 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 123.544 0.738 . . . . 0.0 109.647 -179.711 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -74.08 108.13 6.7 Favored 'General case' 0 N--CA 1.453 -0.308 0 N-CA-C 107.078 -1.453 . . . . 0.0 107.078 178.204 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -44.25 -30.61 0.83 Allowed 'General case' 0 CA--C 1.535 0.386 0 N-CA-C 115.916 1.821 . . . . 0.0 115.916 -177.765 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -86.17 -49.19 7.93 Favored 'General case' 0 CA--C 1.53 0.196 0 CA-C-N 118.703 0.683 . . . . 0.0 110.48 179.153 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -80.66 57.48 2.96 Favored 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 124.109 0.964 . . . . 0.0 112.257 -176.609 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 36.2 pt -153.35 156.63 32.61 Favored Pre-proline 0 CA--C 1.534 0.348 0 C-N-CA 127.634 2.374 . . . . 0.0 106.217 176.649 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -53.07 115.53 2.34 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 C-N-CA 122.51 2.14 . . . . 0.0 111.384 178.065 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -52.88 107.88 0.26 Allowed 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 123.992 0.917 . . . . 0.0 110.083 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 136.46 -30.42 2.7 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 109.835 -1.306 . . . . 0.0 109.835 -178.069 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 69.9 t -75.62 121.89 28.35 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 CA-C-N 117.861 0.831 . . . . 0.0 109.059 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 14.8 t0 -66.35 105.46 1.45 Allowed 'General case' 0 N--CA 1.453 -0.3 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 178.752 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.49 -39.03 21.73 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 124.168 0.987 . . . . 0.0 111.463 178.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 41.4 t -61.68 -29.3 45.9 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.429 0 C-N-CA 122.821 0.448 . . . . 0.0 111.574 -179.359 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.53 -34.03 58.57 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 119.224 0.92 . . . . 0.0 110.979 -178.593 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 25.0 pt -85.74 -32.35 7.0 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.21 0 C-N-CA 123.266 0.626 . . . . 0.0 111.899 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 39.7 m -85.87 136.43 33.3 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 114.273 1.212 . . . . 0.0 114.273 -177.208 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 69.2 mmm -69.01 133.56 89.95 Favored Pre-proline 0 N--CA 1.452 -0.348 0 N-CA-C 103.822 -2.659 . . . . 0.0 103.822 170.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_exo -49.5 114.87 1.49 Allowed 'Trans proline' 0 N--CA 1.456 -0.698 0 C-N-CA 122.201 1.934 . . . . 0.0 109.557 178.197 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -35.44 -44.37 0.29 Allowed 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 126.164 1.786 . . . . 0.0 115.487 -177.244 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 19.9 tp10 -61.0 -37.53 82.83 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 124.566 1.147 . . . . 0.0 111.961 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 64.4 mm-40 -83.09 153.92 24.63 Favored 'General case' 0 N--CA 1.444 -0.751 0 C-N-CA 124.703 1.201 . . . . 0.0 110.181 -178.525 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -156.53 145.8 20.53 Favored 'General case' 0 N--CA 1.446 -0.634 0 CA-C-N 115.393 -0.821 . . . . 0.0 111.833 -178.528 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 43.5 mt -76.85 99.94 5.35 Favored 'General case' 0 N--CA 1.446 -0.631 0 N-CA-C 104.176 -2.527 . . . . 0.0 104.176 177.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -96.47 -22.33 17.19 Favored 'General case' 0 N--CA 1.462 0.171 0 N-CA-C 113.993 1.108 . . . . 0.0 113.993 -176.623 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -93.97 152.94 40.89 Favored Pre-proline 0 CA--C 1.533 0.305 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -66.43 161.99 38.5 Favored 'Trans proline' 0 N--CA 1.453 -0.908 0 C-N-CA 121.773 1.649 . . . . 0.0 110.195 178.207 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 80.14 -53.93 4.45 Favored Glycine 0 CA--C 1.523 0.568 0 CA-C-O 118.228 -1.318 . . . . 0.0 113.404 176.4 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -18.53 111.07 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.399 0 C-N-CA 126.444 1.898 . . . . 0.0 114.388 -177.011 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 14.5 p -100.71 119.07 38.05 Favored 'General case' 0 N--CA 1.446 -0.633 0 C-N-CA 124.619 1.168 . . . . 0.0 112.225 -178.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 10.8 t80 -97.13 105.61 17.79 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 105.06 -2.2 . . . . 0.0 105.06 174.624 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.9 t -94.98 134.46 32.29 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.283 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 -178.686 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.1 p -151.16 161.22 3.52 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 178.485 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.1 m -133.62 142.29 48.03 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 125.501 1.52 . . . . 0.0 107.9 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 62.4 mt -118.82 120.52 37.59 Favored 'General case' 0 N--CA 1.453 -0.31 0 N-CA-C 107.567 -1.272 . . . . 0.0 107.567 179.288 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 9.0 p-10 -95.02 -41.07 9.32 Favored 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 124.178 0.991 . . . . 0.0 112.395 -178.43 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 25.0 m -77.14 125.77 29.86 Favored 'General case' 0 N--CA 1.452 -0.328 0 C-N-CA 123.428 0.691 . . . . 0.0 109.933 -176.564 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 66.3 mttm -65.47 156.02 33.75 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 124.017 0.927 . . . . 0.0 111.477 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 127.23 177.33 14.82 Favored Glycine 0 CA--C 1.526 0.743 0 C-N-CA 123.92 0.771 . . . . 0.0 112.201 177.445 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 7.3 m -94.57 127.73 40.71 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 125.15 1.38 . . . . 0.0 108.914 -179.063 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 15.6 m-85 -115.95 135.81 53.63 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 125.755 1.622 . . . . 0.0 108.643 179.066 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 16.9 m -108.81 136.23 48.71 Favored 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 123.362 0.665 . . . . 0.0 109.419 176.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 20.3 p90 -137.83 168.53 19.5 Favored 'General case' 0 C--O 1.232 0.142 0 CA-C-O 121.77 0.795 . . . . 0.0 111.818 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -156.37 160.62 39.83 Favored 'General case' 0 N--CA 1.453 -0.278 0 CA-C-N 115.322 -0.854 . . . . 0.0 112.532 -178.756 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.4 t -99.74 102.37 13.81 Favored 'General case' 0 CA--C 1.519 -0.226 0 N-CA-C 106.396 -1.705 . . . . 0.0 106.396 176.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -48.24 -55.07 20.19 Favored Pre-proline 0 CA--C 1.532 0.263 0 CA-C-O 118.593 -0.717 . . . . 0.0 112.51 -175.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_exo -50.59 -15.7 1.78 Allowed 'Trans proline' 0 N--CA 1.458 -0.572 0 C-N-CA 123.387 2.725 . . . . 0.0 115.566 178.259 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 39.3 m80 -137.69 31.5 2.52 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 119.757 1.162 . . . . 0.0 110.999 -179.765 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 1.5 pm0 -60.73 -45.64 93.48 Favored 'General case' 0 CA--C 1.534 0.333 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 178.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.99 -35.06 67.09 Favored Glycine 0 CA--C 1.527 0.816 0 C-N-CA 124.272 0.939 . . . . 0.0 111.661 179.1 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -80.96 4.97 17.71 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-N 117.209 0.504 . . . . 0.0 111.465 179.006 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 73.94 25.2 72.15 Favored Glycine 0 CA--C 1.524 0.651 0 CA-C-O 119.147 -0.807 . . . . 0.0 112.573 179.229 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 24.5 ttt -78.96 78.24 5.41 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 119.092 1.446 . . . . 0.0 107.831 177.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 13.5 m -121.25 169.09 12.99 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.245 0 C-N-CA 126.181 1.792 . . . . 0.0 109.915 179.56 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -168.87 177.97 42.43 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.108 -1.197 . . . . 0.0 110.108 178.489 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 58.6 mttm -147.57 161.22 41.57 Favored 'General case' 0 N--CA 1.455 -0.21 0 C-N-CA 123.772 0.829 . . . . 0.0 109.621 -179.48 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 4.2 p -144.88 132.63 16.59 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.246 0 C-N-CA 123.62 0.768 . . . . 0.0 109.1 178.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.3 m -103.41 106.88 17.51 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.965 1.306 . . . . 0.0 109.665 -178.44 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 32.6 t -82.55 106.97 13.95 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.574 0 N-CA-C 105.905 -1.887 . . . . 0.0 105.905 178.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 25.6 m120 . . . . . 0 C--O 1.231 0.127 0 C-N-CA 124.279 1.032 . . . . 0.0 111.042 -176.637 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 21.1 mt . . . . . 0 N--CA 1.451 -0.379 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 45.9 tt0 -87.86 107.48 18.7 Favored 'General case' 0 N--CA 1.452 -0.343 0 N-CA-C 105.546 -2.02 . . . . 0.0 105.546 175.516 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 38.7 t -99.35 118.66 46.28 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.455 0 C-N-CA 123.813 0.845 . . . . 0.0 108.833 -177.645 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 59.1 mt -81.98 122.05 27.3 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 179.297 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 70.4 mt -87.39 89.93 8.18 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 105.321 -2.103 . . . . 0.0 105.321 177.128 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 118.25 166.36 13.7 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 109.098 -1.601 . . . . 0.0 109.098 -177.408 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 5.4 p -136.26 48.56 2.15 Favored 'General case' 0 N--CA 1.461 0.102 0 CA-C-O 122.798 1.285 . . . . 0.0 113.259 -178.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.44 -62.13 0.62 Allowed Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 128.238 2.828 . . . . 0.0 113.364 176.636 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.402 ' C ' ' H ' ' A' ' 11' ' ' SER . 7.5 p-10 -78.31 42.97 0.44 Allowed 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 123.981 0.913 . . . . 0.0 112.268 -175.578 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 75.55 -31.22 1.21 Allowed Glycine 0 CA--C 1.528 0.891 0 C-N-CA 124.934 1.254 . . . . 0.0 113.388 178.305 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.402 ' H ' ' C ' ' A' ' 9' ' ' ASP . 7.4 t -40.44 106.27 0.05 Allowed 'General case' 0 C--O 1.237 0.443 0 C-N-CA 126.178 1.791 . . . . 0.0 112.141 -178.522 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 48.9 mt -75.2 69.96 2.11 Favored 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 128.196 2.598 . . . . 0.0 111.551 -176.399 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.6 m -136.49 153.38 30.78 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 C-N-CA 122.86 0.464 . . . . 0.0 110.233 179.034 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 61.5 m-85 -88.57 127.27 35.55 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 105.096 -2.187 . . . . 0.0 105.096 176.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 38.8 t -120.79 114.42 32.61 Favored Pre-proline 0 CA--C 1.533 0.313 0 CA-C-O 118.175 -0.916 . . . . 0.0 108.688 178.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -73.06 147.91 90.88 Favored 'Cis proline' 0 CA--C 1.535 0.574 0 CA-C-N 120.49 1.211 . . . . 0.0 111.423 -0.455 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.4 m -78.77 -33.02 46.76 Favored 'General case' 0 CA--C 1.529 0.148 0 C-N-CA 123.715 0.806 . . . . 0.0 111.809 179.826 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -138.75 141.25 38.85 Favored 'General case' 0 N--CA 1.454 -0.241 0 N-CA-C 105.288 -2.115 . . . . 0.0 105.288 178.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 13.3 p90 -168.1 172.44 8.74 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 123.904 0.882 . . . . 0.0 108.739 -178.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 14.9 m -133.26 137.7 46.16 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 123.918 0.887 . . . . 0.0 108.685 -179.09 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.3 m -139.9 155.02 71.2 Favored Pre-proline 0 CA--C 1.531 0.234 0 C-N-CA 124.26 1.024 . . . . 0.0 110.145 -178.61 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -77.11 151.21 30.22 Favored 'Trans proline' 0 N--CA 1.451 -0.992 0 C-N-CA 121.845 1.697 . . . . 0.0 110.64 177.638 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 14.7 m -49.79 126.55 14.19 Favored 'General case' 0 N--CA 1.457 -0.112 0 C-N-CA 123.328 0.651 . . . . 0.0 109.993 175.579 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 103.21 -6.64 50.81 Favored Glycine 0 CA--C 1.526 0.752 0 CA-C-O 119.082 -0.844 . . . . 0.0 111.678 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -61.65 136.87 58.17 Favored 'General case' 0 CA--C 1.534 0.329 0 CA-C-N 119.117 1.458 . . . . 0.0 110.43 178.567 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 61.0 mttp -94.93 98.56 10.79 Favored 'General case' 0 N--CA 1.446 -0.657 0 C-N-CA 127.244 2.218 . . . . 0.0 107.436 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 56.3 mt -81.45 137.4 21.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 -179.247 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 60.4 t -120.53 102.51 12.54 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.187 0 C-N-CA 125.017 1.327 . . . . 0.0 108.703 -178.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -88.46 107.03 18.65 Favored 'General case' 0 CA--C 1.53 0.183 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 178.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 64.6 tttm -103.35 128.45 50.43 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 124.49 1.116 . . . . 0.0 113.379 -175.556 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -62.27 108.69 1.14 Allowed 'General case' 0 N--CA 1.464 0.26 0 N-CA-C 109.155 -0.684 . . . . 0.0 109.155 176.654 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 20.2 t-20 -94.05 -69.93 0.73 Allowed 'General case' 0 C--N 1.339 0.152 0 C-N-CA 123.434 0.693 . . . . 0.0 110.71 -179.403 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -154.89 166.0 34.9 Favored 'General case' 0 C--N 1.331 -0.213 0 C-N-CA 123.899 0.88 . . . . 0.0 109.586 -177.722 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 64.51 23.04 68.31 Favored Glycine 0 CA--C 1.534 1.234 0 N-CA-C 111.938 -0.465 . . . . 0.0 111.938 -178.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 15.3 p90 -71.94 166.84 36.72 Favored Pre-proline 0 CA--C 1.543 0.697 0 N-CA-C 106.177 -1.786 . . . . 0.0 106.177 177.231 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -70.38 161.31 88.25 Favored 'Cis proline' 0 N--CA 1.448 -1.201 0 CA-C-N 120.227 1.117 . . . . 0.0 114.928 3.708 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 -150.69 168.28 24.84 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.207 -178.606 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -159.19 177.48 11.01 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 104.029 -2.582 . . . . 0.0 104.029 175.243 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 41.6 t -132.19 119.35 39.8 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 -179.625 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 25.6 t -114.57 122.24 68.29 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.679 0 N-CA-C 105.602 -1.999 . . . . 0.0 105.602 177.501 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 59.5 m-85 -86.32 125.56 33.7 Favored 'General case' 0 N--CA 1.446 -0.668 0 N-CA-C 105.868 -1.901 . . . . 0.0 105.868 177.046 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 12.1 t0 -64.28 103.48 0.64 Allowed 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 123.059 0.543 . . . . 0.0 110.612 -177.616 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.7 pm0 -45.02 -35.47 2.97 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 125.235 1.414 . . . . 0.0 112.994 177.703 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -70.34 -20.73 62.96 Favored 'General case' 0 CA--C 1.536 0.438 0 N-CA-C 113.277 0.843 . . . . 0.0 113.277 -179.545 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -139.81 74.76 1.48 Allowed 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 123.68 0.792 . . . . 0.0 111.659 -177.732 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 30.5 pt -157.25 157.35 30.32 Favored Pre-proline 0 CA--C 1.532 0.253 0 C-N-CA 128.562 2.745 . . . . 0.0 105.67 175.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -58.67 108.98 0.45 Allowed 'Trans proline' 0 N--CA 1.455 -0.738 0 C-N-CA 122.02 1.813 . . . . 0.0 107.996 173.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -35.08 -43.03 0.19 Allowed 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 126.676 1.99 . . . . 0.0 115.605 -177.01 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -58.21 -29.33 62.69 Favored Glycine 0 CA--C 1.533 1.19 0 CA-C-O 119.893 -0.393 . . . . 0.0 113.538 -179.122 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 42.6 t -84.72 108.11 16.45 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.295 0 CA-C-N 118.21 1.005 . . . . 0.0 109.751 -178.451 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -58.27 114.11 2.26 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 122.955 0.502 . . . . 0.0 109.784 177.716 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.76 -40.82 21.76 Favored 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 124.205 1.002 . . . . 0.0 111.499 179.183 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 48.4 t -60.65 -30.06 46.15 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.398 0 C-N-CA 123.123 0.569 . . . . 0.0 111.768 -179.133 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 37.7 mmtm -76.56 -40.98 48.15 Favored 'General case' 0 CA--C 1.528 0.112 0 CA-C-N 118.715 0.688 . . . . 0.0 110.414 -179.084 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 23.1 pt -78.84 -33.65 16.52 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 N-CA-C 112.223 0.453 . . . . 0.0 112.223 -179.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 41.1 m -79.47 162.35 25.51 Favored 'General case' 0 C--N 1.331 -0.203 0 N-CA-C 113.454 0.909 . . . . 0.0 113.454 -178.089 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 2.7 tmm? -104.94 107.92 59.89 Favored Pre-proline 0 CA--C 1.54 0.576 0 N-CA-C 104.522 -2.399 . . . . 0.0 104.522 175.368 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_exo -38.47 107.37 0.06 OUTLIER 'Trans proline' 0 C--N 1.35 0.606 1 C-N-CA 125.487 4.124 . . . . 0.0 114.966 -176.689 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -50.0 -22.77 1.7 Allowed 'General case' 0 CA--C 1.53 0.195 0 C-N-CA 126.475 1.91 . . . . 0.0 115.413 -178.749 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 30.8 tt0 -58.99 -32.99 70.17 Favored 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 176.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 57.9 mt-10 -110.87 163.25 13.98 Favored 'General case' 0 N--CA 1.444 -0.775 0 C-N-CA 126.494 1.918 . . . . 0.0 107.959 178.546 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -150.22 161.8 41.72 Favored 'General case' 0 N--CA 1.443 -0.81 0 O-C-N 121.53 -0.731 . . . . 0.0 110.426 178.599 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 81.7 mt -78.5 106.06 10.2 Favored 'General case' 0 N--CA 1.446 -0.629 0 N-CA-C 104.488 -2.412 . . . . 0.0 104.488 177.121 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 13.2 t30 -77.0 -62.2 1.73 Allowed 'General case' 0 CA--C 1.528 0.133 0 N-CA-C 114.932 1.456 . . . . 0.0 114.932 -175.034 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.88 157.02 76.95 Favored Pre-proline 0 CA--C 1.533 0.295 0 C-N-CA 123.056 0.542 . . . . 0.0 111.601 -175.534 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -63.66 164.16 22.09 Favored 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 122.2 1.933 . . . . 0.0 109.433 175.335 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 80.92 -37.61 2.34 Favored Glycine 0 CA--C 1.527 0.783 0 CA-C-O 118.231 -1.316 . . . . 0.0 114.305 176.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 66.7 mt-10 -41.69 126.03 2.91 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 119.079 1.44 . . . . 0.0 112.144 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 16.9 p -109.22 127.61 54.38 Favored 'General case' 0 N--CA 1.455 -0.219 0 C-N-CA 125.481 1.512 . . . . 0.0 112.693 -178.552 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 35.5 t80 -106.45 114.02 27.89 Favored 'General case' 0 N--CA 1.456 -0.159 0 N-CA-C 106.05 -1.833 . . . . 0.0 106.05 174.034 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 15.4 t -100.52 141.23 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.236 0 C-N-CA 123.189 0.596 . . . . 0.0 110.464 -177.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 10.7 p -150.45 141.52 16.6 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.208 0 N-CA-C 108.774 -0.825 . . . . 0.0 108.774 177.308 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 23.7 m -108.46 123.57 49.08 Favored 'General case' 0 CA--C 1.528 0.113 0 C-N-CA 123.752 0.821 . . . . 0.0 108.966 -178.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 36.9 mt -104.56 104.15 13.94 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 118.33 0.514 . . . . 0.0 109.798 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -87.19 -53.52 4.81 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 123.974 0.909 . . . . 0.0 111.602 -179.443 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 4.7 m -66.2 128.41 36.0 Favored 'General case' 0 N--CA 1.455 -0.223 0 O-C-N 121.822 -0.549 . . . . 0.0 111.402 -175.571 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 24.9 mtpp -65.89 161.52 21.01 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 124.787 1.235 . . . . 0.0 110.871 179.648 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 132.66 -137.33 9.32 Favored Glycine 0 C--N 1.335 0.503 0 N-CA-C 110.039 -1.225 . . . . 0.0 110.039 177.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 58.8 m -147.79 141.81 25.95 Favored 'General case' 0 N--CA 1.443 -0.824 0 N-CA-C 105.717 -1.957 . . . . 0.0 105.717 179.65 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 12.1 m-85 -129.61 126.43 38.43 Favored 'General case' 0 N--CA 1.446 -0.675 0 C-N-CA 124.302 1.041 . . . . 0.0 108.821 -177.054 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 74.5 m -95.4 145.67 24.97 Favored 'General case' 0 C--N 1.331 -0.201 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 175.668 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 11.7 p90 -143.49 164.5 30.16 Favored 'General case' 0 N--CA 1.455 -0.191 0 CA-C-O 121.435 0.636 . . . . 0.0 112.369 -179.538 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 53.1 p90 -155.32 160.33 40.66 Favored 'General case' 0 N--CA 1.454 -0.256 0 CA-C-N 115.228 -0.896 . . . . 0.0 112.678 -179.714 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 4.3 t -102.44 100.92 11.08 Favored 'General case' 0 CA--C 1.516 -0.341 0 N-CA-C 105.991 -1.855 . . . . 0.0 105.991 176.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.252 0.0 OUTLIER -38.7 -63.07 0.63 Allowed Pre-proline 0 CA--C 1.538 0.511 0 N-CA-C 114.346 1.239 . . . . 0.0 114.346 -175.019 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_exo -50.53 -18.27 3.67 Favored 'Trans proline' 0 CA--C 1.534 0.501 0 C-N-CA 123.635 2.89 . . . . 0.0 115.748 179.111 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 36.6 m80 -131.63 20.19 4.68 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 119.132 0.878 . . . . 0.0 111.293 -179.044 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 66.2 tt0 -60.07 -49.06 79.13 Favored 'General case' 0 CA--C 1.528 0.13 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.226 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.8 -32.22 61.74 Favored Glycine 0 CA--C 1.531 1.073 0 N-CA-C 111.475 -0.65 . . . . 0.0 111.475 178.066 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -81.79 4.12 23.29 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 123.334 0.654 . . . . 0.0 111.718 179.105 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 84.66 16.01 66.9 Favored Glycine 0 CA--C 1.527 0.798 0 CA-C-O 118.851 -0.972 . . . . 0.0 113.509 178.384 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 19.6 ttt -78.48 78.22 4.95 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 119.509 1.655 . . . . 0.0 108.332 178.491 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 5.9 m -128.43 171.71 16.08 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 C-N-CA 125.802 1.641 . . . . 0.0 110.607 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -175.99 -174.7 42.75 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 109.155 -1.578 . . . . 0.0 109.155 177.618 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 52.2 mttp -151.63 169.77 21.33 Favored 'General case' 0 N--CA 1.453 -0.323 0 C-N-CA 124.064 0.946 . . . . 0.0 109.343 179.8 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.3 p -150.37 139.5 15.27 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.382 0 C-N-CA 123.744 0.818 . . . . 0.0 108.972 177.267 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -100.44 133.51 44.76 Favored 'General case' 0 CA--C 1.529 0.168 0 C-N-CA 124.615 1.166 . . . . 0.0 107.89 179.792 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 31.7 t -115.33 109.72 29.35 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.18 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 178.784 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 48.0 p30 . . . . . 0 C--O 1.231 0.117 0 C-N-CA 124.385 1.074 . . . . 0.0 111.878 -177.0 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 20.5 mt . . . . . 0 N--CA 1.452 -0.37 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -88.6 101.94 14.46 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 105.687 -1.968 . . . . 0.0 105.687 175.238 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 41.0 t -99.88 125.28 53.59 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.374 0 C-N-CA 124.251 1.02 . . . . 0.0 109.368 -177.273 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 74.8 mt -88.54 119.05 28.63 Favored 'General case' 0 N--CA 1.446 -0.658 0 N-CA-C 108.015 -1.105 . . . . 0.0 108.015 178.264 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 19.8 mt -83.75 101.98 11.96 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 104.841 -2.281 . . . . 0.0 104.841 176.26 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 101.83 -161.34 17.68 Favored Glycine 0 N--CA 1.447 -0.573 0 N-CA-C 108.043 -2.023 . . . . 0.0 108.043 -178.016 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 54.8 p -153.32 150.34 28.81 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 106.665 -1.606 . . . . 0.0 106.665 179.545 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -50.63 -34.79 28.82 Favored Glycine 0 CA--C 1.531 1.069 0 C-N-CA 123.293 0.473 . . . . 0.0 113.09 -179.809 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -74.29 -4.99 39.48 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 123.668 0.787 . . . . 0.0 112.75 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 97.29 -17.3 59.34 Favored Glycine 0 CA--C 1.527 0.839 0 C-N-CA 124.181 0.896 . . . . 0.0 114.091 178.597 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 33.0 t -56.94 135.03 56.06 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 119.217 1.509 . . . . 0.0 111.739 -178.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 91.6 mt -80.09 78.24 6.75 Favored 'General case' 0 N--CA 1.446 -0.655 0 C-N-CA 125.713 1.605 . . . . 0.0 109.819 -178.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.7 p -138.6 159.1 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.303 0 C-N-CA 123.616 0.767 . . . . 0.0 109.524 178.713 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 30.7 m-85 -97.98 124.49 42.48 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 103.521 -2.77 . . . . 0.0 103.521 175.893 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 43.4 t -120.21 109.32 37.18 Favored Pre-proline 0 CA--C 1.537 0.456 0 CA-C-N 119.337 0.972 . . . . 0.0 109.717 -179.34 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -71.01 157.39 95.59 Favored 'Cis proline' 0 N--CA 1.456 -0.679 0 CA-C-N 120.325 1.152 . . . . 0.0 110.732 -1.448 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.4 p -84.11 -62.67 1.51 Allowed 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 107.577 -1.268 . . . . 0.0 107.577 179.253 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 51.1 mt-10 -107.31 127.98 54.04 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 125.367 1.467 . . . . 0.0 107.925 178.345 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 39.1 p90 -151.5 -177.21 5.95 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.875 0.369 . . . . 0.0 111.607 179.749 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 15.1 m -139.54 145.92 39.26 Favored 'General case' 0 N--CA 1.452 -0.362 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 -179.481 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.6 p -156.34 139.61 11.01 Favored Pre-proline 0 CA--C 1.54 0.576 0 CA-C-N 118.914 0.779 . . . . 0.0 109.977 -178.163 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -55.96 146.85 66.44 Favored 'Trans proline' 0 N--CA 1.458 -0.612 0 C-N-CA 122.558 2.172 . . . . 0.0 113.597 177.432 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 21.6 m -56.87 139.76 50.44 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 123.244 0.618 . . . . 0.0 110.464 177.057 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 89.41 -13.91 62.52 Favored Glycine 0 CA--C 1.529 0.922 0 CA-C-O 119.099 -0.834 . . . . 0.0 113.928 177.46 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 72.7 mm-40 -71.56 149.66 45.48 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 119.218 1.509 . . . . 0.0 110.356 178.716 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 1.7 mptm? -90.26 114.89 27.01 Favored 'General case' 0 N--CA 1.453 -0.323 0 C-N-CA 124.3 1.04 . . . . 0.0 109.274 -179.036 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 69.2 mt -86.54 137.13 21.45 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.267 0 N-CA-C 105.403 -2.073 . . . . 0.0 105.403 177.017 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 62.5 t -120.81 107.14 19.88 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.136 0 C-N-CA 124.515 1.126 . . . . 0.0 108.986 -178.021 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -94.31 101.64 13.6 Favored 'General case' 0 CA--C 1.532 0.279 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 178.441 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -97.85 125.81 42.91 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 125.597 1.559 . . . . 0.0 113.11 -176.134 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 8.0 m-20 -63.3 102.61 0.41 Allowed 'General case' 0 N--CA 1.466 0.36 0 C-N-CA 123.306 0.642 . . . . 0.0 110.092 176.55 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -80.01 -57.44 3.64 Favored 'General case' 0 CA--C 1.519 -0.216 0 C-N-CA 123.075 0.55 . . . . 0.0 110.921 -179.364 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -174.44 178.25 2.02 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 126.561 1.944 . . . . 0.0 106.275 -177.414 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 64.38 19.0 63.91 Favored Glycine 0 CA--C 1.536 1.35 0 CA-C-N 119.098 0.863 . . . . 0.0 112.597 -179.555 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 9.0 p90 -74.07 168.8 22.86 Favored Pre-proline 0 CA--C 1.538 0.517 0 N-CA-C 106.233 -1.765 . . . . 0.0 106.233 177.353 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo -63.94 156.82 71.53 Favored 'Cis proline' 0 N--CA 1.454 -0.838 0 N-CA-C 116.507 1.695 . . . . 0.0 116.507 1.568 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -148.97 171.91 15.58 Favored 'General case' 0 C--O 1.221 -0.445 0 O-C-N 121.691 -0.63 . . . . 0.0 111.166 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 31.1 p-10 -166.47 -179.91 5.19 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 104.704 -2.332 . . . . 0.0 104.704 176.452 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 60.9 t -138.7 115.6 10.99 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.229 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 178.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 67.5 t -119.8 132.02 70.69 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.658 0 N-CA-C 105.618 -1.993 . . . . 0.0 105.618 178.326 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 52.9 m-85 -88.01 130.86 34.84 Favored 'General case' 0 N--CA 1.446 -0.633 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 -179.261 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -73.34 100.86 3.28 Favored 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 122.774 0.429 . . . . 0.0 109.861 -178.302 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -40.71 -38.7 0.95 Allowed 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 125.801 1.64 . . . . 0.0 113.639 178.225 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 36.8 t70 -68.26 -26.11 65.51 Favored 'General case' 0 CA--C 1.535 0.398 0 N-CA-C 113.487 0.921 . . . . 0.0 113.487 -179.055 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 40.2 mt-10 -129.49 61.64 1.55 Allowed 'General case' 0 CA--C 1.535 0.38 0 C-N-CA 124.018 0.927 . . . . 0.0 112.384 -176.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 40.5 pt -153.27 157.31 32.9 Favored Pre-proline 0 CA--C 1.531 0.24 0 C-N-CA 127.603 2.361 . . . . 0.0 105.509 174.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_exo -58.88 104.81 0.2 Allowed 'Trans proline' 0 N--CA 1.455 -0.788 0 C-N-CA 121.828 1.685 . . . . 0.0 108.334 173.703 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -35.15 -43.94 0.23 Allowed 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 126.993 2.117 . . . . 0.0 115.368 -176.752 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -55.21 -33.38 57.88 Favored Glycine 0 CA--C 1.533 1.175 0 C-N-CA 123.178 0.418 . . . . 0.0 112.97 -179.619 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 40.4 t -82.12 95.73 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.386 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 -179.244 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 25.2 t0 -49.03 112.48 0.63 Allowed 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 124.24 1.016 . . . . 0.0 110.679 178.819 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -44.73 -44.71 9.42 Favored 'General case' 0 N--CA 1.454 -0.228 0 C-N-CA 125.748 1.619 . . . . 0.0 111.496 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 59.4 t -54.64 -30.56 22.36 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 C-N-CA 123.544 0.738 . . . . 0.0 112.144 -179.085 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -77.53 -34.95 53.77 Favored 'General case' 0 CA--C 1.531 0.22 0 CA-C-N 118.732 0.696 . . . . 0.0 111.788 -178.464 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 25.1 pt -89.02 -26.14 5.57 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 C-N-CA 123.33 0.652 . . . . 0.0 112.375 -179.083 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 49.4 m -88.16 146.59 25.32 Favored 'General case' 0 N--CA 1.454 -0.232 0 N-CA-C 114.132 1.16 . . . . 0.0 114.132 -177.1 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 42.6 mmm -68.55 127.76 93.14 Favored Pre-proline 0 N--CA 1.451 -0.425 0 N-CA-C 103.713 -2.699 . . . . 0.0 103.713 170.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_exo -50.99 118.57 4.37 Favored 'Trans proline' 0 N--CA 1.456 -0.727 0 C-N-CA 121.905 1.736 . . . . 0.0 108.563 177.6 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -38.86 -37.05 0.32 Allowed 'General case' 0 CA--C 1.537 0.463 0 N-CA-C 115.569 1.692 . . . . 0.0 115.569 -176.532 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -61.77 -38.11 86.81 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 124.019 0.928 . . . . 0.0 111.076 179.278 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 55.4 mm-40 -90.19 151.71 21.43 Favored 'General case' 0 N--CA 1.443 -0.783 0 C-N-CA 125.475 1.51 . . . . 0.0 110.374 -178.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -162.43 154.92 19.32 Favored 'General case' 0 N--CA 1.451 -0.399 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.879 -178.112 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 42.7 mt -82.53 96.12 7.95 Favored 'General case' 0 N--CA 1.447 -0.617 0 C-N-CA 126.548 1.939 . . . . 0.0 106.065 178.242 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 11.9 t30 -79.01 -51.87 9.0 Favored 'General case' 0 C--O 1.225 -0.221 0 N-CA-C 113.204 0.816 . . . . 0.0 113.204 -178.457 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.96 157.73 78.53 Favored Pre-proline 0 CA--C 1.536 0.436 0 C-N-CA 123.475 0.71 . . . . 0.0 112.252 -175.809 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -65.54 165.73 21.92 Favored 'Trans proline' 0 N--CA 1.457 -0.656 0 C-N-CA 122.518 2.145 . . . . 0.0 109.954 175.663 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 79.31 -50.6 3.78 Favored Glycine 0 CA--C 1.526 0.742 0 CA-C-O 118.871 -0.961 . . . . 0.0 113.016 177.076 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 43.3 mm-40 -26.24 118.41 0.07 Allowed 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 126.79 2.036 . . . . 0.0 113.403 -179.424 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 13.3 p -106.54 123.49 48.18 Favored 'General case' 0 N--CA 1.453 -0.292 0 C-N-CA 125.605 1.562 . . . . 0.0 112.827 -178.239 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 19.8 t80 -101.81 115.32 30.29 Favored 'General case' 0 C--O 1.232 0.169 0 N-CA-C 105.835 -1.913 . . . . 0.0 105.835 173.477 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.8 t -100.81 136.88 30.34 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.295 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 -179.606 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.6 p -147.35 150.92 14.19 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.078 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 178.705 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 25.5 m -121.06 130.3 53.71 Favored 'General case' 0 N--CA 1.457 -0.081 0 C-N-CA 124.316 1.046 . . . . 0.0 108.408 -178.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 74.7 mt -113.11 121.32 44.21 Favored 'General case' 0 CA--C 1.53 0.21 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 179.418 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -92.35 -63.22 1.26 Allowed 'General case' 0 CA--C 1.529 0.149 0 C-N-CA 124.152 0.981 . . . . 0.0 112.458 -178.038 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.1 m -65.21 135.1 55.02 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 122.986 0.515 . . . . 0.0 110.318 -174.879 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 61.1 mttp -71.52 156.59 39.25 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 122.998 0.519 . . . . 0.0 111.259 -178.368 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 139.55 175.76 14.41 Favored Glycine 0 CA--C 1.525 0.696 0 C-N-CA 123.558 0.599 . . . . 0.0 111.662 177.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 18.3 m -94.47 112.18 23.95 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 107.51 -1.292 . . . . 0.0 107.51 179.072 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 18.8 m-85 -104.93 125.43 50.93 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 123.686 0.795 . . . . 0.0 109.263 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 7.3 m -98.39 142.12 30.41 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 177.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 12.0 p90 -139.55 163.6 32.13 Favored 'General case' 0 N--CA 1.455 -0.198 0 CA-C-O 121.502 0.668 . . . . 0.0 111.719 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 49.5 p90 -148.99 161.66 41.46 Favored 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 124.855 1.262 . . . . 0.0 111.784 -178.195 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.8 t -105.32 107.48 18.49 Favored 'General case' 0 CA--C 1.522 -0.126 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 177.279 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 1.3 m -41.51 -61.55 1.38 Allowed Pre-proline 0 CA--C 1.535 0.378 0 N-CA-C 115.06 1.504 . . . . 0.0 115.06 -175.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -60.19 -4.84 3.35 Favored 'Trans proline' 0 CA--C 1.536 0.624 0 C-N-CA 121.859 1.706 . . . . 0.0 114.792 -179.042 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 38.7 m80 -134.34 19.67 3.67 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-N 119.73 1.15 . . . . 0.0 110.556 177.443 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 19.6 pt20 -63.35 -42.46 98.9 Favored 'General case' 0 N--CA 1.452 -0.33 0 O-C-N 121.693 -0.629 . . . . 0.0 109.531 179.192 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -61.13 -40.98 99.3 Favored Glycine 0 CA--C 1.529 0.964 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 177.557 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -66.32 -34.14 77.32 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 122.713 0.405 . . . . 0.0 110.117 178.536 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 108.33 31.19 3.59 Favored Glycine 0 CA--C 1.525 0.715 0 C-N-CA 124.287 0.946 . . . . 0.0 112.513 178.072 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -80.18 91.08 5.52 Favored 'General case' 0 C--O 1.237 0.41 0 N-CA-C 106.609 -1.626 . . . . 0.0 106.609 178.122 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 20.1 m -131.12 171.6 17.64 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.246 0 C-N-CA 125.128 1.371 . . . . 0.0 112.15 -177.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -171.27 -179.89 42.66 Favored Glycine 0 CA--C 1.529 0.956 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 177.507 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 81.3 mttt -147.75 155.09 41.33 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-N 117.77 0.785 . . . . 0.0 110.435 -179.657 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 4.3 p -137.75 127.96 36.73 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 C-N-CA 123.938 0.895 . . . . 0.0 109.637 179.197 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -91.99 103.92 16.39 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 107.135 -1.431 . . . . 0.0 107.135 178.736 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 40.0 t -81.37 112.28 19.11 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 N-CA-C 105.386 -2.079 . . . . 0.0 105.386 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 31.1 m120 . . . . . 0 N--CA 1.456 -0.173 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 -178.596 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 8.6 tt . . . . . 0 N--CA 1.453 -0.324 0 CA-C-O 121.142 0.496 . . . . 0.0 111.055 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -94.34 127.81 40.45 Favored 'General case' 0 N--CA 1.455 -0.199 0 C-N-CA 124.263 1.025 . . . . 0.0 109.885 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 43.8 t -118.22 121.83 68.14 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.355 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 179.478 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 36.9 mt -89.62 127.88 35.97 Favored 'General case' 0 N--CA 1.454 -0.262 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 179.247 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 44.1 mt -86.64 96.87 10.26 Favored 'General case' 0 N--CA 1.452 -0.326 0 N-CA-C 106.656 -1.609 . . . . 0.0 106.656 177.822 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 105.39 132.41 7.31 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 -178.679 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 23.9 p -83.0 43.88 0.89 Allowed 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 119.07 1.435 . . . . 0.0 112.802 -178.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.58 -55.14 1.25 Allowed Glycine 0 CA--C 1.527 0.815 0 C-N-CA 126.197 1.856 . . . . 0.0 112.278 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -72.85 34.47 0.07 Allowed 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 126.163 1.785 . . . . 0.0 113.633 -177.554 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 68.08 -13.27 0.74 Allowed Glycine 0 CA--C 1.53 0.996 0 C-N-CA 124.505 1.05 . . . . 0.0 115.035 178.428 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 20.3 t -61.55 129.15 39.72 Favored 'General case' 0 C--N 1.339 0.126 0 CA-C-N 119.328 1.564 . . . . 0.0 109.768 -178.464 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 59.4 mt -75.11 66.76 1.69 Allowed 'General case' 0 N--CA 1.448 -0.534 0 C-N-CA 126.113 1.765 . . . . 0.0 111.857 -175.538 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.8 m -135.06 149.55 29.15 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.182 0 C-N-CA 123.446 0.698 . . . . 0.0 110.856 179.368 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 74.7 m-85 -88.09 135.46 33.41 Favored 'General case' 0 N--CA 1.456 -0.144 0 N-CA-C 105.477 -2.046 . . . . 0.0 105.477 176.549 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 48.4 t -122.67 110.73 31.69 Favored Pre-proline 0 CA--C 1.533 0.305 0 CA-C-O 118.026 -0.987 . . . . 0.0 108.851 178.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -72.87 151.62 97.13 Favored 'Cis proline' 0 N--CA 1.458 -0.565 0 CA-C-N 120.408 1.181 . . . . 0.0 111.175 -0.773 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.2 m -80.66 -48.92 11.92 Favored 'General case' 0 CA--C 1.529 0.161 0 C-N-CA 123.351 0.661 . . . . 0.0 110.799 179.811 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -119.97 129.47 54.32 Favored 'General case' 0 N--CA 1.454 -0.251 0 N-CA-C 105.904 -1.887 . . . . 0.0 105.904 179.821 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 38.2 p90 -157.4 -175.78 5.59 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-N 118.828 0.74 . . . . 0.0 111.963 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 32.9 m -133.97 147.9 51.09 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 125.601 1.561 . . . . 0.0 107.092 178.37 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.4 p -145.71 139.01 14.36 Favored Pre-proline 0 N--CA 1.449 -0.509 0 C-N-CA 123.568 0.747 . . . . 0.0 109.308 -178.156 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 70.7 Cg_exo -53.66 137.26 66.57 Favored 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 122.359 2.039 . . . . 0.0 111.436 177.327 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.6 m -60.13 117.23 4.88 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 179.476 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 109.35 -17.21 31.54 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-O 118.729 -1.039 . . . . 0.0 112.181 -178.119 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -72.17 157.45 37.73 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 119.534 1.667 . . . . 0.0 110.698 179.226 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 57.1 pttt -93.76 135.09 35.42 Favored 'General case' 0 N--CA 1.444 -0.76 0 C-N-CA 124.764 1.226 . . . . 0.0 110.826 -179.695 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 45.6 mt -102.36 130.71 51.81 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.358 0 N-CA-C 104.804 -2.295 . . . . 0.0 104.804 177.055 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 80.6 t -115.27 99.54 8.71 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 C-N-CA 124.819 1.247 . . . . 0.0 108.705 -178.104 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -86.13 103.0 14.37 Favored 'General case' 0 N--CA 1.456 -0.169 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 178.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 60.9 tttp -98.39 128.8 44.95 Favored 'General case' 0 CA--C 1.528 0.131 0 C-N-CA 124.315 1.046 . . . . 0.0 112.27 -177.216 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 38.8 t30 -64.43 110.36 2.25 Favored 'General case' 0 N--CA 1.456 -0.15 0 C-N-CA 123.608 0.763 . . . . 0.0 109.86 177.57 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 59.9 t30 -102.59 -64.74 1.04 Allowed 'General case' 0 C--N 1.339 0.134 0 CA-C-N 118.495 0.589 . . . . 0.0 111.312 -179.207 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -157.17 168.4 27.55 Favored 'General case' 0 C--O 1.226 -0.18 0 C-N-CA 122.869 0.468 . . . . 0.0 111.284 -177.762 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 66.23 24.86 72.19 Favored Glycine 0 CA--C 1.532 1.144 0 O-C-N 121.868 -0.52 . . . . 0.0 112.269 -179.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 10.3 p90 -74.68 169.53 19.42 Favored Pre-proline 0 CA--C 1.543 0.7 0 C-N-CA 125.457 1.503 . . . . 0.0 107.768 179.023 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 95.7 Cg_endo -70.32 162.21 86.17 Favored 'Cis proline' 0 N--CA 1.448 -1.19 0 CA-C-N 120.189 1.103 . . . . 0.0 114.314 2.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 89.9 m-70 -148.9 174.86 11.8 Favored 'General case' 0 C--O 1.22 -0.476 0 O-C-N 121.545 -0.722 . . . . 0.0 111.276 -178.634 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 25.4 p-10 -163.87 179.08 7.3 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 103.858 -2.645 . . . . 0.0 103.858 175.707 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 45.1 t -138.52 117.44 13.81 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.377 0 N-CA-C 107.358 -1.349 . . . . 0.0 107.358 178.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 91.8 t -121.55 138.18 52.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 106.737 -1.579 . . . . 0.0 106.737 178.409 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 76.2 m-85 -97.09 131.82 43.49 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -63.19 116.26 5.26 Favored 'General case' 0 N--CA 1.454 -0.242 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 -178.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.1 pm0 -48.45 -29.57 4.22 Favored 'General case' 0 CA--C 1.533 0.299 0 N-CA-C 115.682 1.734 . . . . 0.0 115.682 -177.719 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 18.0 m-20 -90.07 -52.18 5.08 Favored 'General case' 0 CA--C 1.53 0.178 0 CA-C-N 118.752 0.706 . . . . 0.0 110.101 -179.593 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 80.0 mt-10 -79.92 58.82 3.0 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 124.402 1.081 . . . . 0.0 112.169 -176.721 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 19.2 pt -150.58 151.29 30.45 Favored Pre-proline 0 CA--C 1.532 0.261 0 C-N-CA 127.025 2.13 . . . . 0.0 107.1 176.199 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 21.0 Cg_endo -61.89 117.58 4.43 Favored 'Trans proline' 0 N--CA 1.452 -0.948 0 C-N-CA 121.925 1.75 . . . . 0.0 110.466 178.746 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -46.98 120.91 3.3 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 125.02 1.328 . . . . 0.0 110.963 -179.398 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 126.31 -39.51 1.99 Allowed Glycine 0 CA--C 1.525 0.676 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -178.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 21.7 t -78.28 95.06 1.65 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 53.5 t0 -54.47 114.82 1.81 Allowed 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 123.213 0.605 . . . . 0.0 110.535 179.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -45.44 -43.67 11.59 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 125.554 1.541 . . . . 0.0 111.887 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 55.0 t -57.61 -28.85 32.92 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.344 0 C-N-CA 123.274 0.63 . . . . 0.0 111.805 -178.258 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 28.8 mtpp -79.05 -36.01 41.68 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 118.556 0.616 . . . . 0.0 111.229 -178.723 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 26.2 pt -86.78 -26.11 6.12 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.408 0 C-N-CA 123.201 0.6 . . . . 0.0 112.482 -179.564 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 46.0 m -90.25 148.6 22.8 Favored 'General case' 0 C--N 1.331 -0.2 0 N-CA-C 114.455 1.28 . . . . 0.0 114.455 -176.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 69.5 mmm -80.56 120.74 80.1 Favored Pre-proline 0 CA--C 1.534 0.358 0 N-CA-C 105.749 -1.945 . . . . 0.0 105.749 173.583 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 81.4 Cg_exo -47.02 132.37 17.78 Favored 'Trans proline' 0 N--CA 1.457 -0.625 0 C-N-CA 123.07 2.513 . . . . 0.0 112.073 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 81.9 mt-10 -69.06 68.86 0.18 Allowed 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 125.347 1.459 . . . . 0.0 110.578 -179.8 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -167.08 -47.96 0.02 OUTLIER 'General case' 0 N--CA 1.451 -0.411 0 C-N-CA 129.204 3.002 . . . . 0.0 105.947 -178.585 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 79.5 mt-10 -78.45 148.74 33.44 Favored 'General case' 0 N--CA 1.446 -0.636 0 C-N-CA 124.484 1.114 . . . . 0.0 108.181 178.637 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 2.5 pp -160.27 162.76 33.72 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-O 121.198 0.523 . . . . 0.0 111.279 -179.097 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 37.4 mt -102.51 134.13 46.35 Favored 'General case' 0 N--CA 1.446 -0.662 0 C-N-CA 128.049 2.54 . . . . 0.0 104.598 177.53 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 30.0 t30 -138.77 -46.12 0.49 Allowed 'General case' 0 C--O 1.227 -0.111 0 C-N-CA 122.812 0.445 . . . . 0.0 111.833 -178.029 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -69.95 131.18 89.29 Favored Pre-proline 0 C--O 1.237 0.424 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 -178.575 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -48.56 130.22 21.56 Favored 'Trans proline' 0 N--CA 1.454 -0.823 0 C-N-CA 123.047 2.498 . . . . 0.0 111.538 -179.392 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 99.31 -23.3 36.83 Favored Glycine 0 CA--C 1.525 0.693 0 CA-C-O 117.662 -1.632 . . . . 0.0 114.462 177.627 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 52.4 mt-10 -50.86 125.41 13.36 Favored 'General case' 0 CA--C 1.536 0.438 0 CA-C-N 120.116 1.958 . . . . 0.0 110.849 179.719 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 2.3 p -104.27 140.73 37.44 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 125.514 1.526 . . . . 0.0 112.184 -178.163 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 20.8 t80 -117.79 115.22 24.57 Favored 'General case' 0 C--O 1.232 0.176 0 N-CA-C 104.789 -2.3 . . . . 0.0 104.789 172.259 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.4 t -103.56 139.41 24.57 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.388 0 C-N-CA 123.183 0.593 . . . . 0.0 109.526 -178.497 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.5 p -143.48 156.11 16.61 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 N-CA-C 106.6 -1.63 . . . . 0.0 106.6 176.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 12.5 m -132.29 123.66 27.33 Favored 'General case' 0 C--N 1.333 -0.139 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 -179.286 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 68.1 mt -111.56 102.09 10.45 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 123.254 0.622 . . . . 0.0 109.698 -177.531 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -82.46 -42.73 18.14 Favored 'General case' 0 CA--C 1.529 0.165 0 C-N-CA 124.069 0.947 . . . . 0.0 110.676 178.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 4.4 m -73.21 112.42 9.25 Favored 'General case' 0 N--CA 1.45 -0.458 0 C-N-CA 123.083 0.553 . . . . 0.0 109.87 -177.745 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 25.8 pttm -60.21 152.17 25.35 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 123.077 0.551 . . . . 0.0 111.299 178.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 150.96 -167.94 30.61 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.106 -1.198 . . . . 0.0 110.106 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 23.3 m -113.97 124.71 52.82 Favored 'General case' 0 N--CA 1.454 -0.271 0 N-CA-C 106.435 -1.691 . . . . 0.0 106.435 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -121.01 114.9 22.18 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 124.059 0.944 . . . . 0.0 110.045 -178.164 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 48.7 m -90.51 139.62 30.52 Favored 'General case' 0 C--O 1.233 0.197 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 175.788 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 22.5 p90 -136.41 165.44 25.81 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-O 121.419 0.628 . . . . 0.0 112.071 -179.312 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 49.4 p90 -153.33 161.12 42.69 Favored 'General case' 0 N--CA 1.453 -0.323 0 C-N-CA 124.277 1.031 . . . . 0.0 112.179 -178.498 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 3.7 t -103.1 102.62 12.64 Favored 'General case' 0 CA--C 1.519 -0.239 0 N-CA-C 106.254 -1.758 . . . . 0.0 106.254 176.638 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.263 0.7 OUTLIER -44.67 -56.36 8.67 Favored Pre-proline 0 CA--C 1.535 0.402 0 N-CA-C 113.985 1.106 . . . . 0.0 113.985 -175.131 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_exo -50.93 -18.16 4.07 Favored 'Trans proline' 0 CA--C 1.534 0.514 0 C-N-CA 123.187 2.591 . . . . 0.0 115.042 177.772 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 38.2 m80 -133.85 25.73 3.98 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 123.783 0.833 . . . . 0.0 110.862 -179.599 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 65.7 tt0 -61.61 -50.27 73.27 Favored 'General case' 0 N--CA 1.457 -0.093 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 179.214 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.56 -33.3 62.27 Favored Glycine 0 CA--C 1.532 1.098 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 177.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -79.92 2.17 24.44 Favored 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 123.403 0.681 . . . . 0.0 112.037 179.082 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 79.9 21.84 64.99 Favored Glycine 0 CA--C 1.527 0.832 0 CA-C-O 118.978 -0.901 . . . . 0.0 113.706 178.42 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 22.1 ttt -78.65 80.78 5.0 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 119.321 1.56 . . . . 0.0 107.928 177.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 12.6 m -124.2 170.3 14.54 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.188 0 C-N-CA 125.975 1.71 . . . . 0.0 111.07 -179.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -170.02 178.56 42.8 Favored Glycine 0 CA--C 1.527 0.84 0 N-CA-C 108.848 -1.701 . . . . 0.0 108.848 177.611 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 33.8 mtmm -148.42 149.75 32.28 Favored 'General case' 0 N--CA 1.455 -0.199 0 CA-C-N 118.091 0.946 . . . . 0.0 110.463 -178.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.2 p -135.26 132.17 52.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 C-N-CA 123.121 0.569 . . . . 0.0 109.813 178.132 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.2 m -98.87 103.49 15.45 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 125.05 1.34 . . . . 0.0 107.848 179.341 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 47.0 t -82.59 102.24 8.31 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.753 0 N-CA-C 105.026 -2.213 . . . . 0.0 105.026 -179.189 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 45.5 p-10 . . . . . 0 C--N 1.332 -0.167 0 C-N-CA 124.984 1.314 . . . . 0.0 109.599 -178.059 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 9.9 mp . . . . . 0 CA--C 1.53 0.183 0 CA-C-O 121.275 0.559 . . . . 0.0 111.215 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -80.74 138.91 36.33 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 106.869 -1.53 . . . . 0.0 106.869 175.486 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 60.2 t -129.34 126.59 63.98 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 39.7 mt -87.98 122.53 31.7 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 178.763 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 88.9 mt -81.11 100.01 8.81 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 106.248 -1.76 . . . . 0.0 106.248 177.35 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 95.84 137.96 9.5 Favored Glycine 0 C--N 1.336 0.532 0 N-CA-C 107.402 -2.279 . . . . 0.0 107.402 -177.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 80.8 p -78.97 157.97 28.06 Favored 'General case' 0 N--CA 1.438 -1.037 0 CA-C-O 121.985 0.898 . . . . 0.0 109.21 -179.212 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.4 -34.55 59.69 Favored Glycine 0 CA--C 1.531 1.04 0 CA-C-N 114.608 -1.178 . . . . 0.0 111.085 178.162 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -76.03 -3.77 37.65 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 123.573 0.749 . . . . 0.0 112.256 179.074 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 99.76 -21.14 46.39 Favored Glycine 0 CA--C 1.528 0.847 0 CA-C-O 119.007 -0.885 . . . . 0.0 113.451 178.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 33.4 t -56.81 131.99 51.0 Favored 'General case' 0 C--O 1.237 0.442 0 CA-C-N 119.249 1.524 . . . . 0.0 110.426 -179.641 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 56.4 mt -74.06 68.3 1.38 Allowed 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 126.489 1.916 . . . . 0.0 111.114 -176.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.5 m -134.38 152.94 34.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 C-N-CA 123.739 0.816 . . . . 0.0 109.533 178.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 -82.45 135.95 35.02 Favored 'General case' 0 N--CA 1.454 -0.245 0 N-CA-C 105.529 -2.026 . . . . 0.0 105.529 176.625 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 48.0 t -123.92 110.46 29.44 Favored Pre-proline 0 CA--C 1.535 0.397 0 CA-C-O 118.158 -0.925 . . . . 0.0 108.79 179.296 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -70.43 152.28 93.89 Favored 'Cis proline' 0 N--CA 1.459 -0.524 0 CA-C-N 120.361 1.164 . . . . 0.0 111.543 -0.79 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.4 m -82.3 -44.09 16.67 Favored 'General case' 0 CA--C 1.529 0.145 0 C-N-CA 123.784 0.833 . . . . 0.0 111.019 179.721 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 37.8 tt0 -129.68 133.98 47.4 Favored 'General case' 0 N--CA 1.452 -0.33 0 N-CA-C 106.354 -1.721 . . . . 0.0 106.354 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 30.2 p90 -163.23 -179.26 6.49 Favored 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 122.944 0.498 . . . . 0.0 110.251 -179.177 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 17.7 m -128.69 148.43 50.83 Favored 'General case' 0 N--CA 1.455 -0.191 0 N-CA-C 106.932 -1.507 . . . . 0.0 106.932 177.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.8 p -141.61 127.73 11.13 Favored Pre-proline 0 CA--C 1.538 0.496 0 C-N-CA 123.16 0.584 . . . . 0.0 111.35 -177.211 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -55.57 132.21 50.79 Favored 'Trans proline' 0 N--CA 1.452 -0.921 0 C-N-CA 122.327 2.018 . . . . 0.0 110.55 175.336 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 38.2 m -47.73 127.19 11.34 Favored 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 123.118 0.567 . . . . 0.0 110.042 178.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 99.03 -25.98 26.1 Favored Glycine 0 CA--C 1.531 1.054 0 CA-C-O 118.809 -0.995 . . . . 0.0 113.011 -179.591 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 75.4 mt-10 -74.73 100.91 4.13 Favored 'General case' 0 N--CA 1.454 -0.253 0 CA-C-N 119.742 1.771 . . . . 0.0 108.586 178.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 21.5 pttp -51.66 139.56 20.64 Favored 'General case' 0 N--CA 1.45 -0.44 0 C-N-CA 124.795 1.238 . . . . 0.0 113.926 -178.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 38.1 mt -93.54 133.39 34.82 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.405 0 N-CA-C 105.199 -2.149 . . . . 0.0 105.199 176.784 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 60.7 t -119.21 94.76 3.22 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.202 0 C-N-CA 124.453 1.101 . . . . 0.0 108.49 -178.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -83.27 98.94 9.68 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 122.857 0.463 . . . . 0.0 109.948 -179.384 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 24.3 ttmm -88.35 128.47 35.5 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 125.055 1.342 . . . . 0.0 112.114 -177.653 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 4.8 t30 -67.01 93.82 0.3 Allowed 'General case' 0 CA--C 1.534 0.363 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 177.019 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 42.5 t30 -85.39 -75.77 0.35 Allowed 'General case' 0 C--O 1.228 -0.074 0 N-CA-C 113.162 0.801 . . . . 0.0 113.162 -175.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -143.98 163.67 32.82 Favored 'General case' 0 C--O 1.224 -0.277 0 C-N-CA 123.67 0.788 . . . . 0.0 109.79 -176.456 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 63.65 19.59 62.91 Favored Glycine 0 CA--C 1.535 1.297 0 O-C-N 121.906 -0.496 . . . . 0.0 112.697 -179.591 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 16.2 p90 -72.24 166.53 40.53 Favored Pre-proline 0 CA--C 1.546 0.799 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 177.483 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -68.31 158.06 86.79 Favored 'Cis proline' 0 N--CA 1.447 -1.222 0 N-CA-C 115.754 1.405 . . . . 0.0 115.754 4.246 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 88.9 m-70 -150.74 171.32 17.37 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 114.643 -1.162 . . . . 0.0 109.459 -179.422 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 34.9 p-10 -159.61 173.2 16.46 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 104.663 -2.347 . . . . 0.0 104.663 175.423 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 36.8 t -129.19 111.55 23.03 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.245 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 -178.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.9 t -113.36 131.46 65.03 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.579 0 N-CA-C 106.547 -1.649 . . . . 0.0 106.547 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 -97.01 131.56 43.7 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 179.243 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -71.76 109.17 5.47 Favored 'General case' 0 N--CA 1.454 -0.26 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 -179.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -46.27 -31.97 2.82 Favored 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 115.279 1.585 . . . . 0.0 115.279 -178.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 20.0 m-20 -84.31 -17.96 37.85 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-N 118.518 0.599 . . . . 0.0 111.839 -179.356 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -118.91 59.36 0.83 Allowed 'General case' 0 CA--C 1.532 0.259 0 C-N-CA 124.657 1.183 . . . . 0.0 111.087 -177.078 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 25.0 pt -152.68 151.4 26.71 Favored Pre-proline 0 CA--C 1.531 0.24 0 C-N-CA 126.165 1.786 . . . . 0.0 106.224 176.746 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_endo -57.7 118.2 5.03 Favored 'Trans proline' 0 N--CA 1.453 -0.873 0 C-N-CA 122.316 2.01 . . . . 0.0 111.125 179.43 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -47.85 117.72 2.0 Allowed 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 124.996 1.318 . . . . 0.0 110.695 -179.611 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 128.54 -35.98 2.55 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 -178.504 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 34.7 t -77.4 109.27 11.77 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 46.2 t0 -64.29 112.09 2.91 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 122.676 0.39 . . . . 0.0 110.512 179.634 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.1 -40.05 14.54 Favored 'General case' 0 CA--C 1.528 0.106 0 C-N-CA 125.057 1.343 . . . . 0.0 111.626 178.644 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 55.4 t -61.3 -31.13 49.43 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.349 0 C-N-CA 123.348 0.659 . . . . 0.0 111.641 -179.027 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -78.62 -40.72 33.56 Favored 'General case' 0 C--O 1.227 -0.113 0 CA-C-N 118.515 0.598 . . . . 0.0 110.469 -178.7 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 35.4 pt -78.02 -33.74 18.55 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.252 0 N-CA-C 112.566 0.58 . . . . 0.0 112.566 -178.804 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 50.7 m -78.17 139.92 38.98 Favored 'General case' 0 N--CA 1.455 -0.201 0 N-CA-C 112.774 0.657 . . . . 0.0 112.774 -177.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.2 tmt? -67.34 124.59 89.43 Favored Pre-proline 0 CA--C 1.538 0.513 0 N-CA-C 105.559 -2.015 . . . . 0.0 105.559 176.017 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 81.3 Cg_exo -44.59 110.51 0.22 Allowed 'Trans proline' 0 N--CA 1.458 -0.56 0 C-N-CA 123.885 3.057 . . . . 0.0 113.43 -178.272 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -45.1 -33.94 2.39 Favored 'General case' 0 CA--C 1.531 0.226 0 C-N-CA 125.869 1.668 . . . . 0.0 114.17 -179.281 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -57.65 -33.82 68.71 Favored 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 123.666 0.786 . . . . 0.0 110.972 179.132 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -104.9 159.96 15.39 Favored 'General case' 0 N--CA 1.445 -0.719 0 C-N-CA 125.853 1.661 . . . . 0.0 110.14 -178.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 96.1 mt -145.41 151.77 38.78 Favored 'General case' 0 N--CA 1.454 -0.253 0 N-CA-C 106.588 -1.634 . . . . 0.0 106.588 178.38 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 74.8 mt -78.59 102.05 7.75 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 106.114 -1.81 . . . . 0.0 106.114 177.373 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 31.8 p-10 -83.26 -55.46 4.32 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 124.291 1.037 . . . . 0.0 112.311 -177.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.94 149.57 77.1 Favored Pre-proline 0 CA--C 1.533 0.289 0 C-N-CA 123.203 0.601 . . . . 0.0 111.185 -177.59 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -66.87 164.02 31.25 Favored 'Trans proline' 0 N--CA 1.454 -0.799 0 C-N-CA 122.406 2.071 . . . . 0.0 109.804 177.513 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 79.42 -38.77 2.08 Favored Glycine 0 CA--C 1.528 0.862 0 CA-C-O 118.55 -1.139 . . . . 0.0 113.947 176.295 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -39.86 123.91 1.67 Allowed 'General case' 0 CA--C 1.536 0.437 0 CA-C-N 118.495 1.147 . . . . 0.0 111.696 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 18.0 p -105.03 121.04 42.95 Favored 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 124.662 1.185 . . . . 0.0 112.647 -177.701 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 62.3 t80 -95.13 111.4 23.24 Favored 'General case' 0 N--CA 1.454 -0.239 0 N-CA-C 105.367 -2.086 . . . . 0.0 105.367 174.081 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -100.11 139.92 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 C-N-CA 123.219 0.608 . . . . 0.0 110.54 -177.448 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 11.6 p -146.67 139.28 19.64 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.174 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 176.626 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 14.2 m -126.61 99.01 5.62 Favored 'General case' 0 C--N 1.34 0.187 0 C-N-CA 122.918 0.487 . . . . 0.0 112.286 -176.067 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -87.05 130.54 34.44 Favored 'General case' 0 N--CA 1.439 -0.984 0 C-N-CA 123.057 0.543 . . . . 0.0 111.666 178.329 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -100.9 -45.1 5.54 Favored 'General case' 0 N--CA 1.454 -0.227 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 174.549 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 4.6 m -65.52 115.64 5.96 Favored 'General case' 0 N--CA 1.446 -0.652 0 C-N-CA 124.808 1.243 . . . . 0.0 110.192 -178.231 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 25.9 pttm -63.93 153.59 36.53 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-N 115.159 -0.928 . . . . 0.0 110.896 178.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 147.08 -177.51 25.33 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.401 -1.08 . . . . 0.0 110.401 178.392 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 28.7 m -106.49 121.94 45.29 Favored 'General case' 0 N--CA 1.452 -0.327 0 N-CA-C 106.941 -1.503 . . . . 0.0 106.941 -179.024 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 16.4 m-85 -115.07 122.44 46.16 Favored 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 124.594 1.158 . . . . 0.0 109.735 -178.358 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 41.4 m -98.3 132.86 43.44 Favored 'General case' 0 C--O 1.234 0.248 0 N-CA-C 107.635 -1.246 . . . . 0.0 107.635 175.366 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 21.0 p90 -132.62 165.68 23.88 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-O 121.638 0.732 . . . . 0.0 111.842 -179.438 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 52.4 p90 -156.56 161.92 39.94 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 115.226 -0.897 . . . . 0.0 112.561 -178.601 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.7 t -103.36 99.97 9.83 Favored 'General case' 0 CA--C 1.516 -0.333 0 N-CA-C 106.454 -1.684 . . . . 0.0 106.454 177.177 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.281 13.1 p -35.84 -64.31 0.35 Allowed Pre-proline 0 CA--C 1.541 0.63 0 N-CA-C 115.861 1.8 . . . . 0.0 115.861 -175.654 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -60.68 -7.25 6.99 Favored 'Trans proline' 0 C--N 1.348 0.506 0 C-N-CA 122.663 2.242 . . . . 0.0 115.221 -177.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 36.2 m80 -132.09 15.83 4.65 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 119.674 1.125 . . . . 0.0 110.814 178.22 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 65.6 tt0 -59.5 -46.57 88.45 Favored 'General case' 0 CA--C 1.529 0.163 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 178.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -57.07 -30.45 60.63 Favored Glycine 0 CA--C 1.531 1.082 0 C-N-CA 123.588 0.613 . . . . 0.0 111.579 177.613 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -86.08 8.15 21.91 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 123.599 0.759 . . . . 0.0 111.347 178.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 81.67 16.33 73.44 Favored Glycine 0 CA--C 1.527 0.839 0 CA-C-O 118.762 -1.021 . . . . 0.0 113.371 178.722 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 20.0 ttt -78.25 77.12 4.75 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 119.525 1.663 . . . . 0.0 108.925 178.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.7 m -125.8 170.81 15.33 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.314 0 C-N-CA 125.901 1.68 . . . . 0.0 110.052 179.43 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -170.07 177.27 43.5 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 109.262 -1.535 . . . . 0.0 109.262 177.804 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 59.4 mttp -145.98 157.53 43.88 Favored 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 123.401 0.68 . . . . 0.0 109.677 -178.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.2 p -147.25 130.6 8.77 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 C-N-CA 122.689 0.396 . . . . 0.0 110.417 178.007 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 99.1 m -98.49 102.65 14.46 Favored 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 124.171 0.988 . . . . 0.0 108.85 178.579 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 48.8 t -83.2 132.29 31.75 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.444 0 N-CA-C 105.797 -1.927 . . . . 0.0 105.797 178.686 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.334 -0.106 0 CA-C-N 118.395 0.543 . . . . 0.0 111.416 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 9.8 mp . . . . . 0 CA--C 1.534 0.329 0 CA-C-O 121.41 0.624 . . . . 0.0 111.6 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 -89.12 117.1 27.87 Favored 'General case' 0 N--CA 1.452 -0.326 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 175.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 28.1 t -110.88 112.25 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.238 0 C-N-CA 123.695 0.798 . . . . 0.0 110.305 -177.505 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 53.6 mt -80.29 123.78 28.27 Favored 'General case' 0 N--CA 1.451 -0.403 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 178.427 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 64.9 mt -87.08 110.73 20.3 Favored 'General case' 0 N--CA 1.447 -0.575 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 178.566 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 84.61 126.37 1.45 Allowed Glycine 0 C--N 1.337 0.594 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.709 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 6.1 p -77.64 161.43 27.81 Favored 'General case' 0 N--CA 1.442 -0.827 0 O-C-N 121.48 -1.012 . . . . 0.0 108.689 -179.099 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -44.32 -38.66 5.18 Favored Glycine 0 CA--C 1.531 1.085 0 C-N-CA 125.777 1.656 . . . . 0.0 113.822 -178.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -76.31 4.08 9.6 Favored 'General case' 0 CA--C 1.537 0.48 0 N-CA-C 113.267 0.84 . . . . 0.0 113.267 -179.647 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 86.73 -6.16 83.33 Favored Glycine 0 CA--C 1.529 0.965 0 CA-C-O 118.92 -0.933 . . . . 0.0 113.105 -179.626 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 20.7 t -61.67 135.81 57.76 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-N 119.233 1.517 . . . . 0.0 110.457 -179.108 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 58.1 mt -75.94 65.93 2.09 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 126.064 1.746 . . . . 0.0 111.465 -176.556 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 28.7 m -130.94 152.5 37.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 C-N-CA 123.772 0.829 . . . . 0.0 110.436 179.547 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 73.3 m-85 -89.34 138.07 31.77 Favored 'General case' 0 N--CA 1.455 -0.222 0 N-CA-C 104.973 -2.232 . . . . 0.0 104.973 176.102 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 52.5 t -125.65 105.64 26.91 Favored Pre-proline 0 CA--C 1.537 0.457 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 179.009 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -68.23 158.44 86.05 Favored 'Cis proline' 0 C--N 1.347 0.466 0 CA-C-N 120.031 1.047 . . . . 0.0 111.799 -1.023 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.7 p -84.77 -63.65 1.3 Allowed 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 125.039 1.336 . . . . 0.0 108.907 179.672 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -117.8 135.66 53.92 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 125.102 1.361 . . . . 0.0 107.435 178.541 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 43.4 p90 -158.59 175.34 13.78 Favored 'General case' 0 C--N 1.333 -0.127 0 CA-C-O 121.22 0.533 . . . . 0.0 111.724 -178.455 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 24.0 p -128.33 147.18 50.61 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 107.19 -1.411 . . . . 0.0 107.19 178.358 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.0 p -149.93 140.46 14.06 Favored Pre-proline 0 CA--C 1.537 0.456 0 CA-C-N 118.843 0.747 . . . . 0.0 110.662 -178.08 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -52.87 138.79 60.76 Favored 'Trans proline' 0 CA--C 1.538 0.706 0 C-N-CA 122.609 2.206 . . . . 0.0 112.44 176.378 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 23.5 m -57.96 131.85 51.66 Favored 'General case' 0 CA--C 1.53 0.191 0 C-N-CA 122.875 0.47 . . . . 0.0 111.125 179.601 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 101.52 -18.1 54.0 Favored Glycine 0 CA--C 1.526 0.774 0 CA-C-O 119.156 -0.802 . . . . 0.0 112.92 179.57 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 81.5 mm-40 -68.7 156.5 38.12 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-N 119.075 1.438 . . . . 0.0 112.823 -179.198 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 24.0 ttmm -91.49 142.05 28.08 Favored 'General case' 0 N--CA 1.452 -0.372 0 C-N-CA 125.965 1.706 . . . . 0.0 110.14 -179.786 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 40.6 mt -120.88 134.42 64.35 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.343 0 N-CA-C 105.929 -1.878 . . . . 0.0 105.929 178.307 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 97.6 t -124.15 101.53 9.25 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 C-N-CA 125.236 1.414 . . . . 0.0 108.571 -177.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -86.25 136.19 33.26 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 106.115 -1.809 . . . . 0.0 106.115 176.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 12.1 tmtt? -135.27 132.46 37.81 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 118.986 0.812 . . . . 0.0 112.4 -177.369 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 6.2 m-20 -66.47 101.4 0.76 Allowed 'General case' 0 C--N 1.341 0.203 0 C-N-CA 123.69 0.796 . . . . 0.0 108.886 177.77 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 38.7 t30 -92.38 -61.84 1.53 Allowed 'General case' 0 N--CA 1.455 -0.224 0 CA-C-O 121.34 0.59 . . . . 0.0 109.951 -179.663 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -150.77 -179.47 7.29 Favored 'General case' 0 C--O 1.223 -0.299 0 C-N-CA 124.065 0.946 . . . . 0.0 108.898 -179.029 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 52.72 17.12 4.41 Favored Glycine 0 CA--C 1.538 1.503 0 N-CA-C 115.534 0.973 . . . . 0.0 115.534 178.574 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 14.5 p90 -73.85 167.62 33.61 Favored Pre-proline 0 CA--C 1.539 0.531 0 N-CA-C 106.921 -1.511 . . . . 0.0 106.921 178.535 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo -63.4 157.87 67.55 Favored 'Cis proline' 0 N--CA 1.454 -0.82 0 N-CA-C 117.407 2.041 . . . . 0.0 117.407 2.638 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 90.8 m-70 -152.47 169.0 23.67 Favored 'General case' 0 N--CA 1.453 -0.3 0 O-C-N 121.598 -0.689 . . . . 0.0 111.638 179.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 51.4 p30 -162.15 178.64 8.59 Favored 'General case' 0 N--CA 1.452 -0.332 0 N-CA-C 104.606 -2.368 . . . . 0.0 104.606 174.707 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 34.8 t -135.46 123.4 37.7 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 71.1 t -123.07 139.27 50.35 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.58 0 N-CA-C 105.558 -2.016 . . . . 0.0 105.558 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -103.99 135.37 45.63 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 108.165 -1.05 . . . . 0.0 108.165 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -66.44 122.08 16.73 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 -179.482 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -74.43 50.2 0.4 Allowed 'General case' 0 CA--C 1.538 0.511 0 N-CA-C 113.956 1.095 . . . . 0.0 113.956 -178.509 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -161.7 -64.79 0.05 Allowed 'General case' 0 N--CA 1.456 -0.129 0 C-N-CA 125.19 1.396 . . . . 0.0 108.987 177.3 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -83.0 63.81 7.28 Favored 'General case' 0 CA--C 1.538 0.496 0 CA-C-O 122.069 0.938 . . . . 0.0 110.274 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 26.8 pt -145.3 153.63 52.54 Favored Pre-proline 0 CA--C 1.536 0.408 0 C-N-CA 129.763 3.225 . . . . 0.0 105.523 177.019 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo -57.92 114.81 2.12 Favored 'Trans proline' 0 N--CA 1.455 -0.79 0 C-N-CA 121.628 1.552 . . . . 0.0 111.699 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -48.11 112.07 0.53 Allowed 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 125.384 1.474 . . . . 0.0 110.735 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 131.12 -34.08 2.69 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 109.721 -1.351 . . . . 0.0 109.721 -178.822 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 42.8 t -77.32 111.48 14.17 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.23 0 CA-C-N 117.565 0.683 . . . . 0.0 109.214 -179.863 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 40.7 t0 -64.23 109.86 2.01 Favored 'General case' 0 CA--C 1.532 0.277 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 178.734 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.51 -38.79 14.68 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 125.131 1.372 . . . . 0.0 111.97 179.508 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 60.0 t -60.63 -28.9 43.73 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.311 0 C-N-CA 123.331 0.653 . . . . 0.0 111.789 -179.109 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 47.1 mmtm -75.84 -40.99 53.73 Favored 'General case' 0 CA--C 1.53 0.197 0 CA-C-N 118.571 0.623 . . . . 0.0 110.688 -178.408 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 21.5 pt -80.68 -38.75 17.67 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.289 0 N-CA-C 112.576 0.584 . . . . 0.0 112.576 -179.463 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 31.5 m -76.9 135.5 38.81 Favored 'General case' 0 N--CA 1.454 -0.252 0 N-CA-C 114.0 1.111 . . . . 0.0 114.0 -176.085 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 84.7 mtp -73.43 139.27 78.16 Favored Pre-proline 0 N--CA 1.449 -0.524 0 N-CA-C 104.721 -2.326 . . . . 0.0 104.721 173.218 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -64.98 126.4 16.46 Favored 'Trans proline' 0 N--CA 1.45 -1.051 0 N-CA-C 107.799 -1.654 . . . . 0.0 107.799 178.439 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -44.79 -34.87 2.46 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 125.053 1.341 . . . . 0.0 114.148 -177.322 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 11.2 tm-20 -56.26 -37.07 69.3 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 124.346 1.058 . . . . 0.0 110.713 178.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 52.2 mt-10 -92.93 148.2 22.21 Favored 'General case' 0 N--CA 1.444 -0.742 0 C-N-CA 124.478 1.111 . . . . 0.0 110.207 -178.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -160.22 151.3 19.16 Favored 'General case' 0 N--CA 1.444 -0.725 0 CA-C-N 115.661 -0.7 . . . . 0.0 110.934 178.551 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 47.3 mt -80.69 106.12 12.45 Favored 'General case' 0 N--CA 1.441 -0.885 0 N-CA-C 103.561 -2.755 . . . . 0.0 103.561 177.671 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 29.0 p-10 -89.19 -38.19 14.46 Favored 'General case' 0 C--N 1.332 -0.16 0 C-N-CA 124.803 1.241 . . . . 0.0 113.153 -176.732 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.68 155.89 45.38 Favored Pre-proline 0 CA--C 1.534 0.344 0 C-N-CA 123.895 0.878 . . . . 0.0 110.882 -178.054 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -66.11 164.68 26.78 Favored 'Trans proline' 0 N--CA 1.456 -0.702 0 C-N-CA 122.419 2.079 . . . . 0.0 109.753 176.629 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 79.73 -44.03 2.69 Favored Glycine 0 CA--C 1.528 0.86 0 CA-C-O 118.78 -1.011 . . . . 0.0 113.59 176.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 53.7 mt-10 -41.19 134.03 2.2 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 124.959 1.304 . . . . 0.0 111.686 -179.399 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 69.0 p -114.18 167.71 10.45 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 123.826 0.85 . . . . 0.0 113.268 -177.147 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 3.7 t80 -140.65 114.41 8.9 Favored 'General case' 0 N--CA 1.455 -0.213 0 N-CA-C 103.849 -2.649 . . . . 0.0 103.849 174.717 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 41.3 t -106.82 144.78 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.296 0 C-N-CA 123.703 0.801 . . . . 0.0 109.638 -177.4 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 13.7 p -152.02 167.25 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.204 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 177.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 57.2 m -145.88 122.72 11.28 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 105.765 -1.939 . . . . 0.0 105.765 179.49 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 66.3 mt -107.08 99.56 9.1 Favored 'General case' 0 N--CA 1.455 -0.192 0 CA-C-O 121.303 0.573 . . . . 0.0 111.389 -175.168 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -77.14 -47.14 21.2 Favored 'General case' 0 N--CA 1.455 -0.217 0 C-N-CA 123.835 0.854 . . . . 0.0 110.539 178.143 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.7 m -72.48 122.82 21.93 Favored 'General case' 0 N--CA 1.451 -0.382 0 C-N-CA 123.012 0.525 . . . . 0.0 110.599 -177.664 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 50.6 tttm -67.02 155.18 39.32 Favored 'General case' 0 N--CA 1.436 -1.168 0 C-N-CA 126.906 2.082 . . . . 0.0 110.316 179.177 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 132.8 178.24 15.42 Favored Glycine 0 CA--C 1.526 0.761 0 C-N-CA 124.798 1.19 . . . . 0.0 111.378 178.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 74.7 m -102.13 119.83 39.44 Favored 'General case' 0 CA--C 1.52 -0.201 0 C-N-CA 124.119 0.968 . . . . 0.0 108.756 -179.283 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 37.2 m-85 -105.92 112.65 25.79 Favored 'General case' 0 N--CA 1.445 -0.681 0 C-N-CA 125.794 1.638 . . . . 0.0 109.833 -179.035 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 4.1 m -85.87 128.7 34.88 Favored 'General case' 0 C--O 1.234 0.28 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 177.368 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 35.4 p90 -132.19 167.65 19.42 Favored 'General case' 0 N--CA 1.457 -0.1 0 CA-C-O 121.822 0.82 . . . . 0.0 112.562 -179.142 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 50.5 p90 -159.96 162.48 34.41 Favored 'General case' 0 N--CA 1.452 -0.372 0 CA-C-N 114.977 -1.01 . . . . 0.0 111.569 -179.37 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.2 t -99.6 102.9 14.55 Favored 'General case' 0 CA--C 1.518 -0.279 0 N-CA-C 106.575 -1.639 . . . . 0.0 106.575 177.52 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.312 16.9 p -40.44 -61.2 1.25 Allowed Pre-proline 0 CA--C 1.538 0.518 0 N-CA-C 115.795 1.776 . . . . 0.0 115.795 -174.489 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -60.12 -6.09 4.66 Favored 'Trans proline' 0 CA--C 1.537 0.638 0 C-N-CA 122.208 1.939 . . . . 0.0 114.924 -178.751 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 35.8 m80 -134.43 14.24 3.78 Favored 'General case' 0 CA--C 1.532 0.254 0 CA-C-N 119.694 1.134 . . . . 0.0 111.355 178.671 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 16.6 pt20 -60.66 -42.83 97.82 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 119.147 0.885 . . . . 0.0 109.217 179.259 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -58.48 -31.39 66.61 Favored Glycine 0 CA--C 1.531 1.071 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 177.18 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -85.12 5.25 30.61 Favored 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 123.556 0.743 . . . . 0.0 111.333 178.91 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 83.89 17.24 65.89 Favored Glycine 0 CA--C 1.528 0.849 0 CA-C-O 118.795 -1.003 . . . . 0.0 113.591 178.726 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 21.8 ttt -78.72 77.16 5.21 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 119.593 1.696 . . . . 0.0 108.494 178.144 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 11.6 m -120.24 169.95 10.69 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 C-N-CA 125.984 1.714 . . . . 0.0 110.404 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -169.45 174.19 43.79 Favored Glycine 0 CA--C 1.527 0.83 0 N-CA-C 109.108 -1.597 . . . . 0.0 109.108 178.112 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 54.2 mttp -149.4 139.04 21.71 Favored 'General case' 0 C--O 1.231 0.083 0 CA-C-N 118.173 0.986 . . . . 0.0 109.756 -178.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 6.0 p -125.66 120.17 56.83 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.139 0 CA-C-O 120.921 0.391 . . . . 0.0 110.519 178.798 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 48.6 m -94.22 100.58 12.63 Favored 'General case' 0 N--CA 1.455 -0.203 0 C-N-CA 124.68 1.192 . . . . 0.0 109.342 178.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 44.7 t -79.69 107.09 11.73 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.012 0 N-CA-C 104.397 -2.445 . . . . 0.0 104.397 179.536 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 51.1 p-10 . . . . . 0 N--CA 1.456 -0.16 0 C-N-CA 125.157 1.383 . . . . 0.0 110.291 -177.034 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 8.5 tt . . . . . 0 N--CA 1.454 -0.275 0 CA-C-O 121.065 0.46 . . . . 0.0 110.935 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -84.08 119.49 25.02 Favored 'General case' 0 N--CA 1.453 -0.294 0 C-N-CA 123.224 0.61 . . . . 0.0 110.093 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 47.1 t -112.24 111.0 34.28 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 105.855 -1.906 . . . . 0.0 105.855 178.517 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 31.7 mt -90.46 120.4 31.54 Favored 'General case' 0 N--CA 1.45 -0.462 0 O-C-N 121.822 -0.549 . . . . 0.0 109.706 -178.68 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -79.47 106.88 11.82 Favored 'General case' 0 N--CA 1.444 -0.738 0 N-CA-C 105.909 -1.886 . . . . 0.0 105.909 174.378 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 97.03 132.8 7.54 Favored Glycine 0 CA--C 1.523 0.586 0 C-N-CA 125.871 1.701 . . . . 0.0 112.329 178.666 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.6 p -82.78 47.87 1.26 Allowed 'General case' 0 N--CA 1.456 -0.135 0 C-N-CA 124.43 1.092 . . . . 0.0 111.197 179.325 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 70.74 -52.2 0.91 Allowed Glycine 0 CA--C 1.527 0.781 0 C-N-CA 126.598 2.047 . . . . 0.0 113.078 -179.668 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -72.1 38.07 0.07 Allowed 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 126.05 1.74 . . . . 0.0 113.851 -177.298 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 59.17 3.04 1.62 Allowed Glycine 0 CA--C 1.531 1.075 0 N-CA-C 115.911 1.124 . . . . 0.0 115.911 178.569 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 27.7 t -64.31 145.45 56.0 Favored 'General case' 0 N--CA 1.455 -0.181 0 CA-C-N 119.131 1.465 . . . . 0.0 110.87 -178.661 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 93.0 mt -86.43 73.26 10.16 Favored 'General case' 0 N--CA 1.447 -0.58 0 C-N-CA 124.044 0.938 . . . . 0.0 109.482 -178.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.9 m -137.01 143.97 33.4 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.217 0 C-N-CA 123.05 0.54 . . . . 0.0 111.204 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -90.27 122.84 33.55 Favored 'General case' 0 N--CA 1.46 0.051 0 N-CA-C 103.695 -2.706 . . . . 0.0 103.695 174.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.8 t -113.94 100.56 52.62 Favored Pre-proline 0 CA--C 1.536 0.422 0 CA-C-O 118.237 -0.887 . . . . 0.0 109.984 -179.271 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -81.01 164.24 78.26 Favored 'Cis proline' 0 N--CA 1.46 -0.463 0 CA-C-N 120.605 1.252 . . . . 0.0 111.257 -1.618 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 15.7 p -92.61 -62.86 1.31 Allowed 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 107.576 -1.268 . . . . 0.0 107.576 177.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 10.8 mp0 -98.21 126.85 43.85 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 125.835 1.654 . . . . 0.0 107.532 178.428 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.9 p90 -160.55 -175.57 5.08 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-O 121.541 0.686 . . . . 0.0 111.847 179.631 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 35.3 m -135.97 146.07 46.85 Favored 'General case' 0 N--CA 1.45 -0.426 0 N-CA-C 106.204 -1.776 . . . . 0.0 106.204 178.245 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 1.4 p -147.21 140.56 15.02 Favored Pre-proline 0 N--CA 1.449 -0.496 0 CA-C-O 118.367 -0.825 . . . . 0.0 109.631 -178.343 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_exo -60.71 144.13 99.5 Favored 'Trans proline' 0 N--CA 1.456 -0.689 0 C-N-CA 121.671 1.58 . . . . 0.0 112.678 179.411 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.2 m -56.35 128.0 33.7 Favored 'General case' 0 N--CA 1.454 -0.233 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 176.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.76 -3.57 78.1 Favored Glycine 0 CA--C 1.526 0.719 0 CA-C-O 119.012 -0.882 . . . . 0.0 112.198 179.35 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -70.64 149.3 47.17 Favored 'General case' 0 CA--C 1.534 0.361 0 CA-C-N 119.033 1.417 . . . . 0.0 109.124 178.025 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -90.44 105.09 17.58 Favored 'General case' 0 N--CA 1.447 -0.582 0 C-N-CA 124.868 1.267 . . . . 0.0 108.585 -178.563 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 34.6 mt -81.09 130.7 35.43 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.343 0 N-CA-C 105.381 -2.081 . . . . 0.0 105.381 177.364 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 67.9 t -117.69 97.58 5.58 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 C-N-CA 124.904 1.281 . . . . 0.0 108.665 -178.439 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -84.47 97.16 9.38 Favored 'General case' 0 N--CA 1.456 -0.158 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 178.011 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 28.4 ttpp -99.3 129.29 45.5 Favored 'General case' 0 CA--C 1.528 0.126 0 C-N-CA 123.746 0.818 . . . . 0.0 112.691 -176.444 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 5.2 m-20 -69.63 105.3 2.64 Favored 'General case' 0 N--CA 1.455 -0.2 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 177.456 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 51.5 t30 -89.17 -57.42 2.9 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 178.466 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -164.37 175.28 10.14 Favored 'General case' 0 CA--C 1.529 0.167 0 C-N-CA 124.095 0.958 . . . . 0.0 109.328 179.802 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 71.09 16.07 74.78 Favored Glycine 0 CA--C 1.531 1.084 0 O-C-N 121.753 -0.592 . . . . 0.0 113.095 179.19 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 21.5 p90 -67.77 166.4 23.24 Favored Pre-proline 0 CA--C 1.545 0.785 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 178.178 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -69.7 151.4 91.26 Favored 'Cis proline' 0 N--CA 1.447 -1.23 0 N-CA-C 116.395 1.652 . . . . 0.0 116.395 5.161 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 88.8 m-70 -144.93 156.92 44.24 Favored 'General case' 0 N--CA 1.451 -0.387 0 O-C-N 121.695 -0.628 . . . . 0.0 111.093 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 56.6 p30 -158.18 175.52 13.66 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 103.966 -2.605 . . . . 0.0 103.966 175.287 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 42.0 t -137.98 121.08 20.12 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.36 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 -179.027 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 95.9 t -117.33 131.9 68.69 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.621 0 N-CA-C 105.83 -1.915 . . . . 0.0 105.83 178.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -96.91 131.2 43.92 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 107.24 -1.393 . . . . 0.0 107.24 179.425 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 35.6 t0 -67.21 108.74 2.81 Favored 'General case' 0 N--CA 1.451 -0.393 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 -179.131 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -47.82 -31.33 4.84 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.028 0.931 . . . . 0.0 113.45 178.865 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 34.4 t70 -75.74 -22.38 56.57 Favored 'General case' 0 CA--C 1.536 0.426 0 N-CA-C 112.741 0.645 . . . . 0.0 112.741 179.563 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -128.39 68.07 1.37 Allowed 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 124.453 1.101 . . . . 0.0 111.791 -177.042 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 31.8 pt -153.67 157.34 32.66 Favored Pre-proline 0 CA--C 1.535 0.371 0 C-N-CA 127.884 2.474 . . . . 0.0 105.79 175.825 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_exo -56.33 115.62 2.6 Favored 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.559 2.173 . . . . 0.0 111.07 178.391 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.34 107.33 0.27 Allowed 'General case' 0 N--CA 1.455 -0.178 0 C-N-CA 123.608 0.763 . . . . 0.0 109.676 179.569 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 137.79 -32.29 2.39 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 -177.805 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 57.3 t -76.84 107.37 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.262 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 179.354 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 45.0 t0 -57.99 108.15 0.56 Allowed 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 123.252 0.621 . . . . 0.0 110.777 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.63 -38.6 32.77 Favored 'General case' 0 C--O 1.223 -0.295 0 C-N-CA 123.73 0.812 . . . . 0.0 111.228 178.883 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 46.7 t -58.67 -27.22 33.76 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 CA-C-N 118.071 0.396 . . . . 0.0 111.863 -179.44 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 44.0 mmtm -82.55 -41.93 18.98 Favored 'General case' 0 CA--C 1.529 0.172 0 CA-C-N 118.611 0.641 . . . . 0.0 110.839 -179.392 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 24.6 pt -78.03 -46.9 25.83 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.29 0 N-CA-C 112.005 0.372 . . . . 0.0 112.005 -179.29 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 60.7 m -73.22 128.41 35.4 Favored 'General case' 0 N--CA 1.451 -0.422 0 C-N-CA 124.224 1.01 . . . . 0.0 113.01 -176.018 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 88.4 mmm -66.08 133.73 94.78 Favored Pre-proline 0 N--CA 1.451 -0.422 0 N-CA-C 105.401 -2.074 . . . . 0.0 105.401 174.661 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 21.0 Cg_endo -59.59 116.52 3.34 Favored 'Trans proline' 0 N--CA 1.453 -0.894 0 C-N-CA 121.495 1.463 . . . . 0.0 108.829 179.798 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -28.76 -48.89 0.07 Allowed 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 128.174 2.59 . . . . 0.0 116.062 -176.467 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 14.2 tm-20 -61.19 -37.71 83.93 Favored 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 124.579 1.152 . . . . 0.0 112.182 -178.374 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 53.5 mt-10 -84.04 143.44 29.75 Favored 'General case' 0 N--CA 1.446 -0.64 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 -178.266 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -159.45 149.61 18.97 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-O 121.713 0.768 . . . . 0.0 112.292 -178.043 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 63.0 mt -79.02 106.03 10.77 Favored 'General case' 0 N--CA 1.444 -0.749 0 N-CA-C 104.862 -2.273 . . . . 0.0 104.862 178.151 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 65.6 t30 -112.29 42.14 1.86 Allowed 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 124.259 1.024 . . . . 0.0 112.747 -177.732 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -158.0 158.26 29.97 Favored Pre-proline 0 C--O 1.233 0.186 0 N-CA-C 107.045 -1.465 . . . . 0.0 107.045 178.366 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 96.8 Cg_endo -73.92 167.78 26.39 Favored 'Trans proline' 0 N--CA 1.451 -0.999 0 C-N-CA 121.542 1.495 . . . . 0.0 109.313 178.242 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 78.63 -42.65 2.26 Favored Glycine 0 CA--C 1.527 0.84 0 CA-C-O 118.74 -1.033 . . . . 0.0 114.411 175.756 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 47.7 mt-10 -42.4 131.57 3.69 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 118.494 1.147 . . . . 0.0 112.442 -179.609 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 20.8 p -118.33 127.4 53.66 Favored 'General case' 0 N--CA 1.457 -0.122 0 N-CA-C 113.675 0.991 . . . . 0.0 113.675 -178.554 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 2.4 t80 -100.15 107.16 18.97 Favored 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 103.682 -2.71 . . . . 0.0 103.682 172.367 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 38.8 t -100.08 140.11 19.99 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.162 0 C-N-CA 123.415 0.686 . . . . 0.0 109.674 -178.026 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.2 p -150.31 135.03 9.69 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.254 0 C-N-CA 122.766 0.426 . . . . 0.0 110.319 177.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 19.7 m -103.57 100.4 10.24 Favored 'General case' 0 CA--C 1.53 0.207 0 C-N-CA 124.59 1.156 . . . . 0.0 109.0 -179.595 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 59.5 mt -90.19 99.73 12.69 Favored 'General case' 0 CA--C 1.53 0.192 0 CA-C-O 121.074 0.464 . . . . 0.0 109.82 -179.555 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -79.13 -55.34 5.18 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 123.216 0.606 . . . . 0.0 111.27 178.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.5 m -64.58 119.48 10.56 Favored 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 123.386 0.674 . . . . 0.0 110.388 -176.119 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.86 161.5 20.98 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 123.449 0.7 . . . . 0.0 112.373 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 133.87 178.77 15.83 Favored Glycine 0 CA--C 1.525 0.718 0 C-N-CA 125.565 1.555 . . . . 0.0 110.74 178.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 7.4 m -96.29 114.55 26.24 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 124.417 1.087 . . . . 0.0 109.336 -178.531 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 29.8 m-85 -105.09 111.05 23.67 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 124.684 1.193 . . . . 0.0 109.217 179.73 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 18.3 m -88.01 137.58 32.21 Favored 'General case' 0 C--O 1.232 0.172 0 N-CA-C 107.517 -1.29 . . . . 0.0 107.517 177.379 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 28.5 p90 -140.95 167.24 22.67 Favored 'General case' 0 C--N 1.339 0.124 0 CA-C-N 119.06 0.845 . . . . 0.0 113.266 -178.177 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 53.7 p90 -154.31 160.49 41.77 Favored 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 114.924 -1.034 . . . . 0.0 112.202 -179.658 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.6 t -104.24 99.31 9.03 Favored 'General case' 0 CA--C 1.519 -0.241 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 177.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -33.79 -62.99 0.33 Allowed Pre-proline 0 CA--C 1.537 0.45 0 N-CA-C 115.927 1.825 . . . . 0.0 115.927 -176.296 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -60.4 -7.04 6.19 Favored 'Trans proline' 0 C--N 1.348 0.546 0 C-N-CA 122.307 2.005 . . . . 0.0 114.92 -177.558 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 36.3 m80 -135.62 14.65 3.42 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 119.416 1.007 . . . . 0.0 111.124 178.505 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 14.6 pt20 -61.04 -41.24 96.2 Favored 'General case' 0 N--CA 1.454 -0.262 0 O-C-N 121.442 -0.786 . . . . 0.0 109.489 179.531 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -58.46 -29.45 63.59 Favored Glycine 0 CA--C 1.532 1.119 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 177.039 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.91 11.86 19.13 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 123.804 0.842 . . . . 0.0 110.864 178.798 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 74.47 21.87 78.18 Favored Glycine 0 CA--C 1.527 0.8 0 CA-C-O 119.112 -0.826 . . . . 0.0 113.171 178.877 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -78.86 80.55 5.2 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 119.255 1.528 . . . . 0.0 107.464 178.156 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 12.4 m -123.49 171.76 11.94 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 C-N-CA 125.579 1.552 . . . . 0.0 111.691 -178.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -167.12 178.79 41.15 Favored Glycine 0 CA--C 1.529 0.948 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 178.18 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 39.1 ttpt -158.48 130.57 6.82 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 -178.518 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.7 p -119.25 128.27 75.83 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 CA-C-O 121.391 0.615 . . . . 0.0 110.346 -178.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.4 m -94.37 98.78 11.13 Favored 'General case' 0 N--CA 1.452 -0.336 0 N-CA-C 107.514 -1.291 . . . . 0.0 107.514 179.151 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 45.2 t -80.31 114.28 20.97 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.587 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 -178.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 77.7 m-20 . . . . . 0 C--O 1.233 0.212 0 C-N-CA 123.664 0.785 . . . . 0.0 109.085 -178.112 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 9.3 mp . . . . . 0 CA--C 1.534 0.364 0 CA-C-O 121.702 0.763 . . . . 0.0 111.524 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 36.4 mt-10 -87.76 90.9 8.56 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 105.612 -1.996 . . . . 0.0 105.612 175.116 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 28.3 t -87.22 119.29 34.69 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.454 0 CA-C-N 114.968 -1.015 . . . . 0.0 108.923 -176.757 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 58.1 mt -88.27 121.47 30.7 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 179.189 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -78.01 103.18 7.78 Favored 'General case' 0 N--CA 1.445 -0.685 0 N-CA-C 105.815 -1.92 . . . . 0.0 105.815 173.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 97.1 152.31 28.6 Favored Glycine 0 N--CA 1.446 -0.675 0 C-N-CA 123.91 0.766 . . . . 0.0 111.331 179.083 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 78.9 p -85.59 173.46 10.15 Favored 'General case' 0 N--CA 1.44 -0.938 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 177.783 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -52.51 -43.94 58.97 Favored Glycine 0 CA--C 1.531 1.07 0 N-CA-C 111.265 -0.734 . . . . 0.0 111.265 178.679 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -79.81 11.78 3.05 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 123.362 0.665 . . . . 0.0 112.316 178.76 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 69.44 27.46 73.51 Favored Glycine 0 CA--C 1.524 0.639 0 CA-C-O 119.07 -0.85 . . . . 0.0 114.009 178.712 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 27.1 t -73.42 145.21 45.98 Favored 'General case' 0 C--N 1.34 0.155 0 N-CA-C 106.084 -1.821 . . . . 0.0 106.084 176.899 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 76.1 mt -76.12 64.75 2.01 Favored 'General case' 0 N--CA 1.449 -0.482 0 C-N-CA 124.363 1.065 . . . . 0.0 111.798 -176.102 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.2 m -132.89 139.45 49.6 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.215 0 C-N-CA 124.069 0.948 . . . . 0.0 111.268 -179.124 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 36.2 m-85 -82.83 129.52 35.01 Favored 'General case' 0 C--O 1.232 0.171 0 N-CA-C 104.314 -2.476 . . . . 0.0 104.314 175.201 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 25.2 t -117.84 105.2 47.93 Favored Pre-proline 0 CA--C 1.535 0.368 0 CA-C-O 118.168 -0.92 . . . . 0.0 108.963 179.561 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -75.13 164.81 87.47 Favored 'Cis proline' 0 C--N 1.348 0.518 0 CA-C-N 120.482 1.208 . . . . 0.0 111.505 -1.332 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 7.0 p -90.4 -62.29 1.49 Allowed 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 125.352 1.461 . . . . 0.0 108.655 179.207 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -106.42 137.48 44.32 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 126.313 1.845 . . . . 0.0 106.366 177.174 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 18.0 p90 -163.63 -174.73 3.82 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 118.38 0.536 . . . . 0.0 110.871 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 24.2 m -140.1 149.19 42.77 Favored 'General case' 0 N--CA 1.455 -0.212 0 C-N-CA 124.783 1.233 . . . . 0.0 108.813 -178.636 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 29.0 m -148.88 151.68 35.45 Favored Pre-proline 0 N--CA 1.463 0.2 0 C-N-CA 123.585 0.754 . . . . 0.0 110.332 -179.695 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -70.94 150.19 60.63 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 C-N-CA 121.778 1.652 . . . . 0.0 110.135 176.309 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 60.0 m -55.04 118.84 4.66 Favored 'General case' 0 CA--C 1.53 0.187 0 C-N-CA 123.308 0.643 . . . . 0.0 109.329 177.754 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 106.01 -5.6 39.51 Favored Glycine 0 CA--C 1.528 0.894 0 CA-C-O 118.877 -0.957 . . . . 0.0 112.802 -179.159 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -59.58 136.3 57.94 Favored 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 119.41 1.605 . . . . 0.0 110.623 179.374 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -90.98 93.15 9.07 Favored 'General case' 0 N--CA 1.445 -0.7 0 N-CA-C 106.013 -1.847 . . . . 0.0 106.013 177.457 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 63.4 mt -75.2 137.84 22.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 -178.616 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 67.9 t -115.75 102.41 13.67 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.296 0 C-N-CA 124.659 1.184 . . . . 0.0 108.479 -178.239 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -90.16 101.62 14.33 Favored 'General case' 0 CA--C 1.53 0.177 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 177.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 26.7 ttpp -99.99 129.54 46.07 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 124.774 1.229 . . . . 0.0 112.633 -176.596 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 39.6 t30 -66.82 115.35 6.5 Favored 'General case' 0 CA--C 1.528 0.098 0 CA-C-O 118.805 -0.617 . . . . 0.0 110.342 177.856 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 43.6 t30 -97.04 -73.82 0.59 Allowed 'General case' 0 N--CA 1.457 -0.114 0 CA-C-O 121.111 0.481 . . . . 0.0 110.664 179.835 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -157.95 170.97 21.12 Favored 'General case' 0 C--N 1.332 -0.183 0 C-N-CA 124.783 1.233 . . . . 0.0 108.16 -177.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 71.59 17.57 76.54 Favored Glycine 0 CA--C 1.534 1.263 0 O-C-N 121.487 -0.758 . . . . 0.0 112.252 -178.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 7.4 p90 -72.09 170.49 12.39 Favored Pre-proline 0 CA--C 1.54 0.559 0 C-N-CA 125.946 1.698 . . . . 0.0 107.77 178.59 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_exo -64.99 152.07 76.22 Favored 'Cis proline' 0 N--CA 1.451 -0.982 0 N-CA-C 115.581 1.339 . . . . 0.0 115.581 2.19 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 87.6 m-70 -141.74 170.11 16.34 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 123.311 0.645 . . . . 0.0 109.485 179.235 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 46.7 p30 -168.71 177.4 5.14 Favored 'General case' 0 N--CA 1.451 -0.423 0 N-CA-C 104.109 -2.552 . . . . 0.0 104.109 175.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 39.6 t -135.95 112.43 13.09 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.274 0 N-CA-C 107.262 -1.384 . . . . 0.0 107.262 -179.063 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 48.4 t -116.96 133.35 63.96 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 N-CA-C 105.98 -1.859 . . . . 0.0 105.98 -179.141 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 55.0 m-85 -93.69 142.69 27.07 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -179.138 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -74.62 97.95 3.29 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.749 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -39.89 -35.97 0.41 Allowed 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 125.842 1.657 . . . . 0.0 115.324 -179.234 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -82.77 -27.64 30.88 Favored 'General case' 0 CA--C 1.535 0.375 0 N-CA-C 112.607 0.595 . . . . 0.0 112.607 -179.715 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 47.5 tt0 -112.22 61.28 0.63 Allowed 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 124.62 1.168 . . . . 0.0 111.438 -176.475 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 36.8 pt -157.01 158.3 31.12 Favored Pre-proline 0 CA--C 1.535 0.374 0 C-N-CA 128.468 2.707 . . . . 0.0 105.721 176.817 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -55.4 111.94 0.9 Allowed 'Trans proline' 0 N--CA 1.456 -0.717 0 C-N-CA 122.498 2.132 . . . . 0.0 109.59 175.537 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -33.08 -48.47 0.22 Allowed 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 126.855 2.062 . . . . 0.0 115.619 -177.517 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -58.87 -29.12 64.28 Favored Glycine 0 CA--C 1.533 1.182 0 O-C-N 122.131 -0.356 . . . . 0.0 113.78 -178.457 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 43.1 t -82.19 96.28 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 CA-C-N 118.154 0.977 . . . . 0.0 109.759 -178.193 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 6.7 t0 -52.77 116.71 2.46 Favored 'General case' 0 CA--C 1.535 0.392 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 176.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -46.77 -38.51 10.18 Favored 'General case' 0 N--CA 1.456 -0.17 0 C-N-CA 126.085 1.754 . . . . 0.0 112.552 -178.734 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 59.9 t -59.54 -28.17 39.31 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 C-N-CA 123.006 0.522 . . . . 0.0 111.443 -179.276 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 41.7 mtmt -74.28 -45.57 46.86 Favored 'General case' 0 CA--C 1.528 0.125 0 O-C-N 121.666 -0.646 . . . . 0.0 110.602 -179.111 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 25.6 pt -79.59 -32.81 14.72 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 N-CA-C 113.008 0.744 . . . . 0.0 113.008 -177.766 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 47.1 m -77.39 130.54 37.23 Favored 'General case' 0 N--CA 1.452 -0.327 0 C-N-CA 123.148 0.579 . . . . 0.0 112.035 -178.034 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.5 tmt? -63.83 124.05 83.67 Favored Pre-proline 0 N--CA 1.449 -0.508 0 N-CA-C 104.869 -2.271 . . . . 0.0 104.869 175.738 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_exo -42.64 107.18 0.08 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.565 0 C-N-CA 123.985 3.123 . . . . 0.0 112.567 -178.121 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -41.1 -39.6 1.3 Allowed 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 126.397 1.879 . . . . 0.0 114.323 -177.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -58.74 -34.47 71.43 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 124.314 1.046 . . . . 0.0 110.752 -179.677 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 88.5 mt-10 -94.46 154.51 17.39 Favored 'General case' 0 N--CA 1.445 -0.713 0 C-N-CA 125.825 1.65 . . . . 0.0 108.501 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 5.1 mp -143.72 144.67 31.95 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-O 121.378 0.609 . . . . 0.0 110.745 -178.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 59.9 mt -80.67 93.42 6.15 Favored 'General case' 0 N--CA 1.444 -0.735 0 N-CA-C 103.046 -2.946 . . . . 0.0 103.046 174.01 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -109.65 -42.2 4.36 Favored 'General case' 0 C--N 1.333 -0.116 0 C-N-CA 124.273 1.029 . . . . 0.0 111.22 -176.736 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.27 134.61 73.63 Favored Pre-proline 0 C--O 1.236 0.356 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 -178.694 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_exo -50.7 132.51 36.56 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 C-N-CA 122.571 2.181 . . . . 0.0 110.903 179.776 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 92.73 -15.09 63.42 Favored Glycine 0 CA--C 1.527 0.821 0 CA-C-O 117.325 -1.82 . . . . 0.0 115.782 176.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -52.76 125.54 17.12 Favored 'General case' 0 CA--C 1.537 0.457 0 CA-C-N 121.045 2.423 . . . . 0.0 110.923 179.302 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 12.1 p -105.26 122.46 45.98 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 125.827 1.651 . . . . 0.0 112.395 -178.725 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 54.3 t80 -103.85 108.35 19.64 Favored 'General case' 0 N--CA 1.454 -0.235 0 N-CA-C 105.984 -1.858 . . . . 0.0 105.984 174.301 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 15.8 t -96.65 136.93 25.84 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 -178.609 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.5 p -145.51 127.06 8.29 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.404 0 CA-C-N 118.428 0.558 . . . . 0.0 110.97 178.628 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 7.9 m -88.73 101.97 14.53 Favored 'General case' 0 CA--C 1.53 0.174 0 C-N-CA 125.45 1.5 . . . . 0.0 110.239 -179.489 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 22.4 mt -87.33 87.45 7.43 Favored 'General case' 0 N--CA 1.462 0.151 0 CA-C-N 118.585 0.63 . . . . 0.0 109.357 179.394 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -69.5 -46.74 65.86 Favored 'General case' 0 CA--C 1.532 0.281 0 N-CA-C 113.399 0.889 . . . . 0.0 113.399 -179.703 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 2.0 m -78.83 127.47 32.09 Favored 'General case' 0 N--CA 1.454 -0.268 0 O-C-N 121.866 -0.521 . . . . 0.0 112.113 -175.23 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.1 155.38 37.0 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 122.987 0.515 . . . . 0.0 110.599 176.784 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 138.91 175.35 13.95 Favored Glycine 0 CA--C 1.525 0.67 0 C-N-CA 125.137 1.351 . . . . 0.0 109.984 179.445 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -100.0 116.04 31.12 Favored 'General case' 0 N--CA 1.451 -0.396 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 17.9 m-85 -107.83 131.33 54.59 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 124.379 1.071 . . . . 0.0 109.806 -178.101 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 18.2 m -102.31 139.27 38.14 Favored 'General case' 0 C--O 1.233 0.233 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 176.099 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 26.1 p90 -140.81 169.52 17.48 Favored 'General case' 0 CA--C 1.521 -0.151 0 CA-C-O 121.586 0.708 . . . . 0.0 111.204 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 43.4 p90 -157.57 160.61 38.32 Favored 'General case' 0 N--CA 1.45 -0.462 0 CA-C-N 115.601 -0.727 . . . . 0.0 112.016 -178.81 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 t -97.63 99.88 11.26 Favored 'General case' 0 CA--C 1.512 -0.485 0 N-CA-C 105.68 -1.97 . . . . 0.0 105.68 177.334 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.371 4.9 p -43.43 -56.5 6.77 Favored Pre-proline 0 CA--C 1.54 0.572 0 N-CA-C 114.323 1.231 . . . . 0.0 114.323 -175.175 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_exo -47.27 -20.04 1.26 Allowed 'Trans proline' 0 CA--C 1.534 0.518 0 C-N-CA 123.6 2.867 . . . . 0.0 116.103 177.248 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 38.5 m80 -136.13 18.37 3.2 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-N 119.15 0.887 . . . . 0.0 111.806 -178.298 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 16.8 pt20 -60.88 -41.97 97.04 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-N 119.047 0.84 . . . . 0.0 109.539 179.533 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -58.39 -29.48 63.41 Favored Glycine 0 CA--C 1.532 1.155 0 N-CA-C 111.209 -0.756 . . . . 0.0 111.209 177.145 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.34 10.6 21.81 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 123.718 0.807 . . . . 0.0 111.084 178.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 79.33 17.1 76.98 Favored Glycine 0 CA--C 1.526 0.772 0 CA-C-O 118.758 -1.023 . . . . 0.0 113.801 178.484 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 22.9 ttt -79.26 77.35 5.79 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 119.703 1.751 . . . . 0.0 108.265 178.213 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 14.3 m -117.87 170.58 7.11 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.319 0 C-N-CA 125.909 1.684 . . . . 0.0 110.198 179.809 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -164.86 176.54 40.64 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 178.092 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 53.8 tttp -154.68 154.48 32.99 Favored 'General case' 0 N--CA 1.454 -0.253 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 -176.074 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.4 p -145.53 134.2 17.0 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.159 0 O-C-N 121.987 -0.445 . . . . 0.0 110.988 -178.773 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.7 m -100.15 94.51 6.27 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 125.65 1.58 . . . . 0.0 110.852 -178.002 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 21.4 t -80.17 120.28 31.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 105.459 -2.052 . . . . 0.0 105.459 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 5.8 p30 . . . . . 0 C--N 1.332 -0.157 0 C-N-CA 123.483 0.713 . . . . 0.0 111.652 -174.914 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 3.0 tm? . . . . . 0 N--CA 1.454 -0.268 0 N-CA-C 108.663 -0.865 . . . . 0.0 108.663 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -91.29 119.74 31.59 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 114.337 -1.301 . . . . 0.0 110.997 -177.38 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 39.0 t -113.23 118.24 57.55 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.332 0 N-CA-C 107.364 -1.347 . . . . 0.0 107.364 178.386 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 64.3 mt -89.1 120.86 30.88 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 -179.77 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -78.76 111.22 14.65 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 106.799 -1.556 . . . . 0.0 106.799 175.158 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 93.61 138.75 9.12 Favored Glycine 0 N--CA 1.446 -0.649 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.168 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 68.4 p -81.8 158.34 24.14 Favored 'General case' 0 N--CA 1.437 -1.11 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 178.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.0 -33.87 57.58 Favored Glycine 0 CA--C 1.53 1.025 0 CA-C-N 115.252 -0.885 . . . . 0.0 111.512 178.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -75.8 -3.71 36.57 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 123.597 0.759 . . . . 0.0 112.292 178.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 99.51 -20.85 47.98 Favored Glycine 0 CA--C 1.527 0.794 0 CA-C-O 118.892 -0.949 . . . . 0.0 113.486 178.782 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 22.7 t -57.31 131.63 50.62 Favored 'General case' 0 C--O 1.239 0.516 0 CA-C-N 119.336 1.568 . . . . 0.0 110.682 -179.228 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 56.8 mt -73.03 65.63 0.77 Allowed 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 127.085 2.154 . . . . 0.0 112.412 -176.222 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 2.4 t -123.2 151.36 27.55 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.442 0 C-N-CA 124.247 1.019 . . . . 0.0 108.785 178.859 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 33.2 m-85 -86.17 129.74 34.75 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 104.125 -2.546 . . . . 0.0 104.125 175.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 48.8 t -118.44 104.62 47.49 Favored Pre-proline 0 CA--C 1.537 0.445 0 CA-C-O 118.324 -0.846 . . . . 0.0 108.877 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -75.05 161.78 94.14 Favored 'Cis proline' 0 C--N 1.347 0.499 0 CA-C-N 120.338 1.157 . . . . 0.0 111.597 -1.073 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 6.2 p -91.89 -60.47 1.85 Allowed 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 125.502 1.521 . . . . 0.0 108.609 179.212 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -105.4 127.01 52.75 Favored 'General case' 0 N--CA 1.453 -0.282 0 C-N-CA 126.238 1.815 . . . . 0.0 106.616 177.69 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 14.6 p90 -160.03 -175.36 5.05 Favored 'General case' 0 C--O 1.232 0.18 0 CA-C-O 121.08 0.467 . . . . 0.0 110.792 179.867 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 66.1 p -147.02 156.84 43.35 Favored 'General case' 0 N--CA 1.451 -0.403 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 18.1 m -152.75 151.28 26.35 Favored Pre-proline 0 CA--C 1.531 0.245 0 C-N-CA 123.61 0.764 . . . . 0.0 109.539 -178.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -73.17 148.52 44.4 Favored 'Trans proline' 0 N--CA 1.451 -1.0 0 C-N-CA 121.781 1.654 . . . . 0.0 110.761 177.812 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 64.7 m -48.93 121.24 4.52 Favored 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 122.996 0.518 . . . . 0.0 110.55 176.048 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 106.39 -9.72 42.14 Favored Glycine 0 CA--C 1.529 0.961 0 C-N-CA 124.165 0.888 . . . . 0.0 112.642 179.431 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -63.3 135.81 57.28 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-N 118.813 1.307 . . . . 0.0 109.979 179.242 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 52.9 mtpt -91.54 106.03 18.19 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 125.409 1.483 . . . . 0.0 108.659 179.386 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 40.4 mt -85.21 135.12 25.53 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 -179.672 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 64.7 t -119.73 100.3 9.27 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.34 0 C-N-CA 126.134 1.774 . . . . 0.0 108.152 -178.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -87.06 107.18 18.32 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 178.025 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 62.9 tttp -105.91 131.97 52.58 Favored 'General case' 0 CA--C 1.531 0.243 0 C-N-CA 125.266 1.426 . . . . 0.0 112.78 -176.408 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 8.1 m-20 -68.56 112.53 5.41 Favored 'General case' 0 C--O 1.232 0.132 0 C-N-CA 123.149 0.579 . . . . 0.0 110.021 177.538 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 24.5 t30 -97.46 -72.22 0.65 Allowed 'General case' 0 N--CA 1.456 -0.171 0 CA-C-O 121.052 0.453 . . . . 0.0 109.851 178.727 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -143.2 167.41 22.18 Favored 'General case' 0 C--N 1.331 -0.219 0 C-N-CA 123.972 0.909 . . . . 0.0 109.521 -178.028 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 62.65 23.78 65.5 Favored Glycine 0 CA--C 1.535 1.295 0 O-C-N 121.839 -0.538 . . . . 0.0 113.774 179.407 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 10.5 p90 -74.74 167.54 35.42 Favored Pre-proline 0 CA--C 1.537 0.463 0 N-CA-C 106.671 -1.603 . . . . 0.0 106.671 176.756 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -62.66 159.91 58.31 Favored 'Cis proline' 0 N--CA 1.456 -0.698 0 N-CA-C 116.99 1.881 . . . . 0.0 116.99 1.072 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 93.3 m-70 -149.67 170.14 19.39 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.809 -179.464 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 37.3 p-10 -163.98 177.04 8.83 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 104.32 -2.474 . . . . 0.0 104.32 176.298 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 39.3 t -138.25 112.17 8.07 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.389 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 179.291 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 64.8 t -116.83 133.69 62.72 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.604 0 N-CA-C 106.052 -1.833 . . . . 0.0 106.052 179.525 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 64.6 m-85 -93.33 140.65 29.32 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 -179.306 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 53.1 t0 -70.76 104.48 2.89 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 179.42 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -48.02 -32.29 6.43 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 124.168 0.987 . . . . 0.0 113.293 178.211 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -92.04 6.39 46.6 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 123.494 0.717 . . . . 0.0 112.871 -178.839 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 20.7 tt0 -150.44 63.36 0.95 Allowed 'General case' 0 CA--C 1.538 0.506 0 CA-C-O 122.108 0.956 . . . . 0.0 110.71 -179.283 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 28.0 pt -155.59 158.2 31.77 Favored Pre-proline 0 CA--C 1.532 0.263 0 C-N-CA 128.573 2.749 . . . . 0.0 105.771 177.459 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_exo -55.93 109.5 0.44 Allowed 'Trans proline' 0 CA--C 1.538 0.692 0 C-N-CA 122.306 2.004 . . . . 0.0 108.585 174.127 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -33.65 -44.21 0.15 Allowed 'General case' 0 N--CA 1.465 0.322 0 C-N-CA 126.789 2.036 . . . . 0.0 115.77 -177.195 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -58.34 -29.84 63.77 Favored Glycine 0 CA--C 1.534 1.221 0 CA-C-O 119.856 -0.413 . . . . 0.0 113.766 -178.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 37.4 t -84.69 107.54 15.86 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.316 0 CA-C-N 118.179 0.99 . . . . 0.0 110.318 -177.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 19.7 t0 -59.29 116.15 3.71 Favored 'General case' 0 CA--C 1.534 0.364 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 177.333 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -46.79 -40.33 13.45 Favored 'General case' 0 N--CA 1.457 -0.113 0 C-N-CA 125.223 1.409 . . . . 0.0 112.012 179.671 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 53.1 t -60.23 -28.88 42.77 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 C-N-CA 122.994 0.518 . . . . 0.0 111.784 -178.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -76.56 -42.11 44.01 Favored 'General case' 0 N--CA 1.462 0.128 0 CA-C-N 118.617 0.644 . . . . 0.0 110.594 -179.006 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 22.7 pt -79.09 -32.84 15.45 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 N-CA-C 112.582 0.586 . . . . 0.0 112.582 -178.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 49.1 m -78.05 141.65 38.71 Favored 'General case' 0 N--CA 1.454 -0.255 0 N-CA-C 112.531 0.567 . . . . 0.0 112.531 -178.261 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 12.8 tpt -58.77 121.39 53.75 Favored Pre-proline 0 CA--C 1.535 0.401 0 N-CA-C 105.583 -2.006 . . . . 0.0 105.583 174.914 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_exo -46.88 103.98 0.06 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.615 0 C-N-CA 123.649 2.9 . . . . 0.0 110.927 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 57.0 mp0 -43.3 -27.86 0.28 Allowed 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 127.056 2.143 . . . . 0.0 114.984 -175.385 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -57.81 -35.51 70.95 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 123.193 0.597 . . . . 0.0 110.843 178.392 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -117.44 158.41 24.53 Favored 'General case' 0 N--CA 1.446 -0.639 0 C-N-CA 125.76 1.624 . . . . 0.0 109.412 -179.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 4.8 mp -145.48 159.56 42.9 Favored 'General case' 0 N--CA 1.452 -0.332 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 -179.444 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 71.9 mt -79.33 96.34 5.96 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 104.391 -2.448 . . . . 0.0 104.391 177.275 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 36.9 p-10 -80.32 -58.2 3.25 Favored 'General case' 0 CA--C 1.529 0.162 0 C-N-CA 124.156 0.982 . . . . 0.0 113.303 -177.17 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -79.75 160.45 69.32 Favored Pre-proline 0 CA--C 1.535 0.403 0 C-N-CA 124.318 1.047 . . . . 0.0 111.902 -176.75 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -64.59 161.89 33.49 Favored 'Trans proline' 0 N--CA 1.458 -0.614 0 C-N-CA 122.29 1.993 . . . . 0.0 109.172 175.081 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 78.74 -39.57 1.99 Allowed Glycine 0 CA--C 1.528 0.853 0 CA-C-O 118.656 -1.08 . . . . 0.0 113.829 177.293 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 79.5 mm-40 -42.03 130.32 3.54 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 124.476 1.111 . . . . 0.0 111.669 179.827 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 6.7 p -110.88 150.4 29.24 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 125.412 1.485 . . . . 0.0 112.424 -177.856 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 30.5 t80 -126.43 113.14 16.46 Favored 'General case' 0 N--CA 1.455 -0.177 0 N-CA-C 105.082 -2.192 . . . . 0.0 105.082 172.466 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 19.6 t -100.41 136.89 29.84 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.398 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 -178.543 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.2 p -150.07 140.88 16.66 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.121 0 N-CA-C 108.275 -1.009 . . . . 0.0 108.275 178.253 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 25.1 m -112.07 127.44 55.91 Favored 'General case' 0 N--CA 1.456 -0.126 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 -178.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 55.5 mt -110.67 124.63 52.29 Favored 'General case' 0 CA--C 1.529 0.137 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 179.713 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -108.48 -47.96 3.41 Favored 'General case' 0 CA--C 1.528 0.126 0 C-N-CA 124.286 1.034 . . . . 0.0 112.096 -178.296 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 5.0 m -66.4 128.69 37.16 Favored 'General case' 0 N--CA 1.454 -0.25 0 O-C-N 121.707 -0.621 . . . . 0.0 109.661 -177.51 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 61.8 mtpt -69.04 155.46 40.33 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 123.02 0.528 . . . . 0.0 110.441 -179.155 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 128.37 175.44 14.07 Favored Glycine 0 CA--C 1.527 0.832 0 C-N-CA 124.389 0.995 . . . . 0.0 111.409 179.023 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 89.3 m -95.25 127.22 41.12 Favored 'General case' 0 N--CA 1.451 -0.405 0 C-N-CA 124.871 1.269 . . . . 0.0 109.288 -179.828 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 25.2 m-85 -115.75 120.69 40.15 Favored 'General case' 0 N--CA 1.447 -0.601 0 C-N-CA 126.051 1.74 . . . . 0.0 108.615 179.398 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 64.1 m -92.37 140.16 29.87 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 177.023 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 22.8 p90 -139.39 165.48 27.1 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-O 121.555 0.693 . . . . 0.0 112.307 -179.52 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -152.66 157.31 40.76 Favored 'General case' 0 N--CA 1.452 -0.342 0 C-N-CA 124.205 1.002 . . . . 0.0 112.64 -178.334 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.4 t -99.68 102.04 13.41 Favored 'General case' 0 CA--C 1.519 -0.234 0 N-CA-C 105.483 -2.043 . . . . 0.0 105.483 176.84 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.28 0.8 OUTLIER -43.12 -57.69 4.92 Favored Pre-proline 0 CA--C 1.535 0.384 0 N-CA-C 114.446 1.276 . . . . 0.0 114.446 -173.692 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -52.17 -20.12 10.31 Favored 'Trans proline' 0 C--N 1.347 0.494 0 C-N-CA 123.146 2.564 . . . . 0.0 115.183 178.833 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 37.1 m80 -130.61 19.01 5.19 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-N 118.697 0.68 . . . . 0.0 111.446 -178.44 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -60.01 -51.17 70.81 Favored 'General case' 0 C--N 1.339 0.128 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 179.707 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.12 -30.26 57.35 Favored Glycine 0 CA--C 1.533 1.177 0 N-CA-C 111.717 -0.553 . . . . 0.0 111.717 177.863 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -84.04 5.83 24.38 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 123.51 0.724 . . . . 0.0 111.72 179.187 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 83.56 15.35 71.25 Favored Glycine 0 CA--C 1.527 0.827 0 CA-C-O 118.991 -0.894 . . . . 0.0 113.71 178.347 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 19.2 ttt -78.44 79.65 4.86 Favored 'General case' 0 C--O 1.236 0.377 0 CA-C-N 119.527 1.664 . . . . 0.0 108.595 178.657 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 10.7 m -126.56 169.46 17.96 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.207 0 C-N-CA 125.917 1.687 . . . . 0.0 110.813 179.842 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -169.03 179.45 41.74 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 109.276 -1.53 . . . . 0.0 109.276 178.343 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 58.7 mttm -149.64 149.46 30.67 Favored 'General case' 0 N--CA 1.455 -0.203 0 CA-C-N 117.66 0.73 . . . . 0.0 109.588 -179.014 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 6.6 p -135.72 127.29 45.04 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.3 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 178.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 71.6 m -102.09 106.46 17.34 Favored 'General case' 0 C--N 1.333 -0.143 0 C-N-CA 123.772 0.829 . . . . 0.0 110.436 179.487 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 44.6 t -79.69 122.99 35.97 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.633 0 N-CA-C 106.643 -1.614 . . . . 0.0 106.643 179.021 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 48.7 p30 . . . . . 0 C--N 1.333 -0.122 0 C-N-CA 124.895 1.278 . . . . 0.0 111.034 -177.605 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 8.5 mp . . . . . 0 CA--C 1.531 0.233 0 CA-C-O 120.663 0.268 . . . . 0.0 110.688 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 78.4 tt0 -90.98 116.28 28.65 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 176.767 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 48.1 t -106.05 122.48 59.75 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 -179.361 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 40.8 mt -86.03 120.82 27.83 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 177.886 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 5.1 tp -78.19 98.53 5.88 Favored 'General case' 0 N--CA 1.429 -1.489 0 C-N-CA 125.424 1.49 . . . . 0.0 107.525 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 91.72 145.34 15.07 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 108.7 -1.76 . . . . 0.0 108.7 -178.393 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 78.0 p -78.86 154.94 29.37 Favored 'General case' 0 N--CA 1.44 -0.948 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 179.574 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -53.16 -35.39 49.41 Favored Glycine 0 CA--C 1.529 0.942 0 CA-C-N 114.979 -1.01 . . . . 0.0 111.697 178.808 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -74.82 -4.42 37.66 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 123.53 0.732 . . . . 0.0 112.506 179.404 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 101.08 -20.75 46.25 Favored Glycine 0 CA--C 1.527 0.782 0 CA-C-O 118.763 -1.021 . . . . 0.0 113.292 178.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 28.6 t -56.81 132.13 51.4 Favored 'General case' 0 C--O 1.239 0.536 0 CA-C-N 119.391 1.595 . . . . 0.0 110.603 -179.332 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -71.55 69.28 0.61 Allowed 'General case' 0 N--CA 1.44 -0.935 0 C-N-CA 126.806 2.042 . . . . 0.0 111.676 -177.457 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.5 m -135.06 141.74 42.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 C-N-CA 123.708 0.803 . . . . 0.0 109.403 178.383 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 88.2 m-85 -79.16 135.2 36.75 Favored 'General case' 0 N--CA 1.455 -0.186 0 N-CA-C 105.291 -2.115 . . . . 0.0 105.291 176.81 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.8 t -120.09 104.35 43.92 Favored Pre-proline 0 CA--C 1.534 0.339 0 CA-C-O 118.25 -0.881 . . . . 0.0 109.094 179.567 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -73.85 164.16 88.15 Favored 'Cis proline' 0 C--N 1.348 0.524 0 CA-C-N 120.301 1.143 . . . . 0.0 112.179 -1.412 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 10.5 p -97.59 -62.28 1.27 Allowed 'General case' 0 N--CA 1.452 -0.331 0 C-N-CA 125.681 1.592 . . . . 0.0 109.236 179.32 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 -103.54 123.96 47.89 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 126.106 1.763 . . . . 0.0 106.857 178.345 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -158.06 174.3 15.43 Favored 'General case' 0 CA--C 1.528 0.118 0 CA-C-N 118.9 0.773 . . . . 0.0 112.013 179.486 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.4 p -116.67 147.83 41.59 Favored 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 125.478 1.511 . . . . 0.0 107.555 178.461 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.8 p -141.79 136.25 15.18 Favored Pre-proline 0 CA--C 1.536 0.428 0 CA-C-O 118.443 -0.789 . . . . 0.0 109.036 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_exo -63.03 142.73 88.86 Favored 'Trans proline' 0 N--CA 1.456 -0.693 0 C-N-CA 122.043 1.828 . . . . 0.0 111.363 177.091 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.8 m -45.8 121.61 3.25 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 124.265 1.026 . . . . 0.0 111.778 177.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 84.96 -5.79 81.39 Favored Glycine 0 CA--C 1.525 0.69 0 CA-C-O 118.502 -1.166 . . . . 0.0 114.411 177.407 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -74.97 147.77 40.55 Favored 'General case' 0 CA--C 1.537 0.444 0 CA-C-N 119.954 1.877 . . . . 0.0 108.084 177.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 2.7 ptpp? -92.79 138.88 31.11 Favored 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 124.007 0.923 . . . . 0.0 112.499 -177.844 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 48.8 mt -105.05 136.76 37.42 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 C-N-CA 126.292 1.837 . . . . 0.0 106.06 179.166 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 58.4 t -117.92 100.29 9.81 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 C-N-CA 125.355 1.462 . . . . 0.0 108.832 -178.7 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -84.5 100.06 11.11 Favored 'General case' 0 C--N 1.334 -0.073 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 178.418 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 64.4 tttm -92.07 125.0 36.58 Favored 'General case' 0 C--O 1.231 0.127 0 C-N-CA 123.73 0.812 . . . . 0.0 110.621 -178.622 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 49.3 t30 -63.19 111.11 2.09 Favored 'General case' 0 CA--C 1.528 0.119 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 177.367 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 36.2 t30 -99.65 -76.45 0.55 Allowed 'General case' 0 N--CA 1.457 -0.079 0 C-N-CA 122.94 0.496 . . . . 0.0 112.256 -177.036 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -151.08 174.92 12.62 Favored 'General case' 0 C--O 1.224 -0.26 0 C-N-CA 124.012 0.925 . . . . 0.0 109.383 -176.807 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 62.3 17.96 57.22 Favored Glycine 0 CA--C 1.535 1.294 0 O-C-N 121.679 -0.638 . . . . 0.0 112.519 -179.119 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 3.9 p90 -78.25 169.5 20.56 Favored Pre-proline 0 CA--C 1.538 0.509 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 179.153 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_exo -64.45 160.25 68.42 Favored 'Cis proline' 0 N--CA 1.449 -1.098 0 N-CA-C 116.07 1.527 . . . . 0.0 116.07 1.605 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 90.7 m-70 -152.29 177.69 10.29 Favored 'General case' 0 N--CA 1.45 -0.467 0 CA-C-N 115.118 -0.946 . . . . 0.0 109.769 179.578 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 53.4 p30 -162.94 169.78 19.14 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 105.064 -2.198 . . . . 0.0 105.064 173.556 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 44.3 t -123.93 104.55 14.22 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.333 0 N-CA-C 106.62 -1.622 . . . . 0.0 106.62 -177.522 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 38.8 t -116.33 135.26 57.13 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.366 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 -179.316 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 55.7 m-85 -100.65 138.19 38.04 Favored 'General case' 0 N--CA 1.454 -0.272 0 C-N-CA 123.267 0.627 . . . . 0.0 109.68 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -70.14 114.1 7.97 Favored 'General case' 0 N--CA 1.454 -0.26 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 -179.81 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -47.85 -30.57 4.17 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 115.825 1.787 . . . . 0.0 115.825 -178.471 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 23.5 t70 -88.61 -50.15 6.45 Favored 'General case' 0 CA--C 1.53 0.204 0 CA-C-N 118.52 0.6 . . . . 0.0 110.649 179.88 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -80.22 57.07 2.63 Favored 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 124.087 0.955 . . . . 0.0 112.413 -176.397 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 20.2 pt -150.14 149.0 26.11 Favored Pre-proline 0 CA--C 1.534 0.36 0 C-N-CA 127.376 2.27 . . . . 0.0 106.537 176.805 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -65.6 124.63 13.08 Favored 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 122.096 1.864 . . . . 0.0 110.504 179.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -52.0 109.95 0.43 Allowed 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 124.802 1.241 . . . . 0.0 111.228 -179.456 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 153.09 -56.77 0.43 Allowed Glycine 0 CA--C 1.522 0.517 0 N-CA-C 108.249 -1.94 . . . . 0.0 108.249 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 41.8 t -83.21 93.09 2.87 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.429 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 179.285 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -58.96 134.33 56.86 Favored 'General case' 0 CA--C 1.532 0.251 0 N-CA-C 109.319 -0.622 . . . . 0.0 109.319 177.807 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -39.56 -43.82 1.36 Allowed 'General case' 0 C--N 1.331 -0.196 0 C-N-CA 127.389 2.275 . . . . 0.0 113.963 179.52 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 98.9 t -55.62 -30.41 26.68 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.333 0 CA-C-N 118.119 0.418 . . . . 0.0 110.918 -179.378 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 33.1 mtmm -75.85 -18.83 59.3 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-O 118.451 -0.785 . . . . 0.0 112.868 -179.278 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -115.32 -20.91 5.59 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-N 119.196 0.907 . . . . 0.0 113.065 179.642 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 35.6 m -84.13 127.46 33.93 Favored 'General case' 0 N--CA 1.451 -0.386 0 C-N-CA 123.869 0.868 . . . . 0.0 112.038 -178.577 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 7.2 tmm? -69.39 124.91 91.48 Favored Pre-proline 0 CA--C 1.536 0.432 0 N-CA-C 103.801 -2.666 . . . . 0.0 103.801 175.071 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 1.6 Cg_exo -29.2 99.02 0.02 OUTLIER 'Trans proline' 0 C--N 1.349 0.582 1 C-N-CA 125.462 4.108 . . . . 0.0 115.006 -177.875 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -37.9 -44.18 0.75 Allowed 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 127.851 2.46 . . . . 0.0 114.793 -177.838 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -59.87 -33.18 71.47 Favored 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 123.501 0.72 . . . . 0.0 111.246 -178.697 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 47.4 mm-40 -93.18 163.38 13.65 Favored 'General case' 0 N--CA 1.442 -0.87 0 C-N-CA 124.942 1.297 . . . . 0.0 110.254 -178.908 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 4.8 mp -144.99 143.23 30.4 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-N 115.219 -0.901 . . . . 0.0 110.503 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 44.1 mt -78.1 105.68 9.49 Favored 'General case' 0 N--CA 1.445 -0.68 0 N-CA-C 103.778 -2.675 . . . . 0.0 103.778 175.295 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 34.3 p-10 -101.25 -52.98 3.12 Favored 'General case' 0 N--CA 1.455 -0.183 0 C-N-CA 124.796 1.238 . . . . 0.0 111.733 -177.151 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -71.85 136.65 82.65 Favored Pre-proline 0 CA--C 1.531 0.245 0 CA-C-N 118.723 0.692 . . . . 0.0 110.069 -177.477 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -63.61 149.73 90.22 Favored 'Trans proline' 0 N--CA 1.451 -1.009 0 C-N-CA 122.142 1.895 . . . . 0.0 109.659 179.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 97.54 -34.98 4.76 Favored Glycine 0 CA--C 1.523 0.591 0 CA-C-O 118.623 -1.098 . . . . 0.0 112.777 177.855 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 76.9 mt-10 -45.28 118.72 1.81 Allowed 'General case' 0 CA--C 1.536 0.419 0 CA-C-N 118.537 1.169 . . . . 0.0 111.665 -179.696 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 11.0 p -101.88 120.46 40.42 Favored 'General case' 0 N--CA 1.452 -0.356 0 C-N-CA 124.992 1.317 . . . . 0.0 111.551 -179.485 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 38.4 t80 -101.34 108.06 19.58 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 106.422 -1.695 . . . . 0.0 106.422 175.124 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 14.6 t -93.91 139.86 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.301 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 -179.263 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 9.9 p -148.61 142.64 18.79 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.153 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 177.778 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 7.8 m -117.21 124.44 49.09 Favored 'General case' 0 CA--C 1.527 0.072 0 C-N-CA 124.318 1.047 . . . . 0.0 109.495 -177.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 44.3 mt -105.55 98.51 8.19 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 123.156 0.583 . . . . 0.0 109.777 -179.394 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -74.67 -58.36 3.34 Favored 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 123.782 0.833 . . . . 0.0 112.709 -179.38 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 4.1 m -70.42 128.87 37.68 Favored 'General case' 0 N--CA 1.453 -0.325 0 C-N-CA 123.495 0.718 . . . . 0.0 111.465 -175.116 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 57.5 mtmt -65.35 156.04 33.43 Favored 'General case' 0 N--CA 1.455 -0.194 0 C-N-CA 123.438 0.695 . . . . 0.0 110.8 179.115 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 142.44 -166.46 26.45 Favored Glycine 0 CA--C 1.521 0.446 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 179.33 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 88.5 m -117.44 123.83 47.35 Favored 'General case' 0 N--CA 1.454 -0.245 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 179.612 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -114.81 124.3 51.39 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 124.348 1.059 . . . . 0.0 108.58 -178.553 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 13.2 m -99.81 134.29 42.92 Favored 'General case' 0 C--O 1.233 0.205 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 177.868 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 40.3 p90 -133.67 166.96 21.39 Favored 'General case' 0 CA--C 1.521 -0.161 0 CA-C-O 121.588 0.708 . . . . 0.0 111.625 -179.552 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 46.6 p90 -159.01 165.09 34.82 Favored 'General case' 0 N--CA 1.45 -0.43 0 CA-C-N 115.453 -0.794 . . . . 0.0 112.322 -177.76 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.5 t -106.09 97.18 7.03 Favored 'General case' 0 CA--C 1.519 -0.243 0 N-CA-C 106.638 -1.615 . . . . 0.0 106.638 177.377 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.304 16.1 p -31.1 -64.56 0.21 Allowed Pre-proline 0 CA--C 1.544 0.721 0 N-CA-C 117.138 2.273 . . . . 0.0 117.138 -174.474 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -61.89 -16.49 49.76 Favored 'Trans proline' 0 C--N 1.347 0.468 0 C-N-CA 122.576 2.184 . . . . 0.0 114.294 -177.338 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 34.7 m170 -119.08 9.26 11.76 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 123.322 0.649 . . . . 0.0 110.747 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 66.4 tt0 -58.34 -49.69 76.28 Favored 'General case' 0 CA--C 1.529 0.144 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 179.228 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -57.45 -30.32 61.67 Favored Glycine 0 CA--C 1.531 1.067 0 N-CA-C 111.475 -0.65 . . . . 0.0 111.475 177.45 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -84.8 5.45 28.54 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 123.774 0.83 . . . . 0.0 111.577 179.091 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 87.37 11.39 69.21 Favored Glycine 0 CA--C 1.527 0.823 0 CA-C-O 118.608 -1.107 . . . . 0.0 113.833 178.263 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 22.2 ttt -78.9 77.26 5.38 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 119.812 1.806 . . . . 0.0 108.614 178.334 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 10.8 m -122.94 169.13 14.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 C-N-CA 126.042 1.737 . . . . 0.0 108.96 178.568 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -162.42 172.34 38.49 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 108.491 -1.843 . . . . 0.0 108.491 178.51 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 6.9 ttpm? -151.4 141.33 22.02 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 -176.765 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 6.0 p -132.97 126.43 53.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 CA-C-O 121.057 0.456 . . . . 0.0 110.697 -179.025 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 21.0 m -97.17 105.84 18.06 Favored 'General case' 0 C--O 1.235 0.324 0 C-N-CA 124.724 1.21 . . . . 0.0 109.222 179.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 40.8 t -79.91 103.02 6.36 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.621 0 N-CA-C 106.484 -1.673 . . . . 0.0 106.484 -179.743 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 . . . . . 0 C--O 1.235 0.313 0 C-N-CA 125.205 1.402 . . . . 0.0 109.487 -177.206 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 9.3 tt . . . . . 0 N--CA 1.454 -0.269 0 CA-C-O 121.451 0.644 . . . . 0.0 110.274 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -90.71 128.54 36.69 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 123.685 0.794 . . . . 0.0 110.895 -178.699 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 44.2 t -120.55 123.94 71.45 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 N-CA-C 106.112 -1.81 . . . . 0.0 106.112 177.492 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 32.5 mt -96.65 122.91 40.09 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 118.383 0.538 . . . . 0.0 110.206 -179.478 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.2 mm? -79.68 101.9 8.65 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 106.316 -1.735 . . . . 0.0 106.316 174.111 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 108.84 127.69 5.58 Favored Glycine 0 CA--C 1.522 0.522 0 C-N-CA 124.788 1.185 . . . . 0.0 111.576 179.688 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 14.9 p -84.34 46.84 1.26 Allowed 'General case' 0 N--CA 1.457 -0.092 0 O-C-N 121.434 -1.039 . . . . 0.0 111.314 179.279 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 72.07 -55.73 1.45 Allowed Glycine 0 CA--C 1.527 0.83 0 C-N-CA 126.071 1.796 . . . . 0.0 111.991 -179.26 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -73.17 33.69 0.07 Allowed 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 126.038 1.735 . . . . 0.0 113.743 -177.519 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 57.33 8.42 3.56 Favored Glycine 0 CA--C 1.531 1.069 0 C-N-CA 124.875 1.226 . . . . 0.0 115.848 179.207 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 22.8 t -68.63 141.43 55.39 Favored 'General case' 0 N--CA 1.457 -0.107 0 CA-C-N 119.532 1.666 . . . . 0.0 109.502 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 68.9 mt -78.1 66.57 3.74 Favored 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 124.411 1.084 . . . . 0.0 111.781 -176.048 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.6 p -138.44 150.08 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.217 0 CA-C-O 121.788 0.804 . . . . 0.0 111.715 -179.494 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 58.7 m-85 -92.38 126.33 37.42 Favored 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 105.185 -2.154 . . . . 0.0 105.185 177.78 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 48.8 t -115.39 107.47 49.17 Favored Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 119.629 1.104 . . . . 0.0 109.448 179.609 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -77.27 155.84 96.66 Favored 'Cis proline' 0 CA--C 1.536 0.613 0 CA-C-N 120.706 1.288 . . . . 0.0 111.729 -1.3 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.5 m -84.83 -55.1 4.26 Favored 'General case' 0 CA--C 1.527 0.096 0 C-N-CA 123.357 0.663 . . . . 0.0 110.302 179.232 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 58.9 mt-10 -114.0 131.87 56.19 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 -179.471 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 53.0 p90 -161.13 -178.41 6.73 Favored 'General case' 0 C--O 1.234 0.255 0 CA-C-O 121.372 0.606 . . . . 0.0 112.081 -178.114 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 35.2 p -140.02 140.26 36.18 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 124.948 1.299 . . . . 0.0 109.257 -179.249 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.4 m -145.47 152.19 49.05 Favored Pre-proline 0 CA--C 1.532 0.257 0 C-N-CA 124.553 1.141 . . . . 0.0 108.136 178.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo -71.67 151.44 58.03 Favored 'Trans proline' 0 N--CA 1.451 -0.998 0 C-N-CA 121.78 1.653 . . . . 0.0 111.16 179.842 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 56.7 m -49.31 127.15 14.42 Favored 'General case' 0 C--N 1.332 -0.18 0 C-N-CA 124.343 1.057 . . . . 0.0 111.508 178.479 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 92.9 -10.74 73.44 Favored Glycine 0 CA--C 1.527 0.817 0 CA-C-O 118.911 -0.938 . . . . 0.0 112.829 178.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -70.47 141.96 51.98 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 119.392 1.596 . . . . 0.0 108.43 178.601 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 20.4 pttp -82.01 160.45 23.27 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 123.928 0.891 . . . . 0.0 111.131 -179.018 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 15.8 mt -131.44 129.05 61.84 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 N-CA-C 105.355 -2.091 . . . . 0.0 105.355 177.775 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 75.3 t -116.37 98.06 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.202 0 C-N-CA 125.851 1.66 . . . . 0.0 107.928 -177.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -86.5 96.57 10.1 Favored 'General case' 0 CA--C 1.529 0.17 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.773 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -90.52 128.98 36.72 Favored 'General case' 0 CA--C 1.531 0.212 0 C-N-CA 125.027 1.331 . . . . 0.0 112.046 -177.6 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 45.6 t30 -69.15 116.66 9.85 Favored 'General case' 0 N--CA 1.457 -0.119 0 CA-C-O 118.393 -0.813 . . . . 0.0 109.947 177.938 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 50.2 t30 -103.4 -66.23 0.96 Allowed 'General case' 0 C--N 1.339 0.135 0 CA-C-N 118.702 0.683 . . . . 0.0 110.551 179.474 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -160.17 169.25 23.67 Favored 'General case' 0 C--O 1.225 -0.196 0 C-N-CA 123.254 0.622 . . . . 0.0 110.452 -177.684 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 71.66 18.91 77.61 Favored Glycine 0 CA--C 1.532 1.094 0 O-C-N 121.823 -0.548 . . . . 0.0 111.878 -179.512 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 10.4 p90 -71.37 168.92 17.64 Favored Pre-proline 0 CA--C 1.54 0.568 0 C-N-CA 126.001 1.72 . . . . 0.0 108.598 -179.815 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 75.8 Cg_endo -70.93 158.44 94.52 Favored 'Cis proline' 0 N--CA 1.449 -1.104 0 N-CA-C 115.042 1.131 . . . . 0.0 115.042 3.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 90.3 m-70 -146.8 160.83 41.78 Favored 'General case' 0 C--O 1.222 -0.391 0 O-C-N 121.59 -0.694 . . . . 0.0 112.72 -177.808 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 52.1 p30 -157.53 177.69 11.13 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 106.39 -1.707 . . . . 0.0 106.39 176.437 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 23.4 t -132.55 113.95 21.91 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 -179.27 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 25.5 t -118.98 132.11 69.82 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 N-CA-C 105.601 -2.0 . . . . 0.0 105.601 178.522 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -93.99 136.78 33.91 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -71.02 104.75 3.08 Favored 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 -178.66 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -35.26 -37.34 0.08 Allowed 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 127.416 2.287 . . . . 0.0 115.401 178.275 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 24.9 m-20 -85.47 -53.24 5.32 Favored 'General case' 0 CA--C 1.53 0.188 0 CA-C-N 118.545 0.611 . . . . 0.0 110.301 179.43 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 38.3 mm-40 -80.91 58.28 3.34 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 124.031 0.933 . . . . 0.0 112.906 -176.706 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 36.1 pt -152.31 159.15 33.16 Favored Pre-proline 0 CA--C 1.534 0.336 0 C-N-CA 128.452 2.701 . . . . 0.0 105.633 175.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -53.12 110.84 0.53 Allowed 'Trans proline' 0 N--CA 1.456 -0.684 0 C-N-CA 122.365 2.044 . . . . 0.0 111.162 177.22 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -51.77 108.23 0.26 Allowed 'General case' 0 CA--C 1.529 0.156 0 C-N-CA 124.119 0.968 . . . . 0.0 110.284 -179.507 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 133.83 -29.42 3.1 Favored Glycine 0 CA--C 1.527 0.795 0 N-CA-C 109.958 -1.257 . . . . 0.0 109.958 -178.133 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 88.5 t -74.94 117.91 19.91 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.279 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 179.763 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -63.13 102.81 0.41 Allowed 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 122.953 0.501 . . . . 0.0 110.335 179.454 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.71 -40.5 20.38 Favored 'General case' 0 N--CA 1.456 -0.168 0 C-N-CA 124.424 1.09 . . . . 0.0 111.381 179.094 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 44.6 t -58.94 -28.62 38.9 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 C-N-CA 123.03 0.532 . . . . 0.0 111.844 -179.132 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 33.3 pttt -75.7 -31.96 59.9 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 119.497 1.044 . . . . 0.0 111.571 -178.622 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 26.4 pt -91.78 -31.45 4.89 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.36 0 C-N-CA 123.728 0.811 . . . . 0.0 111.925 -178.79 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 35.5 m -87.74 142.95 27.42 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 124.73 1.212 . . . . 0.0 114.196 -176.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 87.2 mtp -75.26 144.6 78.74 Favored Pre-proline 0 N--CA 1.45 -0.428 0 N-CA-C 104.656 -2.35 . . . . 0.0 104.656 171.213 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -61.19 122.16 10.72 Favored 'Trans proline' 0 N--CA 1.452 -0.945 0 N-CA-C 107.322 -1.838 . . . . 0.0 107.322 176.504 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -34.57 -36.38 0.05 OUTLIER 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 127.79 2.436 . . . . 0.0 116.831 -175.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -77.35 -30.08 53.68 Favored 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 123.645 0.778 . . . . 0.0 112.14 -177.905 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 76.3 mm-40 -82.1 148.61 28.46 Favored 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 123.191 0.596 . . . . 0.0 109.549 -179.053 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -162.79 152.4 15.63 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 113.339 0.866 . . . . 0.0 113.339 -176.882 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 63.9 mt -82.32 127.65 33.43 Favored 'General case' 0 N--CA 1.446 -0.644 0 N-CA-C 106.041 -1.837 . . . . 0.0 106.041 176.353 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 23.8 t30 -118.21 -47.89 2.55 Favored 'General case' 0 C--O 1.225 -0.189 0 C-N-CA 123.267 0.627 . . . . 0.0 110.469 178.617 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -67.07 136.9 94.25 Favored Pre-proline 0 CA--C 1.533 0.322 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -178.666 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -64.68 145.04 86.06 Favored 'Trans proline' 0 N--CA 1.452 -0.954 0 C-N-CA 122.462 2.108 . . . . 0.0 109.949 -178.511 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.23 -30.21 8.98 Favored Glycine 0 CA--C 1.523 0.563 0 CA-C-O 118.729 -1.04 . . . . 0.0 113.678 177.042 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 65.9 mm-40 -52.97 135.68 36.3 Favored 'General case' 0 CA--C 1.535 0.381 0 CA-C-N 118.859 1.329 . . . . 0.0 110.655 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 17.3 p -114.31 123.91 50.69 Favored 'General case' 0 N--CA 1.454 -0.251 0 C-N-CA 124.863 1.265 . . . . 0.0 113.515 -177.235 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 43.0 t80 -94.7 108.89 20.87 Favored 'General case' 0 C--O 1.233 0.194 0 N-CA-C 105.069 -2.197 . . . . 0.0 105.069 172.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.8 t -96.28 137.99 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.356 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 -179.21 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 13.5 p -147.55 168.5 4.54 Favored 'Isoleucine or valine' 0 C--O 1.232 0.142 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 177.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 40.9 m -149.51 136.72 19.85 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 67.5 mt -118.52 112.87 20.46 Favored 'General case' 0 CA--C 1.53 0.202 0 C-N-CA 123.681 0.792 . . . . 0.0 109.786 -177.752 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -88.23 -42.84 12.02 Favored 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 123.68 0.792 . . . . 0.0 111.473 179.692 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -71.52 127.97 34.3 Favored 'General case' 0 N--CA 1.453 -0.324 0 C-N-CA 124.095 0.958 . . . . 0.0 109.878 -177.432 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.7 mttp -66.84 160.18 26.58 Favored 'General case' 0 CA--C 1.53 0.175 0 C-N-CA 123.386 0.674 . . . . 0.0 111.683 178.87 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 129.64 177.39 14.85 Favored Glycine 0 CA--C 1.525 0.716 0 C-N-CA 124.33 0.967 . . . . 0.0 112.591 176.756 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 14.7 m -95.32 112.46 24.17 Favored 'General case' 0 N--CA 1.453 -0.277 0 C-N-CA 124.769 1.227 . . . . 0.0 108.192 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 26.2 m-85 -104.04 111.72 24.41 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 124.01 0.924 . . . . 0.0 109.47 -179.626 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 20.1 m -86.14 138.38 31.96 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 107.985 -1.116 . . . . 0.0 107.985 177.163 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 34.3 p90 -135.83 164.66 27.41 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 123.099 0.56 . . . . 0.0 111.241 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 56.0 p90 -155.31 164.22 39.06 Favored 'General case' 0 N--CA 1.45 -0.462 0 CA-C-N 114.934 -1.03 . . . . 0.0 112.089 -177.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 6.3 t -105.11 106.97 17.71 Favored 'General case' 0 CA--C 1.523 -0.064 0 N-CA-C 106.212 -1.774 . . . . 0.0 106.212 177.229 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.304 52.3 p -43.42 -60.25 2.67 Favored Pre-proline 0 CA--C 1.539 0.554 0 N-CA-C 115.776 1.769 . . . . 0.0 115.776 -173.124 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -61.38 -7.56 8.82 Favored 'Trans proline' 0 C--N 1.348 0.52 0 C-N-CA 122.21 1.94 . . . . 0.0 114.365 -178.526 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 34.7 m80 -131.34 16.84 4.96 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 119.504 1.047 . . . . 0.0 111.039 179.644 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 65.6 tt0 -60.22 -49.54 77.22 Favored 'General case' 0 C--N 1.34 0.164 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 179.048 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.77 -32.12 61.54 Favored Glycine 0 CA--C 1.53 0.976 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 177.832 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -81.49 3.89 23.12 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 123.326 0.65 . . . . 0.0 111.711 179.117 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 81.92 17.82 69.11 Favored Glycine 0 CA--C 1.526 0.775 0 CA-C-O 118.944 -0.92 . . . . 0.0 113.259 178.836 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 21.5 ttt -78.58 80.03 4.98 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-N 119.369 1.584 . . . . 0.0 107.997 178.317 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 6.8 m -127.39 170.61 16.99 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.249 0 C-N-CA 126.196 1.798 . . . . 0.0 110.949 -179.853 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -166.65 175.11 42.06 Favored Glycine 0 CA--C 1.528 0.855 0 N-CA-C 109.134 -1.587 . . . . 0.0 109.134 178.251 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 58.9 mttm -147.27 126.35 12.88 Favored 'General case' 0 N--CA 1.461 0.095 0 CA-C-N 118.037 0.919 . . . . 0.0 110.947 -178.627 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 6.8 p -113.17 124.77 70.13 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.167 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 178.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.7 m -94.14 104.23 16.25 Favored 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 124.111 0.965 . . . . 0.0 109.06 -179.648 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 21.9 t -81.89 98.6 4.47 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 N-CA-C 103.98 -2.6 . . . . 0.0 103.98 178.651 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 37.2 t-20 . . . . . 0 N--CA 1.454 -0.256 0 C-N-CA 124.898 1.279 . . . . 0.0 112.925 -175.008 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.4 tm-20 . . . . . 0 CA--C 1.533 0.291 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 25.8 t -109.72 128.92 65.43 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.293 0 C-N-CA 125.891 1.676 . . . . 0.0 109.193 179.63 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 62.4 mt -94.6 126.69 40.05 Favored 'General case' 0 C--O 1.233 0.222 0 N-CA-C 108.307 -0.998 . . . . 0.0 108.307 177.455 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 55.2 mt -86.55 99.03 11.4 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 105.942 -1.873 . . . . 0.0 105.942 177.871 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 101.17 134.0 8.34 Favored Glycine 0 CA--C 1.525 0.706 0 C-N-CA 125.539 1.542 . . . . 0.0 109.583 -178.495 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 22.3 p -82.87 42.86 0.81 Allowed 'General case' 0 N--CA 1.462 0.157 0 O-C-N 120.944 -1.327 . . . . 0.0 112.875 -178.798 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.24 -53.46 1.08 Allowed Glycine 0 CA--C 1.527 0.784 0 C-N-CA 126.18 1.848 . . . . 0.0 112.691 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -73.1 36.27 0.08 Allowed 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 125.837 1.655 . . . . 0.0 113.675 -177.539 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 70.39 -19.83 0.63 Allowed Glycine 0 CA--C 1.53 1.003 0 C-N-CA 124.808 1.194 . . . . 0.0 115.08 177.785 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 32.9 t -56.66 129.21 40.08 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-N 118.515 1.157 . . . . 0.0 110.916 -178.146 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 55.5 mt -77.31 65.87 2.97 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 126.378 1.871 . . . . 0.0 112.071 -175.492 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 29.6 m -130.32 144.24 38.58 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.213 0 C-N-CA 123.174 0.59 . . . . 0.0 111.475 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 37.7 m-85 -84.76 129.21 34.86 Favored 'General case' 0 N--CA 1.456 -0.138 0 N-CA-C 104.764 -2.31 . . . . 0.0 104.764 175.723 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.9 t -117.56 102.8 51.61 Favored Pre-proline 0 CA--C 1.534 0.334 0 CA-C-O 117.986 -1.007 . . . . 0.0 108.992 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -76.89 166.83 81.62 Favored 'Cis proline' 0 CA--C 1.535 0.554 0 CA-C-N 120.373 1.169 . . . . 0.0 111.23 -1.375 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 29.2 t -103.14 -60.42 1.55 Allowed 'General case' 0 CA--C 1.531 0.216 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 178.023 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 4.3 tm-20 -102.3 125.78 49.11 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 106.11 -1.811 . . . . 0.0 106.11 178.457 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.1 p90 -161.65 -176.69 5.44 Favored 'General case' 0 CA--C 1.535 0.372 0 CA-C-N 119.118 0.872 . . . . 0.0 112.757 -179.362 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.0 m -130.14 147.03 51.83 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 126.284 1.834 . . . . 0.0 108.605 179.686 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.0 m -145.25 152.17 49.85 Favored Pre-proline 0 CA--C 1.528 0.134 0 C-N-CA 125.086 1.354 . . . . 0.0 108.28 178.465 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -73.7 158.02 47.52 Favored 'Trans proline' 0 N--CA 1.453 -0.905 0 C-N-CA 121.931 1.754 . . . . 0.0 110.514 176.935 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 50.2 m -56.3 126.13 24.91 Favored 'General case' 0 CA--C 1.529 0.149 0 C-N-CA 123.221 0.608 . . . . 0.0 109.98 177.441 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 89.82 6.5 69.79 Favored Glycine 0 CA--C 1.526 0.73 0 CA-C-O 118.887 -0.952 . . . . 0.0 112.598 -179.621 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -61.8 138.14 58.31 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 119.315 1.557 . . . . 0.0 110.854 178.884 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 15.3 ptpt -93.49 95.85 9.52 Favored 'General case' 0 N--CA 1.444 -0.736 0 C-N-CA 126.394 1.878 . . . . 0.0 106.534 177.384 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 39.6 mt -83.04 136.14 23.41 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 -179.716 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 90.8 t -118.92 132.95 67.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 105.032 -2.21 . . . . 0.0 105.032 179.012 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 94.9 m-85 -121.44 123.57 42.38 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 106.33 -1.73 . . . . 0.0 106.33 178.94 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 7.7 ttpm? -120.15 136.57 54.57 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 118.812 0.733 . . . . 0.0 112.875 -178.369 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 6.6 m-20 -67.72 99.6 0.82 Allowed 'General case' 0 C--O 1.232 0.161 0 C-N-CA 124.108 0.963 . . . . 0.0 109.279 177.095 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 57.8 t30 -87.17 -59.75 2.17 Favored 'General case' 0 N--CA 1.455 -0.192 0 N-CA-C 109.443 -0.576 . . . . 0.0 109.443 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -161.08 167.51 26.17 Favored 'General case' 0 C--O 1.226 -0.179 0 C-N-CA 123.617 0.767 . . . . 0.0 109.841 -179.293 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 68.89 20.37 74.4 Favored Glycine 0 CA--C 1.533 1.177 0 O-C-N 121.834 -0.541 . . . . 0.0 113.181 179.308 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.454 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 18.6 p90 -68.61 166.66 24.43 Favored Pre-proline 0 CA--C 1.546 0.797 0 N-CA-C 106.53 -1.656 . . . . 0.0 106.53 177.043 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.454 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 73.7 Cg_endo -69.97 156.34 93.41 Favored 'Cis proline' 0 N--CA 1.449 -1.136 0 CA-C-N 120.446 1.195 . . . . 0.0 114.488 4.215 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 87.9 m-70 -147.61 168.95 20.69 Favored 'General case' 0 N--CA 1.449 -0.498 0 O-C-N 121.638 -0.664 . . . . 0.0 111.49 -179.197 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 51.6 p30 -163.82 174.01 12.07 Favored 'General case' 0 N--CA 1.451 -0.416 0 N-CA-C 104.948 -2.242 . . . . 0.0 104.948 176.48 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 22.9 t -133.81 103.92 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.323 0 N-CA-C 107.062 -1.459 . . . . 0.0 107.062 -179.507 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.2 t -110.92 135.86 48.74 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 N-CA-C 105.896 -1.89 . . . . 0.0 105.896 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.411 ' CG ' HG13 ' A' ' 55' ' ' ILE . 53.5 m-85 -95.81 139.42 32.06 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 -179.833 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -72.02 111.09 6.97 Favored 'General case' 0 N--CA 1.45 -0.444 0 N-CA-C 107.7 -1.222 . . . . 0.0 107.7 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -46.16 -31.3 2.33 Favored 'General case' 0 CA--C 1.532 0.274 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -178.218 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -81.99 -50.92 8.58 Favored 'General case' 0 CA--C 1.531 0.25 0 CA-C-N 118.392 0.542 . . . . 0.0 109.662 178.614 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 40.3 mt-10 -80.45 56.65 2.61 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 124.143 0.977 . . . . 0.0 112.713 -177.066 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 26.4 pt -151.53 149.71 24.89 Favored Pre-proline 0 CA--C 1.534 0.329 0 C-N-CA 126.06 1.744 . . . . 0.0 107.715 175.816 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -69.11 116.26 4.4 Favored 'Trans proline' 0 N--CA 1.45 -1.068 0 C-N-CA 121.692 1.595 . . . . 0.0 108.706 176.77 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -33.65 -40.61 0.08 Allowed 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 127.741 2.416 . . . . 0.0 115.192 -177.997 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -50.98 -35.58 32.81 Favored Glycine 0 CA--C 1.533 1.16 0 C-N-CA 123.532 0.587 . . . . 0.0 112.805 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 48.2 t -103.53 103.77 15.65 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.209 0 CA-C-N 117.862 0.831 . . . . 0.0 108.945 -179.577 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -63.39 135.23 56.82 Favored 'General case' 0 CA--C 1.535 0.402 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 177.912 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -43.24 -41.26 3.79 Favored 'General case' 0 C--O 1.231 0.104 0 C-N-CA 126.182 1.793 . . . . 0.0 114.212 -179.504 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 85.8 t -56.88 -27.99 27.53 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 C-N-CA 123.03 0.532 . . . . 0.0 110.767 -179.459 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 34.5 mmtp -76.27 -19.11 58.62 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-O 118.438 -0.791 . . . . 0.0 112.539 -179.198 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.411 HG13 ' CG ' ' A' ' 41' ' ' PHE . 0.1 OUTLIER -117.11 -23.37 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 N-CA-C 113.491 0.923 . . . . 0.0 113.491 -179.761 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 31.3 m -84.09 129.82 34.89 Favored 'General case' 0 N--CA 1.453 -0.308 0 N-CA-C 113.892 1.071 . . . . 0.0 113.892 -177.207 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 15.0 tpt . . . . . 0 CA--C 1.54 0.559 0 N-CA-C 104.824 -2.287 . . . . 0.0 104.824 173.85 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.449 -0.483 0 CA-C-O 121.79 0.805 . . . . 0.0 111.247 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 50.9 mt -76.81 96.27 4.24 Favored 'General case' 0 N--CA 1.444 -0.743 0 N-CA-C 103.278 -2.86 . . . . 0.0 103.278 177.783 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 4.0 p30 -88.0 -40.42 13.89 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 126.228 1.811 . . . . 0.0 113.515 -175.207 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -95.63 156.44 37.44 Favored Pre-proline 0 CA--C 1.535 0.374 0 C-N-CA 123.823 0.849 . . . . 0.0 110.142 -178.448 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -64.69 161.42 35.82 Favored 'Trans proline' 0 N--CA 1.457 -0.664 0 C-N-CA 122.245 1.964 . . . . 0.0 109.545 176.897 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 78.54 -34.5 1.81 Allowed Glycine 0 CA--C 1.529 0.931 0 CA-C-O 118.59 -1.117 . . . . 0.0 114.182 177.205 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 50.6 mt-10 -48.46 140.98 7.26 Favored 'General case' 0 CA--C 1.533 0.324 0 CA-C-N 119.062 1.431 . . . . 0.0 111.056 179.17 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 2.5 p -120.14 161.44 21.02 Favored 'General case' 0 N--CA 1.453 -0.316 0 C-N-CA 124.732 1.213 . . . . 0.0 111.84 -177.028 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 47.4 t80 -137.1 147.83 46.32 Favored 'General case' 0 N--CA 1.456 -0.13 0 N-CA-C 104.608 -2.367 . . . . 0.0 104.608 173.731 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 25.9 t -136.21 145.03 31.49 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.097 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 -178.46 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.8 p -152.62 138.13 11.17 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 178.739 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 33.8 m -105.6 112.25 25.26 Favored 'General case' 0 CA--C 1.528 0.129 0 C-N-CA 123.927 0.891 . . . . 0.0 108.801 -179.183 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 27.6 mt -93.19 88.5 6.07 Favored 'General case' 0 CA--C 1.529 0.167 0 CA-C-O 121.247 0.546 . . . . 0.0 110.84 -178.541 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -60.9 -69.12 0.25 Allowed 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 124.747 1.219 . . . . 0.0 114.052 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 2.8 m -73.2 138.82 45.88 Favored 'General case' 0 N--CA 1.452 -0.354 0 C-N-CA 124.098 0.959 . . . . 0.0 113.459 -172.174 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -62.72 154.17 30.37 Favored 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 123.711 0.804 . . . . 0.0 110.189 177.839 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 145.31 -170.3 26.71 Favored Glycine 0 C--N 1.334 0.456 0 N-CA-C 111.194 -0.763 . . . . 0.0 111.194 178.333 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 24.0 m -112.24 120.44 41.76 Favored 'General case' 0 N--CA 1.453 -0.304 0 N-CA-C 106.451 -1.685 . . . . 0.0 106.451 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 34.7 m-85 -117.28 107.32 14.26 Favored 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 124.046 0.938 . . . . 0.0 109.327 -178.232 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -92.5 139.58 30.44 Favored 'General case' 0 C--O 1.232 0.171 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 177.601 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 32.9 p90 -137.27 167.45 21.56 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 121.387 0.613 . . . . 0.0 111.613 -178.389 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 44.8 p90 -155.84 161.03 40.68 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 114.933 -1.03 . . . . 0.0 112.379 -178.461 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.4 t -101.72 103.77 14.55 Favored 'General case' 0 CA--C 1.519 -0.241 0 N-CA-C 105.308 -2.108 . . . . 0.0 105.308 176.674 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.344 77.7 p -45.48 -58.25 6.26 Favored Pre-proline 0 CA--C 1.537 0.452 0 N-CA-C 115.723 1.749 . . . . 0.0 115.723 -173.258 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -60.3 -7.79 7.38 Favored 'Trans proline' 0 N--CA 1.458 -0.57 0 C-N-CA 121.994 1.796 . . . . 0.0 114.527 -179.414 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 35.1 m80 -132.78 18.96 4.2 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 119.843 1.201 . . . . 0.0 111.427 179.064 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 31.8 tt0 -58.07 -49.86 75.45 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 178.133 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -55.96 -32.04 59.06 Favored Glycine 0 CA--C 1.531 1.046 0 C-N-CA 123.798 0.713 . . . . 0.0 112.005 178.61 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -82.32 4.12 25.05 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 117.497 0.648 . . . . 0.0 111.56 179.277 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 83.11 16.01 70.7 Favored Glycine 0 CA--C 1.526 0.727 0 CA-C-O 119.019 -0.878 . . . . 0.0 112.967 178.967 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 20.5 ttt -78.76 77.96 5.22 Favored 'General case' 0 C--O 1.237 0.398 0 CA-C-N 119.322 1.561 . . . . 0.0 108.569 178.917 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 8.1 m -128.0 174.65 11.16 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 C-N-CA 125.984 1.714 . . . . 0.0 110.993 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -166.66 174.08 42.06 Favored Glycine 0 CA--C 1.526 0.766 0 N-CA-C 111.053 -0.819 . . . . 0.0 111.053 177.461 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 23.6 ttmm -149.01 110.88 4.57 Favored 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 124.389 1.076 . . . . 0.0 110.057 -177.128 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.1 p -106.53 128.87 60.78 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.356 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 179.799 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.0 m -100.99 110.2 22.2 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 124.73 1.212 . . . . 0.0 110.354 -177.36 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 24.0 t -83.92 101.32 8.35 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.768 0 N-CA-C 105.799 -1.926 . . . . 0.0 105.799 179.614 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 2.7 m-80 . . . . . 0 N--CA 1.451 -0.402 0 C-N-CA 125.749 1.62 . . . . 0.0 108.922 -177.892 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 14.6 tp10 . . . . . 0 N--CA 1.452 -0.367 0 N-CA-C 104.756 -2.313 . . . . 0.0 104.756 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 41.6 t -118.14 130.9 72.32 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 -178.827 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 68.8 mt -94.54 126.24 39.7 Favored 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 178.838 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 82.3 mt -90.13 98.94 12.06 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 105.835 -1.913 . . . . 0.0 105.835 177.046 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 110.57 -161.27 12.93 Favored Glycine 0 N--CA 1.447 -0.606 0 N-CA-C 109.095 -1.602 . . . . 0.0 109.095 -178.563 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 19.9 p -155.9 158.35 37.84 Favored 'General case' 0 N--CA 1.447 -0.591 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 -179.551 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.55 -39.99 31.16 Favored Glycine 0 CA--C 1.53 1.015 0 C-N-CA 123.538 0.59 . . . . 0.0 112.27 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -79.21 11.38 2.89 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 124.124 0.97 . . . . 0.0 112.642 179.218 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 70.12 14.02 70.62 Favored Glycine 0 CA--C 1.527 0.832 0 C-N-CA 124.605 1.098 . . . . 0.0 114.35 178.037 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 47.3 t -77.39 135.22 38.31 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 119.417 1.609 . . . . 0.0 108.82 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.497 ' H ' HD22 ' A' ' 12' ' ' LEU . 1.7 mm? -73.57 67.98 1.14 Allowed 'General case' 0 N--CA 1.443 -0.793 0 C-N-CA 126.011 1.724 . . . . 0.0 111.179 -178.249 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 20.9 m -129.76 153.16 38.41 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 C-N-CA 123.477 0.711 . . . . 0.0 110.4 179.498 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 39.5 m-85 -93.33 131.44 38.48 Favored 'General case' 0 C--N 1.332 -0.169 0 N-CA-C 104.132 -2.544 . . . . 0.0 104.132 175.929 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.3 t -125.03 109.66 27.43 Favored Pre-proline 0 CA--C 1.534 0.362 0 CA-C-N 119.161 0.891 . . . . 0.0 108.906 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_endo -72.04 150.77 95.08 Favored 'Cis proline' 0 N--CA 1.459 -0.533 0 CA-C-N 120.209 1.11 . . . . 0.0 110.987 -1.478 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.2 m -77.17 -48.08 18.62 Favored 'General case' 0 N--CA 1.456 -0.133 0 C-N-CA 123.036 0.534 . . . . 0.0 110.258 179.444 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -124.68 134.28 52.92 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 179.475 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 39.0 p90 -158.67 -176.83 6.11 Favored 'General case' 0 C--O 1.233 0.215 0 O-C-N 123.181 0.301 . . . . 0.0 110.7 -178.701 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 16.0 m -133.95 149.77 51.27 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 125.036 1.334 . . . . 0.0 107.925 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.7 p -144.98 138.99 14.73 Favored Pre-proline 0 CA--C 1.537 0.445 0 C-N-CA 123.796 0.839 . . . . 0.0 109.962 -177.843 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_exo -65.3 140.54 64.64 Favored 'Trans proline' 0 N--CA 1.455 -0.743 0 CA-C-N 120.746 1.302 . . . . 0.0 110.241 176.996 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 52.2 m -52.42 122.35 8.64 Favored 'General case' 0 N--CA 1.455 -0.193 0 C-N-CA 124.161 0.984 . . . . 0.0 110.857 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 102.56 -19.13 48.86 Favored Glycine 0 CA--C 1.528 0.877 0 CA-C-O 118.82 -0.989 . . . . 0.0 113.051 179.446 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -73.19 143.78 47.07 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-N 119.658 1.729 . . . . 0.0 110.25 179.312 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 18.3 ptmt -81.16 144.2 31.83 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 124.424 1.09 . . . . 0.0 111.58 -178.852 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 35.9 mt -113.2 130.48 67.04 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 178.424 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 59.7 t -114.25 102.63 14.15 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.245 0 C-N-CA 125.135 1.374 . . . . 0.0 108.017 -179.258 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -90.92 98.5 11.82 Favored 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 178.85 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 27.0 ttpp -91.75 132.38 36.44 Favored 'General case' 0 CA--C 1.528 0.132 0 C-N-CA 123.581 0.752 . . . . 0.0 112.724 -177.608 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 54.5 t-20 -66.21 110.25 2.95 Favored 'General case' 0 CA--C 1.53 0.21 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 176.395 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 -87.34 -72.96 0.49 Allowed 'General case' 0 C--N 1.338 0.078 0 CA-C-N 118.31 0.504 . . . . 0.0 110.843 -179.11 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -163.46 175.43 10.76 Favored 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 125.131 1.372 . . . . 0.0 107.732 -177.747 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 65.36 24.11 70.53 Favored Glycine 0 CA--C 1.534 1.272 0 CA-C-N 118.694 0.679 . . . . 0.0 111.594 -178.8 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.529 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 17.1 p90 -74.72 169.05 21.7 Favored Pre-proline 0 CA--C 1.542 0.668 0 N-CA-C 107.108 -1.442 . . . . 0.0 107.108 178.411 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.529 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 88.3 Cg_endo -69.53 158.3 90.45 Favored 'Cis proline' 0 N--CA 1.448 -1.201 0 CA-C-O 123.115 1.215 . . . . 0.0 114.994 3.731 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 88.2 m-70 -149.55 172.94 14.2 Favored 'General case' 0 N--CA 1.445 -0.711 0 CA-C-N 114.693 -1.14 . . . . 0.0 109.356 179.542 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 48.0 p30 -169.77 173.11 6.38 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 104.435 -2.432 . . . . 0.0 104.435 176.514 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 37.6 t -130.14 110.51 19.4 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.222 0 N-CA-C 107.767 -1.197 . . . . 0.0 107.767 -178.54 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.9 t -113.03 129.12 69.27 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.606 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 -179.737 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 62.2 m-85 -91.04 133.17 35.52 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 178.658 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -68.61 110.57 4.3 Favored 'General case' 0 N--CA 1.452 -0.352 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 -179.751 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -41.75 -35.0 0.7 Allowed 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 126.154 1.782 . . . . 0.0 115.747 -177.988 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -85.14 -50.01 7.77 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 118.5 0.591 . . . . 0.0 110.879 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -79.67 56.56 2.27 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 124.271 1.028 . . . . 0.0 112.412 -176.362 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 31.8 pt -153.35 156.57 32.57 Favored Pre-proline 0 CA--C 1.533 0.304 0 C-N-CA 126.689 1.996 . . . . 0.0 107.473 176.673 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_exo -53.62 109.5 0.38 Allowed 'Trans proline' 0 N--CA 1.456 -0.681 0 C-N-CA 122.819 2.346 . . . . 0.0 111.141 177.001 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -52.28 106.42 0.15 Allowed 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 124.203 1.001 . . . . 0.0 110.107 -179.772 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 142.29 -35.57 1.73 Allowed Glycine 0 CA--C 1.526 0.756 0 N-CA-C 109.005 -1.638 . . . . 0.0 109.005 -177.699 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 47.2 t -77.08 108.19 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 179.285 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 45.2 t0 -59.11 109.11 0.78 Allowed 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 123.039 0.535 . . . . 0.0 110.566 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.34 -40.42 17.21 Favored 'General case' 0 N--CA 1.453 -0.313 0 C-N-CA 125.079 1.351 . . . . 0.0 111.531 179.274 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 54.4 t -58.33 -28.77 36.3 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 C-N-CA 123.491 0.717 . . . . 0.0 111.925 -179.088 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 2.6 mmmp? -82.34 -40.66 21.1 Favored 'General case' 0 N--CA 1.461 0.122 0 CA-C-N 118.709 0.686 . . . . 0.0 110.909 -178.902 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.427 HD13 HG21 ' A' ' 55' ' ' ILE . 33.1 pt -78.14 -30.26 15.84 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.209 0 N-CA-C 112.191 0.441 . . . . 0.0 112.191 -179.842 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 35.5 m -90.7 146.74 23.76 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 114.667 1.358 . . . . 0.0 114.667 -176.792 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 48.2 mmm . . . . . 0 N--CA 1.448 -0.556 0 N-CA-C 102.066 -3.309 . . . . 0.0 102.066 169.005 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 92.3 mt . . . . . 0 N--CA 1.45 -0.442 0 CA-C-O 120.755 0.312 . . . . 0.0 110.446 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 84.4 mt -86.23 99.85 11.83 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 104.421 -2.437 . . . . 0.0 104.421 175.245 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 33.0 p-10 -86.57 -51.4 6.19 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 124.189 0.996 . . . . 0.0 111.736 -177.556 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.91 143.49 66.51 Favored Pre-proline 0 CA--C 1.533 0.322 0 O-C-N 121.932 -0.48 . . . . 0.0 110.468 -177.894 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -64.91 152.4 82.4 Favored 'Trans proline' 0 N--CA 1.453 -0.872 0 C-N-CA 122.522 2.148 . . . . 0.0 109.513 178.322 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 86.14 -24.52 7.97 Favored Glycine 0 CA--C 1.527 0.822 0 CA-C-O 118.41 -1.217 . . . . 0.0 114.09 177.125 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 66.1 mt-10 -51.8 127.43 20.83 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-N 119.465 1.633 . . . . 0.0 110.522 179.11 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 11.8 p -105.63 120.7 42.32 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 124.772 1.229 . . . . 0.0 112.334 -178.713 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 25.1 t80 -95.01 107.54 19.58 Favored 'General case' 0 N--CA 1.452 -0.372 0 N-CA-C 104.743 -2.317 . . . . 0.0 104.743 173.576 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 22.6 t -95.63 138.13 22.0 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 -178.954 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 10.9 p -145.85 168.81 7.06 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.17 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 177.548 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 29.1 m -147.02 130.39 16.66 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 64.6 mt -114.31 116.85 29.62 Favored 'General case' 0 CA--C 1.531 0.224 0 C-N-CA 123.636 0.774 . . . . 0.0 109.766 -177.601 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -91.3 -46.37 8.08 Favored 'General case' 0 CA--C 1.531 0.239 0 C-N-CA 124.195 0.998 . . . . 0.0 111.716 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.7 m -73.22 121.03 19.66 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 122.792 0.437 . . . . 0.0 110.712 -177.069 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 23.4 pttm -64.77 153.17 40.69 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 122.918 0.487 . . . . 0.0 111.462 178.778 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 139.18 174.28 13.45 Favored Glycine 0 CA--C 1.529 0.911 0 C-N-CA 125.552 1.548 . . . . 0.0 110.467 179.426 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 99.0 m -99.01 116.95 32.42 Favored 'General case' 0 N--CA 1.456 -0.128 0 C-N-CA 124.296 1.038 . . . . 0.0 108.646 179.457 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 10.7 m-85 -103.82 134.31 47.34 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 125.368 1.467 . . . . 0.0 108.05 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 20.2 m -104.3 139.51 39.19 Favored 'General case' 0 C--O 1.232 0.173 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 176.333 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 15.6 p90 -138.13 166.37 24.3 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-O 121.474 0.654 . . . . 0.0 111.946 -179.421 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 43.7 p90 -152.22 162.45 41.11 Favored 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 124.393 1.077 . . . . 0.0 112.294 -178.697 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.6 t -101.57 106.68 17.79 Favored 'General case' 0 CA--C 1.52 -0.174 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 176.95 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 4.9 t -38.82 -64.21 0.51 Allowed Pre-proline 0 CA--C 1.542 0.645 0 N-CA-C 115.349 1.611 . . . . 0.0 115.349 -175.413 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -64.09 -4.31 7.44 Favored 'Trans proline' 0 C--N 1.348 0.537 0 C-N-CA 122.467 2.111 . . . . 0.0 114.533 -177.966 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 37.0 m80 -130.42 20.81 5.2 Favored 'General case' 0 N--CA 1.455 -0.216 0 CA-C-N 119.461 1.028 . . . . 0.0 110.698 179.041 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 4.6 tp60 -58.43 -51.97 67.58 Favored 'General case' 0 CA--C 1.533 0.296 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 177.093 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.13 -33.55 61.19 Favored Glycine 0 CA--C 1.532 1.129 0 C-N-CA 123.526 0.584 . . . . 0.0 111.866 178.276 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -81.54 1.57 33.01 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 123.284 0.634 . . . . 0.0 111.953 179.265 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 77.14 23.82 67.74 Favored Glycine 0 CA--C 1.526 0.757 0 CA-C-O 119.231 -0.76 . . . . 0.0 113.512 178.711 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 26.1 ttt -79.27 80.47 5.63 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-N 119.207 1.504 . . . . 0.0 107.406 177.728 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 16.5 m -121.65 169.49 12.91 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.191 0 C-N-CA 125.943 1.697 . . . . 0.0 110.878 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -170.93 179.47 42.81 Favored Glycine 0 CA--C 1.526 0.733 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 178.139 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 49.6 mttp -148.17 161.4 41.53 Favored 'General case' 0 CA--C 1.528 0.132 0 CA-C-N 117.985 0.893 . . . . 0.0 110.581 -179.474 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 3.8 p -145.04 124.01 5.84 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 C-N-CA 123.488 0.715 . . . . 0.0 110.201 178.869 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 99.1 m -98.32 98.22 9.49 Favored 'General case' 0 C--O 1.236 0.359 0 C-N-CA 124.641 1.176 . . . . 0.0 111.214 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 30.2 t -75.88 120.35 25.6 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.631 0 N-CA-C 104.617 -2.364 . . . . 0.0 104.617 179.184 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 5.5 p30 . . . . . 0 N--CA 1.464 0.238 0 N-CA-C 112.634 0.605 . . . . 0.0 112.634 -174.034 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 . . . . . 0 N--CA 1.456 -0.172 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 33.5 t -91.97 138.27 20.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 C-N-CA 125.39 1.476 . . . . 0.0 109.076 -179.503 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 72.3 mt -99.76 125.44 45.67 Favored 'General case' 0 N--CA 1.45 -0.43 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 177.816 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 59.0 mt -86.46 101.93 13.61 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 105.855 -1.906 . . . . 0.0 105.855 178.196 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 95.87 157.88 32.01 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 108.347 -1.901 . . . . 0.0 108.347 -178.196 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 53.9 p -107.57 159.71 16.23 Favored 'General case' 0 N--CA 1.445 -0.718 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 -179.833 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.91 -34.62 61.81 Favored Glycine 0 CA--C 1.529 0.937 0 C-N-CA 124.183 0.897 . . . . 0.0 111.262 178.689 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -75.66 -2.9 31.64 Favored 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 123.519 0.728 . . . . 0.0 112.243 178.902 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 96.36 -17.86 58.51 Favored Glycine 0 CA--C 1.526 0.764 0 CA-C-O 118.903 -0.943 . . . . 0.0 113.556 178.671 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 32.8 t -57.27 132.35 52.76 Favored 'General case' 0 C--O 1.238 0.487 0 CA-C-N 119.4 1.6 . . . . 0.0 110.487 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 47.8 mt -77.59 67.39 3.49 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 126.818 2.047 . . . . 0.0 110.384 -177.087 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.6 m -128.2 153.76 38.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 C-N-CA 123.264 0.626 . . . . 0.0 110.611 179.862 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -87.43 130.64 34.6 Favored 'General case' 0 N--CA 1.453 -0.311 0 N-CA-C 104.153 -2.536 . . . . 0.0 104.153 175.259 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 35.3 t -120.45 108.96 37.06 Favored Pre-proline 0 CA--C 1.535 0.385 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_endo -73.3 157.2 99.31 Favored 'Cis proline' 0 N--CA 1.459 -0.552 0 CA-C-N 120.332 1.154 . . . . 0.0 110.48 -1.566 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.5 m -79.16 -43.33 24.19 Favored 'General case' 0 C--N 1.332 -0.153 0 C-N-CA 123.054 0.542 . . . . 0.0 110.884 -179.598 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -129.08 145.18 51.34 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 106.669 -1.604 . . . . 0.0 106.669 178.192 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 19.2 p90 -166.52 -179.62 5.01 Favored 'General case' 0 C--O 1.235 0.342 0 C-N-CA 123.213 0.605 . . . . 0.0 110.186 -177.665 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 37.1 p -139.71 136.29 34.06 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 124.422 1.089 . . . . 0.0 108.684 -178.858 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 33.7 m -130.09 146.27 60.76 Favored Pre-proline 0 CA--C 1.533 0.298 0 C-N-CA 124.177 0.991 . . . . 0.0 110.185 179.606 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_exo -57.67 144.34 93.09 Favored 'Trans proline' 0 N--CA 1.455 -0.742 0 C-N-CA 122.591 2.194 . . . . 0.0 110.845 174.785 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 16.3 m -51.26 119.58 4.19 Favored 'General case' 0 CA--C 1.529 0.149 0 C-N-CA 122.608 0.363 . . . . 0.0 110.955 177.846 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 96.72 -7.48 65.44 Favored Glycine 0 CA--C 1.525 0.68 0 CA-C-O 118.426 -1.208 . . . . 0.0 113.618 178.526 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -69.18 152.96 44.46 Favored 'General case' 0 CA--C 1.531 0.224 0 CA-C-N 119.953 1.877 . . . . 0.0 110.494 178.28 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 64.4 mttp -83.36 142.0 31.35 Favored 'General case' 0 N--CA 1.446 -0.666 0 C-N-CA 124.172 0.989 . . . . 0.0 109.882 -178.502 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 37.8 mt -120.56 130.08 74.89 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 105.963 -1.866 . . . . 0.0 105.963 178.386 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 84.9 t -121.88 131.42 73.16 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.428 0 N-CA-C 106.459 -1.682 . . . . 0.0 106.459 -179.242 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -118.19 103.47 9.88 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 178.799 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 38.0 ttpt -100.76 131.3 46.72 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 123.886 0.874 . . . . 0.0 113.296 -175.858 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 6.2 m-20 -64.96 107.81 1.61 Allowed 'General case' 0 C--O 1.232 0.137 0 C-N-CA 124.124 0.969 . . . . 0.0 109.975 177.708 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 7.0 t30 -87.67 -64.42 1.15 Allowed 'General case' 0 N--CA 1.456 -0.148 0 CA-C-O 121.496 0.665 . . . . 0.0 110.089 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -163.1 172.8 14.36 Favored 'General case' 0 C--N 1.331 -0.213 0 C-N-CA 125.54 1.536 . . . . 0.0 107.191 -178.961 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 66.2 20.28 69.05 Favored Glycine 0 CA--C 1.534 1.219 0 CA-C-N 118.291 0.496 . . . . 0.0 112.839 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.505 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 23.4 p90 -69.96 166.94 27.89 Favored Pre-proline 0 CA--C 1.549 0.905 0 N-CA-C 106.444 -1.688 . . . . 0.0 106.444 177.177 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.505 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 88.3 Cg_endo -69.94 156.43 93.27 Favored 'Cis proline' 0 N--CA 1.444 -1.386 0 N-CA-C 115.712 1.389 . . . . 0.0 115.712 4.719 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 86.9 m-70 -147.81 164.86 32.34 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.83 -179.773 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 56.0 p30 -162.36 177.62 9.39 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 104.986 -2.228 . . . . 0.0 104.986 177.259 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 33.6 t -135.66 111.01 11.88 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 -179.547 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 93.9 t -115.19 130.47 69.68 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.586 0 N-CA-C 106.394 -1.706 . . . . 0.0 106.394 179.568 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 54.4 m-85 -87.59 136.31 33.0 Favored 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 123.4 0.68 . . . . 0.0 109.755 -179.394 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 43.7 t0 -73.11 103.89 4.01 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -47.54 -32.46 5.37 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 124.139 0.976 . . . . 0.0 113.555 179.207 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -77.3 -17.19 58.53 Favored 'General case' 0 CA--C 1.535 0.386 0 N-CA-C 112.983 0.734 . . . . 0.0 112.983 -179.78 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 81.5 mm-40 -132.91 65.9 1.58 Allowed 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.112 0.965 . . . . 0.0 111.801 -177.17 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 29.3 pt -153.3 153.49 29.44 Favored Pre-proline 0 CA--C 1.533 0.326 0 C-N-CA 127.542 2.337 . . . . 0.0 105.851 175.784 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -60.47 113.47 1.7 Allowed 'Trans proline' 0 N--CA 1.452 -0.964 0 C-N-CA 121.972 1.781 . . . . 0.0 110.556 178.293 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -51.5 108.37 0.26 Allowed 'General case' 0 N--CA 1.453 -0.276 0 C-N-CA 125.111 1.364 . . . . 0.0 110.397 -179.248 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 143.61 -37.51 1.45 Allowed Glycine 0 CA--C 1.524 0.617 0 N-CA-C 109.019 -1.632 . . . . 0.0 109.019 -178.428 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 45.8 t -77.58 113.82 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.239 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 41.9 t0 -60.94 111.65 1.75 Allowed 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 122.769 0.428 . . . . 0.0 110.114 179.543 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.4 -41.47 20.0 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 124.685 1.194 . . . . 0.0 111.149 178.91 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 48.6 t -59.7 -29.16 42.19 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.395 0 C-N-CA 123.283 0.633 . . . . 0.0 112.048 -179.053 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 64.3 mttp -78.71 -40.93 32.31 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-N 119.055 0.843 . . . . 0.0 110.772 -179.173 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.416 HD13 HG21 ' A' ' 55' ' ' ILE . 23.1 pt -77.6 -33.36 19.12 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 N-CA-C 111.917 0.34 . . . . 0.0 111.917 -179.767 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 49.1 m -82.55 138.97 34.11 Favored 'General case' 0 N--CA 1.452 -0.341 0 N-CA-C 113.935 1.087 . . . . 0.0 113.935 -177.602 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 15.7 tpt . . . . . 0 N--CA 1.449 -0.498 0 N-CA-C 101.956 -3.35 . . . . 0.0 101.956 170.813 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.445 -0.68 0 CA-C-O 120.962 0.41 . . . . 0.0 110.971 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 73.8 mt -77.86 112.39 14.68 Favored 'General case' 0 N--CA 1.448 -0.575 0 N-CA-C 105.059 -2.2 . . . . 0.0 105.059 178.199 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 63.7 t30 -115.54 46.69 1.45 Allowed 'General case' 0 N--CA 1.464 0.247 0 C-N-CA 124.2 1.0 . . . . 0.0 112.491 -177.03 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -160.5 155.39 20.74 Favored Pre-proline 0 CA--C 1.531 0.22 0 N-CA-C 107.08 -1.452 . . . . 0.0 107.08 178.204 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -73.02 162.64 40.42 Favored 'Trans proline' 0 N--CA 1.454 -0.833 0 C-N-CA 122.013 1.808 . . . . 0.0 109.332 178.993 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 77.42 -35.94 1.56 Allowed Glycine 0 CA--C 1.529 0.938 0 CA-C-O 118.798 -1.001 . . . . 0.0 114.709 176.256 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 74.5 mm-40 -47.0 134.45 10.39 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 118.783 1.291 . . . . 0.0 111.387 179.165 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 21.8 p -119.53 132.56 55.78 Favored 'General case' 0 N--CA 1.456 -0.134 0 N-CA-C 113.83 1.048 . . . . 0.0 113.83 -177.436 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 31.9 t80 -100.91 140.38 35.28 Favored 'General case' 0 CA--C 1.529 0.166 0 N-CA-C 103.801 -2.666 . . . . 0.0 103.801 170.746 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 22.0 t -128.89 145.45 35.71 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.109 0 CA-C-N 119.007 0.821 . . . . 0.0 109.74 -177.647 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 12.5 p -152.23 169.23 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.197 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 178.367 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 83.6 m -149.06 133.62 17.68 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 106.264 -1.754 . . . . 0.0 106.264 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 79.2 mt -121.25 112.14 18.25 Favored 'General case' 0 CA--C 1.53 0.189 0 C-N-CA 123.234 0.614 . . . . 0.0 110.52 -177.305 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -93.86 -39.86 10.48 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 124.427 1.091 . . . . 0.0 110.543 178.777 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 6.4 m -70.19 122.11 18.85 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 123.594 0.758 . . . . 0.0 110.091 -178.162 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 20.8 mmtm -59.24 160.29 6.66 Favored 'General case' 0 CA--C 1.529 0.14 0 C-N-CA 124.186 0.995 . . . . 0.0 110.988 -179.692 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 134.96 -170.29 22.91 Favored Glycine 0 CA--C 1.524 0.6 0 C-N-CA 123.604 0.621 . . . . 0.0 111.822 177.703 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 25.3 m -121.26 130.34 53.62 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 105.503 -2.036 . . . . 0.0 105.503 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 16.5 m-85 -124.05 135.01 53.29 Favored 'General case' 0 N--CA 1.448 -0.525 0 C-N-CA 124.106 0.962 . . . . 0.0 109.818 -176.595 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 19.2 m -108.81 143.6 37.77 Favored 'General case' 0 C--O 1.233 0.199 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 175.644 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 11.8 p90 -143.89 171.31 14.41 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-O 121.15 0.5 . . . . 0.0 111.167 -179.308 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 34.4 p90 -157.76 167.38 30.21 Favored 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 123.805 0.842 . . . . 0.0 111.917 -179.176 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.3 t -102.99 109.31 20.8 Favored 'General case' 0 N--CA 1.463 0.181 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 177.494 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -40.92 -61.09 1.37 Allowed Pre-proline 0 CA--C 1.535 0.395 0 N-CA-C 115.659 1.725 . . . . 0.0 115.659 -173.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 63.6 Cg_endo -65.96 -4.2 9.71 Favored 'Trans proline' 0 N--CA 1.457 -0.638 0 C-N-CA 121.885 1.723 . . . . 0.0 114.87 -177.878 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 34.9 m80 -135.21 4.78 3.22 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-N 120.183 1.356 . . . . 0.0 113.185 -179.395 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 16.2 pt20 -55.7 -44.38 77.33 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 119.652 1.115 . . . . 0.0 109.975 178.988 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -59.17 -28.15 63.71 Favored Glycine 0 CA--C 1.531 1.037 0 N-CA-C 111.454 -0.659 . . . . 0.0 111.454 177.598 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.83 10.09 24.96 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 123.875 0.87 . . . . 0.0 110.843 178.771 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 87.31 10.22 71.47 Favored Glycine 0 CA--C 1.527 0.819 0 CA-C-O 118.558 -1.135 . . . . 0.0 113.789 178.29 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 18.4 ttt -78.96 76.54 5.45 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 119.791 1.796 . . . . 0.0 109.17 179.006 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 9.5 m -123.36 169.72 14.42 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 C-N-CA 126.388 1.875 . . . . 0.0 109.664 179.172 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -170.02 -179.8 41.85 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 110.211 -1.156 . . . . 0.0 110.211 178.156 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 54.1 mtmt -145.44 163.18 35.45 Favored 'General case' 0 N--CA 1.455 -0.224 0 C-N-CA 124.218 1.007 . . . . 0.0 110.29 -178.294 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.4 p -152.93 136.14 7.54 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 C-N-CA 123.898 0.879 . . . . 0.0 108.975 177.34 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -107.26 130.43 54.75 Favored 'General case' 0 C--N 1.332 -0.167 0 C-N-CA 124.441 1.096 . . . . 0.0 109.167 -179.633 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 43.4 t -99.8 97.81 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 N-CA-C 106.078 -1.823 . . . . 0.0 106.078 179.252 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 17.4 m-20 . . . . . 0 C--O 1.236 0.377 0 C-N-CA 123.604 0.762 . . . . 0.0 109.551 -176.728 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 69.2 tt0 . . . . . 0 N--CA 1.453 -0.279 0 N-CA-C 105.142 -2.17 . . . . 0.0 105.142 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 38.4 t -78.56 111.31 15.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 -176.713 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 57.8 mt -79.59 123.53 27.69 Favored 'General case' 0 N--CA 1.451 -0.416 0 N-CA-C 108.377 -0.971 . . . . 0.0 108.377 179.814 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 79.4 mt -84.23 107.41 16.52 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 178.903 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 86.56 130.48 2.79 Favored Glycine 0 C--N 1.337 0.599 0 N-CA-C 108.536 -1.826 . . . . 0.0 108.536 -179.014 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 5.0 p -78.99 157.46 28.13 Favored 'General case' 0 N--CA 1.441 -0.883 0 CA-C-N 118.461 1.131 . . . . 0.0 108.623 -178.898 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -43.94 -37.85 4.35 Favored Glycine 0 CA--C 1.531 1.06 0 C-N-CA 125.871 1.701 . . . . 0.0 113.76 -179.292 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -75.67 2.26 12.44 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 123.952 0.901 . . . . 0.0 113.253 -179.473 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 91.19 -10.33 75.22 Favored Glycine 0 CA--C 1.528 0.862 0 CA-C-O 118.828 -0.985 . . . . 0.0 113.188 -179.563 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.2 t -61.35 134.3 56.78 Favored 'General case' 0 C--N 1.343 0.293 0 CA-C-N 119.447 1.623 . . . . 0.0 110.518 -179.046 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 56.2 mt -76.63 66.06 2.53 Favored 'General case' 0 N--CA 1.447 -0.59 0 C-N-CA 126.079 1.751 . . . . 0.0 111.292 -176.312 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 29.4 m -131.13 148.65 32.94 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 C-N-CA 123.767 0.827 . . . . 0.0 110.361 179.437 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 49.9 m-85 -82.0 138.74 34.84 Favored 'General case' 0 N--CA 1.455 -0.204 0 N-CA-C 104.485 -2.413 . . . . 0.0 104.485 175.525 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.4 t -123.78 107.09 31.46 Favored Pre-proline 0 CA--C 1.533 0.302 0 CA-C-O 118.33 -0.843 . . . . 0.0 108.755 179.422 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_exo -70.45 154.69 95.22 Favored 'Cis proline' 0 C--N 1.346 0.429 0 CA-C-N 119.877 0.992 . . . . 0.0 112.015 -0.809 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.6 m -80.24 -45.44 17.97 Favored 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 177.927 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -126.98 142.5 51.54 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 105.84 -1.911 . . . . 0.0 105.84 177.642 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 33.8 p90 -166.88 175.62 7.59 Favored 'General case' 0 N--CA 1.455 -0.202 0 C-N-CA 123.637 0.775 . . . . 0.0 109.319 -178.893 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 16.4 m -134.8 143.16 46.92 Favored 'General case' 0 N--CA 1.45 -0.439 0 C-N-CA 124.499 1.12 . . . . 0.0 108.187 -179.652 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 32.7 m -137.73 149.51 64.9 Favored Pre-proline 0 CA--C 1.53 0.192 0 C-N-CA 124.632 1.173 . . . . 0.0 108.675 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -71.66 148.66 53.51 Favored 'Trans proline' 0 N--CA 1.448 -1.163 0 C-N-CA 121.76 1.64 . . . . 0.0 108.902 176.426 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 52.3 m -49.01 121.75 5.11 Favored 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 123.434 0.694 . . . . 0.0 110.961 178.572 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 99.51 -10.42 61.12 Favored Glycine 0 CA--C 1.526 0.766 0 CA-C-O 118.452 -1.193 . . . . 0.0 113.513 178.926 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -65.6 144.54 56.9 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 119.982 1.891 . . . . 0.0 108.969 178.394 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.2 ptmt -89.36 140.85 29.09 Favored 'General case' 0 N--CA 1.443 -0.825 0 N-CA-C 108.606 -0.886 . . . . 0.0 108.606 178.866 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 35.8 mt -112.61 131.94 62.74 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.386 0 N-CA-C 105.305 -2.109 . . . . 0.0 105.305 179.066 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 95.2 t -119.01 101.07 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.351 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 -179.071 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -86.27 132.66 33.94 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 106.228 -1.768 . . . . 0.0 106.228 177.357 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 61.1 tttp -131.27 130.54 42.96 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 119.237 0.926 . . . . 0.0 112.629 -176.699 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 4.1 m-20 -64.18 105.95 0.99 Allowed 'General case' 0 C--O 1.232 0.153 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 176.796 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 36.0 t30 -97.44 -69.72 0.75 Allowed 'General case' 0 N--CA 1.456 -0.162 0 CA-C-O 121.121 0.486 . . . . 0.0 110.521 -179.58 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -143.46 170.42 15.84 Favored 'General case' 0 C--O 1.224 -0.271 0 C-N-CA 124.102 0.961 . . . . 0.0 109.15 -178.56 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 57.75 19.68 36.81 Favored Glycine 0 CA--C 1.536 1.393 0 CA-C-N 118.748 0.703 . . . . 0.0 114.094 179.56 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.497 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 27.0 p90 -71.25 167.02 33.12 Favored Pre-proline 0 CA--C 1.542 0.662 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 178.026 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.497 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 94.6 Cg_endo -70.49 160.42 90.25 Favored 'Cis proline' 0 N--CA 1.448 -1.153 0 N-CA-C 115.571 1.335 . . . . 0.0 115.571 4.336 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 86.7 m-70 -151.87 173.16 15.12 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.672 -178.841 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 57.2 p30 -163.14 178.25 8.41 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 105.035 -2.209 . . . . 0.0 105.035 176.397 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 24.0 t -135.39 110.23 11.51 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.307 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 -179.207 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 53.7 t -112.93 131.02 65.69 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 N-CA-C 106.552 -1.647 . . . . 0.0 106.552 179.545 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -92.02 132.64 36.4 Favored 'General case' 0 N--CA 1.45 -0.43 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 178.411 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -71.74 101.2 2.52 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 -178.881 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -37.61 -36.68 0.18 Allowed 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 126.676 1.99 . . . . 0.0 115.681 179.48 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 72.6 m-20 -77.94 -43.71 29.04 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-N 118.747 0.703 . . . . 0.0 110.343 179.755 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -93.32 57.58 2.68 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 124.487 1.115 . . . . 0.0 113.028 -176.502 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 37.5 pt -154.98 157.86 32.0 Favored Pre-proline 0 CA--C 1.533 0.306 0 C-N-CA 126.392 1.877 . . . . 0.0 106.879 176.238 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -57.85 108.15 0.36 Allowed 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 122.09 1.86 . . . . 0.0 108.245 173.812 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -35.08 -43.4 0.2 Allowed 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 126.829 2.052 . . . . 0.0 115.433 -177.084 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -57.68 -31.59 64.09 Favored Glycine 0 CA--C 1.533 1.218 0 C-N-CA 123.114 0.387 . . . . 0.0 113.341 -179.208 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 41.8 t -83.54 99.94 6.61 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 CA-C-N 117.945 0.873 . . . . 0.0 109.186 -178.595 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 17.4 t0 -53.6 113.29 1.12 Allowed 'General case' 0 CA--C 1.536 0.405 0 C-N-CA 123.321 0.648 . . . . 0.0 110.306 178.149 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -46.67 -39.91 12.23 Favored 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 125.778 1.631 . . . . 0.0 112.295 -179.874 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 54.0 t -59.11 -27.72 36.92 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 C-N-CA 123.101 0.561 . . . . 0.0 111.706 -178.904 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 2.9 mmmp? -77.91 -42.94 31.5 Favored 'General case' 0 CA--C 1.529 0.16 0 CA-C-N 118.675 0.671 . . . . 0.0 110.837 -179.096 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.407 HG21 HD13 ' A' ' 55' ' ' ILE . 26.4 pt -78.78 -33.44 16.49 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.339 0 N-CA-C 112.284 0.475 . . . . 0.0 112.284 -179.037 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 44.4 m -80.52 141.69 34.9 Favored 'General case' 0 C--N 1.333 -0.112 0 N-CA-C 114.96 1.467 . . . . 0.0 114.96 -176.599 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 CA--C 1.539 0.528 0 N-CA-C 103.031 -2.951 . . . . 0.0 103.031 172.008 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 2.2 pp . . . . . 0 N--CA 1.448 -0.547 0 CA-C-O 121.419 0.628 . . . . 0.0 112.072 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 72.9 mt -86.82 109.12 19.06 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 104.166 -2.531 . . . . 0.0 104.166 177.075 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 34.6 p-10 -81.14 -55.45 4.74 Favored 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 123.936 0.895 . . . . 0.0 113.282 -176.658 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.32 156.76 78.59 Favored Pre-proline 0 CA--C 1.535 0.373 0 C-N-CA 123.918 0.887 . . . . 0.0 112.302 -176.426 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -67.04 163.39 34.14 Favored 'Trans proline' 0 N--CA 1.455 -0.74 0 C-N-CA 122.364 2.043 . . . . 0.0 108.967 175.109 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 79.1 -36.48 1.94 Allowed Glycine 0 CA--C 1.528 0.897 0 CA-C-O 119.041 -0.866 . . . . 0.0 113.62 177.336 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 50.7 mm-40 -42.26 129.14 3.81 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 124.606 1.162 . . . . 0.0 110.683 178.564 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -111.83 159.76 18.01 Favored 'General case' 0 N--CA 1.452 -0.354 0 C-N-CA 124.665 1.186 . . . . 0.0 112.393 -177.07 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 75.8 t80 -138.24 111.58 8.03 Favored 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 105.136 -2.172 . . . . 0.0 105.136 174.623 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 37.4 t -101.71 142.2 16.69 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 C-N-CA 123.686 0.794 . . . . 0.0 109.657 -177.635 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 12.1 p -149.51 168.0 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 177.648 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 28.7 m -147.46 129.61 15.54 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 107.367 -1.346 . . . . 0.0 107.367 -179.858 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 62.3 mt -113.26 107.45 15.91 Favored 'General case' 0 CA--C 1.53 0.183 0 C-N-CA 123.461 0.704 . . . . 0.0 110.319 -177.394 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -86.99 -45.03 11.15 Favored 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 123.65 0.78 . . . . 0.0 111.347 179.397 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.7 m -71.88 122.34 20.61 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 123.05 0.54 . . . . 0.0 110.742 -177.063 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 55.6 mttp -59.9 160.85 7.2 Favored 'General case' 0 N--CA 1.456 -0.17 0 C-N-CA 124.835 1.254 . . . . 0.0 112.342 179.482 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 136.94 -142.82 13.98 Favored Glycine 0 C--N 1.334 0.469 0 N-CA-C 110.209 -1.156 . . . . 0.0 110.209 177.285 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 85.2 m -146.14 135.2 22.65 Favored 'General case' 0 N--CA 1.444 -0.75 0 N-CA-C 105.221 -2.14 . . . . 0.0 105.221 178.929 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 10.6 m-85 -124.7 130.08 51.74 Favored 'General case' 0 N--CA 1.446 -0.672 0 C-N-CA 123.937 0.895 . . . . 0.0 108.669 -176.456 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 17.7 m -100.32 141.52 33.05 Favored 'General case' 0 C--O 1.233 0.191 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 176.425 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 20.3 p90 -140.0 168.98 18.56 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-O 121.293 0.568 . . . . 0.0 111.275 -179.443 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 52.2 p90 -158.34 166.53 32.08 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 115.52 -0.764 . . . . 0.0 111.788 -179.264 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.3 t -105.49 107.63 18.72 Favored 'General case' 0 CA--C 1.519 -0.247 0 N-CA-C 105.817 -1.92 . . . . 0.0 105.817 177.346 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.305 0.3 OUTLIER -49.37 -56.15 17.93 Favored Pre-proline 0 CA--C 1.532 0.273 0 CA-C-N 119.119 0.872 . . . . 0.0 113.057 -174.667 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_exo -46.29 -19.49 0.65 Allowed 'Trans proline' 0 N--CA 1.457 -0.654 0 C-N-CA 123.741 2.961 . . . . 0.0 115.883 177.422 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 38.0 m80 -136.63 18.27 3.09 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 119.829 1.195 . . . . 0.0 112.16 179.764 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 15.2 pt20 -60.57 -41.69 95.14 Favored 'General case' 0 N--CA 1.455 -0.204 0 CA-C-N 119.16 0.891 . . . . 0.0 109.58 179.491 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -58.33 -28.99 62.57 Favored Glycine 0 CA--C 1.532 1.136 0 N-CA-C 111.334 -0.707 . . . . 0.0 111.334 177.203 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -90.44 11.42 21.67 Favored 'General case' 0 CA--C 1.534 0.327 0 C-N-CA 123.781 0.832 . . . . 0.0 110.954 178.908 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 78.64 19.11 74.22 Favored Glycine 0 CA--C 1.527 0.819 0 CA-C-O 118.604 -1.109 . . . . 0.0 113.575 178.657 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 22.5 ttt -78.69 76.58 5.18 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-N 119.775 1.788 . . . . 0.0 108.756 178.147 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 10.2 m -120.86 172.54 7.76 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 C-N-CA 126.191 1.796 . . . . 0.0 109.787 179.566 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -170.52 177.34 43.73 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 177.672 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 58.6 mttp -146.63 157.26 43.68 Favored 'General case' 0 CA--C 1.526 0.047 0 CA-C-N 117.53 0.665 . . . . 0.0 110.623 -178.855 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 5.5 p -143.82 126.14 11.47 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.289 0 C-N-CA 123.152 0.581 . . . . 0.0 110.48 177.847 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.28 124.06 34.06 Favored 'General case' 0 CA--C 1.53 0.179 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 177.958 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 40.7 t -100.28 95.04 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.209 0 N-CA-C 103.161 -2.903 . . . . 0.0 103.161 177.302 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 . . . . . 0 N--CA 1.453 -0.297 0 C-N-CA 125.019 1.328 . . . . 0.0 113.108 -173.945 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 . . . . . 0 N--CA 1.453 -0.298 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 40.6 t -87.77 121.52 38.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 C-N-CA 124.51 1.124 . . . . 0.0 108.527 -179.463 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 70.0 mt -85.07 122.48 29.34 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 108.588 -0.894 . . . . 0.0 108.588 179.065 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 72.2 mt -86.84 99.88 12.14 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 106.103 -1.814 . . . . 0.0 106.103 177.783 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 100.9 151.29 25.04 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 108.713 -1.755 . . . . 0.0 108.713 -178.862 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 96.5 p -86.73 172.94 9.79 Favored 'General case' 0 N--CA 1.445 -0.711 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 177.378 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -54.08 -43.25 73.03 Favored Glycine 0 CA--C 1.53 0.971 0 N-CA-C 110.4 -1.08 . . . . 0.0 110.4 178.219 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -81.29 13.78 2.74 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 123.313 0.645 . . . . 0.0 112.221 178.926 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 74.48 16.98 79.8 Favored Glycine 0 CA--C 1.526 0.737 0 CA-C-O 118.849 -0.973 . . . . 0.0 114.156 178.2 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 22.8 t -71.33 140.13 50.13 Favored 'General case' 0 C--N 1.34 0.161 0 CA-C-N 119.443 1.622 . . . . 0.0 107.119 178.293 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 67.6 mt -76.52 67.65 2.71 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 125.136 1.374 . . . . 0.0 111.954 -175.411 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 26.0 m -135.17 150.17 29.4 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.21 0 C-N-CA 123.593 0.757 . . . . 0.0 110.498 179.654 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 45.3 m-85 -89.58 129.44 36.04 Favored 'General case' 0 N--CA 1.457 -0.099 0 N-CA-C 104.809 -2.293 . . . . 0.0 104.809 175.757 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 37.0 t -122.5 107.74 34.07 Favored Pre-proline 0 CA--C 1.537 0.467 0 CA-C-O 118.496 -0.764 . . . . 0.0 109.162 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -71.69 161.5 91.04 Favored 'Cis proline' 0 N--CA 1.457 -0.635 0 CA-C-N 120.227 1.117 . . . . 0.0 111.044 -1.355 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 6.2 p -86.21 -64.71 1.11 Allowed 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 178.345 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 64.9 tt0 -102.6 127.15 49.82 Favored 'General case' 0 N--CA 1.454 -0.275 0 C-N-CA 125.819 1.648 . . . . 0.0 107.577 178.47 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 33.9 p90 -150.34 -171.51 3.93 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-O 121.578 0.704 . . . . 0.0 111.998 178.87 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 7.0 m -141.63 146.8 36.63 Favored 'General case' 0 N--CA 1.45 -0.431 0 C-N-CA 124.655 1.182 . . . . 0.0 108.229 -178.943 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.0 p -148.85 137.89 12.21 Favored Pre-proline 0 CA--C 1.539 0.552 0 C-N-CA 123.28 0.632 . . . . 0.0 110.501 -177.911 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_exo -66.59 139.7 54.25 Favored 'Trans proline' 0 N--CA 1.455 -0.736 0 C-N-CA 121.424 1.416 . . . . 0.0 111.013 176.585 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 63.1 m -46.7 127.63 9.82 Favored 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 123.708 0.803 . . . . 0.0 110.978 177.125 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 94.96 -23.82 31.37 Favored Glycine 0 CA--C 1.529 0.946 0 CA-C-O 119.188 -0.784 . . . . 0.0 113.338 178.673 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 74.9 mm-40 -74.15 96.1 2.69 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 119.469 1.634 . . . . 0.0 109.318 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -41.42 126.5 2.84 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 125.734 1.614 . . . . 0.0 114.119 179.499 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 60.3 mt -90.06 136.77 22.98 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.314 0 N-CA-C 105.943 -1.873 . . . . 0.0 105.943 178.036 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 66.6 t -117.76 119.39 61.46 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.33 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 179.532 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 95.3 m-85 -106.16 109.38 21.3 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 178.338 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 62.5 tttp -105.16 129.31 53.58 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 124.489 1.115 . . . . 0.0 113.322 -175.159 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 3.6 m-20 -65.58 110.54 2.77 Favored 'General case' 0 C--O 1.23 0.07 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 176.834 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 51.1 t-20 -84.33 -72.08 0.48 Allowed 'General case' 0 N--CA 1.456 -0.166 0 N-CA-C 111.738 0.273 . . . . 0.0 111.738 -178.653 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -146.24 -53.54 0.25 Allowed 'General case' 0 C--O 1.225 -0.199 0 N-CA-C 114.359 1.244 . . . . 0.0 114.359 -175.82 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -69.69 33.88 0.37 Allowed Glycine 0 CA--C 1.538 1.494 0 N-CA-C 116.24 1.256 . . . . 0.0 116.24 -176.762 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.435 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 18.9 p90 -73.34 165.71 50.45 Favored Pre-proline 0 CA--C 1.543 0.705 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 179.783 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.435 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 34.0 Cg_exo -62.27 149.38 60.03 Favored 'Cis proline' 0 N--CA 1.451 -0.992 0 N-CA-C 116.425 1.663 . . . . 0.0 116.425 2.446 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 91.8 m-70 -145.95 172.6 13.13 Favored 'General case' 0 N--CA 1.447 -0.59 0 O-C-N 121.715 -0.616 . . . . 0.0 110.157 179.19 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 22.9 p-10 -169.42 175.85 5.33 Favored 'General case' 0 N--CA 1.447 -0.583 0 N-CA-C 104.048 -2.575 . . . . 0.0 104.048 176.875 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 46.5 t -137.99 114.67 11.4 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.332 0 N-CA-C 107.225 -1.398 . . . . 0.0 107.225 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 62.0 t -119.46 135.97 58.12 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 106.335 -1.728 . . . . 0.0 106.335 179.427 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 57.2 m-85 -89.23 135.5 33.54 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 123.219 0.608 . . . . 0.0 109.682 -178.933 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 7.3 t0 -74.85 99.46 3.79 Favored 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 124.315 1.046 . . . . 0.0 109.721 -179.06 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -44.21 -34.33 1.84 Allowed 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 124.687 1.195 . . . . 0.0 113.59 178.714 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -66.96 -25.58 66.41 Favored 'General case' 0 CA--C 1.536 0.419 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 179.831 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -135.36 76.23 1.61 Allowed 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 123.683 0.793 . . . . 0.0 111.136 -177.312 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 25.8 pt -153.66 149.94 22.16 Favored Pre-proline 0 CA--C 1.535 0.382 0 C-N-CA 127.372 2.269 . . . . 0.0 105.354 175.228 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -64.56 131.68 30.49 Favored 'Trans proline' 0 N--CA 1.453 -0.886 0 C-N-CA 121.746 1.631 . . . . 0.0 109.773 178.886 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -51.72 143.23 13.2 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 124.027 0.931 . . . . 0.0 112.061 -178.532 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 105.13 -41.35 2.18 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 110.365 -1.094 . . . . 0.0 110.365 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 19.7 t -79.25 93.23 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 CA-C-N 117.45 0.625 . . . . 0.0 109.337 -179.286 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 18.3 t0 -55.85 118.57 4.71 Favored 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 123.09 0.556 . . . . 0.0 110.494 178.606 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -44.31 -46.25 9.12 Favored 'General case' 0 CA--C 1.529 0.135 0 C-N-CA 125.662 1.585 . . . . 0.0 111.532 179.02 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 48.4 t -56.68 -31.03 33.77 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.471 0 C-N-CA 122.786 0.434 . . . . 0.0 111.926 -178.633 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 65.6 mttp -75.71 -39.46 57.31 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-N 118.678 0.672 . . . . 0.0 111.008 -178.834 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.418 HD13 HG21 ' A' ' 55' ' ' ILE . 20.6 pt -81.15 -28.27 10.85 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.271 0 N-CA-C 112.428 0.529 . . . . 0.0 112.428 -179.521 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 63.2 m -74.95 144.86 43.03 Favored 'General case' 0 N--CA 1.455 -0.224 0 O-C-N 121.778 -0.576 . . . . 0.0 112.534 -178.313 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 7.7 tmm? . . . . . 0 CA--C 1.537 0.463 0 N-CA-C 106.185 -1.783 . . . . 0.0 106.185 177.239 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 88.4 mt . . . . . 0 N--CA 1.454 -0.24 0 N-CA-C 106.407 -1.701 . . . . 0.0 106.407 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 67.8 mt -83.91 96.68 8.89 Favored 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 104.722 -2.325 . . . . 0.0 104.722 176.492 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -105.59 34.08 3.44 Favored 'General case' 0 CA--C 1.536 0.434 0 C-N-CA 124.499 1.12 . . . . 0.0 113.878 -177.45 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -151.43 156.49 34.86 Favored Pre-proline 0 CA--C 1.531 0.22 0 N-CA-C 108.106 -1.072 . . . . 0.0 108.106 179.639 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -72.79 163.54 38.13 Favored 'Trans proline' 0 N--CA 1.455 -0.782 0 C-N-CA 121.885 1.724 . . . . 0.0 109.816 179.324 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 78.07 -44.71 2.41 Favored Glycine 0 CA--C 1.526 0.771 0 CA-C-O 118.557 -1.135 . . . . 0.0 114.523 175.687 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 55.2 mm-40 -38.33 122.82 1.11 Allowed 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 124.82 1.248 . . . . 0.0 113.058 -178.809 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 17.9 p -109.13 134.03 52.24 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 125.316 1.446 . . . . 0.0 112.95 -178.104 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 17.5 t80 -107.55 143.27 36.2 Favored 'General case' 0 CA--C 1.528 0.097 0 N-CA-C 104.591 -2.374 . . . . 0.0 104.591 171.936 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 20.4 t -128.57 140.13 50.05 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.16 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 -179.057 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 12.8 p -146.01 144.9 20.55 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.134 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 178.301 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 7.6 m -115.25 106.65 14.29 Favored 'General case' 0 N--CA 1.454 -0.23 0 C-N-CA 124.356 1.062 . . . . 0.0 109.849 -178.6 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 50.5 mt -95.06 129.18 42.25 Favored 'General case' 0 CA--C 1.531 0.217 0 N-CA-C 107.52 -1.289 . . . . 0.0 107.52 177.913 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 13.9 m-20 -113.85 -46.53 3.02 Favored 'General case' 0 CA--C 1.527 0.08 0 C-N-CA 123.988 0.915 . . . . 0.0 111.24 -178.638 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 4.5 m -66.22 118.98 10.71 Favored 'General case' 0 N--CA 1.452 -0.362 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 -178.67 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 64.4 mttm -63.79 152.64 38.9 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 123.337 0.655 . . . . 0.0 110.306 -179.282 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 145.41 -157.81 27.46 Favored Glycine 0 CA--C 1.522 0.469 0 N-CA-C 109.328 -1.509 . . . . 0.0 109.328 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 15.3 m -123.59 132.33 53.85 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 106.535 -1.654 . . . . 0.0 106.535 -179.627 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 19.6 m-85 -125.02 119.93 30.1 Favored 'General case' 0 N--CA 1.447 -0.624 0 C-N-CA 123.681 0.793 . . . . 0.0 108.906 -178.912 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 70.2 m -91.51 144.88 25.1 Favored 'General case' 0 C--O 1.233 0.213 0 N-CA-C 107.699 -1.223 . . . . 0.0 107.699 175.612 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 17.4 p90 -141.22 164.14 31.07 Favored 'General case' 0 N--CA 1.455 -0.222 0 CA-C-O 121.237 0.541 . . . . 0.0 110.771 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 53.3 p90 -150.7 160.16 44.03 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-N 115.061 -0.972 . . . . 0.0 112.713 -177.424 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 11.6 t -99.41 106.16 18.19 Favored 'General case' 0 CA--C 1.522 -0.104 0 N-CA-C 105.877 -1.898 . . . . 0.0 105.877 176.453 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 4.5 m -38.83 -60.03 1.23 Allowed Pre-proline 0 CA--C 1.536 0.44 0 N-CA-C 115.976 1.843 . . . . 0.0 115.976 -174.474 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 89.3 Cg_endo -72.06 -2.53 11.7 Favored 'Trans proline' 0 N--CA 1.458 -0.612 0 C-N-CA 122.056 1.837 . . . . 0.0 114.602 -178.576 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 32.9 m170 -132.96 3.86 3.77 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 120.35 1.432 . . . . 0.0 113.723 -178.152 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 15.1 pt20 -52.72 -42.81 65.2 Favored 'General case' 0 CA--C 1.534 0.355 0 CA-C-N 119.009 0.822 . . . . 0.0 110.196 178.002 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -58.52 -28.77 62.8 Favored Glycine 0 CA--C 1.53 1.021 0 C-N-CA 123.951 0.786 . . . . 0.0 111.763 178.167 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -90.74 11.94 20.74 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 123.83 0.852 . . . . 0.0 110.505 178.661 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 82.97 13.0 78.64 Favored Glycine 0 CA--C 1.527 0.825 0 CA-C-O 118.632 -1.094 . . . . 0.0 113.227 178.932 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 20.5 ttt -77.66 79.82 4.14 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 119.708 1.754 . . . . 0.0 109.473 178.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 11.0 m -131.36 169.66 21.29 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.199 0 C-N-CA 126.158 1.783 . . . . 0.0 110.298 179.1 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -168.02 179.73 41.07 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 109.321 -1.511 . . . . 0.0 109.321 178.017 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 33.8 mtmm -148.32 150.5 33.73 Favored 'General case' 0 N--CA 1.456 -0.159 0 C-N-CA 123.944 0.898 . . . . 0.0 110.439 -178.429 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.0 p -135.33 131.17 51.62 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.252 0 C-N-CA 122.973 0.509 . . . . 0.0 109.948 178.76 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.0 m -98.27 100.87 12.2 Favored 'General case' 0 CA--C 1.534 0.361 0 C-N-CA 125.212 1.405 . . . . 0.0 109.396 -179.64 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 43.6 t -79.92 114.9 21.46 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.388 0 N-CA-C 105.277 -2.119 . . . . 0.0 105.277 -179.553 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 6.6 p30 . . . . . 0 C--N 1.333 -0.133 0 C-N-CA 123.426 0.691 . . . . 0.0 111.946 -174.673 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 . . . . . 0 N--CA 1.449 -0.5 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 58.6 t -132.99 117.56 29.8 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.683 0 N-CA-C 106.217 -1.772 . . . . 0.0 106.217 178.585 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 38.7 mt -84.89 119.22 25.1 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 179.427 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 49.0 mt -82.52 83.07 7.68 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 104.372 -2.455 . . . . 0.0 104.372 176.534 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 121.38 152.1 8.68 Favored Glycine 0 CA--C 1.527 0.812 0 C-N-CA 125.708 1.623 . . . . 0.0 109.616 -176.675 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 50.5 p -114.8 44.65 1.73 Allowed 'General case' 0 CA--C 1.522 -0.121 0 C-N-CA 124.28 1.032 . . . . 0.0 111.799 -179.394 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 74.87 -56.81 2.65 Favored Glycine 0 CA--C 1.523 0.542 0 C-N-CA 126.023 1.773 . . . . 0.0 111.401 179.294 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -73.72 34.37 0.08 Allowed 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 125.406 1.482 . . . . 0.0 113.625 -177.697 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 58.94 4.39 2.24 Favored Glycine 0 CA--C 1.532 1.102 0 C-N-CA 124.828 1.204 . . . . 0.0 115.837 178.743 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.3 t -64.97 138.6 58.46 Favored 'General case' 0 N--CA 1.456 -0.146 0 CA-C-N 119.528 1.664 . . . . 0.0 110.12 -179.009 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 71.0 mt -79.98 64.69 4.9 Favored 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 124.807 1.243 . . . . 0.0 110.604 -177.098 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 28.0 m -133.68 145.13 34.02 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.223 0 C-N-CA 123.253 0.621 . . . . 0.0 112.421 -178.467 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 68.8 m-85 -89.21 125.96 35.29 Favored 'General case' 0 N--CA 1.455 -0.224 0 N-CA-C 104.037 -2.579 . . . . 0.0 104.037 175.536 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 22.4 t -118.02 110.17 40.17 Favored Pre-proline 0 CA--C 1.532 0.267 0 CA-C-N 119.529 1.059 . . . . 0.0 109.218 179.25 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -74.81 153.64 99.27 Favored 'Cis proline' 0 CA--C 1.535 0.57 0 CA-C-N 120.392 1.176 . . . . 0.0 111.164 -1.375 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.2 m -80.87 -45.55 16.66 Favored 'General case' 0 CA--C 1.528 0.127 0 C-N-CA 123.324 0.65 . . . . 0.0 110.805 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -123.58 130.96 53.45 Favored 'General case' 0 N--CA 1.451 -0.396 0 N-CA-C 104.657 -2.349 . . . . 0.0 104.657 178.46 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 42.1 p90 -157.96 -177.54 6.64 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 118.435 0.562 . . . . 0.0 111.175 -177.765 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.9 p -126.09 151.26 47.44 Favored 'General case' 0 N--CA 1.448 -0.569 0 C-N-CA 125.809 1.644 . . . . 0.0 108.758 178.962 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.8 p -145.53 134.36 11.05 Favored Pre-proline 0 CA--C 1.539 0.52 0 C-N-CA 123.893 0.877 . . . . 0.0 109.136 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -64.64 136.88 51.9 Favored 'Trans proline' 0 N--CA 1.455 -0.782 0 C-N-CA 121.536 1.491 . . . . 0.0 110.096 175.917 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 48.6 m -49.69 122.1 6.0 Favored 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 123.796 0.838 . . . . 0.0 111.131 179.325 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.46 -17.25 58.74 Favored Glycine 0 CA--C 1.529 0.938 0 CA-C-O 118.816 -0.991 . . . . 0.0 113.554 179.006 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 71.1 mm-40 -70.25 167.05 18.78 Favored 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 119.623 1.712 . . . . 0.0 111.428 179.679 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -92.95 146.88 23.29 Favored 'General case' 0 N--CA 1.45 -0.434 0 C-N-CA 125.029 1.331 . . . . 0.0 111.017 -179.213 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 32.1 mt -125.23 126.41 70.8 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.424 0 N-CA-C 103.682 -2.71 . . . . 0.0 103.682 176.349 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 57.2 t -112.39 96.61 4.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 C-N-CA 125.081 1.352 . . . . 0.0 108.896 -178.259 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -81.69 97.13 7.77 Favored 'General case' 0 CA--C 1.531 0.239 0 N-CA-C 106.862 -1.533 . . . . 0.0 106.862 178.305 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 63.5 tttp -93.98 127.81 39.97 Favored 'General case' 0 CA--C 1.53 0.187 0 C-N-CA 124.884 1.274 . . . . 0.0 113.557 -174.75 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -67.7 93.51 0.38 Allowed 'General case' 0 CA--C 1.533 0.324 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 176.78 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 14.0 t-20 -80.69 -67.25 0.79 Allowed 'General case' 0 N--CA 1.455 -0.221 0 C-N-CA 123.342 0.657 . . . . 0.0 110.654 -179.354 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -161.05 167.93 25.43 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.258 -176.848 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 68.87 17.5 71.51 Favored Glycine 0 CA--C 1.533 1.199 0 O-C-N 121.587 -0.695 . . . . 0.0 112.144 -179.236 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.45 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 32.8 p90 -70.12 165.95 38.38 Favored Pre-proline 0 CA--C 1.545 0.771 0 N-CA-C 106.325 -1.732 . . . . 0.0 106.325 177.351 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.45 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 92.3 Cg_endo -68.97 155.53 91.03 Favored 'Cis proline' 0 N--CA 1.446 -1.274 0 N-CA-C 115.525 1.317 . . . . 0.0 115.525 4.85 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 90.1 m-70 -147.72 170.32 17.82 Favored 'General case' 0 N--CA 1.449 -0.478 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.464 -179.683 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 40.4 p-10 -160.55 175.37 12.79 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 104.423 -2.436 . . . . 0.0 104.423 176.639 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 21.9 t -136.15 106.52 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.314 0 N-CA-C 106.787 -1.56 . . . . 0.0 106.787 -179.779 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 55.5 t -113.17 133.95 57.4 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 106.422 -1.696 . . . . 0.0 106.422 179.229 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 56.9 m-85 -96.18 140.82 30.33 Favored 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 123.544 0.738 . . . . 0.0 109.647 -179.711 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -74.08 108.13 6.7 Favored 'General case' 0 N--CA 1.453 -0.308 0 N-CA-C 107.078 -1.453 . . . . 0.0 107.078 178.204 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -44.25 -30.61 0.83 Allowed 'General case' 0 CA--C 1.535 0.386 0 N-CA-C 115.916 1.821 . . . . 0.0 115.916 -177.765 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -86.17 -49.19 7.93 Favored 'General case' 0 CA--C 1.53 0.196 0 CA-C-N 118.703 0.683 . . . . 0.0 110.48 179.153 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -80.66 57.48 2.96 Favored 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 124.109 0.964 . . . . 0.0 112.257 -176.609 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 36.2 pt -153.35 156.63 32.61 Favored Pre-proline 0 CA--C 1.534 0.348 0 C-N-CA 127.634 2.374 . . . . 0.0 106.217 176.649 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -53.07 115.53 2.34 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 C-N-CA 122.51 2.14 . . . . 0.0 111.384 178.065 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -52.88 107.88 0.26 Allowed 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 123.992 0.917 . . . . 0.0 110.083 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 136.46 -30.42 2.7 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 109.835 -1.306 . . . . 0.0 109.835 -178.069 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 69.9 t -75.62 121.89 28.35 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 CA-C-N 117.861 0.831 . . . . 0.0 109.059 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 14.8 t0 -66.35 105.46 1.45 Allowed 'General case' 0 N--CA 1.453 -0.3 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 178.752 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.49 -39.03 21.73 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 124.168 0.987 . . . . 0.0 111.463 178.982 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 41.4 t -61.68 -29.3 45.9 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.429 0 C-N-CA 122.821 0.448 . . . . 0.0 111.574 -179.359 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.53 -34.03 58.57 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 119.224 0.92 . . . . 0.0 110.979 -178.593 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.4 HD13 HG21 ' A' ' 55' ' ' ILE . 25.0 pt -85.74 -32.35 7.0 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.21 0 C-N-CA 123.266 0.626 . . . . 0.0 111.899 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 39.7 m -85.87 136.43 33.3 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 114.273 1.212 . . . . 0.0 114.273 -177.208 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 69.2 mmm . . . . . 0 N--CA 1.452 -0.348 0 N-CA-C 103.822 -2.659 . . . . 0.0 103.822 170.936 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.446 -0.634 0 CA-C-O 121.393 0.616 . . . . 0.0 111.833 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 43.5 mt -76.85 99.94 5.35 Favored 'General case' 0 N--CA 1.446 -0.631 0 N-CA-C 104.176 -2.527 . . . . 0.0 104.176 177.891 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -96.47 -22.33 17.19 Favored 'General case' 0 N--CA 1.462 0.171 0 N-CA-C 113.993 1.108 . . . . 0.0 113.993 -176.623 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -93.97 152.94 40.89 Favored Pre-proline 0 CA--C 1.533 0.305 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -66.43 161.99 38.5 Favored 'Trans proline' 0 N--CA 1.453 -0.908 0 C-N-CA 121.773 1.649 . . . . 0.0 110.195 178.207 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 80.14 -53.93 4.45 Favored Glycine 0 CA--C 1.523 0.568 0 CA-C-O 118.228 -1.318 . . . . 0.0 113.404 176.4 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -18.53 111.07 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.399 0 C-N-CA 126.444 1.898 . . . . 0.0 114.388 -177.011 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 14.5 p -100.71 119.07 38.05 Favored 'General case' 0 N--CA 1.446 -0.633 0 C-N-CA 124.619 1.168 . . . . 0.0 112.225 -178.976 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 10.8 t80 -97.13 105.61 17.79 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 105.06 -2.2 . . . . 0.0 105.06 174.624 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.9 t -94.98 134.46 32.29 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.283 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 -178.686 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.1 p -151.16 161.22 3.52 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 178.485 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.1 m -133.62 142.29 48.03 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 125.501 1.52 . . . . 0.0 107.9 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 62.4 mt -118.82 120.52 37.59 Favored 'General case' 0 N--CA 1.453 -0.31 0 N-CA-C 107.567 -1.272 . . . . 0.0 107.567 179.288 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 9.0 p-10 -95.02 -41.07 9.32 Favored 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 124.178 0.991 . . . . 0.0 112.395 -178.43 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 25.0 m -77.14 125.77 29.86 Favored 'General case' 0 N--CA 1.452 -0.328 0 C-N-CA 123.428 0.691 . . . . 0.0 109.933 -176.564 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 66.3 mttm -65.47 156.02 33.75 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 124.017 0.927 . . . . 0.0 111.477 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 127.23 177.33 14.82 Favored Glycine 0 CA--C 1.526 0.743 0 C-N-CA 123.92 0.771 . . . . 0.0 112.201 177.445 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 7.3 m -94.57 127.73 40.71 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 125.15 1.38 . . . . 0.0 108.914 -179.063 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 15.6 m-85 -115.95 135.81 53.63 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 125.755 1.622 . . . . 0.0 108.643 179.066 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 16.9 m -108.81 136.23 48.71 Favored 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 123.362 0.665 . . . . 0.0 109.419 176.915 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 20.3 p90 -137.83 168.53 19.5 Favored 'General case' 0 C--O 1.232 0.142 0 CA-C-O 121.77 0.795 . . . . 0.0 111.818 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -156.37 160.62 39.83 Favored 'General case' 0 N--CA 1.453 -0.278 0 CA-C-N 115.322 -0.854 . . . . 0.0 112.532 -178.756 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.4 t -99.74 102.37 13.81 Favored 'General case' 0 CA--C 1.519 -0.226 0 N-CA-C 106.396 -1.705 . . . . 0.0 106.396 176.867 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -48.24 -55.07 20.19 Favored Pre-proline 0 CA--C 1.532 0.263 0 CA-C-O 118.593 -0.717 . . . . 0.0 112.51 -175.877 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_exo -50.59 -15.7 1.78 Allowed 'Trans proline' 0 N--CA 1.458 -0.572 0 C-N-CA 123.387 2.725 . . . . 0.0 115.566 178.259 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 39.3 m80 -137.69 31.5 2.52 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 119.757 1.162 . . . . 0.0 110.999 -179.765 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 1.5 pm0 -60.73 -45.64 93.48 Favored 'General case' 0 CA--C 1.534 0.333 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 178.75 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.99 -35.06 67.09 Favored Glycine 0 CA--C 1.527 0.816 0 C-N-CA 124.272 0.939 . . . . 0.0 111.661 179.1 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -80.96 4.97 17.71 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-N 117.209 0.504 . . . . 0.0 111.465 179.006 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 73.94 25.2 72.15 Favored Glycine 0 CA--C 1.524 0.651 0 CA-C-O 119.147 -0.807 . . . . 0.0 112.573 179.229 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 24.5 ttt -78.96 78.24 5.41 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 119.092 1.446 . . . . 0.0 107.831 177.976 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 13.5 m -121.25 169.09 12.99 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.245 0 C-N-CA 126.181 1.792 . . . . 0.0 109.915 179.56 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -168.87 177.97 42.43 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.108 -1.197 . . . . 0.0 110.108 178.489 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 58.6 mttm -147.57 161.22 41.57 Favored 'General case' 0 N--CA 1.455 -0.21 0 C-N-CA 123.772 0.829 . . . . 0.0 109.621 -179.48 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 4.2 p -144.88 132.63 16.59 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.246 0 C-N-CA 123.62 0.768 . . . . 0.0 109.1 178.807 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.3 m -103.41 106.88 17.51 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.965 1.306 . . . . 0.0 109.665 -178.44 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 32.6 t -82.55 106.97 13.95 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.574 0 N-CA-C 105.905 -1.887 . . . . 0.0 105.905 178.898 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 25.6 m120 . . . . . 0 C--O 1.231 0.127 0 C-N-CA 124.279 1.032 . . . . 0.0 111.042 -176.637 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 45.9 tt0 . . . . . 0 N--CA 1.452 -0.343 0 N-CA-C 105.546 -2.02 . . . . 0.0 105.546 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 38.7 t -99.35 118.66 46.28 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.455 0 C-N-CA 123.813 0.845 . . . . 0.0 108.833 -177.645 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 59.1 mt -81.98 122.05 27.3 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 179.297 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 70.4 mt -87.39 89.93 8.18 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 105.321 -2.103 . . . . 0.0 105.321 177.128 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 118.25 166.36 13.7 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 109.098 -1.601 . . . . 0.0 109.098 -177.408 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 5.4 p -136.26 48.56 2.15 Favored 'General case' 0 N--CA 1.461 0.102 0 CA-C-O 122.798 1.285 . . . . 0.0 113.259 -178.938 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.44 -62.13 0.62 Allowed Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 128.238 2.828 . . . . 0.0 113.364 176.636 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -78.31 42.97 0.44 Allowed 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 123.981 0.913 . . . . 0.0 112.268 -175.578 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 75.55 -31.22 1.21 Allowed Glycine 0 CA--C 1.528 0.891 0 C-N-CA 124.934 1.254 . . . . 0.0 113.388 178.305 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 7.4 t -40.44 106.27 0.05 Allowed 'General case' 0 C--O 1.237 0.443 0 C-N-CA 126.178 1.791 . . . . 0.0 112.141 -178.522 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 48.9 mt -75.2 69.96 2.11 Favored 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 128.196 2.598 . . . . 0.0 111.551 -176.399 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.6 m -136.49 153.38 30.78 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 C-N-CA 122.86 0.464 . . . . 0.0 110.233 179.034 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 61.5 m-85 -88.57 127.27 35.55 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 105.096 -2.187 . . . . 0.0 105.096 176.859 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 38.8 t -120.79 114.42 32.61 Favored Pre-proline 0 CA--C 1.533 0.313 0 CA-C-O 118.175 -0.916 . . . . 0.0 108.688 178.902 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -73.06 147.91 90.88 Favored 'Cis proline' 0 CA--C 1.535 0.574 0 CA-C-N 120.49 1.211 . . . . 0.0 111.423 -0.455 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.4 m -78.77 -33.02 46.76 Favored 'General case' 0 CA--C 1.529 0.148 0 C-N-CA 123.715 0.806 . . . . 0.0 111.809 179.826 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -138.75 141.25 38.85 Favored 'General case' 0 N--CA 1.454 -0.241 0 N-CA-C 105.288 -2.115 . . . . 0.0 105.288 178.951 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 13.3 p90 -168.1 172.44 8.74 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 123.904 0.882 . . . . 0.0 108.739 -178.486 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 14.9 m -133.26 137.7 46.16 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 123.918 0.887 . . . . 0.0 108.685 -179.09 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.3 m -139.9 155.02 71.2 Favored Pre-proline 0 CA--C 1.531 0.234 0 C-N-CA 124.26 1.024 . . . . 0.0 110.145 -178.61 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -77.11 151.21 30.22 Favored 'Trans proline' 0 N--CA 1.451 -0.992 0 C-N-CA 121.845 1.697 . . . . 0.0 110.64 177.638 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 14.7 m -49.79 126.55 14.19 Favored 'General case' 0 N--CA 1.457 -0.112 0 C-N-CA 123.328 0.651 . . . . 0.0 109.993 175.579 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 103.21 -6.64 50.81 Favored Glycine 0 CA--C 1.526 0.752 0 CA-C-O 119.082 -0.844 . . . . 0.0 111.678 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -61.65 136.87 58.17 Favored 'General case' 0 CA--C 1.534 0.329 0 CA-C-N 119.117 1.458 . . . . 0.0 110.43 178.567 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 61.0 mttp -94.93 98.56 10.79 Favored 'General case' 0 N--CA 1.446 -0.657 0 C-N-CA 127.244 2.218 . . . . 0.0 107.436 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 56.3 mt -81.45 137.4 21.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 -179.247 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 60.4 t -120.53 102.51 12.54 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.187 0 C-N-CA 125.017 1.327 . . . . 0.0 108.703 -178.767 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -88.46 107.03 18.65 Favored 'General case' 0 CA--C 1.53 0.183 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 178.669 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 64.6 tttm -103.35 128.45 50.43 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 124.49 1.116 . . . . 0.0 113.379 -175.556 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -62.27 108.69 1.14 Allowed 'General case' 0 N--CA 1.464 0.26 0 N-CA-C 109.155 -0.684 . . . . 0.0 109.155 176.654 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 20.2 t-20 -94.05 -69.93 0.73 Allowed 'General case' 0 C--N 1.339 0.152 0 C-N-CA 123.434 0.693 . . . . 0.0 110.71 -179.403 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -154.89 166.0 34.9 Favored 'General case' 0 C--N 1.331 -0.213 0 C-N-CA 123.899 0.88 . . . . 0.0 109.586 -177.722 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 64.51 23.04 68.31 Favored Glycine 0 CA--C 1.534 1.234 0 N-CA-C 111.938 -0.465 . . . . 0.0 111.938 -178.971 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.491 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 15.3 p90 -71.94 166.84 36.72 Favored Pre-proline 0 CA--C 1.543 0.697 0 N-CA-C 106.177 -1.786 . . . . 0.0 106.177 177.231 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.491 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 86.6 Cg_endo -70.38 161.31 88.25 Favored 'Cis proline' 0 N--CA 1.448 -1.201 0 CA-C-N 120.227 1.117 . . . . 0.0 114.928 3.708 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 -150.69 168.28 24.84 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.207 -178.606 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -159.19 177.48 11.01 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 104.029 -2.582 . . . . 0.0 104.029 175.243 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 41.6 t -132.19 119.35 39.8 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 -179.625 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 25.6 t -114.57 122.24 68.29 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.679 0 N-CA-C 105.602 -1.999 . . . . 0.0 105.602 177.501 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 59.5 m-85 -86.32 125.56 33.7 Favored 'General case' 0 N--CA 1.446 -0.668 0 N-CA-C 105.868 -1.901 . . . . 0.0 105.868 177.046 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 12.1 t0 -64.28 103.48 0.64 Allowed 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 123.059 0.543 . . . . 0.0 110.612 -177.616 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.7 pm0 -45.02 -35.47 2.97 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 125.235 1.414 . . . . 0.0 112.994 177.703 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -70.34 -20.73 62.96 Favored 'General case' 0 CA--C 1.536 0.438 0 N-CA-C 113.277 0.843 . . . . 0.0 113.277 -179.545 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -139.81 74.76 1.48 Allowed 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 123.68 0.792 . . . . 0.0 111.659 -177.732 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 30.5 pt -157.25 157.35 30.32 Favored Pre-proline 0 CA--C 1.532 0.253 0 C-N-CA 128.562 2.745 . . . . 0.0 105.67 175.845 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -58.67 108.98 0.45 Allowed 'Trans proline' 0 N--CA 1.455 -0.738 0 C-N-CA 122.02 1.813 . . . . 0.0 107.996 173.802 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -35.08 -43.03 0.19 Allowed 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 126.676 1.99 . . . . 0.0 115.605 -177.01 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -58.21 -29.33 62.69 Favored Glycine 0 CA--C 1.533 1.19 0 CA-C-O 119.893 -0.393 . . . . 0.0 113.538 -179.122 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 42.6 t -84.72 108.11 16.45 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.295 0 CA-C-N 118.21 1.005 . . . . 0.0 109.751 -178.451 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -58.27 114.11 2.26 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 122.955 0.502 . . . . 0.0 109.784 177.716 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.76 -40.82 21.76 Favored 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 124.205 1.002 . . . . 0.0 111.499 179.183 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 48.4 t -60.65 -30.06 46.15 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.398 0 C-N-CA 123.123 0.569 . . . . 0.0 111.768 -179.133 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 37.7 mmtm -76.56 -40.98 48.15 Favored 'General case' 0 CA--C 1.528 0.112 0 CA-C-N 118.715 0.688 . . . . 0.0 110.414 -179.084 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.408 HD13 HG21 ' A' ' 55' ' ' ILE . 23.1 pt -78.84 -33.65 16.52 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 N-CA-C 112.223 0.453 . . . . 0.0 112.223 -179.76 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 41.1 m -79.47 162.35 25.51 Favored 'General case' 0 C--N 1.331 -0.203 0 N-CA-C 113.454 0.909 . . . . 0.0 113.454 -178.089 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 2.7 tmm? . . . . . 0 CA--C 1.54 0.576 0 N-CA-C 104.522 -2.399 . . . . 0.0 104.522 175.368 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.426 ' N ' HD13 ' A' ' 62' ' ' LEU . 0.0 OUTLIER . . . . . 0 N--CA 1.443 -0.81 0 CA-C-O 121.241 0.543 . . . . 0.0 110.426 . . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 81.7 mt -78.5 106.06 10.2 Favored 'General case' 0 N--CA 1.446 -0.629 0 N-CA-C 104.488 -2.412 . . . . 0.0 104.488 177.121 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 13.2 t30 -77.0 -62.2 1.73 Allowed 'General case' 0 CA--C 1.528 0.133 0 N-CA-C 114.932 1.456 . . . . 0.0 114.932 -175.034 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.88 157.02 76.95 Favored Pre-proline 0 CA--C 1.533 0.295 0 C-N-CA 123.056 0.542 . . . . 0.0 111.601 -175.534 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -63.66 164.16 22.09 Favored 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 122.2 1.933 . . . . 0.0 109.433 175.335 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 80.92 -37.61 2.34 Favored Glycine 0 CA--C 1.527 0.783 0 CA-C-O 118.231 -1.316 . . . . 0.0 114.305 176.777 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 66.7 mt-10 -41.69 126.03 2.91 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 119.079 1.44 . . . . 0.0 112.144 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 16.9 p -109.22 127.61 54.38 Favored 'General case' 0 N--CA 1.455 -0.219 0 C-N-CA 125.481 1.512 . . . . 0.0 112.693 -178.552 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 35.5 t80 -106.45 114.02 27.89 Favored 'General case' 0 N--CA 1.456 -0.159 0 N-CA-C 106.05 -1.833 . . . . 0.0 106.05 174.034 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 15.4 t -100.52 141.23 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.236 0 C-N-CA 123.189 0.596 . . . . 0.0 110.464 -177.925 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 10.7 p -150.45 141.52 16.6 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.208 0 N-CA-C 108.774 -0.825 . . . . 0.0 108.774 177.308 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 23.7 m -108.46 123.57 49.08 Favored 'General case' 0 CA--C 1.528 0.113 0 C-N-CA 123.752 0.821 . . . . 0.0 108.966 -178.88 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 36.9 mt -104.56 104.15 13.94 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 118.33 0.514 . . . . 0.0 109.798 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -87.19 -53.52 4.81 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 123.974 0.909 . . . . 0.0 111.602 -179.443 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 4.7 m -66.2 128.41 36.0 Favored 'General case' 0 N--CA 1.455 -0.223 0 O-C-N 121.822 -0.549 . . . . 0.0 111.402 -175.571 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 24.9 mtpp -65.89 161.52 21.01 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 124.787 1.235 . . . . 0.0 110.871 179.648 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 132.66 -137.33 9.32 Favored Glycine 0 C--N 1.335 0.503 0 N-CA-C 110.039 -1.225 . . . . 0.0 110.039 177.972 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 58.8 m -147.79 141.81 25.95 Favored 'General case' 0 N--CA 1.443 -0.824 0 N-CA-C 105.717 -1.957 . . . . 0.0 105.717 179.65 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 12.1 m-85 -129.61 126.43 38.43 Favored 'General case' 0 N--CA 1.446 -0.675 0 C-N-CA 124.302 1.041 . . . . 0.0 108.821 -177.054 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 74.5 m -95.4 145.67 24.97 Favored 'General case' 0 C--N 1.331 -0.201 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 175.668 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 11.7 p90 -143.49 164.5 30.16 Favored 'General case' 0 N--CA 1.455 -0.191 0 CA-C-O 121.435 0.636 . . . . 0.0 112.369 -179.538 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 53.1 p90 -155.32 160.33 40.66 Favored 'General case' 0 N--CA 1.454 -0.256 0 CA-C-N 115.228 -0.896 . . . . 0.0 112.678 -179.714 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 4.3 t -102.44 100.92 11.08 Favored 'General case' 0 CA--C 1.516 -0.341 0 N-CA-C 105.991 -1.855 . . . . 0.0 105.991 176.955 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.252 0.0 OUTLIER -38.7 -63.07 0.63 Allowed Pre-proline 0 CA--C 1.538 0.511 0 N-CA-C 114.346 1.239 . . . . 0.0 114.346 -175.019 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_exo -50.53 -18.27 3.67 Favored 'Trans proline' 0 CA--C 1.534 0.501 0 C-N-CA 123.635 2.89 . . . . 0.0 115.748 179.111 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 36.6 m80 -131.63 20.19 4.68 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 119.132 0.878 . . . . 0.0 111.293 -179.044 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 66.2 tt0 -60.07 -49.06 79.13 Favored 'General case' 0 CA--C 1.528 0.13 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.226 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.8 -32.22 61.74 Favored Glycine 0 CA--C 1.531 1.073 0 N-CA-C 111.475 -0.65 . . . . 0.0 111.475 178.066 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -81.79 4.12 23.29 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 123.334 0.654 . . . . 0.0 111.718 179.105 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 84.66 16.01 66.9 Favored Glycine 0 CA--C 1.527 0.798 0 CA-C-O 118.851 -0.972 . . . . 0.0 113.509 178.384 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 19.6 ttt -78.48 78.22 4.95 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 119.509 1.655 . . . . 0.0 108.332 178.491 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 5.9 m -128.43 171.71 16.08 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 C-N-CA 125.802 1.641 . . . . 0.0 110.607 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -175.99 -174.7 42.75 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 109.155 -1.578 . . . . 0.0 109.155 177.618 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 52.2 mttp -151.63 169.77 21.33 Favored 'General case' 0 N--CA 1.453 -0.323 0 C-N-CA 124.064 0.946 . . . . 0.0 109.343 179.8 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.3 p -150.37 139.5 15.27 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.382 0 C-N-CA 123.744 0.818 . . . . 0.0 108.972 177.267 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -100.44 133.51 44.76 Favored 'General case' 0 CA--C 1.529 0.168 0 C-N-CA 124.615 1.166 . . . . 0.0 107.89 179.792 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 31.7 t -115.33 109.72 29.35 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.18 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 178.784 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 48.0 p30 . . . . . 0 C--O 1.231 0.117 0 C-N-CA 124.385 1.074 . . . . 0.0 111.878 -177.0 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 . . . . . 0 N--CA 1.452 -0.339 0 N-CA-C 105.687 -1.968 . . . . 0.0 105.687 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 41.0 t -99.88 125.28 53.59 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.374 0 C-N-CA 124.251 1.02 . . . . 0.0 109.368 -177.273 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 74.8 mt -88.54 119.05 28.63 Favored 'General case' 0 N--CA 1.446 -0.658 0 N-CA-C 108.015 -1.105 . . . . 0.0 108.015 178.264 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 19.8 mt -83.75 101.98 11.96 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 104.841 -2.281 . . . . 0.0 104.841 176.26 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 101.83 -161.34 17.68 Favored Glycine 0 N--CA 1.447 -0.573 0 N-CA-C 108.043 -2.023 . . . . 0.0 108.043 -178.016 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 54.8 p -153.32 150.34 28.81 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 106.665 -1.606 . . . . 0.0 106.665 179.545 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -50.63 -34.79 28.82 Favored Glycine 0 CA--C 1.531 1.069 0 C-N-CA 123.293 0.473 . . . . 0.0 113.09 -179.809 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -74.29 -4.99 39.48 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 123.668 0.787 . . . . 0.0 112.75 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 97.29 -17.3 59.34 Favored Glycine 0 CA--C 1.527 0.839 0 C-N-CA 124.181 0.896 . . . . 0.0 114.091 178.597 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 33.0 t -56.94 135.03 56.06 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 119.217 1.509 . . . . 0.0 111.739 -178.937 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 91.6 mt -80.09 78.24 6.75 Favored 'General case' 0 N--CA 1.446 -0.655 0 C-N-CA 125.713 1.605 . . . . 0.0 109.819 -178.824 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.7 p -138.6 159.1 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.303 0 C-N-CA 123.616 0.767 . . . . 0.0 109.524 178.713 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 30.7 m-85 -97.98 124.49 42.48 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 103.521 -2.77 . . . . 0.0 103.521 175.893 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 43.4 t -120.21 109.32 37.18 Favored Pre-proline 0 CA--C 1.537 0.456 0 CA-C-N 119.337 0.972 . . . . 0.0 109.717 -179.34 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -71.01 157.39 95.59 Favored 'Cis proline' 0 N--CA 1.456 -0.679 0 CA-C-N 120.325 1.152 . . . . 0.0 110.732 -1.448 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.4 p -84.11 -62.67 1.51 Allowed 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 107.577 -1.268 . . . . 0.0 107.577 179.253 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 51.1 mt-10 -107.31 127.98 54.04 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 125.367 1.467 . . . . 0.0 107.925 178.345 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 39.1 p90 -151.5 -177.21 5.95 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.875 0.369 . . . . 0.0 111.607 179.749 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 15.1 m -139.54 145.92 39.26 Favored 'General case' 0 N--CA 1.452 -0.362 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 -179.481 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.6 p -156.34 139.61 11.01 Favored Pre-proline 0 CA--C 1.54 0.576 0 CA-C-N 118.914 0.779 . . . . 0.0 109.977 -178.163 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -55.96 146.85 66.44 Favored 'Trans proline' 0 N--CA 1.458 -0.612 0 C-N-CA 122.558 2.172 . . . . 0.0 113.597 177.432 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 21.6 m -56.87 139.76 50.44 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 123.244 0.618 . . . . 0.0 110.464 177.057 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 89.41 -13.91 62.52 Favored Glycine 0 CA--C 1.529 0.922 0 CA-C-O 119.099 -0.834 . . . . 0.0 113.928 177.46 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 72.7 mm-40 -71.56 149.66 45.48 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 119.218 1.509 . . . . 0.0 110.356 178.716 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 1.7 mptm? -90.26 114.89 27.01 Favored 'General case' 0 N--CA 1.453 -0.323 0 C-N-CA 124.3 1.04 . . . . 0.0 109.274 -179.036 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 69.2 mt -86.54 137.13 21.45 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.267 0 N-CA-C 105.403 -2.073 . . . . 0.0 105.403 177.017 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 62.5 t -120.81 107.14 19.88 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.136 0 C-N-CA 124.515 1.126 . . . . 0.0 108.986 -178.021 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -94.31 101.64 13.6 Favored 'General case' 0 CA--C 1.532 0.279 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 178.441 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -97.85 125.81 42.91 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 125.597 1.559 . . . . 0.0 113.11 -176.134 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 8.0 m-20 -63.3 102.61 0.41 Allowed 'General case' 0 N--CA 1.466 0.36 0 C-N-CA 123.306 0.642 . . . . 0.0 110.092 176.55 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 64.3 t-20 -80.01 -57.44 3.64 Favored 'General case' 0 CA--C 1.519 -0.216 0 C-N-CA 123.075 0.55 . . . . 0.0 110.921 -179.364 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -174.44 178.25 2.02 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 126.561 1.944 . . . . 0.0 106.275 -177.414 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 64.38 19.0 63.91 Favored Glycine 0 CA--C 1.536 1.35 0 CA-C-N 119.098 0.863 . . . . 0.0 112.597 -179.555 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.48 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 9.0 p90 -74.07 168.8 22.86 Favored Pre-proline 0 CA--C 1.538 0.517 0 N-CA-C 106.233 -1.765 . . . . 0.0 106.233 177.353 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.48 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 41.0 Cg_exo -63.94 156.82 71.53 Favored 'Cis proline' 0 N--CA 1.454 -0.838 0 N-CA-C 116.507 1.695 . . . . 0.0 116.507 1.568 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -148.97 171.91 15.58 Favored 'General case' 0 C--O 1.221 -0.445 0 O-C-N 121.691 -0.63 . . . . 0.0 111.166 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 31.1 p-10 -166.47 -179.91 5.19 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 104.704 -2.332 . . . . 0.0 104.704 176.452 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 60.9 t -138.7 115.6 10.99 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.229 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 178.66 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 67.5 t -119.8 132.02 70.69 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.658 0 N-CA-C 105.618 -1.993 . . . . 0.0 105.618 178.326 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 52.9 m-85 -88.01 130.86 34.84 Favored 'General case' 0 N--CA 1.446 -0.633 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 -179.261 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -73.34 100.86 3.28 Favored 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 122.774 0.429 . . . . 0.0 109.861 -178.302 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -40.71 -38.7 0.95 Allowed 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 125.801 1.64 . . . . 0.0 113.639 178.225 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 36.8 t70 -68.26 -26.11 65.51 Favored 'General case' 0 CA--C 1.535 0.398 0 N-CA-C 113.487 0.921 . . . . 0.0 113.487 -179.055 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 40.2 mt-10 -129.49 61.64 1.55 Allowed 'General case' 0 CA--C 1.535 0.38 0 C-N-CA 124.018 0.927 . . . . 0.0 112.384 -176.812 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 40.5 pt -153.27 157.31 32.9 Favored Pre-proline 0 CA--C 1.531 0.24 0 C-N-CA 127.603 2.361 . . . . 0.0 105.509 174.914 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_exo -58.88 104.81 0.2 Allowed 'Trans proline' 0 N--CA 1.455 -0.788 0 C-N-CA 121.828 1.685 . . . . 0.0 108.334 173.703 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -35.15 -43.94 0.23 Allowed 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 126.993 2.117 . . . . 0.0 115.368 -176.752 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -55.21 -33.38 57.88 Favored Glycine 0 CA--C 1.533 1.175 0 C-N-CA 123.178 0.418 . . . . 0.0 112.97 -179.619 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 40.4 t -82.12 95.73 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.386 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 -179.244 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 25.2 t0 -49.03 112.48 0.63 Allowed 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 124.24 1.016 . . . . 0.0 110.679 178.819 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -44.73 -44.71 9.42 Favored 'General case' 0 N--CA 1.454 -0.228 0 C-N-CA 125.748 1.619 . . . . 0.0 111.496 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 59.4 t -54.64 -30.56 22.36 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 C-N-CA 123.544 0.738 . . . . 0.0 112.144 -179.085 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -77.53 -34.95 53.77 Favored 'General case' 0 CA--C 1.531 0.22 0 CA-C-N 118.732 0.696 . . . . 0.0 111.788 -178.464 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.426 HD13 HG21 ' A' ' 55' ' ' ILE . 25.1 pt -89.02 -26.14 5.57 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 C-N-CA 123.33 0.652 . . . . 0.0 112.375 -179.083 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 49.4 m -88.16 146.59 25.32 Favored 'General case' 0 N--CA 1.454 -0.232 0 N-CA-C 114.132 1.16 . . . . 0.0 114.132 -177.1 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 42.6 mmm . . . . . 0 N--CA 1.451 -0.425 0 N-CA-C 103.713 -2.699 . . . . 0.0 103.713 170.947 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.451 -0.399 0 CA-C-O 121.467 0.651 . . . . 0.0 111.879 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 42.7 mt -82.53 96.12 7.95 Favored 'General case' 0 N--CA 1.447 -0.617 0 C-N-CA 126.548 1.939 . . . . 0.0 106.065 178.242 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 11.9 t30 -79.01 -51.87 9.0 Favored 'General case' 0 C--O 1.225 -0.221 0 N-CA-C 113.204 0.816 . . . . 0.0 113.204 -178.457 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.96 157.73 78.53 Favored Pre-proline 0 CA--C 1.536 0.436 0 C-N-CA 123.475 0.71 . . . . 0.0 112.252 -175.809 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -65.54 165.73 21.92 Favored 'Trans proline' 0 N--CA 1.457 -0.656 0 C-N-CA 122.518 2.145 . . . . 0.0 109.954 175.663 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 79.31 -50.6 3.78 Favored Glycine 0 CA--C 1.526 0.742 0 CA-C-O 118.871 -0.961 . . . . 0.0 113.016 177.076 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 43.3 mm-40 -26.24 118.41 0.07 Allowed 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 126.79 2.036 . . . . 0.0 113.403 -179.424 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 13.3 p -106.54 123.49 48.18 Favored 'General case' 0 N--CA 1.453 -0.292 0 C-N-CA 125.605 1.562 . . . . 0.0 112.827 -178.239 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 19.8 t80 -101.81 115.32 30.29 Favored 'General case' 0 C--O 1.232 0.169 0 N-CA-C 105.835 -1.913 . . . . 0.0 105.835 173.477 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.8 t -100.81 136.88 30.34 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.295 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 -179.606 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.6 p -147.35 150.92 14.19 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.078 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 178.705 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 25.5 m -121.06 130.3 53.71 Favored 'General case' 0 N--CA 1.457 -0.081 0 C-N-CA 124.316 1.046 . . . . 0.0 108.408 -178.87 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 74.7 mt -113.11 121.32 44.21 Favored 'General case' 0 CA--C 1.53 0.21 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 179.418 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -92.35 -63.22 1.26 Allowed 'General case' 0 CA--C 1.529 0.149 0 C-N-CA 124.152 0.981 . . . . 0.0 112.458 -178.038 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.1 m -65.21 135.1 55.02 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 122.986 0.515 . . . . 0.0 110.318 -174.879 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 61.1 mttp -71.52 156.59 39.25 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 122.998 0.519 . . . . 0.0 111.259 -178.368 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 139.55 175.76 14.41 Favored Glycine 0 CA--C 1.525 0.696 0 C-N-CA 123.558 0.599 . . . . 0.0 111.662 177.825 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 18.3 m -94.47 112.18 23.95 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 107.51 -1.292 . . . . 0.0 107.51 179.072 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 18.8 m-85 -104.93 125.43 50.93 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 123.686 0.795 . . . . 0.0 109.263 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 7.3 m -98.39 142.12 30.41 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 177.981 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 12.0 p90 -139.55 163.6 32.13 Favored 'General case' 0 N--CA 1.455 -0.198 0 CA-C-O 121.502 0.668 . . . . 0.0 111.719 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 49.5 p90 -148.99 161.66 41.46 Favored 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 124.855 1.262 . . . . 0.0 111.784 -178.195 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.8 t -105.32 107.48 18.49 Favored 'General case' 0 CA--C 1.522 -0.126 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 177.279 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 1.3 m -41.51 -61.55 1.38 Allowed Pre-proline 0 CA--C 1.535 0.378 0 N-CA-C 115.06 1.504 . . . . 0.0 115.06 -175.812 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -60.19 -4.84 3.35 Favored 'Trans proline' 0 CA--C 1.536 0.624 0 C-N-CA 121.859 1.706 . . . . 0.0 114.792 -179.042 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 38.7 m80 -134.34 19.67 3.67 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-N 119.73 1.15 . . . . 0.0 110.556 177.443 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 19.6 pt20 -63.35 -42.46 98.9 Favored 'General case' 0 N--CA 1.452 -0.33 0 O-C-N 121.693 -0.629 . . . . 0.0 109.531 179.192 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -61.13 -40.98 99.3 Favored Glycine 0 CA--C 1.529 0.964 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 177.557 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -66.32 -34.14 77.32 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 122.713 0.405 . . . . 0.0 110.117 178.536 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 108.33 31.19 3.59 Favored Glycine 0 CA--C 1.525 0.715 0 C-N-CA 124.287 0.946 . . . . 0.0 112.513 178.072 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -80.18 91.08 5.52 Favored 'General case' 0 C--O 1.237 0.41 0 N-CA-C 106.609 -1.626 . . . . 0.0 106.609 178.122 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 20.1 m -131.12 171.6 17.64 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.246 0 C-N-CA 125.128 1.371 . . . . 0.0 112.15 -177.966 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -171.27 -179.89 42.66 Favored Glycine 0 CA--C 1.529 0.956 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 177.507 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 81.3 mttt -147.75 155.09 41.33 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-N 117.77 0.785 . . . . 0.0 110.435 -179.657 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 4.3 p -137.75 127.96 36.73 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 C-N-CA 123.938 0.895 . . . . 0.0 109.637 179.197 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -91.99 103.92 16.39 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 107.135 -1.431 . . . . 0.0 107.135 178.736 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 40.0 t -81.37 112.28 19.11 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 N-CA-C 105.386 -2.079 . . . . 0.0 105.386 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 31.1 m120 . . . . . 0 N--CA 1.456 -0.173 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 -178.596 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 . . . . . 0 N--CA 1.455 -0.199 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 43.8 t -118.22 121.83 68.14 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.355 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 179.478 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 36.9 mt -89.62 127.88 35.97 Favored 'General case' 0 N--CA 1.454 -0.262 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 179.247 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 44.1 mt -86.64 96.87 10.26 Favored 'General case' 0 N--CA 1.452 -0.326 0 N-CA-C 106.656 -1.609 . . . . 0.0 106.656 177.822 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 105.39 132.41 7.31 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 -178.679 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 23.9 p -83.0 43.88 0.89 Allowed 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 119.07 1.435 . . . . 0.0 112.802 -178.842 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.58 -55.14 1.25 Allowed Glycine 0 CA--C 1.527 0.815 0 C-N-CA 126.197 1.856 . . . . 0.0 112.278 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -72.85 34.47 0.07 Allowed 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 126.163 1.785 . . . . 0.0 113.633 -177.554 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 68.08 -13.27 0.74 Allowed Glycine 0 CA--C 1.53 0.996 0 C-N-CA 124.505 1.05 . . . . 0.0 115.035 178.428 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 20.3 t -61.55 129.15 39.72 Favored 'General case' 0 C--N 1.339 0.126 0 CA-C-N 119.328 1.564 . . . . 0.0 109.768 -178.464 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 59.4 mt -75.11 66.76 1.69 Allowed 'General case' 0 N--CA 1.448 -0.534 0 C-N-CA 126.113 1.765 . . . . 0.0 111.857 -175.538 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.8 m -135.06 149.55 29.15 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.182 0 C-N-CA 123.446 0.698 . . . . 0.0 110.856 179.368 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 74.7 m-85 -88.09 135.46 33.41 Favored 'General case' 0 N--CA 1.456 -0.144 0 N-CA-C 105.477 -2.046 . . . . 0.0 105.477 176.549 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 48.4 t -122.67 110.73 31.69 Favored Pre-proline 0 CA--C 1.533 0.305 0 CA-C-O 118.026 -0.987 . . . . 0.0 108.851 178.935 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -72.87 151.62 97.13 Favored 'Cis proline' 0 N--CA 1.458 -0.565 0 CA-C-N 120.408 1.181 . . . . 0.0 111.175 -0.773 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.2 m -80.66 -48.92 11.92 Favored 'General case' 0 CA--C 1.529 0.161 0 C-N-CA 123.351 0.661 . . . . 0.0 110.799 179.811 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -119.97 129.47 54.32 Favored 'General case' 0 N--CA 1.454 -0.251 0 N-CA-C 105.904 -1.887 . . . . 0.0 105.904 179.821 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 38.2 p90 -157.4 -175.78 5.59 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-N 118.828 0.74 . . . . 0.0 111.963 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 32.9 m -133.97 147.9 51.09 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 125.601 1.561 . . . . 0.0 107.092 178.37 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.4 p -145.71 139.01 14.36 Favored Pre-proline 0 N--CA 1.449 -0.509 0 C-N-CA 123.568 0.747 . . . . 0.0 109.308 -178.156 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 70.7 Cg_exo -53.66 137.26 66.57 Favored 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 122.359 2.039 . . . . 0.0 111.436 177.327 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.6 m -60.13 117.23 4.88 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 179.476 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 109.35 -17.21 31.54 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-O 118.729 -1.039 . . . . 0.0 112.181 -178.119 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -72.17 157.45 37.73 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 119.534 1.667 . . . . 0.0 110.698 179.226 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 57.1 pttt -93.76 135.09 35.42 Favored 'General case' 0 N--CA 1.444 -0.76 0 C-N-CA 124.764 1.226 . . . . 0.0 110.826 -179.695 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 45.6 mt -102.36 130.71 51.81 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.358 0 N-CA-C 104.804 -2.295 . . . . 0.0 104.804 177.055 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 80.6 t -115.27 99.54 8.71 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 C-N-CA 124.819 1.247 . . . . 0.0 108.705 -178.104 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -86.13 103.0 14.37 Favored 'General case' 0 N--CA 1.456 -0.169 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 178.924 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 60.9 tttp -98.39 128.8 44.95 Favored 'General case' 0 CA--C 1.528 0.131 0 C-N-CA 124.315 1.046 . . . . 0.0 112.27 -177.216 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 38.8 t30 -64.43 110.36 2.25 Favored 'General case' 0 N--CA 1.456 -0.15 0 C-N-CA 123.608 0.763 . . . . 0.0 109.86 177.57 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 59.9 t30 -102.59 -64.74 1.04 Allowed 'General case' 0 C--N 1.339 0.134 0 CA-C-N 118.495 0.589 . . . . 0.0 111.312 -179.207 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -157.17 168.4 27.55 Favored 'General case' 0 C--O 1.226 -0.18 0 C-N-CA 122.869 0.468 . . . . 0.0 111.284 -177.762 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 66.23 24.86 72.19 Favored Glycine 0 CA--C 1.532 1.144 0 O-C-N 121.868 -0.52 . . . . 0.0 112.269 -179.896 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.541 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 10.3 p90 -74.68 169.53 19.42 Favored Pre-proline 0 CA--C 1.543 0.7 0 C-N-CA 125.457 1.503 . . . . 0.0 107.768 179.023 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.541 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 95.7 Cg_endo -70.32 162.21 86.17 Favored 'Cis proline' 0 N--CA 1.448 -1.19 0 CA-C-N 120.189 1.103 . . . . 0.0 114.314 2.878 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 89.9 m-70 -148.9 174.86 11.8 Favored 'General case' 0 C--O 1.22 -0.476 0 O-C-N 121.545 -0.722 . . . . 0.0 111.276 -178.634 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 25.4 p-10 -163.87 179.08 7.3 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 103.858 -2.645 . . . . 0.0 103.858 175.707 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 45.1 t -138.52 117.44 13.81 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.377 0 N-CA-C 107.358 -1.349 . . . . 0.0 107.358 178.93 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 91.8 t -121.55 138.18 52.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 106.737 -1.579 . . . . 0.0 106.737 178.409 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 76.2 m-85 -97.09 131.82 43.49 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -63.19 116.26 5.26 Favored 'General case' 0 N--CA 1.454 -0.242 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 -178.731 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.1 pm0 -48.45 -29.57 4.22 Favored 'General case' 0 CA--C 1.533 0.299 0 N-CA-C 115.682 1.734 . . . . 0.0 115.682 -177.719 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 18.0 m-20 -90.07 -52.18 5.08 Favored 'General case' 0 CA--C 1.53 0.178 0 CA-C-N 118.752 0.706 . . . . 0.0 110.101 -179.593 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 80.0 mt-10 -79.92 58.82 3.0 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 124.402 1.081 . . . . 0.0 112.169 -176.721 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 19.2 pt -150.58 151.29 30.45 Favored Pre-proline 0 CA--C 1.532 0.261 0 C-N-CA 127.025 2.13 . . . . 0.0 107.1 176.199 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 21.0 Cg_endo -61.89 117.58 4.43 Favored 'Trans proline' 0 N--CA 1.452 -0.948 0 C-N-CA 121.925 1.75 . . . . 0.0 110.466 178.746 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -46.98 120.91 3.3 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 125.02 1.328 . . . . 0.0 110.963 -179.398 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 126.31 -39.51 1.99 Allowed Glycine 0 CA--C 1.525 0.676 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -178.853 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 21.7 t -78.28 95.06 1.65 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 53.5 t0 -54.47 114.82 1.81 Allowed 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 123.213 0.605 . . . . 0.0 110.535 179.697 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -45.44 -43.67 11.59 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 125.554 1.541 . . . . 0.0 111.887 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 55.0 t -57.61 -28.85 32.92 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.344 0 C-N-CA 123.274 0.63 . . . . 0.0 111.805 -178.258 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 28.8 mtpp -79.05 -36.01 41.68 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 118.556 0.616 . . . . 0.0 111.229 -178.723 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.403 HD13 HG21 ' A' ' 55' ' ' ILE . 26.2 pt -86.78 -26.11 6.12 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.408 0 C-N-CA 123.201 0.6 . . . . 0.0 112.482 -179.564 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 46.0 m -90.25 148.6 22.8 Favored 'General case' 0 C--N 1.331 -0.2 0 N-CA-C 114.455 1.28 . . . . 0.0 114.455 -176.831 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 69.5 mmm . . . . . 0 CA--C 1.534 0.358 0 N-CA-C 105.749 -1.945 . . . . 0.0 105.749 173.583 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 2.5 pp . . . . . 0 N--CA 1.451 -0.415 0 CA-C-O 121.198 0.523 . . . . 0.0 111.279 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 37.4 mt -102.51 134.13 46.35 Favored 'General case' 0 N--CA 1.446 -0.662 0 C-N-CA 128.049 2.54 . . . . 0.0 104.598 177.53 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 30.0 t30 -138.77 -46.12 0.49 Allowed 'General case' 0 C--O 1.227 -0.111 0 C-N-CA 122.812 0.445 . . . . 0.0 111.833 -178.029 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -69.95 131.18 89.29 Favored Pre-proline 0 C--O 1.237 0.424 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 -178.575 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -48.56 130.22 21.56 Favored 'Trans proline' 0 N--CA 1.454 -0.823 0 C-N-CA 123.047 2.498 . . . . 0.0 111.538 -179.392 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 99.31 -23.3 36.83 Favored Glycine 0 CA--C 1.525 0.693 0 CA-C-O 117.662 -1.632 . . . . 0.0 114.462 177.627 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 52.4 mt-10 -50.86 125.41 13.36 Favored 'General case' 0 CA--C 1.536 0.438 0 CA-C-N 120.116 1.958 . . . . 0.0 110.849 179.719 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 2.3 p -104.27 140.73 37.44 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 125.514 1.526 . . . . 0.0 112.184 -178.163 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 20.8 t80 -117.79 115.22 24.57 Favored 'General case' 0 C--O 1.232 0.176 0 N-CA-C 104.789 -2.3 . . . . 0.0 104.789 172.259 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.4 t -103.56 139.41 24.57 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.388 0 C-N-CA 123.183 0.593 . . . . 0.0 109.526 -178.497 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.5 p -143.48 156.11 16.61 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 N-CA-C 106.6 -1.63 . . . . 0.0 106.6 176.854 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 12.5 m -132.29 123.66 27.33 Favored 'General case' 0 C--N 1.333 -0.139 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 -179.286 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 68.1 mt -111.56 102.09 10.45 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 123.254 0.622 . . . . 0.0 109.698 -177.531 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -82.46 -42.73 18.14 Favored 'General case' 0 CA--C 1.529 0.165 0 C-N-CA 124.069 0.947 . . . . 0.0 110.676 178.929 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 4.4 m -73.21 112.42 9.25 Favored 'General case' 0 N--CA 1.45 -0.458 0 C-N-CA 123.083 0.553 . . . . 0.0 109.87 -177.745 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 25.8 pttm -60.21 152.17 25.35 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 123.077 0.551 . . . . 0.0 111.299 178.867 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 150.96 -167.94 30.61 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.106 -1.198 . . . . 0.0 110.106 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 23.3 m -113.97 124.71 52.82 Favored 'General case' 0 N--CA 1.454 -0.271 0 N-CA-C 106.435 -1.691 . . . . 0.0 106.435 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -121.01 114.9 22.18 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 124.059 0.944 . . . . 0.0 110.045 -178.164 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 48.7 m -90.51 139.62 30.52 Favored 'General case' 0 C--O 1.233 0.197 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 175.788 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 22.5 p90 -136.41 165.44 25.81 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-O 121.419 0.628 . . . . 0.0 112.071 -179.312 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 49.4 p90 -153.33 161.12 42.69 Favored 'General case' 0 N--CA 1.453 -0.323 0 C-N-CA 124.277 1.031 . . . . 0.0 112.179 -178.498 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 3.7 t -103.1 102.62 12.64 Favored 'General case' 0 CA--C 1.519 -0.239 0 N-CA-C 106.254 -1.758 . . . . 0.0 106.254 176.638 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.263 0.7 OUTLIER -44.67 -56.36 8.67 Favored Pre-proline 0 CA--C 1.535 0.402 0 N-CA-C 113.985 1.106 . . . . 0.0 113.985 -175.131 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_exo -50.93 -18.16 4.07 Favored 'Trans proline' 0 CA--C 1.534 0.514 0 C-N-CA 123.187 2.591 . . . . 0.0 115.042 177.772 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 38.2 m80 -133.85 25.73 3.98 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 123.783 0.833 . . . . 0.0 110.862 -179.599 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 65.7 tt0 -61.61 -50.27 73.27 Favored 'General case' 0 N--CA 1.457 -0.093 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 179.214 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.56 -33.3 62.27 Favored Glycine 0 CA--C 1.532 1.098 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 177.984 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -79.92 2.17 24.44 Favored 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 123.403 0.681 . . . . 0.0 112.037 179.082 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 79.9 21.84 64.99 Favored Glycine 0 CA--C 1.527 0.832 0 CA-C-O 118.978 -0.901 . . . . 0.0 113.706 178.42 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 22.1 ttt -78.65 80.78 5.0 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 119.321 1.56 . . . . 0.0 107.928 177.874 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 12.6 m -124.2 170.3 14.54 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.188 0 C-N-CA 125.975 1.71 . . . . 0.0 111.07 -179.765 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -170.02 178.56 42.8 Favored Glycine 0 CA--C 1.527 0.84 0 N-CA-C 108.848 -1.701 . . . . 0.0 108.848 177.611 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 33.8 mtmm -148.42 149.75 32.28 Favored 'General case' 0 N--CA 1.455 -0.199 0 CA-C-N 118.091 0.946 . . . . 0.0 110.463 -178.926 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.2 p -135.26 132.17 52.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 C-N-CA 123.121 0.569 . . . . 0.0 109.813 178.132 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.2 m -98.87 103.49 15.45 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 125.05 1.34 . . . . 0.0 107.848 179.341 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 47.0 t -82.59 102.24 8.31 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.753 0 N-CA-C 105.026 -2.213 . . . . 0.0 105.026 -179.189 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 45.5 p-10 . . . . . 0 C--N 1.332 -0.167 0 C-N-CA 124.984 1.314 . . . . 0.0 109.599 -178.059 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 . . . . . 0 N--CA 1.45 -0.466 0 N-CA-C 106.869 -1.53 . . . . 0.0 106.869 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 60.2 t -129.34 126.59 63.98 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 39.7 mt -87.98 122.53 31.7 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 178.763 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 88.9 mt -81.11 100.01 8.81 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 106.248 -1.76 . . . . 0.0 106.248 177.35 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 95.84 137.96 9.5 Favored Glycine 0 C--N 1.336 0.532 0 N-CA-C 107.402 -2.279 . . . . 0.0 107.402 -177.886 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 80.8 p -78.97 157.97 28.06 Favored 'General case' 0 N--CA 1.438 -1.037 0 CA-C-O 121.985 0.898 . . . . 0.0 109.21 -179.212 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.4 -34.55 59.69 Favored Glycine 0 CA--C 1.531 1.04 0 CA-C-N 114.608 -1.178 . . . . 0.0 111.085 178.162 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -76.03 -3.77 37.65 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 123.573 0.749 . . . . 0.0 112.256 179.074 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 99.76 -21.14 46.39 Favored Glycine 0 CA--C 1.528 0.847 0 CA-C-O 119.007 -0.885 . . . . 0.0 113.451 178.849 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 33.4 t -56.81 131.99 51.0 Favored 'General case' 0 C--O 1.237 0.442 0 CA-C-N 119.249 1.524 . . . . 0.0 110.426 -179.641 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 56.4 mt -74.06 68.3 1.38 Allowed 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 126.489 1.916 . . . . 0.0 111.114 -176.937 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.5 m -134.38 152.94 34.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 C-N-CA 123.739 0.816 . . . . 0.0 109.533 178.534 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 -82.45 135.95 35.02 Favored 'General case' 0 N--CA 1.454 -0.245 0 N-CA-C 105.529 -2.026 . . . . 0.0 105.529 176.625 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 48.0 t -123.92 110.46 29.44 Favored Pre-proline 0 CA--C 1.535 0.397 0 CA-C-O 118.158 -0.925 . . . . 0.0 108.79 179.296 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -70.43 152.28 93.89 Favored 'Cis proline' 0 N--CA 1.459 -0.524 0 CA-C-N 120.361 1.164 . . . . 0.0 111.543 -0.79 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.4 m -82.3 -44.09 16.67 Favored 'General case' 0 CA--C 1.529 0.145 0 C-N-CA 123.784 0.833 . . . . 0.0 111.019 179.721 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 37.8 tt0 -129.68 133.98 47.4 Favored 'General case' 0 N--CA 1.452 -0.33 0 N-CA-C 106.354 -1.721 . . . . 0.0 106.354 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 30.2 p90 -163.23 -179.26 6.49 Favored 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 122.944 0.498 . . . . 0.0 110.251 -179.177 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 17.7 m -128.69 148.43 50.83 Favored 'General case' 0 N--CA 1.455 -0.191 0 N-CA-C 106.932 -1.507 . . . . 0.0 106.932 177.928 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.8 p -141.61 127.73 11.13 Favored Pre-proline 0 CA--C 1.538 0.496 0 C-N-CA 123.16 0.584 . . . . 0.0 111.35 -177.211 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -55.57 132.21 50.79 Favored 'Trans proline' 0 N--CA 1.452 -0.921 0 C-N-CA 122.327 2.018 . . . . 0.0 110.55 175.336 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 38.2 m -47.73 127.19 11.34 Favored 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 123.118 0.567 . . . . 0.0 110.042 178.896 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 99.03 -25.98 26.1 Favored Glycine 0 CA--C 1.531 1.054 0 CA-C-O 118.809 -0.995 . . . . 0.0 113.011 -179.591 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 75.4 mt-10 -74.73 100.91 4.13 Favored 'General case' 0 N--CA 1.454 -0.253 0 CA-C-N 119.742 1.771 . . . . 0.0 108.586 178.95 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 21.5 pttp -51.66 139.56 20.64 Favored 'General case' 0 N--CA 1.45 -0.44 0 C-N-CA 124.795 1.238 . . . . 0.0 113.926 -178.886 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 38.1 mt -93.54 133.39 34.82 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.405 0 N-CA-C 105.199 -2.149 . . . . 0.0 105.199 176.784 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 60.7 t -119.21 94.76 3.22 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.202 0 C-N-CA 124.453 1.101 . . . . 0.0 108.49 -178.159 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -83.27 98.94 9.68 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 122.857 0.463 . . . . 0.0 109.948 -179.384 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 24.3 ttmm -88.35 128.47 35.5 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 125.055 1.342 . . . . 0.0 112.114 -177.653 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 4.8 t30 -67.01 93.82 0.3 Allowed 'General case' 0 CA--C 1.534 0.363 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 177.019 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 42.5 t30 -85.39 -75.77 0.35 Allowed 'General case' 0 C--O 1.228 -0.074 0 N-CA-C 113.162 0.801 . . . . 0.0 113.162 -175.871 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -143.98 163.67 32.82 Favored 'General case' 0 C--O 1.224 -0.277 0 C-N-CA 123.67 0.788 . . . . 0.0 109.79 -176.456 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 63.65 19.59 62.91 Favored Glycine 0 CA--C 1.535 1.297 0 O-C-N 121.906 -0.496 . . . . 0.0 112.697 -179.591 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.468 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 16.2 p90 -72.24 166.53 40.53 Favored Pre-proline 0 CA--C 1.546 0.799 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 177.483 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.468 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 95.4 Cg_endo -68.31 158.06 86.79 Favored 'Cis proline' 0 N--CA 1.447 -1.222 0 N-CA-C 115.754 1.405 . . . . 0.0 115.754 4.246 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 88.9 m-70 -150.74 171.32 17.37 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 114.643 -1.162 . . . . 0.0 109.459 -179.422 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 34.9 p-10 -159.61 173.2 16.46 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 104.663 -2.347 . . . . 0.0 104.663 175.423 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 36.8 t -129.19 111.55 23.03 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.245 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 -178.979 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.9 t -113.36 131.46 65.03 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.579 0 N-CA-C 106.547 -1.649 . . . . 0.0 106.547 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.41 ' CG ' HD12 ' A' ' 55' ' ' ILE . 67.8 m-85 -97.01 131.56 43.7 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 179.243 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -71.76 109.17 5.47 Favored 'General case' 0 N--CA 1.454 -0.26 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 -179.677 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -46.27 -31.97 2.82 Favored 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 115.279 1.585 . . . . 0.0 115.279 -178.979 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 20.0 m-20 -84.31 -17.96 37.85 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-N 118.518 0.599 . . . . 0.0 111.839 -179.356 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -118.91 59.36 0.83 Allowed 'General case' 0 CA--C 1.532 0.259 0 C-N-CA 124.657 1.183 . . . . 0.0 111.087 -177.078 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 25.0 pt -152.68 151.4 26.71 Favored Pre-proline 0 CA--C 1.531 0.24 0 C-N-CA 126.165 1.786 . . . . 0.0 106.224 176.746 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_endo -57.7 118.2 5.03 Favored 'Trans proline' 0 N--CA 1.453 -0.873 0 C-N-CA 122.316 2.01 . . . . 0.0 111.125 179.43 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -47.85 117.72 2.0 Allowed 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 124.996 1.318 . . . . 0.0 110.695 -179.611 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 128.54 -35.98 2.55 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 -178.504 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 34.7 t -77.4 109.27 11.77 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 46.2 t0 -64.29 112.09 2.91 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 122.676 0.39 . . . . 0.0 110.512 179.634 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.1 -40.05 14.54 Favored 'General case' 0 CA--C 1.528 0.106 0 C-N-CA 125.057 1.343 . . . . 0.0 111.626 178.644 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 55.4 t -61.3 -31.13 49.43 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.349 0 C-N-CA 123.348 0.659 . . . . 0.0 111.641 -179.027 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -78.62 -40.72 33.56 Favored 'General case' 0 C--O 1.227 -0.113 0 CA-C-N 118.515 0.598 . . . . 0.0 110.469 -178.7 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.41 HD12 ' CG ' ' A' ' 41' ' ' PHE . 35.4 pt -78.02 -33.74 18.55 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.252 0 N-CA-C 112.566 0.58 . . . . 0.0 112.566 -178.804 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 50.7 m -78.17 139.92 38.98 Favored 'General case' 0 N--CA 1.455 -0.201 0 N-CA-C 112.774 0.657 . . . . 0.0 112.774 -177.94 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.2 tmt? . . . . . 0 CA--C 1.538 0.513 0 N-CA-C 105.559 -2.015 . . . . 0.0 105.559 176.017 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 96.1 mt . . . . . 0 N--CA 1.454 -0.253 0 N-CA-C 106.588 -1.634 . . . . 0.0 106.588 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 74.8 mt -78.59 102.05 7.75 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 106.114 -1.81 . . . . 0.0 106.114 177.373 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 31.8 p-10 -83.26 -55.46 4.32 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 124.291 1.037 . . . . 0.0 112.311 -177.905 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.94 149.57 77.1 Favored Pre-proline 0 CA--C 1.533 0.289 0 C-N-CA 123.203 0.601 . . . . 0.0 111.185 -177.59 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -66.87 164.02 31.25 Favored 'Trans proline' 0 N--CA 1.454 -0.799 0 C-N-CA 122.406 2.071 . . . . 0.0 109.804 177.513 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 79.42 -38.77 2.08 Favored Glycine 0 CA--C 1.528 0.862 0 CA-C-O 118.55 -1.139 . . . . 0.0 113.947 176.295 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -39.86 123.91 1.67 Allowed 'General case' 0 CA--C 1.536 0.437 0 CA-C-N 118.495 1.147 . . . . 0.0 111.696 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 18.0 p -105.03 121.04 42.95 Favored 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 124.662 1.185 . . . . 0.0 112.647 -177.701 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 62.3 t80 -95.13 111.4 23.24 Favored 'General case' 0 N--CA 1.454 -0.239 0 N-CA-C 105.367 -2.086 . . . . 0.0 105.367 174.081 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -100.11 139.92 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 C-N-CA 123.219 0.608 . . . . 0.0 110.54 -177.448 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 11.6 p -146.67 139.28 19.64 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.174 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 176.626 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 14.2 m -126.61 99.01 5.62 Favored 'General case' 0 C--N 1.34 0.187 0 C-N-CA 122.918 0.487 . . . . 0.0 112.286 -176.067 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.423 ' H ' HD22 ' A' ' 74' ' ' LEU . 1.6 mm? -87.05 130.54 34.44 Favored 'General case' 0 N--CA 1.439 -0.984 0 C-N-CA 123.057 0.543 . . . . 0.0 111.666 178.329 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -100.9 -45.1 5.54 Favored 'General case' 0 N--CA 1.454 -0.227 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 174.549 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 4.6 m -65.52 115.64 5.96 Favored 'General case' 0 N--CA 1.446 -0.652 0 C-N-CA 124.808 1.243 . . . . 0.0 110.192 -178.231 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 25.9 pttm -63.93 153.59 36.53 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-N 115.159 -0.928 . . . . 0.0 110.896 178.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 147.08 -177.51 25.33 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.401 -1.08 . . . . 0.0 110.401 178.392 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 28.7 m -106.49 121.94 45.29 Favored 'General case' 0 N--CA 1.452 -0.327 0 N-CA-C 106.941 -1.503 . . . . 0.0 106.941 -179.024 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 16.4 m-85 -115.07 122.44 46.16 Favored 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 124.594 1.158 . . . . 0.0 109.735 -178.358 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 41.4 m -98.3 132.86 43.44 Favored 'General case' 0 C--O 1.234 0.248 0 N-CA-C 107.635 -1.246 . . . . 0.0 107.635 175.366 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 21.0 p90 -132.62 165.68 23.88 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-O 121.638 0.732 . . . . 0.0 111.842 -179.438 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 52.4 p90 -156.56 161.92 39.94 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 115.226 -0.897 . . . . 0.0 112.561 -178.601 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.7 t -103.36 99.97 9.83 Favored 'General case' 0 CA--C 1.516 -0.333 0 N-CA-C 106.454 -1.684 . . . . 0.0 106.454 177.177 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.281 13.1 p -35.84 -64.31 0.35 Allowed Pre-proline 0 CA--C 1.541 0.63 0 N-CA-C 115.861 1.8 . . . . 0.0 115.861 -175.654 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -60.68 -7.25 6.99 Favored 'Trans proline' 0 C--N 1.348 0.506 0 C-N-CA 122.663 2.242 . . . . 0.0 115.221 -177.82 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 36.2 m80 -132.09 15.83 4.65 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 119.674 1.125 . . . . 0.0 110.814 178.22 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 65.6 tt0 -59.5 -46.57 88.45 Favored 'General case' 0 CA--C 1.529 0.163 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 178.943 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -57.07 -30.45 60.63 Favored Glycine 0 CA--C 1.531 1.082 0 C-N-CA 123.588 0.613 . . . . 0.0 111.579 177.613 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -86.08 8.15 21.91 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 123.599 0.759 . . . . 0.0 111.347 178.933 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 81.67 16.33 73.44 Favored Glycine 0 CA--C 1.527 0.839 0 CA-C-O 118.762 -1.021 . . . . 0.0 113.371 178.722 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 20.0 ttt -78.25 77.12 4.75 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 119.525 1.663 . . . . 0.0 108.925 178.754 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.7 m -125.8 170.81 15.33 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.314 0 C-N-CA 125.901 1.68 . . . . 0.0 110.052 179.43 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -170.07 177.27 43.5 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 109.262 -1.535 . . . . 0.0 109.262 177.804 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 59.4 mttp -145.98 157.53 43.88 Favored 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 123.401 0.68 . . . . 0.0 109.677 -178.879 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.2 p -147.25 130.6 8.77 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 C-N-CA 122.689 0.396 . . . . 0.0 110.417 178.007 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 99.1 m -98.49 102.65 14.46 Favored 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 124.171 0.988 . . . . 0.0 108.85 178.579 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 48.8 t -83.2 132.29 31.75 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.444 0 N-CA-C 105.797 -1.927 . . . . 0.0 105.797 178.686 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.334 -0.106 0 CA-C-N 118.395 0.543 . . . . 0.0 111.416 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 . . . . . 0 N--CA 1.452 -0.326 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 28.1 t -110.88 112.25 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.238 0 C-N-CA 123.695 0.798 . . . . 0.0 110.305 -177.505 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 53.6 mt -80.29 123.78 28.27 Favored 'General case' 0 N--CA 1.451 -0.403 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 178.427 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 64.9 mt -87.08 110.73 20.3 Favored 'General case' 0 N--CA 1.447 -0.575 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 178.566 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 84.61 126.37 1.45 Allowed Glycine 0 C--N 1.337 0.594 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.709 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 6.1 p -77.64 161.43 27.81 Favored 'General case' 0 N--CA 1.442 -0.827 0 O-C-N 121.48 -1.012 . . . . 0.0 108.689 -179.099 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -44.32 -38.66 5.18 Favored Glycine 0 CA--C 1.531 1.085 0 C-N-CA 125.777 1.656 . . . . 0.0 113.822 -178.924 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -76.31 4.08 9.6 Favored 'General case' 0 CA--C 1.537 0.48 0 N-CA-C 113.267 0.84 . . . . 0.0 113.267 -179.647 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 86.73 -6.16 83.33 Favored Glycine 0 CA--C 1.529 0.965 0 CA-C-O 118.92 -0.933 . . . . 0.0 113.105 -179.626 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 20.7 t -61.67 135.81 57.76 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-N 119.233 1.517 . . . . 0.0 110.457 -179.108 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 58.1 mt -75.94 65.93 2.09 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 126.064 1.746 . . . . 0.0 111.465 -176.556 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 28.7 m -130.94 152.5 37.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 C-N-CA 123.772 0.829 . . . . 0.0 110.436 179.547 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 73.3 m-85 -89.34 138.07 31.77 Favored 'General case' 0 N--CA 1.455 -0.222 0 N-CA-C 104.973 -2.232 . . . . 0.0 104.973 176.102 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 52.5 t -125.65 105.64 26.91 Favored Pre-proline 0 CA--C 1.537 0.457 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 179.009 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -68.23 158.44 86.05 Favored 'Cis proline' 0 C--N 1.347 0.466 0 CA-C-N 120.031 1.047 . . . . 0.0 111.799 -1.023 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.7 p -84.77 -63.65 1.3 Allowed 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 125.039 1.336 . . . . 0.0 108.907 179.672 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -117.8 135.66 53.92 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 125.102 1.361 . . . . 0.0 107.435 178.541 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 43.4 p90 -158.59 175.34 13.78 Favored 'General case' 0 C--N 1.333 -0.127 0 CA-C-O 121.22 0.533 . . . . 0.0 111.724 -178.455 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 24.0 p -128.33 147.18 50.61 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 107.19 -1.411 . . . . 0.0 107.19 178.358 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.0 p -149.93 140.46 14.06 Favored Pre-proline 0 CA--C 1.537 0.456 0 CA-C-N 118.843 0.747 . . . . 0.0 110.662 -178.08 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -52.87 138.79 60.76 Favored 'Trans proline' 0 CA--C 1.538 0.706 0 C-N-CA 122.609 2.206 . . . . 0.0 112.44 176.378 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 23.5 m -57.96 131.85 51.66 Favored 'General case' 0 CA--C 1.53 0.191 0 C-N-CA 122.875 0.47 . . . . 0.0 111.125 179.601 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 101.52 -18.1 54.0 Favored Glycine 0 CA--C 1.526 0.774 0 CA-C-O 119.156 -0.802 . . . . 0.0 112.92 179.57 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 81.5 mm-40 -68.7 156.5 38.12 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-N 119.075 1.438 . . . . 0.0 112.823 -179.198 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 24.0 ttmm -91.49 142.05 28.08 Favored 'General case' 0 N--CA 1.452 -0.372 0 C-N-CA 125.965 1.706 . . . . 0.0 110.14 -179.786 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 40.6 mt -120.88 134.42 64.35 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.343 0 N-CA-C 105.929 -1.878 . . . . 0.0 105.929 178.307 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 97.6 t -124.15 101.53 9.25 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 C-N-CA 125.236 1.414 . . . . 0.0 108.571 -177.908 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -86.25 136.19 33.26 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 106.115 -1.809 . . . . 0.0 106.115 176.945 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 12.1 tmtt? -135.27 132.46 37.81 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 118.986 0.812 . . . . 0.0 112.4 -177.369 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 6.2 m-20 -66.47 101.4 0.76 Allowed 'General case' 0 C--N 1.341 0.203 0 C-N-CA 123.69 0.796 . . . . 0.0 108.886 177.77 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 38.7 t30 -92.38 -61.84 1.53 Allowed 'General case' 0 N--CA 1.455 -0.224 0 CA-C-O 121.34 0.59 . . . . 0.0 109.951 -179.663 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -150.77 -179.47 7.29 Favored 'General case' 0 C--O 1.223 -0.299 0 C-N-CA 124.065 0.946 . . . . 0.0 108.898 -179.029 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 52.72 17.12 4.41 Favored Glycine 0 CA--C 1.538 1.503 0 N-CA-C 115.534 0.973 . . . . 0.0 115.534 178.574 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.449 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 14.5 p90 -73.85 167.62 33.61 Favored Pre-proline 0 CA--C 1.539 0.531 0 N-CA-C 106.921 -1.511 . . . . 0.0 106.921 178.535 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.449 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 33.0 Cg_exo -63.4 157.87 67.55 Favored 'Cis proline' 0 N--CA 1.454 -0.82 0 N-CA-C 117.407 2.041 . . . . 0.0 117.407 2.638 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 90.8 m-70 -152.47 169.0 23.67 Favored 'General case' 0 N--CA 1.453 -0.3 0 O-C-N 121.598 -0.689 . . . . 0.0 111.638 179.843 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 51.4 p30 -162.15 178.64 8.59 Favored 'General case' 0 N--CA 1.452 -0.332 0 N-CA-C 104.606 -2.368 . . . . 0.0 104.606 174.707 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 34.8 t -135.46 123.4 37.7 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 71.1 t -123.07 139.27 50.35 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.58 0 N-CA-C 105.558 -2.016 . . . . 0.0 105.558 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.406 ' CG ' HD12 ' A' ' 55' ' ' ILE . 80.5 m-85 -103.99 135.37 45.63 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 108.165 -1.05 . . . . 0.0 108.165 -179.918 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -66.44 122.08 16.73 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 -179.482 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -74.43 50.2 0.4 Allowed 'General case' 0 CA--C 1.538 0.511 0 N-CA-C 113.956 1.095 . . . . 0.0 113.956 -178.509 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -161.7 -64.79 0.05 Allowed 'General case' 0 N--CA 1.456 -0.129 0 C-N-CA 125.19 1.396 . . . . 0.0 108.987 177.3 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -83.0 63.81 7.28 Favored 'General case' 0 CA--C 1.538 0.496 0 CA-C-O 122.069 0.938 . . . . 0.0 110.274 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 26.8 pt -145.3 153.63 52.54 Favored Pre-proline 0 CA--C 1.536 0.408 0 C-N-CA 129.763 3.225 . . . . 0.0 105.523 177.019 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo -57.92 114.81 2.12 Favored 'Trans proline' 0 N--CA 1.455 -0.79 0 C-N-CA 121.628 1.552 . . . . 0.0 111.699 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -48.11 112.07 0.53 Allowed 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 125.384 1.474 . . . . 0.0 110.735 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 131.12 -34.08 2.69 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 109.721 -1.351 . . . . 0.0 109.721 -178.822 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 42.8 t -77.32 111.48 14.17 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.23 0 CA-C-N 117.565 0.683 . . . . 0.0 109.214 -179.863 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 40.7 t0 -64.23 109.86 2.01 Favored 'General case' 0 CA--C 1.532 0.277 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 178.734 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.51 -38.79 14.68 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 125.131 1.372 . . . . 0.0 111.97 179.508 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 60.0 t -60.63 -28.9 43.73 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.311 0 C-N-CA 123.331 0.653 . . . . 0.0 111.789 -179.109 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 47.1 mmtm -75.84 -40.99 53.73 Favored 'General case' 0 CA--C 1.53 0.197 0 CA-C-N 118.571 0.623 . . . . 0.0 110.688 -178.408 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.406 HD12 ' CG ' ' A' ' 41' ' ' PHE . 21.5 pt -80.68 -38.75 17.67 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.289 0 N-CA-C 112.576 0.584 . . . . 0.0 112.576 -179.463 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 31.5 m -76.9 135.5 38.81 Favored 'General case' 0 N--CA 1.454 -0.252 0 N-CA-C 114.0 1.111 . . . . 0.0 114.0 -176.085 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 84.7 mtp . . . . . 0 N--CA 1.449 -0.524 0 N-CA-C 104.721 -2.326 . . . . 0.0 104.721 173.218 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.444 -0.725 0 CA-C-O 121.463 0.649 . . . . 0.0 110.934 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 47.3 mt -80.69 106.12 12.45 Favored 'General case' 0 N--CA 1.441 -0.885 0 N-CA-C 103.561 -2.755 . . . . 0.0 103.561 177.671 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 29.0 p-10 -89.19 -38.19 14.46 Favored 'General case' 0 C--N 1.332 -0.16 0 C-N-CA 124.803 1.241 . . . . 0.0 113.153 -176.732 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.68 155.89 45.38 Favored Pre-proline 0 CA--C 1.534 0.344 0 C-N-CA 123.895 0.878 . . . . 0.0 110.882 -178.054 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -66.11 164.68 26.78 Favored 'Trans proline' 0 N--CA 1.456 -0.702 0 C-N-CA 122.419 2.079 . . . . 0.0 109.753 176.629 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 79.73 -44.03 2.69 Favored Glycine 0 CA--C 1.528 0.86 0 CA-C-O 118.78 -1.011 . . . . 0.0 113.59 176.921 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 53.7 mt-10 -41.19 134.03 2.2 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 124.959 1.304 . . . . 0.0 111.686 -179.399 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 69.0 p -114.18 167.71 10.45 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 123.826 0.85 . . . . 0.0 113.268 -177.147 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 3.7 t80 -140.65 114.41 8.9 Favored 'General case' 0 N--CA 1.455 -0.213 0 N-CA-C 103.849 -2.649 . . . . 0.0 103.849 174.717 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 41.3 t -106.82 144.78 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.296 0 C-N-CA 123.703 0.801 . . . . 0.0 109.638 -177.4 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 13.7 p -152.02 167.25 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.204 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 177.912 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 57.2 m -145.88 122.72 11.28 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 105.765 -1.939 . . . . 0.0 105.765 179.49 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 66.3 mt -107.08 99.56 9.1 Favored 'General case' 0 N--CA 1.455 -0.192 0 CA-C-O 121.303 0.573 . . . . 0.0 111.389 -175.168 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -77.14 -47.14 21.2 Favored 'General case' 0 N--CA 1.455 -0.217 0 C-N-CA 123.835 0.854 . . . . 0.0 110.539 178.143 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.7 m -72.48 122.82 21.93 Favored 'General case' 0 N--CA 1.451 -0.382 0 C-N-CA 123.012 0.525 . . . . 0.0 110.599 -177.664 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 50.6 tttm -67.02 155.18 39.32 Favored 'General case' 0 N--CA 1.436 -1.168 0 C-N-CA 126.906 2.082 . . . . 0.0 110.316 179.177 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 132.8 178.24 15.42 Favored Glycine 0 CA--C 1.526 0.761 0 C-N-CA 124.798 1.19 . . . . 0.0 111.378 178.962 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 74.7 m -102.13 119.83 39.44 Favored 'General case' 0 CA--C 1.52 -0.201 0 C-N-CA 124.119 0.968 . . . . 0.0 108.756 -179.283 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 37.2 m-85 -105.92 112.65 25.79 Favored 'General case' 0 N--CA 1.445 -0.681 0 C-N-CA 125.794 1.638 . . . . 0.0 109.833 -179.035 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 4.1 m -85.87 128.7 34.88 Favored 'General case' 0 C--O 1.234 0.28 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 177.368 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 35.4 p90 -132.19 167.65 19.42 Favored 'General case' 0 N--CA 1.457 -0.1 0 CA-C-O 121.822 0.82 . . . . 0.0 112.562 -179.142 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 50.5 p90 -159.96 162.48 34.41 Favored 'General case' 0 N--CA 1.452 -0.372 0 CA-C-N 114.977 -1.01 . . . . 0.0 111.569 -179.37 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.2 t -99.6 102.9 14.55 Favored 'General case' 0 CA--C 1.518 -0.279 0 N-CA-C 106.575 -1.639 . . . . 0.0 106.575 177.52 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.312 16.9 p -40.44 -61.2 1.25 Allowed Pre-proline 0 CA--C 1.538 0.518 0 N-CA-C 115.795 1.776 . . . . 0.0 115.795 -174.489 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -60.12 -6.09 4.66 Favored 'Trans proline' 0 CA--C 1.537 0.638 0 C-N-CA 122.208 1.939 . . . . 0.0 114.924 -178.751 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 35.8 m80 -134.43 14.24 3.78 Favored 'General case' 0 CA--C 1.532 0.254 0 CA-C-N 119.694 1.134 . . . . 0.0 111.355 178.671 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 16.6 pt20 -60.66 -42.83 97.82 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 119.147 0.885 . . . . 0.0 109.217 179.259 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -58.48 -31.39 66.61 Favored Glycine 0 CA--C 1.531 1.071 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 177.18 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -85.12 5.25 30.61 Favored 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 123.556 0.743 . . . . 0.0 111.333 178.91 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 83.89 17.24 65.89 Favored Glycine 0 CA--C 1.528 0.849 0 CA-C-O 118.795 -1.003 . . . . 0.0 113.591 178.726 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 21.8 ttt -78.72 77.16 5.21 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 119.593 1.696 . . . . 0.0 108.494 178.144 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 11.6 m -120.24 169.95 10.69 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 C-N-CA 125.984 1.714 . . . . 0.0 110.404 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -169.45 174.19 43.79 Favored Glycine 0 CA--C 1.527 0.83 0 N-CA-C 109.108 -1.597 . . . . 0.0 109.108 178.112 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 54.2 mttp -149.4 139.04 21.71 Favored 'General case' 0 C--O 1.231 0.083 0 CA-C-N 118.173 0.986 . . . . 0.0 109.756 -178.978 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 6.0 p -125.66 120.17 56.83 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.139 0 CA-C-O 120.921 0.391 . . . . 0.0 110.519 178.798 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 48.6 m -94.22 100.58 12.63 Favored 'General case' 0 N--CA 1.455 -0.203 0 C-N-CA 124.68 1.192 . . . . 0.0 109.342 178.949 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 44.7 t -79.69 107.09 11.73 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.012 0 N-CA-C 104.397 -2.445 . . . . 0.0 104.397 179.536 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 51.1 p-10 . . . . . 0 N--CA 1.456 -0.16 0 C-N-CA 125.157 1.383 . . . . 0.0 110.291 -177.034 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 . . . . . 0 N--CA 1.453 -0.294 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 47.1 t -112.24 111.0 34.28 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 105.855 -1.906 . . . . 0.0 105.855 178.517 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 31.7 mt -90.46 120.4 31.54 Favored 'General case' 0 N--CA 1.45 -0.462 0 O-C-N 121.822 -0.549 . . . . 0.0 109.706 -178.68 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.434 ' HB3' ' CD2' ' A' ' 37' ' ' HIS . 1.9 mm? -79.47 106.88 11.82 Favored 'General case' 0 N--CA 1.444 -0.738 0 N-CA-C 105.909 -1.886 . . . . 0.0 105.909 174.378 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 97.03 132.8 7.54 Favored Glycine 0 CA--C 1.523 0.586 0 C-N-CA 125.871 1.701 . . . . 0.0 112.329 178.666 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.6 p -82.78 47.87 1.26 Allowed 'General case' 0 N--CA 1.456 -0.135 0 C-N-CA 124.43 1.092 . . . . 0.0 111.197 179.325 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 70.74 -52.2 0.91 Allowed Glycine 0 CA--C 1.527 0.781 0 C-N-CA 126.598 2.047 . . . . 0.0 113.078 -179.668 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -72.1 38.07 0.07 Allowed 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 126.05 1.74 . . . . 0.0 113.851 -177.298 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 59.17 3.04 1.62 Allowed Glycine 0 CA--C 1.531 1.075 0 N-CA-C 115.911 1.124 . . . . 0.0 115.911 178.569 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 27.7 t -64.31 145.45 56.0 Favored 'General case' 0 N--CA 1.455 -0.181 0 CA-C-N 119.131 1.465 . . . . 0.0 110.87 -178.661 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 93.0 mt -86.43 73.26 10.16 Favored 'General case' 0 N--CA 1.447 -0.58 0 C-N-CA 124.044 0.938 . . . . 0.0 109.482 -178.83 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.9 m -137.01 143.97 33.4 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.217 0 C-N-CA 123.05 0.54 . . . . 0.0 111.204 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -90.27 122.84 33.55 Favored 'General case' 0 N--CA 1.46 0.051 0 N-CA-C 103.695 -2.706 . . . . 0.0 103.695 174.865 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.8 t -113.94 100.56 52.62 Favored Pre-proline 0 CA--C 1.536 0.422 0 CA-C-O 118.237 -0.887 . . . . 0.0 109.984 -179.271 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -81.01 164.24 78.26 Favored 'Cis proline' 0 N--CA 1.46 -0.463 0 CA-C-N 120.605 1.252 . . . . 0.0 111.257 -1.618 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 15.7 p -92.61 -62.86 1.31 Allowed 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 107.576 -1.268 . . . . 0.0 107.576 177.956 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 10.8 mp0 -98.21 126.85 43.85 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 125.835 1.654 . . . . 0.0 107.532 178.428 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.9 p90 -160.55 -175.57 5.08 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-O 121.541 0.686 . . . . 0.0 111.847 179.631 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 35.3 m -135.97 146.07 46.85 Favored 'General case' 0 N--CA 1.45 -0.426 0 N-CA-C 106.204 -1.776 . . . . 0.0 106.204 178.245 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 1.4 p -147.21 140.56 15.02 Favored Pre-proline 0 N--CA 1.449 -0.496 0 CA-C-O 118.367 -0.825 . . . . 0.0 109.631 -178.343 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_exo -60.71 144.13 99.5 Favored 'Trans proline' 0 N--CA 1.456 -0.689 0 C-N-CA 121.671 1.58 . . . . 0.0 112.678 179.411 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.2 m -56.35 128.0 33.7 Favored 'General case' 0 N--CA 1.454 -0.233 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 176.949 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.76 -3.57 78.1 Favored Glycine 0 CA--C 1.526 0.719 0 CA-C-O 119.012 -0.882 . . . . 0.0 112.198 179.35 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -70.64 149.3 47.17 Favored 'General case' 0 CA--C 1.534 0.361 0 CA-C-N 119.033 1.417 . . . . 0.0 109.124 178.025 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -90.44 105.09 17.58 Favored 'General case' 0 N--CA 1.447 -0.582 0 C-N-CA 124.868 1.267 . . . . 0.0 108.585 -178.563 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 34.6 mt -81.09 130.7 35.43 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.343 0 N-CA-C 105.381 -2.081 . . . . 0.0 105.381 177.364 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 67.9 t -117.69 97.58 5.58 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 C-N-CA 124.904 1.281 . . . . 0.0 108.665 -178.439 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -84.47 97.16 9.38 Favored 'General case' 0 N--CA 1.456 -0.158 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 178.011 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 28.4 ttpp -99.3 129.29 45.5 Favored 'General case' 0 CA--C 1.528 0.126 0 C-N-CA 123.746 0.818 . . . . 0.0 112.691 -176.444 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 5.2 m-20 -69.63 105.3 2.64 Favored 'General case' 0 N--CA 1.455 -0.2 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 177.456 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 51.5 t30 -89.17 -57.42 2.9 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 178.466 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -164.37 175.28 10.14 Favored 'General case' 0 CA--C 1.529 0.167 0 C-N-CA 124.095 0.958 . . . . 0.0 109.328 179.802 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 71.09 16.07 74.78 Favored Glycine 0 CA--C 1.531 1.084 0 O-C-N 121.753 -0.592 . . . . 0.0 113.095 179.19 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.508 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 21.5 p90 -67.77 166.4 23.24 Favored Pre-proline 0 CA--C 1.545 0.785 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 178.178 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.508 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 83.5 Cg_endo -69.7 151.4 91.26 Favored 'Cis proline' 0 N--CA 1.447 -1.23 0 N-CA-C 116.395 1.652 . . . . 0.0 116.395 5.161 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.434 ' CD2' ' HB3' ' A' ' 5' ' ' LEU . 88.8 m-70 -144.93 156.92 44.24 Favored 'General case' 0 N--CA 1.451 -0.387 0 O-C-N 121.695 -0.628 . . . . 0.0 111.093 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 56.6 p30 -158.18 175.52 13.66 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 103.966 -2.605 . . . . 0.0 103.966 175.287 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 42.0 t -137.98 121.08 20.12 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.36 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 -179.027 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 95.9 t -117.33 131.9 68.69 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.621 0 N-CA-C 105.83 -1.915 . . . . 0.0 105.83 178.949 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -96.91 131.2 43.92 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 107.24 -1.393 . . . . 0.0 107.24 179.425 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 35.6 t0 -67.21 108.74 2.81 Favored 'General case' 0 N--CA 1.451 -0.393 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 -179.131 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -47.82 -31.33 4.84 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.028 0.931 . . . . 0.0 113.45 178.865 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 34.4 t70 -75.74 -22.38 56.57 Favored 'General case' 0 CA--C 1.536 0.426 0 N-CA-C 112.741 0.645 . . . . 0.0 112.741 179.563 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -128.39 68.07 1.37 Allowed 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 124.453 1.101 . . . . 0.0 111.791 -177.042 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 31.8 pt -153.67 157.34 32.66 Favored Pre-proline 0 CA--C 1.535 0.371 0 C-N-CA 127.884 2.474 . . . . 0.0 105.79 175.825 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_exo -56.33 115.62 2.6 Favored 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.559 2.173 . . . . 0.0 111.07 178.391 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.34 107.33 0.27 Allowed 'General case' 0 N--CA 1.455 -0.178 0 C-N-CA 123.608 0.763 . . . . 0.0 109.676 179.569 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 137.79 -32.29 2.39 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 -177.805 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 57.3 t -76.84 107.37 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.262 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 179.354 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 45.0 t0 -57.99 108.15 0.56 Allowed 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 123.252 0.621 . . . . 0.0 110.777 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.63 -38.6 32.77 Favored 'General case' 0 C--O 1.223 -0.295 0 C-N-CA 123.73 0.812 . . . . 0.0 111.228 178.883 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 46.7 t -58.67 -27.22 33.76 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 CA-C-N 118.071 0.396 . . . . 0.0 111.863 -179.44 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 44.0 mmtm -82.55 -41.93 18.98 Favored 'General case' 0 CA--C 1.529 0.172 0 CA-C-N 118.611 0.641 . . . . 0.0 110.839 -179.392 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 24.6 pt -78.03 -46.9 25.83 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.29 0 N-CA-C 112.005 0.372 . . . . 0.0 112.005 -179.29 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 60.7 m -73.22 128.41 35.4 Favored 'General case' 0 N--CA 1.451 -0.422 0 C-N-CA 124.224 1.01 . . . . 0.0 113.01 -176.018 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 88.4 mmm . . . . . 0 N--CA 1.451 -0.422 0 N-CA-C 105.401 -2.074 . . . . 0.0 105.401 174.661 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.448 -0.555 0 CA-C-O 121.713 0.768 . . . . 0.0 112.292 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 63.0 mt -79.02 106.03 10.77 Favored 'General case' 0 N--CA 1.444 -0.749 0 N-CA-C 104.862 -2.273 . . . . 0.0 104.862 178.151 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 65.6 t30 -112.29 42.14 1.86 Allowed 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 124.259 1.024 . . . . 0.0 112.747 -177.732 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -158.0 158.26 29.97 Favored Pre-proline 0 C--O 1.233 0.186 0 N-CA-C 107.045 -1.465 . . . . 0.0 107.045 178.366 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 96.8 Cg_endo -73.92 167.78 26.39 Favored 'Trans proline' 0 N--CA 1.451 -0.999 0 C-N-CA 121.542 1.495 . . . . 0.0 109.313 178.242 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 78.63 -42.65 2.26 Favored Glycine 0 CA--C 1.527 0.84 0 CA-C-O 118.74 -1.033 . . . . 0.0 114.411 175.756 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 47.7 mt-10 -42.4 131.57 3.69 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 118.494 1.147 . . . . 0.0 112.442 -179.609 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 20.8 p -118.33 127.4 53.66 Favored 'General case' 0 N--CA 1.457 -0.122 0 N-CA-C 113.675 0.991 . . . . 0.0 113.675 -178.554 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 2.4 t80 -100.15 107.16 18.97 Favored 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 103.682 -2.71 . . . . 0.0 103.682 172.367 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 38.8 t -100.08 140.11 19.99 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.162 0 C-N-CA 123.415 0.686 . . . . 0.0 109.674 -178.026 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.2 p -150.31 135.03 9.69 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.254 0 C-N-CA 122.766 0.426 . . . . 0.0 110.319 177.847 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 19.7 m -103.57 100.4 10.24 Favored 'General case' 0 CA--C 1.53 0.207 0 C-N-CA 124.59 1.156 . . . . 0.0 109.0 -179.595 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 59.5 mt -90.19 99.73 12.69 Favored 'General case' 0 CA--C 1.53 0.192 0 CA-C-O 121.074 0.464 . . . . 0.0 109.82 -179.555 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -79.13 -55.34 5.18 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 123.216 0.606 . . . . 0.0 111.27 178.863 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.5 m -64.58 119.48 10.56 Favored 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 123.386 0.674 . . . . 0.0 110.388 -176.119 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.86 161.5 20.98 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 123.449 0.7 . . . . 0.0 112.373 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 133.87 178.77 15.83 Favored Glycine 0 CA--C 1.525 0.718 0 C-N-CA 125.565 1.555 . . . . 0.0 110.74 178.974 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 7.4 m -96.29 114.55 26.24 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 124.417 1.087 . . . . 0.0 109.336 -178.531 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 29.8 m-85 -105.09 111.05 23.67 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 124.684 1.193 . . . . 0.0 109.217 179.73 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 18.3 m -88.01 137.58 32.21 Favored 'General case' 0 C--O 1.232 0.172 0 N-CA-C 107.517 -1.29 . . . . 0.0 107.517 177.379 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 28.5 p90 -140.95 167.24 22.67 Favored 'General case' 0 C--N 1.339 0.124 0 CA-C-N 119.06 0.845 . . . . 0.0 113.266 -178.177 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 53.7 p90 -154.31 160.49 41.77 Favored 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 114.924 -1.034 . . . . 0.0 112.202 -179.658 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.6 t -104.24 99.31 9.03 Favored 'General case' 0 CA--C 1.519 -0.241 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 177.925 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -33.79 -62.99 0.33 Allowed Pre-proline 0 CA--C 1.537 0.45 0 N-CA-C 115.927 1.825 . . . . 0.0 115.927 -176.296 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -60.4 -7.04 6.19 Favored 'Trans proline' 0 C--N 1.348 0.546 0 C-N-CA 122.307 2.005 . . . . 0.0 114.92 -177.558 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 36.3 m80 -135.62 14.65 3.42 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 119.416 1.007 . . . . 0.0 111.124 178.505 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 14.6 pt20 -61.04 -41.24 96.2 Favored 'General case' 0 N--CA 1.454 -0.262 0 O-C-N 121.442 -0.786 . . . . 0.0 109.489 179.531 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -58.46 -29.45 63.59 Favored Glycine 0 CA--C 1.532 1.119 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 177.039 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.91 11.86 19.13 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 123.804 0.842 . . . . 0.0 110.864 178.798 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 74.47 21.87 78.18 Favored Glycine 0 CA--C 1.527 0.8 0 CA-C-O 119.112 -0.826 . . . . 0.0 113.171 178.877 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -78.86 80.55 5.2 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 119.255 1.528 . . . . 0.0 107.464 178.156 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 12.4 m -123.49 171.76 11.94 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 C-N-CA 125.579 1.552 . . . . 0.0 111.691 -178.851 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -167.12 178.79 41.15 Favored Glycine 0 CA--C 1.529 0.948 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 178.18 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 39.1 ttpt -158.48 130.57 6.82 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 -178.518 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.7 p -119.25 128.27 75.83 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 CA-C-O 121.391 0.615 . . . . 0.0 110.346 -178.995 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.4 m -94.37 98.78 11.13 Favored 'General case' 0 N--CA 1.452 -0.336 0 N-CA-C 107.514 -1.291 . . . . 0.0 107.514 179.151 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 45.2 t -80.31 114.28 20.97 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.587 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 -178.981 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 77.7 m-20 . . . . . 0 C--O 1.233 0.212 0 C-N-CA 123.664 0.785 . . . . 0.0 109.085 -178.112 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 36.4 mt-10 . . . . . 0 N--CA 1.451 -0.378 0 N-CA-C 105.612 -1.996 . . . . 0.0 105.612 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 28.3 t -87.22 119.29 34.69 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.454 0 CA-C-N 114.968 -1.015 . . . . 0.0 108.923 -176.757 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 58.1 mt -88.27 121.47 30.7 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 179.189 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.414 ' HB3' ' CD2' ' A' ' 37' ' ' HIS . 1.4 mm? -78.01 103.18 7.78 Favored 'General case' 0 N--CA 1.445 -0.685 0 N-CA-C 105.815 -1.92 . . . . 0.0 105.815 173.976 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 97.1 152.31 28.6 Favored Glycine 0 N--CA 1.446 -0.675 0 C-N-CA 123.91 0.766 . . . . 0.0 111.331 179.083 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 78.9 p -85.59 173.46 10.15 Favored 'General case' 0 N--CA 1.44 -0.938 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 177.783 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -52.51 -43.94 58.97 Favored Glycine 0 CA--C 1.531 1.07 0 N-CA-C 111.265 -0.734 . . . . 0.0 111.265 178.679 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -79.81 11.78 3.05 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 123.362 0.665 . . . . 0.0 112.316 178.76 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 69.44 27.46 73.51 Favored Glycine 0 CA--C 1.524 0.639 0 CA-C-O 119.07 -0.85 . . . . 0.0 114.009 178.712 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 27.1 t -73.42 145.21 45.98 Favored 'General case' 0 C--N 1.34 0.155 0 N-CA-C 106.084 -1.821 . . . . 0.0 106.084 176.899 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 76.1 mt -76.12 64.75 2.01 Favored 'General case' 0 N--CA 1.449 -0.482 0 C-N-CA 124.363 1.065 . . . . 0.0 111.798 -176.102 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.2 m -132.89 139.45 49.6 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.215 0 C-N-CA 124.069 0.948 . . . . 0.0 111.268 -179.124 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 36.2 m-85 -82.83 129.52 35.01 Favored 'General case' 0 C--O 1.232 0.171 0 N-CA-C 104.314 -2.476 . . . . 0.0 104.314 175.201 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 25.2 t -117.84 105.2 47.93 Favored Pre-proline 0 CA--C 1.535 0.368 0 CA-C-O 118.168 -0.92 . . . . 0.0 108.963 179.561 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -75.13 164.81 87.47 Favored 'Cis proline' 0 C--N 1.348 0.518 0 CA-C-N 120.482 1.208 . . . . 0.0 111.505 -1.332 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 7.0 p -90.4 -62.29 1.49 Allowed 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 125.352 1.461 . . . . 0.0 108.655 179.207 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -106.42 137.48 44.32 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 126.313 1.845 . . . . 0.0 106.366 177.174 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 18.0 p90 -163.63 -174.73 3.82 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 118.38 0.536 . . . . 0.0 110.871 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 24.2 m -140.1 149.19 42.77 Favored 'General case' 0 N--CA 1.455 -0.212 0 C-N-CA 124.783 1.233 . . . . 0.0 108.813 -178.636 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 29.0 m -148.88 151.68 35.45 Favored Pre-proline 0 N--CA 1.463 0.2 0 C-N-CA 123.585 0.754 . . . . 0.0 110.332 -179.695 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -70.94 150.19 60.63 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 C-N-CA 121.778 1.652 . . . . 0.0 110.135 176.309 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 60.0 m -55.04 118.84 4.66 Favored 'General case' 0 CA--C 1.53 0.187 0 C-N-CA 123.308 0.643 . . . . 0.0 109.329 177.754 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 106.01 -5.6 39.51 Favored Glycine 0 CA--C 1.528 0.894 0 CA-C-O 118.877 -0.957 . . . . 0.0 112.802 -179.159 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -59.58 136.3 57.94 Favored 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 119.41 1.605 . . . . 0.0 110.623 179.374 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -90.98 93.15 9.07 Favored 'General case' 0 N--CA 1.445 -0.7 0 N-CA-C 106.013 -1.847 . . . . 0.0 106.013 177.457 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 63.4 mt -75.2 137.84 22.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 -178.616 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 67.9 t -115.75 102.41 13.67 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.296 0 C-N-CA 124.659 1.184 . . . . 0.0 108.479 -178.239 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -90.16 101.62 14.33 Favored 'General case' 0 CA--C 1.53 0.177 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 177.805 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 26.7 ttpp -99.99 129.54 46.07 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 124.774 1.229 . . . . 0.0 112.633 -176.596 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 39.6 t30 -66.82 115.35 6.5 Favored 'General case' 0 CA--C 1.528 0.098 0 CA-C-O 118.805 -0.617 . . . . 0.0 110.342 177.856 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 43.6 t30 -97.04 -73.82 0.59 Allowed 'General case' 0 N--CA 1.457 -0.114 0 CA-C-O 121.111 0.481 . . . . 0.0 110.664 179.835 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -157.95 170.97 21.12 Favored 'General case' 0 C--N 1.332 -0.183 0 C-N-CA 124.783 1.233 . . . . 0.0 108.16 -177.944 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 71.59 17.57 76.54 Favored Glycine 0 CA--C 1.534 1.263 0 O-C-N 121.487 -0.758 . . . . 0.0 112.252 -178.965 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.519 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 7.4 p90 -72.09 170.49 12.39 Favored Pre-proline 0 CA--C 1.54 0.559 0 C-N-CA 125.946 1.698 . . . . 0.0 107.77 178.59 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.519 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 26.9 Cg_exo -64.99 152.07 76.22 Favored 'Cis proline' 0 N--CA 1.451 -0.982 0 N-CA-C 115.581 1.339 . . . . 0.0 115.581 2.19 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.414 ' CD2' ' HB3' ' A' ' 5' ' ' LEU . 87.6 m-70 -141.74 170.11 16.34 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 123.311 0.645 . . . . 0.0 109.485 179.235 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 46.7 p30 -168.71 177.4 5.14 Favored 'General case' 0 N--CA 1.451 -0.423 0 N-CA-C 104.109 -2.552 . . . . 0.0 104.109 175.706 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 39.6 t -135.95 112.43 13.09 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.274 0 N-CA-C 107.262 -1.384 . . . . 0.0 107.262 -179.063 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 48.4 t -116.96 133.35 63.96 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 N-CA-C 105.98 -1.859 . . . . 0.0 105.98 -179.141 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.436 ' CG ' HD12 ' A' ' 55' ' ' ILE . 55.0 m-85 -93.69 142.69 27.07 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -179.138 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -74.62 97.95 3.29 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.749 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -39.89 -35.97 0.41 Allowed 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 125.842 1.657 . . . . 0.0 115.324 -179.234 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -82.77 -27.64 30.88 Favored 'General case' 0 CA--C 1.535 0.375 0 N-CA-C 112.607 0.595 . . . . 0.0 112.607 -179.715 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 47.5 tt0 -112.22 61.28 0.63 Allowed 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 124.62 1.168 . . . . 0.0 111.438 -176.475 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 36.8 pt -157.01 158.3 31.12 Favored Pre-proline 0 CA--C 1.535 0.374 0 C-N-CA 128.468 2.707 . . . . 0.0 105.721 176.817 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -55.4 111.94 0.9 Allowed 'Trans proline' 0 N--CA 1.456 -0.717 0 C-N-CA 122.498 2.132 . . . . 0.0 109.59 175.537 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -33.08 -48.47 0.22 Allowed 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 126.855 2.062 . . . . 0.0 115.619 -177.517 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -58.87 -29.12 64.28 Favored Glycine 0 CA--C 1.533 1.182 0 O-C-N 122.131 -0.356 . . . . 0.0 113.78 -178.457 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 43.1 t -82.19 96.28 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 CA-C-N 118.154 0.977 . . . . 0.0 109.759 -178.193 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 6.7 t0 -52.77 116.71 2.46 Favored 'General case' 0 CA--C 1.535 0.392 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 176.706 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -46.77 -38.51 10.18 Favored 'General case' 0 N--CA 1.456 -0.17 0 C-N-CA 126.085 1.754 . . . . 0.0 112.552 -178.734 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 59.9 t -59.54 -28.17 39.31 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 C-N-CA 123.006 0.522 . . . . 0.0 111.443 -179.276 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 41.7 mtmt -74.28 -45.57 46.86 Favored 'General case' 0 CA--C 1.528 0.125 0 O-C-N 121.666 -0.646 . . . . 0.0 110.602 -179.111 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.436 HD12 ' CG ' ' A' ' 41' ' ' PHE . 25.6 pt -79.59 -32.81 14.72 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 N-CA-C 113.008 0.744 . . . . 0.0 113.008 -177.766 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 47.1 m -77.39 130.54 37.23 Favored 'General case' 0 N--CA 1.452 -0.327 0 C-N-CA 123.148 0.579 . . . . 0.0 112.035 -178.034 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.5 tmt? . . . . . 0 N--CA 1.449 -0.508 0 N-CA-C 104.869 -2.271 . . . . 0.0 104.869 175.738 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 5.1 mp . . . . . 0 N--CA 1.451 -0.397 0 CA-C-O 121.378 0.609 . . . . 0.0 110.745 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 59.9 mt -80.67 93.42 6.15 Favored 'General case' 0 N--CA 1.444 -0.735 0 N-CA-C 103.046 -2.946 . . . . 0.0 103.046 174.01 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -109.65 -42.2 4.36 Favored 'General case' 0 C--N 1.333 -0.116 0 C-N-CA 124.273 1.029 . . . . 0.0 111.22 -176.736 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.27 134.61 73.63 Favored Pre-proline 0 C--O 1.236 0.356 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 -178.694 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_exo -50.7 132.51 36.56 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 C-N-CA 122.571 2.181 . . . . 0.0 110.903 179.776 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 92.73 -15.09 63.42 Favored Glycine 0 CA--C 1.527 0.821 0 CA-C-O 117.325 -1.82 . . . . 0.0 115.782 176.918 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -52.76 125.54 17.12 Favored 'General case' 0 CA--C 1.537 0.457 0 CA-C-N 121.045 2.423 . . . . 0.0 110.923 179.302 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 12.1 p -105.26 122.46 45.98 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 125.827 1.651 . . . . 0.0 112.395 -178.725 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 54.3 t80 -103.85 108.35 19.64 Favored 'General case' 0 N--CA 1.454 -0.235 0 N-CA-C 105.984 -1.858 . . . . 0.0 105.984 174.301 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 15.8 t -96.65 136.93 25.84 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 -178.609 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.5 p -145.51 127.06 8.29 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.404 0 CA-C-N 118.428 0.558 . . . . 0.0 110.97 178.628 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 7.9 m -88.73 101.97 14.53 Favored 'General case' 0 CA--C 1.53 0.174 0 C-N-CA 125.45 1.5 . . . . 0.0 110.239 -179.489 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 22.4 mt -87.33 87.45 7.43 Favored 'General case' 0 N--CA 1.462 0.151 0 CA-C-N 118.585 0.63 . . . . 0.0 109.357 179.394 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -69.5 -46.74 65.86 Favored 'General case' 0 CA--C 1.532 0.281 0 N-CA-C 113.399 0.889 . . . . 0.0 113.399 -179.703 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 2.0 m -78.83 127.47 32.09 Favored 'General case' 0 N--CA 1.454 -0.268 0 O-C-N 121.866 -0.521 . . . . 0.0 112.113 -175.23 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.1 155.38 37.0 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 122.987 0.515 . . . . 0.0 110.599 176.784 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 138.91 175.35 13.95 Favored Glycine 0 CA--C 1.525 0.67 0 C-N-CA 125.137 1.351 . . . . 0.0 109.984 179.445 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -100.0 116.04 31.12 Favored 'General case' 0 N--CA 1.451 -0.396 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 17.9 m-85 -107.83 131.33 54.59 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 124.379 1.071 . . . . 0.0 109.806 -178.101 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 18.2 m -102.31 139.27 38.14 Favored 'General case' 0 C--O 1.233 0.233 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 176.099 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 26.1 p90 -140.81 169.52 17.48 Favored 'General case' 0 CA--C 1.521 -0.151 0 CA-C-O 121.586 0.708 . . . . 0.0 111.204 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 43.4 p90 -157.57 160.61 38.32 Favored 'General case' 0 N--CA 1.45 -0.462 0 CA-C-N 115.601 -0.727 . . . . 0.0 112.016 -178.81 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 t -97.63 99.88 11.26 Favored 'General case' 0 CA--C 1.512 -0.485 0 N-CA-C 105.68 -1.97 . . . . 0.0 105.68 177.334 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.371 4.9 p -43.43 -56.5 6.77 Favored Pre-proline 0 CA--C 1.54 0.572 0 N-CA-C 114.323 1.231 . . . . 0.0 114.323 -175.175 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_exo -47.27 -20.04 1.26 Allowed 'Trans proline' 0 CA--C 1.534 0.518 0 C-N-CA 123.6 2.867 . . . . 0.0 116.103 177.248 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 38.5 m80 -136.13 18.37 3.2 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-N 119.15 0.887 . . . . 0.0 111.806 -178.298 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 16.8 pt20 -60.88 -41.97 97.04 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-N 119.047 0.84 . . . . 0.0 109.539 179.533 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -58.39 -29.48 63.41 Favored Glycine 0 CA--C 1.532 1.155 0 N-CA-C 111.209 -0.756 . . . . 0.0 111.209 177.145 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.34 10.6 21.81 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 123.718 0.807 . . . . 0.0 111.084 178.946 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 79.33 17.1 76.98 Favored Glycine 0 CA--C 1.526 0.772 0 CA-C-O 118.758 -1.023 . . . . 0.0 113.801 178.484 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 22.9 ttt -79.26 77.35 5.79 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 119.703 1.751 . . . . 0.0 108.265 178.213 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 14.3 m -117.87 170.58 7.11 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.319 0 C-N-CA 125.909 1.684 . . . . 0.0 110.198 179.809 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -164.86 176.54 40.64 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 178.092 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 53.8 tttp -154.68 154.48 32.99 Favored 'General case' 0 N--CA 1.454 -0.253 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 -176.074 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.4 p -145.53 134.2 17.0 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.159 0 O-C-N 121.987 -0.445 . . . . 0.0 110.988 -178.773 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.7 m -100.15 94.51 6.27 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 125.65 1.58 . . . . 0.0 110.852 -178.002 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 21.4 t -80.17 120.28 31.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 105.459 -2.052 . . . . 0.0 105.459 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 5.8 p30 . . . . . 0 C--N 1.332 -0.157 0 C-N-CA 123.483 0.713 . . . . 0.0 111.652 -174.914 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 . . . . . 0 N--CA 1.453 -0.308 0 CA-C-O 120.171 0.034 . . . . 0.0 110.997 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 39.0 t -113.23 118.24 57.55 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.332 0 N-CA-C 107.364 -1.347 . . . . 0.0 107.364 178.386 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 64.3 mt -89.1 120.86 30.88 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 -179.77 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -78.76 111.22 14.65 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 106.799 -1.556 . . . . 0.0 106.799 175.158 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 93.61 138.75 9.12 Favored Glycine 0 N--CA 1.446 -0.649 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.168 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 68.4 p -81.8 158.34 24.14 Favored 'General case' 0 N--CA 1.437 -1.11 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 178.906 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.0 -33.87 57.58 Favored Glycine 0 CA--C 1.53 1.025 0 CA-C-N 115.252 -0.885 . . . . 0.0 111.512 178.969 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -75.8 -3.71 36.57 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 123.597 0.759 . . . . 0.0 112.292 178.962 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 99.51 -20.85 47.98 Favored Glycine 0 CA--C 1.527 0.794 0 CA-C-O 118.892 -0.949 . . . . 0.0 113.486 178.782 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 22.7 t -57.31 131.63 50.62 Favored 'General case' 0 C--O 1.239 0.516 0 CA-C-N 119.336 1.568 . . . . 0.0 110.682 -179.228 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 56.8 mt -73.03 65.63 0.77 Allowed 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 127.085 2.154 . . . . 0.0 112.412 -176.222 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 2.4 t -123.2 151.36 27.55 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.442 0 C-N-CA 124.247 1.019 . . . . 0.0 108.785 178.859 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 33.2 m-85 -86.17 129.74 34.75 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 104.125 -2.546 . . . . 0.0 104.125 175.97 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 48.8 t -118.44 104.62 47.49 Favored Pre-proline 0 CA--C 1.537 0.445 0 CA-C-O 118.324 -0.846 . . . . 0.0 108.877 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -75.05 161.78 94.14 Favored 'Cis proline' 0 C--N 1.347 0.499 0 CA-C-N 120.338 1.157 . . . . 0.0 111.597 -1.073 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 6.2 p -91.89 -60.47 1.85 Allowed 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 125.502 1.521 . . . . 0.0 108.609 179.212 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -105.4 127.01 52.75 Favored 'General case' 0 N--CA 1.453 -0.282 0 C-N-CA 126.238 1.815 . . . . 0.0 106.616 177.69 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 14.6 p90 -160.03 -175.36 5.05 Favored 'General case' 0 C--O 1.232 0.18 0 CA-C-O 121.08 0.467 . . . . 0.0 110.792 179.867 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 66.1 p -147.02 156.84 43.35 Favored 'General case' 0 N--CA 1.451 -0.403 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 18.1 m -152.75 151.28 26.35 Favored Pre-proline 0 CA--C 1.531 0.245 0 C-N-CA 123.61 0.764 . . . . 0.0 109.539 -178.901 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -73.17 148.52 44.4 Favored 'Trans proline' 0 N--CA 1.451 -1.0 0 C-N-CA 121.781 1.654 . . . . 0.0 110.761 177.812 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 64.7 m -48.93 121.24 4.52 Favored 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 122.996 0.518 . . . . 0.0 110.55 176.048 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 106.39 -9.72 42.14 Favored Glycine 0 CA--C 1.529 0.961 0 C-N-CA 124.165 0.888 . . . . 0.0 112.642 179.431 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -63.3 135.81 57.28 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-N 118.813 1.307 . . . . 0.0 109.979 179.242 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 52.9 mtpt -91.54 106.03 18.19 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 125.409 1.483 . . . . 0.0 108.659 179.386 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 40.4 mt -85.21 135.12 25.53 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 -179.672 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 64.7 t -119.73 100.3 9.27 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.34 0 C-N-CA 126.134 1.774 . . . . 0.0 108.152 -178.921 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -87.06 107.18 18.32 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 178.025 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 62.9 tttp -105.91 131.97 52.58 Favored 'General case' 0 CA--C 1.531 0.243 0 C-N-CA 125.266 1.426 . . . . 0.0 112.78 -176.408 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 8.1 m-20 -68.56 112.53 5.41 Favored 'General case' 0 C--O 1.232 0.132 0 C-N-CA 123.149 0.579 . . . . 0.0 110.021 177.538 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 24.5 t30 -97.46 -72.22 0.65 Allowed 'General case' 0 N--CA 1.456 -0.171 0 CA-C-O 121.052 0.453 . . . . 0.0 109.851 178.727 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -143.2 167.41 22.18 Favored 'General case' 0 C--N 1.331 -0.219 0 C-N-CA 123.972 0.909 . . . . 0.0 109.521 -178.028 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 62.65 23.78 65.5 Favored Glycine 0 CA--C 1.535 1.295 0 O-C-N 121.839 -0.538 . . . . 0.0 113.774 179.407 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.438 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 10.5 p90 -74.74 167.54 35.42 Favored Pre-proline 0 CA--C 1.537 0.463 0 N-CA-C 106.671 -1.603 . . . . 0.0 106.671 176.756 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.438 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 50.8 Cg_exo -62.66 159.91 58.31 Favored 'Cis proline' 0 N--CA 1.456 -0.698 0 N-CA-C 116.99 1.881 . . . . 0.0 116.99 1.072 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 93.3 m-70 -149.67 170.14 19.39 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.809 -179.464 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 37.3 p-10 -163.98 177.04 8.83 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 104.32 -2.474 . . . . 0.0 104.32 176.298 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 39.3 t -138.25 112.17 8.07 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.389 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 179.291 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 64.8 t -116.83 133.69 62.72 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.604 0 N-CA-C 106.052 -1.833 . . . . 0.0 106.052 179.525 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 64.6 m-85 -93.33 140.65 29.32 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 -179.306 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 53.1 t0 -70.76 104.48 2.89 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 179.42 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -48.02 -32.29 6.43 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 124.168 0.987 . . . . 0.0 113.293 178.211 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -92.04 6.39 46.6 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 123.494 0.717 . . . . 0.0 112.871 -178.839 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 20.7 tt0 -150.44 63.36 0.95 Allowed 'General case' 0 CA--C 1.538 0.506 0 CA-C-O 122.108 0.956 . . . . 0.0 110.71 -179.283 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 28.0 pt -155.59 158.2 31.77 Favored Pre-proline 0 CA--C 1.532 0.263 0 C-N-CA 128.573 2.749 . . . . 0.0 105.771 177.459 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_exo -55.93 109.5 0.44 Allowed 'Trans proline' 0 CA--C 1.538 0.692 0 C-N-CA 122.306 2.004 . . . . 0.0 108.585 174.127 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -33.65 -44.21 0.15 Allowed 'General case' 0 N--CA 1.465 0.322 0 C-N-CA 126.789 2.036 . . . . 0.0 115.77 -177.195 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -58.34 -29.84 63.77 Favored Glycine 0 CA--C 1.534 1.221 0 CA-C-O 119.856 -0.413 . . . . 0.0 113.766 -178.921 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 37.4 t -84.69 107.54 15.86 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.316 0 CA-C-N 118.179 0.99 . . . . 0.0 110.318 -177.94 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 19.7 t0 -59.29 116.15 3.71 Favored 'General case' 0 CA--C 1.534 0.364 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 177.333 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -46.79 -40.33 13.45 Favored 'General case' 0 N--CA 1.457 -0.113 0 C-N-CA 125.223 1.409 . . . . 0.0 112.012 179.671 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 53.1 t -60.23 -28.88 42.77 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 C-N-CA 122.994 0.518 . . . . 0.0 111.784 -178.969 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -76.56 -42.11 44.01 Favored 'General case' 0 N--CA 1.462 0.128 0 CA-C-N 118.617 0.644 . . . . 0.0 110.594 -179.006 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.411 HG21 HD13 ' A' ' 55' ' ' ILE . 22.7 pt -79.09 -32.84 15.45 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 N-CA-C 112.582 0.586 . . . . 0.0 112.582 -178.944 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 49.1 m -78.05 141.65 38.71 Favored 'General case' 0 N--CA 1.454 -0.255 0 N-CA-C 112.531 0.567 . . . . 0.0 112.531 -178.261 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 12.8 tpt . . . . . 0 CA--C 1.535 0.401 0 N-CA-C 105.583 -2.006 . . . . 0.0 105.583 174.914 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 4.8 mp . . . . . 0 N--CA 1.452 -0.332 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 71.9 mt -79.33 96.34 5.96 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 104.391 -2.448 . . . . 0.0 104.391 177.275 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 36.9 p-10 -80.32 -58.2 3.25 Favored 'General case' 0 CA--C 1.529 0.162 0 C-N-CA 124.156 0.982 . . . . 0.0 113.303 -177.17 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -79.75 160.45 69.32 Favored Pre-proline 0 CA--C 1.535 0.403 0 C-N-CA 124.318 1.047 . . . . 0.0 111.902 -176.75 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -64.59 161.89 33.49 Favored 'Trans proline' 0 N--CA 1.458 -0.614 0 C-N-CA 122.29 1.993 . . . . 0.0 109.172 175.081 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 78.74 -39.57 1.99 Allowed Glycine 0 CA--C 1.528 0.853 0 CA-C-O 118.656 -1.08 . . . . 0.0 113.829 177.293 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 79.5 mm-40 -42.03 130.32 3.54 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 124.476 1.111 . . . . 0.0 111.669 179.827 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 6.7 p -110.88 150.4 29.24 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 125.412 1.485 . . . . 0.0 112.424 -177.856 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 30.5 t80 -126.43 113.14 16.46 Favored 'General case' 0 N--CA 1.455 -0.177 0 N-CA-C 105.082 -2.192 . . . . 0.0 105.082 172.466 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 19.6 t -100.41 136.89 29.84 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.398 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 -178.543 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.2 p -150.07 140.88 16.66 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.121 0 N-CA-C 108.275 -1.009 . . . . 0.0 108.275 178.253 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 25.1 m -112.07 127.44 55.91 Favored 'General case' 0 N--CA 1.456 -0.126 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 -178.985 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 55.5 mt -110.67 124.63 52.29 Favored 'General case' 0 CA--C 1.529 0.137 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 179.713 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -108.48 -47.96 3.41 Favored 'General case' 0 CA--C 1.528 0.126 0 C-N-CA 124.286 1.034 . . . . 0.0 112.096 -178.296 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 5.0 m -66.4 128.69 37.16 Favored 'General case' 0 N--CA 1.454 -0.25 0 O-C-N 121.707 -0.621 . . . . 0.0 109.661 -177.51 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 61.8 mtpt -69.04 155.46 40.33 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 123.02 0.528 . . . . 0.0 110.441 -179.155 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 128.37 175.44 14.07 Favored Glycine 0 CA--C 1.527 0.832 0 C-N-CA 124.389 0.995 . . . . 0.0 111.409 179.023 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 89.3 m -95.25 127.22 41.12 Favored 'General case' 0 N--CA 1.451 -0.405 0 C-N-CA 124.871 1.269 . . . . 0.0 109.288 -179.828 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 25.2 m-85 -115.75 120.69 40.15 Favored 'General case' 0 N--CA 1.447 -0.601 0 C-N-CA 126.051 1.74 . . . . 0.0 108.615 179.398 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 64.1 m -92.37 140.16 29.87 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 177.023 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 22.8 p90 -139.39 165.48 27.1 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-O 121.555 0.693 . . . . 0.0 112.307 -179.52 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -152.66 157.31 40.76 Favored 'General case' 0 N--CA 1.452 -0.342 0 C-N-CA 124.205 1.002 . . . . 0.0 112.64 -178.334 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.4 t -99.68 102.04 13.41 Favored 'General case' 0 CA--C 1.519 -0.234 0 N-CA-C 105.483 -2.043 . . . . 0.0 105.483 176.84 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.28 0.8 OUTLIER -43.12 -57.69 4.92 Favored Pre-proline 0 CA--C 1.535 0.384 0 N-CA-C 114.446 1.276 . . . . 0.0 114.446 -173.692 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -52.17 -20.12 10.31 Favored 'Trans proline' 0 C--N 1.347 0.494 0 C-N-CA 123.146 2.564 . . . . 0.0 115.183 178.833 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 37.1 m80 -130.61 19.01 5.19 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-N 118.697 0.68 . . . . 0.0 111.446 -178.44 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -60.01 -51.17 70.81 Favored 'General case' 0 C--N 1.339 0.128 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 179.707 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.12 -30.26 57.35 Favored Glycine 0 CA--C 1.533 1.177 0 N-CA-C 111.717 -0.553 . . . . 0.0 111.717 177.863 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -84.04 5.83 24.38 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 123.51 0.724 . . . . 0.0 111.72 179.187 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 83.56 15.35 71.25 Favored Glycine 0 CA--C 1.527 0.827 0 CA-C-O 118.991 -0.894 . . . . 0.0 113.71 178.347 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 19.2 ttt -78.44 79.65 4.86 Favored 'General case' 0 C--O 1.236 0.377 0 CA-C-N 119.527 1.664 . . . . 0.0 108.595 178.657 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 10.7 m -126.56 169.46 17.96 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.207 0 C-N-CA 125.917 1.687 . . . . 0.0 110.813 179.842 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -169.03 179.45 41.74 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 109.276 -1.53 . . . . 0.0 109.276 178.343 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 58.7 mttm -149.64 149.46 30.67 Favored 'General case' 0 N--CA 1.455 -0.203 0 CA-C-N 117.66 0.73 . . . . 0.0 109.588 -179.014 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 6.6 p -135.72 127.29 45.04 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.3 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 178.893 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 71.6 m -102.09 106.46 17.34 Favored 'General case' 0 C--N 1.333 -0.143 0 C-N-CA 123.772 0.829 . . . . 0.0 110.436 179.487 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 44.6 t -79.69 122.99 35.97 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.633 0 N-CA-C 106.643 -1.614 . . . . 0.0 106.643 179.021 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 48.7 p30 . . . . . 0 C--N 1.333 -0.122 0 C-N-CA 124.895 1.278 . . . . 0.0 111.034 -177.605 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 78.4 tt0 . . . . . 0 N--CA 1.452 -0.348 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 48.1 t -106.05 122.48 59.75 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 -179.361 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 40.8 mt -86.03 120.82 27.83 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 177.886 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.447 HD12 ' HA ' ' A' ' 5' ' ' LEU . 5.1 tp -78.19 98.53 5.88 Favored 'General case' 0 N--CA 1.429 -1.489 0 C-N-CA 125.424 1.49 . . . . 0.0 107.525 179.863 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 91.72 145.34 15.07 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 108.7 -1.76 . . . . 0.0 108.7 -178.393 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 78.0 p -78.86 154.94 29.37 Favored 'General case' 0 N--CA 1.44 -0.948 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 179.574 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -53.16 -35.39 49.41 Favored Glycine 0 CA--C 1.529 0.942 0 CA-C-N 114.979 -1.01 . . . . 0.0 111.697 178.808 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -74.82 -4.42 37.66 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 123.53 0.732 . . . . 0.0 112.506 179.404 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 101.08 -20.75 46.25 Favored Glycine 0 CA--C 1.527 0.782 0 CA-C-O 118.763 -1.021 . . . . 0.0 113.292 178.965 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 28.6 t -56.81 132.13 51.4 Favored 'General case' 0 C--O 1.239 0.536 0 CA-C-N 119.391 1.595 . . . . 0.0 110.603 -179.332 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.444 ' H ' HD22 ' A' ' 12' ' ' LEU . 1.9 mm? -71.55 69.28 0.61 Allowed 'General case' 0 N--CA 1.44 -0.935 0 C-N-CA 126.806 2.042 . . . . 0.0 111.676 -177.457 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.5 m -135.06 141.74 42.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 C-N-CA 123.708 0.803 . . . . 0.0 109.403 178.383 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 88.2 m-85 -79.16 135.2 36.75 Favored 'General case' 0 N--CA 1.455 -0.186 0 N-CA-C 105.291 -2.115 . . . . 0.0 105.291 176.81 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.8 t -120.09 104.35 43.92 Favored Pre-proline 0 CA--C 1.534 0.339 0 CA-C-O 118.25 -0.881 . . . . 0.0 109.094 179.567 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -73.85 164.16 88.15 Favored 'Cis proline' 0 C--N 1.348 0.524 0 CA-C-N 120.301 1.143 . . . . 0.0 112.179 -1.412 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 10.5 p -97.59 -62.28 1.27 Allowed 'General case' 0 N--CA 1.452 -0.331 0 C-N-CA 125.681 1.592 . . . . 0.0 109.236 179.32 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 -103.54 123.96 47.89 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 126.106 1.763 . . . . 0.0 106.857 178.345 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -158.06 174.3 15.43 Favored 'General case' 0 CA--C 1.528 0.118 0 CA-C-N 118.9 0.773 . . . . 0.0 112.013 179.486 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.4 p -116.67 147.83 41.59 Favored 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 125.478 1.511 . . . . 0.0 107.555 178.461 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.8 p -141.79 136.25 15.18 Favored Pre-proline 0 CA--C 1.536 0.428 0 CA-C-O 118.443 -0.789 . . . . 0.0 109.036 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_exo -63.03 142.73 88.86 Favored 'Trans proline' 0 N--CA 1.456 -0.693 0 C-N-CA 122.043 1.828 . . . . 0.0 111.363 177.091 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.8 m -45.8 121.61 3.25 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 124.265 1.026 . . . . 0.0 111.778 177.919 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 84.96 -5.79 81.39 Favored Glycine 0 CA--C 1.525 0.69 0 CA-C-O 118.502 -1.166 . . . . 0.0 114.411 177.407 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -74.97 147.77 40.55 Favored 'General case' 0 CA--C 1.537 0.444 0 CA-C-N 119.954 1.877 . . . . 0.0 108.084 177.923 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 2.7 ptpp? -92.79 138.88 31.11 Favored 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 124.007 0.923 . . . . 0.0 112.499 -177.844 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 48.8 mt -105.05 136.76 37.42 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 C-N-CA 126.292 1.837 . . . . 0.0 106.06 179.166 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 58.4 t -117.92 100.29 9.81 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 C-N-CA 125.355 1.462 . . . . 0.0 108.832 -178.7 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -84.5 100.06 11.11 Favored 'General case' 0 C--N 1.334 -0.073 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 178.418 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 64.4 tttm -92.07 125.0 36.58 Favored 'General case' 0 C--O 1.231 0.127 0 C-N-CA 123.73 0.812 . . . . 0.0 110.621 -178.622 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 49.3 t30 -63.19 111.11 2.09 Favored 'General case' 0 CA--C 1.528 0.119 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 177.367 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 36.2 t30 -99.65 -76.45 0.55 Allowed 'General case' 0 N--CA 1.457 -0.079 0 C-N-CA 122.94 0.496 . . . . 0.0 112.256 -177.036 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -151.08 174.92 12.62 Favored 'General case' 0 C--O 1.224 -0.26 0 C-N-CA 124.012 0.925 . . . . 0.0 109.383 -176.807 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 62.3 17.96 57.22 Favored Glycine 0 CA--C 1.535 1.294 0 O-C-N 121.679 -0.638 . . . . 0.0 112.519 -179.119 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.494 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.9 p90 -78.25 169.5 20.56 Favored Pre-proline 0 CA--C 1.538 0.509 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 179.153 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.494 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 37.2 Cg_exo -64.45 160.25 68.42 Favored 'Cis proline' 0 N--CA 1.449 -1.098 0 N-CA-C 116.07 1.527 . . . . 0.0 116.07 1.605 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 90.7 m-70 -152.29 177.69 10.29 Favored 'General case' 0 N--CA 1.45 -0.467 0 CA-C-N 115.118 -0.946 . . . . 0.0 109.769 179.578 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 53.4 p30 -162.94 169.78 19.14 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 105.064 -2.198 . . . . 0.0 105.064 173.556 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 44.3 t -123.93 104.55 14.22 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.333 0 N-CA-C 106.62 -1.622 . . . . 0.0 106.62 -177.522 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 38.8 t -116.33 135.26 57.13 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.366 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 -179.316 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.421 ' CG ' HG13 ' A' ' 55' ' ' ILE . 55.7 m-85 -100.65 138.19 38.04 Favored 'General case' 0 N--CA 1.454 -0.272 0 C-N-CA 123.267 0.627 . . . . 0.0 109.68 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -70.14 114.1 7.97 Favored 'General case' 0 N--CA 1.454 -0.26 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 -179.81 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -47.85 -30.57 4.17 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 115.825 1.787 . . . . 0.0 115.825 -178.471 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 23.5 t70 -88.61 -50.15 6.45 Favored 'General case' 0 CA--C 1.53 0.204 0 CA-C-N 118.52 0.6 . . . . 0.0 110.649 179.88 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -80.22 57.07 2.63 Favored 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 124.087 0.955 . . . . 0.0 112.413 -176.397 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 20.2 pt -150.14 149.0 26.11 Favored Pre-proline 0 CA--C 1.534 0.36 0 C-N-CA 127.376 2.27 . . . . 0.0 106.537 176.805 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -65.6 124.63 13.08 Favored 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 122.096 1.864 . . . . 0.0 110.504 179.896 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -52.0 109.95 0.43 Allowed 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 124.802 1.241 . . . . 0.0 111.228 -179.456 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 153.09 -56.77 0.43 Allowed Glycine 0 CA--C 1.522 0.517 0 N-CA-C 108.249 -1.94 . . . . 0.0 108.249 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 41.8 t -83.21 93.09 2.87 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.429 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 179.285 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -58.96 134.33 56.86 Favored 'General case' 0 CA--C 1.532 0.251 0 N-CA-C 109.319 -0.622 . . . . 0.0 109.319 177.807 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -39.56 -43.82 1.36 Allowed 'General case' 0 C--N 1.331 -0.196 0 C-N-CA 127.389 2.275 . . . . 0.0 113.963 179.52 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 98.9 t -55.62 -30.41 26.68 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.333 0 CA-C-N 118.119 0.418 . . . . 0.0 110.918 -179.378 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 33.1 mtmm -75.85 -18.83 59.3 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-O 118.451 -0.785 . . . . 0.0 112.868 -179.278 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.421 HG13 ' CG ' ' A' ' 41' ' ' PHE . 0.1 OUTLIER -115.32 -20.91 5.59 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-N 119.196 0.907 . . . . 0.0 113.065 179.642 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 35.6 m -84.13 127.46 33.93 Favored 'General case' 0 N--CA 1.451 -0.386 0 C-N-CA 123.869 0.868 . . . . 0.0 112.038 -178.577 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 7.2 tmm? . . . . . 0 CA--C 1.536 0.432 0 N-CA-C 103.801 -2.666 . . . . 0.0 103.801 175.071 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 4.8 mp . . . . . 0 N--CA 1.45 -0.469 0 CA-C-O 121.036 0.446 . . . . 0.0 110.503 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 44.1 mt -78.1 105.68 9.49 Favored 'General case' 0 N--CA 1.445 -0.68 0 N-CA-C 103.778 -2.675 . . . . 0.0 103.778 175.295 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 34.3 p-10 -101.25 -52.98 3.12 Favored 'General case' 0 N--CA 1.455 -0.183 0 C-N-CA 124.796 1.238 . . . . 0.0 111.733 -177.151 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -71.85 136.65 82.65 Favored Pre-proline 0 CA--C 1.531 0.245 0 CA-C-N 118.723 0.692 . . . . 0.0 110.069 -177.477 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -63.61 149.73 90.22 Favored 'Trans proline' 0 N--CA 1.451 -1.009 0 C-N-CA 122.142 1.895 . . . . 0.0 109.659 179.704 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 97.54 -34.98 4.76 Favored Glycine 0 CA--C 1.523 0.591 0 CA-C-O 118.623 -1.098 . . . . 0.0 112.777 177.855 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 76.9 mt-10 -45.28 118.72 1.81 Allowed 'General case' 0 CA--C 1.536 0.419 0 CA-C-N 118.537 1.169 . . . . 0.0 111.665 -179.696 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 11.0 p -101.88 120.46 40.42 Favored 'General case' 0 N--CA 1.452 -0.356 0 C-N-CA 124.992 1.317 . . . . 0.0 111.551 -179.485 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 38.4 t80 -101.34 108.06 19.58 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 106.422 -1.695 . . . . 0.0 106.422 175.124 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 14.6 t -93.91 139.86 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.301 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 -179.263 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 9.9 p -148.61 142.64 18.79 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.153 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 177.778 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 7.8 m -117.21 124.44 49.09 Favored 'General case' 0 CA--C 1.527 0.072 0 C-N-CA 124.318 1.047 . . . . 0.0 109.495 -177.951 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 44.3 mt -105.55 98.51 8.19 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 123.156 0.583 . . . . 0.0 109.777 -179.394 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -74.67 -58.36 3.34 Favored 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 123.782 0.833 . . . . 0.0 112.709 -179.38 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 4.1 m -70.42 128.87 37.68 Favored 'General case' 0 N--CA 1.453 -0.325 0 C-N-CA 123.495 0.718 . . . . 0.0 111.465 -175.116 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 57.5 mtmt -65.35 156.04 33.43 Favored 'General case' 0 N--CA 1.455 -0.194 0 C-N-CA 123.438 0.695 . . . . 0.0 110.8 179.115 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 142.44 -166.46 26.45 Favored Glycine 0 CA--C 1.521 0.446 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 179.33 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 88.5 m -117.44 123.83 47.35 Favored 'General case' 0 N--CA 1.454 -0.245 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 179.612 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -114.81 124.3 51.39 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 124.348 1.059 . . . . 0.0 108.58 -178.553 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 13.2 m -99.81 134.29 42.92 Favored 'General case' 0 C--O 1.233 0.205 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 177.868 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 40.3 p90 -133.67 166.96 21.39 Favored 'General case' 0 CA--C 1.521 -0.161 0 CA-C-O 121.588 0.708 . . . . 0.0 111.625 -179.552 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 46.6 p90 -159.01 165.09 34.82 Favored 'General case' 0 N--CA 1.45 -0.43 0 CA-C-N 115.453 -0.794 . . . . 0.0 112.322 -177.76 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.5 t -106.09 97.18 7.03 Favored 'General case' 0 CA--C 1.519 -0.243 0 N-CA-C 106.638 -1.615 . . . . 0.0 106.638 177.377 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.304 16.1 p -31.1 -64.56 0.21 Allowed Pre-proline 0 CA--C 1.544 0.721 0 N-CA-C 117.138 2.273 . . . . 0.0 117.138 -174.474 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -61.89 -16.49 49.76 Favored 'Trans proline' 0 C--N 1.347 0.468 0 C-N-CA 122.576 2.184 . . . . 0.0 114.294 -177.338 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 34.7 m170 -119.08 9.26 11.76 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 123.322 0.649 . . . . 0.0 110.747 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 66.4 tt0 -58.34 -49.69 76.28 Favored 'General case' 0 CA--C 1.529 0.144 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 179.228 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -57.45 -30.32 61.67 Favored Glycine 0 CA--C 1.531 1.067 0 N-CA-C 111.475 -0.65 . . . . 0.0 111.475 177.45 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -84.8 5.45 28.54 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 123.774 0.83 . . . . 0.0 111.577 179.091 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 87.37 11.39 69.21 Favored Glycine 0 CA--C 1.527 0.823 0 CA-C-O 118.608 -1.107 . . . . 0.0 113.833 178.263 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 22.2 ttt -78.9 77.26 5.38 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 119.812 1.806 . . . . 0.0 108.614 178.334 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 10.8 m -122.94 169.13 14.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 C-N-CA 126.042 1.737 . . . . 0.0 108.96 178.568 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -162.42 172.34 38.49 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 108.491 -1.843 . . . . 0.0 108.491 178.51 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 6.9 ttpm? -151.4 141.33 22.02 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 -176.765 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 6.0 p -132.97 126.43 53.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 CA-C-O 121.057 0.456 . . . . 0.0 110.697 -179.025 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 21.0 m -97.17 105.84 18.06 Favored 'General case' 0 C--O 1.235 0.324 0 C-N-CA 124.724 1.21 . . . . 0.0 109.222 179.775 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 40.8 t -79.91 103.02 6.36 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.621 0 N-CA-C 106.484 -1.673 . . . . 0.0 106.484 -179.743 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 . . . . . 0 C--O 1.235 0.313 0 C-N-CA 125.205 1.402 . . . . 0.0 109.487 -177.206 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 . . . . . 0 N--CA 1.453 -0.32 0 CA-C-O 120.267 0.08 . . . . 0.0 110.895 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 44.2 t -120.55 123.94 71.45 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 N-CA-C 106.112 -1.81 . . . . 0.0 106.112 177.492 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 32.5 mt -96.65 122.91 40.09 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 118.383 0.538 . . . . 0.0 110.206 -179.478 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.507 ' HB3' ' CD2' ' A' ' 37' ' ' HIS . 1.2 mm? -79.68 101.9 8.65 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 106.316 -1.735 . . . . 0.0 106.316 174.111 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 108.84 127.69 5.58 Favored Glycine 0 CA--C 1.522 0.522 0 C-N-CA 124.788 1.185 . . . . 0.0 111.576 179.688 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 14.9 p -84.34 46.84 1.26 Allowed 'General case' 0 N--CA 1.457 -0.092 0 O-C-N 121.434 -1.039 . . . . 0.0 111.314 179.279 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 72.07 -55.73 1.45 Allowed Glycine 0 CA--C 1.527 0.83 0 C-N-CA 126.071 1.796 . . . . 0.0 111.991 -179.26 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -73.17 33.69 0.07 Allowed 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 126.038 1.735 . . . . 0.0 113.743 -177.519 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 57.33 8.42 3.56 Favored Glycine 0 CA--C 1.531 1.069 0 C-N-CA 124.875 1.226 . . . . 0.0 115.848 179.207 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 22.8 t -68.63 141.43 55.39 Favored 'General case' 0 N--CA 1.457 -0.107 0 CA-C-N 119.532 1.666 . . . . 0.0 109.502 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 68.9 mt -78.1 66.57 3.74 Favored 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 124.411 1.084 . . . . 0.0 111.781 -176.048 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.6 p -138.44 150.08 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.217 0 CA-C-O 121.788 0.804 . . . . 0.0 111.715 -179.494 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 58.7 m-85 -92.38 126.33 37.42 Favored 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 105.185 -2.154 . . . . 0.0 105.185 177.78 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 48.8 t -115.39 107.47 49.17 Favored Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 119.629 1.104 . . . . 0.0 109.448 179.609 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -77.27 155.84 96.66 Favored 'Cis proline' 0 CA--C 1.536 0.613 0 CA-C-N 120.706 1.288 . . . . 0.0 111.729 -1.3 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.5 m -84.83 -55.1 4.26 Favored 'General case' 0 CA--C 1.527 0.096 0 C-N-CA 123.357 0.663 . . . . 0.0 110.302 179.232 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 58.9 mt-10 -114.0 131.87 56.19 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 -179.471 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 53.0 p90 -161.13 -178.41 6.73 Favored 'General case' 0 C--O 1.234 0.255 0 CA-C-O 121.372 0.606 . . . . 0.0 112.081 -178.114 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 35.2 p -140.02 140.26 36.18 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 124.948 1.299 . . . . 0.0 109.257 -179.249 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.4 m -145.47 152.19 49.05 Favored Pre-proline 0 CA--C 1.532 0.257 0 C-N-CA 124.553 1.141 . . . . 0.0 108.136 178.898 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo -71.67 151.44 58.03 Favored 'Trans proline' 0 N--CA 1.451 -0.998 0 C-N-CA 121.78 1.653 . . . . 0.0 111.16 179.842 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 56.7 m -49.31 127.15 14.42 Favored 'General case' 0 C--N 1.332 -0.18 0 C-N-CA 124.343 1.057 . . . . 0.0 111.508 178.479 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 92.9 -10.74 73.44 Favored Glycine 0 CA--C 1.527 0.817 0 CA-C-O 118.911 -0.938 . . . . 0.0 112.829 178.88 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -70.47 141.96 51.98 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 119.392 1.596 . . . . 0.0 108.43 178.601 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 20.4 pttp -82.01 160.45 23.27 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 123.928 0.891 . . . . 0.0 111.131 -179.018 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 15.8 mt -131.44 129.05 61.84 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 N-CA-C 105.355 -2.091 . . . . 0.0 105.355 177.775 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 75.3 t -116.37 98.06 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.202 0 C-N-CA 125.851 1.66 . . . . 0.0 107.928 -177.957 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -86.5 96.57 10.1 Favored 'General case' 0 CA--C 1.529 0.17 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.773 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -90.52 128.98 36.72 Favored 'General case' 0 CA--C 1.531 0.212 0 C-N-CA 125.027 1.331 . . . . 0.0 112.046 -177.6 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 45.6 t30 -69.15 116.66 9.85 Favored 'General case' 0 N--CA 1.457 -0.119 0 CA-C-O 118.393 -0.813 . . . . 0.0 109.947 177.938 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 50.2 t30 -103.4 -66.23 0.96 Allowed 'General case' 0 C--N 1.339 0.135 0 CA-C-N 118.702 0.683 . . . . 0.0 110.551 179.474 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -160.17 169.25 23.67 Favored 'General case' 0 C--O 1.225 -0.196 0 C-N-CA 123.254 0.622 . . . . 0.0 110.452 -177.684 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 71.66 18.91 77.61 Favored Glycine 0 CA--C 1.532 1.094 0 O-C-N 121.823 -0.548 . . . . 0.0 111.878 -179.512 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.557 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 10.4 p90 -71.37 168.92 17.64 Favored Pre-proline 0 CA--C 1.54 0.568 0 C-N-CA 126.001 1.72 . . . . 0.0 108.598 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.557 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 75.8 Cg_endo -70.93 158.44 94.52 Favored 'Cis proline' 0 N--CA 1.449 -1.104 0 N-CA-C 115.042 1.131 . . . . 0.0 115.042 3.947 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.507 ' CD2' ' HB3' ' A' ' 5' ' ' LEU . 90.3 m-70 -146.8 160.83 41.78 Favored 'General case' 0 C--O 1.222 -0.391 0 O-C-N 121.59 -0.694 . . . . 0.0 112.72 -177.808 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 52.1 p30 -157.53 177.69 11.13 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 106.39 -1.707 . . . . 0.0 106.39 176.437 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 23.4 t -132.55 113.95 21.91 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 -179.27 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 25.5 t -118.98 132.11 69.82 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 N-CA-C 105.601 -2.0 . . . . 0.0 105.601 178.522 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -93.99 136.78 33.91 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -71.02 104.75 3.08 Favored 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 -178.66 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -35.26 -37.34 0.08 Allowed 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 127.416 2.287 . . . . 0.0 115.401 178.275 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 24.9 m-20 -85.47 -53.24 5.32 Favored 'General case' 0 CA--C 1.53 0.188 0 CA-C-N 118.545 0.611 . . . . 0.0 110.301 179.43 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 38.3 mm-40 -80.91 58.28 3.34 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 124.031 0.933 . . . . 0.0 112.906 -176.706 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 36.1 pt -152.31 159.15 33.16 Favored Pre-proline 0 CA--C 1.534 0.336 0 C-N-CA 128.452 2.701 . . . . 0.0 105.633 175.946 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -53.12 110.84 0.53 Allowed 'Trans proline' 0 N--CA 1.456 -0.684 0 C-N-CA 122.365 2.044 . . . . 0.0 111.162 177.22 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -51.77 108.23 0.26 Allowed 'General case' 0 CA--C 1.529 0.156 0 C-N-CA 124.119 0.968 . . . . 0.0 110.284 -179.507 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 133.83 -29.42 3.1 Favored Glycine 0 CA--C 1.527 0.795 0 N-CA-C 109.958 -1.257 . . . . 0.0 109.958 -178.133 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 88.5 t -74.94 117.91 19.91 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.279 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 179.763 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -63.13 102.81 0.41 Allowed 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 122.953 0.501 . . . . 0.0 110.335 179.454 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.71 -40.5 20.38 Favored 'General case' 0 N--CA 1.456 -0.168 0 C-N-CA 124.424 1.09 . . . . 0.0 111.381 179.094 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 44.6 t -58.94 -28.62 38.9 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 C-N-CA 123.03 0.532 . . . . 0.0 111.844 -179.132 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 33.3 pttt -75.7 -31.96 59.9 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 119.497 1.044 . . . . 0.0 111.571 -178.622 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.437 HD13 HG21 ' A' ' 55' ' ' ILE . 26.4 pt -91.78 -31.45 4.89 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.36 0 C-N-CA 123.728 0.811 . . . . 0.0 111.925 -178.79 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 35.5 m -87.74 142.95 27.42 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 124.73 1.212 . . . . 0.0 114.196 -176.748 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 87.2 mtp . . . . . 0 N--CA 1.45 -0.428 0 N-CA-C 104.656 -2.35 . . . . 0.0 104.656 171.213 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.449 -0.475 0 N-CA-C 113.339 0.866 . . . . 0.0 113.339 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 63.9 mt -82.32 127.65 33.43 Favored 'General case' 0 N--CA 1.446 -0.644 0 N-CA-C 106.041 -1.837 . . . . 0.0 106.041 176.353 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 23.8 t30 -118.21 -47.89 2.55 Favored 'General case' 0 C--O 1.225 -0.189 0 C-N-CA 123.267 0.627 . . . . 0.0 110.469 178.617 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -67.07 136.9 94.25 Favored Pre-proline 0 CA--C 1.533 0.322 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -178.666 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -64.68 145.04 86.06 Favored 'Trans proline' 0 N--CA 1.452 -0.954 0 C-N-CA 122.462 2.108 . . . . 0.0 109.949 -178.511 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.23 -30.21 8.98 Favored Glycine 0 CA--C 1.523 0.563 0 CA-C-O 118.729 -1.04 . . . . 0.0 113.678 177.042 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 65.9 mm-40 -52.97 135.68 36.3 Favored 'General case' 0 CA--C 1.535 0.381 0 CA-C-N 118.859 1.329 . . . . 0.0 110.655 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 17.3 p -114.31 123.91 50.69 Favored 'General case' 0 N--CA 1.454 -0.251 0 C-N-CA 124.863 1.265 . . . . 0.0 113.515 -177.235 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 43.0 t80 -94.7 108.89 20.87 Favored 'General case' 0 C--O 1.233 0.194 0 N-CA-C 105.069 -2.197 . . . . 0.0 105.069 172.88 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.8 t -96.28 137.99 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.356 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 -179.21 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 13.5 p -147.55 168.5 4.54 Favored 'Isoleucine or valine' 0 C--O 1.232 0.142 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 177.981 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 40.9 m -149.51 136.72 19.85 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 67.5 mt -118.52 112.87 20.46 Favored 'General case' 0 CA--C 1.53 0.202 0 C-N-CA 123.681 0.792 . . . . 0.0 109.786 -177.752 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -88.23 -42.84 12.02 Favored 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 123.68 0.792 . . . . 0.0 111.473 179.692 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -71.52 127.97 34.3 Favored 'General case' 0 N--CA 1.453 -0.324 0 C-N-CA 124.095 0.958 . . . . 0.0 109.878 -177.432 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.7 mttp -66.84 160.18 26.58 Favored 'General case' 0 CA--C 1.53 0.175 0 C-N-CA 123.386 0.674 . . . . 0.0 111.683 178.87 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 129.64 177.39 14.85 Favored Glycine 0 CA--C 1.525 0.716 0 C-N-CA 124.33 0.967 . . . . 0.0 112.591 176.756 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 14.7 m -95.32 112.46 24.17 Favored 'General case' 0 N--CA 1.453 -0.277 0 C-N-CA 124.769 1.227 . . . . 0.0 108.192 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 26.2 m-85 -104.04 111.72 24.41 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 124.01 0.924 . . . . 0.0 109.47 -179.626 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 20.1 m -86.14 138.38 31.96 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 107.985 -1.116 . . . . 0.0 107.985 177.163 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 34.3 p90 -135.83 164.66 27.41 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 123.099 0.56 . . . . 0.0 111.241 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 56.0 p90 -155.31 164.22 39.06 Favored 'General case' 0 N--CA 1.45 -0.462 0 CA-C-N 114.934 -1.03 . . . . 0.0 112.089 -177.981 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 6.3 t -105.11 106.97 17.71 Favored 'General case' 0 CA--C 1.523 -0.064 0 N-CA-C 106.212 -1.774 . . . . 0.0 106.212 177.229 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.304 52.3 p -43.42 -60.25 2.67 Favored Pre-proline 0 CA--C 1.539 0.554 0 N-CA-C 115.776 1.769 . . . . 0.0 115.776 -173.124 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -61.38 -7.56 8.82 Favored 'Trans proline' 0 C--N 1.348 0.52 0 C-N-CA 122.21 1.94 . . . . 0.0 114.365 -178.526 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 34.7 m80 -131.34 16.84 4.96 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 119.504 1.047 . . . . 0.0 111.039 179.644 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 65.6 tt0 -60.22 -49.54 77.22 Favored 'General case' 0 C--N 1.34 0.164 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 179.048 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.77 -32.12 61.54 Favored Glycine 0 CA--C 1.53 0.976 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 177.832 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -81.49 3.89 23.12 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 123.326 0.65 . . . . 0.0 111.711 179.117 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 81.92 17.82 69.11 Favored Glycine 0 CA--C 1.526 0.775 0 CA-C-O 118.944 -0.92 . . . . 0.0 113.259 178.836 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 21.5 ttt -78.58 80.03 4.98 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-N 119.369 1.584 . . . . 0.0 107.997 178.317 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 6.8 m -127.39 170.61 16.99 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.249 0 C-N-CA 126.196 1.798 . . . . 0.0 110.949 -179.853 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -166.65 175.11 42.06 Favored Glycine 0 CA--C 1.528 0.855 0 N-CA-C 109.134 -1.587 . . . . 0.0 109.134 178.251 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 58.9 mttm -147.27 126.35 12.88 Favored 'General case' 0 N--CA 1.461 0.095 0 CA-C-N 118.037 0.919 . . . . 0.0 110.947 -178.627 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 6.8 p -113.17 124.77 70.13 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.167 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 178.997 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.7 m -94.14 104.23 16.25 Favored 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 124.111 0.965 . . . . 0.0 109.06 -179.648 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 21.9 t -81.89 98.6 4.47 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 N-CA-C 103.98 -2.6 . . . . 0.0 103.98 178.651 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 37.2 t-20 . . . . . 0 N--CA 1.454 -0.256 0 C-N-CA 124.898 1.279 . . . . 0.0 112.925 -175.008 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 8.9 tt . . . . . 0 CA--C 1.532 0.255 0 N-CA-C 110.26 -0.274 . . . . 0.0 110.26 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.4 tm-20 -94.7 119.43 33.31 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 123.84 0.856 . . . . 0.0 109.374 -179.3 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 25.8 t -109.72 128.92 65.43 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.293 0 C-N-CA 125.891 1.676 . . . . 0.0 109.193 179.63 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 62.4 mt -94.6 126.69 40.05 Favored 'General case' 0 C--O 1.233 0.222 0 N-CA-C 108.307 -0.998 . . . . 0.0 108.307 177.455 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 55.2 mt -86.55 99.03 11.4 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 105.942 -1.873 . . . . 0.0 105.942 177.871 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 101.17 134.0 8.34 Favored Glycine 0 CA--C 1.525 0.706 0 C-N-CA 125.539 1.542 . . . . 0.0 109.583 -178.495 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 22.3 p -82.87 42.86 0.81 Allowed 'General case' 0 N--CA 1.462 0.157 0 O-C-N 120.944 -1.327 . . . . 0.0 112.875 -178.798 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.24 -53.46 1.08 Allowed Glycine 0 CA--C 1.527 0.784 0 C-N-CA 126.18 1.848 . . . . 0.0 112.691 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -73.1 36.27 0.08 Allowed 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 125.837 1.655 . . . . 0.0 113.675 -177.539 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 70.39 -19.83 0.63 Allowed Glycine 0 CA--C 1.53 1.003 0 C-N-CA 124.808 1.194 . . . . 0.0 115.08 177.785 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 32.9 t -56.66 129.21 40.08 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-N 118.515 1.157 . . . . 0.0 110.916 -178.146 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 55.5 mt -77.31 65.87 2.97 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 126.378 1.871 . . . . 0.0 112.071 -175.492 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 29.6 m -130.32 144.24 38.58 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.213 0 C-N-CA 123.174 0.59 . . . . 0.0 111.475 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 37.7 m-85 -84.76 129.21 34.86 Favored 'General case' 0 N--CA 1.456 -0.138 0 N-CA-C 104.764 -2.31 . . . . 0.0 104.764 175.723 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.9 t -117.56 102.8 51.61 Favored Pre-proline 0 CA--C 1.534 0.334 0 CA-C-O 117.986 -1.007 . . . . 0.0 108.992 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -76.89 166.83 81.62 Favored 'Cis proline' 0 CA--C 1.535 0.554 0 CA-C-N 120.373 1.169 . . . . 0.0 111.23 -1.375 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 29.2 t -103.14 -60.42 1.55 Allowed 'General case' 0 CA--C 1.531 0.216 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 178.023 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 4.3 tm-20 -102.3 125.78 49.11 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 106.11 -1.811 . . . . 0.0 106.11 178.457 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.1 p90 -161.65 -176.69 5.44 Favored 'General case' 0 CA--C 1.535 0.372 0 CA-C-N 119.118 0.872 . . . . 0.0 112.757 -179.362 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.0 m -130.14 147.03 51.83 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 126.284 1.834 . . . . 0.0 108.605 179.686 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.0 m -145.25 152.17 49.85 Favored Pre-proline 0 CA--C 1.528 0.134 0 C-N-CA 125.086 1.354 . . . . 0.0 108.28 178.465 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -73.7 158.02 47.52 Favored 'Trans proline' 0 N--CA 1.453 -0.905 0 C-N-CA 121.931 1.754 . . . . 0.0 110.514 176.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 50.2 m -56.3 126.13 24.91 Favored 'General case' 0 CA--C 1.529 0.149 0 C-N-CA 123.221 0.608 . . . . 0.0 109.98 177.441 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 89.82 6.5 69.79 Favored Glycine 0 CA--C 1.526 0.73 0 CA-C-O 118.887 -0.952 . . . . 0.0 112.598 -179.621 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -61.8 138.14 58.31 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 119.315 1.557 . . . . 0.0 110.854 178.884 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 15.3 ptpt -93.49 95.85 9.52 Favored 'General case' 0 N--CA 1.444 -0.736 0 C-N-CA 126.394 1.878 . . . . 0.0 106.534 177.384 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 39.6 mt -83.04 136.14 23.41 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 -179.716 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 90.8 t -118.92 132.95 67.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 105.032 -2.21 . . . . 0.0 105.032 179.012 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 94.9 m-85 -121.44 123.57 42.38 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 106.33 -1.73 . . . . 0.0 106.33 178.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 7.7 ttpm? -120.15 136.57 54.57 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 118.812 0.733 . . . . 0.0 112.875 -178.369 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 6.6 m-20 -67.72 99.6 0.82 Allowed 'General case' 0 C--O 1.232 0.161 0 C-N-CA 124.108 0.963 . . . . 0.0 109.279 177.095 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 57.8 t30 -87.17 -59.75 2.17 Favored 'General case' 0 N--CA 1.455 -0.192 0 N-CA-C 109.443 -0.576 . . . . 0.0 109.443 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -161.08 167.51 26.17 Favored 'General case' 0 C--O 1.226 -0.179 0 C-N-CA 123.617 0.767 . . . . 0.0 109.841 -179.293 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 68.89 20.37 74.4 Favored Glycine 0 CA--C 1.533 1.177 0 O-C-N 121.834 -0.541 . . . . 0.0 113.181 179.308 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.454 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 18.6 p90 -68.61 166.66 24.43 Favored Pre-proline 0 CA--C 1.546 0.797 0 N-CA-C 106.53 -1.656 . . . . 0.0 106.53 177.043 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.454 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 73.7 Cg_endo -69.97 156.34 93.41 Favored 'Cis proline' 0 N--CA 1.449 -1.136 0 CA-C-N 120.446 1.195 . . . . 0.0 114.488 4.215 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 87.9 m-70 -147.61 168.95 20.69 Favored 'General case' 0 N--CA 1.449 -0.498 0 O-C-N 121.638 -0.664 . . . . 0.0 111.49 -179.197 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 51.6 p30 -163.82 174.01 12.07 Favored 'General case' 0 N--CA 1.451 -0.416 0 N-CA-C 104.948 -2.242 . . . . 0.0 104.948 176.48 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 22.9 t -133.81 103.92 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.323 0 N-CA-C 107.062 -1.459 . . . . 0.0 107.062 -179.507 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.2 t -110.92 135.86 48.74 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 N-CA-C 105.896 -1.89 . . . . 0.0 105.896 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.411 ' CG ' HG13 ' A' ' 55' ' ' ILE . 53.5 m-85 -95.81 139.42 32.06 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 -179.833 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -72.02 111.09 6.97 Favored 'General case' 0 N--CA 1.45 -0.444 0 N-CA-C 107.7 -1.222 . . . . 0.0 107.7 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -46.16 -31.3 2.33 Favored 'General case' 0 CA--C 1.532 0.274 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -178.218 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -81.99 -50.92 8.58 Favored 'General case' 0 CA--C 1.531 0.25 0 CA-C-N 118.392 0.542 . . . . 0.0 109.662 178.614 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 40.3 mt-10 -80.45 56.65 2.61 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 124.143 0.977 . . . . 0.0 112.713 -177.066 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 26.4 pt -151.53 149.71 24.89 Favored Pre-proline 0 CA--C 1.534 0.329 0 C-N-CA 126.06 1.744 . . . . 0.0 107.715 175.816 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -69.11 116.26 4.4 Favored 'Trans proline' 0 N--CA 1.45 -1.068 0 C-N-CA 121.692 1.595 . . . . 0.0 108.706 176.77 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -33.65 -40.61 0.08 Allowed 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 127.741 2.416 . . . . 0.0 115.192 -177.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -50.98 -35.58 32.81 Favored Glycine 0 CA--C 1.533 1.16 0 C-N-CA 123.532 0.587 . . . . 0.0 112.805 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 48.2 t -103.53 103.77 15.65 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.209 0 CA-C-N 117.862 0.831 . . . . 0.0 108.945 -179.577 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -63.39 135.23 56.82 Favored 'General case' 0 CA--C 1.535 0.402 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 177.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -43.24 -41.26 3.79 Favored 'General case' 0 C--O 1.231 0.104 0 C-N-CA 126.182 1.793 . . . . 0.0 114.212 -179.504 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 85.8 t -56.88 -27.99 27.53 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 C-N-CA 123.03 0.532 . . . . 0.0 110.767 -179.459 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 34.5 mmtp -76.27 -19.11 58.62 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-O 118.438 -0.791 . . . . 0.0 112.539 -179.198 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.411 HG13 ' CG ' ' A' ' 41' ' ' PHE . 0.1 OUTLIER -117.11 -23.37 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 N-CA-C 113.491 0.923 . . . . 0.0 113.491 -179.761 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 31.3 m -84.09 129.82 34.89 Favored 'General case' 0 N--CA 1.453 -0.308 0 N-CA-C 113.892 1.071 . . . . 0.0 113.892 -177.207 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 15.0 tpt -66.18 121.57 77.08 Favored Pre-proline 0 CA--C 1.54 0.559 0 N-CA-C 104.824 -2.287 . . . . 0.0 104.824 173.85 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 90.5 Cg_exo -47.99 121.58 6.12 Favored 'Trans proline' 0 N--CA 1.457 -0.636 0 C-N-CA 123.0 2.467 . . . . 0.0 112.902 -178.094 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 21.2 mm-40 -42.51 -38.23 1.88 Allowed 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 126.009 1.724 . . . . 0.0 113.372 179.854 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 43.0 tt0 -54.63 -36.01 64.06 Favored 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 124.821 1.248 . . . . 0.0 111.562 179.54 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 49.9 mt-10 -105.02 157.1 17.46 Favored 'General case' 0 N--CA 1.445 -0.693 0 C-N-CA 125.736 1.615 . . . . 0.0 110.734 -177.621 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -161.17 151.81 18.08 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-O 121.79 0.805 . . . . 0.0 111.247 177.558 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 50.9 mt -76.81 96.27 4.24 Favored 'General case' 0 N--CA 1.444 -0.743 0 N-CA-C 103.278 -2.86 . . . . 0.0 103.278 177.783 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 4.0 p30 -88.0 -40.42 13.89 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 126.228 1.811 . . . . 0.0 113.515 -175.207 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -95.63 156.44 37.44 Favored Pre-proline 0 CA--C 1.535 0.374 0 C-N-CA 123.823 0.849 . . . . 0.0 110.142 -178.448 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -64.69 161.42 35.82 Favored 'Trans proline' 0 N--CA 1.457 -0.664 0 C-N-CA 122.245 1.964 . . . . 0.0 109.545 176.897 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 78.54 -34.5 1.81 Allowed Glycine 0 CA--C 1.529 0.931 0 CA-C-O 118.59 -1.117 . . . . 0.0 114.182 177.205 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 50.6 mt-10 -48.46 140.98 7.26 Favored 'General case' 0 CA--C 1.533 0.324 0 CA-C-N 119.062 1.431 . . . . 0.0 111.056 179.17 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 2.5 p -120.14 161.44 21.02 Favored 'General case' 0 N--CA 1.453 -0.316 0 C-N-CA 124.732 1.213 . . . . 0.0 111.84 -177.028 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 47.4 t80 -137.1 147.83 46.32 Favored 'General case' 0 N--CA 1.456 -0.13 0 N-CA-C 104.608 -2.367 . . . . 0.0 104.608 173.731 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 25.9 t -136.21 145.03 31.49 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.097 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 -178.46 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.8 p -152.62 138.13 11.17 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 178.739 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 33.8 m -105.6 112.25 25.26 Favored 'General case' 0 CA--C 1.528 0.129 0 C-N-CA 123.927 0.891 . . . . 0.0 108.801 -179.183 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 27.6 mt -93.19 88.5 6.07 Favored 'General case' 0 CA--C 1.529 0.167 0 CA-C-O 121.247 0.546 . . . . 0.0 110.84 -178.541 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -60.9 -69.12 0.25 Allowed 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 124.747 1.219 . . . . 0.0 114.052 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 2.8 m -73.2 138.82 45.88 Favored 'General case' 0 N--CA 1.452 -0.354 0 C-N-CA 124.098 0.959 . . . . 0.0 113.459 -172.174 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -62.72 154.17 30.37 Favored 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 123.711 0.804 . . . . 0.0 110.189 177.839 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 145.31 -170.3 26.71 Favored Glycine 0 C--N 1.334 0.456 0 N-CA-C 111.194 -0.763 . . . . 0.0 111.194 178.333 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 24.0 m -112.24 120.44 41.76 Favored 'General case' 0 N--CA 1.453 -0.304 0 N-CA-C 106.451 -1.685 . . . . 0.0 106.451 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 34.7 m-85 -117.28 107.32 14.26 Favored 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 124.046 0.938 . . . . 0.0 109.327 -178.232 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -92.5 139.58 30.44 Favored 'General case' 0 C--O 1.232 0.171 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 177.601 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 32.9 p90 -137.27 167.45 21.56 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 121.387 0.613 . . . . 0.0 111.613 -178.389 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 44.8 p90 -155.84 161.03 40.68 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 114.933 -1.03 . . . . 0.0 112.379 -178.461 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.4 t -101.72 103.77 14.55 Favored 'General case' 0 CA--C 1.519 -0.241 0 N-CA-C 105.308 -2.108 . . . . 0.0 105.308 176.674 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.344 77.7 p -45.48 -58.25 6.26 Favored Pre-proline 0 CA--C 1.537 0.452 0 N-CA-C 115.723 1.749 . . . . 0.0 115.723 -173.258 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -60.3 -7.79 7.38 Favored 'Trans proline' 0 N--CA 1.458 -0.57 0 C-N-CA 121.994 1.796 . . . . 0.0 114.527 -179.414 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 35.1 m80 -132.78 18.96 4.2 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 119.843 1.201 . . . . 0.0 111.427 179.064 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 31.8 tt0 -58.07 -49.86 75.45 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 178.133 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -55.96 -32.04 59.06 Favored Glycine 0 CA--C 1.531 1.046 0 C-N-CA 123.798 0.713 . . . . 0.0 112.005 178.61 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -82.32 4.12 25.05 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 117.497 0.648 . . . . 0.0 111.56 179.277 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 83.11 16.01 70.7 Favored Glycine 0 CA--C 1.526 0.727 0 CA-C-O 119.019 -0.878 . . . . 0.0 112.967 178.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 20.5 ttt -78.76 77.96 5.22 Favored 'General case' 0 C--O 1.237 0.398 0 CA-C-N 119.322 1.561 . . . . 0.0 108.569 178.917 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 8.1 m -128.0 174.65 11.16 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 C-N-CA 125.984 1.714 . . . . 0.0 110.993 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -166.66 174.08 42.06 Favored Glycine 0 CA--C 1.526 0.766 0 N-CA-C 111.053 -0.819 . . . . 0.0 111.053 177.461 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 23.6 ttmm -149.01 110.88 4.57 Favored 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 124.389 1.076 . . . . 0.0 110.057 -177.128 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.1 p -106.53 128.87 60.78 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.356 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 179.799 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.0 m -100.99 110.2 22.2 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 124.73 1.212 . . . . 0.0 110.354 -177.36 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 24.0 t -83.92 101.32 8.35 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.768 0 N-CA-C 105.799 -1.926 . . . . 0.0 105.799 179.614 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 2.7 m-80 . . . . . 0 N--CA 1.451 -0.402 0 C-N-CA 125.749 1.62 . . . . 0.0 108.922 -177.892 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 4.0 mm? . . . . . 0 N--CA 1.455 -0.208 0 CA-C-O 121.396 0.617 . . . . 0.0 111.705 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 14.6 tp10 -113.77 118.48 34.4 Favored 'General case' 0 N--CA 1.452 -0.367 0 N-CA-C 104.756 -2.313 . . . . 0.0 104.756 177.101 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 41.6 t -118.14 130.9 72.32 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 -178.827 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 68.8 mt -94.54 126.24 39.7 Favored 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 178.838 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 82.3 mt -90.13 98.94 12.06 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 105.835 -1.913 . . . . 0.0 105.835 177.046 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 110.57 -161.27 12.93 Favored Glycine 0 N--CA 1.447 -0.606 0 N-CA-C 109.095 -1.602 . . . . 0.0 109.095 -178.563 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 19.9 p -155.9 158.35 37.84 Favored 'General case' 0 N--CA 1.447 -0.591 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 -179.551 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.55 -39.99 31.16 Favored Glycine 0 CA--C 1.53 1.015 0 C-N-CA 123.538 0.59 . . . . 0.0 112.27 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -79.21 11.38 2.89 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 124.124 0.97 . . . . 0.0 112.642 179.218 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 70.12 14.02 70.62 Favored Glycine 0 CA--C 1.527 0.832 0 C-N-CA 124.605 1.098 . . . . 0.0 114.35 178.037 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 47.3 t -77.39 135.22 38.31 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 119.417 1.609 . . . . 0.0 108.82 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.497 ' H ' HD22 ' A' ' 12' ' ' LEU . 1.7 mm? -73.57 67.98 1.14 Allowed 'General case' 0 N--CA 1.443 -0.793 0 C-N-CA 126.011 1.724 . . . . 0.0 111.179 -178.249 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 20.9 m -129.76 153.16 38.41 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 C-N-CA 123.477 0.711 . . . . 0.0 110.4 179.498 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 39.5 m-85 -93.33 131.44 38.48 Favored 'General case' 0 C--N 1.332 -0.169 0 N-CA-C 104.132 -2.544 . . . . 0.0 104.132 175.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.3 t -125.03 109.66 27.43 Favored Pre-proline 0 CA--C 1.534 0.362 0 CA-C-N 119.161 0.891 . . . . 0.0 108.906 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_endo -72.04 150.77 95.08 Favored 'Cis proline' 0 N--CA 1.459 -0.533 0 CA-C-N 120.209 1.11 . . . . 0.0 110.987 -1.478 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.2 m -77.17 -48.08 18.62 Favored 'General case' 0 N--CA 1.456 -0.133 0 C-N-CA 123.036 0.534 . . . . 0.0 110.258 179.444 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -124.68 134.28 52.92 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 179.475 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 39.0 p90 -158.67 -176.83 6.11 Favored 'General case' 0 C--O 1.233 0.215 0 O-C-N 123.181 0.301 . . . . 0.0 110.7 -178.701 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 16.0 m -133.95 149.77 51.27 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 125.036 1.334 . . . . 0.0 107.925 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.7 p -144.98 138.99 14.73 Favored Pre-proline 0 CA--C 1.537 0.445 0 C-N-CA 123.796 0.839 . . . . 0.0 109.962 -177.843 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_exo -65.3 140.54 64.64 Favored 'Trans proline' 0 N--CA 1.455 -0.743 0 CA-C-N 120.746 1.302 . . . . 0.0 110.241 176.996 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 52.2 m -52.42 122.35 8.64 Favored 'General case' 0 N--CA 1.455 -0.193 0 C-N-CA 124.161 0.984 . . . . 0.0 110.857 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 102.56 -19.13 48.86 Favored Glycine 0 CA--C 1.528 0.877 0 CA-C-O 118.82 -0.989 . . . . 0.0 113.051 179.446 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -73.19 143.78 47.07 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-N 119.658 1.729 . . . . 0.0 110.25 179.312 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 18.3 ptmt -81.16 144.2 31.83 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 124.424 1.09 . . . . 0.0 111.58 -178.852 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 35.9 mt -113.2 130.48 67.04 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 178.424 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 59.7 t -114.25 102.63 14.15 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.245 0 C-N-CA 125.135 1.374 . . . . 0.0 108.017 -179.258 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -90.92 98.5 11.82 Favored 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 178.85 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 27.0 ttpp -91.75 132.38 36.44 Favored 'General case' 0 CA--C 1.528 0.132 0 C-N-CA 123.581 0.752 . . . . 0.0 112.724 -177.608 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 54.5 t-20 -66.21 110.25 2.95 Favored 'General case' 0 CA--C 1.53 0.21 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 176.395 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 -87.34 -72.96 0.49 Allowed 'General case' 0 C--N 1.338 0.078 0 CA-C-N 118.31 0.504 . . . . 0.0 110.843 -179.11 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -163.46 175.43 10.76 Favored 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 125.131 1.372 . . . . 0.0 107.732 -177.747 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 65.36 24.11 70.53 Favored Glycine 0 CA--C 1.534 1.272 0 CA-C-N 118.694 0.679 . . . . 0.0 111.594 -178.8 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.529 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 17.1 p90 -74.72 169.05 21.7 Favored Pre-proline 0 CA--C 1.542 0.668 0 N-CA-C 107.108 -1.442 . . . . 0.0 107.108 178.411 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.529 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 88.3 Cg_endo -69.53 158.3 90.45 Favored 'Cis proline' 0 N--CA 1.448 -1.201 0 CA-C-O 123.115 1.215 . . . . 0.0 114.994 3.731 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 88.2 m-70 -149.55 172.94 14.2 Favored 'General case' 0 N--CA 1.445 -0.711 0 CA-C-N 114.693 -1.14 . . . . 0.0 109.356 179.542 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 48.0 p30 -169.77 173.11 6.38 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 104.435 -2.432 . . . . 0.0 104.435 176.514 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 37.6 t -130.14 110.51 19.4 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.222 0 N-CA-C 107.767 -1.197 . . . . 0.0 107.767 -178.54 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.9 t -113.03 129.12 69.27 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.606 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 -179.737 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 62.2 m-85 -91.04 133.17 35.52 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 178.658 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -68.61 110.57 4.3 Favored 'General case' 0 N--CA 1.452 -0.352 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 -179.751 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -41.75 -35.0 0.7 Allowed 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 126.154 1.782 . . . . 0.0 115.747 -177.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -85.14 -50.01 7.77 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 118.5 0.591 . . . . 0.0 110.879 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -79.67 56.56 2.27 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 124.271 1.028 . . . . 0.0 112.412 -176.362 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 31.8 pt -153.35 156.57 32.57 Favored Pre-proline 0 CA--C 1.533 0.304 0 C-N-CA 126.689 1.996 . . . . 0.0 107.473 176.673 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_exo -53.62 109.5 0.38 Allowed 'Trans proline' 0 N--CA 1.456 -0.681 0 C-N-CA 122.819 2.346 . . . . 0.0 111.141 177.001 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -52.28 106.42 0.15 Allowed 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 124.203 1.001 . . . . 0.0 110.107 -179.772 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 142.29 -35.57 1.73 Allowed Glycine 0 CA--C 1.526 0.756 0 N-CA-C 109.005 -1.638 . . . . 0.0 109.005 -177.699 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 47.2 t -77.08 108.19 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 179.285 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 45.2 t0 -59.11 109.11 0.78 Allowed 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 123.039 0.535 . . . . 0.0 110.566 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.34 -40.42 17.21 Favored 'General case' 0 N--CA 1.453 -0.313 0 C-N-CA 125.079 1.351 . . . . 0.0 111.531 179.274 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 54.4 t -58.33 -28.77 36.3 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 C-N-CA 123.491 0.717 . . . . 0.0 111.925 -179.088 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 2.6 mmmp? -82.34 -40.66 21.1 Favored 'General case' 0 N--CA 1.461 0.122 0 CA-C-N 118.709 0.686 . . . . 0.0 110.909 -178.902 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.427 HD13 HG21 ' A' ' 55' ' ' ILE . 33.1 pt -78.14 -30.26 15.84 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.209 0 N-CA-C 112.191 0.441 . . . . 0.0 112.191 -179.842 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 35.5 m -90.7 146.74 23.76 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 114.667 1.358 . . . . 0.0 114.667 -176.792 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 48.2 mmm -74.67 128.05 86.18 Favored Pre-proline 0 N--CA 1.448 -0.556 0 N-CA-C 102.066 -3.309 . . . . 0.0 102.066 169.005 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -61.33 133.44 46.33 Favored 'Trans proline' 0 N--CA 1.453 -0.878 0 N-CA-C 107.213 -1.88 . . . . 0.0 107.213 178.609 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -43.32 -35.18 1.41 Allowed 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 124.506 1.122 . . . . 0.0 113.812 -176.757 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -55.0 -41.64 71.49 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 124.999 1.319 . . . . 0.0 111.414 178.399 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 74.9 mm-40 -85.3 144.41 28.1 Favored 'General case' 0 N--CA 1.444 -0.737 0 C-N-CA 124.186 0.994 . . . . 0.0 111.122 -177.904 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 92.3 mt -143.49 145.25 32.43 Favored 'General case' 0 N--CA 1.45 -0.442 0 C-N-CA 124.729 1.212 . . . . 0.0 110.446 -177.886 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 84.4 mt -86.23 99.85 11.83 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 104.421 -2.437 . . . . 0.0 104.421 175.245 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 33.0 p-10 -86.57 -51.4 6.19 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 124.189 0.996 . . . . 0.0 111.736 -177.556 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.91 143.49 66.51 Favored Pre-proline 0 CA--C 1.533 0.322 0 O-C-N 121.932 -0.48 . . . . 0.0 110.468 -177.894 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -64.91 152.4 82.4 Favored 'Trans proline' 0 N--CA 1.453 -0.872 0 C-N-CA 122.522 2.148 . . . . 0.0 109.513 178.322 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 86.14 -24.52 7.97 Favored Glycine 0 CA--C 1.527 0.822 0 CA-C-O 118.41 -1.217 . . . . 0.0 114.09 177.125 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 66.1 mt-10 -51.8 127.43 20.83 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-N 119.465 1.633 . . . . 0.0 110.522 179.11 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 11.8 p -105.63 120.7 42.32 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 124.772 1.229 . . . . 0.0 112.334 -178.713 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 25.1 t80 -95.01 107.54 19.58 Favored 'General case' 0 N--CA 1.452 -0.372 0 N-CA-C 104.743 -2.317 . . . . 0.0 104.743 173.576 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 22.6 t -95.63 138.13 22.0 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 -178.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 10.9 p -145.85 168.81 7.06 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.17 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 177.548 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 29.1 m -147.02 130.39 16.66 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 64.6 mt -114.31 116.85 29.62 Favored 'General case' 0 CA--C 1.531 0.224 0 C-N-CA 123.636 0.774 . . . . 0.0 109.766 -177.601 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -91.3 -46.37 8.08 Favored 'General case' 0 CA--C 1.531 0.239 0 C-N-CA 124.195 0.998 . . . . 0.0 111.716 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.7 m -73.22 121.03 19.66 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 122.792 0.437 . . . . 0.0 110.712 -177.069 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 23.4 pttm -64.77 153.17 40.69 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 122.918 0.487 . . . . 0.0 111.462 178.778 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 139.18 174.28 13.45 Favored Glycine 0 CA--C 1.529 0.911 0 C-N-CA 125.552 1.548 . . . . 0.0 110.467 179.426 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 99.0 m -99.01 116.95 32.42 Favored 'General case' 0 N--CA 1.456 -0.128 0 C-N-CA 124.296 1.038 . . . . 0.0 108.646 179.457 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 10.7 m-85 -103.82 134.31 47.34 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 125.368 1.467 . . . . 0.0 108.05 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 20.2 m -104.3 139.51 39.19 Favored 'General case' 0 C--O 1.232 0.173 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 176.333 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 15.6 p90 -138.13 166.37 24.3 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-O 121.474 0.654 . . . . 0.0 111.946 -179.421 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 43.7 p90 -152.22 162.45 41.11 Favored 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 124.393 1.077 . . . . 0.0 112.294 -178.697 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.6 t -101.57 106.68 17.79 Favored 'General case' 0 CA--C 1.52 -0.174 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 176.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 4.9 t -38.82 -64.21 0.51 Allowed Pre-proline 0 CA--C 1.542 0.645 0 N-CA-C 115.349 1.611 . . . . 0.0 115.349 -175.413 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -64.09 -4.31 7.44 Favored 'Trans proline' 0 C--N 1.348 0.537 0 C-N-CA 122.467 2.111 . . . . 0.0 114.533 -177.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 37.0 m80 -130.42 20.81 5.2 Favored 'General case' 0 N--CA 1.455 -0.216 0 CA-C-N 119.461 1.028 . . . . 0.0 110.698 179.041 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 4.6 tp60 -58.43 -51.97 67.58 Favored 'General case' 0 CA--C 1.533 0.296 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 177.093 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.13 -33.55 61.19 Favored Glycine 0 CA--C 1.532 1.129 0 C-N-CA 123.526 0.584 . . . . 0.0 111.866 178.276 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -81.54 1.57 33.01 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 123.284 0.634 . . . . 0.0 111.953 179.265 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 77.14 23.82 67.74 Favored Glycine 0 CA--C 1.526 0.757 0 CA-C-O 119.231 -0.76 . . . . 0.0 113.512 178.711 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 26.1 ttt -79.27 80.47 5.63 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-N 119.207 1.504 . . . . 0.0 107.406 177.728 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 16.5 m -121.65 169.49 12.91 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.191 0 C-N-CA 125.943 1.697 . . . . 0.0 110.878 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -170.93 179.47 42.81 Favored Glycine 0 CA--C 1.526 0.733 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 178.139 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 49.6 mttp -148.17 161.4 41.53 Favored 'General case' 0 CA--C 1.528 0.132 0 CA-C-N 117.985 0.893 . . . . 0.0 110.581 -179.474 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 3.8 p -145.04 124.01 5.84 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 C-N-CA 123.488 0.715 . . . . 0.0 110.201 178.869 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 99.1 m -98.32 98.22 9.49 Favored 'General case' 0 C--O 1.236 0.359 0 C-N-CA 124.641 1.176 . . . . 0.0 111.214 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 30.2 t -75.88 120.35 25.6 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.631 0 N-CA-C 104.617 -2.364 . . . . 0.0 104.617 179.184 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 5.5 p30 . . . . . 0 N--CA 1.464 0.238 0 N-CA-C 112.634 0.605 . . . . 0.0 112.634 -174.034 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 6.0 tp . . . . . 0 CA--C 1.533 0.298 0 CA-C-O 121.024 0.44 . . . . 0.0 111.274 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 -93.08 95.76 9.63 Favored 'General case' 0 N--CA 1.456 -0.172 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 177.228 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 33.5 t -91.97 138.27 20.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 C-N-CA 125.39 1.476 . . . . 0.0 109.076 -179.503 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 72.3 mt -99.76 125.44 45.67 Favored 'General case' 0 N--CA 1.45 -0.43 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 177.816 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 59.0 mt -86.46 101.93 13.61 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 105.855 -1.906 . . . . 0.0 105.855 178.196 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 95.87 157.88 32.01 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 108.347 -1.901 . . . . 0.0 108.347 -178.196 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 53.9 p -107.57 159.71 16.23 Favored 'General case' 0 N--CA 1.445 -0.718 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 -179.833 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.91 -34.62 61.81 Favored Glycine 0 CA--C 1.529 0.937 0 C-N-CA 124.183 0.897 . . . . 0.0 111.262 178.689 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -75.66 -2.9 31.64 Favored 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 123.519 0.728 . . . . 0.0 112.243 178.902 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 96.36 -17.86 58.51 Favored Glycine 0 CA--C 1.526 0.764 0 CA-C-O 118.903 -0.943 . . . . 0.0 113.556 178.671 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 32.8 t -57.27 132.35 52.76 Favored 'General case' 0 C--O 1.238 0.487 0 CA-C-N 119.4 1.6 . . . . 0.0 110.487 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 47.8 mt -77.59 67.39 3.49 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 126.818 2.047 . . . . 0.0 110.384 -177.087 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.6 m -128.2 153.76 38.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 C-N-CA 123.264 0.626 . . . . 0.0 110.611 179.862 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -87.43 130.64 34.6 Favored 'General case' 0 N--CA 1.453 -0.311 0 N-CA-C 104.153 -2.536 . . . . 0.0 104.153 175.259 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 35.3 t -120.45 108.96 37.06 Favored Pre-proline 0 CA--C 1.535 0.385 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_endo -73.3 157.2 99.31 Favored 'Cis proline' 0 N--CA 1.459 -0.552 0 CA-C-N 120.332 1.154 . . . . 0.0 110.48 -1.566 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.5 m -79.16 -43.33 24.19 Favored 'General case' 0 C--N 1.332 -0.153 0 C-N-CA 123.054 0.542 . . . . 0.0 110.884 -179.598 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -129.08 145.18 51.34 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 106.669 -1.604 . . . . 0.0 106.669 178.192 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 19.2 p90 -166.52 -179.62 5.01 Favored 'General case' 0 C--O 1.235 0.342 0 C-N-CA 123.213 0.605 . . . . 0.0 110.186 -177.665 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 37.1 p -139.71 136.29 34.06 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 124.422 1.089 . . . . 0.0 108.684 -178.858 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 33.7 m -130.09 146.27 60.76 Favored Pre-proline 0 CA--C 1.533 0.298 0 C-N-CA 124.177 0.991 . . . . 0.0 110.185 179.606 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_exo -57.67 144.34 93.09 Favored 'Trans proline' 0 N--CA 1.455 -0.742 0 C-N-CA 122.591 2.194 . . . . 0.0 110.845 174.785 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 16.3 m -51.26 119.58 4.19 Favored 'General case' 0 CA--C 1.529 0.149 0 C-N-CA 122.608 0.363 . . . . 0.0 110.955 177.846 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 96.72 -7.48 65.44 Favored Glycine 0 CA--C 1.525 0.68 0 CA-C-O 118.426 -1.208 . . . . 0.0 113.618 178.526 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -69.18 152.96 44.46 Favored 'General case' 0 CA--C 1.531 0.224 0 CA-C-N 119.953 1.877 . . . . 0.0 110.494 178.28 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 64.4 mttp -83.36 142.0 31.35 Favored 'General case' 0 N--CA 1.446 -0.666 0 C-N-CA 124.172 0.989 . . . . 0.0 109.882 -178.502 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 37.8 mt -120.56 130.08 74.89 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 105.963 -1.866 . . . . 0.0 105.963 178.386 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 84.9 t -121.88 131.42 73.16 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.428 0 N-CA-C 106.459 -1.682 . . . . 0.0 106.459 -179.242 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -118.19 103.47 9.88 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 178.799 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 38.0 ttpt -100.76 131.3 46.72 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 123.886 0.874 . . . . 0.0 113.296 -175.858 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 6.2 m-20 -64.96 107.81 1.61 Allowed 'General case' 0 C--O 1.232 0.137 0 C-N-CA 124.124 0.969 . . . . 0.0 109.975 177.708 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 7.0 t30 -87.67 -64.42 1.15 Allowed 'General case' 0 N--CA 1.456 -0.148 0 CA-C-O 121.496 0.665 . . . . 0.0 110.089 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -163.1 172.8 14.36 Favored 'General case' 0 C--N 1.331 -0.213 0 C-N-CA 125.54 1.536 . . . . 0.0 107.191 -178.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 66.2 20.28 69.05 Favored Glycine 0 CA--C 1.534 1.219 0 CA-C-N 118.291 0.496 . . . . 0.0 112.839 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.505 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 23.4 p90 -69.96 166.94 27.89 Favored Pre-proline 0 CA--C 1.549 0.905 0 N-CA-C 106.444 -1.688 . . . . 0.0 106.444 177.177 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.505 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 88.3 Cg_endo -69.94 156.43 93.27 Favored 'Cis proline' 0 N--CA 1.444 -1.386 0 N-CA-C 115.712 1.389 . . . . 0.0 115.712 4.719 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 86.9 m-70 -147.81 164.86 32.34 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.83 -179.773 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 56.0 p30 -162.36 177.62 9.39 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 104.986 -2.228 . . . . 0.0 104.986 177.259 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 33.6 t -135.66 111.01 11.88 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 -179.547 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 93.9 t -115.19 130.47 69.68 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.586 0 N-CA-C 106.394 -1.706 . . . . 0.0 106.394 179.568 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 54.4 m-85 -87.59 136.31 33.0 Favored 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 123.4 0.68 . . . . 0.0 109.755 -179.394 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 43.7 t0 -73.11 103.89 4.01 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -47.54 -32.46 5.37 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 124.139 0.976 . . . . 0.0 113.555 179.207 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -77.3 -17.19 58.53 Favored 'General case' 0 CA--C 1.535 0.386 0 N-CA-C 112.983 0.734 . . . . 0.0 112.983 -179.78 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 81.5 mm-40 -132.91 65.9 1.58 Allowed 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.112 0.965 . . . . 0.0 111.801 -177.17 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 29.3 pt -153.3 153.49 29.44 Favored Pre-proline 0 CA--C 1.533 0.326 0 C-N-CA 127.542 2.337 . . . . 0.0 105.851 175.784 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -60.47 113.47 1.7 Allowed 'Trans proline' 0 N--CA 1.452 -0.964 0 C-N-CA 121.972 1.781 . . . . 0.0 110.556 178.293 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -51.5 108.37 0.26 Allowed 'General case' 0 N--CA 1.453 -0.276 0 C-N-CA 125.111 1.364 . . . . 0.0 110.397 -179.248 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 143.61 -37.51 1.45 Allowed Glycine 0 CA--C 1.524 0.617 0 N-CA-C 109.019 -1.632 . . . . 0.0 109.019 -178.428 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 45.8 t -77.58 113.82 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.239 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 41.9 t0 -60.94 111.65 1.75 Allowed 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 122.769 0.428 . . . . 0.0 110.114 179.543 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.4 -41.47 20.0 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 124.685 1.194 . . . . 0.0 111.149 178.91 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 48.6 t -59.7 -29.16 42.19 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.395 0 C-N-CA 123.283 0.633 . . . . 0.0 112.048 -179.053 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 64.3 mttp -78.71 -40.93 32.31 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-N 119.055 0.843 . . . . 0.0 110.772 -179.173 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.416 HD13 HG21 ' A' ' 55' ' ' ILE . 23.1 pt -77.6 -33.36 19.12 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 N-CA-C 111.917 0.34 . . . . 0.0 111.917 -179.767 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 49.1 m -82.55 138.97 34.11 Favored 'General case' 0 N--CA 1.452 -0.341 0 N-CA-C 113.935 1.087 . . . . 0.0 113.935 -177.602 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 15.7 tpt -70.85 126.16 92.11 Favored Pre-proline 0 N--CA 1.449 -0.498 0 N-CA-C 101.956 -3.35 . . . . 0.0 101.956 170.813 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 76.2 Cg_exo -43.91 119.27 1.88 Allowed 'Trans proline' 0 N--CA 1.457 -0.66 0 C-N-CA 122.929 2.419 . . . . 0.0 111.51 -178.457 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -47.0 -34.97 6.08 Favored 'General case' 0 CA--C 1.532 0.255 0 C-N-CA 125.162 1.385 . . . . 0.0 113.708 -177.465 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 31.0 tp10 -61.61 -34.51 75.77 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.325 1.05 . . . . 0.0 110.729 179.009 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 63.0 mt-10 -91.68 154.61 18.88 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 124.911 1.284 . . . . 0.0 110.508 -178.61 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -160.97 139.75 10.09 Favored 'General case' 0 N--CA 1.445 -0.68 0 CA-C-N 115.015 -0.993 . . . . 0.0 110.971 179.867 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 73.8 mt -77.86 112.39 14.68 Favored 'General case' 0 N--CA 1.448 -0.575 0 N-CA-C 105.059 -2.2 . . . . 0.0 105.059 178.199 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 63.7 t30 -115.54 46.69 1.45 Allowed 'General case' 0 N--CA 1.464 0.247 0 C-N-CA 124.2 1.0 . . . . 0.0 112.491 -177.03 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -160.5 155.39 20.74 Favored Pre-proline 0 CA--C 1.531 0.22 0 N-CA-C 107.08 -1.452 . . . . 0.0 107.08 178.204 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -73.02 162.64 40.42 Favored 'Trans proline' 0 N--CA 1.454 -0.833 0 C-N-CA 122.013 1.808 . . . . 0.0 109.332 178.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 77.42 -35.94 1.56 Allowed Glycine 0 CA--C 1.529 0.938 0 CA-C-O 118.798 -1.001 . . . . 0.0 114.709 176.256 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 74.5 mm-40 -47.0 134.45 10.39 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 118.783 1.291 . . . . 0.0 111.387 179.165 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 21.8 p -119.53 132.56 55.78 Favored 'General case' 0 N--CA 1.456 -0.134 0 N-CA-C 113.83 1.048 . . . . 0.0 113.83 -177.436 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 31.9 t80 -100.91 140.38 35.28 Favored 'General case' 0 CA--C 1.529 0.166 0 N-CA-C 103.801 -2.666 . . . . 0.0 103.801 170.746 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 22.0 t -128.89 145.45 35.71 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.109 0 CA-C-N 119.007 0.821 . . . . 0.0 109.74 -177.647 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 12.5 p -152.23 169.23 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.197 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 178.367 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 83.6 m -149.06 133.62 17.68 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 106.264 -1.754 . . . . 0.0 106.264 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 79.2 mt -121.25 112.14 18.25 Favored 'General case' 0 CA--C 1.53 0.189 0 C-N-CA 123.234 0.614 . . . . 0.0 110.52 -177.305 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -93.86 -39.86 10.48 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 124.427 1.091 . . . . 0.0 110.543 178.777 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 6.4 m -70.19 122.11 18.85 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 123.594 0.758 . . . . 0.0 110.091 -178.162 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 20.8 mmtm -59.24 160.29 6.66 Favored 'General case' 0 CA--C 1.529 0.14 0 C-N-CA 124.186 0.995 . . . . 0.0 110.988 -179.692 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 134.96 -170.29 22.91 Favored Glycine 0 CA--C 1.524 0.6 0 C-N-CA 123.604 0.621 . . . . 0.0 111.822 177.703 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 25.3 m -121.26 130.34 53.62 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 105.503 -2.036 . . . . 0.0 105.503 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 16.5 m-85 -124.05 135.01 53.29 Favored 'General case' 0 N--CA 1.448 -0.525 0 C-N-CA 124.106 0.962 . . . . 0.0 109.818 -176.595 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 19.2 m -108.81 143.6 37.77 Favored 'General case' 0 C--O 1.233 0.199 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 175.644 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 11.8 p90 -143.89 171.31 14.41 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-O 121.15 0.5 . . . . 0.0 111.167 -179.308 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 34.4 p90 -157.76 167.38 30.21 Favored 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 123.805 0.842 . . . . 0.0 111.917 -179.176 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.3 t -102.99 109.31 20.8 Favored 'General case' 0 N--CA 1.463 0.181 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 177.494 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -40.92 -61.09 1.37 Allowed Pre-proline 0 CA--C 1.535 0.395 0 N-CA-C 115.659 1.725 . . . . 0.0 115.659 -173.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 63.6 Cg_endo -65.96 -4.2 9.71 Favored 'Trans proline' 0 N--CA 1.457 -0.638 0 C-N-CA 121.885 1.723 . . . . 0.0 114.87 -177.878 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 34.9 m80 -135.21 4.78 3.22 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-N 120.183 1.356 . . . . 0.0 113.185 -179.395 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 16.2 pt20 -55.7 -44.38 77.33 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 119.652 1.115 . . . . 0.0 109.975 178.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -59.17 -28.15 63.71 Favored Glycine 0 CA--C 1.531 1.037 0 N-CA-C 111.454 -0.659 . . . . 0.0 111.454 177.598 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.83 10.09 24.96 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 123.875 0.87 . . . . 0.0 110.843 178.771 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 87.31 10.22 71.47 Favored Glycine 0 CA--C 1.527 0.819 0 CA-C-O 118.558 -1.135 . . . . 0.0 113.789 178.29 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 18.4 ttt -78.96 76.54 5.45 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 119.791 1.796 . . . . 0.0 109.17 179.006 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 9.5 m -123.36 169.72 14.42 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 C-N-CA 126.388 1.875 . . . . 0.0 109.664 179.172 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -170.02 -179.8 41.85 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 110.211 -1.156 . . . . 0.0 110.211 178.156 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 54.1 mtmt -145.44 163.18 35.45 Favored 'General case' 0 N--CA 1.455 -0.224 0 C-N-CA 124.218 1.007 . . . . 0.0 110.29 -178.294 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.4 p -152.93 136.14 7.54 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 C-N-CA 123.898 0.879 . . . . 0.0 108.975 177.34 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -107.26 130.43 54.75 Favored 'General case' 0 C--N 1.332 -0.167 0 C-N-CA 124.441 1.096 . . . . 0.0 109.167 -179.633 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 43.4 t -99.8 97.81 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 N-CA-C 106.078 -1.823 . . . . 0.0 106.078 179.252 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 17.4 m-20 . . . . . 0 C--O 1.236 0.377 0 C-N-CA 123.604 0.762 . . . . 0.0 109.551 -176.728 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' LEU . . . . . 0.527 ' H1 ' HD13 ' A' ' 1' ' ' LEU . 0.1 OUTLIER . . . . . 0 N--CA 1.451 -0.416 0 N-CA-C 105.976 -1.861 . . . . 0.0 105.976 . . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 69.2 tt0 -83.12 85.24 7.23 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 105.142 -2.17 . . . . 0.0 105.142 174.744 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 38.4 t -78.56 111.31 15.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 -176.713 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 57.8 mt -79.59 123.53 27.69 Favored 'General case' 0 N--CA 1.451 -0.416 0 N-CA-C 108.377 -0.971 . . . . 0.0 108.377 179.814 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 79.4 mt -84.23 107.41 16.52 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 178.903 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 86.56 130.48 2.79 Favored Glycine 0 C--N 1.337 0.599 0 N-CA-C 108.536 -1.826 . . . . 0.0 108.536 -179.014 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 5.0 p -78.99 157.46 28.13 Favored 'General case' 0 N--CA 1.441 -0.883 0 CA-C-N 118.461 1.131 . . . . 0.0 108.623 -178.898 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -43.94 -37.85 4.35 Favored Glycine 0 CA--C 1.531 1.06 0 C-N-CA 125.871 1.701 . . . . 0.0 113.76 -179.292 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -75.67 2.26 12.44 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 123.952 0.901 . . . . 0.0 113.253 -179.473 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 91.19 -10.33 75.22 Favored Glycine 0 CA--C 1.528 0.862 0 CA-C-O 118.828 -0.985 . . . . 0.0 113.188 -179.563 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.2 t -61.35 134.3 56.78 Favored 'General case' 0 C--N 1.343 0.293 0 CA-C-N 119.447 1.623 . . . . 0.0 110.518 -179.046 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 56.2 mt -76.63 66.06 2.53 Favored 'General case' 0 N--CA 1.447 -0.59 0 C-N-CA 126.079 1.751 . . . . 0.0 111.292 -176.312 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 29.4 m -131.13 148.65 32.94 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 C-N-CA 123.767 0.827 . . . . 0.0 110.361 179.437 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 49.9 m-85 -82.0 138.74 34.84 Favored 'General case' 0 N--CA 1.455 -0.204 0 N-CA-C 104.485 -2.413 . . . . 0.0 104.485 175.525 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.4 t -123.78 107.09 31.46 Favored Pre-proline 0 CA--C 1.533 0.302 0 CA-C-O 118.33 -0.843 . . . . 0.0 108.755 179.422 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_exo -70.45 154.69 95.22 Favored 'Cis proline' 0 C--N 1.346 0.429 0 CA-C-N 119.877 0.992 . . . . 0.0 112.015 -0.809 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.6 m -80.24 -45.44 17.97 Favored 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 177.927 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -126.98 142.5 51.54 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 105.84 -1.911 . . . . 0.0 105.84 177.642 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 33.8 p90 -166.88 175.62 7.59 Favored 'General case' 0 N--CA 1.455 -0.202 0 C-N-CA 123.637 0.775 . . . . 0.0 109.319 -178.893 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 16.4 m -134.8 143.16 46.92 Favored 'General case' 0 N--CA 1.45 -0.439 0 C-N-CA 124.499 1.12 . . . . 0.0 108.187 -179.652 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 32.7 m -137.73 149.51 64.9 Favored Pre-proline 0 CA--C 1.53 0.192 0 C-N-CA 124.632 1.173 . . . . 0.0 108.675 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -71.66 148.66 53.51 Favored 'Trans proline' 0 N--CA 1.448 -1.163 0 C-N-CA 121.76 1.64 . . . . 0.0 108.902 176.426 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 52.3 m -49.01 121.75 5.11 Favored 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 123.434 0.694 . . . . 0.0 110.961 178.572 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 99.51 -10.42 61.12 Favored Glycine 0 CA--C 1.526 0.766 0 CA-C-O 118.452 -1.193 . . . . 0.0 113.513 178.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -65.6 144.54 56.9 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 119.982 1.891 . . . . 0.0 108.969 178.394 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.2 ptmt -89.36 140.85 29.09 Favored 'General case' 0 N--CA 1.443 -0.825 0 N-CA-C 108.606 -0.886 . . . . 0.0 108.606 178.866 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 35.8 mt -112.61 131.94 62.74 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.386 0 N-CA-C 105.305 -2.109 . . . . 0.0 105.305 179.066 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 95.2 t -119.01 101.07 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.351 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 -179.071 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -86.27 132.66 33.94 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 106.228 -1.768 . . . . 0.0 106.228 177.357 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 61.1 tttp -131.27 130.54 42.96 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 119.237 0.926 . . . . 0.0 112.629 -176.699 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 4.1 m-20 -64.18 105.95 0.99 Allowed 'General case' 0 C--O 1.232 0.153 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 176.796 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 36.0 t30 -97.44 -69.72 0.75 Allowed 'General case' 0 N--CA 1.456 -0.162 0 CA-C-O 121.121 0.486 . . . . 0.0 110.521 -179.58 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -143.46 170.42 15.84 Favored 'General case' 0 C--O 1.224 -0.271 0 C-N-CA 124.102 0.961 . . . . 0.0 109.15 -178.56 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 57.75 19.68 36.81 Favored Glycine 0 CA--C 1.536 1.393 0 CA-C-N 118.748 0.703 . . . . 0.0 114.094 179.56 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.497 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 27.0 p90 -71.25 167.02 33.12 Favored Pre-proline 0 CA--C 1.542 0.662 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 178.026 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.497 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 94.6 Cg_endo -70.49 160.42 90.25 Favored 'Cis proline' 0 N--CA 1.448 -1.153 0 N-CA-C 115.571 1.335 . . . . 0.0 115.571 4.336 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 86.7 m-70 -151.87 173.16 15.12 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.672 -178.841 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 57.2 p30 -163.14 178.25 8.41 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 105.035 -2.209 . . . . 0.0 105.035 176.397 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 24.0 t -135.39 110.23 11.51 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.307 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 -179.207 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 53.7 t -112.93 131.02 65.69 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 N-CA-C 106.552 -1.647 . . . . 0.0 106.552 179.545 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -92.02 132.64 36.4 Favored 'General case' 0 N--CA 1.45 -0.43 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 178.411 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -71.74 101.2 2.52 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 -178.881 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -37.61 -36.68 0.18 Allowed 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 126.676 1.99 . . . . 0.0 115.681 179.48 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 72.6 m-20 -77.94 -43.71 29.04 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-N 118.747 0.703 . . . . 0.0 110.343 179.755 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -93.32 57.58 2.68 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 124.487 1.115 . . . . 0.0 113.028 -176.502 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 37.5 pt -154.98 157.86 32.0 Favored Pre-proline 0 CA--C 1.533 0.306 0 C-N-CA 126.392 1.877 . . . . 0.0 106.879 176.238 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -57.85 108.15 0.36 Allowed 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 122.09 1.86 . . . . 0.0 108.245 173.812 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -35.08 -43.4 0.2 Allowed 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 126.829 2.052 . . . . 0.0 115.433 -177.084 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -57.68 -31.59 64.09 Favored Glycine 0 CA--C 1.533 1.218 0 C-N-CA 123.114 0.387 . . . . 0.0 113.341 -179.208 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 41.8 t -83.54 99.94 6.61 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 CA-C-N 117.945 0.873 . . . . 0.0 109.186 -178.595 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 17.4 t0 -53.6 113.29 1.12 Allowed 'General case' 0 CA--C 1.536 0.405 0 C-N-CA 123.321 0.648 . . . . 0.0 110.306 178.149 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -46.67 -39.91 12.23 Favored 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 125.778 1.631 . . . . 0.0 112.295 -179.874 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 54.0 t -59.11 -27.72 36.92 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 C-N-CA 123.101 0.561 . . . . 0.0 111.706 -178.904 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 2.9 mmmp? -77.91 -42.94 31.5 Favored 'General case' 0 CA--C 1.529 0.16 0 CA-C-N 118.675 0.671 . . . . 0.0 110.837 -179.096 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.407 HG21 HD13 ' A' ' 55' ' ' ILE . 26.4 pt -78.78 -33.44 16.49 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.339 0 N-CA-C 112.284 0.475 . . . . 0.0 112.284 -179.037 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 44.4 m -80.52 141.69 34.9 Favored 'General case' 0 C--N 1.333 -0.112 0 N-CA-C 114.96 1.467 . . . . 0.0 114.96 -176.599 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -73.69 137.85 77.1 Favored Pre-proline 0 CA--C 1.539 0.528 0 N-CA-C 103.031 -2.951 . . . . 0.0 103.031 172.008 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_endo -48.97 107.31 0.14 Allowed 'Trans proline' 0 CA--C 1.535 0.568 0 C-N-CA 122.768 2.312 . . . . 0.0 112.173 -178.565 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -35.91 -43.55 0.32 Allowed 'General case' 0 C--O 1.233 0.204 0 C-N-CA 128.283 2.633 . . . . 0.0 116.598 -176.334 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 13.8 tm-20 -73.81 -32.39 63.71 Favored 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 124.576 1.15 . . . . 0.0 111.637 -178.363 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 51.8 mt-10 -84.93 165.45 17.62 Favored 'General case' 0 N--CA 1.446 -0.647 0 C-N-CA 124.118 0.967 . . . . 0.0 109.426 -177.435 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 2.2 pp -157.65 160.72 38.31 Favored 'General case' 0 N--CA 1.448 -0.547 0 CA-C-O 121.419 0.628 . . . . 0.0 112.072 -178.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 72.9 mt -86.82 109.12 19.06 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 104.166 -2.531 . . . . 0.0 104.166 177.075 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 34.6 p-10 -81.14 -55.45 4.74 Favored 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 123.936 0.895 . . . . 0.0 113.282 -176.658 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.32 156.76 78.59 Favored Pre-proline 0 CA--C 1.535 0.373 0 C-N-CA 123.918 0.887 . . . . 0.0 112.302 -176.426 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -67.04 163.39 34.14 Favored 'Trans proline' 0 N--CA 1.455 -0.74 0 C-N-CA 122.364 2.043 . . . . 0.0 108.967 175.109 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 79.1 -36.48 1.94 Allowed Glycine 0 CA--C 1.528 0.897 0 CA-C-O 119.041 -0.866 . . . . 0.0 113.62 177.336 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 50.7 mm-40 -42.26 129.14 3.81 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 124.606 1.162 . . . . 0.0 110.683 178.564 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -111.83 159.76 18.01 Favored 'General case' 0 N--CA 1.452 -0.354 0 C-N-CA 124.665 1.186 . . . . 0.0 112.393 -177.07 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 75.8 t80 -138.24 111.58 8.03 Favored 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 105.136 -2.172 . . . . 0.0 105.136 174.623 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 37.4 t -101.71 142.2 16.69 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 C-N-CA 123.686 0.794 . . . . 0.0 109.657 -177.635 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 12.1 p -149.51 168.0 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 177.648 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 28.7 m -147.46 129.61 15.54 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 107.367 -1.346 . . . . 0.0 107.367 -179.858 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 62.3 mt -113.26 107.45 15.91 Favored 'General case' 0 CA--C 1.53 0.183 0 C-N-CA 123.461 0.704 . . . . 0.0 110.319 -177.394 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -86.99 -45.03 11.15 Favored 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 123.65 0.78 . . . . 0.0 111.347 179.397 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.7 m -71.88 122.34 20.61 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 123.05 0.54 . . . . 0.0 110.742 -177.063 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 55.6 mttp -59.9 160.85 7.2 Favored 'General case' 0 N--CA 1.456 -0.17 0 C-N-CA 124.835 1.254 . . . . 0.0 112.342 179.482 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 136.94 -142.82 13.98 Favored Glycine 0 C--N 1.334 0.469 0 N-CA-C 110.209 -1.156 . . . . 0.0 110.209 177.285 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 85.2 m -146.14 135.2 22.65 Favored 'General case' 0 N--CA 1.444 -0.75 0 N-CA-C 105.221 -2.14 . . . . 0.0 105.221 178.929 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 10.6 m-85 -124.7 130.08 51.74 Favored 'General case' 0 N--CA 1.446 -0.672 0 C-N-CA 123.937 0.895 . . . . 0.0 108.669 -176.456 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 17.7 m -100.32 141.52 33.05 Favored 'General case' 0 C--O 1.233 0.191 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 176.425 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 20.3 p90 -140.0 168.98 18.56 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-O 121.293 0.568 . . . . 0.0 111.275 -179.443 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 52.2 p90 -158.34 166.53 32.08 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 115.52 -0.764 . . . . 0.0 111.788 -179.264 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.3 t -105.49 107.63 18.72 Favored 'General case' 0 CA--C 1.519 -0.247 0 N-CA-C 105.817 -1.92 . . . . 0.0 105.817 177.346 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.305 0.3 OUTLIER -49.37 -56.15 17.93 Favored Pre-proline 0 CA--C 1.532 0.273 0 CA-C-N 119.119 0.872 . . . . 0.0 113.057 -174.667 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_exo -46.29 -19.49 0.65 Allowed 'Trans proline' 0 N--CA 1.457 -0.654 0 C-N-CA 123.741 2.961 . . . . 0.0 115.883 177.422 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 38.0 m80 -136.63 18.27 3.09 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 119.829 1.195 . . . . 0.0 112.16 179.764 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 15.2 pt20 -60.57 -41.69 95.14 Favored 'General case' 0 N--CA 1.455 -0.204 0 CA-C-N 119.16 0.891 . . . . 0.0 109.58 179.491 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -58.33 -28.99 62.57 Favored Glycine 0 CA--C 1.532 1.136 0 N-CA-C 111.334 -0.707 . . . . 0.0 111.334 177.203 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -90.44 11.42 21.67 Favored 'General case' 0 CA--C 1.534 0.327 0 C-N-CA 123.781 0.832 . . . . 0.0 110.954 178.908 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 78.64 19.11 74.22 Favored Glycine 0 CA--C 1.527 0.819 0 CA-C-O 118.604 -1.109 . . . . 0.0 113.575 178.657 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 22.5 ttt -78.69 76.58 5.18 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-N 119.775 1.788 . . . . 0.0 108.756 178.147 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 10.2 m -120.86 172.54 7.76 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 C-N-CA 126.191 1.796 . . . . 0.0 109.787 179.566 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -170.52 177.34 43.73 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 177.672 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 58.6 mttp -146.63 157.26 43.68 Favored 'General case' 0 CA--C 1.526 0.047 0 CA-C-N 117.53 0.665 . . . . 0.0 110.623 -178.855 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 5.5 p -143.82 126.14 11.47 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.289 0 C-N-CA 123.152 0.581 . . . . 0.0 110.48 177.847 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.28 124.06 34.06 Favored 'General case' 0 CA--C 1.53 0.179 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 177.958 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 40.7 t -100.28 95.04 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.209 0 N-CA-C 103.161 -2.903 . . . . 0.0 103.161 177.302 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 . . . . . 0 N--CA 1.453 -0.297 0 C-N-CA 125.019 1.328 . . . . 0.0 113.108 -173.945 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 8.2 mp . . . . . 0 N--CA 1.451 -0.387 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -98.79 97.61 8.81 Favored 'General case' 0 N--CA 1.453 -0.298 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 178.24 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 40.6 t -87.77 121.52 38.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 C-N-CA 124.51 1.124 . . . . 0.0 108.527 -179.463 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 70.0 mt -85.07 122.48 29.34 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 108.588 -0.894 . . . . 0.0 108.588 179.065 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 72.2 mt -86.84 99.88 12.14 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 106.103 -1.814 . . . . 0.0 106.103 177.783 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 100.9 151.29 25.04 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 108.713 -1.755 . . . . 0.0 108.713 -178.862 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 96.5 p -86.73 172.94 9.79 Favored 'General case' 0 N--CA 1.445 -0.711 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 177.378 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -54.08 -43.25 73.03 Favored Glycine 0 CA--C 1.53 0.971 0 N-CA-C 110.4 -1.08 . . . . 0.0 110.4 178.219 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -81.29 13.78 2.74 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 123.313 0.645 . . . . 0.0 112.221 178.926 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 74.48 16.98 79.8 Favored Glycine 0 CA--C 1.526 0.737 0 CA-C-O 118.849 -0.973 . . . . 0.0 114.156 178.2 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 22.8 t -71.33 140.13 50.13 Favored 'General case' 0 C--N 1.34 0.161 0 CA-C-N 119.443 1.622 . . . . 0.0 107.119 178.293 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 67.6 mt -76.52 67.65 2.71 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 125.136 1.374 . . . . 0.0 111.954 -175.411 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 26.0 m -135.17 150.17 29.4 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.21 0 C-N-CA 123.593 0.757 . . . . 0.0 110.498 179.654 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 45.3 m-85 -89.58 129.44 36.04 Favored 'General case' 0 N--CA 1.457 -0.099 0 N-CA-C 104.809 -2.293 . . . . 0.0 104.809 175.757 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 37.0 t -122.5 107.74 34.07 Favored Pre-proline 0 CA--C 1.537 0.467 0 CA-C-O 118.496 -0.764 . . . . 0.0 109.162 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -71.69 161.5 91.04 Favored 'Cis proline' 0 N--CA 1.457 -0.635 0 CA-C-N 120.227 1.117 . . . . 0.0 111.044 -1.355 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 6.2 p -86.21 -64.71 1.11 Allowed 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 178.345 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 64.9 tt0 -102.6 127.15 49.82 Favored 'General case' 0 N--CA 1.454 -0.275 0 C-N-CA 125.819 1.648 . . . . 0.0 107.577 178.47 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 33.9 p90 -150.34 -171.51 3.93 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-O 121.578 0.704 . . . . 0.0 111.998 178.87 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 7.0 m -141.63 146.8 36.63 Favored 'General case' 0 N--CA 1.45 -0.431 0 C-N-CA 124.655 1.182 . . . . 0.0 108.229 -178.943 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.0 p -148.85 137.89 12.21 Favored Pre-proline 0 CA--C 1.539 0.552 0 C-N-CA 123.28 0.632 . . . . 0.0 110.501 -177.911 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_exo -66.59 139.7 54.25 Favored 'Trans proline' 0 N--CA 1.455 -0.736 0 C-N-CA 121.424 1.416 . . . . 0.0 111.013 176.585 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 63.1 m -46.7 127.63 9.82 Favored 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 123.708 0.803 . . . . 0.0 110.978 177.125 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 94.96 -23.82 31.37 Favored Glycine 0 CA--C 1.529 0.946 0 CA-C-O 119.188 -0.784 . . . . 0.0 113.338 178.673 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 74.9 mm-40 -74.15 96.1 2.69 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 119.469 1.634 . . . . 0.0 109.318 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -41.42 126.5 2.84 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 125.734 1.614 . . . . 0.0 114.119 179.499 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 60.3 mt -90.06 136.77 22.98 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.314 0 N-CA-C 105.943 -1.873 . . . . 0.0 105.943 178.036 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 66.6 t -117.76 119.39 61.46 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.33 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 179.532 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 95.3 m-85 -106.16 109.38 21.3 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 178.338 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 62.5 tttp -105.16 129.31 53.58 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 124.489 1.115 . . . . 0.0 113.322 -175.159 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 3.6 m-20 -65.58 110.54 2.77 Favored 'General case' 0 C--O 1.23 0.07 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 176.834 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 51.1 t-20 -84.33 -72.08 0.48 Allowed 'General case' 0 N--CA 1.456 -0.166 0 N-CA-C 111.738 0.273 . . . . 0.0 111.738 -178.653 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -146.24 -53.54 0.25 Allowed 'General case' 0 C--O 1.225 -0.199 0 N-CA-C 114.359 1.244 . . . . 0.0 114.359 -175.82 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -69.69 33.88 0.37 Allowed Glycine 0 CA--C 1.538 1.494 0 N-CA-C 116.24 1.256 . . . . 0.0 116.24 -176.762 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.435 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 18.9 p90 -73.34 165.71 50.45 Favored Pre-proline 0 CA--C 1.543 0.705 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 179.783 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.435 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 34.0 Cg_exo -62.27 149.38 60.03 Favored 'Cis proline' 0 N--CA 1.451 -0.992 0 N-CA-C 116.425 1.663 . . . . 0.0 116.425 2.446 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 91.8 m-70 -145.95 172.6 13.13 Favored 'General case' 0 N--CA 1.447 -0.59 0 O-C-N 121.715 -0.616 . . . . 0.0 110.157 179.19 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 22.9 p-10 -169.42 175.85 5.33 Favored 'General case' 0 N--CA 1.447 -0.583 0 N-CA-C 104.048 -2.575 . . . . 0.0 104.048 176.875 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 46.5 t -137.99 114.67 11.4 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.332 0 N-CA-C 107.225 -1.398 . . . . 0.0 107.225 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 62.0 t -119.46 135.97 58.12 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 106.335 -1.728 . . . . 0.0 106.335 179.427 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 57.2 m-85 -89.23 135.5 33.54 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 123.219 0.608 . . . . 0.0 109.682 -178.933 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 7.3 t0 -74.85 99.46 3.79 Favored 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 124.315 1.046 . . . . 0.0 109.721 -179.06 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -44.21 -34.33 1.84 Allowed 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 124.687 1.195 . . . . 0.0 113.59 178.714 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -66.96 -25.58 66.41 Favored 'General case' 0 CA--C 1.536 0.419 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 179.831 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -135.36 76.23 1.61 Allowed 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 123.683 0.793 . . . . 0.0 111.136 -177.312 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 25.8 pt -153.66 149.94 22.16 Favored Pre-proline 0 CA--C 1.535 0.382 0 C-N-CA 127.372 2.269 . . . . 0.0 105.354 175.228 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -64.56 131.68 30.49 Favored 'Trans proline' 0 N--CA 1.453 -0.886 0 C-N-CA 121.746 1.631 . . . . 0.0 109.773 178.886 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -51.72 143.23 13.2 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 124.027 0.931 . . . . 0.0 112.061 -178.532 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 105.13 -41.35 2.18 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 110.365 -1.094 . . . . 0.0 110.365 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 19.7 t -79.25 93.23 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 CA-C-N 117.45 0.625 . . . . 0.0 109.337 -179.286 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 18.3 t0 -55.85 118.57 4.71 Favored 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 123.09 0.556 . . . . 0.0 110.494 178.606 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -44.31 -46.25 9.12 Favored 'General case' 0 CA--C 1.529 0.135 0 C-N-CA 125.662 1.585 . . . . 0.0 111.532 179.02 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 48.4 t -56.68 -31.03 33.77 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.471 0 C-N-CA 122.786 0.434 . . . . 0.0 111.926 -178.633 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 65.6 mttp -75.71 -39.46 57.31 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-N 118.678 0.672 . . . . 0.0 111.008 -178.834 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.418 HD13 HG21 ' A' ' 55' ' ' ILE . 20.6 pt -81.15 -28.27 10.85 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.271 0 N-CA-C 112.428 0.529 . . . . 0.0 112.428 -179.521 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 63.2 m -74.95 144.86 43.03 Favored 'General case' 0 N--CA 1.455 -0.224 0 O-C-N 121.778 -0.576 . . . . 0.0 112.534 -178.313 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 7.7 tmm? -65.7 126.87 92.48 Favored Pre-proline 0 CA--C 1.537 0.463 0 N-CA-C 106.185 -1.783 . . . . 0.0 106.185 177.239 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_exo -33.54 99.28 0.02 OUTLIER 'Trans proline' 0 N--CA 1.459 -0.541 0 C-N-CA 125.195 3.93 . . . . 0.0 114.16 179.519 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 59.0 mp0 -50.58 -27.19 6.3 Favored 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 126.918 2.087 . . . . 0.0 113.894 -177.081 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.7 tm-20 -63.22 -30.75 71.83 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 122.702 0.401 . . . . 0.0 110.208 178.871 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 48.1 mt-10 -104.49 172.06 7.0 Favored 'General case' 0 N--CA 1.446 -0.655 0 C-N-CA 125.579 1.551 . . . . 0.0 109.896 -178.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 88.4 mt -151.4 145.83 25.53 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 106.407 -1.701 . . . . 0.0 106.407 177.385 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 67.8 mt -83.91 96.68 8.89 Favored 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 104.722 -2.325 . . . . 0.0 104.722 176.492 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -105.59 34.08 3.44 Favored 'General case' 0 CA--C 1.536 0.434 0 C-N-CA 124.499 1.12 . . . . 0.0 113.878 -177.45 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -151.43 156.49 34.86 Favored Pre-proline 0 CA--C 1.531 0.22 0 N-CA-C 108.106 -1.072 . . . . 0.0 108.106 179.639 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -72.79 163.54 38.13 Favored 'Trans proline' 0 N--CA 1.455 -0.782 0 C-N-CA 121.885 1.724 . . . . 0.0 109.816 179.324 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 78.07 -44.71 2.41 Favored Glycine 0 CA--C 1.526 0.771 0 CA-C-O 118.557 -1.135 . . . . 0.0 114.523 175.687 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 55.2 mm-40 -38.33 122.82 1.11 Allowed 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 124.82 1.248 . . . . 0.0 113.058 -178.809 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 17.9 p -109.13 134.03 52.24 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 125.316 1.446 . . . . 0.0 112.95 -178.104 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 17.5 t80 -107.55 143.27 36.2 Favored 'General case' 0 CA--C 1.528 0.097 0 N-CA-C 104.591 -2.374 . . . . 0.0 104.591 171.936 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 20.4 t -128.57 140.13 50.05 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.16 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 -179.057 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 12.8 p -146.01 144.9 20.55 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.134 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 178.301 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 7.6 m -115.25 106.65 14.29 Favored 'General case' 0 N--CA 1.454 -0.23 0 C-N-CA 124.356 1.062 . . . . 0.0 109.849 -178.6 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 50.5 mt -95.06 129.18 42.25 Favored 'General case' 0 CA--C 1.531 0.217 0 N-CA-C 107.52 -1.289 . . . . 0.0 107.52 177.913 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 13.9 m-20 -113.85 -46.53 3.02 Favored 'General case' 0 CA--C 1.527 0.08 0 C-N-CA 123.988 0.915 . . . . 0.0 111.24 -178.638 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 4.5 m -66.22 118.98 10.71 Favored 'General case' 0 N--CA 1.452 -0.362 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 -178.67 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 64.4 mttm -63.79 152.64 38.9 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 123.337 0.655 . . . . 0.0 110.306 -179.282 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 145.41 -157.81 27.46 Favored Glycine 0 CA--C 1.522 0.469 0 N-CA-C 109.328 -1.509 . . . . 0.0 109.328 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 15.3 m -123.59 132.33 53.85 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 106.535 -1.654 . . . . 0.0 106.535 -179.627 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 19.6 m-85 -125.02 119.93 30.1 Favored 'General case' 0 N--CA 1.447 -0.624 0 C-N-CA 123.681 0.793 . . . . 0.0 108.906 -178.912 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 70.2 m -91.51 144.88 25.1 Favored 'General case' 0 C--O 1.233 0.213 0 N-CA-C 107.699 -1.223 . . . . 0.0 107.699 175.612 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 17.4 p90 -141.22 164.14 31.07 Favored 'General case' 0 N--CA 1.455 -0.222 0 CA-C-O 121.237 0.541 . . . . 0.0 110.771 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 53.3 p90 -150.7 160.16 44.03 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-N 115.061 -0.972 . . . . 0.0 112.713 -177.424 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 11.6 t -99.41 106.16 18.19 Favored 'General case' 0 CA--C 1.522 -0.104 0 N-CA-C 105.877 -1.898 . . . . 0.0 105.877 176.453 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 4.5 m -38.83 -60.03 1.23 Allowed Pre-proline 0 CA--C 1.536 0.44 0 N-CA-C 115.976 1.843 . . . . 0.0 115.976 -174.474 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 89.3 Cg_endo -72.06 -2.53 11.7 Favored 'Trans proline' 0 N--CA 1.458 -0.612 0 C-N-CA 122.056 1.837 . . . . 0.0 114.602 -178.576 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 32.9 m170 -132.96 3.86 3.77 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 120.35 1.432 . . . . 0.0 113.723 -178.152 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 15.1 pt20 -52.72 -42.81 65.2 Favored 'General case' 0 CA--C 1.534 0.355 0 CA-C-N 119.009 0.822 . . . . 0.0 110.196 178.002 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -58.52 -28.77 62.8 Favored Glycine 0 CA--C 1.53 1.021 0 C-N-CA 123.951 0.786 . . . . 0.0 111.763 178.167 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -90.74 11.94 20.74 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 123.83 0.852 . . . . 0.0 110.505 178.661 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 82.97 13.0 78.64 Favored Glycine 0 CA--C 1.527 0.825 0 CA-C-O 118.632 -1.094 . . . . 0.0 113.227 178.932 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 20.5 ttt -77.66 79.82 4.14 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 119.708 1.754 . . . . 0.0 109.473 178.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 11.0 m -131.36 169.66 21.29 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.199 0 C-N-CA 126.158 1.783 . . . . 0.0 110.298 179.1 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -168.02 179.73 41.07 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 109.321 -1.511 . . . . 0.0 109.321 178.017 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 33.8 mtmm -148.32 150.5 33.73 Favored 'General case' 0 N--CA 1.456 -0.159 0 C-N-CA 123.944 0.898 . . . . 0.0 110.439 -178.429 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.0 p -135.33 131.17 51.62 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.252 0 C-N-CA 122.973 0.509 . . . . 0.0 109.948 178.76 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.0 m -98.27 100.87 12.2 Favored 'General case' 0 CA--C 1.534 0.361 0 C-N-CA 125.212 1.405 . . . . 0.0 109.396 -179.64 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 43.6 t -79.92 114.9 21.46 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.388 0 N-CA-C 105.277 -2.119 . . . . 0.0 105.277 -179.553 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 6.6 p30 . . . . . 0 C--N 1.333 -0.133 0 C-N-CA 123.426 0.691 . . . . 0.0 111.946 -174.673 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 62.6 tp . . . . . 0 N--CA 1.45 -0.433 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -150.39 163.38 38.52 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 123.791 0.836 . . . . 0.0 109.652 -178.8 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 58.6 t -132.99 117.56 29.8 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.683 0 N-CA-C 106.217 -1.772 . . . . 0.0 106.217 178.585 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 38.7 mt -84.89 119.22 25.1 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 179.427 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 49.0 mt -82.52 83.07 7.68 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 104.372 -2.455 . . . . 0.0 104.372 176.534 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 121.38 152.1 8.68 Favored Glycine 0 CA--C 1.527 0.812 0 C-N-CA 125.708 1.623 . . . . 0.0 109.616 -176.675 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 50.5 p -114.8 44.65 1.73 Allowed 'General case' 0 CA--C 1.522 -0.121 0 C-N-CA 124.28 1.032 . . . . 0.0 111.799 -179.394 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 74.87 -56.81 2.65 Favored Glycine 0 CA--C 1.523 0.542 0 C-N-CA 126.023 1.773 . . . . 0.0 111.401 179.294 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -73.72 34.37 0.08 Allowed 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 125.406 1.482 . . . . 0.0 113.625 -177.697 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 58.94 4.39 2.24 Favored Glycine 0 CA--C 1.532 1.102 0 C-N-CA 124.828 1.204 . . . . 0.0 115.837 178.743 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.3 t -64.97 138.6 58.46 Favored 'General case' 0 N--CA 1.456 -0.146 0 CA-C-N 119.528 1.664 . . . . 0.0 110.12 -179.009 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 71.0 mt -79.98 64.69 4.9 Favored 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 124.807 1.243 . . . . 0.0 110.604 -177.098 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 28.0 m -133.68 145.13 34.02 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.223 0 C-N-CA 123.253 0.621 . . . . 0.0 112.421 -178.467 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 68.8 m-85 -89.21 125.96 35.29 Favored 'General case' 0 N--CA 1.455 -0.224 0 N-CA-C 104.037 -2.579 . . . . 0.0 104.037 175.536 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 22.4 t -118.02 110.17 40.17 Favored Pre-proline 0 CA--C 1.532 0.267 0 CA-C-N 119.529 1.059 . . . . 0.0 109.218 179.25 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -74.81 153.64 99.27 Favored 'Cis proline' 0 CA--C 1.535 0.57 0 CA-C-N 120.392 1.176 . . . . 0.0 111.164 -1.375 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.2 m -80.87 -45.55 16.66 Favored 'General case' 0 CA--C 1.528 0.127 0 C-N-CA 123.324 0.65 . . . . 0.0 110.805 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -123.58 130.96 53.45 Favored 'General case' 0 N--CA 1.451 -0.396 0 N-CA-C 104.657 -2.349 . . . . 0.0 104.657 178.46 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 42.1 p90 -157.96 -177.54 6.64 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 118.435 0.562 . . . . 0.0 111.175 -177.765 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.9 p -126.09 151.26 47.44 Favored 'General case' 0 N--CA 1.448 -0.569 0 C-N-CA 125.809 1.644 . . . . 0.0 108.758 178.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.8 p -145.53 134.36 11.05 Favored Pre-proline 0 CA--C 1.539 0.52 0 C-N-CA 123.893 0.877 . . . . 0.0 109.136 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -64.64 136.88 51.9 Favored 'Trans proline' 0 N--CA 1.455 -0.782 0 C-N-CA 121.536 1.491 . . . . 0.0 110.096 175.917 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 48.6 m -49.69 122.1 6.0 Favored 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 123.796 0.838 . . . . 0.0 111.131 179.325 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.46 -17.25 58.74 Favored Glycine 0 CA--C 1.529 0.938 0 CA-C-O 118.816 -0.991 . . . . 0.0 113.554 179.006 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 71.1 mm-40 -70.25 167.05 18.78 Favored 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 119.623 1.712 . . . . 0.0 111.428 179.679 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -92.95 146.88 23.29 Favored 'General case' 0 N--CA 1.45 -0.434 0 C-N-CA 125.029 1.331 . . . . 0.0 111.017 -179.213 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 32.1 mt -125.23 126.41 70.8 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.424 0 N-CA-C 103.682 -2.71 . . . . 0.0 103.682 176.349 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 57.2 t -112.39 96.61 4.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 C-N-CA 125.081 1.352 . . . . 0.0 108.896 -178.259 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -81.69 97.13 7.77 Favored 'General case' 0 CA--C 1.531 0.239 0 N-CA-C 106.862 -1.533 . . . . 0.0 106.862 178.305 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 63.5 tttp -93.98 127.81 39.97 Favored 'General case' 0 CA--C 1.53 0.187 0 C-N-CA 124.884 1.274 . . . . 0.0 113.557 -174.75 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -67.7 93.51 0.38 Allowed 'General case' 0 CA--C 1.533 0.324 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 176.78 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 14.0 t-20 -80.69 -67.25 0.79 Allowed 'General case' 0 N--CA 1.455 -0.221 0 C-N-CA 123.342 0.657 . . . . 0.0 110.654 -179.354 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -161.05 167.93 25.43 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.258 -176.848 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 68.87 17.5 71.51 Favored Glycine 0 CA--C 1.533 1.199 0 O-C-N 121.587 -0.695 . . . . 0.0 112.144 -179.236 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.45 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 32.8 p90 -70.12 165.95 38.38 Favored Pre-proline 0 CA--C 1.545 0.771 0 N-CA-C 106.325 -1.732 . . . . 0.0 106.325 177.351 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.45 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 92.3 Cg_endo -68.97 155.53 91.03 Favored 'Cis proline' 0 N--CA 1.446 -1.274 0 N-CA-C 115.525 1.317 . . . . 0.0 115.525 4.85 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 90.1 m-70 -147.72 170.32 17.82 Favored 'General case' 0 N--CA 1.449 -0.478 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.464 -179.683 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 40.4 p-10 -160.55 175.37 12.79 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 104.423 -2.436 . . . . 0.0 104.423 176.639 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 21.9 t -136.15 106.52 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.314 0 N-CA-C 106.787 -1.56 . . . . 0.0 106.787 -179.779 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 55.5 t -113.17 133.95 57.4 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 106.422 -1.696 . . . . 0.0 106.422 179.229 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 56.9 m-85 -96.18 140.82 30.33 Favored 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 123.544 0.738 . . . . 0.0 109.647 -179.711 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -74.08 108.13 6.7 Favored 'General case' 0 N--CA 1.453 -0.308 0 N-CA-C 107.078 -1.453 . . . . 0.0 107.078 178.204 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -44.25 -30.61 0.83 Allowed 'General case' 0 CA--C 1.535 0.386 0 N-CA-C 115.916 1.821 . . . . 0.0 115.916 -177.765 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -86.17 -49.19 7.93 Favored 'General case' 0 CA--C 1.53 0.196 0 CA-C-N 118.703 0.683 . . . . 0.0 110.48 179.153 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -80.66 57.48 2.96 Favored 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 124.109 0.964 . . . . 0.0 112.257 -176.609 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 36.2 pt -153.35 156.63 32.61 Favored Pre-proline 0 CA--C 1.534 0.348 0 C-N-CA 127.634 2.374 . . . . 0.0 106.217 176.649 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -53.07 115.53 2.34 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 C-N-CA 122.51 2.14 . . . . 0.0 111.384 178.065 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -52.88 107.88 0.26 Allowed 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 123.992 0.917 . . . . 0.0 110.083 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 136.46 -30.42 2.7 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 109.835 -1.306 . . . . 0.0 109.835 -178.069 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 69.9 t -75.62 121.89 28.35 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 CA-C-N 117.861 0.831 . . . . 0.0 109.059 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 14.8 t0 -66.35 105.46 1.45 Allowed 'General case' 0 N--CA 1.453 -0.3 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 178.752 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.49 -39.03 21.73 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 124.168 0.987 . . . . 0.0 111.463 178.982 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 41.4 t -61.68 -29.3 45.9 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.429 0 C-N-CA 122.821 0.448 . . . . 0.0 111.574 -179.359 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.53 -34.03 58.57 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 119.224 0.92 . . . . 0.0 110.979 -178.593 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.4 HD13 HG21 ' A' ' 55' ' ' ILE . 25.0 pt -85.74 -32.35 7.0 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.21 0 C-N-CA 123.266 0.626 . . . . 0.0 111.899 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 39.7 m -85.87 136.43 33.3 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 114.273 1.212 . . . . 0.0 114.273 -177.208 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 69.2 mmm -69.01 133.56 89.95 Favored Pre-proline 0 N--CA 1.452 -0.348 0 N-CA-C 103.822 -2.659 . . . . 0.0 103.822 170.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_exo -49.5 114.87 1.49 Allowed 'Trans proline' 0 N--CA 1.456 -0.698 0 C-N-CA 122.201 1.934 . . . . 0.0 109.557 178.197 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -35.44 -44.37 0.29 Allowed 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 126.164 1.786 . . . . 0.0 115.487 -177.244 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 19.9 tp10 -61.0 -37.53 82.83 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 124.566 1.147 . . . . 0.0 111.961 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 64.4 mm-40 -83.09 153.92 24.63 Favored 'General case' 0 N--CA 1.444 -0.751 0 C-N-CA 124.703 1.201 . . . . 0.0 110.181 -178.525 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -156.53 145.8 20.53 Favored 'General case' 0 N--CA 1.446 -0.634 0 CA-C-N 115.393 -0.821 . . . . 0.0 111.833 -178.528 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 43.5 mt -76.85 99.94 5.35 Favored 'General case' 0 N--CA 1.446 -0.631 0 N-CA-C 104.176 -2.527 . . . . 0.0 104.176 177.891 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -96.47 -22.33 17.19 Favored 'General case' 0 N--CA 1.462 0.171 0 N-CA-C 113.993 1.108 . . . . 0.0 113.993 -176.623 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -93.97 152.94 40.89 Favored Pre-proline 0 CA--C 1.533 0.305 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -66.43 161.99 38.5 Favored 'Trans proline' 0 N--CA 1.453 -0.908 0 C-N-CA 121.773 1.649 . . . . 0.0 110.195 178.207 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 80.14 -53.93 4.45 Favored Glycine 0 CA--C 1.523 0.568 0 CA-C-O 118.228 -1.318 . . . . 0.0 113.404 176.4 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -18.53 111.07 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.399 0 C-N-CA 126.444 1.898 . . . . 0.0 114.388 -177.011 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 14.5 p -100.71 119.07 38.05 Favored 'General case' 0 N--CA 1.446 -0.633 0 C-N-CA 124.619 1.168 . . . . 0.0 112.225 -178.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 10.8 t80 -97.13 105.61 17.79 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 105.06 -2.2 . . . . 0.0 105.06 174.624 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.9 t -94.98 134.46 32.29 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.283 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 -178.686 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.1 p -151.16 161.22 3.52 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 178.485 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.1 m -133.62 142.29 48.03 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 125.501 1.52 . . . . 0.0 107.9 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 62.4 mt -118.82 120.52 37.59 Favored 'General case' 0 N--CA 1.453 -0.31 0 N-CA-C 107.567 -1.272 . . . . 0.0 107.567 179.288 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 9.0 p-10 -95.02 -41.07 9.32 Favored 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 124.178 0.991 . . . . 0.0 112.395 -178.43 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 25.0 m -77.14 125.77 29.86 Favored 'General case' 0 N--CA 1.452 -0.328 0 C-N-CA 123.428 0.691 . . . . 0.0 109.933 -176.564 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 66.3 mttm -65.47 156.02 33.75 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 124.017 0.927 . . . . 0.0 111.477 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 127.23 177.33 14.82 Favored Glycine 0 CA--C 1.526 0.743 0 C-N-CA 123.92 0.771 . . . . 0.0 112.201 177.445 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 7.3 m -94.57 127.73 40.71 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 125.15 1.38 . . . . 0.0 108.914 -179.063 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 15.6 m-85 -115.95 135.81 53.63 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 125.755 1.622 . . . . 0.0 108.643 179.066 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 16.9 m -108.81 136.23 48.71 Favored 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 123.362 0.665 . . . . 0.0 109.419 176.915 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 20.3 p90 -137.83 168.53 19.5 Favored 'General case' 0 C--O 1.232 0.142 0 CA-C-O 121.77 0.795 . . . . 0.0 111.818 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -156.37 160.62 39.83 Favored 'General case' 0 N--CA 1.453 -0.278 0 CA-C-N 115.322 -0.854 . . . . 0.0 112.532 -178.756 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.4 t -99.74 102.37 13.81 Favored 'General case' 0 CA--C 1.519 -0.226 0 N-CA-C 106.396 -1.705 . . . . 0.0 106.396 176.867 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -48.24 -55.07 20.19 Favored Pre-proline 0 CA--C 1.532 0.263 0 CA-C-O 118.593 -0.717 . . . . 0.0 112.51 -175.877 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_exo -50.59 -15.7 1.78 Allowed 'Trans proline' 0 N--CA 1.458 -0.572 0 C-N-CA 123.387 2.725 . . . . 0.0 115.566 178.259 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 39.3 m80 -137.69 31.5 2.52 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 119.757 1.162 . . . . 0.0 110.999 -179.765 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 1.5 pm0 -60.73 -45.64 93.48 Favored 'General case' 0 CA--C 1.534 0.333 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 178.75 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.99 -35.06 67.09 Favored Glycine 0 CA--C 1.527 0.816 0 C-N-CA 124.272 0.939 . . . . 0.0 111.661 179.1 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -80.96 4.97 17.71 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-N 117.209 0.504 . . . . 0.0 111.465 179.006 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 73.94 25.2 72.15 Favored Glycine 0 CA--C 1.524 0.651 0 CA-C-O 119.147 -0.807 . . . . 0.0 112.573 179.229 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 24.5 ttt -78.96 78.24 5.41 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 119.092 1.446 . . . . 0.0 107.831 177.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 13.5 m -121.25 169.09 12.99 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.245 0 C-N-CA 126.181 1.792 . . . . 0.0 109.915 179.56 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -168.87 177.97 42.43 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.108 -1.197 . . . . 0.0 110.108 178.489 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 58.6 mttm -147.57 161.22 41.57 Favored 'General case' 0 N--CA 1.455 -0.21 0 C-N-CA 123.772 0.829 . . . . 0.0 109.621 -179.48 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 4.2 p -144.88 132.63 16.59 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.246 0 C-N-CA 123.62 0.768 . . . . 0.0 109.1 178.807 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.3 m -103.41 106.88 17.51 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.965 1.306 . . . . 0.0 109.665 -178.44 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 32.6 t -82.55 106.97 13.95 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.574 0 N-CA-C 105.905 -1.887 . . . . 0.0 105.905 178.898 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 25.6 m120 . . . . . 0 C--O 1.231 0.127 0 C-N-CA 124.279 1.032 . . . . 0.0 111.042 -176.637 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 21.1 mt . . . . . 0 N--CA 1.451 -0.379 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 45.9 tt0 -87.86 107.48 18.7 Favored 'General case' 0 N--CA 1.452 -0.343 0 N-CA-C 105.546 -2.02 . . . . 0.0 105.546 175.516 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 38.7 t -99.35 118.66 46.28 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.455 0 C-N-CA 123.813 0.845 . . . . 0.0 108.833 -177.645 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 59.1 mt -81.98 122.05 27.3 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 179.297 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 70.4 mt -87.39 89.93 8.18 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 105.321 -2.103 . . . . 0.0 105.321 177.128 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 118.25 166.36 13.7 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 109.098 -1.601 . . . . 0.0 109.098 -177.408 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 5.4 p -136.26 48.56 2.15 Favored 'General case' 0 N--CA 1.461 0.102 0 CA-C-O 122.798 1.285 . . . . 0.0 113.259 -178.938 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.44 -62.13 0.62 Allowed Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 128.238 2.828 . . . . 0.0 113.364 176.636 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -78.31 42.97 0.44 Allowed 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 123.981 0.913 . . . . 0.0 112.268 -175.578 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 75.55 -31.22 1.21 Allowed Glycine 0 CA--C 1.528 0.891 0 C-N-CA 124.934 1.254 . . . . 0.0 113.388 178.305 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 7.4 t -40.44 106.27 0.05 Allowed 'General case' 0 C--O 1.237 0.443 0 C-N-CA 126.178 1.791 . . . . 0.0 112.141 -178.522 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 48.9 mt -75.2 69.96 2.11 Favored 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 128.196 2.598 . . . . 0.0 111.551 -176.399 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.6 m -136.49 153.38 30.78 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 C-N-CA 122.86 0.464 . . . . 0.0 110.233 179.034 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 61.5 m-85 -88.57 127.27 35.55 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 105.096 -2.187 . . . . 0.0 105.096 176.859 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 38.8 t -120.79 114.42 32.61 Favored Pre-proline 0 CA--C 1.533 0.313 0 CA-C-O 118.175 -0.916 . . . . 0.0 108.688 178.902 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -73.06 147.91 90.88 Favored 'Cis proline' 0 CA--C 1.535 0.574 0 CA-C-N 120.49 1.211 . . . . 0.0 111.423 -0.455 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.4 m -78.77 -33.02 46.76 Favored 'General case' 0 CA--C 1.529 0.148 0 C-N-CA 123.715 0.806 . . . . 0.0 111.809 179.826 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -138.75 141.25 38.85 Favored 'General case' 0 N--CA 1.454 -0.241 0 N-CA-C 105.288 -2.115 . . . . 0.0 105.288 178.951 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 13.3 p90 -168.1 172.44 8.74 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 123.904 0.882 . . . . 0.0 108.739 -178.486 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 14.9 m -133.26 137.7 46.16 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 123.918 0.887 . . . . 0.0 108.685 -179.09 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.3 m -139.9 155.02 71.2 Favored Pre-proline 0 CA--C 1.531 0.234 0 C-N-CA 124.26 1.024 . . . . 0.0 110.145 -178.61 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -77.11 151.21 30.22 Favored 'Trans proline' 0 N--CA 1.451 -0.992 0 C-N-CA 121.845 1.697 . . . . 0.0 110.64 177.638 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 14.7 m -49.79 126.55 14.19 Favored 'General case' 0 N--CA 1.457 -0.112 0 C-N-CA 123.328 0.651 . . . . 0.0 109.993 175.579 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 103.21 -6.64 50.81 Favored Glycine 0 CA--C 1.526 0.752 0 CA-C-O 119.082 -0.844 . . . . 0.0 111.678 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -61.65 136.87 58.17 Favored 'General case' 0 CA--C 1.534 0.329 0 CA-C-N 119.117 1.458 . . . . 0.0 110.43 178.567 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 61.0 mttp -94.93 98.56 10.79 Favored 'General case' 0 N--CA 1.446 -0.657 0 C-N-CA 127.244 2.218 . . . . 0.0 107.436 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 56.3 mt -81.45 137.4 21.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 -179.247 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 60.4 t -120.53 102.51 12.54 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.187 0 C-N-CA 125.017 1.327 . . . . 0.0 108.703 -178.767 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -88.46 107.03 18.65 Favored 'General case' 0 CA--C 1.53 0.183 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 178.669 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 64.6 tttm -103.35 128.45 50.43 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 124.49 1.116 . . . . 0.0 113.379 -175.556 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -62.27 108.69 1.14 Allowed 'General case' 0 N--CA 1.464 0.26 0 N-CA-C 109.155 -0.684 . . . . 0.0 109.155 176.654 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 20.2 t-20 -94.05 -69.93 0.73 Allowed 'General case' 0 C--N 1.339 0.152 0 C-N-CA 123.434 0.693 . . . . 0.0 110.71 -179.403 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -154.89 166.0 34.9 Favored 'General case' 0 C--N 1.331 -0.213 0 C-N-CA 123.899 0.88 . . . . 0.0 109.586 -177.722 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 64.51 23.04 68.31 Favored Glycine 0 CA--C 1.534 1.234 0 N-CA-C 111.938 -0.465 . . . . 0.0 111.938 -178.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.491 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 15.3 p90 -71.94 166.84 36.72 Favored Pre-proline 0 CA--C 1.543 0.697 0 N-CA-C 106.177 -1.786 . . . . 0.0 106.177 177.231 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.491 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 86.6 Cg_endo -70.38 161.31 88.25 Favored 'Cis proline' 0 N--CA 1.448 -1.201 0 CA-C-N 120.227 1.117 . . . . 0.0 114.928 3.708 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 -150.69 168.28 24.84 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.207 -178.606 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -159.19 177.48 11.01 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 104.029 -2.582 . . . . 0.0 104.029 175.243 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 41.6 t -132.19 119.35 39.8 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 -179.625 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 25.6 t -114.57 122.24 68.29 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.679 0 N-CA-C 105.602 -1.999 . . . . 0.0 105.602 177.501 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 59.5 m-85 -86.32 125.56 33.7 Favored 'General case' 0 N--CA 1.446 -0.668 0 N-CA-C 105.868 -1.901 . . . . 0.0 105.868 177.046 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 12.1 t0 -64.28 103.48 0.64 Allowed 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 123.059 0.543 . . . . 0.0 110.612 -177.616 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.7 pm0 -45.02 -35.47 2.97 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 125.235 1.414 . . . . 0.0 112.994 177.703 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -70.34 -20.73 62.96 Favored 'General case' 0 CA--C 1.536 0.438 0 N-CA-C 113.277 0.843 . . . . 0.0 113.277 -179.545 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -139.81 74.76 1.48 Allowed 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 123.68 0.792 . . . . 0.0 111.659 -177.732 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 30.5 pt -157.25 157.35 30.32 Favored Pre-proline 0 CA--C 1.532 0.253 0 C-N-CA 128.562 2.745 . . . . 0.0 105.67 175.845 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -58.67 108.98 0.45 Allowed 'Trans proline' 0 N--CA 1.455 -0.738 0 C-N-CA 122.02 1.813 . . . . 0.0 107.996 173.802 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -35.08 -43.03 0.19 Allowed 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 126.676 1.99 . . . . 0.0 115.605 -177.01 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -58.21 -29.33 62.69 Favored Glycine 0 CA--C 1.533 1.19 0 CA-C-O 119.893 -0.393 . . . . 0.0 113.538 -179.122 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 42.6 t -84.72 108.11 16.45 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.295 0 CA-C-N 118.21 1.005 . . . . 0.0 109.751 -178.451 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -58.27 114.11 2.26 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 122.955 0.502 . . . . 0.0 109.784 177.716 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.76 -40.82 21.76 Favored 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 124.205 1.002 . . . . 0.0 111.499 179.183 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 48.4 t -60.65 -30.06 46.15 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.398 0 C-N-CA 123.123 0.569 . . . . 0.0 111.768 -179.133 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 37.7 mmtm -76.56 -40.98 48.15 Favored 'General case' 0 CA--C 1.528 0.112 0 CA-C-N 118.715 0.688 . . . . 0.0 110.414 -179.084 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.408 HD13 HG21 ' A' ' 55' ' ' ILE . 23.1 pt -78.84 -33.65 16.52 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 N-CA-C 112.223 0.453 . . . . 0.0 112.223 -179.76 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 41.1 m -79.47 162.35 25.51 Favored 'General case' 0 C--N 1.331 -0.203 0 N-CA-C 113.454 0.909 . . . . 0.0 113.454 -178.089 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 2.7 tmm? -104.94 107.92 59.89 Favored Pre-proline 0 CA--C 1.54 0.576 0 N-CA-C 104.522 -2.399 . . . . 0.0 104.522 175.368 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_exo -38.47 107.37 0.06 OUTLIER 'Trans proline' 0 C--N 1.35 0.606 1 C-N-CA 125.487 4.124 . . . . 0.0 114.966 -176.689 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -50.0 -22.77 1.7 Allowed 'General case' 0 CA--C 1.53 0.195 0 C-N-CA 126.475 1.91 . . . . 0.0 115.413 -178.749 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 30.8 tt0 -58.99 -32.99 70.17 Favored 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 176.797 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 57.9 mt-10 -110.87 163.25 13.98 Favored 'General case' 0 N--CA 1.444 -0.775 0 C-N-CA 126.494 1.918 . . . . 0.0 107.959 178.546 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.426 ' N ' HD13 ' A' ' 62' ' ' LEU . 0.0 OUTLIER -150.22 161.8 41.72 Favored 'General case' 0 N--CA 1.443 -0.81 0 O-C-N 121.53 -0.731 . . . . 0.0 110.426 178.599 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 81.7 mt -78.5 106.06 10.2 Favored 'General case' 0 N--CA 1.446 -0.629 0 N-CA-C 104.488 -2.412 . . . . 0.0 104.488 177.121 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 13.2 t30 -77.0 -62.2 1.73 Allowed 'General case' 0 CA--C 1.528 0.133 0 N-CA-C 114.932 1.456 . . . . 0.0 114.932 -175.034 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.88 157.02 76.95 Favored Pre-proline 0 CA--C 1.533 0.295 0 C-N-CA 123.056 0.542 . . . . 0.0 111.601 -175.534 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -63.66 164.16 22.09 Favored 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 122.2 1.933 . . . . 0.0 109.433 175.335 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 80.92 -37.61 2.34 Favored Glycine 0 CA--C 1.527 0.783 0 CA-C-O 118.231 -1.316 . . . . 0.0 114.305 176.777 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 66.7 mt-10 -41.69 126.03 2.91 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 119.079 1.44 . . . . 0.0 112.144 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 16.9 p -109.22 127.61 54.38 Favored 'General case' 0 N--CA 1.455 -0.219 0 C-N-CA 125.481 1.512 . . . . 0.0 112.693 -178.552 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 35.5 t80 -106.45 114.02 27.89 Favored 'General case' 0 N--CA 1.456 -0.159 0 N-CA-C 106.05 -1.833 . . . . 0.0 106.05 174.034 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 15.4 t -100.52 141.23 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.236 0 C-N-CA 123.189 0.596 . . . . 0.0 110.464 -177.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 10.7 p -150.45 141.52 16.6 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.208 0 N-CA-C 108.774 -0.825 . . . . 0.0 108.774 177.308 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 23.7 m -108.46 123.57 49.08 Favored 'General case' 0 CA--C 1.528 0.113 0 C-N-CA 123.752 0.821 . . . . 0.0 108.966 -178.88 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 36.9 mt -104.56 104.15 13.94 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 118.33 0.514 . . . . 0.0 109.798 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -87.19 -53.52 4.81 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 123.974 0.909 . . . . 0.0 111.602 -179.443 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 4.7 m -66.2 128.41 36.0 Favored 'General case' 0 N--CA 1.455 -0.223 0 O-C-N 121.822 -0.549 . . . . 0.0 111.402 -175.571 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 24.9 mtpp -65.89 161.52 21.01 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 124.787 1.235 . . . . 0.0 110.871 179.648 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 132.66 -137.33 9.32 Favored Glycine 0 C--N 1.335 0.503 0 N-CA-C 110.039 -1.225 . . . . 0.0 110.039 177.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 58.8 m -147.79 141.81 25.95 Favored 'General case' 0 N--CA 1.443 -0.824 0 N-CA-C 105.717 -1.957 . . . . 0.0 105.717 179.65 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 12.1 m-85 -129.61 126.43 38.43 Favored 'General case' 0 N--CA 1.446 -0.675 0 C-N-CA 124.302 1.041 . . . . 0.0 108.821 -177.054 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 74.5 m -95.4 145.67 24.97 Favored 'General case' 0 C--N 1.331 -0.201 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 175.668 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 11.7 p90 -143.49 164.5 30.16 Favored 'General case' 0 N--CA 1.455 -0.191 0 CA-C-O 121.435 0.636 . . . . 0.0 112.369 -179.538 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 53.1 p90 -155.32 160.33 40.66 Favored 'General case' 0 N--CA 1.454 -0.256 0 CA-C-N 115.228 -0.896 . . . . 0.0 112.678 -179.714 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 4.3 t -102.44 100.92 11.08 Favored 'General case' 0 CA--C 1.516 -0.341 0 N-CA-C 105.991 -1.855 . . . . 0.0 105.991 176.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.252 0.0 OUTLIER -38.7 -63.07 0.63 Allowed Pre-proline 0 CA--C 1.538 0.511 0 N-CA-C 114.346 1.239 . . . . 0.0 114.346 -175.019 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_exo -50.53 -18.27 3.67 Favored 'Trans proline' 0 CA--C 1.534 0.501 0 C-N-CA 123.635 2.89 . . . . 0.0 115.748 179.111 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 36.6 m80 -131.63 20.19 4.68 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 119.132 0.878 . . . . 0.0 111.293 -179.044 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 66.2 tt0 -60.07 -49.06 79.13 Favored 'General case' 0 CA--C 1.528 0.13 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.226 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.8 -32.22 61.74 Favored Glycine 0 CA--C 1.531 1.073 0 N-CA-C 111.475 -0.65 . . . . 0.0 111.475 178.066 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -81.79 4.12 23.29 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 123.334 0.654 . . . . 0.0 111.718 179.105 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 84.66 16.01 66.9 Favored Glycine 0 CA--C 1.527 0.798 0 CA-C-O 118.851 -0.972 . . . . 0.0 113.509 178.384 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 19.6 ttt -78.48 78.22 4.95 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 119.509 1.655 . . . . 0.0 108.332 178.491 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 5.9 m -128.43 171.71 16.08 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 C-N-CA 125.802 1.641 . . . . 0.0 110.607 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -175.99 -174.7 42.75 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 109.155 -1.578 . . . . 0.0 109.155 177.618 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 52.2 mttp -151.63 169.77 21.33 Favored 'General case' 0 N--CA 1.453 -0.323 0 C-N-CA 124.064 0.946 . . . . 0.0 109.343 179.8 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.3 p -150.37 139.5 15.27 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.382 0 C-N-CA 123.744 0.818 . . . . 0.0 108.972 177.267 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -100.44 133.51 44.76 Favored 'General case' 0 CA--C 1.529 0.168 0 C-N-CA 124.615 1.166 . . . . 0.0 107.89 179.792 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 31.7 t -115.33 109.72 29.35 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.18 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 178.784 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 48.0 p30 . . . . . 0 C--O 1.231 0.117 0 C-N-CA 124.385 1.074 . . . . 0.0 111.878 -177.0 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 20.5 mt . . . . . 0 N--CA 1.452 -0.37 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -88.6 101.94 14.46 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 105.687 -1.968 . . . . 0.0 105.687 175.238 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 41.0 t -99.88 125.28 53.59 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.374 0 C-N-CA 124.251 1.02 . . . . 0.0 109.368 -177.273 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 74.8 mt -88.54 119.05 28.63 Favored 'General case' 0 N--CA 1.446 -0.658 0 N-CA-C 108.015 -1.105 . . . . 0.0 108.015 178.264 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 19.8 mt -83.75 101.98 11.96 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 104.841 -2.281 . . . . 0.0 104.841 176.26 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 101.83 -161.34 17.68 Favored Glycine 0 N--CA 1.447 -0.573 0 N-CA-C 108.043 -2.023 . . . . 0.0 108.043 -178.016 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 54.8 p -153.32 150.34 28.81 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 106.665 -1.606 . . . . 0.0 106.665 179.545 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -50.63 -34.79 28.82 Favored Glycine 0 CA--C 1.531 1.069 0 C-N-CA 123.293 0.473 . . . . 0.0 113.09 -179.809 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -74.29 -4.99 39.48 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 123.668 0.787 . . . . 0.0 112.75 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 97.29 -17.3 59.34 Favored Glycine 0 CA--C 1.527 0.839 0 C-N-CA 124.181 0.896 . . . . 0.0 114.091 178.597 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 33.0 t -56.94 135.03 56.06 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 119.217 1.509 . . . . 0.0 111.739 -178.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 91.6 mt -80.09 78.24 6.75 Favored 'General case' 0 N--CA 1.446 -0.655 0 C-N-CA 125.713 1.605 . . . . 0.0 109.819 -178.824 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.7 p -138.6 159.1 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.303 0 C-N-CA 123.616 0.767 . . . . 0.0 109.524 178.713 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 30.7 m-85 -97.98 124.49 42.48 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 103.521 -2.77 . . . . 0.0 103.521 175.893 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 43.4 t -120.21 109.32 37.18 Favored Pre-proline 0 CA--C 1.537 0.456 0 CA-C-N 119.337 0.972 . . . . 0.0 109.717 -179.34 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -71.01 157.39 95.59 Favored 'Cis proline' 0 N--CA 1.456 -0.679 0 CA-C-N 120.325 1.152 . . . . 0.0 110.732 -1.448 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.4 p -84.11 -62.67 1.51 Allowed 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 107.577 -1.268 . . . . 0.0 107.577 179.253 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 51.1 mt-10 -107.31 127.98 54.04 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 125.367 1.467 . . . . 0.0 107.925 178.345 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 39.1 p90 -151.5 -177.21 5.95 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.875 0.369 . . . . 0.0 111.607 179.749 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 15.1 m -139.54 145.92 39.26 Favored 'General case' 0 N--CA 1.452 -0.362 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 -179.481 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.6 p -156.34 139.61 11.01 Favored Pre-proline 0 CA--C 1.54 0.576 0 CA-C-N 118.914 0.779 . . . . 0.0 109.977 -178.163 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -55.96 146.85 66.44 Favored 'Trans proline' 0 N--CA 1.458 -0.612 0 C-N-CA 122.558 2.172 . . . . 0.0 113.597 177.432 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 21.6 m -56.87 139.76 50.44 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 123.244 0.618 . . . . 0.0 110.464 177.057 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 89.41 -13.91 62.52 Favored Glycine 0 CA--C 1.529 0.922 0 CA-C-O 119.099 -0.834 . . . . 0.0 113.928 177.46 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 72.7 mm-40 -71.56 149.66 45.48 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 119.218 1.509 . . . . 0.0 110.356 178.716 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 1.7 mptm? -90.26 114.89 27.01 Favored 'General case' 0 N--CA 1.453 -0.323 0 C-N-CA 124.3 1.04 . . . . 0.0 109.274 -179.036 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 69.2 mt -86.54 137.13 21.45 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.267 0 N-CA-C 105.403 -2.073 . . . . 0.0 105.403 177.017 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 62.5 t -120.81 107.14 19.88 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.136 0 C-N-CA 124.515 1.126 . . . . 0.0 108.986 -178.021 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -94.31 101.64 13.6 Favored 'General case' 0 CA--C 1.532 0.279 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 178.441 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -97.85 125.81 42.91 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 125.597 1.559 . . . . 0.0 113.11 -176.134 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 8.0 m-20 -63.3 102.61 0.41 Allowed 'General case' 0 N--CA 1.466 0.36 0 C-N-CA 123.306 0.642 . . . . 0.0 110.092 176.55 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 64.3 t-20 -80.01 -57.44 3.64 Favored 'General case' 0 CA--C 1.519 -0.216 0 C-N-CA 123.075 0.55 . . . . 0.0 110.921 -179.364 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -174.44 178.25 2.02 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 126.561 1.944 . . . . 0.0 106.275 -177.414 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 64.38 19.0 63.91 Favored Glycine 0 CA--C 1.536 1.35 0 CA-C-N 119.098 0.863 . . . . 0.0 112.597 -179.555 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.48 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 9.0 p90 -74.07 168.8 22.86 Favored Pre-proline 0 CA--C 1.538 0.517 0 N-CA-C 106.233 -1.765 . . . . 0.0 106.233 177.353 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.48 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 41.0 Cg_exo -63.94 156.82 71.53 Favored 'Cis proline' 0 N--CA 1.454 -0.838 0 N-CA-C 116.507 1.695 . . . . 0.0 116.507 1.568 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -148.97 171.91 15.58 Favored 'General case' 0 C--O 1.221 -0.445 0 O-C-N 121.691 -0.63 . . . . 0.0 111.166 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 31.1 p-10 -166.47 -179.91 5.19 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 104.704 -2.332 . . . . 0.0 104.704 176.452 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 60.9 t -138.7 115.6 10.99 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.229 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 178.66 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 67.5 t -119.8 132.02 70.69 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.658 0 N-CA-C 105.618 -1.993 . . . . 0.0 105.618 178.326 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 52.9 m-85 -88.01 130.86 34.84 Favored 'General case' 0 N--CA 1.446 -0.633 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 -179.261 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -73.34 100.86 3.28 Favored 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 122.774 0.429 . . . . 0.0 109.861 -178.302 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -40.71 -38.7 0.95 Allowed 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 125.801 1.64 . . . . 0.0 113.639 178.225 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 36.8 t70 -68.26 -26.11 65.51 Favored 'General case' 0 CA--C 1.535 0.398 0 N-CA-C 113.487 0.921 . . . . 0.0 113.487 -179.055 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 40.2 mt-10 -129.49 61.64 1.55 Allowed 'General case' 0 CA--C 1.535 0.38 0 C-N-CA 124.018 0.927 . . . . 0.0 112.384 -176.812 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 40.5 pt -153.27 157.31 32.9 Favored Pre-proline 0 CA--C 1.531 0.24 0 C-N-CA 127.603 2.361 . . . . 0.0 105.509 174.914 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_exo -58.88 104.81 0.2 Allowed 'Trans proline' 0 N--CA 1.455 -0.788 0 C-N-CA 121.828 1.685 . . . . 0.0 108.334 173.703 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -35.15 -43.94 0.23 Allowed 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 126.993 2.117 . . . . 0.0 115.368 -176.752 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -55.21 -33.38 57.88 Favored Glycine 0 CA--C 1.533 1.175 0 C-N-CA 123.178 0.418 . . . . 0.0 112.97 -179.619 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 40.4 t -82.12 95.73 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.386 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 -179.244 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 25.2 t0 -49.03 112.48 0.63 Allowed 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 124.24 1.016 . . . . 0.0 110.679 178.819 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -44.73 -44.71 9.42 Favored 'General case' 0 N--CA 1.454 -0.228 0 C-N-CA 125.748 1.619 . . . . 0.0 111.496 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 59.4 t -54.64 -30.56 22.36 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 C-N-CA 123.544 0.738 . . . . 0.0 112.144 -179.085 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -77.53 -34.95 53.77 Favored 'General case' 0 CA--C 1.531 0.22 0 CA-C-N 118.732 0.696 . . . . 0.0 111.788 -178.464 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.426 HD13 HG21 ' A' ' 55' ' ' ILE . 25.1 pt -89.02 -26.14 5.57 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 C-N-CA 123.33 0.652 . . . . 0.0 112.375 -179.083 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 49.4 m -88.16 146.59 25.32 Favored 'General case' 0 N--CA 1.454 -0.232 0 N-CA-C 114.132 1.16 . . . . 0.0 114.132 -177.1 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 42.6 mmm -68.55 127.76 93.14 Favored Pre-proline 0 N--CA 1.451 -0.425 0 N-CA-C 103.713 -2.699 . . . . 0.0 103.713 170.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_exo -50.99 118.57 4.37 Favored 'Trans proline' 0 N--CA 1.456 -0.727 0 C-N-CA 121.905 1.736 . . . . 0.0 108.563 177.6 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -38.86 -37.05 0.32 Allowed 'General case' 0 CA--C 1.537 0.463 0 N-CA-C 115.569 1.692 . . . . 0.0 115.569 -176.532 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -61.77 -38.11 86.81 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 124.019 0.928 . . . . 0.0 111.076 179.278 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 55.4 mm-40 -90.19 151.71 21.43 Favored 'General case' 0 N--CA 1.443 -0.783 0 C-N-CA 125.475 1.51 . . . . 0.0 110.374 -178.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -162.43 154.92 19.32 Favored 'General case' 0 N--CA 1.451 -0.399 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.879 -178.112 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 42.7 mt -82.53 96.12 7.95 Favored 'General case' 0 N--CA 1.447 -0.617 0 C-N-CA 126.548 1.939 . . . . 0.0 106.065 178.242 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 11.9 t30 -79.01 -51.87 9.0 Favored 'General case' 0 C--O 1.225 -0.221 0 N-CA-C 113.204 0.816 . . . . 0.0 113.204 -178.457 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.96 157.73 78.53 Favored Pre-proline 0 CA--C 1.536 0.436 0 C-N-CA 123.475 0.71 . . . . 0.0 112.252 -175.809 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -65.54 165.73 21.92 Favored 'Trans proline' 0 N--CA 1.457 -0.656 0 C-N-CA 122.518 2.145 . . . . 0.0 109.954 175.663 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 79.31 -50.6 3.78 Favored Glycine 0 CA--C 1.526 0.742 0 CA-C-O 118.871 -0.961 . . . . 0.0 113.016 177.076 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 43.3 mm-40 -26.24 118.41 0.07 Allowed 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 126.79 2.036 . . . . 0.0 113.403 -179.424 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 13.3 p -106.54 123.49 48.18 Favored 'General case' 0 N--CA 1.453 -0.292 0 C-N-CA 125.605 1.562 . . . . 0.0 112.827 -178.239 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 19.8 t80 -101.81 115.32 30.29 Favored 'General case' 0 C--O 1.232 0.169 0 N-CA-C 105.835 -1.913 . . . . 0.0 105.835 173.477 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.8 t -100.81 136.88 30.34 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.295 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 -179.606 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.6 p -147.35 150.92 14.19 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.078 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 178.705 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 25.5 m -121.06 130.3 53.71 Favored 'General case' 0 N--CA 1.457 -0.081 0 C-N-CA 124.316 1.046 . . . . 0.0 108.408 -178.87 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 74.7 mt -113.11 121.32 44.21 Favored 'General case' 0 CA--C 1.53 0.21 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 179.418 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -92.35 -63.22 1.26 Allowed 'General case' 0 CA--C 1.529 0.149 0 C-N-CA 124.152 0.981 . . . . 0.0 112.458 -178.038 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.1 m -65.21 135.1 55.02 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 122.986 0.515 . . . . 0.0 110.318 -174.879 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 61.1 mttp -71.52 156.59 39.25 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 122.998 0.519 . . . . 0.0 111.259 -178.368 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 139.55 175.76 14.41 Favored Glycine 0 CA--C 1.525 0.696 0 C-N-CA 123.558 0.599 . . . . 0.0 111.662 177.825 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 18.3 m -94.47 112.18 23.95 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 107.51 -1.292 . . . . 0.0 107.51 179.072 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 18.8 m-85 -104.93 125.43 50.93 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 123.686 0.795 . . . . 0.0 109.263 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 7.3 m -98.39 142.12 30.41 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 177.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 12.0 p90 -139.55 163.6 32.13 Favored 'General case' 0 N--CA 1.455 -0.198 0 CA-C-O 121.502 0.668 . . . . 0.0 111.719 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 49.5 p90 -148.99 161.66 41.46 Favored 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 124.855 1.262 . . . . 0.0 111.784 -178.195 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.8 t -105.32 107.48 18.49 Favored 'General case' 0 CA--C 1.522 -0.126 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 177.279 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 1.3 m -41.51 -61.55 1.38 Allowed Pre-proline 0 CA--C 1.535 0.378 0 N-CA-C 115.06 1.504 . . . . 0.0 115.06 -175.812 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -60.19 -4.84 3.35 Favored 'Trans proline' 0 CA--C 1.536 0.624 0 C-N-CA 121.859 1.706 . . . . 0.0 114.792 -179.042 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 38.7 m80 -134.34 19.67 3.67 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-N 119.73 1.15 . . . . 0.0 110.556 177.443 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 19.6 pt20 -63.35 -42.46 98.9 Favored 'General case' 0 N--CA 1.452 -0.33 0 O-C-N 121.693 -0.629 . . . . 0.0 109.531 179.192 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -61.13 -40.98 99.3 Favored Glycine 0 CA--C 1.529 0.964 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 177.557 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -66.32 -34.14 77.32 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 122.713 0.405 . . . . 0.0 110.117 178.536 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 108.33 31.19 3.59 Favored Glycine 0 CA--C 1.525 0.715 0 C-N-CA 124.287 0.946 . . . . 0.0 112.513 178.072 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -80.18 91.08 5.52 Favored 'General case' 0 C--O 1.237 0.41 0 N-CA-C 106.609 -1.626 . . . . 0.0 106.609 178.122 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 20.1 m -131.12 171.6 17.64 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.246 0 C-N-CA 125.128 1.371 . . . . 0.0 112.15 -177.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -171.27 -179.89 42.66 Favored Glycine 0 CA--C 1.529 0.956 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 177.507 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 81.3 mttt -147.75 155.09 41.33 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-N 117.77 0.785 . . . . 0.0 110.435 -179.657 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 4.3 p -137.75 127.96 36.73 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 C-N-CA 123.938 0.895 . . . . 0.0 109.637 179.197 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -91.99 103.92 16.39 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 107.135 -1.431 . . . . 0.0 107.135 178.736 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 40.0 t -81.37 112.28 19.11 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 N-CA-C 105.386 -2.079 . . . . 0.0 105.386 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 31.1 m120 . . . . . 0 N--CA 1.456 -0.173 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 -178.596 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 8.6 tt . . . . . 0 N--CA 1.453 -0.324 0 CA-C-O 121.142 0.496 . . . . 0.0 111.055 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -94.34 127.81 40.45 Favored 'General case' 0 N--CA 1.455 -0.199 0 C-N-CA 124.263 1.025 . . . . 0.0 109.885 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 43.8 t -118.22 121.83 68.14 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.355 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 179.478 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 36.9 mt -89.62 127.88 35.97 Favored 'General case' 0 N--CA 1.454 -0.262 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 179.247 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 44.1 mt -86.64 96.87 10.26 Favored 'General case' 0 N--CA 1.452 -0.326 0 N-CA-C 106.656 -1.609 . . . . 0.0 106.656 177.822 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 105.39 132.41 7.31 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 -178.679 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 23.9 p -83.0 43.88 0.89 Allowed 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 119.07 1.435 . . . . 0.0 112.802 -178.842 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.58 -55.14 1.25 Allowed Glycine 0 CA--C 1.527 0.815 0 C-N-CA 126.197 1.856 . . . . 0.0 112.278 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -72.85 34.47 0.07 Allowed 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 126.163 1.785 . . . . 0.0 113.633 -177.554 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 68.08 -13.27 0.74 Allowed Glycine 0 CA--C 1.53 0.996 0 C-N-CA 124.505 1.05 . . . . 0.0 115.035 178.428 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 20.3 t -61.55 129.15 39.72 Favored 'General case' 0 C--N 1.339 0.126 0 CA-C-N 119.328 1.564 . . . . 0.0 109.768 -178.464 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 59.4 mt -75.11 66.76 1.69 Allowed 'General case' 0 N--CA 1.448 -0.534 0 C-N-CA 126.113 1.765 . . . . 0.0 111.857 -175.538 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.8 m -135.06 149.55 29.15 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.182 0 C-N-CA 123.446 0.698 . . . . 0.0 110.856 179.368 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 74.7 m-85 -88.09 135.46 33.41 Favored 'General case' 0 N--CA 1.456 -0.144 0 N-CA-C 105.477 -2.046 . . . . 0.0 105.477 176.549 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 48.4 t -122.67 110.73 31.69 Favored Pre-proline 0 CA--C 1.533 0.305 0 CA-C-O 118.026 -0.987 . . . . 0.0 108.851 178.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -72.87 151.62 97.13 Favored 'Cis proline' 0 N--CA 1.458 -0.565 0 CA-C-N 120.408 1.181 . . . . 0.0 111.175 -0.773 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.2 m -80.66 -48.92 11.92 Favored 'General case' 0 CA--C 1.529 0.161 0 C-N-CA 123.351 0.661 . . . . 0.0 110.799 179.811 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -119.97 129.47 54.32 Favored 'General case' 0 N--CA 1.454 -0.251 0 N-CA-C 105.904 -1.887 . . . . 0.0 105.904 179.821 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 38.2 p90 -157.4 -175.78 5.59 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-N 118.828 0.74 . . . . 0.0 111.963 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 32.9 m -133.97 147.9 51.09 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 125.601 1.561 . . . . 0.0 107.092 178.37 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.4 p -145.71 139.01 14.36 Favored Pre-proline 0 N--CA 1.449 -0.509 0 C-N-CA 123.568 0.747 . . . . 0.0 109.308 -178.156 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 70.7 Cg_exo -53.66 137.26 66.57 Favored 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 122.359 2.039 . . . . 0.0 111.436 177.327 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.6 m -60.13 117.23 4.88 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 179.476 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 109.35 -17.21 31.54 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-O 118.729 -1.039 . . . . 0.0 112.181 -178.119 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -72.17 157.45 37.73 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 119.534 1.667 . . . . 0.0 110.698 179.226 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 57.1 pttt -93.76 135.09 35.42 Favored 'General case' 0 N--CA 1.444 -0.76 0 C-N-CA 124.764 1.226 . . . . 0.0 110.826 -179.695 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 45.6 mt -102.36 130.71 51.81 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.358 0 N-CA-C 104.804 -2.295 . . . . 0.0 104.804 177.055 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 80.6 t -115.27 99.54 8.71 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 C-N-CA 124.819 1.247 . . . . 0.0 108.705 -178.104 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -86.13 103.0 14.37 Favored 'General case' 0 N--CA 1.456 -0.169 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 178.924 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 60.9 tttp -98.39 128.8 44.95 Favored 'General case' 0 CA--C 1.528 0.131 0 C-N-CA 124.315 1.046 . . . . 0.0 112.27 -177.216 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 38.8 t30 -64.43 110.36 2.25 Favored 'General case' 0 N--CA 1.456 -0.15 0 C-N-CA 123.608 0.763 . . . . 0.0 109.86 177.57 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 59.9 t30 -102.59 -64.74 1.04 Allowed 'General case' 0 C--N 1.339 0.134 0 CA-C-N 118.495 0.589 . . . . 0.0 111.312 -179.207 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -157.17 168.4 27.55 Favored 'General case' 0 C--O 1.226 -0.18 0 C-N-CA 122.869 0.468 . . . . 0.0 111.284 -177.762 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 66.23 24.86 72.19 Favored Glycine 0 CA--C 1.532 1.144 0 O-C-N 121.868 -0.52 . . . . 0.0 112.269 -179.896 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.541 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 10.3 p90 -74.68 169.53 19.42 Favored Pre-proline 0 CA--C 1.543 0.7 0 C-N-CA 125.457 1.503 . . . . 0.0 107.768 179.023 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.541 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 95.7 Cg_endo -70.32 162.21 86.17 Favored 'Cis proline' 0 N--CA 1.448 -1.19 0 CA-C-N 120.189 1.103 . . . . 0.0 114.314 2.878 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 89.9 m-70 -148.9 174.86 11.8 Favored 'General case' 0 C--O 1.22 -0.476 0 O-C-N 121.545 -0.722 . . . . 0.0 111.276 -178.634 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 25.4 p-10 -163.87 179.08 7.3 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 103.858 -2.645 . . . . 0.0 103.858 175.707 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 45.1 t -138.52 117.44 13.81 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.377 0 N-CA-C 107.358 -1.349 . . . . 0.0 107.358 178.93 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 91.8 t -121.55 138.18 52.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 106.737 -1.579 . . . . 0.0 106.737 178.409 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 76.2 m-85 -97.09 131.82 43.49 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -63.19 116.26 5.26 Favored 'General case' 0 N--CA 1.454 -0.242 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 -178.731 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.1 pm0 -48.45 -29.57 4.22 Favored 'General case' 0 CA--C 1.533 0.299 0 N-CA-C 115.682 1.734 . . . . 0.0 115.682 -177.719 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 18.0 m-20 -90.07 -52.18 5.08 Favored 'General case' 0 CA--C 1.53 0.178 0 CA-C-N 118.752 0.706 . . . . 0.0 110.101 -179.593 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 80.0 mt-10 -79.92 58.82 3.0 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 124.402 1.081 . . . . 0.0 112.169 -176.721 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 19.2 pt -150.58 151.29 30.45 Favored Pre-proline 0 CA--C 1.532 0.261 0 C-N-CA 127.025 2.13 . . . . 0.0 107.1 176.199 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 21.0 Cg_endo -61.89 117.58 4.43 Favored 'Trans proline' 0 N--CA 1.452 -0.948 0 C-N-CA 121.925 1.75 . . . . 0.0 110.466 178.746 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -46.98 120.91 3.3 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 125.02 1.328 . . . . 0.0 110.963 -179.398 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 126.31 -39.51 1.99 Allowed Glycine 0 CA--C 1.525 0.676 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -178.853 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 21.7 t -78.28 95.06 1.65 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 53.5 t0 -54.47 114.82 1.81 Allowed 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 123.213 0.605 . . . . 0.0 110.535 179.697 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -45.44 -43.67 11.59 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 125.554 1.541 . . . . 0.0 111.887 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 55.0 t -57.61 -28.85 32.92 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.344 0 C-N-CA 123.274 0.63 . . . . 0.0 111.805 -178.258 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 28.8 mtpp -79.05 -36.01 41.68 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 118.556 0.616 . . . . 0.0 111.229 -178.723 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.403 HD13 HG21 ' A' ' 55' ' ' ILE . 26.2 pt -86.78 -26.11 6.12 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.408 0 C-N-CA 123.201 0.6 . . . . 0.0 112.482 -179.564 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 46.0 m -90.25 148.6 22.8 Favored 'General case' 0 C--N 1.331 -0.2 0 N-CA-C 114.455 1.28 . . . . 0.0 114.455 -176.831 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 69.5 mmm -80.56 120.74 80.1 Favored Pre-proline 0 CA--C 1.534 0.358 0 N-CA-C 105.749 -1.945 . . . . 0.0 105.749 173.583 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 81.4 Cg_exo -47.02 132.37 17.78 Favored 'Trans proline' 0 N--CA 1.457 -0.625 0 C-N-CA 123.07 2.513 . . . . 0.0 112.073 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 81.9 mt-10 -69.06 68.86 0.18 Allowed 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 125.347 1.459 . . . . 0.0 110.578 -179.8 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -167.08 -47.96 0.02 OUTLIER 'General case' 0 N--CA 1.451 -0.411 0 C-N-CA 129.204 3.002 . . . . 0.0 105.947 -178.585 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 79.5 mt-10 -78.45 148.74 33.44 Favored 'General case' 0 N--CA 1.446 -0.636 0 C-N-CA 124.484 1.114 . . . . 0.0 108.181 178.637 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 2.5 pp -160.27 162.76 33.72 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-O 121.198 0.523 . . . . 0.0 111.279 -179.097 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 37.4 mt -102.51 134.13 46.35 Favored 'General case' 0 N--CA 1.446 -0.662 0 C-N-CA 128.049 2.54 . . . . 0.0 104.598 177.53 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 30.0 t30 -138.77 -46.12 0.49 Allowed 'General case' 0 C--O 1.227 -0.111 0 C-N-CA 122.812 0.445 . . . . 0.0 111.833 -178.029 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -69.95 131.18 89.29 Favored Pre-proline 0 C--O 1.237 0.424 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 -178.575 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -48.56 130.22 21.56 Favored 'Trans proline' 0 N--CA 1.454 -0.823 0 C-N-CA 123.047 2.498 . . . . 0.0 111.538 -179.392 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 99.31 -23.3 36.83 Favored Glycine 0 CA--C 1.525 0.693 0 CA-C-O 117.662 -1.632 . . . . 0.0 114.462 177.627 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 52.4 mt-10 -50.86 125.41 13.36 Favored 'General case' 0 CA--C 1.536 0.438 0 CA-C-N 120.116 1.958 . . . . 0.0 110.849 179.719 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 2.3 p -104.27 140.73 37.44 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 125.514 1.526 . . . . 0.0 112.184 -178.163 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 20.8 t80 -117.79 115.22 24.57 Favored 'General case' 0 C--O 1.232 0.176 0 N-CA-C 104.789 -2.3 . . . . 0.0 104.789 172.259 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.4 t -103.56 139.41 24.57 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.388 0 C-N-CA 123.183 0.593 . . . . 0.0 109.526 -178.497 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.5 p -143.48 156.11 16.61 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 N-CA-C 106.6 -1.63 . . . . 0.0 106.6 176.854 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 12.5 m -132.29 123.66 27.33 Favored 'General case' 0 C--N 1.333 -0.139 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 -179.286 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 68.1 mt -111.56 102.09 10.45 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 123.254 0.622 . . . . 0.0 109.698 -177.531 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -82.46 -42.73 18.14 Favored 'General case' 0 CA--C 1.529 0.165 0 C-N-CA 124.069 0.947 . . . . 0.0 110.676 178.929 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 4.4 m -73.21 112.42 9.25 Favored 'General case' 0 N--CA 1.45 -0.458 0 C-N-CA 123.083 0.553 . . . . 0.0 109.87 -177.745 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 25.8 pttm -60.21 152.17 25.35 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 123.077 0.551 . . . . 0.0 111.299 178.867 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 150.96 -167.94 30.61 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.106 -1.198 . . . . 0.0 110.106 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 23.3 m -113.97 124.71 52.82 Favored 'General case' 0 N--CA 1.454 -0.271 0 N-CA-C 106.435 -1.691 . . . . 0.0 106.435 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -121.01 114.9 22.18 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 124.059 0.944 . . . . 0.0 110.045 -178.164 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 48.7 m -90.51 139.62 30.52 Favored 'General case' 0 C--O 1.233 0.197 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 175.788 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 22.5 p90 -136.41 165.44 25.81 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-O 121.419 0.628 . . . . 0.0 112.071 -179.312 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 49.4 p90 -153.33 161.12 42.69 Favored 'General case' 0 N--CA 1.453 -0.323 0 C-N-CA 124.277 1.031 . . . . 0.0 112.179 -178.498 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 3.7 t -103.1 102.62 12.64 Favored 'General case' 0 CA--C 1.519 -0.239 0 N-CA-C 106.254 -1.758 . . . . 0.0 106.254 176.638 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.263 0.7 OUTLIER -44.67 -56.36 8.67 Favored Pre-proline 0 CA--C 1.535 0.402 0 N-CA-C 113.985 1.106 . . . . 0.0 113.985 -175.131 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_exo -50.93 -18.16 4.07 Favored 'Trans proline' 0 CA--C 1.534 0.514 0 C-N-CA 123.187 2.591 . . . . 0.0 115.042 177.772 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 38.2 m80 -133.85 25.73 3.98 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 123.783 0.833 . . . . 0.0 110.862 -179.599 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 65.7 tt0 -61.61 -50.27 73.27 Favored 'General case' 0 N--CA 1.457 -0.093 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 179.214 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.56 -33.3 62.27 Favored Glycine 0 CA--C 1.532 1.098 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 177.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -79.92 2.17 24.44 Favored 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 123.403 0.681 . . . . 0.0 112.037 179.082 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 79.9 21.84 64.99 Favored Glycine 0 CA--C 1.527 0.832 0 CA-C-O 118.978 -0.901 . . . . 0.0 113.706 178.42 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 22.1 ttt -78.65 80.78 5.0 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 119.321 1.56 . . . . 0.0 107.928 177.874 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 12.6 m -124.2 170.3 14.54 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.188 0 C-N-CA 125.975 1.71 . . . . 0.0 111.07 -179.765 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -170.02 178.56 42.8 Favored Glycine 0 CA--C 1.527 0.84 0 N-CA-C 108.848 -1.701 . . . . 0.0 108.848 177.611 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 33.8 mtmm -148.42 149.75 32.28 Favored 'General case' 0 N--CA 1.455 -0.199 0 CA-C-N 118.091 0.946 . . . . 0.0 110.463 -178.926 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.2 p -135.26 132.17 52.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 C-N-CA 123.121 0.569 . . . . 0.0 109.813 178.132 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.2 m -98.87 103.49 15.45 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 125.05 1.34 . . . . 0.0 107.848 179.341 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 47.0 t -82.59 102.24 8.31 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.753 0 N-CA-C 105.026 -2.213 . . . . 0.0 105.026 -179.189 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 45.5 p-10 . . . . . 0 C--N 1.332 -0.167 0 C-N-CA 124.984 1.314 . . . . 0.0 109.599 -178.059 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 9.9 mp . . . . . 0 CA--C 1.53 0.183 0 CA-C-O 121.275 0.559 . . . . 0.0 111.215 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -80.74 138.91 36.33 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 106.869 -1.53 . . . . 0.0 106.869 175.486 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 60.2 t -129.34 126.59 63.98 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 39.7 mt -87.98 122.53 31.7 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 178.763 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 88.9 mt -81.11 100.01 8.81 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 106.248 -1.76 . . . . 0.0 106.248 177.35 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 95.84 137.96 9.5 Favored Glycine 0 C--N 1.336 0.532 0 N-CA-C 107.402 -2.279 . . . . 0.0 107.402 -177.886 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 80.8 p -78.97 157.97 28.06 Favored 'General case' 0 N--CA 1.438 -1.037 0 CA-C-O 121.985 0.898 . . . . 0.0 109.21 -179.212 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.4 -34.55 59.69 Favored Glycine 0 CA--C 1.531 1.04 0 CA-C-N 114.608 -1.178 . . . . 0.0 111.085 178.162 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -76.03 -3.77 37.65 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 123.573 0.749 . . . . 0.0 112.256 179.074 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 99.76 -21.14 46.39 Favored Glycine 0 CA--C 1.528 0.847 0 CA-C-O 119.007 -0.885 . . . . 0.0 113.451 178.849 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 33.4 t -56.81 131.99 51.0 Favored 'General case' 0 C--O 1.237 0.442 0 CA-C-N 119.249 1.524 . . . . 0.0 110.426 -179.641 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 56.4 mt -74.06 68.3 1.38 Allowed 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 126.489 1.916 . . . . 0.0 111.114 -176.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.5 m -134.38 152.94 34.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 C-N-CA 123.739 0.816 . . . . 0.0 109.533 178.534 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 -82.45 135.95 35.02 Favored 'General case' 0 N--CA 1.454 -0.245 0 N-CA-C 105.529 -2.026 . . . . 0.0 105.529 176.625 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 48.0 t -123.92 110.46 29.44 Favored Pre-proline 0 CA--C 1.535 0.397 0 CA-C-O 118.158 -0.925 . . . . 0.0 108.79 179.296 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -70.43 152.28 93.89 Favored 'Cis proline' 0 N--CA 1.459 -0.524 0 CA-C-N 120.361 1.164 . . . . 0.0 111.543 -0.79 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.4 m -82.3 -44.09 16.67 Favored 'General case' 0 CA--C 1.529 0.145 0 C-N-CA 123.784 0.833 . . . . 0.0 111.019 179.721 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 37.8 tt0 -129.68 133.98 47.4 Favored 'General case' 0 N--CA 1.452 -0.33 0 N-CA-C 106.354 -1.721 . . . . 0.0 106.354 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 30.2 p90 -163.23 -179.26 6.49 Favored 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 122.944 0.498 . . . . 0.0 110.251 -179.177 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 17.7 m -128.69 148.43 50.83 Favored 'General case' 0 N--CA 1.455 -0.191 0 N-CA-C 106.932 -1.507 . . . . 0.0 106.932 177.928 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.8 p -141.61 127.73 11.13 Favored Pre-proline 0 CA--C 1.538 0.496 0 C-N-CA 123.16 0.584 . . . . 0.0 111.35 -177.211 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -55.57 132.21 50.79 Favored 'Trans proline' 0 N--CA 1.452 -0.921 0 C-N-CA 122.327 2.018 . . . . 0.0 110.55 175.336 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 38.2 m -47.73 127.19 11.34 Favored 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 123.118 0.567 . . . . 0.0 110.042 178.896 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 99.03 -25.98 26.1 Favored Glycine 0 CA--C 1.531 1.054 0 CA-C-O 118.809 -0.995 . . . . 0.0 113.011 -179.591 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 75.4 mt-10 -74.73 100.91 4.13 Favored 'General case' 0 N--CA 1.454 -0.253 0 CA-C-N 119.742 1.771 . . . . 0.0 108.586 178.95 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 21.5 pttp -51.66 139.56 20.64 Favored 'General case' 0 N--CA 1.45 -0.44 0 C-N-CA 124.795 1.238 . . . . 0.0 113.926 -178.886 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 38.1 mt -93.54 133.39 34.82 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.405 0 N-CA-C 105.199 -2.149 . . . . 0.0 105.199 176.784 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 60.7 t -119.21 94.76 3.22 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.202 0 C-N-CA 124.453 1.101 . . . . 0.0 108.49 -178.159 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -83.27 98.94 9.68 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 122.857 0.463 . . . . 0.0 109.948 -179.384 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 24.3 ttmm -88.35 128.47 35.5 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 125.055 1.342 . . . . 0.0 112.114 -177.653 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 4.8 t30 -67.01 93.82 0.3 Allowed 'General case' 0 CA--C 1.534 0.363 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 177.019 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 42.5 t30 -85.39 -75.77 0.35 Allowed 'General case' 0 C--O 1.228 -0.074 0 N-CA-C 113.162 0.801 . . . . 0.0 113.162 -175.871 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -143.98 163.67 32.82 Favored 'General case' 0 C--O 1.224 -0.277 0 C-N-CA 123.67 0.788 . . . . 0.0 109.79 -176.456 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 63.65 19.59 62.91 Favored Glycine 0 CA--C 1.535 1.297 0 O-C-N 121.906 -0.496 . . . . 0.0 112.697 -179.591 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.468 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 16.2 p90 -72.24 166.53 40.53 Favored Pre-proline 0 CA--C 1.546 0.799 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 177.483 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.468 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 95.4 Cg_endo -68.31 158.06 86.79 Favored 'Cis proline' 0 N--CA 1.447 -1.222 0 N-CA-C 115.754 1.405 . . . . 0.0 115.754 4.246 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 88.9 m-70 -150.74 171.32 17.37 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 114.643 -1.162 . . . . 0.0 109.459 -179.422 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 34.9 p-10 -159.61 173.2 16.46 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 104.663 -2.347 . . . . 0.0 104.663 175.423 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 36.8 t -129.19 111.55 23.03 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.245 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 -178.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.9 t -113.36 131.46 65.03 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.579 0 N-CA-C 106.547 -1.649 . . . . 0.0 106.547 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.41 ' CG ' HD12 ' A' ' 55' ' ' ILE . 67.8 m-85 -97.01 131.56 43.7 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 179.243 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -71.76 109.17 5.47 Favored 'General case' 0 N--CA 1.454 -0.26 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 -179.677 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -46.27 -31.97 2.82 Favored 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 115.279 1.585 . . . . 0.0 115.279 -178.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 20.0 m-20 -84.31 -17.96 37.85 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-N 118.518 0.599 . . . . 0.0 111.839 -179.356 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -118.91 59.36 0.83 Allowed 'General case' 0 CA--C 1.532 0.259 0 C-N-CA 124.657 1.183 . . . . 0.0 111.087 -177.078 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 25.0 pt -152.68 151.4 26.71 Favored Pre-proline 0 CA--C 1.531 0.24 0 C-N-CA 126.165 1.786 . . . . 0.0 106.224 176.746 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_endo -57.7 118.2 5.03 Favored 'Trans proline' 0 N--CA 1.453 -0.873 0 C-N-CA 122.316 2.01 . . . . 0.0 111.125 179.43 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -47.85 117.72 2.0 Allowed 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 124.996 1.318 . . . . 0.0 110.695 -179.611 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 128.54 -35.98 2.55 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 -178.504 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 34.7 t -77.4 109.27 11.77 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 46.2 t0 -64.29 112.09 2.91 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 122.676 0.39 . . . . 0.0 110.512 179.634 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.1 -40.05 14.54 Favored 'General case' 0 CA--C 1.528 0.106 0 C-N-CA 125.057 1.343 . . . . 0.0 111.626 178.644 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 55.4 t -61.3 -31.13 49.43 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.349 0 C-N-CA 123.348 0.659 . . . . 0.0 111.641 -179.027 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -78.62 -40.72 33.56 Favored 'General case' 0 C--O 1.227 -0.113 0 CA-C-N 118.515 0.598 . . . . 0.0 110.469 -178.7 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.41 HD12 ' CG ' ' A' ' 41' ' ' PHE . 35.4 pt -78.02 -33.74 18.55 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.252 0 N-CA-C 112.566 0.58 . . . . 0.0 112.566 -178.804 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 50.7 m -78.17 139.92 38.98 Favored 'General case' 0 N--CA 1.455 -0.201 0 N-CA-C 112.774 0.657 . . . . 0.0 112.774 -177.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.2 tmt? -67.34 124.59 89.43 Favored Pre-proline 0 CA--C 1.538 0.513 0 N-CA-C 105.559 -2.015 . . . . 0.0 105.559 176.017 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 81.3 Cg_exo -44.59 110.51 0.22 Allowed 'Trans proline' 0 N--CA 1.458 -0.56 0 C-N-CA 123.885 3.057 . . . . 0.0 113.43 -178.272 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -45.1 -33.94 2.39 Favored 'General case' 0 CA--C 1.531 0.226 0 C-N-CA 125.869 1.668 . . . . 0.0 114.17 -179.281 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -57.65 -33.82 68.71 Favored 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 123.666 0.786 . . . . 0.0 110.972 179.132 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -104.9 159.96 15.39 Favored 'General case' 0 N--CA 1.445 -0.719 0 C-N-CA 125.853 1.661 . . . . 0.0 110.14 -178.672 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 96.1 mt -145.41 151.77 38.78 Favored 'General case' 0 N--CA 1.454 -0.253 0 N-CA-C 106.588 -1.634 . . . . 0.0 106.588 178.38 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 74.8 mt -78.59 102.05 7.75 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 106.114 -1.81 . . . . 0.0 106.114 177.373 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 31.8 p-10 -83.26 -55.46 4.32 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 124.291 1.037 . . . . 0.0 112.311 -177.905 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.94 149.57 77.1 Favored Pre-proline 0 CA--C 1.533 0.289 0 C-N-CA 123.203 0.601 . . . . 0.0 111.185 -177.59 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -66.87 164.02 31.25 Favored 'Trans proline' 0 N--CA 1.454 -0.799 0 C-N-CA 122.406 2.071 . . . . 0.0 109.804 177.513 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 79.42 -38.77 2.08 Favored Glycine 0 CA--C 1.528 0.862 0 CA-C-O 118.55 -1.139 . . . . 0.0 113.947 176.295 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -39.86 123.91 1.67 Allowed 'General case' 0 CA--C 1.536 0.437 0 CA-C-N 118.495 1.147 . . . . 0.0 111.696 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 18.0 p -105.03 121.04 42.95 Favored 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 124.662 1.185 . . . . 0.0 112.647 -177.701 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 62.3 t80 -95.13 111.4 23.24 Favored 'General case' 0 N--CA 1.454 -0.239 0 N-CA-C 105.367 -2.086 . . . . 0.0 105.367 174.081 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -100.11 139.92 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 C-N-CA 123.219 0.608 . . . . 0.0 110.54 -177.448 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 11.6 p -146.67 139.28 19.64 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.174 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 176.626 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 14.2 m -126.61 99.01 5.62 Favored 'General case' 0 C--N 1.34 0.187 0 C-N-CA 122.918 0.487 . . . . 0.0 112.286 -176.067 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.423 ' H ' HD22 ' A' ' 74' ' ' LEU . 1.6 mm? -87.05 130.54 34.44 Favored 'General case' 0 N--CA 1.439 -0.984 0 C-N-CA 123.057 0.543 . . . . 0.0 111.666 178.329 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -100.9 -45.1 5.54 Favored 'General case' 0 N--CA 1.454 -0.227 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 174.549 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 4.6 m -65.52 115.64 5.96 Favored 'General case' 0 N--CA 1.446 -0.652 0 C-N-CA 124.808 1.243 . . . . 0.0 110.192 -178.231 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 25.9 pttm -63.93 153.59 36.53 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-N 115.159 -0.928 . . . . 0.0 110.896 178.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 147.08 -177.51 25.33 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.401 -1.08 . . . . 0.0 110.401 178.392 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 28.7 m -106.49 121.94 45.29 Favored 'General case' 0 N--CA 1.452 -0.327 0 N-CA-C 106.941 -1.503 . . . . 0.0 106.941 -179.024 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 16.4 m-85 -115.07 122.44 46.16 Favored 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 124.594 1.158 . . . . 0.0 109.735 -178.358 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 41.4 m -98.3 132.86 43.44 Favored 'General case' 0 C--O 1.234 0.248 0 N-CA-C 107.635 -1.246 . . . . 0.0 107.635 175.366 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 21.0 p90 -132.62 165.68 23.88 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-O 121.638 0.732 . . . . 0.0 111.842 -179.438 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 52.4 p90 -156.56 161.92 39.94 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 115.226 -0.897 . . . . 0.0 112.561 -178.601 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.7 t -103.36 99.97 9.83 Favored 'General case' 0 CA--C 1.516 -0.333 0 N-CA-C 106.454 -1.684 . . . . 0.0 106.454 177.177 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.281 13.1 p -35.84 -64.31 0.35 Allowed Pre-proline 0 CA--C 1.541 0.63 0 N-CA-C 115.861 1.8 . . . . 0.0 115.861 -175.654 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -60.68 -7.25 6.99 Favored 'Trans proline' 0 C--N 1.348 0.506 0 C-N-CA 122.663 2.242 . . . . 0.0 115.221 -177.82 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 36.2 m80 -132.09 15.83 4.65 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 119.674 1.125 . . . . 0.0 110.814 178.22 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 65.6 tt0 -59.5 -46.57 88.45 Favored 'General case' 0 CA--C 1.529 0.163 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 178.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -57.07 -30.45 60.63 Favored Glycine 0 CA--C 1.531 1.082 0 C-N-CA 123.588 0.613 . . . . 0.0 111.579 177.613 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -86.08 8.15 21.91 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 123.599 0.759 . . . . 0.0 111.347 178.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 81.67 16.33 73.44 Favored Glycine 0 CA--C 1.527 0.839 0 CA-C-O 118.762 -1.021 . . . . 0.0 113.371 178.722 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 20.0 ttt -78.25 77.12 4.75 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 119.525 1.663 . . . . 0.0 108.925 178.754 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.7 m -125.8 170.81 15.33 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.314 0 C-N-CA 125.901 1.68 . . . . 0.0 110.052 179.43 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -170.07 177.27 43.5 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 109.262 -1.535 . . . . 0.0 109.262 177.804 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 59.4 mttp -145.98 157.53 43.88 Favored 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 123.401 0.68 . . . . 0.0 109.677 -178.879 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.2 p -147.25 130.6 8.77 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 C-N-CA 122.689 0.396 . . . . 0.0 110.417 178.007 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 99.1 m -98.49 102.65 14.46 Favored 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 124.171 0.988 . . . . 0.0 108.85 178.579 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 48.8 t -83.2 132.29 31.75 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.444 0 N-CA-C 105.797 -1.927 . . . . 0.0 105.797 178.686 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.334 -0.106 0 CA-C-N 118.395 0.543 . . . . 0.0 111.416 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' LEU . . . . . 0.507 ' H1 ' HD12 ' A' ' 1' ' ' LEU . 9.8 mp . . . . . 0 CA--C 1.534 0.329 0 CA-C-O 121.41 0.624 . . . . 0.0 111.6 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 -89.12 117.1 27.87 Favored 'General case' 0 N--CA 1.452 -0.326 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 175.985 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 28.1 t -110.88 112.25 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.238 0 C-N-CA 123.695 0.798 . . . . 0.0 110.305 -177.505 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 53.6 mt -80.29 123.78 28.27 Favored 'General case' 0 N--CA 1.451 -0.403 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 178.427 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 64.9 mt -87.08 110.73 20.3 Favored 'General case' 0 N--CA 1.447 -0.575 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 178.566 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 84.61 126.37 1.45 Allowed Glycine 0 C--N 1.337 0.594 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.709 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 6.1 p -77.64 161.43 27.81 Favored 'General case' 0 N--CA 1.442 -0.827 0 O-C-N 121.48 -1.012 . . . . 0.0 108.689 -179.099 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -44.32 -38.66 5.18 Favored Glycine 0 CA--C 1.531 1.085 0 C-N-CA 125.777 1.656 . . . . 0.0 113.822 -178.924 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -76.31 4.08 9.6 Favored 'General case' 0 CA--C 1.537 0.48 0 N-CA-C 113.267 0.84 . . . . 0.0 113.267 -179.647 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 86.73 -6.16 83.33 Favored Glycine 0 CA--C 1.529 0.965 0 CA-C-O 118.92 -0.933 . . . . 0.0 113.105 -179.626 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 20.7 t -61.67 135.81 57.76 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-N 119.233 1.517 . . . . 0.0 110.457 -179.108 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 58.1 mt -75.94 65.93 2.09 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 126.064 1.746 . . . . 0.0 111.465 -176.556 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 28.7 m -130.94 152.5 37.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 C-N-CA 123.772 0.829 . . . . 0.0 110.436 179.547 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 73.3 m-85 -89.34 138.07 31.77 Favored 'General case' 0 N--CA 1.455 -0.222 0 N-CA-C 104.973 -2.232 . . . . 0.0 104.973 176.102 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 52.5 t -125.65 105.64 26.91 Favored Pre-proline 0 CA--C 1.537 0.457 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 179.009 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -68.23 158.44 86.05 Favored 'Cis proline' 0 C--N 1.347 0.466 0 CA-C-N 120.031 1.047 . . . . 0.0 111.799 -1.023 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.7 p -84.77 -63.65 1.3 Allowed 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 125.039 1.336 . . . . 0.0 108.907 179.672 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -117.8 135.66 53.92 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 125.102 1.361 . . . . 0.0 107.435 178.541 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 43.4 p90 -158.59 175.34 13.78 Favored 'General case' 0 C--N 1.333 -0.127 0 CA-C-O 121.22 0.533 . . . . 0.0 111.724 -178.455 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 24.0 p -128.33 147.18 50.61 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 107.19 -1.411 . . . . 0.0 107.19 178.358 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.0 p -149.93 140.46 14.06 Favored Pre-proline 0 CA--C 1.537 0.456 0 CA-C-N 118.843 0.747 . . . . 0.0 110.662 -178.08 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -52.87 138.79 60.76 Favored 'Trans proline' 0 CA--C 1.538 0.706 0 C-N-CA 122.609 2.206 . . . . 0.0 112.44 176.378 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 23.5 m -57.96 131.85 51.66 Favored 'General case' 0 CA--C 1.53 0.191 0 C-N-CA 122.875 0.47 . . . . 0.0 111.125 179.601 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 101.52 -18.1 54.0 Favored Glycine 0 CA--C 1.526 0.774 0 CA-C-O 119.156 -0.802 . . . . 0.0 112.92 179.57 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 81.5 mm-40 -68.7 156.5 38.12 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-N 119.075 1.438 . . . . 0.0 112.823 -179.198 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 24.0 ttmm -91.49 142.05 28.08 Favored 'General case' 0 N--CA 1.452 -0.372 0 C-N-CA 125.965 1.706 . . . . 0.0 110.14 -179.786 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 40.6 mt -120.88 134.42 64.35 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.343 0 N-CA-C 105.929 -1.878 . . . . 0.0 105.929 178.307 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 97.6 t -124.15 101.53 9.25 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 C-N-CA 125.236 1.414 . . . . 0.0 108.571 -177.908 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -86.25 136.19 33.26 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 106.115 -1.809 . . . . 0.0 106.115 176.945 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 12.1 tmtt? -135.27 132.46 37.81 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 118.986 0.812 . . . . 0.0 112.4 -177.369 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 6.2 m-20 -66.47 101.4 0.76 Allowed 'General case' 0 C--N 1.341 0.203 0 C-N-CA 123.69 0.796 . . . . 0.0 108.886 177.77 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 38.7 t30 -92.38 -61.84 1.53 Allowed 'General case' 0 N--CA 1.455 -0.224 0 CA-C-O 121.34 0.59 . . . . 0.0 109.951 -179.663 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -150.77 -179.47 7.29 Favored 'General case' 0 C--O 1.223 -0.299 0 C-N-CA 124.065 0.946 . . . . 0.0 108.898 -179.029 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 52.72 17.12 4.41 Favored Glycine 0 CA--C 1.538 1.503 0 N-CA-C 115.534 0.973 . . . . 0.0 115.534 178.574 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.449 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 14.5 p90 -73.85 167.62 33.61 Favored Pre-proline 0 CA--C 1.539 0.531 0 N-CA-C 106.921 -1.511 . . . . 0.0 106.921 178.535 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.449 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 33.0 Cg_exo -63.4 157.87 67.55 Favored 'Cis proline' 0 N--CA 1.454 -0.82 0 N-CA-C 117.407 2.041 . . . . 0.0 117.407 2.638 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 90.8 m-70 -152.47 169.0 23.67 Favored 'General case' 0 N--CA 1.453 -0.3 0 O-C-N 121.598 -0.689 . . . . 0.0 111.638 179.843 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 51.4 p30 -162.15 178.64 8.59 Favored 'General case' 0 N--CA 1.452 -0.332 0 N-CA-C 104.606 -2.368 . . . . 0.0 104.606 174.707 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 34.8 t -135.46 123.4 37.7 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 71.1 t -123.07 139.27 50.35 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.58 0 N-CA-C 105.558 -2.016 . . . . 0.0 105.558 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.406 ' CG ' HD12 ' A' ' 55' ' ' ILE . 80.5 m-85 -103.99 135.37 45.63 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 108.165 -1.05 . . . . 0.0 108.165 -179.918 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -66.44 122.08 16.73 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 -179.482 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -74.43 50.2 0.4 Allowed 'General case' 0 CA--C 1.538 0.511 0 N-CA-C 113.956 1.095 . . . . 0.0 113.956 -178.509 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -161.7 -64.79 0.05 Allowed 'General case' 0 N--CA 1.456 -0.129 0 C-N-CA 125.19 1.396 . . . . 0.0 108.987 177.3 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -83.0 63.81 7.28 Favored 'General case' 0 CA--C 1.538 0.496 0 CA-C-O 122.069 0.938 . . . . 0.0 110.274 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 26.8 pt -145.3 153.63 52.54 Favored Pre-proline 0 CA--C 1.536 0.408 0 C-N-CA 129.763 3.225 . . . . 0.0 105.523 177.019 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo -57.92 114.81 2.12 Favored 'Trans proline' 0 N--CA 1.455 -0.79 0 C-N-CA 121.628 1.552 . . . . 0.0 111.699 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -48.11 112.07 0.53 Allowed 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 125.384 1.474 . . . . 0.0 110.735 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 131.12 -34.08 2.69 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 109.721 -1.351 . . . . 0.0 109.721 -178.822 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 42.8 t -77.32 111.48 14.17 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.23 0 CA-C-N 117.565 0.683 . . . . 0.0 109.214 -179.863 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 40.7 t0 -64.23 109.86 2.01 Favored 'General case' 0 CA--C 1.532 0.277 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 178.734 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.51 -38.79 14.68 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 125.131 1.372 . . . . 0.0 111.97 179.508 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 60.0 t -60.63 -28.9 43.73 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.311 0 C-N-CA 123.331 0.653 . . . . 0.0 111.789 -179.109 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 47.1 mmtm -75.84 -40.99 53.73 Favored 'General case' 0 CA--C 1.53 0.197 0 CA-C-N 118.571 0.623 . . . . 0.0 110.688 -178.408 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.406 HD12 ' CG ' ' A' ' 41' ' ' PHE . 21.5 pt -80.68 -38.75 17.67 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.289 0 N-CA-C 112.576 0.584 . . . . 0.0 112.576 -179.463 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 31.5 m -76.9 135.5 38.81 Favored 'General case' 0 N--CA 1.454 -0.252 0 N-CA-C 114.0 1.111 . . . . 0.0 114.0 -176.085 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 84.7 mtp -73.43 139.27 78.16 Favored Pre-proline 0 N--CA 1.449 -0.524 0 N-CA-C 104.721 -2.326 . . . . 0.0 104.721 173.218 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -64.98 126.4 16.46 Favored 'Trans proline' 0 N--CA 1.45 -1.051 0 N-CA-C 107.799 -1.654 . . . . 0.0 107.799 178.439 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -44.79 -34.87 2.46 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 125.053 1.341 . . . . 0.0 114.148 -177.322 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 11.2 tm-20 -56.26 -37.07 69.3 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 124.346 1.058 . . . . 0.0 110.713 178.865 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 52.2 mt-10 -92.93 148.2 22.21 Favored 'General case' 0 N--CA 1.444 -0.742 0 C-N-CA 124.478 1.111 . . . . 0.0 110.207 -178.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -160.22 151.3 19.16 Favored 'General case' 0 N--CA 1.444 -0.725 0 CA-C-N 115.661 -0.7 . . . . 0.0 110.934 178.551 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 47.3 mt -80.69 106.12 12.45 Favored 'General case' 0 N--CA 1.441 -0.885 0 N-CA-C 103.561 -2.755 . . . . 0.0 103.561 177.671 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 29.0 p-10 -89.19 -38.19 14.46 Favored 'General case' 0 C--N 1.332 -0.16 0 C-N-CA 124.803 1.241 . . . . 0.0 113.153 -176.732 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.68 155.89 45.38 Favored Pre-proline 0 CA--C 1.534 0.344 0 C-N-CA 123.895 0.878 . . . . 0.0 110.882 -178.054 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -66.11 164.68 26.78 Favored 'Trans proline' 0 N--CA 1.456 -0.702 0 C-N-CA 122.419 2.079 . . . . 0.0 109.753 176.629 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 79.73 -44.03 2.69 Favored Glycine 0 CA--C 1.528 0.86 0 CA-C-O 118.78 -1.011 . . . . 0.0 113.59 176.921 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 53.7 mt-10 -41.19 134.03 2.2 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 124.959 1.304 . . . . 0.0 111.686 -179.399 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 69.0 p -114.18 167.71 10.45 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 123.826 0.85 . . . . 0.0 113.268 -177.147 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 3.7 t80 -140.65 114.41 8.9 Favored 'General case' 0 N--CA 1.455 -0.213 0 N-CA-C 103.849 -2.649 . . . . 0.0 103.849 174.717 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 41.3 t -106.82 144.78 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.296 0 C-N-CA 123.703 0.801 . . . . 0.0 109.638 -177.4 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 13.7 p -152.02 167.25 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.204 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 177.912 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 57.2 m -145.88 122.72 11.28 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 105.765 -1.939 . . . . 0.0 105.765 179.49 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 66.3 mt -107.08 99.56 9.1 Favored 'General case' 0 N--CA 1.455 -0.192 0 CA-C-O 121.303 0.573 . . . . 0.0 111.389 -175.168 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -77.14 -47.14 21.2 Favored 'General case' 0 N--CA 1.455 -0.217 0 C-N-CA 123.835 0.854 . . . . 0.0 110.539 178.143 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.7 m -72.48 122.82 21.93 Favored 'General case' 0 N--CA 1.451 -0.382 0 C-N-CA 123.012 0.525 . . . . 0.0 110.599 -177.664 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 50.6 tttm -67.02 155.18 39.32 Favored 'General case' 0 N--CA 1.436 -1.168 0 C-N-CA 126.906 2.082 . . . . 0.0 110.316 179.177 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 132.8 178.24 15.42 Favored Glycine 0 CA--C 1.526 0.761 0 C-N-CA 124.798 1.19 . . . . 0.0 111.378 178.962 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 74.7 m -102.13 119.83 39.44 Favored 'General case' 0 CA--C 1.52 -0.201 0 C-N-CA 124.119 0.968 . . . . 0.0 108.756 -179.283 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 37.2 m-85 -105.92 112.65 25.79 Favored 'General case' 0 N--CA 1.445 -0.681 0 C-N-CA 125.794 1.638 . . . . 0.0 109.833 -179.035 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 4.1 m -85.87 128.7 34.88 Favored 'General case' 0 C--O 1.234 0.28 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 177.368 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 35.4 p90 -132.19 167.65 19.42 Favored 'General case' 0 N--CA 1.457 -0.1 0 CA-C-O 121.822 0.82 . . . . 0.0 112.562 -179.142 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 50.5 p90 -159.96 162.48 34.41 Favored 'General case' 0 N--CA 1.452 -0.372 0 CA-C-N 114.977 -1.01 . . . . 0.0 111.569 -179.37 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.2 t -99.6 102.9 14.55 Favored 'General case' 0 CA--C 1.518 -0.279 0 N-CA-C 106.575 -1.639 . . . . 0.0 106.575 177.52 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.312 16.9 p -40.44 -61.2 1.25 Allowed Pre-proline 0 CA--C 1.538 0.518 0 N-CA-C 115.795 1.776 . . . . 0.0 115.795 -174.489 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -60.12 -6.09 4.66 Favored 'Trans proline' 0 CA--C 1.537 0.638 0 C-N-CA 122.208 1.939 . . . . 0.0 114.924 -178.751 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 35.8 m80 -134.43 14.24 3.78 Favored 'General case' 0 CA--C 1.532 0.254 0 CA-C-N 119.694 1.134 . . . . 0.0 111.355 178.671 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 16.6 pt20 -60.66 -42.83 97.82 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 119.147 0.885 . . . . 0.0 109.217 179.259 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -58.48 -31.39 66.61 Favored Glycine 0 CA--C 1.531 1.071 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 177.18 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -85.12 5.25 30.61 Favored 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 123.556 0.743 . . . . 0.0 111.333 178.91 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 83.89 17.24 65.89 Favored Glycine 0 CA--C 1.528 0.849 0 CA-C-O 118.795 -1.003 . . . . 0.0 113.591 178.726 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 21.8 ttt -78.72 77.16 5.21 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 119.593 1.696 . . . . 0.0 108.494 178.144 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 11.6 m -120.24 169.95 10.69 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 C-N-CA 125.984 1.714 . . . . 0.0 110.404 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -169.45 174.19 43.79 Favored Glycine 0 CA--C 1.527 0.83 0 N-CA-C 109.108 -1.597 . . . . 0.0 109.108 178.112 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 54.2 mttp -149.4 139.04 21.71 Favored 'General case' 0 C--O 1.231 0.083 0 CA-C-N 118.173 0.986 . . . . 0.0 109.756 -178.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 6.0 p -125.66 120.17 56.83 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.139 0 CA-C-O 120.921 0.391 . . . . 0.0 110.519 178.798 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 48.6 m -94.22 100.58 12.63 Favored 'General case' 0 N--CA 1.455 -0.203 0 C-N-CA 124.68 1.192 . . . . 0.0 109.342 178.949 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 44.7 t -79.69 107.09 11.73 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.012 0 N-CA-C 104.397 -2.445 . . . . 0.0 104.397 179.536 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 51.1 p-10 . . . . . 0 N--CA 1.456 -0.16 0 C-N-CA 125.157 1.383 . . . . 0.0 110.291 -177.034 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 8.5 tt . . . . . 0 N--CA 1.454 -0.275 0 CA-C-O 121.065 0.46 . . . . 0.0 110.935 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -84.08 119.49 25.02 Favored 'General case' 0 N--CA 1.453 -0.294 0 C-N-CA 123.224 0.61 . . . . 0.0 110.093 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 47.1 t -112.24 111.0 34.28 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 105.855 -1.906 . . . . 0.0 105.855 178.517 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 31.7 mt -90.46 120.4 31.54 Favored 'General case' 0 N--CA 1.45 -0.462 0 O-C-N 121.822 -0.549 . . . . 0.0 109.706 -178.68 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.434 ' HB3' ' CD2' ' A' ' 37' ' ' HIS . 1.9 mm? -79.47 106.88 11.82 Favored 'General case' 0 N--CA 1.444 -0.738 0 N-CA-C 105.909 -1.886 . . . . 0.0 105.909 174.378 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 97.03 132.8 7.54 Favored Glycine 0 CA--C 1.523 0.586 0 C-N-CA 125.871 1.701 . . . . 0.0 112.329 178.666 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.6 p -82.78 47.87 1.26 Allowed 'General case' 0 N--CA 1.456 -0.135 0 C-N-CA 124.43 1.092 . . . . 0.0 111.197 179.325 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 70.74 -52.2 0.91 Allowed Glycine 0 CA--C 1.527 0.781 0 C-N-CA 126.598 2.047 . . . . 0.0 113.078 -179.668 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -72.1 38.07 0.07 Allowed 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 126.05 1.74 . . . . 0.0 113.851 -177.298 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 59.17 3.04 1.62 Allowed Glycine 0 CA--C 1.531 1.075 0 N-CA-C 115.911 1.124 . . . . 0.0 115.911 178.569 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 27.7 t -64.31 145.45 56.0 Favored 'General case' 0 N--CA 1.455 -0.181 0 CA-C-N 119.131 1.465 . . . . 0.0 110.87 -178.661 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 93.0 mt -86.43 73.26 10.16 Favored 'General case' 0 N--CA 1.447 -0.58 0 C-N-CA 124.044 0.938 . . . . 0.0 109.482 -178.83 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.9 m -137.01 143.97 33.4 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.217 0 C-N-CA 123.05 0.54 . . . . 0.0 111.204 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -90.27 122.84 33.55 Favored 'General case' 0 N--CA 1.46 0.051 0 N-CA-C 103.695 -2.706 . . . . 0.0 103.695 174.865 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.8 t -113.94 100.56 52.62 Favored Pre-proline 0 CA--C 1.536 0.422 0 CA-C-O 118.237 -0.887 . . . . 0.0 109.984 -179.271 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -81.01 164.24 78.26 Favored 'Cis proline' 0 N--CA 1.46 -0.463 0 CA-C-N 120.605 1.252 . . . . 0.0 111.257 -1.618 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 15.7 p -92.61 -62.86 1.31 Allowed 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 107.576 -1.268 . . . . 0.0 107.576 177.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 10.8 mp0 -98.21 126.85 43.85 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 125.835 1.654 . . . . 0.0 107.532 178.428 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.9 p90 -160.55 -175.57 5.08 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-O 121.541 0.686 . . . . 0.0 111.847 179.631 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 35.3 m -135.97 146.07 46.85 Favored 'General case' 0 N--CA 1.45 -0.426 0 N-CA-C 106.204 -1.776 . . . . 0.0 106.204 178.245 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 1.4 p -147.21 140.56 15.02 Favored Pre-proline 0 N--CA 1.449 -0.496 0 CA-C-O 118.367 -0.825 . . . . 0.0 109.631 -178.343 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_exo -60.71 144.13 99.5 Favored 'Trans proline' 0 N--CA 1.456 -0.689 0 C-N-CA 121.671 1.58 . . . . 0.0 112.678 179.411 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.2 m -56.35 128.0 33.7 Favored 'General case' 0 N--CA 1.454 -0.233 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 176.949 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.76 -3.57 78.1 Favored Glycine 0 CA--C 1.526 0.719 0 CA-C-O 119.012 -0.882 . . . . 0.0 112.198 179.35 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -70.64 149.3 47.17 Favored 'General case' 0 CA--C 1.534 0.361 0 CA-C-N 119.033 1.417 . . . . 0.0 109.124 178.025 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -90.44 105.09 17.58 Favored 'General case' 0 N--CA 1.447 -0.582 0 C-N-CA 124.868 1.267 . . . . 0.0 108.585 -178.563 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 34.6 mt -81.09 130.7 35.43 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.343 0 N-CA-C 105.381 -2.081 . . . . 0.0 105.381 177.364 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 67.9 t -117.69 97.58 5.58 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 C-N-CA 124.904 1.281 . . . . 0.0 108.665 -178.439 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -84.47 97.16 9.38 Favored 'General case' 0 N--CA 1.456 -0.158 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 178.011 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 28.4 ttpp -99.3 129.29 45.5 Favored 'General case' 0 CA--C 1.528 0.126 0 C-N-CA 123.746 0.818 . . . . 0.0 112.691 -176.444 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 5.2 m-20 -69.63 105.3 2.64 Favored 'General case' 0 N--CA 1.455 -0.2 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 177.456 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 51.5 t30 -89.17 -57.42 2.9 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 178.466 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -164.37 175.28 10.14 Favored 'General case' 0 CA--C 1.529 0.167 0 C-N-CA 124.095 0.958 . . . . 0.0 109.328 179.802 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 71.09 16.07 74.78 Favored Glycine 0 CA--C 1.531 1.084 0 O-C-N 121.753 -0.592 . . . . 0.0 113.095 179.19 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.508 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 21.5 p90 -67.77 166.4 23.24 Favored Pre-proline 0 CA--C 1.545 0.785 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 178.178 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.508 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 83.5 Cg_endo -69.7 151.4 91.26 Favored 'Cis proline' 0 N--CA 1.447 -1.23 0 N-CA-C 116.395 1.652 . . . . 0.0 116.395 5.161 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.434 ' CD2' ' HB3' ' A' ' 5' ' ' LEU . 88.8 m-70 -144.93 156.92 44.24 Favored 'General case' 0 N--CA 1.451 -0.387 0 O-C-N 121.695 -0.628 . . . . 0.0 111.093 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 56.6 p30 -158.18 175.52 13.66 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 103.966 -2.605 . . . . 0.0 103.966 175.287 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 42.0 t -137.98 121.08 20.12 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.36 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 -179.027 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 95.9 t -117.33 131.9 68.69 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.621 0 N-CA-C 105.83 -1.915 . . . . 0.0 105.83 178.949 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -96.91 131.2 43.92 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 107.24 -1.393 . . . . 0.0 107.24 179.425 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 35.6 t0 -67.21 108.74 2.81 Favored 'General case' 0 N--CA 1.451 -0.393 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 -179.131 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -47.82 -31.33 4.84 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.028 0.931 . . . . 0.0 113.45 178.865 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 34.4 t70 -75.74 -22.38 56.57 Favored 'General case' 0 CA--C 1.536 0.426 0 N-CA-C 112.741 0.645 . . . . 0.0 112.741 179.563 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -128.39 68.07 1.37 Allowed 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 124.453 1.101 . . . . 0.0 111.791 -177.042 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 31.8 pt -153.67 157.34 32.66 Favored Pre-proline 0 CA--C 1.535 0.371 0 C-N-CA 127.884 2.474 . . . . 0.0 105.79 175.825 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_exo -56.33 115.62 2.6 Favored 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.559 2.173 . . . . 0.0 111.07 178.391 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.34 107.33 0.27 Allowed 'General case' 0 N--CA 1.455 -0.178 0 C-N-CA 123.608 0.763 . . . . 0.0 109.676 179.569 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 137.79 -32.29 2.39 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 -177.805 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 57.3 t -76.84 107.37 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.262 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 179.354 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 45.0 t0 -57.99 108.15 0.56 Allowed 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 123.252 0.621 . . . . 0.0 110.777 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.63 -38.6 32.77 Favored 'General case' 0 C--O 1.223 -0.295 0 C-N-CA 123.73 0.812 . . . . 0.0 111.228 178.883 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 46.7 t -58.67 -27.22 33.76 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 CA-C-N 118.071 0.396 . . . . 0.0 111.863 -179.44 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 44.0 mmtm -82.55 -41.93 18.98 Favored 'General case' 0 CA--C 1.529 0.172 0 CA-C-N 118.611 0.641 . . . . 0.0 110.839 -179.392 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 24.6 pt -78.03 -46.9 25.83 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.29 0 N-CA-C 112.005 0.372 . . . . 0.0 112.005 -179.29 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 60.7 m -73.22 128.41 35.4 Favored 'General case' 0 N--CA 1.451 -0.422 0 C-N-CA 124.224 1.01 . . . . 0.0 113.01 -176.018 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 88.4 mmm -66.08 133.73 94.78 Favored Pre-proline 0 N--CA 1.451 -0.422 0 N-CA-C 105.401 -2.074 . . . . 0.0 105.401 174.661 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 21.0 Cg_endo -59.59 116.52 3.34 Favored 'Trans proline' 0 N--CA 1.453 -0.894 0 C-N-CA 121.495 1.463 . . . . 0.0 108.829 179.798 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -28.76 -48.89 0.07 Allowed 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 128.174 2.59 . . . . 0.0 116.062 -176.467 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 14.2 tm-20 -61.19 -37.71 83.93 Favored 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 124.579 1.152 . . . . 0.0 112.182 -178.374 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 53.5 mt-10 -84.04 143.44 29.75 Favored 'General case' 0 N--CA 1.446 -0.64 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 -178.266 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -159.45 149.61 18.97 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-O 121.713 0.768 . . . . 0.0 112.292 -178.043 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 63.0 mt -79.02 106.03 10.77 Favored 'General case' 0 N--CA 1.444 -0.749 0 N-CA-C 104.862 -2.273 . . . . 0.0 104.862 178.151 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 65.6 t30 -112.29 42.14 1.86 Allowed 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 124.259 1.024 . . . . 0.0 112.747 -177.732 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -158.0 158.26 29.97 Favored Pre-proline 0 C--O 1.233 0.186 0 N-CA-C 107.045 -1.465 . . . . 0.0 107.045 178.366 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 96.8 Cg_endo -73.92 167.78 26.39 Favored 'Trans proline' 0 N--CA 1.451 -0.999 0 C-N-CA 121.542 1.495 . . . . 0.0 109.313 178.242 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 78.63 -42.65 2.26 Favored Glycine 0 CA--C 1.527 0.84 0 CA-C-O 118.74 -1.033 . . . . 0.0 114.411 175.756 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 47.7 mt-10 -42.4 131.57 3.69 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 118.494 1.147 . . . . 0.0 112.442 -179.609 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 20.8 p -118.33 127.4 53.66 Favored 'General case' 0 N--CA 1.457 -0.122 0 N-CA-C 113.675 0.991 . . . . 0.0 113.675 -178.554 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 2.4 t80 -100.15 107.16 18.97 Favored 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 103.682 -2.71 . . . . 0.0 103.682 172.367 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 38.8 t -100.08 140.11 19.99 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.162 0 C-N-CA 123.415 0.686 . . . . 0.0 109.674 -178.026 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.2 p -150.31 135.03 9.69 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.254 0 C-N-CA 122.766 0.426 . . . . 0.0 110.319 177.847 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 19.7 m -103.57 100.4 10.24 Favored 'General case' 0 CA--C 1.53 0.207 0 C-N-CA 124.59 1.156 . . . . 0.0 109.0 -179.595 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 59.5 mt -90.19 99.73 12.69 Favored 'General case' 0 CA--C 1.53 0.192 0 CA-C-O 121.074 0.464 . . . . 0.0 109.82 -179.555 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -79.13 -55.34 5.18 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 123.216 0.606 . . . . 0.0 111.27 178.863 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.5 m -64.58 119.48 10.56 Favored 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 123.386 0.674 . . . . 0.0 110.388 -176.119 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.86 161.5 20.98 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 123.449 0.7 . . . . 0.0 112.373 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 133.87 178.77 15.83 Favored Glycine 0 CA--C 1.525 0.718 0 C-N-CA 125.565 1.555 . . . . 0.0 110.74 178.974 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 7.4 m -96.29 114.55 26.24 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 124.417 1.087 . . . . 0.0 109.336 -178.531 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 29.8 m-85 -105.09 111.05 23.67 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 124.684 1.193 . . . . 0.0 109.217 179.73 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 18.3 m -88.01 137.58 32.21 Favored 'General case' 0 C--O 1.232 0.172 0 N-CA-C 107.517 -1.29 . . . . 0.0 107.517 177.379 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 28.5 p90 -140.95 167.24 22.67 Favored 'General case' 0 C--N 1.339 0.124 0 CA-C-N 119.06 0.845 . . . . 0.0 113.266 -178.177 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 53.7 p90 -154.31 160.49 41.77 Favored 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 114.924 -1.034 . . . . 0.0 112.202 -179.658 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.6 t -104.24 99.31 9.03 Favored 'General case' 0 CA--C 1.519 -0.241 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 177.925 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -33.79 -62.99 0.33 Allowed Pre-proline 0 CA--C 1.537 0.45 0 N-CA-C 115.927 1.825 . . . . 0.0 115.927 -176.296 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -60.4 -7.04 6.19 Favored 'Trans proline' 0 C--N 1.348 0.546 0 C-N-CA 122.307 2.005 . . . . 0.0 114.92 -177.558 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 36.3 m80 -135.62 14.65 3.42 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 119.416 1.007 . . . . 0.0 111.124 178.505 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 14.6 pt20 -61.04 -41.24 96.2 Favored 'General case' 0 N--CA 1.454 -0.262 0 O-C-N 121.442 -0.786 . . . . 0.0 109.489 179.531 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -58.46 -29.45 63.59 Favored Glycine 0 CA--C 1.532 1.119 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 177.039 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.91 11.86 19.13 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 123.804 0.842 . . . . 0.0 110.864 178.798 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 74.47 21.87 78.18 Favored Glycine 0 CA--C 1.527 0.8 0 CA-C-O 119.112 -0.826 . . . . 0.0 113.171 178.877 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -78.86 80.55 5.2 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 119.255 1.528 . . . . 0.0 107.464 178.156 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 12.4 m -123.49 171.76 11.94 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 C-N-CA 125.579 1.552 . . . . 0.0 111.691 -178.851 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -167.12 178.79 41.15 Favored Glycine 0 CA--C 1.529 0.948 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 178.18 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 39.1 ttpt -158.48 130.57 6.82 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 -178.518 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.7 p -119.25 128.27 75.83 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 CA-C-O 121.391 0.615 . . . . 0.0 110.346 -178.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.4 m -94.37 98.78 11.13 Favored 'General case' 0 N--CA 1.452 -0.336 0 N-CA-C 107.514 -1.291 . . . . 0.0 107.514 179.151 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 45.2 t -80.31 114.28 20.97 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.587 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 -178.981 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 77.7 m-20 . . . . . 0 C--O 1.233 0.212 0 C-N-CA 123.664 0.785 . . . . 0.0 109.085 -178.112 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 9.3 mp . . . . . 0 CA--C 1.534 0.364 0 CA-C-O 121.702 0.763 . . . . 0.0 111.524 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 36.4 mt-10 -87.76 90.9 8.56 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 105.612 -1.996 . . . . 0.0 105.612 175.116 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 28.3 t -87.22 119.29 34.69 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.454 0 CA-C-N 114.968 -1.015 . . . . 0.0 108.923 -176.757 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 58.1 mt -88.27 121.47 30.7 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 179.189 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.414 ' HB3' ' CD2' ' A' ' 37' ' ' HIS . 1.4 mm? -78.01 103.18 7.78 Favored 'General case' 0 N--CA 1.445 -0.685 0 N-CA-C 105.815 -1.92 . . . . 0.0 105.815 173.976 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 97.1 152.31 28.6 Favored Glycine 0 N--CA 1.446 -0.675 0 C-N-CA 123.91 0.766 . . . . 0.0 111.331 179.083 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 78.9 p -85.59 173.46 10.15 Favored 'General case' 0 N--CA 1.44 -0.938 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 177.783 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -52.51 -43.94 58.97 Favored Glycine 0 CA--C 1.531 1.07 0 N-CA-C 111.265 -0.734 . . . . 0.0 111.265 178.679 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -79.81 11.78 3.05 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 123.362 0.665 . . . . 0.0 112.316 178.76 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 69.44 27.46 73.51 Favored Glycine 0 CA--C 1.524 0.639 0 CA-C-O 119.07 -0.85 . . . . 0.0 114.009 178.712 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 27.1 t -73.42 145.21 45.98 Favored 'General case' 0 C--N 1.34 0.155 0 N-CA-C 106.084 -1.821 . . . . 0.0 106.084 176.899 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 76.1 mt -76.12 64.75 2.01 Favored 'General case' 0 N--CA 1.449 -0.482 0 C-N-CA 124.363 1.065 . . . . 0.0 111.798 -176.102 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.2 m -132.89 139.45 49.6 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.215 0 C-N-CA 124.069 0.948 . . . . 0.0 111.268 -179.124 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 36.2 m-85 -82.83 129.52 35.01 Favored 'General case' 0 C--O 1.232 0.171 0 N-CA-C 104.314 -2.476 . . . . 0.0 104.314 175.201 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 25.2 t -117.84 105.2 47.93 Favored Pre-proline 0 CA--C 1.535 0.368 0 CA-C-O 118.168 -0.92 . . . . 0.0 108.963 179.561 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -75.13 164.81 87.47 Favored 'Cis proline' 0 C--N 1.348 0.518 0 CA-C-N 120.482 1.208 . . . . 0.0 111.505 -1.332 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 7.0 p -90.4 -62.29 1.49 Allowed 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 125.352 1.461 . . . . 0.0 108.655 179.207 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -106.42 137.48 44.32 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 126.313 1.845 . . . . 0.0 106.366 177.174 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 18.0 p90 -163.63 -174.73 3.82 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 118.38 0.536 . . . . 0.0 110.871 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 24.2 m -140.1 149.19 42.77 Favored 'General case' 0 N--CA 1.455 -0.212 0 C-N-CA 124.783 1.233 . . . . 0.0 108.813 -178.636 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 29.0 m -148.88 151.68 35.45 Favored Pre-proline 0 N--CA 1.463 0.2 0 C-N-CA 123.585 0.754 . . . . 0.0 110.332 -179.695 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -70.94 150.19 60.63 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 C-N-CA 121.778 1.652 . . . . 0.0 110.135 176.309 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 60.0 m -55.04 118.84 4.66 Favored 'General case' 0 CA--C 1.53 0.187 0 C-N-CA 123.308 0.643 . . . . 0.0 109.329 177.754 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 106.01 -5.6 39.51 Favored Glycine 0 CA--C 1.528 0.894 0 CA-C-O 118.877 -0.957 . . . . 0.0 112.802 -179.159 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -59.58 136.3 57.94 Favored 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 119.41 1.605 . . . . 0.0 110.623 179.374 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -90.98 93.15 9.07 Favored 'General case' 0 N--CA 1.445 -0.7 0 N-CA-C 106.013 -1.847 . . . . 0.0 106.013 177.457 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 63.4 mt -75.2 137.84 22.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 -178.616 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 67.9 t -115.75 102.41 13.67 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.296 0 C-N-CA 124.659 1.184 . . . . 0.0 108.479 -178.239 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -90.16 101.62 14.33 Favored 'General case' 0 CA--C 1.53 0.177 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 177.805 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 26.7 ttpp -99.99 129.54 46.07 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 124.774 1.229 . . . . 0.0 112.633 -176.596 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 39.6 t30 -66.82 115.35 6.5 Favored 'General case' 0 CA--C 1.528 0.098 0 CA-C-O 118.805 -0.617 . . . . 0.0 110.342 177.856 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 43.6 t30 -97.04 -73.82 0.59 Allowed 'General case' 0 N--CA 1.457 -0.114 0 CA-C-O 121.111 0.481 . . . . 0.0 110.664 179.835 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -157.95 170.97 21.12 Favored 'General case' 0 C--N 1.332 -0.183 0 C-N-CA 124.783 1.233 . . . . 0.0 108.16 -177.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 71.59 17.57 76.54 Favored Glycine 0 CA--C 1.534 1.263 0 O-C-N 121.487 -0.758 . . . . 0.0 112.252 -178.965 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.519 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 7.4 p90 -72.09 170.49 12.39 Favored Pre-proline 0 CA--C 1.54 0.559 0 C-N-CA 125.946 1.698 . . . . 0.0 107.77 178.59 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.519 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 26.9 Cg_exo -64.99 152.07 76.22 Favored 'Cis proline' 0 N--CA 1.451 -0.982 0 N-CA-C 115.581 1.339 . . . . 0.0 115.581 2.19 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.414 ' CD2' ' HB3' ' A' ' 5' ' ' LEU . 87.6 m-70 -141.74 170.11 16.34 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 123.311 0.645 . . . . 0.0 109.485 179.235 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 46.7 p30 -168.71 177.4 5.14 Favored 'General case' 0 N--CA 1.451 -0.423 0 N-CA-C 104.109 -2.552 . . . . 0.0 104.109 175.706 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 39.6 t -135.95 112.43 13.09 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.274 0 N-CA-C 107.262 -1.384 . . . . 0.0 107.262 -179.063 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 48.4 t -116.96 133.35 63.96 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 N-CA-C 105.98 -1.859 . . . . 0.0 105.98 -179.141 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.436 ' CG ' HD12 ' A' ' 55' ' ' ILE . 55.0 m-85 -93.69 142.69 27.07 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -179.138 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -74.62 97.95 3.29 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.749 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -39.89 -35.97 0.41 Allowed 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 125.842 1.657 . . . . 0.0 115.324 -179.234 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -82.77 -27.64 30.88 Favored 'General case' 0 CA--C 1.535 0.375 0 N-CA-C 112.607 0.595 . . . . 0.0 112.607 -179.715 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 47.5 tt0 -112.22 61.28 0.63 Allowed 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 124.62 1.168 . . . . 0.0 111.438 -176.475 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 36.8 pt -157.01 158.3 31.12 Favored Pre-proline 0 CA--C 1.535 0.374 0 C-N-CA 128.468 2.707 . . . . 0.0 105.721 176.817 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -55.4 111.94 0.9 Allowed 'Trans proline' 0 N--CA 1.456 -0.717 0 C-N-CA 122.498 2.132 . . . . 0.0 109.59 175.537 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -33.08 -48.47 0.22 Allowed 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 126.855 2.062 . . . . 0.0 115.619 -177.517 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -58.87 -29.12 64.28 Favored Glycine 0 CA--C 1.533 1.182 0 O-C-N 122.131 -0.356 . . . . 0.0 113.78 -178.457 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 43.1 t -82.19 96.28 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 CA-C-N 118.154 0.977 . . . . 0.0 109.759 -178.193 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 6.7 t0 -52.77 116.71 2.46 Favored 'General case' 0 CA--C 1.535 0.392 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 176.706 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -46.77 -38.51 10.18 Favored 'General case' 0 N--CA 1.456 -0.17 0 C-N-CA 126.085 1.754 . . . . 0.0 112.552 -178.734 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 59.9 t -59.54 -28.17 39.31 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 C-N-CA 123.006 0.522 . . . . 0.0 111.443 -179.276 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 41.7 mtmt -74.28 -45.57 46.86 Favored 'General case' 0 CA--C 1.528 0.125 0 O-C-N 121.666 -0.646 . . . . 0.0 110.602 -179.111 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.436 HD12 ' CG ' ' A' ' 41' ' ' PHE . 25.6 pt -79.59 -32.81 14.72 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 N-CA-C 113.008 0.744 . . . . 0.0 113.008 -177.766 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 47.1 m -77.39 130.54 37.23 Favored 'General case' 0 N--CA 1.452 -0.327 0 C-N-CA 123.148 0.579 . . . . 0.0 112.035 -178.034 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.5 tmt? -63.83 124.05 83.67 Favored Pre-proline 0 N--CA 1.449 -0.508 0 N-CA-C 104.869 -2.271 . . . . 0.0 104.869 175.738 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_exo -42.64 107.18 0.08 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.565 0 C-N-CA 123.985 3.123 . . . . 0.0 112.567 -178.121 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -41.1 -39.6 1.3 Allowed 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 126.397 1.879 . . . . 0.0 114.323 -177.906 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -58.74 -34.47 71.43 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 124.314 1.046 . . . . 0.0 110.752 -179.677 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 88.5 mt-10 -94.46 154.51 17.39 Favored 'General case' 0 N--CA 1.445 -0.713 0 C-N-CA 125.825 1.65 . . . . 0.0 108.501 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 5.1 mp -143.72 144.67 31.95 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-O 121.378 0.609 . . . . 0.0 110.745 -178.97 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 59.9 mt -80.67 93.42 6.15 Favored 'General case' 0 N--CA 1.444 -0.735 0 N-CA-C 103.046 -2.946 . . . . 0.0 103.046 174.01 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -109.65 -42.2 4.36 Favored 'General case' 0 C--N 1.333 -0.116 0 C-N-CA 124.273 1.029 . . . . 0.0 111.22 -176.736 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.27 134.61 73.63 Favored Pre-proline 0 C--O 1.236 0.356 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 -178.694 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_exo -50.7 132.51 36.56 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 C-N-CA 122.571 2.181 . . . . 0.0 110.903 179.776 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 92.73 -15.09 63.42 Favored Glycine 0 CA--C 1.527 0.821 0 CA-C-O 117.325 -1.82 . . . . 0.0 115.782 176.918 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -52.76 125.54 17.12 Favored 'General case' 0 CA--C 1.537 0.457 0 CA-C-N 121.045 2.423 . . . . 0.0 110.923 179.302 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 12.1 p -105.26 122.46 45.98 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 125.827 1.651 . . . . 0.0 112.395 -178.725 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 54.3 t80 -103.85 108.35 19.64 Favored 'General case' 0 N--CA 1.454 -0.235 0 N-CA-C 105.984 -1.858 . . . . 0.0 105.984 174.301 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 15.8 t -96.65 136.93 25.84 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 -178.609 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.5 p -145.51 127.06 8.29 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.404 0 CA-C-N 118.428 0.558 . . . . 0.0 110.97 178.628 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 7.9 m -88.73 101.97 14.53 Favored 'General case' 0 CA--C 1.53 0.174 0 C-N-CA 125.45 1.5 . . . . 0.0 110.239 -179.489 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 22.4 mt -87.33 87.45 7.43 Favored 'General case' 0 N--CA 1.462 0.151 0 CA-C-N 118.585 0.63 . . . . 0.0 109.357 179.394 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -69.5 -46.74 65.86 Favored 'General case' 0 CA--C 1.532 0.281 0 N-CA-C 113.399 0.889 . . . . 0.0 113.399 -179.703 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 2.0 m -78.83 127.47 32.09 Favored 'General case' 0 N--CA 1.454 -0.268 0 O-C-N 121.866 -0.521 . . . . 0.0 112.113 -175.23 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.1 155.38 37.0 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 122.987 0.515 . . . . 0.0 110.599 176.784 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 138.91 175.35 13.95 Favored Glycine 0 CA--C 1.525 0.67 0 C-N-CA 125.137 1.351 . . . . 0.0 109.984 179.445 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -100.0 116.04 31.12 Favored 'General case' 0 N--CA 1.451 -0.396 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 17.9 m-85 -107.83 131.33 54.59 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 124.379 1.071 . . . . 0.0 109.806 -178.101 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 18.2 m -102.31 139.27 38.14 Favored 'General case' 0 C--O 1.233 0.233 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 176.099 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 26.1 p90 -140.81 169.52 17.48 Favored 'General case' 0 CA--C 1.521 -0.151 0 CA-C-O 121.586 0.708 . . . . 0.0 111.204 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 43.4 p90 -157.57 160.61 38.32 Favored 'General case' 0 N--CA 1.45 -0.462 0 CA-C-N 115.601 -0.727 . . . . 0.0 112.016 -178.81 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 t -97.63 99.88 11.26 Favored 'General case' 0 CA--C 1.512 -0.485 0 N-CA-C 105.68 -1.97 . . . . 0.0 105.68 177.334 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.371 4.9 p -43.43 -56.5 6.77 Favored Pre-proline 0 CA--C 1.54 0.572 0 N-CA-C 114.323 1.231 . . . . 0.0 114.323 -175.175 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_exo -47.27 -20.04 1.26 Allowed 'Trans proline' 0 CA--C 1.534 0.518 0 C-N-CA 123.6 2.867 . . . . 0.0 116.103 177.248 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 38.5 m80 -136.13 18.37 3.2 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-N 119.15 0.887 . . . . 0.0 111.806 -178.298 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 16.8 pt20 -60.88 -41.97 97.04 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-N 119.047 0.84 . . . . 0.0 109.539 179.533 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -58.39 -29.48 63.41 Favored Glycine 0 CA--C 1.532 1.155 0 N-CA-C 111.209 -0.756 . . . . 0.0 111.209 177.145 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.34 10.6 21.81 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 123.718 0.807 . . . . 0.0 111.084 178.946 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 79.33 17.1 76.98 Favored Glycine 0 CA--C 1.526 0.772 0 CA-C-O 118.758 -1.023 . . . . 0.0 113.801 178.484 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 22.9 ttt -79.26 77.35 5.79 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 119.703 1.751 . . . . 0.0 108.265 178.213 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 14.3 m -117.87 170.58 7.11 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.319 0 C-N-CA 125.909 1.684 . . . . 0.0 110.198 179.809 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -164.86 176.54 40.64 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 178.092 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 53.8 tttp -154.68 154.48 32.99 Favored 'General case' 0 N--CA 1.454 -0.253 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 -176.074 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.4 p -145.53 134.2 17.0 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.159 0 O-C-N 121.987 -0.445 . . . . 0.0 110.988 -178.773 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.7 m -100.15 94.51 6.27 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 125.65 1.58 . . . . 0.0 110.852 -178.002 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 21.4 t -80.17 120.28 31.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 105.459 -2.052 . . . . 0.0 105.459 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 5.8 p30 . . . . . 0 C--N 1.332 -0.157 0 C-N-CA 123.483 0.713 . . . . 0.0 111.652 -174.914 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 3.0 tm? . . . . . 0 N--CA 1.454 -0.268 0 N-CA-C 108.663 -0.865 . . . . 0.0 108.663 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -91.29 119.74 31.59 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 114.337 -1.301 . . . . 0.0 110.997 -177.38 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 39.0 t -113.23 118.24 57.55 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.332 0 N-CA-C 107.364 -1.347 . . . . 0.0 107.364 178.386 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 64.3 mt -89.1 120.86 30.88 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 -179.77 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -78.76 111.22 14.65 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 106.799 -1.556 . . . . 0.0 106.799 175.158 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 93.61 138.75 9.12 Favored Glycine 0 N--CA 1.446 -0.649 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.168 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 68.4 p -81.8 158.34 24.14 Favored 'General case' 0 N--CA 1.437 -1.11 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 178.906 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.0 -33.87 57.58 Favored Glycine 0 CA--C 1.53 1.025 0 CA-C-N 115.252 -0.885 . . . . 0.0 111.512 178.969 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -75.8 -3.71 36.57 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 123.597 0.759 . . . . 0.0 112.292 178.962 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 99.51 -20.85 47.98 Favored Glycine 0 CA--C 1.527 0.794 0 CA-C-O 118.892 -0.949 . . . . 0.0 113.486 178.782 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 22.7 t -57.31 131.63 50.62 Favored 'General case' 0 C--O 1.239 0.516 0 CA-C-N 119.336 1.568 . . . . 0.0 110.682 -179.228 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 56.8 mt -73.03 65.63 0.77 Allowed 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 127.085 2.154 . . . . 0.0 112.412 -176.222 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 2.4 t -123.2 151.36 27.55 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.442 0 C-N-CA 124.247 1.019 . . . . 0.0 108.785 178.859 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 33.2 m-85 -86.17 129.74 34.75 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 104.125 -2.546 . . . . 0.0 104.125 175.97 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 48.8 t -118.44 104.62 47.49 Favored Pre-proline 0 CA--C 1.537 0.445 0 CA-C-O 118.324 -0.846 . . . . 0.0 108.877 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -75.05 161.78 94.14 Favored 'Cis proline' 0 C--N 1.347 0.499 0 CA-C-N 120.338 1.157 . . . . 0.0 111.597 -1.073 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 6.2 p -91.89 -60.47 1.85 Allowed 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 125.502 1.521 . . . . 0.0 108.609 179.212 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -105.4 127.01 52.75 Favored 'General case' 0 N--CA 1.453 -0.282 0 C-N-CA 126.238 1.815 . . . . 0.0 106.616 177.69 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 14.6 p90 -160.03 -175.36 5.05 Favored 'General case' 0 C--O 1.232 0.18 0 CA-C-O 121.08 0.467 . . . . 0.0 110.792 179.867 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 66.1 p -147.02 156.84 43.35 Favored 'General case' 0 N--CA 1.451 -0.403 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 18.1 m -152.75 151.28 26.35 Favored Pre-proline 0 CA--C 1.531 0.245 0 C-N-CA 123.61 0.764 . . . . 0.0 109.539 -178.901 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -73.17 148.52 44.4 Favored 'Trans proline' 0 N--CA 1.451 -1.0 0 C-N-CA 121.781 1.654 . . . . 0.0 110.761 177.812 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 64.7 m -48.93 121.24 4.52 Favored 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 122.996 0.518 . . . . 0.0 110.55 176.048 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 106.39 -9.72 42.14 Favored Glycine 0 CA--C 1.529 0.961 0 C-N-CA 124.165 0.888 . . . . 0.0 112.642 179.431 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -63.3 135.81 57.28 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-N 118.813 1.307 . . . . 0.0 109.979 179.242 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 52.9 mtpt -91.54 106.03 18.19 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 125.409 1.483 . . . . 0.0 108.659 179.386 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 40.4 mt -85.21 135.12 25.53 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 -179.672 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 64.7 t -119.73 100.3 9.27 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.34 0 C-N-CA 126.134 1.774 . . . . 0.0 108.152 -178.921 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -87.06 107.18 18.32 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 178.025 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 62.9 tttp -105.91 131.97 52.58 Favored 'General case' 0 CA--C 1.531 0.243 0 C-N-CA 125.266 1.426 . . . . 0.0 112.78 -176.408 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 8.1 m-20 -68.56 112.53 5.41 Favored 'General case' 0 C--O 1.232 0.132 0 C-N-CA 123.149 0.579 . . . . 0.0 110.021 177.538 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 24.5 t30 -97.46 -72.22 0.65 Allowed 'General case' 0 N--CA 1.456 -0.171 0 CA-C-O 121.052 0.453 . . . . 0.0 109.851 178.727 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -143.2 167.41 22.18 Favored 'General case' 0 C--N 1.331 -0.219 0 C-N-CA 123.972 0.909 . . . . 0.0 109.521 -178.028 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 62.65 23.78 65.5 Favored Glycine 0 CA--C 1.535 1.295 0 O-C-N 121.839 -0.538 . . . . 0.0 113.774 179.407 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.438 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 10.5 p90 -74.74 167.54 35.42 Favored Pre-proline 0 CA--C 1.537 0.463 0 N-CA-C 106.671 -1.603 . . . . 0.0 106.671 176.756 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.438 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 50.8 Cg_exo -62.66 159.91 58.31 Favored 'Cis proline' 0 N--CA 1.456 -0.698 0 N-CA-C 116.99 1.881 . . . . 0.0 116.99 1.072 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 93.3 m-70 -149.67 170.14 19.39 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.809 -179.464 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 37.3 p-10 -163.98 177.04 8.83 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 104.32 -2.474 . . . . 0.0 104.32 176.298 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 39.3 t -138.25 112.17 8.07 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.389 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 179.291 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 64.8 t -116.83 133.69 62.72 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.604 0 N-CA-C 106.052 -1.833 . . . . 0.0 106.052 179.525 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 64.6 m-85 -93.33 140.65 29.32 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 -179.306 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 53.1 t0 -70.76 104.48 2.89 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 179.42 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -48.02 -32.29 6.43 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 124.168 0.987 . . . . 0.0 113.293 178.211 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -92.04 6.39 46.6 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 123.494 0.717 . . . . 0.0 112.871 -178.839 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 20.7 tt0 -150.44 63.36 0.95 Allowed 'General case' 0 CA--C 1.538 0.506 0 CA-C-O 122.108 0.956 . . . . 0.0 110.71 -179.283 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 28.0 pt -155.59 158.2 31.77 Favored Pre-proline 0 CA--C 1.532 0.263 0 C-N-CA 128.573 2.749 . . . . 0.0 105.771 177.459 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_exo -55.93 109.5 0.44 Allowed 'Trans proline' 0 CA--C 1.538 0.692 0 C-N-CA 122.306 2.004 . . . . 0.0 108.585 174.127 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -33.65 -44.21 0.15 Allowed 'General case' 0 N--CA 1.465 0.322 0 C-N-CA 126.789 2.036 . . . . 0.0 115.77 -177.195 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -58.34 -29.84 63.77 Favored Glycine 0 CA--C 1.534 1.221 0 CA-C-O 119.856 -0.413 . . . . 0.0 113.766 -178.921 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 37.4 t -84.69 107.54 15.86 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.316 0 CA-C-N 118.179 0.99 . . . . 0.0 110.318 -177.94 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 19.7 t0 -59.29 116.15 3.71 Favored 'General case' 0 CA--C 1.534 0.364 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 177.333 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -46.79 -40.33 13.45 Favored 'General case' 0 N--CA 1.457 -0.113 0 C-N-CA 125.223 1.409 . . . . 0.0 112.012 179.671 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 53.1 t -60.23 -28.88 42.77 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 C-N-CA 122.994 0.518 . . . . 0.0 111.784 -178.969 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -76.56 -42.11 44.01 Favored 'General case' 0 N--CA 1.462 0.128 0 CA-C-N 118.617 0.644 . . . . 0.0 110.594 -179.006 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.411 HG21 HD13 ' A' ' 55' ' ' ILE . 22.7 pt -79.09 -32.84 15.45 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 N-CA-C 112.582 0.586 . . . . 0.0 112.582 -178.944 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 49.1 m -78.05 141.65 38.71 Favored 'General case' 0 N--CA 1.454 -0.255 0 N-CA-C 112.531 0.567 . . . . 0.0 112.531 -178.261 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 12.8 tpt -58.77 121.39 53.75 Favored Pre-proline 0 CA--C 1.535 0.401 0 N-CA-C 105.583 -2.006 . . . . 0.0 105.583 174.914 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_exo -46.88 103.98 0.06 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.615 0 C-N-CA 123.649 2.9 . . . . 0.0 110.927 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 57.0 mp0 -43.3 -27.86 0.28 Allowed 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 127.056 2.143 . . . . 0.0 114.984 -175.385 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -57.81 -35.51 70.95 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 123.193 0.597 . . . . 0.0 110.843 178.392 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -117.44 158.41 24.53 Favored 'General case' 0 N--CA 1.446 -0.639 0 C-N-CA 125.76 1.624 . . . . 0.0 109.412 -179.894 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 4.8 mp -145.48 159.56 42.9 Favored 'General case' 0 N--CA 1.452 -0.332 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 -179.444 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 71.9 mt -79.33 96.34 5.96 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 104.391 -2.448 . . . . 0.0 104.391 177.275 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 36.9 p-10 -80.32 -58.2 3.25 Favored 'General case' 0 CA--C 1.529 0.162 0 C-N-CA 124.156 0.982 . . . . 0.0 113.303 -177.17 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -79.75 160.45 69.32 Favored Pre-proline 0 CA--C 1.535 0.403 0 C-N-CA 124.318 1.047 . . . . 0.0 111.902 -176.75 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -64.59 161.89 33.49 Favored 'Trans proline' 0 N--CA 1.458 -0.614 0 C-N-CA 122.29 1.993 . . . . 0.0 109.172 175.081 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 78.74 -39.57 1.99 Allowed Glycine 0 CA--C 1.528 0.853 0 CA-C-O 118.656 -1.08 . . . . 0.0 113.829 177.293 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 79.5 mm-40 -42.03 130.32 3.54 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 124.476 1.111 . . . . 0.0 111.669 179.827 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 6.7 p -110.88 150.4 29.24 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 125.412 1.485 . . . . 0.0 112.424 -177.856 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 30.5 t80 -126.43 113.14 16.46 Favored 'General case' 0 N--CA 1.455 -0.177 0 N-CA-C 105.082 -2.192 . . . . 0.0 105.082 172.466 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 19.6 t -100.41 136.89 29.84 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.398 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 -178.543 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.2 p -150.07 140.88 16.66 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.121 0 N-CA-C 108.275 -1.009 . . . . 0.0 108.275 178.253 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 25.1 m -112.07 127.44 55.91 Favored 'General case' 0 N--CA 1.456 -0.126 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 -178.985 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 55.5 mt -110.67 124.63 52.29 Favored 'General case' 0 CA--C 1.529 0.137 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 179.713 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -108.48 -47.96 3.41 Favored 'General case' 0 CA--C 1.528 0.126 0 C-N-CA 124.286 1.034 . . . . 0.0 112.096 -178.296 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 5.0 m -66.4 128.69 37.16 Favored 'General case' 0 N--CA 1.454 -0.25 0 O-C-N 121.707 -0.621 . . . . 0.0 109.661 -177.51 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 61.8 mtpt -69.04 155.46 40.33 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 123.02 0.528 . . . . 0.0 110.441 -179.155 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 128.37 175.44 14.07 Favored Glycine 0 CA--C 1.527 0.832 0 C-N-CA 124.389 0.995 . . . . 0.0 111.409 179.023 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 89.3 m -95.25 127.22 41.12 Favored 'General case' 0 N--CA 1.451 -0.405 0 C-N-CA 124.871 1.269 . . . . 0.0 109.288 -179.828 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 25.2 m-85 -115.75 120.69 40.15 Favored 'General case' 0 N--CA 1.447 -0.601 0 C-N-CA 126.051 1.74 . . . . 0.0 108.615 179.398 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 64.1 m -92.37 140.16 29.87 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 177.023 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 22.8 p90 -139.39 165.48 27.1 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-O 121.555 0.693 . . . . 0.0 112.307 -179.52 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -152.66 157.31 40.76 Favored 'General case' 0 N--CA 1.452 -0.342 0 C-N-CA 124.205 1.002 . . . . 0.0 112.64 -178.334 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.4 t -99.68 102.04 13.41 Favored 'General case' 0 CA--C 1.519 -0.234 0 N-CA-C 105.483 -2.043 . . . . 0.0 105.483 176.84 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.28 0.8 OUTLIER -43.12 -57.69 4.92 Favored Pre-proline 0 CA--C 1.535 0.384 0 N-CA-C 114.446 1.276 . . . . 0.0 114.446 -173.692 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -52.17 -20.12 10.31 Favored 'Trans proline' 0 C--N 1.347 0.494 0 C-N-CA 123.146 2.564 . . . . 0.0 115.183 178.833 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 37.1 m80 -130.61 19.01 5.19 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-N 118.697 0.68 . . . . 0.0 111.446 -178.44 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -60.01 -51.17 70.81 Favored 'General case' 0 C--N 1.339 0.128 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 179.707 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.12 -30.26 57.35 Favored Glycine 0 CA--C 1.533 1.177 0 N-CA-C 111.717 -0.553 . . . . 0.0 111.717 177.863 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -84.04 5.83 24.38 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 123.51 0.724 . . . . 0.0 111.72 179.187 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 83.56 15.35 71.25 Favored Glycine 0 CA--C 1.527 0.827 0 CA-C-O 118.991 -0.894 . . . . 0.0 113.71 178.347 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 19.2 ttt -78.44 79.65 4.86 Favored 'General case' 0 C--O 1.236 0.377 0 CA-C-N 119.527 1.664 . . . . 0.0 108.595 178.657 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 10.7 m -126.56 169.46 17.96 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.207 0 C-N-CA 125.917 1.687 . . . . 0.0 110.813 179.842 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -169.03 179.45 41.74 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 109.276 -1.53 . . . . 0.0 109.276 178.343 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 58.7 mttm -149.64 149.46 30.67 Favored 'General case' 0 N--CA 1.455 -0.203 0 CA-C-N 117.66 0.73 . . . . 0.0 109.588 -179.014 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 6.6 p -135.72 127.29 45.04 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.3 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 178.893 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 71.6 m -102.09 106.46 17.34 Favored 'General case' 0 C--N 1.333 -0.143 0 C-N-CA 123.772 0.829 . . . . 0.0 110.436 179.487 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 44.6 t -79.69 122.99 35.97 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.633 0 N-CA-C 106.643 -1.614 . . . . 0.0 106.643 179.021 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 48.7 p30 . . . . . 0 C--N 1.333 -0.122 0 C-N-CA 124.895 1.278 . . . . 0.0 111.034 -177.605 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 8.5 mp . . . . . 0 CA--C 1.531 0.233 0 CA-C-O 120.663 0.268 . . . . 0.0 110.688 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 78.4 tt0 -90.98 116.28 28.65 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 176.767 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 48.1 t -106.05 122.48 59.75 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 -179.361 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 40.8 mt -86.03 120.82 27.83 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 177.886 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.447 HD12 ' HA ' ' A' ' 5' ' ' LEU . 5.1 tp -78.19 98.53 5.88 Favored 'General case' 0 N--CA 1.429 -1.489 0 C-N-CA 125.424 1.49 . . . . 0.0 107.525 179.863 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 91.72 145.34 15.07 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 108.7 -1.76 . . . . 0.0 108.7 -178.393 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 78.0 p -78.86 154.94 29.37 Favored 'General case' 0 N--CA 1.44 -0.948 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 179.574 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -53.16 -35.39 49.41 Favored Glycine 0 CA--C 1.529 0.942 0 CA-C-N 114.979 -1.01 . . . . 0.0 111.697 178.808 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -74.82 -4.42 37.66 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 123.53 0.732 . . . . 0.0 112.506 179.404 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 101.08 -20.75 46.25 Favored Glycine 0 CA--C 1.527 0.782 0 CA-C-O 118.763 -1.021 . . . . 0.0 113.292 178.965 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 28.6 t -56.81 132.13 51.4 Favored 'General case' 0 C--O 1.239 0.536 0 CA-C-N 119.391 1.595 . . . . 0.0 110.603 -179.332 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.444 ' H ' HD22 ' A' ' 12' ' ' LEU . 1.9 mm? -71.55 69.28 0.61 Allowed 'General case' 0 N--CA 1.44 -0.935 0 C-N-CA 126.806 2.042 . . . . 0.0 111.676 -177.457 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.5 m -135.06 141.74 42.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 C-N-CA 123.708 0.803 . . . . 0.0 109.403 178.383 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 88.2 m-85 -79.16 135.2 36.75 Favored 'General case' 0 N--CA 1.455 -0.186 0 N-CA-C 105.291 -2.115 . . . . 0.0 105.291 176.81 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.8 t -120.09 104.35 43.92 Favored Pre-proline 0 CA--C 1.534 0.339 0 CA-C-O 118.25 -0.881 . . . . 0.0 109.094 179.567 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -73.85 164.16 88.15 Favored 'Cis proline' 0 C--N 1.348 0.524 0 CA-C-N 120.301 1.143 . . . . 0.0 112.179 -1.412 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 10.5 p -97.59 -62.28 1.27 Allowed 'General case' 0 N--CA 1.452 -0.331 0 C-N-CA 125.681 1.592 . . . . 0.0 109.236 179.32 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 -103.54 123.96 47.89 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 126.106 1.763 . . . . 0.0 106.857 178.345 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -158.06 174.3 15.43 Favored 'General case' 0 CA--C 1.528 0.118 0 CA-C-N 118.9 0.773 . . . . 0.0 112.013 179.486 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.4 p -116.67 147.83 41.59 Favored 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 125.478 1.511 . . . . 0.0 107.555 178.461 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.8 p -141.79 136.25 15.18 Favored Pre-proline 0 CA--C 1.536 0.428 0 CA-C-O 118.443 -0.789 . . . . 0.0 109.036 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_exo -63.03 142.73 88.86 Favored 'Trans proline' 0 N--CA 1.456 -0.693 0 C-N-CA 122.043 1.828 . . . . 0.0 111.363 177.091 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.8 m -45.8 121.61 3.25 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 124.265 1.026 . . . . 0.0 111.778 177.919 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 84.96 -5.79 81.39 Favored Glycine 0 CA--C 1.525 0.69 0 CA-C-O 118.502 -1.166 . . . . 0.0 114.411 177.407 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -74.97 147.77 40.55 Favored 'General case' 0 CA--C 1.537 0.444 0 CA-C-N 119.954 1.877 . . . . 0.0 108.084 177.923 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 2.7 ptpp? -92.79 138.88 31.11 Favored 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 124.007 0.923 . . . . 0.0 112.499 -177.844 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 48.8 mt -105.05 136.76 37.42 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 C-N-CA 126.292 1.837 . . . . 0.0 106.06 179.166 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 58.4 t -117.92 100.29 9.81 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 C-N-CA 125.355 1.462 . . . . 0.0 108.832 -178.7 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -84.5 100.06 11.11 Favored 'General case' 0 C--N 1.334 -0.073 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 178.418 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 64.4 tttm -92.07 125.0 36.58 Favored 'General case' 0 C--O 1.231 0.127 0 C-N-CA 123.73 0.812 . . . . 0.0 110.621 -178.622 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 49.3 t30 -63.19 111.11 2.09 Favored 'General case' 0 CA--C 1.528 0.119 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 177.367 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 36.2 t30 -99.65 -76.45 0.55 Allowed 'General case' 0 N--CA 1.457 -0.079 0 C-N-CA 122.94 0.496 . . . . 0.0 112.256 -177.036 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -151.08 174.92 12.62 Favored 'General case' 0 C--O 1.224 -0.26 0 C-N-CA 124.012 0.925 . . . . 0.0 109.383 -176.807 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 62.3 17.96 57.22 Favored Glycine 0 CA--C 1.535 1.294 0 O-C-N 121.679 -0.638 . . . . 0.0 112.519 -179.119 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.494 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.9 p90 -78.25 169.5 20.56 Favored Pre-proline 0 CA--C 1.538 0.509 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 179.153 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.494 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 37.2 Cg_exo -64.45 160.25 68.42 Favored 'Cis proline' 0 N--CA 1.449 -1.098 0 N-CA-C 116.07 1.527 . . . . 0.0 116.07 1.605 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 90.7 m-70 -152.29 177.69 10.29 Favored 'General case' 0 N--CA 1.45 -0.467 0 CA-C-N 115.118 -0.946 . . . . 0.0 109.769 179.578 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 53.4 p30 -162.94 169.78 19.14 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 105.064 -2.198 . . . . 0.0 105.064 173.556 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 44.3 t -123.93 104.55 14.22 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.333 0 N-CA-C 106.62 -1.622 . . . . 0.0 106.62 -177.522 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 38.8 t -116.33 135.26 57.13 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.366 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 -179.316 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.421 ' CG ' HG13 ' A' ' 55' ' ' ILE . 55.7 m-85 -100.65 138.19 38.04 Favored 'General case' 0 N--CA 1.454 -0.272 0 C-N-CA 123.267 0.627 . . . . 0.0 109.68 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -70.14 114.1 7.97 Favored 'General case' 0 N--CA 1.454 -0.26 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 -179.81 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -47.85 -30.57 4.17 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 115.825 1.787 . . . . 0.0 115.825 -178.471 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 23.5 t70 -88.61 -50.15 6.45 Favored 'General case' 0 CA--C 1.53 0.204 0 CA-C-N 118.52 0.6 . . . . 0.0 110.649 179.88 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -80.22 57.07 2.63 Favored 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 124.087 0.955 . . . . 0.0 112.413 -176.397 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 20.2 pt -150.14 149.0 26.11 Favored Pre-proline 0 CA--C 1.534 0.36 0 C-N-CA 127.376 2.27 . . . . 0.0 106.537 176.805 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -65.6 124.63 13.08 Favored 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 122.096 1.864 . . . . 0.0 110.504 179.896 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -52.0 109.95 0.43 Allowed 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 124.802 1.241 . . . . 0.0 111.228 -179.456 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 153.09 -56.77 0.43 Allowed Glycine 0 CA--C 1.522 0.517 0 N-CA-C 108.249 -1.94 . . . . 0.0 108.249 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 41.8 t -83.21 93.09 2.87 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.429 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 179.285 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -58.96 134.33 56.86 Favored 'General case' 0 CA--C 1.532 0.251 0 N-CA-C 109.319 -0.622 . . . . 0.0 109.319 177.807 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -39.56 -43.82 1.36 Allowed 'General case' 0 C--N 1.331 -0.196 0 C-N-CA 127.389 2.275 . . . . 0.0 113.963 179.52 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 98.9 t -55.62 -30.41 26.68 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.333 0 CA-C-N 118.119 0.418 . . . . 0.0 110.918 -179.378 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 33.1 mtmm -75.85 -18.83 59.3 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-O 118.451 -0.785 . . . . 0.0 112.868 -179.278 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.421 HG13 ' CG ' ' A' ' 41' ' ' PHE . 0.1 OUTLIER -115.32 -20.91 5.59 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-N 119.196 0.907 . . . . 0.0 113.065 179.642 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 35.6 m -84.13 127.46 33.93 Favored 'General case' 0 N--CA 1.451 -0.386 0 C-N-CA 123.869 0.868 . . . . 0.0 112.038 -178.577 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 7.2 tmm? -69.39 124.91 91.48 Favored Pre-proline 0 CA--C 1.536 0.432 0 N-CA-C 103.801 -2.666 . . . . 0.0 103.801 175.071 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 1.6 Cg_exo -29.2 99.02 0.02 OUTLIER 'Trans proline' 0 C--N 1.349 0.582 1 C-N-CA 125.462 4.108 . . . . 0.0 115.006 -177.875 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -37.9 -44.18 0.75 Allowed 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 127.851 2.46 . . . . 0.0 114.793 -177.838 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -59.87 -33.18 71.47 Favored 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 123.501 0.72 . . . . 0.0 111.246 -178.697 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 47.4 mm-40 -93.18 163.38 13.65 Favored 'General case' 0 N--CA 1.442 -0.87 0 C-N-CA 124.942 1.297 . . . . 0.0 110.254 -178.908 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 4.8 mp -144.99 143.23 30.4 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-N 115.219 -0.901 . . . . 0.0 110.503 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 44.1 mt -78.1 105.68 9.49 Favored 'General case' 0 N--CA 1.445 -0.68 0 N-CA-C 103.778 -2.675 . . . . 0.0 103.778 175.295 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 34.3 p-10 -101.25 -52.98 3.12 Favored 'General case' 0 N--CA 1.455 -0.183 0 C-N-CA 124.796 1.238 . . . . 0.0 111.733 -177.151 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -71.85 136.65 82.65 Favored Pre-proline 0 CA--C 1.531 0.245 0 CA-C-N 118.723 0.692 . . . . 0.0 110.069 -177.477 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -63.61 149.73 90.22 Favored 'Trans proline' 0 N--CA 1.451 -1.009 0 C-N-CA 122.142 1.895 . . . . 0.0 109.659 179.704 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 97.54 -34.98 4.76 Favored Glycine 0 CA--C 1.523 0.591 0 CA-C-O 118.623 -1.098 . . . . 0.0 112.777 177.855 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 76.9 mt-10 -45.28 118.72 1.81 Allowed 'General case' 0 CA--C 1.536 0.419 0 CA-C-N 118.537 1.169 . . . . 0.0 111.665 -179.696 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 11.0 p -101.88 120.46 40.42 Favored 'General case' 0 N--CA 1.452 -0.356 0 C-N-CA 124.992 1.317 . . . . 0.0 111.551 -179.485 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 38.4 t80 -101.34 108.06 19.58 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 106.422 -1.695 . . . . 0.0 106.422 175.124 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 14.6 t -93.91 139.86 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.301 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 -179.263 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 9.9 p -148.61 142.64 18.79 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.153 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 177.778 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 7.8 m -117.21 124.44 49.09 Favored 'General case' 0 CA--C 1.527 0.072 0 C-N-CA 124.318 1.047 . . . . 0.0 109.495 -177.951 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 44.3 mt -105.55 98.51 8.19 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 123.156 0.583 . . . . 0.0 109.777 -179.394 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -74.67 -58.36 3.34 Favored 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 123.782 0.833 . . . . 0.0 112.709 -179.38 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 4.1 m -70.42 128.87 37.68 Favored 'General case' 0 N--CA 1.453 -0.325 0 C-N-CA 123.495 0.718 . . . . 0.0 111.465 -175.116 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 57.5 mtmt -65.35 156.04 33.43 Favored 'General case' 0 N--CA 1.455 -0.194 0 C-N-CA 123.438 0.695 . . . . 0.0 110.8 179.115 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 142.44 -166.46 26.45 Favored Glycine 0 CA--C 1.521 0.446 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 179.33 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 88.5 m -117.44 123.83 47.35 Favored 'General case' 0 N--CA 1.454 -0.245 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 179.612 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -114.81 124.3 51.39 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 124.348 1.059 . . . . 0.0 108.58 -178.553 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 13.2 m -99.81 134.29 42.92 Favored 'General case' 0 C--O 1.233 0.205 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 177.868 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 40.3 p90 -133.67 166.96 21.39 Favored 'General case' 0 CA--C 1.521 -0.161 0 CA-C-O 121.588 0.708 . . . . 0.0 111.625 -179.552 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 46.6 p90 -159.01 165.09 34.82 Favored 'General case' 0 N--CA 1.45 -0.43 0 CA-C-N 115.453 -0.794 . . . . 0.0 112.322 -177.76 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.5 t -106.09 97.18 7.03 Favored 'General case' 0 CA--C 1.519 -0.243 0 N-CA-C 106.638 -1.615 . . . . 0.0 106.638 177.377 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.304 16.1 p -31.1 -64.56 0.21 Allowed Pre-proline 0 CA--C 1.544 0.721 0 N-CA-C 117.138 2.273 . . . . 0.0 117.138 -174.474 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -61.89 -16.49 49.76 Favored 'Trans proline' 0 C--N 1.347 0.468 0 C-N-CA 122.576 2.184 . . . . 0.0 114.294 -177.338 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 34.7 m170 -119.08 9.26 11.76 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 123.322 0.649 . . . . 0.0 110.747 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 66.4 tt0 -58.34 -49.69 76.28 Favored 'General case' 0 CA--C 1.529 0.144 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 179.228 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -57.45 -30.32 61.67 Favored Glycine 0 CA--C 1.531 1.067 0 N-CA-C 111.475 -0.65 . . . . 0.0 111.475 177.45 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -84.8 5.45 28.54 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 123.774 0.83 . . . . 0.0 111.577 179.091 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 87.37 11.39 69.21 Favored Glycine 0 CA--C 1.527 0.823 0 CA-C-O 118.608 -1.107 . . . . 0.0 113.833 178.263 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 22.2 ttt -78.9 77.26 5.38 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 119.812 1.806 . . . . 0.0 108.614 178.334 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 10.8 m -122.94 169.13 14.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 C-N-CA 126.042 1.737 . . . . 0.0 108.96 178.568 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -162.42 172.34 38.49 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 108.491 -1.843 . . . . 0.0 108.491 178.51 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 6.9 ttpm? -151.4 141.33 22.02 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 -176.765 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 6.0 p -132.97 126.43 53.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 CA-C-O 121.057 0.456 . . . . 0.0 110.697 -179.025 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 21.0 m -97.17 105.84 18.06 Favored 'General case' 0 C--O 1.235 0.324 0 C-N-CA 124.724 1.21 . . . . 0.0 109.222 179.775 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 40.8 t -79.91 103.02 6.36 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.621 0 N-CA-C 106.484 -1.673 . . . . 0.0 106.484 -179.743 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 . . . . . 0 C--O 1.235 0.313 0 C-N-CA 125.205 1.402 . . . . 0.0 109.487 -177.206 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 9.3 tt . . . . . 0 N--CA 1.454 -0.269 0 CA-C-O 121.451 0.644 . . . . 0.0 110.274 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -90.71 128.54 36.69 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 123.685 0.794 . . . . 0.0 110.895 -178.699 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 44.2 t -120.55 123.94 71.45 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 N-CA-C 106.112 -1.81 . . . . 0.0 106.112 177.492 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 32.5 mt -96.65 122.91 40.09 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 118.383 0.538 . . . . 0.0 110.206 -179.478 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.507 ' HB3' ' CD2' ' A' ' 37' ' ' HIS . 1.2 mm? -79.68 101.9 8.65 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 106.316 -1.735 . . . . 0.0 106.316 174.111 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 108.84 127.69 5.58 Favored Glycine 0 CA--C 1.522 0.522 0 C-N-CA 124.788 1.185 . . . . 0.0 111.576 179.688 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 14.9 p -84.34 46.84 1.26 Allowed 'General case' 0 N--CA 1.457 -0.092 0 O-C-N 121.434 -1.039 . . . . 0.0 111.314 179.279 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 72.07 -55.73 1.45 Allowed Glycine 0 CA--C 1.527 0.83 0 C-N-CA 126.071 1.796 . . . . 0.0 111.991 -179.26 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -73.17 33.69 0.07 Allowed 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 126.038 1.735 . . . . 0.0 113.743 -177.519 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 57.33 8.42 3.56 Favored Glycine 0 CA--C 1.531 1.069 0 C-N-CA 124.875 1.226 . . . . 0.0 115.848 179.207 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 22.8 t -68.63 141.43 55.39 Favored 'General case' 0 N--CA 1.457 -0.107 0 CA-C-N 119.532 1.666 . . . . 0.0 109.502 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 68.9 mt -78.1 66.57 3.74 Favored 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 124.411 1.084 . . . . 0.0 111.781 -176.048 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.6 p -138.44 150.08 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.217 0 CA-C-O 121.788 0.804 . . . . 0.0 111.715 -179.494 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 58.7 m-85 -92.38 126.33 37.42 Favored 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 105.185 -2.154 . . . . 0.0 105.185 177.78 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 48.8 t -115.39 107.47 49.17 Favored Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 119.629 1.104 . . . . 0.0 109.448 179.609 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -77.27 155.84 96.66 Favored 'Cis proline' 0 CA--C 1.536 0.613 0 CA-C-N 120.706 1.288 . . . . 0.0 111.729 -1.3 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.5 m -84.83 -55.1 4.26 Favored 'General case' 0 CA--C 1.527 0.096 0 C-N-CA 123.357 0.663 . . . . 0.0 110.302 179.232 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 58.9 mt-10 -114.0 131.87 56.19 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 -179.471 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 53.0 p90 -161.13 -178.41 6.73 Favored 'General case' 0 C--O 1.234 0.255 0 CA-C-O 121.372 0.606 . . . . 0.0 112.081 -178.114 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 35.2 p -140.02 140.26 36.18 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 124.948 1.299 . . . . 0.0 109.257 -179.249 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.4 m -145.47 152.19 49.05 Favored Pre-proline 0 CA--C 1.532 0.257 0 C-N-CA 124.553 1.141 . . . . 0.0 108.136 178.898 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo -71.67 151.44 58.03 Favored 'Trans proline' 0 N--CA 1.451 -0.998 0 C-N-CA 121.78 1.653 . . . . 0.0 111.16 179.842 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 56.7 m -49.31 127.15 14.42 Favored 'General case' 0 C--N 1.332 -0.18 0 C-N-CA 124.343 1.057 . . . . 0.0 111.508 178.479 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 92.9 -10.74 73.44 Favored Glycine 0 CA--C 1.527 0.817 0 CA-C-O 118.911 -0.938 . . . . 0.0 112.829 178.88 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -70.47 141.96 51.98 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 119.392 1.596 . . . . 0.0 108.43 178.601 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 20.4 pttp -82.01 160.45 23.27 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 123.928 0.891 . . . . 0.0 111.131 -179.018 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 15.8 mt -131.44 129.05 61.84 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 N-CA-C 105.355 -2.091 . . . . 0.0 105.355 177.775 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 75.3 t -116.37 98.06 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.202 0 C-N-CA 125.851 1.66 . . . . 0.0 107.928 -177.957 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -86.5 96.57 10.1 Favored 'General case' 0 CA--C 1.529 0.17 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.773 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -90.52 128.98 36.72 Favored 'General case' 0 CA--C 1.531 0.212 0 C-N-CA 125.027 1.331 . . . . 0.0 112.046 -177.6 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 45.6 t30 -69.15 116.66 9.85 Favored 'General case' 0 N--CA 1.457 -0.119 0 CA-C-O 118.393 -0.813 . . . . 0.0 109.947 177.938 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 50.2 t30 -103.4 -66.23 0.96 Allowed 'General case' 0 C--N 1.339 0.135 0 CA-C-N 118.702 0.683 . . . . 0.0 110.551 179.474 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -160.17 169.25 23.67 Favored 'General case' 0 C--O 1.225 -0.196 0 C-N-CA 123.254 0.622 . . . . 0.0 110.452 -177.684 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 71.66 18.91 77.61 Favored Glycine 0 CA--C 1.532 1.094 0 O-C-N 121.823 -0.548 . . . . 0.0 111.878 -179.512 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.557 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 10.4 p90 -71.37 168.92 17.64 Favored Pre-proline 0 CA--C 1.54 0.568 0 C-N-CA 126.001 1.72 . . . . 0.0 108.598 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.557 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 75.8 Cg_endo -70.93 158.44 94.52 Favored 'Cis proline' 0 N--CA 1.449 -1.104 0 N-CA-C 115.042 1.131 . . . . 0.0 115.042 3.947 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.507 ' CD2' ' HB3' ' A' ' 5' ' ' LEU . 90.3 m-70 -146.8 160.83 41.78 Favored 'General case' 0 C--O 1.222 -0.391 0 O-C-N 121.59 -0.694 . . . . 0.0 112.72 -177.808 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 52.1 p30 -157.53 177.69 11.13 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 106.39 -1.707 . . . . 0.0 106.39 176.437 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 23.4 t -132.55 113.95 21.91 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 -179.27 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 25.5 t -118.98 132.11 69.82 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 N-CA-C 105.601 -2.0 . . . . 0.0 105.601 178.522 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -93.99 136.78 33.91 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -71.02 104.75 3.08 Favored 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 -178.66 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -35.26 -37.34 0.08 Allowed 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 127.416 2.287 . . . . 0.0 115.401 178.275 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 24.9 m-20 -85.47 -53.24 5.32 Favored 'General case' 0 CA--C 1.53 0.188 0 CA-C-N 118.545 0.611 . . . . 0.0 110.301 179.43 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 38.3 mm-40 -80.91 58.28 3.34 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 124.031 0.933 . . . . 0.0 112.906 -176.706 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 36.1 pt -152.31 159.15 33.16 Favored Pre-proline 0 CA--C 1.534 0.336 0 C-N-CA 128.452 2.701 . . . . 0.0 105.633 175.946 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -53.12 110.84 0.53 Allowed 'Trans proline' 0 N--CA 1.456 -0.684 0 C-N-CA 122.365 2.044 . . . . 0.0 111.162 177.22 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -51.77 108.23 0.26 Allowed 'General case' 0 CA--C 1.529 0.156 0 C-N-CA 124.119 0.968 . . . . 0.0 110.284 -179.507 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 133.83 -29.42 3.1 Favored Glycine 0 CA--C 1.527 0.795 0 N-CA-C 109.958 -1.257 . . . . 0.0 109.958 -178.133 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 88.5 t -74.94 117.91 19.91 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.279 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 179.763 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -63.13 102.81 0.41 Allowed 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 122.953 0.501 . . . . 0.0 110.335 179.454 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.71 -40.5 20.38 Favored 'General case' 0 N--CA 1.456 -0.168 0 C-N-CA 124.424 1.09 . . . . 0.0 111.381 179.094 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 44.6 t -58.94 -28.62 38.9 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 C-N-CA 123.03 0.532 . . . . 0.0 111.844 -179.132 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 33.3 pttt -75.7 -31.96 59.9 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 119.497 1.044 . . . . 0.0 111.571 -178.622 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.437 HD13 HG21 ' A' ' 55' ' ' ILE . 26.4 pt -91.78 -31.45 4.89 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.36 0 C-N-CA 123.728 0.811 . . . . 0.0 111.925 -178.79 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 35.5 m -87.74 142.95 27.42 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 124.73 1.212 . . . . 0.0 114.196 -176.748 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 87.2 mtp -75.26 144.6 78.74 Favored Pre-proline 0 N--CA 1.45 -0.428 0 N-CA-C 104.656 -2.35 . . . . 0.0 104.656 171.213 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -61.19 122.16 10.72 Favored 'Trans proline' 0 N--CA 1.452 -0.945 0 N-CA-C 107.322 -1.838 . . . . 0.0 107.322 176.504 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -34.57 -36.38 0.05 OUTLIER 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 127.79 2.436 . . . . 0.0 116.831 -175.911 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -77.35 -30.08 53.68 Favored 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 123.645 0.778 . . . . 0.0 112.14 -177.905 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 76.3 mm-40 -82.1 148.61 28.46 Favored 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 123.191 0.596 . . . . 0.0 109.549 -179.053 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -162.79 152.4 15.63 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 113.339 0.866 . . . . 0.0 113.339 -176.882 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 63.9 mt -82.32 127.65 33.43 Favored 'General case' 0 N--CA 1.446 -0.644 0 N-CA-C 106.041 -1.837 . . . . 0.0 106.041 176.353 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 23.8 t30 -118.21 -47.89 2.55 Favored 'General case' 0 C--O 1.225 -0.189 0 C-N-CA 123.267 0.627 . . . . 0.0 110.469 178.617 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -67.07 136.9 94.25 Favored Pre-proline 0 CA--C 1.533 0.322 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -178.666 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -64.68 145.04 86.06 Favored 'Trans proline' 0 N--CA 1.452 -0.954 0 C-N-CA 122.462 2.108 . . . . 0.0 109.949 -178.511 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.23 -30.21 8.98 Favored Glycine 0 CA--C 1.523 0.563 0 CA-C-O 118.729 -1.04 . . . . 0.0 113.678 177.042 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 65.9 mm-40 -52.97 135.68 36.3 Favored 'General case' 0 CA--C 1.535 0.381 0 CA-C-N 118.859 1.329 . . . . 0.0 110.655 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 17.3 p -114.31 123.91 50.69 Favored 'General case' 0 N--CA 1.454 -0.251 0 C-N-CA 124.863 1.265 . . . . 0.0 113.515 -177.235 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 43.0 t80 -94.7 108.89 20.87 Favored 'General case' 0 C--O 1.233 0.194 0 N-CA-C 105.069 -2.197 . . . . 0.0 105.069 172.88 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.8 t -96.28 137.99 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.356 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 -179.21 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 13.5 p -147.55 168.5 4.54 Favored 'Isoleucine or valine' 0 C--O 1.232 0.142 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 177.981 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 40.9 m -149.51 136.72 19.85 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 67.5 mt -118.52 112.87 20.46 Favored 'General case' 0 CA--C 1.53 0.202 0 C-N-CA 123.681 0.792 . . . . 0.0 109.786 -177.752 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -88.23 -42.84 12.02 Favored 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 123.68 0.792 . . . . 0.0 111.473 179.692 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -71.52 127.97 34.3 Favored 'General case' 0 N--CA 1.453 -0.324 0 C-N-CA 124.095 0.958 . . . . 0.0 109.878 -177.432 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.7 mttp -66.84 160.18 26.58 Favored 'General case' 0 CA--C 1.53 0.175 0 C-N-CA 123.386 0.674 . . . . 0.0 111.683 178.87 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 129.64 177.39 14.85 Favored Glycine 0 CA--C 1.525 0.716 0 C-N-CA 124.33 0.967 . . . . 0.0 112.591 176.756 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 14.7 m -95.32 112.46 24.17 Favored 'General case' 0 N--CA 1.453 -0.277 0 C-N-CA 124.769 1.227 . . . . 0.0 108.192 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 26.2 m-85 -104.04 111.72 24.41 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 124.01 0.924 . . . . 0.0 109.47 -179.626 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 20.1 m -86.14 138.38 31.96 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 107.985 -1.116 . . . . 0.0 107.985 177.163 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 34.3 p90 -135.83 164.66 27.41 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 123.099 0.56 . . . . 0.0 111.241 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 56.0 p90 -155.31 164.22 39.06 Favored 'General case' 0 N--CA 1.45 -0.462 0 CA-C-N 114.934 -1.03 . . . . 0.0 112.089 -177.981 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 6.3 t -105.11 106.97 17.71 Favored 'General case' 0 CA--C 1.523 -0.064 0 N-CA-C 106.212 -1.774 . . . . 0.0 106.212 177.229 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.304 52.3 p -43.42 -60.25 2.67 Favored Pre-proline 0 CA--C 1.539 0.554 0 N-CA-C 115.776 1.769 . . . . 0.0 115.776 -173.124 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -61.38 -7.56 8.82 Favored 'Trans proline' 0 C--N 1.348 0.52 0 C-N-CA 122.21 1.94 . . . . 0.0 114.365 -178.526 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 34.7 m80 -131.34 16.84 4.96 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 119.504 1.047 . . . . 0.0 111.039 179.644 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 65.6 tt0 -60.22 -49.54 77.22 Favored 'General case' 0 C--N 1.34 0.164 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 179.048 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.77 -32.12 61.54 Favored Glycine 0 CA--C 1.53 0.976 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 177.832 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -81.49 3.89 23.12 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 123.326 0.65 . . . . 0.0 111.711 179.117 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 81.92 17.82 69.11 Favored Glycine 0 CA--C 1.526 0.775 0 CA-C-O 118.944 -0.92 . . . . 0.0 113.259 178.836 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 21.5 ttt -78.58 80.03 4.98 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-N 119.369 1.584 . . . . 0.0 107.997 178.317 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 6.8 m -127.39 170.61 16.99 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.249 0 C-N-CA 126.196 1.798 . . . . 0.0 110.949 -179.853 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -166.65 175.11 42.06 Favored Glycine 0 CA--C 1.528 0.855 0 N-CA-C 109.134 -1.587 . . . . 0.0 109.134 178.251 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 58.9 mttm -147.27 126.35 12.88 Favored 'General case' 0 N--CA 1.461 0.095 0 CA-C-N 118.037 0.919 . . . . 0.0 110.947 -178.627 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 6.8 p -113.17 124.77 70.13 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.167 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 178.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.7 m -94.14 104.23 16.25 Favored 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 124.111 0.965 . . . . 0.0 109.06 -179.648 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 21.9 t -81.89 98.6 4.47 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 N-CA-C 103.98 -2.6 . . . . 0.0 103.98 178.651 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 37.2 t-20 . . . . . 0 N--CA 1.454 -0.256 0 C-N-CA 124.898 1.279 . . . . 0.0 112.925 -175.008 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.4 tm-20 . . . . . 0 CA--C 1.533 0.291 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 25.8 t -109.72 128.92 65.43 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.293 0 C-N-CA 125.891 1.676 . . . . 0.0 109.193 179.63 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 62.4 mt -94.6 126.69 40.05 Favored 'General case' 0 C--O 1.233 0.222 0 N-CA-C 108.307 -0.998 . . . . 0.0 108.307 177.455 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 55.2 mt -86.55 99.03 11.4 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 105.942 -1.873 . . . . 0.0 105.942 177.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 101.17 134.0 8.34 Favored Glycine 0 CA--C 1.525 0.706 0 C-N-CA 125.539 1.542 . . . . 0.0 109.583 -178.495 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 22.3 p -82.87 42.86 0.81 Allowed 'General case' 0 N--CA 1.462 0.157 0 O-C-N 120.944 -1.327 . . . . 0.0 112.875 -178.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.24 -53.46 1.08 Allowed Glycine 0 CA--C 1.527 0.784 0 C-N-CA 126.18 1.848 . . . . 0.0 112.691 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -73.1 36.27 0.08 Allowed 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 125.837 1.655 . . . . 0.0 113.675 -177.539 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 70.39 -19.83 0.63 Allowed Glycine 0 CA--C 1.53 1.003 0 C-N-CA 124.808 1.194 . . . . 0.0 115.08 177.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 32.9 t -56.66 129.21 40.08 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-N 118.515 1.157 . . . . 0.0 110.916 -178.146 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 55.5 mt -77.31 65.87 2.97 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 126.378 1.871 . . . . 0.0 112.071 -175.492 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 29.6 m -130.32 144.24 38.58 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.213 0 C-N-CA 123.174 0.59 . . . . 0.0 111.475 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 37.7 m-85 -84.76 129.21 34.86 Favored 'General case' 0 N--CA 1.456 -0.138 0 N-CA-C 104.764 -2.31 . . . . 0.0 104.764 175.723 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.9 t -117.56 102.8 51.61 Favored Pre-proline 0 CA--C 1.534 0.334 0 CA-C-O 117.986 -1.007 . . . . 0.0 108.992 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -76.89 166.83 81.62 Favored 'Cis proline' 0 CA--C 1.535 0.554 0 CA-C-N 120.373 1.169 . . . . 0.0 111.23 -1.375 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 29.2 t -103.14 -60.42 1.55 Allowed 'General case' 0 CA--C 1.531 0.216 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 178.023 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 4.3 tm-20 -102.3 125.78 49.11 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 106.11 -1.811 . . . . 0.0 106.11 178.457 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.1 p90 -161.65 -176.69 5.44 Favored 'General case' 0 CA--C 1.535 0.372 0 CA-C-N 119.118 0.872 . . . . 0.0 112.757 -179.362 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.0 m -130.14 147.03 51.83 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 126.284 1.834 . . . . 0.0 108.605 179.686 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.0 m -145.25 152.17 49.85 Favored Pre-proline 0 CA--C 1.528 0.134 0 C-N-CA 125.086 1.354 . . . . 0.0 108.28 178.465 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -73.7 158.02 47.52 Favored 'Trans proline' 0 N--CA 1.453 -0.905 0 C-N-CA 121.931 1.754 . . . . 0.0 110.514 176.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 50.2 m -56.3 126.13 24.91 Favored 'General case' 0 CA--C 1.529 0.149 0 C-N-CA 123.221 0.608 . . . . 0.0 109.98 177.441 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 89.82 6.5 69.79 Favored Glycine 0 CA--C 1.526 0.73 0 CA-C-O 118.887 -0.952 . . . . 0.0 112.598 -179.621 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -61.8 138.14 58.31 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 119.315 1.557 . . . . 0.0 110.854 178.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 15.3 ptpt -93.49 95.85 9.52 Favored 'General case' 0 N--CA 1.444 -0.736 0 C-N-CA 126.394 1.878 . . . . 0.0 106.534 177.384 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 39.6 mt -83.04 136.14 23.41 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 -179.716 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 90.8 t -118.92 132.95 67.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 105.032 -2.21 . . . . 0.0 105.032 179.012 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 94.9 m-85 -121.44 123.57 42.38 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 106.33 -1.73 . . . . 0.0 106.33 178.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 7.7 ttpm? -120.15 136.57 54.57 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 118.812 0.733 . . . . 0.0 112.875 -178.369 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 6.6 m-20 -67.72 99.6 0.82 Allowed 'General case' 0 C--O 1.232 0.161 0 C-N-CA 124.108 0.963 . . . . 0.0 109.279 177.095 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 57.8 t30 -87.17 -59.75 2.17 Favored 'General case' 0 N--CA 1.455 -0.192 0 N-CA-C 109.443 -0.576 . . . . 0.0 109.443 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -161.08 167.51 26.17 Favored 'General case' 0 C--O 1.226 -0.179 0 C-N-CA 123.617 0.767 . . . . 0.0 109.841 -179.293 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 68.89 20.37 74.4 Favored Glycine 0 CA--C 1.533 1.177 0 O-C-N 121.834 -0.541 . . . . 0.0 113.181 179.308 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.454 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 18.6 p90 -68.61 166.66 24.43 Favored Pre-proline 0 CA--C 1.546 0.797 0 N-CA-C 106.53 -1.656 . . . . 0.0 106.53 177.043 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.454 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 73.7 Cg_endo -69.97 156.34 93.41 Favored 'Cis proline' 0 N--CA 1.449 -1.136 0 CA-C-N 120.446 1.195 . . . . 0.0 114.488 4.215 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 87.9 m-70 -147.61 168.95 20.69 Favored 'General case' 0 N--CA 1.449 -0.498 0 O-C-N 121.638 -0.664 . . . . 0.0 111.49 -179.197 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 51.6 p30 -163.82 174.01 12.07 Favored 'General case' 0 N--CA 1.451 -0.416 0 N-CA-C 104.948 -2.242 . . . . 0.0 104.948 176.48 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 22.9 t -133.81 103.92 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.323 0 N-CA-C 107.062 -1.459 . . . . 0.0 107.062 -179.507 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.2 t -110.92 135.86 48.74 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 N-CA-C 105.896 -1.89 . . . . 0.0 105.896 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.411 ' CG ' HG13 ' A' ' 55' ' ' ILE . 53.5 m-85 -95.81 139.42 32.06 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 -179.833 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -72.02 111.09 6.97 Favored 'General case' 0 N--CA 1.45 -0.444 0 N-CA-C 107.7 -1.222 . . . . 0.0 107.7 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -46.16 -31.3 2.33 Favored 'General case' 0 CA--C 1.532 0.274 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -178.218 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -81.99 -50.92 8.58 Favored 'General case' 0 CA--C 1.531 0.25 0 CA-C-N 118.392 0.542 . . . . 0.0 109.662 178.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 40.3 mt-10 -80.45 56.65 2.61 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 124.143 0.977 . . . . 0.0 112.713 -177.066 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 26.4 pt -151.53 149.71 24.89 Favored Pre-proline 0 CA--C 1.534 0.329 0 C-N-CA 126.06 1.744 . . . . 0.0 107.715 175.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -69.11 116.26 4.4 Favored 'Trans proline' 0 N--CA 1.45 -1.068 0 C-N-CA 121.692 1.595 . . . . 0.0 108.706 176.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -33.65 -40.61 0.08 Allowed 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 127.741 2.416 . . . . 0.0 115.192 -177.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -50.98 -35.58 32.81 Favored Glycine 0 CA--C 1.533 1.16 0 C-N-CA 123.532 0.587 . . . . 0.0 112.805 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 48.2 t -103.53 103.77 15.65 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.209 0 CA-C-N 117.862 0.831 . . . . 0.0 108.945 -179.577 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -63.39 135.23 56.82 Favored 'General case' 0 CA--C 1.535 0.402 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 177.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -43.24 -41.26 3.79 Favored 'General case' 0 C--O 1.231 0.104 0 C-N-CA 126.182 1.793 . . . . 0.0 114.212 -179.504 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 85.8 t -56.88 -27.99 27.53 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 C-N-CA 123.03 0.532 . . . . 0.0 110.767 -179.459 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 34.5 mmtp -76.27 -19.11 58.62 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-O 118.438 -0.791 . . . . 0.0 112.539 -179.198 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.411 HG13 ' CG ' ' A' ' 41' ' ' PHE . 0.1 OUTLIER -117.11 -23.37 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 N-CA-C 113.491 0.923 . . . . 0.0 113.491 -179.761 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 31.3 m -84.09 129.82 34.89 Favored 'General case' 0 N--CA 1.453 -0.308 0 N-CA-C 113.892 1.071 . . . . 0.0 113.892 -177.207 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 15.0 tpt . . . . . 0 CA--C 1.54 0.559 0 N-CA-C 104.824 -2.287 . . . . 0.0 104.824 173.85 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.449 -0.483 0 CA-C-O 121.79 0.805 . . . . 0.0 111.247 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 50.9 mt -76.81 96.27 4.24 Favored 'General case' 0 N--CA 1.444 -0.743 0 N-CA-C 103.278 -2.86 . . . . 0.0 103.278 177.783 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 4.0 p30 -88.0 -40.42 13.89 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 126.228 1.811 . . . . 0.0 113.515 -175.207 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -95.63 156.44 37.44 Favored Pre-proline 0 CA--C 1.535 0.374 0 C-N-CA 123.823 0.849 . . . . 0.0 110.142 -178.448 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -64.69 161.42 35.82 Favored 'Trans proline' 0 N--CA 1.457 -0.664 0 C-N-CA 122.245 1.964 . . . . 0.0 109.545 176.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 78.54 -34.5 1.81 Allowed Glycine 0 CA--C 1.529 0.931 0 CA-C-O 118.59 -1.117 . . . . 0.0 114.182 177.205 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 50.6 mt-10 -48.46 140.98 7.26 Favored 'General case' 0 CA--C 1.533 0.324 0 CA-C-N 119.062 1.431 . . . . 0.0 111.056 179.17 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 2.5 p -120.14 161.44 21.02 Favored 'General case' 0 N--CA 1.453 -0.316 0 C-N-CA 124.732 1.213 . . . . 0.0 111.84 -177.028 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 47.4 t80 -137.1 147.83 46.32 Favored 'General case' 0 N--CA 1.456 -0.13 0 N-CA-C 104.608 -2.367 . . . . 0.0 104.608 173.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 25.9 t -136.21 145.03 31.49 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.097 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 -178.46 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.8 p -152.62 138.13 11.17 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 178.739 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 33.8 m -105.6 112.25 25.26 Favored 'General case' 0 CA--C 1.528 0.129 0 C-N-CA 123.927 0.891 . . . . 0.0 108.801 -179.183 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 27.6 mt -93.19 88.5 6.07 Favored 'General case' 0 CA--C 1.529 0.167 0 CA-C-O 121.247 0.546 . . . . 0.0 110.84 -178.541 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -60.9 -69.12 0.25 Allowed 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 124.747 1.219 . . . . 0.0 114.052 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 2.8 m -73.2 138.82 45.88 Favored 'General case' 0 N--CA 1.452 -0.354 0 C-N-CA 124.098 0.959 . . . . 0.0 113.459 -172.174 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -62.72 154.17 30.37 Favored 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 123.711 0.804 . . . . 0.0 110.189 177.839 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 145.31 -170.3 26.71 Favored Glycine 0 C--N 1.334 0.456 0 N-CA-C 111.194 -0.763 . . . . 0.0 111.194 178.333 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 24.0 m -112.24 120.44 41.76 Favored 'General case' 0 N--CA 1.453 -0.304 0 N-CA-C 106.451 -1.685 . . . . 0.0 106.451 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 34.7 m-85 -117.28 107.32 14.26 Favored 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 124.046 0.938 . . . . 0.0 109.327 -178.232 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -92.5 139.58 30.44 Favored 'General case' 0 C--O 1.232 0.171 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 177.601 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 32.9 p90 -137.27 167.45 21.56 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 121.387 0.613 . . . . 0.0 111.613 -178.389 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 44.8 p90 -155.84 161.03 40.68 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 114.933 -1.03 . . . . 0.0 112.379 -178.461 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.4 t -101.72 103.77 14.55 Favored 'General case' 0 CA--C 1.519 -0.241 0 N-CA-C 105.308 -2.108 . . . . 0.0 105.308 176.674 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.344 77.7 p -45.48 -58.25 6.26 Favored Pre-proline 0 CA--C 1.537 0.452 0 N-CA-C 115.723 1.749 . . . . 0.0 115.723 -173.258 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -60.3 -7.79 7.38 Favored 'Trans proline' 0 N--CA 1.458 -0.57 0 C-N-CA 121.994 1.796 . . . . 0.0 114.527 -179.414 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 35.1 m80 -132.78 18.96 4.2 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 119.843 1.201 . . . . 0.0 111.427 179.064 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 31.8 tt0 -58.07 -49.86 75.45 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 178.133 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -55.96 -32.04 59.06 Favored Glycine 0 CA--C 1.531 1.046 0 C-N-CA 123.798 0.713 . . . . 0.0 112.005 178.61 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -82.32 4.12 25.05 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 117.497 0.648 . . . . 0.0 111.56 179.277 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 83.11 16.01 70.7 Favored Glycine 0 CA--C 1.526 0.727 0 CA-C-O 119.019 -0.878 . . . . 0.0 112.967 178.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 20.5 ttt -78.76 77.96 5.22 Favored 'General case' 0 C--O 1.237 0.398 0 CA-C-N 119.322 1.561 . . . . 0.0 108.569 178.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 8.1 m -128.0 174.65 11.16 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 C-N-CA 125.984 1.714 . . . . 0.0 110.993 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -166.66 174.08 42.06 Favored Glycine 0 CA--C 1.526 0.766 0 N-CA-C 111.053 -0.819 . . . . 0.0 111.053 177.461 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 23.6 ttmm -149.01 110.88 4.57 Favored 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 124.389 1.076 . . . . 0.0 110.057 -177.128 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.1 p -106.53 128.87 60.78 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.356 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 179.799 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.0 m -100.99 110.2 22.2 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 124.73 1.212 . . . . 0.0 110.354 -177.36 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 24.0 t -83.92 101.32 8.35 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.768 0 N-CA-C 105.799 -1.926 . . . . 0.0 105.799 179.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 2.7 m-80 . . . . . 0 N--CA 1.451 -0.402 0 C-N-CA 125.749 1.62 . . . . 0.0 108.922 -177.892 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 14.6 tp10 . . . . . 0 N--CA 1.452 -0.367 0 N-CA-C 104.756 -2.313 . . . . 0.0 104.756 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 41.6 t -118.14 130.9 72.32 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 -178.827 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 68.8 mt -94.54 126.24 39.7 Favored 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 178.838 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 82.3 mt -90.13 98.94 12.06 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 105.835 -1.913 . . . . 0.0 105.835 177.046 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 110.57 -161.27 12.93 Favored Glycine 0 N--CA 1.447 -0.606 0 N-CA-C 109.095 -1.602 . . . . 0.0 109.095 -178.563 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 19.9 p -155.9 158.35 37.84 Favored 'General case' 0 N--CA 1.447 -0.591 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 -179.551 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.55 -39.99 31.16 Favored Glycine 0 CA--C 1.53 1.015 0 C-N-CA 123.538 0.59 . . . . 0.0 112.27 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -79.21 11.38 2.89 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 124.124 0.97 . . . . 0.0 112.642 179.218 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 70.12 14.02 70.62 Favored Glycine 0 CA--C 1.527 0.832 0 C-N-CA 124.605 1.098 . . . . 0.0 114.35 178.037 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 47.3 t -77.39 135.22 38.31 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 119.417 1.609 . . . . 0.0 108.82 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.497 ' H ' HD22 ' A' ' 12' ' ' LEU . 1.7 mm? -73.57 67.98 1.14 Allowed 'General case' 0 N--CA 1.443 -0.793 0 C-N-CA 126.011 1.724 . . . . 0.0 111.179 -178.249 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 20.9 m -129.76 153.16 38.41 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 C-N-CA 123.477 0.711 . . . . 0.0 110.4 179.498 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 39.5 m-85 -93.33 131.44 38.48 Favored 'General case' 0 C--N 1.332 -0.169 0 N-CA-C 104.132 -2.544 . . . . 0.0 104.132 175.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.3 t -125.03 109.66 27.43 Favored Pre-proline 0 CA--C 1.534 0.362 0 CA-C-N 119.161 0.891 . . . . 0.0 108.906 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_endo -72.04 150.77 95.08 Favored 'Cis proline' 0 N--CA 1.459 -0.533 0 CA-C-N 120.209 1.11 . . . . 0.0 110.987 -1.478 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.2 m -77.17 -48.08 18.62 Favored 'General case' 0 N--CA 1.456 -0.133 0 C-N-CA 123.036 0.534 . . . . 0.0 110.258 179.444 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -124.68 134.28 52.92 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 179.475 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 39.0 p90 -158.67 -176.83 6.11 Favored 'General case' 0 C--O 1.233 0.215 0 O-C-N 123.181 0.301 . . . . 0.0 110.7 -178.701 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 16.0 m -133.95 149.77 51.27 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 125.036 1.334 . . . . 0.0 107.925 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.7 p -144.98 138.99 14.73 Favored Pre-proline 0 CA--C 1.537 0.445 0 C-N-CA 123.796 0.839 . . . . 0.0 109.962 -177.843 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_exo -65.3 140.54 64.64 Favored 'Trans proline' 0 N--CA 1.455 -0.743 0 CA-C-N 120.746 1.302 . . . . 0.0 110.241 176.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 52.2 m -52.42 122.35 8.64 Favored 'General case' 0 N--CA 1.455 -0.193 0 C-N-CA 124.161 0.984 . . . . 0.0 110.857 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 102.56 -19.13 48.86 Favored Glycine 0 CA--C 1.528 0.877 0 CA-C-O 118.82 -0.989 . . . . 0.0 113.051 179.446 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -73.19 143.78 47.07 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-N 119.658 1.729 . . . . 0.0 110.25 179.312 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 18.3 ptmt -81.16 144.2 31.83 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 124.424 1.09 . . . . 0.0 111.58 -178.852 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 35.9 mt -113.2 130.48 67.04 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 178.424 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 59.7 t -114.25 102.63 14.15 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.245 0 C-N-CA 125.135 1.374 . . . . 0.0 108.017 -179.258 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -90.92 98.5 11.82 Favored 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 178.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 27.0 ttpp -91.75 132.38 36.44 Favored 'General case' 0 CA--C 1.528 0.132 0 C-N-CA 123.581 0.752 . . . . 0.0 112.724 -177.608 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 54.5 t-20 -66.21 110.25 2.95 Favored 'General case' 0 CA--C 1.53 0.21 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 176.395 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 -87.34 -72.96 0.49 Allowed 'General case' 0 C--N 1.338 0.078 0 CA-C-N 118.31 0.504 . . . . 0.0 110.843 -179.11 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -163.46 175.43 10.76 Favored 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 125.131 1.372 . . . . 0.0 107.732 -177.747 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 65.36 24.11 70.53 Favored Glycine 0 CA--C 1.534 1.272 0 CA-C-N 118.694 0.679 . . . . 0.0 111.594 -178.8 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.529 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 17.1 p90 -74.72 169.05 21.7 Favored Pre-proline 0 CA--C 1.542 0.668 0 N-CA-C 107.108 -1.442 . . . . 0.0 107.108 178.411 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.529 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 88.3 Cg_endo -69.53 158.3 90.45 Favored 'Cis proline' 0 N--CA 1.448 -1.201 0 CA-C-O 123.115 1.215 . . . . 0.0 114.994 3.731 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 88.2 m-70 -149.55 172.94 14.2 Favored 'General case' 0 N--CA 1.445 -0.711 0 CA-C-N 114.693 -1.14 . . . . 0.0 109.356 179.542 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 48.0 p30 -169.77 173.11 6.38 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 104.435 -2.432 . . . . 0.0 104.435 176.514 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 37.6 t -130.14 110.51 19.4 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.222 0 N-CA-C 107.767 -1.197 . . . . 0.0 107.767 -178.54 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.9 t -113.03 129.12 69.27 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.606 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 -179.737 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 62.2 m-85 -91.04 133.17 35.52 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 178.658 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -68.61 110.57 4.3 Favored 'General case' 0 N--CA 1.452 -0.352 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 -179.751 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -41.75 -35.0 0.7 Allowed 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 126.154 1.782 . . . . 0.0 115.747 -177.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -85.14 -50.01 7.77 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 118.5 0.591 . . . . 0.0 110.879 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -79.67 56.56 2.27 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 124.271 1.028 . . . . 0.0 112.412 -176.362 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 31.8 pt -153.35 156.57 32.57 Favored Pre-proline 0 CA--C 1.533 0.304 0 C-N-CA 126.689 1.996 . . . . 0.0 107.473 176.673 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_exo -53.62 109.5 0.38 Allowed 'Trans proline' 0 N--CA 1.456 -0.681 0 C-N-CA 122.819 2.346 . . . . 0.0 111.141 177.001 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -52.28 106.42 0.15 Allowed 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 124.203 1.001 . . . . 0.0 110.107 -179.772 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 142.29 -35.57 1.73 Allowed Glycine 0 CA--C 1.526 0.756 0 N-CA-C 109.005 -1.638 . . . . 0.0 109.005 -177.699 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 47.2 t -77.08 108.19 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 179.285 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 45.2 t0 -59.11 109.11 0.78 Allowed 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 123.039 0.535 . . . . 0.0 110.566 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.34 -40.42 17.21 Favored 'General case' 0 N--CA 1.453 -0.313 0 C-N-CA 125.079 1.351 . . . . 0.0 111.531 179.274 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 54.4 t -58.33 -28.77 36.3 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 C-N-CA 123.491 0.717 . . . . 0.0 111.925 -179.088 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 2.6 mmmp? -82.34 -40.66 21.1 Favored 'General case' 0 N--CA 1.461 0.122 0 CA-C-N 118.709 0.686 . . . . 0.0 110.909 -178.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.427 HD13 HG21 ' A' ' 55' ' ' ILE . 33.1 pt -78.14 -30.26 15.84 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.209 0 N-CA-C 112.191 0.441 . . . . 0.0 112.191 -179.842 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 35.5 m -90.7 146.74 23.76 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 114.667 1.358 . . . . 0.0 114.667 -176.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 48.2 mmm . . . . . 0 N--CA 1.448 -0.556 0 N-CA-C 102.066 -3.309 . . . . 0.0 102.066 169.005 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 92.3 mt . . . . . 0 N--CA 1.45 -0.442 0 CA-C-O 120.755 0.312 . . . . 0.0 110.446 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 84.4 mt -86.23 99.85 11.83 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 104.421 -2.437 . . . . 0.0 104.421 175.245 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 33.0 p-10 -86.57 -51.4 6.19 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 124.189 0.996 . . . . 0.0 111.736 -177.556 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.91 143.49 66.51 Favored Pre-proline 0 CA--C 1.533 0.322 0 O-C-N 121.932 -0.48 . . . . 0.0 110.468 -177.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -64.91 152.4 82.4 Favored 'Trans proline' 0 N--CA 1.453 -0.872 0 C-N-CA 122.522 2.148 . . . . 0.0 109.513 178.322 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 86.14 -24.52 7.97 Favored Glycine 0 CA--C 1.527 0.822 0 CA-C-O 118.41 -1.217 . . . . 0.0 114.09 177.125 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 66.1 mt-10 -51.8 127.43 20.83 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-N 119.465 1.633 . . . . 0.0 110.522 179.11 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 11.8 p -105.63 120.7 42.32 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 124.772 1.229 . . . . 0.0 112.334 -178.713 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 25.1 t80 -95.01 107.54 19.58 Favored 'General case' 0 N--CA 1.452 -0.372 0 N-CA-C 104.743 -2.317 . . . . 0.0 104.743 173.576 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 22.6 t -95.63 138.13 22.0 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 -178.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 10.9 p -145.85 168.81 7.06 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.17 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 177.548 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 29.1 m -147.02 130.39 16.66 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 64.6 mt -114.31 116.85 29.62 Favored 'General case' 0 CA--C 1.531 0.224 0 C-N-CA 123.636 0.774 . . . . 0.0 109.766 -177.601 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -91.3 -46.37 8.08 Favored 'General case' 0 CA--C 1.531 0.239 0 C-N-CA 124.195 0.998 . . . . 0.0 111.716 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.7 m -73.22 121.03 19.66 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 122.792 0.437 . . . . 0.0 110.712 -177.069 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 23.4 pttm -64.77 153.17 40.69 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 122.918 0.487 . . . . 0.0 111.462 178.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 139.18 174.28 13.45 Favored Glycine 0 CA--C 1.529 0.911 0 C-N-CA 125.552 1.548 . . . . 0.0 110.467 179.426 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 99.0 m -99.01 116.95 32.42 Favored 'General case' 0 N--CA 1.456 -0.128 0 C-N-CA 124.296 1.038 . . . . 0.0 108.646 179.457 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 10.7 m-85 -103.82 134.31 47.34 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 125.368 1.467 . . . . 0.0 108.05 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 20.2 m -104.3 139.51 39.19 Favored 'General case' 0 C--O 1.232 0.173 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 176.333 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 15.6 p90 -138.13 166.37 24.3 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-O 121.474 0.654 . . . . 0.0 111.946 -179.421 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 43.7 p90 -152.22 162.45 41.11 Favored 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 124.393 1.077 . . . . 0.0 112.294 -178.697 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.6 t -101.57 106.68 17.79 Favored 'General case' 0 CA--C 1.52 -0.174 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 176.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 4.9 t -38.82 -64.21 0.51 Allowed Pre-proline 0 CA--C 1.542 0.645 0 N-CA-C 115.349 1.611 . . . . 0.0 115.349 -175.413 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -64.09 -4.31 7.44 Favored 'Trans proline' 0 C--N 1.348 0.537 0 C-N-CA 122.467 2.111 . . . . 0.0 114.533 -177.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 37.0 m80 -130.42 20.81 5.2 Favored 'General case' 0 N--CA 1.455 -0.216 0 CA-C-N 119.461 1.028 . . . . 0.0 110.698 179.041 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 4.6 tp60 -58.43 -51.97 67.58 Favored 'General case' 0 CA--C 1.533 0.296 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 177.093 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.13 -33.55 61.19 Favored Glycine 0 CA--C 1.532 1.129 0 C-N-CA 123.526 0.584 . . . . 0.0 111.866 178.276 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -81.54 1.57 33.01 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 123.284 0.634 . . . . 0.0 111.953 179.265 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 77.14 23.82 67.74 Favored Glycine 0 CA--C 1.526 0.757 0 CA-C-O 119.231 -0.76 . . . . 0.0 113.512 178.711 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 26.1 ttt -79.27 80.47 5.63 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-N 119.207 1.504 . . . . 0.0 107.406 177.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 16.5 m -121.65 169.49 12.91 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.191 0 C-N-CA 125.943 1.697 . . . . 0.0 110.878 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -170.93 179.47 42.81 Favored Glycine 0 CA--C 1.526 0.733 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 178.139 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 49.6 mttp -148.17 161.4 41.53 Favored 'General case' 0 CA--C 1.528 0.132 0 CA-C-N 117.985 0.893 . . . . 0.0 110.581 -179.474 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 3.8 p -145.04 124.01 5.84 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 C-N-CA 123.488 0.715 . . . . 0.0 110.201 178.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 99.1 m -98.32 98.22 9.49 Favored 'General case' 0 C--O 1.236 0.359 0 C-N-CA 124.641 1.176 . . . . 0.0 111.214 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 30.2 t -75.88 120.35 25.6 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.631 0 N-CA-C 104.617 -2.364 . . . . 0.0 104.617 179.184 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 5.5 p30 . . . . . 0 N--CA 1.464 0.238 0 N-CA-C 112.634 0.605 . . . . 0.0 112.634 -174.034 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 . . . . . 0 N--CA 1.456 -0.172 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 33.5 t -91.97 138.27 20.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 C-N-CA 125.39 1.476 . . . . 0.0 109.076 -179.503 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 72.3 mt -99.76 125.44 45.67 Favored 'General case' 0 N--CA 1.45 -0.43 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 177.816 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 59.0 mt -86.46 101.93 13.61 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 105.855 -1.906 . . . . 0.0 105.855 178.196 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 95.87 157.88 32.01 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 108.347 -1.901 . . . . 0.0 108.347 -178.196 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 53.9 p -107.57 159.71 16.23 Favored 'General case' 0 N--CA 1.445 -0.718 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 -179.833 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.91 -34.62 61.81 Favored Glycine 0 CA--C 1.529 0.937 0 C-N-CA 124.183 0.897 . . . . 0.0 111.262 178.689 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -75.66 -2.9 31.64 Favored 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 123.519 0.728 . . . . 0.0 112.243 178.902 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 96.36 -17.86 58.51 Favored Glycine 0 CA--C 1.526 0.764 0 CA-C-O 118.903 -0.943 . . . . 0.0 113.556 178.671 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 32.8 t -57.27 132.35 52.76 Favored 'General case' 0 C--O 1.238 0.487 0 CA-C-N 119.4 1.6 . . . . 0.0 110.487 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 47.8 mt -77.59 67.39 3.49 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 126.818 2.047 . . . . 0.0 110.384 -177.087 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.6 m -128.2 153.76 38.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 C-N-CA 123.264 0.626 . . . . 0.0 110.611 179.862 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -87.43 130.64 34.6 Favored 'General case' 0 N--CA 1.453 -0.311 0 N-CA-C 104.153 -2.536 . . . . 0.0 104.153 175.259 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 35.3 t -120.45 108.96 37.06 Favored Pre-proline 0 CA--C 1.535 0.385 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_endo -73.3 157.2 99.31 Favored 'Cis proline' 0 N--CA 1.459 -0.552 0 CA-C-N 120.332 1.154 . . . . 0.0 110.48 -1.566 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.5 m -79.16 -43.33 24.19 Favored 'General case' 0 C--N 1.332 -0.153 0 C-N-CA 123.054 0.542 . . . . 0.0 110.884 -179.598 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -129.08 145.18 51.34 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 106.669 -1.604 . . . . 0.0 106.669 178.192 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 19.2 p90 -166.52 -179.62 5.01 Favored 'General case' 0 C--O 1.235 0.342 0 C-N-CA 123.213 0.605 . . . . 0.0 110.186 -177.665 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 37.1 p -139.71 136.29 34.06 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 124.422 1.089 . . . . 0.0 108.684 -178.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 33.7 m -130.09 146.27 60.76 Favored Pre-proline 0 CA--C 1.533 0.298 0 C-N-CA 124.177 0.991 . . . . 0.0 110.185 179.606 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_exo -57.67 144.34 93.09 Favored 'Trans proline' 0 N--CA 1.455 -0.742 0 C-N-CA 122.591 2.194 . . . . 0.0 110.845 174.785 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 16.3 m -51.26 119.58 4.19 Favored 'General case' 0 CA--C 1.529 0.149 0 C-N-CA 122.608 0.363 . . . . 0.0 110.955 177.846 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 96.72 -7.48 65.44 Favored Glycine 0 CA--C 1.525 0.68 0 CA-C-O 118.426 -1.208 . . . . 0.0 113.618 178.526 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -69.18 152.96 44.46 Favored 'General case' 0 CA--C 1.531 0.224 0 CA-C-N 119.953 1.877 . . . . 0.0 110.494 178.28 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 64.4 mttp -83.36 142.0 31.35 Favored 'General case' 0 N--CA 1.446 -0.666 0 C-N-CA 124.172 0.989 . . . . 0.0 109.882 -178.502 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 37.8 mt -120.56 130.08 74.89 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 105.963 -1.866 . . . . 0.0 105.963 178.386 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 84.9 t -121.88 131.42 73.16 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.428 0 N-CA-C 106.459 -1.682 . . . . 0.0 106.459 -179.242 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -118.19 103.47 9.88 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 178.799 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 38.0 ttpt -100.76 131.3 46.72 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 123.886 0.874 . . . . 0.0 113.296 -175.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 6.2 m-20 -64.96 107.81 1.61 Allowed 'General case' 0 C--O 1.232 0.137 0 C-N-CA 124.124 0.969 . . . . 0.0 109.975 177.708 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 7.0 t30 -87.67 -64.42 1.15 Allowed 'General case' 0 N--CA 1.456 -0.148 0 CA-C-O 121.496 0.665 . . . . 0.0 110.089 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -163.1 172.8 14.36 Favored 'General case' 0 C--N 1.331 -0.213 0 C-N-CA 125.54 1.536 . . . . 0.0 107.191 -178.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 66.2 20.28 69.05 Favored Glycine 0 CA--C 1.534 1.219 0 CA-C-N 118.291 0.496 . . . . 0.0 112.839 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.505 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 23.4 p90 -69.96 166.94 27.89 Favored Pre-proline 0 CA--C 1.549 0.905 0 N-CA-C 106.444 -1.688 . . . . 0.0 106.444 177.177 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.505 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 88.3 Cg_endo -69.94 156.43 93.27 Favored 'Cis proline' 0 N--CA 1.444 -1.386 0 N-CA-C 115.712 1.389 . . . . 0.0 115.712 4.719 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 86.9 m-70 -147.81 164.86 32.34 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.83 -179.773 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 56.0 p30 -162.36 177.62 9.39 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 104.986 -2.228 . . . . 0.0 104.986 177.259 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 33.6 t -135.66 111.01 11.88 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 -179.547 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 93.9 t -115.19 130.47 69.68 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.586 0 N-CA-C 106.394 -1.706 . . . . 0.0 106.394 179.568 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 54.4 m-85 -87.59 136.31 33.0 Favored 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 123.4 0.68 . . . . 0.0 109.755 -179.394 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 43.7 t0 -73.11 103.89 4.01 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -47.54 -32.46 5.37 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 124.139 0.976 . . . . 0.0 113.555 179.207 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -77.3 -17.19 58.53 Favored 'General case' 0 CA--C 1.535 0.386 0 N-CA-C 112.983 0.734 . . . . 0.0 112.983 -179.78 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 81.5 mm-40 -132.91 65.9 1.58 Allowed 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.112 0.965 . . . . 0.0 111.801 -177.17 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 29.3 pt -153.3 153.49 29.44 Favored Pre-proline 0 CA--C 1.533 0.326 0 C-N-CA 127.542 2.337 . . . . 0.0 105.851 175.784 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -60.47 113.47 1.7 Allowed 'Trans proline' 0 N--CA 1.452 -0.964 0 C-N-CA 121.972 1.781 . . . . 0.0 110.556 178.293 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -51.5 108.37 0.26 Allowed 'General case' 0 N--CA 1.453 -0.276 0 C-N-CA 125.111 1.364 . . . . 0.0 110.397 -179.248 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 143.61 -37.51 1.45 Allowed Glycine 0 CA--C 1.524 0.617 0 N-CA-C 109.019 -1.632 . . . . 0.0 109.019 -178.428 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 45.8 t -77.58 113.82 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.239 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 41.9 t0 -60.94 111.65 1.75 Allowed 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 122.769 0.428 . . . . 0.0 110.114 179.543 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.4 -41.47 20.0 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 124.685 1.194 . . . . 0.0 111.149 178.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 48.6 t -59.7 -29.16 42.19 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.395 0 C-N-CA 123.283 0.633 . . . . 0.0 112.048 -179.053 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 64.3 mttp -78.71 -40.93 32.31 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-N 119.055 0.843 . . . . 0.0 110.772 -179.173 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.416 HD13 HG21 ' A' ' 55' ' ' ILE . 23.1 pt -77.6 -33.36 19.12 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 N-CA-C 111.917 0.34 . . . . 0.0 111.917 -179.767 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 49.1 m -82.55 138.97 34.11 Favored 'General case' 0 N--CA 1.452 -0.341 0 N-CA-C 113.935 1.087 . . . . 0.0 113.935 -177.602 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 15.7 tpt . . . . . 0 N--CA 1.449 -0.498 0 N-CA-C 101.956 -3.35 . . . . 0.0 101.956 170.813 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.445 -0.68 0 CA-C-O 120.962 0.41 . . . . 0.0 110.971 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 73.8 mt -77.86 112.39 14.68 Favored 'General case' 0 N--CA 1.448 -0.575 0 N-CA-C 105.059 -2.2 . . . . 0.0 105.059 178.199 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 63.7 t30 -115.54 46.69 1.45 Allowed 'General case' 0 N--CA 1.464 0.247 0 C-N-CA 124.2 1.0 . . . . 0.0 112.491 -177.03 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -160.5 155.39 20.74 Favored Pre-proline 0 CA--C 1.531 0.22 0 N-CA-C 107.08 -1.452 . . . . 0.0 107.08 178.204 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -73.02 162.64 40.42 Favored 'Trans proline' 0 N--CA 1.454 -0.833 0 C-N-CA 122.013 1.808 . . . . 0.0 109.332 178.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 77.42 -35.94 1.56 Allowed Glycine 0 CA--C 1.529 0.938 0 CA-C-O 118.798 -1.001 . . . . 0.0 114.709 176.256 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 74.5 mm-40 -47.0 134.45 10.39 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 118.783 1.291 . . . . 0.0 111.387 179.165 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 21.8 p -119.53 132.56 55.78 Favored 'General case' 0 N--CA 1.456 -0.134 0 N-CA-C 113.83 1.048 . . . . 0.0 113.83 -177.436 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 31.9 t80 -100.91 140.38 35.28 Favored 'General case' 0 CA--C 1.529 0.166 0 N-CA-C 103.801 -2.666 . . . . 0.0 103.801 170.746 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 22.0 t -128.89 145.45 35.71 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.109 0 CA-C-N 119.007 0.821 . . . . 0.0 109.74 -177.647 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 12.5 p -152.23 169.23 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.197 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 178.367 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 83.6 m -149.06 133.62 17.68 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 106.264 -1.754 . . . . 0.0 106.264 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 79.2 mt -121.25 112.14 18.25 Favored 'General case' 0 CA--C 1.53 0.189 0 C-N-CA 123.234 0.614 . . . . 0.0 110.52 -177.305 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -93.86 -39.86 10.48 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 124.427 1.091 . . . . 0.0 110.543 178.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 6.4 m -70.19 122.11 18.85 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 123.594 0.758 . . . . 0.0 110.091 -178.162 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 20.8 mmtm -59.24 160.29 6.66 Favored 'General case' 0 CA--C 1.529 0.14 0 C-N-CA 124.186 0.995 . . . . 0.0 110.988 -179.692 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 134.96 -170.29 22.91 Favored Glycine 0 CA--C 1.524 0.6 0 C-N-CA 123.604 0.621 . . . . 0.0 111.822 177.703 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 25.3 m -121.26 130.34 53.62 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 105.503 -2.036 . . . . 0.0 105.503 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 16.5 m-85 -124.05 135.01 53.29 Favored 'General case' 0 N--CA 1.448 -0.525 0 C-N-CA 124.106 0.962 . . . . 0.0 109.818 -176.595 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 19.2 m -108.81 143.6 37.77 Favored 'General case' 0 C--O 1.233 0.199 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 175.644 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 11.8 p90 -143.89 171.31 14.41 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-O 121.15 0.5 . . . . 0.0 111.167 -179.308 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 34.4 p90 -157.76 167.38 30.21 Favored 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 123.805 0.842 . . . . 0.0 111.917 -179.176 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.3 t -102.99 109.31 20.8 Favored 'General case' 0 N--CA 1.463 0.181 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 177.494 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -40.92 -61.09 1.37 Allowed Pre-proline 0 CA--C 1.535 0.395 0 N-CA-C 115.659 1.725 . . . . 0.0 115.659 -173.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 63.6 Cg_endo -65.96 -4.2 9.71 Favored 'Trans proline' 0 N--CA 1.457 -0.638 0 C-N-CA 121.885 1.723 . . . . 0.0 114.87 -177.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 34.9 m80 -135.21 4.78 3.22 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-N 120.183 1.356 . . . . 0.0 113.185 -179.395 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 16.2 pt20 -55.7 -44.38 77.33 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 119.652 1.115 . . . . 0.0 109.975 178.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -59.17 -28.15 63.71 Favored Glycine 0 CA--C 1.531 1.037 0 N-CA-C 111.454 -0.659 . . . . 0.0 111.454 177.598 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.83 10.09 24.96 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 123.875 0.87 . . . . 0.0 110.843 178.771 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 87.31 10.22 71.47 Favored Glycine 0 CA--C 1.527 0.819 0 CA-C-O 118.558 -1.135 . . . . 0.0 113.789 178.29 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 18.4 ttt -78.96 76.54 5.45 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 119.791 1.796 . . . . 0.0 109.17 179.006 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 9.5 m -123.36 169.72 14.42 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 C-N-CA 126.388 1.875 . . . . 0.0 109.664 179.172 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -170.02 -179.8 41.85 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 110.211 -1.156 . . . . 0.0 110.211 178.156 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 54.1 mtmt -145.44 163.18 35.45 Favored 'General case' 0 N--CA 1.455 -0.224 0 C-N-CA 124.218 1.007 . . . . 0.0 110.29 -178.294 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.4 p -152.93 136.14 7.54 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 C-N-CA 123.898 0.879 . . . . 0.0 108.975 177.34 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -107.26 130.43 54.75 Favored 'General case' 0 C--N 1.332 -0.167 0 C-N-CA 124.441 1.096 . . . . 0.0 109.167 -179.633 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 43.4 t -99.8 97.81 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 N-CA-C 106.078 -1.823 . . . . 0.0 106.078 179.252 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 17.4 m-20 . . . . . 0 C--O 1.236 0.377 0 C-N-CA 123.604 0.762 . . . . 0.0 109.551 -176.728 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 69.2 tt0 . . . . . 0 N--CA 1.453 -0.279 0 N-CA-C 105.142 -2.17 . . . . 0.0 105.142 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 38.4 t -78.56 111.31 15.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 -176.713 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 57.8 mt -79.59 123.53 27.69 Favored 'General case' 0 N--CA 1.451 -0.416 0 N-CA-C 108.377 -0.971 . . . . 0.0 108.377 179.814 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 79.4 mt -84.23 107.41 16.52 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 178.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 86.56 130.48 2.79 Favored Glycine 0 C--N 1.337 0.599 0 N-CA-C 108.536 -1.826 . . . . 0.0 108.536 -179.014 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 5.0 p -78.99 157.46 28.13 Favored 'General case' 0 N--CA 1.441 -0.883 0 CA-C-N 118.461 1.131 . . . . 0.0 108.623 -178.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -43.94 -37.85 4.35 Favored Glycine 0 CA--C 1.531 1.06 0 C-N-CA 125.871 1.701 . . . . 0.0 113.76 -179.292 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -75.67 2.26 12.44 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 123.952 0.901 . . . . 0.0 113.253 -179.473 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 91.19 -10.33 75.22 Favored Glycine 0 CA--C 1.528 0.862 0 CA-C-O 118.828 -0.985 . . . . 0.0 113.188 -179.563 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.2 t -61.35 134.3 56.78 Favored 'General case' 0 C--N 1.343 0.293 0 CA-C-N 119.447 1.623 . . . . 0.0 110.518 -179.046 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 56.2 mt -76.63 66.06 2.53 Favored 'General case' 0 N--CA 1.447 -0.59 0 C-N-CA 126.079 1.751 . . . . 0.0 111.292 -176.312 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 29.4 m -131.13 148.65 32.94 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 C-N-CA 123.767 0.827 . . . . 0.0 110.361 179.437 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 49.9 m-85 -82.0 138.74 34.84 Favored 'General case' 0 N--CA 1.455 -0.204 0 N-CA-C 104.485 -2.413 . . . . 0.0 104.485 175.525 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.4 t -123.78 107.09 31.46 Favored Pre-proline 0 CA--C 1.533 0.302 0 CA-C-O 118.33 -0.843 . . . . 0.0 108.755 179.422 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_exo -70.45 154.69 95.22 Favored 'Cis proline' 0 C--N 1.346 0.429 0 CA-C-N 119.877 0.992 . . . . 0.0 112.015 -0.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.6 m -80.24 -45.44 17.97 Favored 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 177.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -126.98 142.5 51.54 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 105.84 -1.911 . . . . 0.0 105.84 177.642 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 33.8 p90 -166.88 175.62 7.59 Favored 'General case' 0 N--CA 1.455 -0.202 0 C-N-CA 123.637 0.775 . . . . 0.0 109.319 -178.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 16.4 m -134.8 143.16 46.92 Favored 'General case' 0 N--CA 1.45 -0.439 0 C-N-CA 124.499 1.12 . . . . 0.0 108.187 -179.652 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 32.7 m -137.73 149.51 64.9 Favored Pre-proline 0 CA--C 1.53 0.192 0 C-N-CA 124.632 1.173 . . . . 0.0 108.675 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -71.66 148.66 53.51 Favored 'Trans proline' 0 N--CA 1.448 -1.163 0 C-N-CA 121.76 1.64 . . . . 0.0 108.902 176.426 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 52.3 m -49.01 121.75 5.11 Favored 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 123.434 0.694 . . . . 0.0 110.961 178.572 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 99.51 -10.42 61.12 Favored Glycine 0 CA--C 1.526 0.766 0 CA-C-O 118.452 -1.193 . . . . 0.0 113.513 178.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -65.6 144.54 56.9 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 119.982 1.891 . . . . 0.0 108.969 178.394 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.2 ptmt -89.36 140.85 29.09 Favored 'General case' 0 N--CA 1.443 -0.825 0 N-CA-C 108.606 -0.886 . . . . 0.0 108.606 178.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 35.8 mt -112.61 131.94 62.74 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.386 0 N-CA-C 105.305 -2.109 . . . . 0.0 105.305 179.066 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 95.2 t -119.01 101.07 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.351 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 -179.071 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -86.27 132.66 33.94 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 106.228 -1.768 . . . . 0.0 106.228 177.357 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 61.1 tttp -131.27 130.54 42.96 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 119.237 0.926 . . . . 0.0 112.629 -176.699 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 4.1 m-20 -64.18 105.95 0.99 Allowed 'General case' 0 C--O 1.232 0.153 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 176.796 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 36.0 t30 -97.44 -69.72 0.75 Allowed 'General case' 0 N--CA 1.456 -0.162 0 CA-C-O 121.121 0.486 . . . . 0.0 110.521 -179.58 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -143.46 170.42 15.84 Favored 'General case' 0 C--O 1.224 -0.271 0 C-N-CA 124.102 0.961 . . . . 0.0 109.15 -178.56 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 57.75 19.68 36.81 Favored Glycine 0 CA--C 1.536 1.393 0 CA-C-N 118.748 0.703 . . . . 0.0 114.094 179.56 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.497 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 27.0 p90 -71.25 167.02 33.12 Favored Pre-proline 0 CA--C 1.542 0.662 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 178.026 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.497 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 94.6 Cg_endo -70.49 160.42 90.25 Favored 'Cis proline' 0 N--CA 1.448 -1.153 0 N-CA-C 115.571 1.335 . . . . 0.0 115.571 4.336 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 86.7 m-70 -151.87 173.16 15.12 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.672 -178.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 57.2 p30 -163.14 178.25 8.41 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 105.035 -2.209 . . . . 0.0 105.035 176.397 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 24.0 t -135.39 110.23 11.51 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.307 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 -179.207 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 53.7 t -112.93 131.02 65.69 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 N-CA-C 106.552 -1.647 . . . . 0.0 106.552 179.545 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -92.02 132.64 36.4 Favored 'General case' 0 N--CA 1.45 -0.43 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 178.411 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -71.74 101.2 2.52 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 -178.881 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -37.61 -36.68 0.18 Allowed 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 126.676 1.99 . . . . 0.0 115.681 179.48 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 72.6 m-20 -77.94 -43.71 29.04 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-N 118.747 0.703 . . . . 0.0 110.343 179.755 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -93.32 57.58 2.68 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 124.487 1.115 . . . . 0.0 113.028 -176.502 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 37.5 pt -154.98 157.86 32.0 Favored Pre-proline 0 CA--C 1.533 0.306 0 C-N-CA 126.392 1.877 . . . . 0.0 106.879 176.238 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -57.85 108.15 0.36 Allowed 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 122.09 1.86 . . . . 0.0 108.245 173.812 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -35.08 -43.4 0.2 Allowed 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 126.829 2.052 . . . . 0.0 115.433 -177.084 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -57.68 -31.59 64.09 Favored Glycine 0 CA--C 1.533 1.218 0 C-N-CA 123.114 0.387 . . . . 0.0 113.341 -179.208 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 41.8 t -83.54 99.94 6.61 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 CA-C-N 117.945 0.873 . . . . 0.0 109.186 -178.595 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 17.4 t0 -53.6 113.29 1.12 Allowed 'General case' 0 CA--C 1.536 0.405 0 C-N-CA 123.321 0.648 . . . . 0.0 110.306 178.149 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -46.67 -39.91 12.23 Favored 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 125.778 1.631 . . . . 0.0 112.295 -179.874 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 54.0 t -59.11 -27.72 36.92 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 C-N-CA 123.101 0.561 . . . . 0.0 111.706 -178.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 2.9 mmmp? -77.91 -42.94 31.5 Favored 'General case' 0 CA--C 1.529 0.16 0 CA-C-N 118.675 0.671 . . . . 0.0 110.837 -179.096 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.407 HG21 HD13 ' A' ' 55' ' ' ILE . 26.4 pt -78.78 -33.44 16.49 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.339 0 N-CA-C 112.284 0.475 . . . . 0.0 112.284 -179.037 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 44.4 m -80.52 141.69 34.9 Favored 'General case' 0 C--N 1.333 -0.112 0 N-CA-C 114.96 1.467 . . . . 0.0 114.96 -176.599 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 CA--C 1.539 0.528 0 N-CA-C 103.031 -2.951 . . . . 0.0 103.031 172.008 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 2.2 pp . . . . . 0 N--CA 1.448 -0.547 0 CA-C-O 121.419 0.628 . . . . 0.0 112.072 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 72.9 mt -86.82 109.12 19.06 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 104.166 -2.531 . . . . 0.0 104.166 177.075 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 34.6 p-10 -81.14 -55.45 4.74 Favored 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 123.936 0.895 . . . . 0.0 113.282 -176.658 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.32 156.76 78.59 Favored Pre-proline 0 CA--C 1.535 0.373 0 C-N-CA 123.918 0.887 . . . . 0.0 112.302 -176.426 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -67.04 163.39 34.14 Favored 'Trans proline' 0 N--CA 1.455 -0.74 0 C-N-CA 122.364 2.043 . . . . 0.0 108.967 175.109 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 79.1 -36.48 1.94 Allowed Glycine 0 CA--C 1.528 0.897 0 CA-C-O 119.041 -0.866 . . . . 0.0 113.62 177.336 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 50.7 mm-40 -42.26 129.14 3.81 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 124.606 1.162 . . . . 0.0 110.683 178.564 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -111.83 159.76 18.01 Favored 'General case' 0 N--CA 1.452 -0.354 0 C-N-CA 124.665 1.186 . . . . 0.0 112.393 -177.07 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 75.8 t80 -138.24 111.58 8.03 Favored 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 105.136 -2.172 . . . . 0.0 105.136 174.623 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 37.4 t -101.71 142.2 16.69 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 C-N-CA 123.686 0.794 . . . . 0.0 109.657 -177.635 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 12.1 p -149.51 168.0 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 177.648 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 28.7 m -147.46 129.61 15.54 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 107.367 -1.346 . . . . 0.0 107.367 -179.858 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 62.3 mt -113.26 107.45 15.91 Favored 'General case' 0 CA--C 1.53 0.183 0 C-N-CA 123.461 0.704 . . . . 0.0 110.319 -177.394 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -86.99 -45.03 11.15 Favored 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 123.65 0.78 . . . . 0.0 111.347 179.397 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.7 m -71.88 122.34 20.61 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 123.05 0.54 . . . . 0.0 110.742 -177.063 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 55.6 mttp -59.9 160.85 7.2 Favored 'General case' 0 N--CA 1.456 -0.17 0 C-N-CA 124.835 1.254 . . . . 0.0 112.342 179.482 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 136.94 -142.82 13.98 Favored Glycine 0 C--N 1.334 0.469 0 N-CA-C 110.209 -1.156 . . . . 0.0 110.209 177.285 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 85.2 m -146.14 135.2 22.65 Favored 'General case' 0 N--CA 1.444 -0.75 0 N-CA-C 105.221 -2.14 . . . . 0.0 105.221 178.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 10.6 m-85 -124.7 130.08 51.74 Favored 'General case' 0 N--CA 1.446 -0.672 0 C-N-CA 123.937 0.895 . . . . 0.0 108.669 -176.456 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 17.7 m -100.32 141.52 33.05 Favored 'General case' 0 C--O 1.233 0.191 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 176.425 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 20.3 p90 -140.0 168.98 18.56 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-O 121.293 0.568 . . . . 0.0 111.275 -179.443 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 52.2 p90 -158.34 166.53 32.08 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 115.52 -0.764 . . . . 0.0 111.788 -179.264 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.3 t -105.49 107.63 18.72 Favored 'General case' 0 CA--C 1.519 -0.247 0 N-CA-C 105.817 -1.92 . . . . 0.0 105.817 177.346 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.305 0.3 OUTLIER -49.37 -56.15 17.93 Favored Pre-proline 0 CA--C 1.532 0.273 0 CA-C-N 119.119 0.872 . . . . 0.0 113.057 -174.667 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_exo -46.29 -19.49 0.65 Allowed 'Trans proline' 0 N--CA 1.457 -0.654 0 C-N-CA 123.741 2.961 . . . . 0.0 115.883 177.422 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 38.0 m80 -136.63 18.27 3.09 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 119.829 1.195 . . . . 0.0 112.16 179.764 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 15.2 pt20 -60.57 -41.69 95.14 Favored 'General case' 0 N--CA 1.455 -0.204 0 CA-C-N 119.16 0.891 . . . . 0.0 109.58 179.491 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -58.33 -28.99 62.57 Favored Glycine 0 CA--C 1.532 1.136 0 N-CA-C 111.334 -0.707 . . . . 0.0 111.334 177.203 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -90.44 11.42 21.67 Favored 'General case' 0 CA--C 1.534 0.327 0 C-N-CA 123.781 0.832 . . . . 0.0 110.954 178.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 78.64 19.11 74.22 Favored Glycine 0 CA--C 1.527 0.819 0 CA-C-O 118.604 -1.109 . . . . 0.0 113.575 178.657 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 22.5 ttt -78.69 76.58 5.18 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-N 119.775 1.788 . . . . 0.0 108.756 178.147 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 10.2 m -120.86 172.54 7.76 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 C-N-CA 126.191 1.796 . . . . 0.0 109.787 179.566 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -170.52 177.34 43.73 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 177.672 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 58.6 mttp -146.63 157.26 43.68 Favored 'General case' 0 CA--C 1.526 0.047 0 CA-C-N 117.53 0.665 . . . . 0.0 110.623 -178.855 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 5.5 p -143.82 126.14 11.47 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.289 0 C-N-CA 123.152 0.581 . . . . 0.0 110.48 177.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.28 124.06 34.06 Favored 'General case' 0 CA--C 1.53 0.179 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 177.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 40.7 t -100.28 95.04 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.209 0 N-CA-C 103.161 -2.903 . . . . 0.0 103.161 177.302 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 . . . . . 0 N--CA 1.453 -0.297 0 C-N-CA 125.019 1.328 . . . . 0.0 113.108 -173.945 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 . . . . . 0 N--CA 1.453 -0.298 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 40.6 t -87.77 121.52 38.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 C-N-CA 124.51 1.124 . . . . 0.0 108.527 -179.463 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 70.0 mt -85.07 122.48 29.34 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 108.588 -0.894 . . . . 0.0 108.588 179.065 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 72.2 mt -86.84 99.88 12.14 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 106.103 -1.814 . . . . 0.0 106.103 177.783 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 100.9 151.29 25.04 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 108.713 -1.755 . . . . 0.0 108.713 -178.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 96.5 p -86.73 172.94 9.79 Favored 'General case' 0 N--CA 1.445 -0.711 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 177.378 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -54.08 -43.25 73.03 Favored Glycine 0 CA--C 1.53 0.971 0 N-CA-C 110.4 -1.08 . . . . 0.0 110.4 178.219 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -81.29 13.78 2.74 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 123.313 0.645 . . . . 0.0 112.221 178.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 74.48 16.98 79.8 Favored Glycine 0 CA--C 1.526 0.737 0 CA-C-O 118.849 -0.973 . . . . 0.0 114.156 178.2 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 22.8 t -71.33 140.13 50.13 Favored 'General case' 0 C--N 1.34 0.161 0 CA-C-N 119.443 1.622 . . . . 0.0 107.119 178.293 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 67.6 mt -76.52 67.65 2.71 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 125.136 1.374 . . . . 0.0 111.954 -175.411 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 26.0 m -135.17 150.17 29.4 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.21 0 C-N-CA 123.593 0.757 . . . . 0.0 110.498 179.654 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 45.3 m-85 -89.58 129.44 36.04 Favored 'General case' 0 N--CA 1.457 -0.099 0 N-CA-C 104.809 -2.293 . . . . 0.0 104.809 175.757 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 37.0 t -122.5 107.74 34.07 Favored Pre-proline 0 CA--C 1.537 0.467 0 CA-C-O 118.496 -0.764 . . . . 0.0 109.162 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -71.69 161.5 91.04 Favored 'Cis proline' 0 N--CA 1.457 -0.635 0 CA-C-N 120.227 1.117 . . . . 0.0 111.044 -1.355 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 6.2 p -86.21 -64.71 1.11 Allowed 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 178.345 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 64.9 tt0 -102.6 127.15 49.82 Favored 'General case' 0 N--CA 1.454 -0.275 0 C-N-CA 125.819 1.648 . . . . 0.0 107.577 178.47 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 33.9 p90 -150.34 -171.51 3.93 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-O 121.578 0.704 . . . . 0.0 111.998 178.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 7.0 m -141.63 146.8 36.63 Favored 'General case' 0 N--CA 1.45 -0.431 0 C-N-CA 124.655 1.182 . . . . 0.0 108.229 -178.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.0 p -148.85 137.89 12.21 Favored Pre-proline 0 CA--C 1.539 0.552 0 C-N-CA 123.28 0.632 . . . . 0.0 110.501 -177.911 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_exo -66.59 139.7 54.25 Favored 'Trans proline' 0 N--CA 1.455 -0.736 0 C-N-CA 121.424 1.416 . . . . 0.0 111.013 176.585 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 63.1 m -46.7 127.63 9.82 Favored 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 123.708 0.803 . . . . 0.0 110.978 177.125 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 94.96 -23.82 31.37 Favored Glycine 0 CA--C 1.529 0.946 0 CA-C-O 119.188 -0.784 . . . . 0.0 113.338 178.673 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 74.9 mm-40 -74.15 96.1 2.69 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 119.469 1.634 . . . . 0.0 109.318 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -41.42 126.5 2.84 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 125.734 1.614 . . . . 0.0 114.119 179.499 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 60.3 mt -90.06 136.77 22.98 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.314 0 N-CA-C 105.943 -1.873 . . . . 0.0 105.943 178.036 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 66.6 t -117.76 119.39 61.46 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.33 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 179.532 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 95.3 m-85 -106.16 109.38 21.3 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 178.338 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 62.5 tttp -105.16 129.31 53.58 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 124.489 1.115 . . . . 0.0 113.322 -175.159 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 3.6 m-20 -65.58 110.54 2.77 Favored 'General case' 0 C--O 1.23 0.07 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 176.834 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 51.1 t-20 -84.33 -72.08 0.48 Allowed 'General case' 0 N--CA 1.456 -0.166 0 N-CA-C 111.738 0.273 . . . . 0.0 111.738 -178.653 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -146.24 -53.54 0.25 Allowed 'General case' 0 C--O 1.225 -0.199 0 N-CA-C 114.359 1.244 . . . . 0.0 114.359 -175.82 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -69.69 33.88 0.37 Allowed Glycine 0 CA--C 1.538 1.494 0 N-CA-C 116.24 1.256 . . . . 0.0 116.24 -176.762 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.435 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 18.9 p90 -73.34 165.71 50.45 Favored Pre-proline 0 CA--C 1.543 0.705 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 179.783 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.435 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 34.0 Cg_exo -62.27 149.38 60.03 Favored 'Cis proline' 0 N--CA 1.451 -0.992 0 N-CA-C 116.425 1.663 . . . . 0.0 116.425 2.446 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 91.8 m-70 -145.95 172.6 13.13 Favored 'General case' 0 N--CA 1.447 -0.59 0 O-C-N 121.715 -0.616 . . . . 0.0 110.157 179.19 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 22.9 p-10 -169.42 175.85 5.33 Favored 'General case' 0 N--CA 1.447 -0.583 0 N-CA-C 104.048 -2.575 . . . . 0.0 104.048 176.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 46.5 t -137.99 114.67 11.4 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.332 0 N-CA-C 107.225 -1.398 . . . . 0.0 107.225 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 62.0 t -119.46 135.97 58.12 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 106.335 -1.728 . . . . 0.0 106.335 179.427 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 57.2 m-85 -89.23 135.5 33.54 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 123.219 0.608 . . . . 0.0 109.682 -178.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 7.3 t0 -74.85 99.46 3.79 Favored 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 124.315 1.046 . . . . 0.0 109.721 -179.06 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -44.21 -34.33 1.84 Allowed 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 124.687 1.195 . . . . 0.0 113.59 178.714 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -66.96 -25.58 66.41 Favored 'General case' 0 CA--C 1.536 0.419 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 179.831 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -135.36 76.23 1.61 Allowed 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 123.683 0.793 . . . . 0.0 111.136 -177.312 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 25.8 pt -153.66 149.94 22.16 Favored Pre-proline 0 CA--C 1.535 0.382 0 C-N-CA 127.372 2.269 . . . . 0.0 105.354 175.228 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -64.56 131.68 30.49 Favored 'Trans proline' 0 N--CA 1.453 -0.886 0 C-N-CA 121.746 1.631 . . . . 0.0 109.773 178.886 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -51.72 143.23 13.2 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 124.027 0.931 . . . . 0.0 112.061 -178.532 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 105.13 -41.35 2.18 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 110.365 -1.094 . . . . 0.0 110.365 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 19.7 t -79.25 93.23 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 CA-C-N 117.45 0.625 . . . . 0.0 109.337 -179.286 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 18.3 t0 -55.85 118.57 4.71 Favored 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 123.09 0.556 . . . . 0.0 110.494 178.606 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -44.31 -46.25 9.12 Favored 'General case' 0 CA--C 1.529 0.135 0 C-N-CA 125.662 1.585 . . . . 0.0 111.532 179.02 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 48.4 t -56.68 -31.03 33.77 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.471 0 C-N-CA 122.786 0.434 . . . . 0.0 111.926 -178.633 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 65.6 mttp -75.71 -39.46 57.31 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-N 118.678 0.672 . . . . 0.0 111.008 -178.834 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.418 HD13 HG21 ' A' ' 55' ' ' ILE . 20.6 pt -81.15 -28.27 10.85 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.271 0 N-CA-C 112.428 0.529 . . . . 0.0 112.428 -179.521 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 63.2 m -74.95 144.86 43.03 Favored 'General case' 0 N--CA 1.455 -0.224 0 O-C-N 121.778 -0.576 . . . . 0.0 112.534 -178.313 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 7.7 tmm? . . . . . 0 CA--C 1.537 0.463 0 N-CA-C 106.185 -1.783 . . . . 0.0 106.185 177.239 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 88.4 mt . . . . . 0 N--CA 1.454 -0.24 0 N-CA-C 106.407 -1.701 . . . . 0.0 106.407 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 67.8 mt -83.91 96.68 8.89 Favored 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 104.722 -2.325 . . . . 0.0 104.722 176.492 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -105.59 34.08 3.44 Favored 'General case' 0 CA--C 1.536 0.434 0 C-N-CA 124.499 1.12 . . . . 0.0 113.878 -177.45 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -151.43 156.49 34.86 Favored Pre-proline 0 CA--C 1.531 0.22 0 N-CA-C 108.106 -1.072 . . . . 0.0 108.106 179.639 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -72.79 163.54 38.13 Favored 'Trans proline' 0 N--CA 1.455 -0.782 0 C-N-CA 121.885 1.724 . . . . 0.0 109.816 179.324 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 78.07 -44.71 2.41 Favored Glycine 0 CA--C 1.526 0.771 0 CA-C-O 118.557 -1.135 . . . . 0.0 114.523 175.687 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 55.2 mm-40 -38.33 122.82 1.11 Allowed 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 124.82 1.248 . . . . 0.0 113.058 -178.809 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 17.9 p -109.13 134.03 52.24 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 125.316 1.446 . . . . 0.0 112.95 -178.104 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 17.5 t80 -107.55 143.27 36.2 Favored 'General case' 0 CA--C 1.528 0.097 0 N-CA-C 104.591 -2.374 . . . . 0.0 104.591 171.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 20.4 t -128.57 140.13 50.05 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.16 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 -179.057 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 12.8 p -146.01 144.9 20.55 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.134 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 178.301 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 7.6 m -115.25 106.65 14.29 Favored 'General case' 0 N--CA 1.454 -0.23 0 C-N-CA 124.356 1.062 . . . . 0.0 109.849 -178.6 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 50.5 mt -95.06 129.18 42.25 Favored 'General case' 0 CA--C 1.531 0.217 0 N-CA-C 107.52 -1.289 . . . . 0.0 107.52 177.913 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 13.9 m-20 -113.85 -46.53 3.02 Favored 'General case' 0 CA--C 1.527 0.08 0 C-N-CA 123.988 0.915 . . . . 0.0 111.24 -178.638 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 4.5 m -66.22 118.98 10.71 Favored 'General case' 0 N--CA 1.452 -0.362 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 -178.67 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 64.4 mttm -63.79 152.64 38.9 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 123.337 0.655 . . . . 0.0 110.306 -179.282 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 145.41 -157.81 27.46 Favored Glycine 0 CA--C 1.522 0.469 0 N-CA-C 109.328 -1.509 . . . . 0.0 109.328 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 15.3 m -123.59 132.33 53.85 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 106.535 -1.654 . . . . 0.0 106.535 -179.627 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 19.6 m-85 -125.02 119.93 30.1 Favored 'General case' 0 N--CA 1.447 -0.624 0 C-N-CA 123.681 0.793 . . . . 0.0 108.906 -178.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 70.2 m -91.51 144.88 25.1 Favored 'General case' 0 C--O 1.233 0.213 0 N-CA-C 107.699 -1.223 . . . . 0.0 107.699 175.612 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 17.4 p90 -141.22 164.14 31.07 Favored 'General case' 0 N--CA 1.455 -0.222 0 CA-C-O 121.237 0.541 . . . . 0.0 110.771 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 53.3 p90 -150.7 160.16 44.03 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-N 115.061 -0.972 . . . . 0.0 112.713 -177.424 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 11.6 t -99.41 106.16 18.19 Favored 'General case' 0 CA--C 1.522 -0.104 0 N-CA-C 105.877 -1.898 . . . . 0.0 105.877 176.453 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 4.5 m -38.83 -60.03 1.23 Allowed Pre-proline 0 CA--C 1.536 0.44 0 N-CA-C 115.976 1.843 . . . . 0.0 115.976 -174.474 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 89.3 Cg_endo -72.06 -2.53 11.7 Favored 'Trans proline' 0 N--CA 1.458 -0.612 0 C-N-CA 122.056 1.837 . . . . 0.0 114.602 -178.576 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 32.9 m170 -132.96 3.86 3.77 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 120.35 1.432 . . . . 0.0 113.723 -178.152 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 15.1 pt20 -52.72 -42.81 65.2 Favored 'General case' 0 CA--C 1.534 0.355 0 CA-C-N 119.009 0.822 . . . . 0.0 110.196 178.002 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -58.52 -28.77 62.8 Favored Glycine 0 CA--C 1.53 1.021 0 C-N-CA 123.951 0.786 . . . . 0.0 111.763 178.167 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -90.74 11.94 20.74 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 123.83 0.852 . . . . 0.0 110.505 178.661 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 82.97 13.0 78.64 Favored Glycine 0 CA--C 1.527 0.825 0 CA-C-O 118.632 -1.094 . . . . 0.0 113.227 178.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 20.5 ttt -77.66 79.82 4.14 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 119.708 1.754 . . . . 0.0 109.473 178.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 11.0 m -131.36 169.66 21.29 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.199 0 C-N-CA 126.158 1.783 . . . . 0.0 110.298 179.1 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -168.02 179.73 41.07 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 109.321 -1.511 . . . . 0.0 109.321 178.017 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 33.8 mtmm -148.32 150.5 33.73 Favored 'General case' 0 N--CA 1.456 -0.159 0 C-N-CA 123.944 0.898 . . . . 0.0 110.439 -178.429 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.0 p -135.33 131.17 51.62 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.252 0 C-N-CA 122.973 0.509 . . . . 0.0 109.948 178.76 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.0 m -98.27 100.87 12.2 Favored 'General case' 0 CA--C 1.534 0.361 0 C-N-CA 125.212 1.405 . . . . 0.0 109.396 -179.64 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 43.6 t -79.92 114.9 21.46 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.388 0 N-CA-C 105.277 -2.119 . . . . 0.0 105.277 -179.553 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 6.6 p30 . . . . . 0 C--N 1.333 -0.133 0 C-N-CA 123.426 0.691 . . . . 0.0 111.946 -174.673 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 . . . . . 0 N--CA 1.449 -0.5 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 58.6 t -132.99 117.56 29.8 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.683 0 N-CA-C 106.217 -1.772 . . . . 0.0 106.217 178.585 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 38.7 mt -84.89 119.22 25.1 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 179.427 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 49.0 mt -82.52 83.07 7.68 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 104.372 -2.455 . . . . 0.0 104.372 176.534 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 121.38 152.1 8.68 Favored Glycine 0 CA--C 1.527 0.812 0 C-N-CA 125.708 1.623 . . . . 0.0 109.616 -176.675 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 50.5 p -114.8 44.65 1.73 Allowed 'General case' 0 CA--C 1.522 -0.121 0 C-N-CA 124.28 1.032 . . . . 0.0 111.799 -179.394 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 74.87 -56.81 2.65 Favored Glycine 0 CA--C 1.523 0.542 0 C-N-CA 126.023 1.773 . . . . 0.0 111.401 179.294 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -73.72 34.37 0.08 Allowed 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 125.406 1.482 . . . . 0.0 113.625 -177.697 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 58.94 4.39 2.24 Favored Glycine 0 CA--C 1.532 1.102 0 C-N-CA 124.828 1.204 . . . . 0.0 115.837 178.743 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.3 t -64.97 138.6 58.46 Favored 'General case' 0 N--CA 1.456 -0.146 0 CA-C-N 119.528 1.664 . . . . 0.0 110.12 -179.009 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 71.0 mt -79.98 64.69 4.9 Favored 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 124.807 1.243 . . . . 0.0 110.604 -177.098 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 28.0 m -133.68 145.13 34.02 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.223 0 C-N-CA 123.253 0.621 . . . . 0.0 112.421 -178.467 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 68.8 m-85 -89.21 125.96 35.29 Favored 'General case' 0 N--CA 1.455 -0.224 0 N-CA-C 104.037 -2.579 . . . . 0.0 104.037 175.536 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 22.4 t -118.02 110.17 40.17 Favored Pre-proline 0 CA--C 1.532 0.267 0 CA-C-N 119.529 1.059 . . . . 0.0 109.218 179.25 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -74.81 153.64 99.27 Favored 'Cis proline' 0 CA--C 1.535 0.57 0 CA-C-N 120.392 1.176 . . . . 0.0 111.164 -1.375 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.2 m -80.87 -45.55 16.66 Favored 'General case' 0 CA--C 1.528 0.127 0 C-N-CA 123.324 0.65 . . . . 0.0 110.805 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -123.58 130.96 53.45 Favored 'General case' 0 N--CA 1.451 -0.396 0 N-CA-C 104.657 -2.349 . . . . 0.0 104.657 178.46 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 42.1 p90 -157.96 -177.54 6.64 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 118.435 0.562 . . . . 0.0 111.175 -177.765 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.9 p -126.09 151.26 47.44 Favored 'General case' 0 N--CA 1.448 -0.569 0 C-N-CA 125.809 1.644 . . . . 0.0 108.758 178.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.8 p -145.53 134.36 11.05 Favored Pre-proline 0 CA--C 1.539 0.52 0 C-N-CA 123.893 0.877 . . . . 0.0 109.136 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -64.64 136.88 51.9 Favored 'Trans proline' 0 N--CA 1.455 -0.782 0 C-N-CA 121.536 1.491 . . . . 0.0 110.096 175.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 48.6 m -49.69 122.1 6.0 Favored 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 123.796 0.838 . . . . 0.0 111.131 179.325 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.46 -17.25 58.74 Favored Glycine 0 CA--C 1.529 0.938 0 CA-C-O 118.816 -0.991 . . . . 0.0 113.554 179.006 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 71.1 mm-40 -70.25 167.05 18.78 Favored 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 119.623 1.712 . . . . 0.0 111.428 179.679 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -92.95 146.88 23.29 Favored 'General case' 0 N--CA 1.45 -0.434 0 C-N-CA 125.029 1.331 . . . . 0.0 111.017 -179.213 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 32.1 mt -125.23 126.41 70.8 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.424 0 N-CA-C 103.682 -2.71 . . . . 0.0 103.682 176.349 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 57.2 t -112.39 96.61 4.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 C-N-CA 125.081 1.352 . . . . 0.0 108.896 -178.259 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -81.69 97.13 7.77 Favored 'General case' 0 CA--C 1.531 0.239 0 N-CA-C 106.862 -1.533 . . . . 0.0 106.862 178.305 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 63.5 tttp -93.98 127.81 39.97 Favored 'General case' 0 CA--C 1.53 0.187 0 C-N-CA 124.884 1.274 . . . . 0.0 113.557 -174.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -67.7 93.51 0.38 Allowed 'General case' 0 CA--C 1.533 0.324 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 176.78 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 14.0 t-20 -80.69 -67.25 0.79 Allowed 'General case' 0 N--CA 1.455 -0.221 0 C-N-CA 123.342 0.657 . . . . 0.0 110.654 -179.354 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -161.05 167.93 25.43 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.258 -176.848 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 68.87 17.5 71.51 Favored Glycine 0 CA--C 1.533 1.199 0 O-C-N 121.587 -0.695 . . . . 0.0 112.144 -179.236 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.45 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 32.8 p90 -70.12 165.95 38.38 Favored Pre-proline 0 CA--C 1.545 0.771 0 N-CA-C 106.325 -1.732 . . . . 0.0 106.325 177.351 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.45 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 92.3 Cg_endo -68.97 155.53 91.03 Favored 'Cis proline' 0 N--CA 1.446 -1.274 0 N-CA-C 115.525 1.317 . . . . 0.0 115.525 4.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 90.1 m-70 -147.72 170.32 17.82 Favored 'General case' 0 N--CA 1.449 -0.478 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.464 -179.683 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 40.4 p-10 -160.55 175.37 12.79 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 104.423 -2.436 . . . . 0.0 104.423 176.639 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 21.9 t -136.15 106.52 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.314 0 N-CA-C 106.787 -1.56 . . . . 0.0 106.787 -179.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 55.5 t -113.17 133.95 57.4 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 106.422 -1.696 . . . . 0.0 106.422 179.229 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 56.9 m-85 -96.18 140.82 30.33 Favored 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 123.544 0.738 . . . . 0.0 109.647 -179.711 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -74.08 108.13 6.7 Favored 'General case' 0 N--CA 1.453 -0.308 0 N-CA-C 107.078 -1.453 . . . . 0.0 107.078 178.204 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -44.25 -30.61 0.83 Allowed 'General case' 0 CA--C 1.535 0.386 0 N-CA-C 115.916 1.821 . . . . 0.0 115.916 -177.765 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -86.17 -49.19 7.93 Favored 'General case' 0 CA--C 1.53 0.196 0 CA-C-N 118.703 0.683 . . . . 0.0 110.48 179.153 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -80.66 57.48 2.96 Favored 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 124.109 0.964 . . . . 0.0 112.257 -176.609 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 36.2 pt -153.35 156.63 32.61 Favored Pre-proline 0 CA--C 1.534 0.348 0 C-N-CA 127.634 2.374 . . . . 0.0 106.217 176.649 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -53.07 115.53 2.34 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 C-N-CA 122.51 2.14 . . . . 0.0 111.384 178.065 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -52.88 107.88 0.26 Allowed 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 123.992 0.917 . . . . 0.0 110.083 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 136.46 -30.42 2.7 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 109.835 -1.306 . . . . 0.0 109.835 -178.069 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 69.9 t -75.62 121.89 28.35 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 CA-C-N 117.861 0.831 . . . . 0.0 109.059 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 14.8 t0 -66.35 105.46 1.45 Allowed 'General case' 0 N--CA 1.453 -0.3 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 178.752 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.49 -39.03 21.73 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 124.168 0.987 . . . . 0.0 111.463 178.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 41.4 t -61.68 -29.3 45.9 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.429 0 C-N-CA 122.821 0.448 . . . . 0.0 111.574 -179.359 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.53 -34.03 58.57 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 119.224 0.92 . . . . 0.0 110.979 -178.593 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.4 HD13 HG21 ' A' ' 55' ' ' ILE . 25.0 pt -85.74 -32.35 7.0 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.21 0 C-N-CA 123.266 0.626 . . . . 0.0 111.899 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 39.7 m -85.87 136.43 33.3 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 114.273 1.212 . . . . 0.0 114.273 -177.208 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 69.2 mmm . . . . . 0 N--CA 1.452 -0.348 0 N-CA-C 103.822 -2.659 . . . . 0.0 103.822 170.936 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.446 -0.634 0 CA-C-O 121.393 0.616 . . . . 0.0 111.833 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 43.5 mt -76.85 99.94 5.35 Favored 'General case' 0 N--CA 1.446 -0.631 0 N-CA-C 104.176 -2.527 . . . . 0.0 104.176 177.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -96.47 -22.33 17.19 Favored 'General case' 0 N--CA 1.462 0.171 0 N-CA-C 113.993 1.108 . . . . 0.0 113.993 -176.623 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -93.97 152.94 40.89 Favored Pre-proline 0 CA--C 1.533 0.305 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -66.43 161.99 38.5 Favored 'Trans proline' 0 N--CA 1.453 -0.908 0 C-N-CA 121.773 1.649 . . . . 0.0 110.195 178.207 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 80.14 -53.93 4.45 Favored Glycine 0 CA--C 1.523 0.568 0 CA-C-O 118.228 -1.318 . . . . 0.0 113.404 176.4 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -18.53 111.07 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.399 0 C-N-CA 126.444 1.898 . . . . 0.0 114.388 -177.011 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 14.5 p -100.71 119.07 38.05 Favored 'General case' 0 N--CA 1.446 -0.633 0 C-N-CA 124.619 1.168 . . . . 0.0 112.225 -178.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 10.8 t80 -97.13 105.61 17.79 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 105.06 -2.2 . . . . 0.0 105.06 174.624 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.9 t -94.98 134.46 32.29 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.283 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 -178.686 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.1 p -151.16 161.22 3.52 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 178.485 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.1 m -133.62 142.29 48.03 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 125.501 1.52 . . . . 0.0 107.9 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 62.4 mt -118.82 120.52 37.59 Favored 'General case' 0 N--CA 1.453 -0.31 0 N-CA-C 107.567 -1.272 . . . . 0.0 107.567 179.288 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 9.0 p-10 -95.02 -41.07 9.32 Favored 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 124.178 0.991 . . . . 0.0 112.395 -178.43 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 25.0 m -77.14 125.77 29.86 Favored 'General case' 0 N--CA 1.452 -0.328 0 C-N-CA 123.428 0.691 . . . . 0.0 109.933 -176.564 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 66.3 mttm -65.47 156.02 33.75 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 124.017 0.927 . . . . 0.0 111.477 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 127.23 177.33 14.82 Favored Glycine 0 CA--C 1.526 0.743 0 C-N-CA 123.92 0.771 . . . . 0.0 112.201 177.445 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 7.3 m -94.57 127.73 40.71 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 125.15 1.38 . . . . 0.0 108.914 -179.063 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 15.6 m-85 -115.95 135.81 53.63 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 125.755 1.622 . . . . 0.0 108.643 179.066 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 16.9 m -108.81 136.23 48.71 Favored 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 123.362 0.665 . . . . 0.0 109.419 176.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 20.3 p90 -137.83 168.53 19.5 Favored 'General case' 0 C--O 1.232 0.142 0 CA-C-O 121.77 0.795 . . . . 0.0 111.818 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -156.37 160.62 39.83 Favored 'General case' 0 N--CA 1.453 -0.278 0 CA-C-N 115.322 -0.854 . . . . 0.0 112.532 -178.756 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.4 t -99.74 102.37 13.81 Favored 'General case' 0 CA--C 1.519 -0.226 0 N-CA-C 106.396 -1.705 . . . . 0.0 106.396 176.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -48.24 -55.07 20.19 Favored Pre-proline 0 CA--C 1.532 0.263 0 CA-C-O 118.593 -0.717 . . . . 0.0 112.51 -175.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_exo -50.59 -15.7 1.78 Allowed 'Trans proline' 0 N--CA 1.458 -0.572 0 C-N-CA 123.387 2.725 . . . . 0.0 115.566 178.259 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 39.3 m80 -137.69 31.5 2.52 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 119.757 1.162 . . . . 0.0 110.999 -179.765 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 1.5 pm0 -60.73 -45.64 93.48 Favored 'General case' 0 CA--C 1.534 0.333 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 178.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.99 -35.06 67.09 Favored Glycine 0 CA--C 1.527 0.816 0 C-N-CA 124.272 0.939 . . . . 0.0 111.661 179.1 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -80.96 4.97 17.71 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-N 117.209 0.504 . . . . 0.0 111.465 179.006 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 73.94 25.2 72.15 Favored Glycine 0 CA--C 1.524 0.651 0 CA-C-O 119.147 -0.807 . . . . 0.0 112.573 179.229 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 24.5 ttt -78.96 78.24 5.41 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 119.092 1.446 . . . . 0.0 107.831 177.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 13.5 m -121.25 169.09 12.99 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.245 0 C-N-CA 126.181 1.792 . . . . 0.0 109.915 179.56 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -168.87 177.97 42.43 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.108 -1.197 . . . . 0.0 110.108 178.489 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 58.6 mttm -147.57 161.22 41.57 Favored 'General case' 0 N--CA 1.455 -0.21 0 C-N-CA 123.772 0.829 . . . . 0.0 109.621 -179.48 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 4.2 p -144.88 132.63 16.59 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.246 0 C-N-CA 123.62 0.768 . . . . 0.0 109.1 178.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.3 m -103.41 106.88 17.51 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.965 1.306 . . . . 0.0 109.665 -178.44 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 32.6 t -82.55 106.97 13.95 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.574 0 N-CA-C 105.905 -1.887 . . . . 0.0 105.905 178.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 25.6 m120 . . . . . 0 C--O 1.231 0.127 0 C-N-CA 124.279 1.032 . . . . 0.0 111.042 -176.637 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 45.9 tt0 . . . . . 0 N--CA 1.452 -0.343 0 N-CA-C 105.546 -2.02 . . . . 0.0 105.546 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 38.7 t -99.35 118.66 46.28 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.455 0 C-N-CA 123.813 0.845 . . . . 0.0 108.833 -177.645 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 59.1 mt -81.98 122.05 27.3 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 179.297 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 70.4 mt -87.39 89.93 8.18 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 105.321 -2.103 . . . . 0.0 105.321 177.128 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 118.25 166.36 13.7 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 109.098 -1.601 . . . . 0.0 109.098 -177.408 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 5.4 p -136.26 48.56 2.15 Favored 'General case' 0 N--CA 1.461 0.102 0 CA-C-O 122.798 1.285 . . . . 0.0 113.259 -178.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.44 -62.13 0.62 Allowed Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 128.238 2.828 . . . . 0.0 113.364 176.636 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -78.31 42.97 0.44 Allowed 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 123.981 0.913 . . . . 0.0 112.268 -175.578 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 75.55 -31.22 1.21 Allowed Glycine 0 CA--C 1.528 0.891 0 C-N-CA 124.934 1.254 . . . . 0.0 113.388 178.305 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 7.4 t -40.44 106.27 0.05 Allowed 'General case' 0 C--O 1.237 0.443 0 C-N-CA 126.178 1.791 . . . . 0.0 112.141 -178.522 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 48.9 mt -75.2 69.96 2.11 Favored 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 128.196 2.598 . . . . 0.0 111.551 -176.399 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.6 m -136.49 153.38 30.78 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 C-N-CA 122.86 0.464 . . . . 0.0 110.233 179.034 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 61.5 m-85 -88.57 127.27 35.55 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 105.096 -2.187 . . . . 0.0 105.096 176.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 38.8 t -120.79 114.42 32.61 Favored Pre-proline 0 CA--C 1.533 0.313 0 CA-C-O 118.175 -0.916 . . . . 0.0 108.688 178.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -73.06 147.91 90.88 Favored 'Cis proline' 0 CA--C 1.535 0.574 0 CA-C-N 120.49 1.211 . . . . 0.0 111.423 -0.455 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.4 m -78.77 -33.02 46.76 Favored 'General case' 0 CA--C 1.529 0.148 0 C-N-CA 123.715 0.806 . . . . 0.0 111.809 179.826 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -138.75 141.25 38.85 Favored 'General case' 0 N--CA 1.454 -0.241 0 N-CA-C 105.288 -2.115 . . . . 0.0 105.288 178.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 13.3 p90 -168.1 172.44 8.74 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 123.904 0.882 . . . . 0.0 108.739 -178.486 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 14.9 m -133.26 137.7 46.16 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 123.918 0.887 . . . . 0.0 108.685 -179.09 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.3 m -139.9 155.02 71.2 Favored Pre-proline 0 CA--C 1.531 0.234 0 C-N-CA 124.26 1.024 . . . . 0.0 110.145 -178.61 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -77.11 151.21 30.22 Favored 'Trans proline' 0 N--CA 1.451 -0.992 0 C-N-CA 121.845 1.697 . . . . 0.0 110.64 177.638 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 14.7 m -49.79 126.55 14.19 Favored 'General case' 0 N--CA 1.457 -0.112 0 C-N-CA 123.328 0.651 . . . . 0.0 109.993 175.579 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 103.21 -6.64 50.81 Favored Glycine 0 CA--C 1.526 0.752 0 CA-C-O 119.082 -0.844 . . . . 0.0 111.678 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -61.65 136.87 58.17 Favored 'General case' 0 CA--C 1.534 0.329 0 CA-C-N 119.117 1.458 . . . . 0.0 110.43 178.567 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 61.0 mttp -94.93 98.56 10.79 Favored 'General case' 0 N--CA 1.446 -0.657 0 C-N-CA 127.244 2.218 . . . . 0.0 107.436 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 56.3 mt -81.45 137.4 21.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 -179.247 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 60.4 t -120.53 102.51 12.54 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.187 0 C-N-CA 125.017 1.327 . . . . 0.0 108.703 -178.767 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -88.46 107.03 18.65 Favored 'General case' 0 CA--C 1.53 0.183 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 178.669 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 64.6 tttm -103.35 128.45 50.43 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 124.49 1.116 . . . . 0.0 113.379 -175.556 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -62.27 108.69 1.14 Allowed 'General case' 0 N--CA 1.464 0.26 0 N-CA-C 109.155 -0.684 . . . . 0.0 109.155 176.654 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 20.2 t-20 -94.05 -69.93 0.73 Allowed 'General case' 0 C--N 1.339 0.152 0 C-N-CA 123.434 0.693 . . . . 0.0 110.71 -179.403 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -154.89 166.0 34.9 Favored 'General case' 0 C--N 1.331 -0.213 0 C-N-CA 123.899 0.88 . . . . 0.0 109.586 -177.722 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 64.51 23.04 68.31 Favored Glycine 0 CA--C 1.534 1.234 0 N-CA-C 111.938 -0.465 . . . . 0.0 111.938 -178.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.491 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 15.3 p90 -71.94 166.84 36.72 Favored Pre-proline 0 CA--C 1.543 0.697 0 N-CA-C 106.177 -1.786 . . . . 0.0 106.177 177.231 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.491 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 86.6 Cg_endo -70.38 161.31 88.25 Favored 'Cis proline' 0 N--CA 1.448 -1.201 0 CA-C-N 120.227 1.117 . . . . 0.0 114.928 3.708 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 -150.69 168.28 24.84 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.207 -178.606 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -159.19 177.48 11.01 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 104.029 -2.582 . . . . 0.0 104.029 175.243 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 41.6 t -132.19 119.35 39.8 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 -179.625 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 25.6 t -114.57 122.24 68.29 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.679 0 N-CA-C 105.602 -1.999 . . . . 0.0 105.602 177.501 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 59.5 m-85 -86.32 125.56 33.7 Favored 'General case' 0 N--CA 1.446 -0.668 0 N-CA-C 105.868 -1.901 . . . . 0.0 105.868 177.046 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 12.1 t0 -64.28 103.48 0.64 Allowed 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 123.059 0.543 . . . . 0.0 110.612 -177.616 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.7 pm0 -45.02 -35.47 2.97 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 125.235 1.414 . . . . 0.0 112.994 177.703 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -70.34 -20.73 62.96 Favored 'General case' 0 CA--C 1.536 0.438 0 N-CA-C 113.277 0.843 . . . . 0.0 113.277 -179.545 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -139.81 74.76 1.48 Allowed 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 123.68 0.792 . . . . 0.0 111.659 -177.732 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 30.5 pt -157.25 157.35 30.32 Favored Pre-proline 0 CA--C 1.532 0.253 0 C-N-CA 128.562 2.745 . . . . 0.0 105.67 175.845 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -58.67 108.98 0.45 Allowed 'Trans proline' 0 N--CA 1.455 -0.738 0 C-N-CA 122.02 1.813 . . . . 0.0 107.996 173.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -35.08 -43.03 0.19 Allowed 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 126.676 1.99 . . . . 0.0 115.605 -177.01 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -58.21 -29.33 62.69 Favored Glycine 0 CA--C 1.533 1.19 0 CA-C-O 119.893 -0.393 . . . . 0.0 113.538 -179.122 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 42.6 t -84.72 108.11 16.45 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.295 0 CA-C-N 118.21 1.005 . . . . 0.0 109.751 -178.451 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -58.27 114.11 2.26 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 122.955 0.502 . . . . 0.0 109.784 177.716 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.76 -40.82 21.76 Favored 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 124.205 1.002 . . . . 0.0 111.499 179.183 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 48.4 t -60.65 -30.06 46.15 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.398 0 C-N-CA 123.123 0.569 . . . . 0.0 111.768 -179.133 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 37.7 mmtm -76.56 -40.98 48.15 Favored 'General case' 0 CA--C 1.528 0.112 0 CA-C-N 118.715 0.688 . . . . 0.0 110.414 -179.084 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.408 HD13 HG21 ' A' ' 55' ' ' ILE . 23.1 pt -78.84 -33.65 16.52 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 N-CA-C 112.223 0.453 . . . . 0.0 112.223 -179.76 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 41.1 m -79.47 162.35 25.51 Favored 'General case' 0 C--N 1.331 -0.203 0 N-CA-C 113.454 0.909 . . . . 0.0 113.454 -178.089 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 2.7 tmm? . . . . . 0 CA--C 1.54 0.576 0 N-CA-C 104.522 -2.399 . . . . 0.0 104.522 175.368 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.426 ' N ' HD13 ' A' ' 62' ' ' LEU . 0.0 OUTLIER . . . . . 0 N--CA 1.443 -0.81 0 CA-C-O 121.241 0.543 . . . . 0.0 110.426 . . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 81.7 mt -78.5 106.06 10.2 Favored 'General case' 0 N--CA 1.446 -0.629 0 N-CA-C 104.488 -2.412 . . . . 0.0 104.488 177.121 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 13.2 t30 -77.0 -62.2 1.73 Allowed 'General case' 0 CA--C 1.528 0.133 0 N-CA-C 114.932 1.456 . . . . 0.0 114.932 -175.034 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.88 157.02 76.95 Favored Pre-proline 0 CA--C 1.533 0.295 0 C-N-CA 123.056 0.542 . . . . 0.0 111.601 -175.534 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -63.66 164.16 22.09 Favored 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 122.2 1.933 . . . . 0.0 109.433 175.335 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 80.92 -37.61 2.34 Favored Glycine 0 CA--C 1.527 0.783 0 CA-C-O 118.231 -1.316 . . . . 0.0 114.305 176.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 66.7 mt-10 -41.69 126.03 2.91 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 119.079 1.44 . . . . 0.0 112.144 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 16.9 p -109.22 127.61 54.38 Favored 'General case' 0 N--CA 1.455 -0.219 0 C-N-CA 125.481 1.512 . . . . 0.0 112.693 -178.552 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 35.5 t80 -106.45 114.02 27.89 Favored 'General case' 0 N--CA 1.456 -0.159 0 N-CA-C 106.05 -1.833 . . . . 0.0 106.05 174.034 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 15.4 t -100.52 141.23 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.236 0 C-N-CA 123.189 0.596 . . . . 0.0 110.464 -177.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 10.7 p -150.45 141.52 16.6 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.208 0 N-CA-C 108.774 -0.825 . . . . 0.0 108.774 177.308 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 23.7 m -108.46 123.57 49.08 Favored 'General case' 0 CA--C 1.528 0.113 0 C-N-CA 123.752 0.821 . . . . 0.0 108.966 -178.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 36.9 mt -104.56 104.15 13.94 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 118.33 0.514 . . . . 0.0 109.798 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -87.19 -53.52 4.81 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 123.974 0.909 . . . . 0.0 111.602 -179.443 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 4.7 m -66.2 128.41 36.0 Favored 'General case' 0 N--CA 1.455 -0.223 0 O-C-N 121.822 -0.549 . . . . 0.0 111.402 -175.571 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 24.9 mtpp -65.89 161.52 21.01 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 124.787 1.235 . . . . 0.0 110.871 179.648 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 132.66 -137.33 9.32 Favored Glycine 0 C--N 1.335 0.503 0 N-CA-C 110.039 -1.225 . . . . 0.0 110.039 177.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 58.8 m -147.79 141.81 25.95 Favored 'General case' 0 N--CA 1.443 -0.824 0 N-CA-C 105.717 -1.957 . . . . 0.0 105.717 179.65 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 12.1 m-85 -129.61 126.43 38.43 Favored 'General case' 0 N--CA 1.446 -0.675 0 C-N-CA 124.302 1.041 . . . . 0.0 108.821 -177.054 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 74.5 m -95.4 145.67 24.97 Favored 'General case' 0 C--N 1.331 -0.201 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 175.668 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 11.7 p90 -143.49 164.5 30.16 Favored 'General case' 0 N--CA 1.455 -0.191 0 CA-C-O 121.435 0.636 . . . . 0.0 112.369 -179.538 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 53.1 p90 -155.32 160.33 40.66 Favored 'General case' 0 N--CA 1.454 -0.256 0 CA-C-N 115.228 -0.896 . . . . 0.0 112.678 -179.714 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 4.3 t -102.44 100.92 11.08 Favored 'General case' 0 CA--C 1.516 -0.341 0 N-CA-C 105.991 -1.855 . . . . 0.0 105.991 176.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.252 0.0 OUTLIER -38.7 -63.07 0.63 Allowed Pre-proline 0 CA--C 1.538 0.511 0 N-CA-C 114.346 1.239 . . . . 0.0 114.346 -175.019 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_exo -50.53 -18.27 3.67 Favored 'Trans proline' 0 CA--C 1.534 0.501 0 C-N-CA 123.635 2.89 . . . . 0.0 115.748 179.111 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 36.6 m80 -131.63 20.19 4.68 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 119.132 0.878 . . . . 0.0 111.293 -179.044 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 66.2 tt0 -60.07 -49.06 79.13 Favored 'General case' 0 CA--C 1.528 0.13 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.226 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.8 -32.22 61.74 Favored Glycine 0 CA--C 1.531 1.073 0 N-CA-C 111.475 -0.65 . . . . 0.0 111.475 178.066 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -81.79 4.12 23.29 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 123.334 0.654 . . . . 0.0 111.718 179.105 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 84.66 16.01 66.9 Favored Glycine 0 CA--C 1.527 0.798 0 CA-C-O 118.851 -0.972 . . . . 0.0 113.509 178.384 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 19.6 ttt -78.48 78.22 4.95 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 119.509 1.655 . . . . 0.0 108.332 178.491 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 5.9 m -128.43 171.71 16.08 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 C-N-CA 125.802 1.641 . . . . 0.0 110.607 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -175.99 -174.7 42.75 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 109.155 -1.578 . . . . 0.0 109.155 177.618 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 52.2 mttp -151.63 169.77 21.33 Favored 'General case' 0 N--CA 1.453 -0.323 0 C-N-CA 124.064 0.946 . . . . 0.0 109.343 179.8 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.3 p -150.37 139.5 15.27 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.382 0 C-N-CA 123.744 0.818 . . . . 0.0 108.972 177.267 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -100.44 133.51 44.76 Favored 'General case' 0 CA--C 1.529 0.168 0 C-N-CA 124.615 1.166 . . . . 0.0 107.89 179.792 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 31.7 t -115.33 109.72 29.35 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.18 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 178.784 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 48.0 p30 . . . . . 0 C--O 1.231 0.117 0 C-N-CA 124.385 1.074 . . . . 0.0 111.878 -177.0 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 . . . . . 0 N--CA 1.452 -0.339 0 N-CA-C 105.687 -1.968 . . . . 0.0 105.687 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 41.0 t -99.88 125.28 53.59 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.374 0 C-N-CA 124.251 1.02 . . . . 0.0 109.368 -177.273 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 74.8 mt -88.54 119.05 28.63 Favored 'General case' 0 N--CA 1.446 -0.658 0 N-CA-C 108.015 -1.105 . . . . 0.0 108.015 178.264 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 19.8 mt -83.75 101.98 11.96 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 104.841 -2.281 . . . . 0.0 104.841 176.26 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 101.83 -161.34 17.68 Favored Glycine 0 N--CA 1.447 -0.573 0 N-CA-C 108.043 -2.023 . . . . 0.0 108.043 -178.016 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 54.8 p -153.32 150.34 28.81 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 106.665 -1.606 . . . . 0.0 106.665 179.545 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -50.63 -34.79 28.82 Favored Glycine 0 CA--C 1.531 1.069 0 C-N-CA 123.293 0.473 . . . . 0.0 113.09 -179.809 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -74.29 -4.99 39.48 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 123.668 0.787 . . . . 0.0 112.75 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 97.29 -17.3 59.34 Favored Glycine 0 CA--C 1.527 0.839 0 C-N-CA 124.181 0.896 . . . . 0.0 114.091 178.597 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 33.0 t -56.94 135.03 56.06 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 119.217 1.509 . . . . 0.0 111.739 -178.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 91.6 mt -80.09 78.24 6.75 Favored 'General case' 0 N--CA 1.446 -0.655 0 C-N-CA 125.713 1.605 . . . . 0.0 109.819 -178.824 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.7 p -138.6 159.1 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.303 0 C-N-CA 123.616 0.767 . . . . 0.0 109.524 178.713 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 30.7 m-85 -97.98 124.49 42.48 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 103.521 -2.77 . . . . 0.0 103.521 175.893 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 43.4 t -120.21 109.32 37.18 Favored Pre-proline 0 CA--C 1.537 0.456 0 CA-C-N 119.337 0.972 . . . . 0.0 109.717 -179.34 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -71.01 157.39 95.59 Favored 'Cis proline' 0 N--CA 1.456 -0.679 0 CA-C-N 120.325 1.152 . . . . 0.0 110.732 -1.448 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.4 p -84.11 -62.67 1.51 Allowed 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 107.577 -1.268 . . . . 0.0 107.577 179.253 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 51.1 mt-10 -107.31 127.98 54.04 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 125.367 1.467 . . . . 0.0 107.925 178.345 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 39.1 p90 -151.5 -177.21 5.95 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.875 0.369 . . . . 0.0 111.607 179.749 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 15.1 m -139.54 145.92 39.26 Favored 'General case' 0 N--CA 1.452 -0.362 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 -179.481 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.6 p -156.34 139.61 11.01 Favored Pre-proline 0 CA--C 1.54 0.576 0 CA-C-N 118.914 0.779 . . . . 0.0 109.977 -178.163 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -55.96 146.85 66.44 Favored 'Trans proline' 0 N--CA 1.458 -0.612 0 C-N-CA 122.558 2.172 . . . . 0.0 113.597 177.432 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 21.6 m -56.87 139.76 50.44 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 123.244 0.618 . . . . 0.0 110.464 177.057 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 89.41 -13.91 62.52 Favored Glycine 0 CA--C 1.529 0.922 0 CA-C-O 119.099 -0.834 . . . . 0.0 113.928 177.46 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 72.7 mm-40 -71.56 149.66 45.48 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 119.218 1.509 . . . . 0.0 110.356 178.716 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 1.7 mptm? -90.26 114.89 27.01 Favored 'General case' 0 N--CA 1.453 -0.323 0 C-N-CA 124.3 1.04 . . . . 0.0 109.274 -179.036 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 69.2 mt -86.54 137.13 21.45 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.267 0 N-CA-C 105.403 -2.073 . . . . 0.0 105.403 177.017 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 62.5 t -120.81 107.14 19.88 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.136 0 C-N-CA 124.515 1.126 . . . . 0.0 108.986 -178.021 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -94.31 101.64 13.6 Favored 'General case' 0 CA--C 1.532 0.279 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 178.441 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -97.85 125.81 42.91 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 125.597 1.559 . . . . 0.0 113.11 -176.134 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 8.0 m-20 -63.3 102.61 0.41 Allowed 'General case' 0 N--CA 1.466 0.36 0 C-N-CA 123.306 0.642 . . . . 0.0 110.092 176.55 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -80.01 -57.44 3.64 Favored 'General case' 0 CA--C 1.519 -0.216 0 C-N-CA 123.075 0.55 . . . . 0.0 110.921 -179.364 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -174.44 178.25 2.02 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 126.561 1.944 . . . . 0.0 106.275 -177.414 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 64.38 19.0 63.91 Favored Glycine 0 CA--C 1.536 1.35 0 CA-C-N 119.098 0.863 . . . . 0.0 112.597 -179.555 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.48 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 9.0 p90 -74.07 168.8 22.86 Favored Pre-proline 0 CA--C 1.538 0.517 0 N-CA-C 106.233 -1.765 . . . . 0.0 106.233 177.353 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.48 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 41.0 Cg_exo -63.94 156.82 71.53 Favored 'Cis proline' 0 N--CA 1.454 -0.838 0 N-CA-C 116.507 1.695 . . . . 0.0 116.507 1.568 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -148.97 171.91 15.58 Favored 'General case' 0 C--O 1.221 -0.445 0 O-C-N 121.691 -0.63 . . . . 0.0 111.166 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 31.1 p-10 -166.47 -179.91 5.19 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 104.704 -2.332 . . . . 0.0 104.704 176.452 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 60.9 t -138.7 115.6 10.99 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.229 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 178.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 67.5 t -119.8 132.02 70.69 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.658 0 N-CA-C 105.618 -1.993 . . . . 0.0 105.618 178.326 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 52.9 m-85 -88.01 130.86 34.84 Favored 'General case' 0 N--CA 1.446 -0.633 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 -179.261 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -73.34 100.86 3.28 Favored 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 122.774 0.429 . . . . 0.0 109.861 -178.302 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -40.71 -38.7 0.95 Allowed 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 125.801 1.64 . . . . 0.0 113.639 178.225 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 36.8 t70 -68.26 -26.11 65.51 Favored 'General case' 0 CA--C 1.535 0.398 0 N-CA-C 113.487 0.921 . . . . 0.0 113.487 -179.055 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 40.2 mt-10 -129.49 61.64 1.55 Allowed 'General case' 0 CA--C 1.535 0.38 0 C-N-CA 124.018 0.927 . . . . 0.0 112.384 -176.812 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 40.5 pt -153.27 157.31 32.9 Favored Pre-proline 0 CA--C 1.531 0.24 0 C-N-CA 127.603 2.361 . . . . 0.0 105.509 174.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_exo -58.88 104.81 0.2 Allowed 'Trans proline' 0 N--CA 1.455 -0.788 0 C-N-CA 121.828 1.685 . . . . 0.0 108.334 173.703 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -35.15 -43.94 0.23 Allowed 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 126.993 2.117 . . . . 0.0 115.368 -176.752 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -55.21 -33.38 57.88 Favored Glycine 0 CA--C 1.533 1.175 0 C-N-CA 123.178 0.418 . . . . 0.0 112.97 -179.619 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 40.4 t -82.12 95.73 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.386 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 -179.244 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 25.2 t0 -49.03 112.48 0.63 Allowed 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 124.24 1.016 . . . . 0.0 110.679 178.819 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -44.73 -44.71 9.42 Favored 'General case' 0 N--CA 1.454 -0.228 0 C-N-CA 125.748 1.619 . . . . 0.0 111.496 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 59.4 t -54.64 -30.56 22.36 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 C-N-CA 123.544 0.738 . . . . 0.0 112.144 -179.085 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -77.53 -34.95 53.77 Favored 'General case' 0 CA--C 1.531 0.22 0 CA-C-N 118.732 0.696 . . . . 0.0 111.788 -178.464 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.426 HD13 HG21 ' A' ' 55' ' ' ILE . 25.1 pt -89.02 -26.14 5.57 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 C-N-CA 123.33 0.652 . . . . 0.0 112.375 -179.083 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 49.4 m -88.16 146.59 25.32 Favored 'General case' 0 N--CA 1.454 -0.232 0 N-CA-C 114.132 1.16 . . . . 0.0 114.132 -177.1 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 42.6 mmm . . . . . 0 N--CA 1.451 -0.425 0 N-CA-C 103.713 -2.699 . . . . 0.0 103.713 170.947 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.451 -0.399 0 CA-C-O 121.467 0.651 . . . . 0.0 111.879 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 42.7 mt -82.53 96.12 7.95 Favored 'General case' 0 N--CA 1.447 -0.617 0 C-N-CA 126.548 1.939 . . . . 0.0 106.065 178.242 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 11.9 t30 -79.01 -51.87 9.0 Favored 'General case' 0 C--O 1.225 -0.221 0 N-CA-C 113.204 0.816 . . . . 0.0 113.204 -178.457 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.96 157.73 78.53 Favored Pre-proline 0 CA--C 1.536 0.436 0 C-N-CA 123.475 0.71 . . . . 0.0 112.252 -175.809 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -65.54 165.73 21.92 Favored 'Trans proline' 0 N--CA 1.457 -0.656 0 C-N-CA 122.518 2.145 . . . . 0.0 109.954 175.663 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 79.31 -50.6 3.78 Favored Glycine 0 CA--C 1.526 0.742 0 CA-C-O 118.871 -0.961 . . . . 0.0 113.016 177.076 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 43.3 mm-40 -26.24 118.41 0.07 Allowed 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 126.79 2.036 . . . . 0.0 113.403 -179.424 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 13.3 p -106.54 123.49 48.18 Favored 'General case' 0 N--CA 1.453 -0.292 0 C-N-CA 125.605 1.562 . . . . 0.0 112.827 -178.239 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 19.8 t80 -101.81 115.32 30.29 Favored 'General case' 0 C--O 1.232 0.169 0 N-CA-C 105.835 -1.913 . . . . 0.0 105.835 173.477 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.8 t -100.81 136.88 30.34 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.295 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 -179.606 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.6 p -147.35 150.92 14.19 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.078 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 178.705 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 25.5 m -121.06 130.3 53.71 Favored 'General case' 0 N--CA 1.457 -0.081 0 C-N-CA 124.316 1.046 . . . . 0.0 108.408 -178.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 74.7 mt -113.11 121.32 44.21 Favored 'General case' 0 CA--C 1.53 0.21 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 179.418 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -92.35 -63.22 1.26 Allowed 'General case' 0 CA--C 1.529 0.149 0 C-N-CA 124.152 0.981 . . . . 0.0 112.458 -178.038 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.1 m -65.21 135.1 55.02 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 122.986 0.515 . . . . 0.0 110.318 -174.879 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 61.1 mttp -71.52 156.59 39.25 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 122.998 0.519 . . . . 0.0 111.259 -178.368 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 139.55 175.76 14.41 Favored Glycine 0 CA--C 1.525 0.696 0 C-N-CA 123.558 0.599 . . . . 0.0 111.662 177.825 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 18.3 m -94.47 112.18 23.95 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 107.51 -1.292 . . . . 0.0 107.51 179.072 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 18.8 m-85 -104.93 125.43 50.93 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 123.686 0.795 . . . . 0.0 109.263 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 7.3 m -98.39 142.12 30.41 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 177.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 12.0 p90 -139.55 163.6 32.13 Favored 'General case' 0 N--CA 1.455 -0.198 0 CA-C-O 121.502 0.668 . . . . 0.0 111.719 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 49.5 p90 -148.99 161.66 41.46 Favored 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 124.855 1.262 . . . . 0.0 111.784 -178.195 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.8 t -105.32 107.48 18.49 Favored 'General case' 0 CA--C 1.522 -0.126 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 177.279 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 1.3 m -41.51 -61.55 1.38 Allowed Pre-proline 0 CA--C 1.535 0.378 0 N-CA-C 115.06 1.504 . . . . 0.0 115.06 -175.812 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -60.19 -4.84 3.35 Favored 'Trans proline' 0 CA--C 1.536 0.624 0 C-N-CA 121.859 1.706 . . . . 0.0 114.792 -179.042 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 38.7 m80 -134.34 19.67 3.67 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-N 119.73 1.15 . . . . 0.0 110.556 177.443 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 19.6 pt20 -63.35 -42.46 98.9 Favored 'General case' 0 N--CA 1.452 -0.33 0 O-C-N 121.693 -0.629 . . . . 0.0 109.531 179.192 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -61.13 -40.98 99.3 Favored Glycine 0 CA--C 1.529 0.964 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 177.557 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -66.32 -34.14 77.32 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 122.713 0.405 . . . . 0.0 110.117 178.536 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 108.33 31.19 3.59 Favored Glycine 0 CA--C 1.525 0.715 0 C-N-CA 124.287 0.946 . . . . 0.0 112.513 178.072 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -80.18 91.08 5.52 Favored 'General case' 0 C--O 1.237 0.41 0 N-CA-C 106.609 -1.626 . . . . 0.0 106.609 178.122 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 20.1 m -131.12 171.6 17.64 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.246 0 C-N-CA 125.128 1.371 . . . . 0.0 112.15 -177.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -171.27 -179.89 42.66 Favored Glycine 0 CA--C 1.529 0.956 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 177.507 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 81.3 mttt -147.75 155.09 41.33 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-N 117.77 0.785 . . . . 0.0 110.435 -179.657 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 4.3 p -137.75 127.96 36.73 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 C-N-CA 123.938 0.895 . . . . 0.0 109.637 179.197 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -91.99 103.92 16.39 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 107.135 -1.431 . . . . 0.0 107.135 178.736 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 40.0 t -81.37 112.28 19.11 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 N-CA-C 105.386 -2.079 . . . . 0.0 105.386 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 31.1 m120 . . . . . 0 N--CA 1.456 -0.173 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 -178.596 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 . . . . . 0 N--CA 1.455 -0.199 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 43.8 t -118.22 121.83 68.14 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.355 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 179.478 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 36.9 mt -89.62 127.88 35.97 Favored 'General case' 0 N--CA 1.454 -0.262 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 179.247 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 44.1 mt -86.64 96.87 10.26 Favored 'General case' 0 N--CA 1.452 -0.326 0 N-CA-C 106.656 -1.609 . . . . 0.0 106.656 177.822 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 105.39 132.41 7.31 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 -178.679 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 23.9 p -83.0 43.88 0.89 Allowed 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 119.07 1.435 . . . . 0.0 112.802 -178.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.58 -55.14 1.25 Allowed Glycine 0 CA--C 1.527 0.815 0 C-N-CA 126.197 1.856 . . . . 0.0 112.278 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -72.85 34.47 0.07 Allowed 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 126.163 1.785 . . . . 0.0 113.633 -177.554 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 68.08 -13.27 0.74 Allowed Glycine 0 CA--C 1.53 0.996 0 C-N-CA 124.505 1.05 . . . . 0.0 115.035 178.428 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 20.3 t -61.55 129.15 39.72 Favored 'General case' 0 C--N 1.339 0.126 0 CA-C-N 119.328 1.564 . . . . 0.0 109.768 -178.464 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 59.4 mt -75.11 66.76 1.69 Allowed 'General case' 0 N--CA 1.448 -0.534 0 C-N-CA 126.113 1.765 . . . . 0.0 111.857 -175.538 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.8 m -135.06 149.55 29.15 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.182 0 C-N-CA 123.446 0.698 . . . . 0.0 110.856 179.368 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 74.7 m-85 -88.09 135.46 33.41 Favored 'General case' 0 N--CA 1.456 -0.144 0 N-CA-C 105.477 -2.046 . . . . 0.0 105.477 176.549 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 48.4 t -122.67 110.73 31.69 Favored Pre-proline 0 CA--C 1.533 0.305 0 CA-C-O 118.026 -0.987 . . . . 0.0 108.851 178.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -72.87 151.62 97.13 Favored 'Cis proline' 0 N--CA 1.458 -0.565 0 CA-C-N 120.408 1.181 . . . . 0.0 111.175 -0.773 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.2 m -80.66 -48.92 11.92 Favored 'General case' 0 CA--C 1.529 0.161 0 C-N-CA 123.351 0.661 . . . . 0.0 110.799 179.811 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -119.97 129.47 54.32 Favored 'General case' 0 N--CA 1.454 -0.251 0 N-CA-C 105.904 -1.887 . . . . 0.0 105.904 179.821 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 38.2 p90 -157.4 -175.78 5.59 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-N 118.828 0.74 . . . . 0.0 111.963 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 32.9 m -133.97 147.9 51.09 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 125.601 1.561 . . . . 0.0 107.092 178.37 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.4 p -145.71 139.01 14.36 Favored Pre-proline 0 N--CA 1.449 -0.509 0 C-N-CA 123.568 0.747 . . . . 0.0 109.308 -178.156 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 70.7 Cg_exo -53.66 137.26 66.57 Favored 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 122.359 2.039 . . . . 0.0 111.436 177.327 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.6 m -60.13 117.23 4.88 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 179.476 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 109.35 -17.21 31.54 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-O 118.729 -1.039 . . . . 0.0 112.181 -178.119 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -72.17 157.45 37.73 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 119.534 1.667 . . . . 0.0 110.698 179.226 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 57.1 pttt -93.76 135.09 35.42 Favored 'General case' 0 N--CA 1.444 -0.76 0 C-N-CA 124.764 1.226 . . . . 0.0 110.826 -179.695 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 45.6 mt -102.36 130.71 51.81 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.358 0 N-CA-C 104.804 -2.295 . . . . 0.0 104.804 177.055 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 80.6 t -115.27 99.54 8.71 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 C-N-CA 124.819 1.247 . . . . 0.0 108.705 -178.104 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -86.13 103.0 14.37 Favored 'General case' 0 N--CA 1.456 -0.169 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 178.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 60.9 tttp -98.39 128.8 44.95 Favored 'General case' 0 CA--C 1.528 0.131 0 C-N-CA 124.315 1.046 . . . . 0.0 112.27 -177.216 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 38.8 t30 -64.43 110.36 2.25 Favored 'General case' 0 N--CA 1.456 -0.15 0 C-N-CA 123.608 0.763 . . . . 0.0 109.86 177.57 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 59.9 t30 -102.59 -64.74 1.04 Allowed 'General case' 0 C--N 1.339 0.134 0 CA-C-N 118.495 0.589 . . . . 0.0 111.312 -179.207 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -157.17 168.4 27.55 Favored 'General case' 0 C--O 1.226 -0.18 0 C-N-CA 122.869 0.468 . . . . 0.0 111.284 -177.762 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 66.23 24.86 72.19 Favored Glycine 0 CA--C 1.532 1.144 0 O-C-N 121.868 -0.52 . . . . 0.0 112.269 -179.896 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.541 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 10.3 p90 -74.68 169.53 19.42 Favored Pre-proline 0 CA--C 1.543 0.7 0 C-N-CA 125.457 1.503 . . . . 0.0 107.768 179.023 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.541 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 95.7 Cg_endo -70.32 162.21 86.17 Favored 'Cis proline' 0 N--CA 1.448 -1.19 0 CA-C-N 120.189 1.103 . . . . 0.0 114.314 2.878 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 89.9 m-70 -148.9 174.86 11.8 Favored 'General case' 0 C--O 1.22 -0.476 0 O-C-N 121.545 -0.722 . . . . 0.0 111.276 -178.634 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 25.4 p-10 -163.87 179.08 7.3 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 103.858 -2.645 . . . . 0.0 103.858 175.707 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 45.1 t -138.52 117.44 13.81 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.377 0 N-CA-C 107.358 -1.349 . . . . 0.0 107.358 178.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 91.8 t -121.55 138.18 52.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 106.737 -1.579 . . . . 0.0 106.737 178.409 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 76.2 m-85 -97.09 131.82 43.49 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -63.19 116.26 5.26 Favored 'General case' 0 N--CA 1.454 -0.242 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 -178.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.1 pm0 -48.45 -29.57 4.22 Favored 'General case' 0 CA--C 1.533 0.299 0 N-CA-C 115.682 1.734 . . . . 0.0 115.682 -177.719 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 18.0 m-20 -90.07 -52.18 5.08 Favored 'General case' 0 CA--C 1.53 0.178 0 CA-C-N 118.752 0.706 . . . . 0.0 110.101 -179.593 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 80.0 mt-10 -79.92 58.82 3.0 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 124.402 1.081 . . . . 0.0 112.169 -176.721 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 19.2 pt -150.58 151.29 30.45 Favored Pre-proline 0 CA--C 1.532 0.261 0 C-N-CA 127.025 2.13 . . . . 0.0 107.1 176.199 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 21.0 Cg_endo -61.89 117.58 4.43 Favored 'Trans proline' 0 N--CA 1.452 -0.948 0 C-N-CA 121.925 1.75 . . . . 0.0 110.466 178.746 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -46.98 120.91 3.3 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 125.02 1.328 . . . . 0.0 110.963 -179.398 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 126.31 -39.51 1.99 Allowed Glycine 0 CA--C 1.525 0.676 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -178.853 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 21.7 t -78.28 95.06 1.65 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 53.5 t0 -54.47 114.82 1.81 Allowed 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 123.213 0.605 . . . . 0.0 110.535 179.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -45.44 -43.67 11.59 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 125.554 1.541 . . . . 0.0 111.887 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 55.0 t -57.61 -28.85 32.92 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.344 0 C-N-CA 123.274 0.63 . . . . 0.0 111.805 -178.258 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 28.8 mtpp -79.05 -36.01 41.68 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 118.556 0.616 . . . . 0.0 111.229 -178.723 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.403 HD13 HG21 ' A' ' 55' ' ' ILE . 26.2 pt -86.78 -26.11 6.12 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.408 0 C-N-CA 123.201 0.6 . . . . 0.0 112.482 -179.564 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 46.0 m -90.25 148.6 22.8 Favored 'General case' 0 C--N 1.331 -0.2 0 N-CA-C 114.455 1.28 . . . . 0.0 114.455 -176.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 69.5 mmm . . . . . 0 CA--C 1.534 0.358 0 N-CA-C 105.749 -1.945 . . . . 0.0 105.749 173.583 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 2.5 pp . . . . . 0 N--CA 1.451 -0.415 0 CA-C-O 121.198 0.523 . . . . 0.0 111.279 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 37.4 mt -102.51 134.13 46.35 Favored 'General case' 0 N--CA 1.446 -0.662 0 C-N-CA 128.049 2.54 . . . . 0.0 104.598 177.53 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 30.0 t30 -138.77 -46.12 0.49 Allowed 'General case' 0 C--O 1.227 -0.111 0 C-N-CA 122.812 0.445 . . . . 0.0 111.833 -178.029 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -69.95 131.18 89.29 Favored Pre-proline 0 C--O 1.237 0.424 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 -178.575 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -48.56 130.22 21.56 Favored 'Trans proline' 0 N--CA 1.454 -0.823 0 C-N-CA 123.047 2.498 . . . . 0.0 111.538 -179.392 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 99.31 -23.3 36.83 Favored Glycine 0 CA--C 1.525 0.693 0 CA-C-O 117.662 -1.632 . . . . 0.0 114.462 177.627 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 52.4 mt-10 -50.86 125.41 13.36 Favored 'General case' 0 CA--C 1.536 0.438 0 CA-C-N 120.116 1.958 . . . . 0.0 110.849 179.719 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 2.3 p -104.27 140.73 37.44 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 125.514 1.526 . . . . 0.0 112.184 -178.163 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 20.8 t80 -117.79 115.22 24.57 Favored 'General case' 0 C--O 1.232 0.176 0 N-CA-C 104.789 -2.3 . . . . 0.0 104.789 172.259 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.4 t -103.56 139.41 24.57 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.388 0 C-N-CA 123.183 0.593 . . . . 0.0 109.526 -178.497 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.5 p -143.48 156.11 16.61 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 N-CA-C 106.6 -1.63 . . . . 0.0 106.6 176.854 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 12.5 m -132.29 123.66 27.33 Favored 'General case' 0 C--N 1.333 -0.139 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 -179.286 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 68.1 mt -111.56 102.09 10.45 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 123.254 0.622 . . . . 0.0 109.698 -177.531 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -82.46 -42.73 18.14 Favored 'General case' 0 CA--C 1.529 0.165 0 C-N-CA 124.069 0.947 . . . . 0.0 110.676 178.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 4.4 m -73.21 112.42 9.25 Favored 'General case' 0 N--CA 1.45 -0.458 0 C-N-CA 123.083 0.553 . . . . 0.0 109.87 -177.745 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 25.8 pttm -60.21 152.17 25.35 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 123.077 0.551 . . . . 0.0 111.299 178.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 150.96 -167.94 30.61 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.106 -1.198 . . . . 0.0 110.106 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 23.3 m -113.97 124.71 52.82 Favored 'General case' 0 N--CA 1.454 -0.271 0 N-CA-C 106.435 -1.691 . . . . 0.0 106.435 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -121.01 114.9 22.18 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 124.059 0.944 . . . . 0.0 110.045 -178.164 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 48.7 m -90.51 139.62 30.52 Favored 'General case' 0 C--O 1.233 0.197 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 175.788 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 22.5 p90 -136.41 165.44 25.81 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-O 121.419 0.628 . . . . 0.0 112.071 -179.312 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 49.4 p90 -153.33 161.12 42.69 Favored 'General case' 0 N--CA 1.453 -0.323 0 C-N-CA 124.277 1.031 . . . . 0.0 112.179 -178.498 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 3.7 t -103.1 102.62 12.64 Favored 'General case' 0 CA--C 1.519 -0.239 0 N-CA-C 106.254 -1.758 . . . . 0.0 106.254 176.638 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.263 0.7 OUTLIER -44.67 -56.36 8.67 Favored Pre-proline 0 CA--C 1.535 0.402 0 N-CA-C 113.985 1.106 . . . . 0.0 113.985 -175.131 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_exo -50.93 -18.16 4.07 Favored 'Trans proline' 0 CA--C 1.534 0.514 0 C-N-CA 123.187 2.591 . . . . 0.0 115.042 177.772 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 38.2 m80 -133.85 25.73 3.98 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 123.783 0.833 . . . . 0.0 110.862 -179.599 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 65.7 tt0 -61.61 -50.27 73.27 Favored 'General case' 0 N--CA 1.457 -0.093 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 179.214 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.56 -33.3 62.27 Favored Glycine 0 CA--C 1.532 1.098 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 177.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -79.92 2.17 24.44 Favored 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 123.403 0.681 . . . . 0.0 112.037 179.082 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 79.9 21.84 64.99 Favored Glycine 0 CA--C 1.527 0.832 0 CA-C-O 118.978 -0.901 . . . . 0.0 113.706 178.42 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 22.1 ttt -78.65 80.78 5.0 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 119.321 1.56 . . . . 0.0 107.928 177.874 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 12.6 m -124.2 170.3 14.54 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.188 0 C-N-CA 125.975 1.71 . . . . 0.0 111.07 -179.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -170.02 178.56 42.8 Favored Glycine 0 CA--C 1.527 0.84 0 N-CA-C 108.848 -1.701 . . . . 0.0 108.848 177.611 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 33.8 mtmm -148.42 149.75 32.28 Favored 'General case' 0 N--CA 1.455 -0.199 0 CA-C-N 118.091 0.946 . . . . 0.0 110.463 -178.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.2 p -135.26 132.17 52.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 C-N-CA 123.121 0.569 . . . . 0.0 109.813 178.132 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.2 m -98.87 103.49 15.45 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 125.05 1.34 . . . . 0.0 107.848 179.341 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 47.0 t -82.59 102.24 8.31 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.753 0 N-CA-C 105.026 -2.213 . . . . 0.0 105.026 -179.189 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 45.5 p-10 . . . . . 0 C--N 1.332 -0.167 0 C-N-CA 124.984 1.314 . . . . 0.0 109.599 -178.059 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 . . . . . 0 N--CA 1.45 -0.466 0 N-CA-C 106.869 -1.53 . . . . 0.0 106.869 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 60.2 t -129.34 126.59 63.98 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 39.7 mt -87.98 122.53 31.7 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 178.763 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 88.9 mt -81.11 100.01 8.81 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 106.248 -1.76 . . . . 0.0 106.248 177.35 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 95.84 137.96 9.5 Favored Glycine 0 C--N 1.336 0.532 0 N-CA-C 107.402 -2.279 . . . . 0.0 107.402 -177.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 80.8 p -78.97 157.97 28.06 Favored 'General case' 0 N--CA 1.438 -1.037 0 CA-C-O 121.985 0.898 . . . . 0.0 109.21 -179.212 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.4 -34.55 59.69 Favored Glycine 0 CA--C 1.531 1.04 0 CA-C-N 114.608 -1.178 . . . . 0.0 111.085 178.162 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -76.03 -3.77 37.65 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 123.573 0.749 . . . . 0.0 112.256 179.074 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 99.76 -21.14 46.39 Favored Glycine 0 CA--C 1.528 0.847 0 CA-C-O 119.007 -0.885 . . . . 0.0 113.451 178.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 33.4 t -56.81 131.99 51.0 Favored 'General case' 0 C--O 1.237 0.442 0 CA-C-N 119.249 1.524 . . . . 0.0 110.426 -179.641 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 56.4 mt -74.06 68.3 1.38 Allowed 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 126.489 1.916 . . . . 0.0 111.114 -176.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.5 m -134.38 152.94 34.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 C-N-CA 123.739 0.816 . . . . 0.0 109.533 178.534 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 -82.45 135.95 35.02 Favored 'General case' 0 N--CA 1.454 -0.245 0 N-CA-C 105.529 -2.026 . . . . 0.0 105.529 176.625 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 48.0 t -123.92 110.46 29.44 Favored Pre-proline 0 CA--C 1.535 0.397 0 CA-C-O 118.158 -0.925 . . . . 0.0 108.79 179.296 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -70.43 152.28 93.89 Favored 'Cis proline' 0 N--CA 1.459 -0.524 0 CA-C-N 120.361 1.164 . . . . 0.0 111.543 -0.79 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.4 m -82.3 -44.09 16.67 Favored 'General case' 0 CA--C 1.529 0.145 0 C-N-CA 123.784 0.833 . . . . 0.0 111.019 179.721 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 37.8 tt0 -129.68 133.98 47.4 Favored 'General case' 0 N--CA 1.452 -0.33 0 N-CA-C 106.354 -1.721 . . . . 0.0 106.354 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 30.2 p90 -163.23 -179.26 6.49 Favored 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 122.944 0.498 . . . . 0.0 110.251 -179.177 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 17.7 m -128.69 148.43 50.83 Favored 'General case' 0 N--CA 1.455 -0.191 0 N-CA-C 106.932 -1.507 . . . . 0.0 106.932 177.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.8 p -141.61 127.73 11.13 Favored Pre-proline 0 CA--C 1.538 0.496 0 C-N-CA 123.16 0.584 . . . . 0.0 111.35 -177.211 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -55.57 132.21 50.79 Favored 'Trans proline' 0 N--CA 1.452 -0.921 0 C-N-CA 122.327 2.018 . . . . 0.0 110.55 175.336 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 38.2 m -47.73 127.19 11.34 Favored 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 123.118 0.567 . . . . 0.0 110.042 178.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 99.03 -25.98 26.1 Favored Glycine 0 CA--C 1.531 1.054 0 CA-C-O 118.809 -0.995 . . . . 0.0 113.011 -179.591 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 75.4 mt-10 -74.73 100.91 4.13 Favored 'General case' 0 N--CA 1.454 -0.253 0 CA-C-N 119.742 1.771 . . . . 0.0 108.586 178.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 21.5 pttp -51.66 139.56 20.64 Favored 'General case' 0 N--CA 1.45 -0.44 0 C-N-CA 124.795 1.238 . . . . 0.0 113.926 -178.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 38.1 mt -93.54 133.39 34.82 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.405 0 N-CA-C 105.199 -2.149 . . . . 0.0 105.199 176.784 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 60.7 t -119.21 94.76 3.22 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.202 0 C-N-CA 124.453 1.101 . . . . 0.0 108.49 -178.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -83.27 98.94 9.68 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 122.857 0.463 . . . . 0.0 109.948 -179.384 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 24.3 ttmm -88.35 128.47 35.5 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 125.055 1.342 . . . . 0.0 112.114 -177.653 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 4.8 t30 -67.01 93.82 0.3 Allowed 'General case' 0 CA--C 1.534 0.363 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 177.019 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 42.5 t30 -85.39 -75.77 0.35 Allowed 'General case' 0 C--O 1.228 -0.074 0 N-CA-C 113.162 0.801 . . . . 0.0 113.162 -175.871 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -143.98 163.67 32.82 Favored 'General case' 0 C--O 1.224 -0.277 0 C-N-CA 123.67 0.788 . . . . 0.0 109.79 -176.456 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 63.65 19.59 62.91 Favored Glycine 0 CA--C 1.535 1.297 0 O-C-N 121.906 -0.496 . . . . 0.0 112.697 -179.591 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.468 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 16.2 p90 -72.24 166.53 40.53 Favored Pre-proline 0 CA--C 1.546 0.799 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 177.483 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.468 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 95.4 Cg_endo -68.31 158.06 86.79 Favored 'Cis proline' 0 N--CA 1.447 -1.222 0 N-CA-C 115.754 1.405 . . . . 0.0 115.754 4.246 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 88.9 m-70 -150.74 171.32 17.37 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 114.643 -1.162 . . . . 0.0 109.459 -179.422 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 34.9 p-10 -159.61 173.2 16.46 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 104.663 -2.347 . . . . 0.0 104.663 175.423 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 36.8 t -129.19 111.55 23.03 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.245 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 -178.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.9 t -113.36 131.46 65.03 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.579 0 N-CA-C 106.547 -1.649 . . . . 0.0 106.547 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.41 ' CG ' HD12 ' A' ' 55' ' ' ILE . 67.8 m-85 -97.01 131.56 43.7 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 179.243 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -71.76 109.17 5.47 Favored 'General case' 0 N--CA 1.454 -0.26 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 -179.677 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -46.27 -31.97 2.82 Favored 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 115.279 1.585 . . . . 0.0 115.279 -178.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 20.0 m-20 -84.31 -17.96 37.85 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-N 118.518 0.599 . . . . 0.0 111.839 -179.356 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -118.91 59.36 0.83 Allowed 'General case' 0 CA--C 1.532 0.259 0 C-N-CA 124.657 1.183 . . . . 0.0 111.087 -177.078 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 25.0 pt -152.68 151.4 26.71 Favored Pre-proline 0 CA--C 1.531 0.24 0 C-N-CA 126.165 1.786 . . . . 0.0 106.224 176.746 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_endo -57.7 118.2 5.03 Favored 'Trans proline' 0 N--CA 1.453 -0.873 0 C-N-CA 122.316 2.01 . . . . 0.0 111.125 179.43 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -47.85 117.72 2.0 Allowed 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 124.996 1.318 . . . . 0.0 110.695 -179.611 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 128.54 -35.98 2.55 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 -178.504 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 34.7 t -77.4 109.27 11.77 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 46.2 t0 -64.29 112.09 2.91 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 122.676 0.39 . . . . 0.0 110.512 179.634 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.1 -40.05 14.54 Favored 'General case' 0 CA--C 1.528 0.106 0 C-N-CA 125.057 1.343 . . . . 0.0 111.626 178.644 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 55.4 t -61.3 -31.13 49.43 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.349 0 C-N-CA 123.348 0.659 . . . . 0.0 111.641 -179.027 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -78.62 -40.72 33.56 Favored 'General case' 0 C--O 1.227 -0.113 0 CA-C-N 118.515 0.598 . . . . 0.0 110.469 -178.7 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.41 HD12 ' CG ' ' A' ' 41' ' ' PHE . 35.4 pt -78.02 -33.74 18.55 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.252 0 N-CA-C 112.566 0.58 . . . . 0.0 112.566 -178.804 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 50.7 m -78.17 139.92 38.98 Favored 'General case' 0 N--CA 1.455 -0.201 0 N-CA-C 112.774 0.657 . . . . 0.0 112.774 -177.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.2 tmt? . . . . . 0 CA--C 1.538 0.513 0 N-CA-C 105.559 -2.015 . . . . 0.0 105.559 176.017 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 96.1 mt . . . . . 0 N--CA 1.454 -0.253 0 N-CA-C 106.588 -1.634 . . . . 0.0 106.588 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 74.8 mt -78.59 102.05 7.75 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 106.114 -1.81 . . . . 0.0 106.114 177.373 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 31.8 p-10 -83.26 -55.46 4.32 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 124.291 1.037 . . . . 0.0 112.311 -177.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.94 149.57 77.1 Favored Pre-proline 0 CA--C 1.533 0.289 0 C-N-CA 123.203 0.601 . . . . 0.0 111.185 -177.59 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -66.87 164.02 31.25 Favored 'Trans proline' 0 N--CA 1.454 -0.799 0 C-N-CA 122.406 2.071 . . . . 0.0 109.804 177.513 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 79.42 -38.77 2.08 Favored Glycine 0 CA--C 1.528 0.862 0 CA-C-O 118.55 -1.139 . . . . 0.0 113.947 176.295 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -39.86 123.91 1.67 Allowed 'General case' 0 CA--C 1.536 0.437 0 CA-C-N 118.495 1.147 . . . . 0.0 111.696 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 18.0 p -105.03 121.04 42.95 Favored 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 124.662 1.185 . . . . 0.0 112.647 -177.701 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 62.3 t80 -95.13 111.4 23.24 Favored 'General case' 0 N--CA 1.454 -0.239 0 N-CA-C 105.367 -2.086 . . . . 0.0 105.367 174.081 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -100.11 139.92 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 C-N-CA 123.219 0.608 . . . . 0.0 110.54 -177.448 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 11.6 p -146.67 139.28 19.64 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.174 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 176.626 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 14.2 m -126.61 99.01 5.62 Favored 'General case' 0 C--N 1.34 0.187 0 C-N-CA 122.918 0.487 . . . . 0.0 112.286 -176.067 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.423 ' H ' HD22 ' A' ' 74' ' ' LEU . 1.6 mm? -87.05 130.54 34.44 Favored 'General case' 0 N--CA 1.439 -0.984 0 C-N-CA 123.057 0.543 . . . . 0.0 111.666 178.329 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -100.9 -45.1 5.54 Favored 'General case' 0 N--CA 1.454 -0.227 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 174.549 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 4.6 m -65.52 115.64 5.96 Favored 'General case' 0 N--CA 1.446 -0.652 0 C-N-CA 124.808 1.243 . . . . 0.0 110.192 -178.231 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 25.9 pttm -63.93 153.59 36.53 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-N 115.159 -0.928 . . . . 0.0 110.896 178.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 147.08 -177.51 25.33 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.401 -1.08 . . . . 0.0 110.401 178.392 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 28.7 m -106.49 121.94 45.29 Favored 'General case' 0 N--CA 1.452 -0.327 0 N-CA-C 106.941 -1.503 . . . . 0.0 106.941 -179.024 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 16.4 m-85 -115.07 122.44 46.16 Favored 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 124.594 1.158 . . . . 0.0 109.735 -178.358 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 41.4 m -98.3 132.86 43.44 Favored 'General case' 0 C--O 1.234 0.248 0 N-CA-C 107.635 -1.246 . . . . 0.0 107.635 175.366 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 21.0 p90 -132.62 165.68 23.88 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-O 121.638 0.732 . . . . 0.0 111.842 -179.438 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 52.4 p90 -156.56 161.92 39.94 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 115.226 -0.897 . . . . 0.0 112.561 -178.601 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.7 t -103.36 99.97 9.83 Favored 'General case' 0 CA--C 1.516 -0.333 0 N-CA-C 106.454 -1.684 . . . . 0.0 106.454 177.177 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.281 13.1 p -35.84 -64.31 0.35 Allowed Pre-proline 0 CA--C 1.541 0.63 0 N-CA-C 115.861 1.8 . . . . 0.0 115.861 -175.654 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -60.68 -7.25 6.99 Favored 'Trans proline' 0 C--N 1.348 0.506 0 C-N-CA 122.663 2.242 . . . . 0.0 115.221 -177.82 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 36.2 m80 -132.09 15.83 4.65 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 119.674 1.125 . . . . 0.0 110.814 178.22 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 65.6 tt0 -59.5 -46.57 88.45 Favored 'General case' 0 CA--C 1.529 0.163 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 178.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -57.07 -30.45 60.63 Favored Glycine 0 CA--C 1.531 1.082 0 C-N-CA 123.588 0.613 . . . . 0.0 111.579 177.613 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -86.08 8.15 21.91 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 123.599 0.759 . . . . 0.0 111.347 178.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 81.67 16.33 73.44 Favored Glycine 0 CA--C 1.527 0.839 0 CA-C-O 118.762 -1.021 . . . . 0.0 113.371 178.722 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 20.0 ttt -78.25 77.12 4.75 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 119.525 1.663 . . . . 0.0 108.925 178.754 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.7 m -125.8 170.81 15.33 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.314 0 C-N-CA 125.901 1.68 . . . . 0.0 110.052 179.43 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -170.07 177.27 43.5 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 109.262 -1.535 . . . . 0.0 109.262 177.804 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 59.4 mttp -145.98 157.53 43.88 Favored 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 123.401 0.68 . . . . 0.0 109.677 -178.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.2 p -147.25 130.6 8.77 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 C-N-CA 122.689 0.396 . . . . 0.0 110.417 178.007 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 99.1 m -98.49 102.65 14.46 Favored 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 124.171 0.988 . . . . 0.0 108.85 178.579 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 48.8 t -83.2 132.29 31.75 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.444 0 N-CA-C 105.797 -1.927 . . . . 0.0 105.797 178.686 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.334 -0.106 0 CA-C-N 118.395 0.543 . . . . 0.0 111.416 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 . . . . . 0 N--CA 1.452 -0.326 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 28.1 t -110.88 112.25 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.238 0 C-N-CA 123.695 0.798 . . . . 0.0 110.305 -177.505 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 53.6 mt -80.29 123.78 28.27 Favored 'General case' 0 N--CA 1.451 -0.403 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 178.427 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 64.9 mt -87.08 110.73 20.3 Favored 'General case' 0 N--CA 1.447 -0.575 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 178.566 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 84.61 126.37 1.45 Allowed Glycine 0 C--N 1.337 0.594 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.709 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 6.1 p -77.64 161.43 27.81 Favored 'General case' 0 N--CA 1.442 -0.827 0 O-C-N 121.48 -1.012 . . . . 0.0 108.689 -179.099 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -44.32 -38.66 5.18 Favored Glycine 0 CA--C 1.531 1.085 0 C-N-CA 125.777 1.656 . . . . 0.0 113.822 -178.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -76.31 4.08 9.6 Favored 'General case' 0 CA--C 1.537 0.48 0 N-CA-C 113.267 0.84 . . . . 0.0 113.267 -179.647 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 86.73 -6.16 83.33 Favored Glycine 0 CA--C 1.529 0.965 0 CA-C-O 118.92 -0.933 . . . . 0.0 113.105 -179.626 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 20.7 t -61.67 135.81 57.76 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-N 119.233 1.517 . . . . 0.0 110.457 -179.108 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 58.1 mt -75.94 65.93 2.09 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 126.064 1.746 . . . . 0.0 111.465 -176.556 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 28.7 m -130.94 152.5 37.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 C-N-CA 123.772 0.829 . . . . 0.0 110.436 179.547 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 73.3 m-85 -89.34 138.07 31.77 Favored 'General case' 0 N--CA 1.455 -0.222 0 N-CA-C 104.973 -2.232 . . . . 0.0 104.973 176.102 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 52.5 t -125.65 105.64 26.91 Favored Pre-proline 0 CA--C 1.537 0.457 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 179.009 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -68.23 158.44 86.05 Favored 'Cis proline' 0 C--N 1.347 0.466 0 CA-C-N 120.031 1.047 . . . . 0.0 111.799 -1.023 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.7 p -84.77 -63.65 1.3 Allowed 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 125.039 1.336 . . . . 0.0 108.907 179.672 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -117.8 135.66 53.92 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 125.102 1.361 . . . . 0.0 107.435 178.541 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 43.4 p90 -158.59 175.34 13.78 Favored 'General case' 0 C--N 1.333 -0.127 0 CA-C-O 121.22 0.533 . . . . 0.0 111.724 -178.455 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 24.0 p -128.33 147.18 50.61 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 107.19 -1.411 . . . . 0.0 107.19 178.358 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.0 p -149.93 140.46 14.06 Favored Pre-proline 0 CA--C 1.537 0.456 0 CA-C-N 118.843 0.747 . . . . 0.0 110.662 -178.08 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -52.87 138.79 60.76 Favored 'Trans proline' 0 CA--C 1.538 0.706 0 C-N-CA 122.609 2.206 . . . . 0.0 112.44 176.378 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 23.5 m -57.96 131.85 51.66 Favored 'General case' 0 CA--C 1.53 0.191 0 C-N-CA 122.875 0.47 . . . . 0.0 111.125 179.601 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 101.52 -18.1 54.0 Favored Glycine 0 CA--C 1.526 0.774 0 CA-C-O 119.156 -0.802 . . . . 0.0 112.92 179.57 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 81.5 mm-40 -68.7 156.5 38.12 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-N 119.075 1.438 . . . . 0.0 112.823 -179.198 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 24.0 ttmm -91.49 142.05 28.08 Favored 'General case' 0 N--CA 1.452 -0.372 0 C-N-CA 125.965 1.706 . . . . 0.0 110.14 -179.786 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 40.6 mt -120.88 134.42 64.35 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.343 0 N-CA-C 105.929 -1.878 . . . . 0.0 105.929 178.307 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 97.6 t -124.15 101.53 9.25 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 C-N-CA 125.236 1.414 . . . . 0.0 108.571 -177.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -86.25 136.19 33.26 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 106.115 -1.809 . . . . 0.0 106.115 176.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 12.1 tmtt? -135.27 132.46 37.81 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 118.986 0.812 . . . . 0.0 112.4 -177.369 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 6.2 m-20 -66.47 101.4 0.76 Allowed 'General case' 0 C--N 1.341 0.203 0 C-N-CA 123.69 0.796 . . . . 0.0 108.886 177.77 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 38.7 t30 -92.38 -61.84 1.53 Allowed 'General case' 0 N--CA 1.455 -0.224 0 CA-C-O 121.34 0.59 . . . . 0.0 109.951 -179.663 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -150.77 -179.47 7.29 Favored 'General case' 0 C--O 1.223 -0.299 0 C-N-CA 124.065 0.946 . . . . 0.0 108.898 -179.029 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 52.72 17.12 4.41 Favored Glycine 0 CA--C 1.538 1.503 0 N-CA-C 115.534 0.973 . . . . 0.0 115.534 178.574 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.449 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 14.5 p90 -73.85 167.62 33.61 Favored Pre-proline 0 CA--C 1.539 0.531 0 N-CA-C 106.921 -1.511 . . . . 0.0 106.921 178.535 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.449 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 33.0 Cg_exo -63.4 157.87 67.55 Favored 'Cis proline' 0 N--CA 1.454 -0.82 0 N-CA-C 117.407 2.041 . . . . 0.0 117.407 2.638 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 90.8 m-70 -152.47 169.0 23.67 Favored 'General case' 0 N--CA 1.453 -0.3 0 O-C-N 121.598 -0.689 . . . . 0.0 111.638 179.843 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 51.4 p30 -162.15 178.64 8.59 Favored 'General case' 0 N--CA 1.452 -0.332 0 N-CA-C 104.606 -2.368 . . . . 0.0 104.606 174.707 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 34.8 t -135.46 123.4 37.7 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 71.1 t -123.07 139.27 50.35 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.58 0 N-CA-C 105.558 -2.016 . . . . 0.0 105.558 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.406 ' CG ' HD12 ' A' ' 55' ' ' ILE . 80.5 m-85 -103.99 135.37 45.63 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 108.165 -1.05 . . . . 0.0 108.165 -179.918 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -66.44 122.08 16.73 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 -179.482 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -74.43 50.2 0.4 Allowed 'General case' 0 CA--C 1.538 0.511 0 N-CA-C 113.956 1.095 . . . . 0.0 113.956 -178.509 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -161.7 -64.79 0.05 Allowed 'General case' 0 N--CA 1.456 -0.129 0 C-N-CA 125.19 1.396 . . . . 0.0 108.987 177.3 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -83.0 63.81 7.28 Favored 'General case' 0 CA--C 1.538 0.496 0 CA-C-O 122.069 0.938 . . . . 0.0 110.274 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 26.8 pt -145.3 153.63 52.54 Favored Pre-proline 0 CA--C 1.536 0.408 0 C-N-CA 129.763 3.225 . . . . 0.0 105.523 177.019 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo -57.92 114.81 2.12 Favored 'Trans proline' 0 N--CA 1.455 -0.79 0 C-N-CA 121.628 1.552 . . . . 0.0 111.699 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -48.11 112.07 0.53 Allowed 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 125.384 1.474 . . . . 0.0 110.735 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 131.12 -34.08 2.69 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 109.721 -1.351 . . . . 0.0 109.721 -178.822 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 42.8 t -77.32 111.48 14.17 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.23 0 CA-C-N 117.565 0.683 . . . . 0.0 109.214 -179.863 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 40.7 t0 -64.23 109.86 2.01 Favored 'General case' 0 CA--C 1.532 0.277 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 178.734 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.51 -38.79 14.68 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 125.131 1.372 . . . . 0.0 111.97 179.508 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 60.0 t -60.63 -28.9 43.73 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.311 0 C-N-CA 123.331 0.653 . . . . 0.0 111.789 -179.109 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 47.1 mmtm -75.84 -40.99 53.73 Favored 'General case' 0 CA--C 1.53 0.197 0 CA-C-N 118.571 0.623 . . . . 0.0 110.688 -178.408 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.406 HD12 ' CG ' ' A' ' 41' ' ' PHE . 21.5 pt -80.68 -38.75 17.67 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.289 0 N-CA-C 112.576 0.584 . . . . 0.0 112.576 -179.463 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 31.5 m -76.9 135.5 38.81 Favored 'General case' 0 N--CA 1.454 -0.252 0 N-CA-C 114.0 1.111 . . . . 0.0 114.0 -176.085 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 84.7 mtp . . . . . 0 N--CA 1.449 -0.524 0 N-CA-C 104.721 -2.326 . . . . 0.0 104.721 173.218 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.444 -0.725 0 CA-C-O 121.463 0.649 . . . . 0.0 110.934 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 47.3 mt -80.69 106.12 12.45 Favored 'General case' 0 N--CA 1.441 -0.885 0 N-CA-C 103.561 -2.755 . . . . 0.0 103.561 177.671 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 29.0 p-10 -89.19 -38.19 14.46 Favored 'General case' 0 C--N 1.332 -0.16 0 C-N-CA 124.803 1.241 . . . . 0.0 113.153 -176.732 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.68 155.89 45.38 Favored Pre-proline 0 CA--C 1.534 0.344 0 C-N-CA 123.895 0.878 . . . . 0.0 110.882 -178.054 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -66.11 164.68 26.78 Favored 'Trans proline' 0 N--CA 1.456 -0.702 0 C-N-CA 122.419 2.079 . . . . 0.0 109.753 176.629 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 79.73 -44.03 2.69 Favored Glycine 0 CA--C 1.528 0.86 0 CA-C-O 118.78 -1.011 . . . . 0.0 113.59 176.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 53.7 mt-10 -41.19 134.03 2.2 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 124.959 1.304 . . . . 0.0 111.686 -179.399 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 69.0 p -114.18 167.71 10.45 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 123.826 0.85 . . . . 0.0 113.268 -177.147 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 3.7 t80 -140.65 114.41 8.9 Favored 'General case' 0 N--CA 1.455 -0.213 0 N-CA-C 103.849 -2.649 . . . . 0.0 103.849 174.717 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 41.3 t -106.82 144.78 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.296 0 C-N-CA 123.703 0.801 . . . . 0.0 109.638 -177.4 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 13.7 p -152.02 167.25 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.204 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 177.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 57.2 m -145.88 122.72 11.28 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 105.765 -1.939 . . . . 0.0 105.765 179.49 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 66.3 mt -107.08 99.56 9.1 Favored 'General case' 0 N--CA 1.455 -0.192 0 CA-C-O 121.303 0.573 . . . . 0.0 111.389 -175.168 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -77.14 -47.14 21.2 Favored 'General case' 0 N--CA 1.455 -0.217 0 C-N-CA 123.835 0.854 . . . . 0.0 110.539 178.143 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.7 m -72.48 122.82 21.93 Favored 'General case' 0 N--CA 1.451 -0.382 0 C-N-CA 123.012 0.525 . . . . 0.0 110.599 -177.664 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 50.6 tttm -67.02 155.18 39.32 Favored 'General case' 0 N--CA 1.436 -1.168 0 C-N-CA 126.906 2.082 . . . . 0.0 110.316 179.177 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 132.8 178.24 15.42 Favored Glycine 0 CA--C 1.526 0.761 0 C-N-CA 124.798 1.19 . . . . 0.0 111.378 178.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 74.7 m -102.13 119.83 39.44 Favored 'General case' 0 CA--C 1.52 -0.201 0 C-N-CA 124.119 0.968 . . . . 0.0 108.756 -179.283 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 37.2 m-85 -105.92 112.65 25.79 Favored 'General case' 0 N--CA 1.445 -0.681 0 C-N-CA 125.794 1.638 . . . . 0.0 109.833 -179.035 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 4.1 m -85.87 128.7 34.88 Favored 'General case' 0 C--O 1.234 0.28 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 177.368 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 35.4 p90 -132.19 167.65 19.42 Favored 'General case' 0 N--CA 1.457 -0.1 0 CA-C-O 121.822 0.82 . . . . 0.0 112.562 -179.142 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 50.5 p90 -159.96 162.48 34.41 Favored 'General case' 0 N--CA 1.452 -0.372 0 CA-C-N 114.977 -1.01 . . . . 0.0 111.569 -179.37 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.2 t -99.6 102.9 14.55 Favored 'General case' 0 CA--C 1.518 -0.279 0 N-CA-C 106.575 -1.639 . . . . 0.0 106.575 177.52 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.312 16.9 p -40.44 -61.2 1.25 Allowed Pre-proline 0 CA--C 1.538 0.518 0 N-CA-C 115.795 1.776 . . . . 0.0 115.795 -174.489 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -60.12 -6.09 4.66 Favored 'Trans proline' 0 CA--C 1.537 0.638 0 C-N-CA 122.208 1.939 . . . . 0.0 114.924 -178.751 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 35.8 m80 -134.43 14.24 3.78 Favored 'General case' 0 CA--C 1.532 0.254 0 CA-C-N 119.694 1.134 . . . . 0.0 111.355 178.671 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 16.6 pt20 -60.66 -42.83 97.82 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 119.147 0.885 . . . . 0.0 109.217 179.259 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -58.48 -31.39 66.61 Favored Glycine 0 CA--C 1.531 1.071 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 177.18 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -85.12 5.25 30.61 Favored 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 123.556 0.743 . . . . 0.0 111.333 178.91 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 83.89 17.24 65.89 Favored Glycine 0 CA--C 1.528 0.849 0 CA-C-O 118.795 -1.003 . . . . 0.0 113.591 178.726 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 21.8 ttt -78.72 77.16 5.21 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 119.593 1.696 . . . . 0.0 108.494 178.144 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 11.6 m -120.24 169.95 10.69 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 C-N-CA 125.984 1.714 . . . . 0.0 110.404 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -169.45 174.19 43.79 Favored Glycine 0 CA--C 1.527 0.83 0 N-CA-C 109.108 -1.597 . . . . 0.0 109.108 178.112 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 54.2 mttp -149.4 139.04 21.71 Favored 'General case' 0 C--O 1.231 0.083 0 CA-C-N 118.173 0.986 . . . . 0.0 109.756 -178.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 6.0 p -125.66 120.17 56.83 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.139 0 CA-C-O 120.921 0.391 . . . . 0.0 110.519 178.798 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 48.6 m -94.22 100.58 12.63 Favored 'General case' 0 N--CA 1.455 -0.203 0 C-N-CA 124.68 1.192 . . . . 0.0 109.342 178.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 44.7 t -79.69 107.09 11.73 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.012 0 N-CA-C 104.397 -2.445 . . . . 0.0 104.397 179.536 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 51.1 p-10 . . . . . 0 N--CA 1.456 -0.16 0 C-N-CA 125.157 1.383 . . . . 0.0 110.291 -177.034 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 . . . . . 0 N--CA 1.453 -0.294 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 47.1 t -112.24 111.0 34.28 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 105.855 -1.906 . . . . 0.0 105.855 178.517 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 31.7 mt -90.46 120.4 31.54 Favored 'General case' 0 N--CA 1.45 -0.462 0 O-C-N 121.822 -0.549 . . . . 0.0 109.706 -178.68 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.434 ' HB3' ' CD2' ' A' ' 37' ' ' HIS . 1.9 mm? -79.47 106.88 11.82 Favored 'General case' 0 N--CA 1.444 -0.738 0 N-CA-C 105.909 -1.886 . . . . 0.0 105.909 174.378 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 97.03 132.8 7.54 Favored Glycine 0 CA--C 1.523 0.586 0 C-N-CA 125.871 1.701 . . . . 0.0 112.329 178.666 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.6 p -82.78 47.87 1.26 Allowed 'General case' 0 N--CA 1.456 -0.135 0 C-N-CA 124.43 1.092 . . . . 0.0 111.197 179.325 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 70.74 -52.2 0.91 Allowed Glycine 0 CA--C 1.527 0.781 0 C-N-CA 126.598 2.047 . . . . 0.0 113.078 -179.668 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -72.1 38.07 0.07 Allowed 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 126.05 1.74 . . . . 0.0 113.851 -177.298 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 59.17 3.04 1.62 Allowed Glycine 0 CA--C 1.531 1.075 0 N-CA-C 115.911 1.124 . . . . 0.0 115.911 178.569 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 27.7 t -64.31 145.45 56.0 Favored 'General case' 0 N--CA 1.455 -0.181 0 CA-C-N 119.131 1.465 . . . . 0.0 110.87 -178.661 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 93.0 mt -86.43 73.26 10.16 Favored 'General case' 0 N--CA 1.447 -0.58 0 C-N-CA 124.044 0.938 . . . . 0.0 109.482 -178.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.9 m -137.01 143.97 33.4 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.217 0 C-N-CA 123.05 0.54 . . . . 0.0 111.204 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -90.27 122.84 33.55 Favored 'General case' 0 N--CA 1.46 0.051 0 N-CA-C 103.695 -2.706 . . . . 0.0 103.695 174.865 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.8 t -113.94 100.56 52.62 Favored Pre-proline 0 CA--C 1.536 0.422 0 CA-C-O 118.237 -0.887 . . . . 0.0 109.984 -179.271 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -81.01 164.24 78.26 Favored 'Cis proline' 0 N--CA 1.46 -0.463 0 CA-C-N 120.605 1.252 . . . . 0.0 111.257 -1.618 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 15.7 p -92.61 -62.86 1.31 Allowed 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 107.576 -1.268 . . . . 0.0 107.576 177.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 10.8 mp0 -98.21 126.85 43.85 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 125.835 1.654 . . . . 0.0 107.532 178.428 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.9 p90 -160.55 -175.57 5.08 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-O 121.541 0.686 . . . . 0.0 111.847 179.631 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 35.3 m -135.97 146.07 46.85 Favored 'General case' 0 N--CA 1.45 -0.426 0 N-CA-C 106.204 -1.776 . . . . 0.0 106.204 178.245 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 1.4 p -147.21 140.56 15.02 Favored Pre-proline 0 N--CA 1.449 -0.496 0 CA-C-O 118.367 -0.825 . . . . 0.0 109.631 -178.343 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_exo -60.71 144.13 99.5 Favored 'Trans proline' 0 N--CA 1.456 -0.689 0 C-N-CA 121.671 1.58 . . . . 0.0 112.678 179.411 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.2 m -56.35 128.0 33.7 Favored 'General case' 0 N--CA 1.454 -0.233 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 176.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.76 -3.57 78.1 Favored Glycine 0 CA--C 1.526 0.719 0 CA-C-O 119.012 -0.882 . . . . 0.0 112.198 179.35 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -70.64 149.3 47.17 Favored 'General case' 0 CA--C 1.534 0.361 0 CA-C-N 119.033 1.417 . . . . 0.0 109.124 178.025 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -90.44 105.09 17.58 Favored 'General case' 0 N--CA 1.447 -0.582 0 C-N-CA 124.868 1.267 . . . . 0.0 108.585 -178.563 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 34.6 mt -81.09 130.7 35.43 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.343 0 N-CA-C 105.381 -2.081 . . . . 0.0 105.381 177.364 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 67.9 t -117.69 97.58 5.58 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 C-N-CA 124.904 1.281 . . . . 0.0 108.665 -178.439 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -84.47 97.16 9.38 Favored 'General case' 0 N--CA 1.456 -0.158 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 178.011 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 28.4 ttpp -99.3 129.29 45.5 Favored 'General case' 0 CA--C 1.528 0.126 0 C-N-CA 123.746 0.818 . . . . 0.0 112.691 -176.444 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 5.2 m-20 -69.63 105.3 2.64 Favored 'General case' 0 N--CA 1.455 -0.2 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 177.456 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 51.5 t30 -89.17 -57.42 2.9 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 178.466 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -164.37 175.28 10.14 Favored 'General case' 0 CA--C 1.529 0.167 0 C-N-CA 124.095 0.958 . . . . 0.0 109.328 179.802 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 71.09 16.07 74.78 Favored Glycine 0 CA--C 1.531 1.084 0 O-C-N 121.753 -0.592 . . . . 0.0 113.095 179.19 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.508 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 21.5 p90 -67.77 166.4 23.24 Favored Pre-proline 0 CA--C 1.545 0.785 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 178.178 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.508 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 83.5 Cg_endo -69.7 151.4 91.26 Favored 'Cis proline' 0 N--CA 1.447 -1.23 0 N-CA-C 116.395 1.652 . . . . 0.0 116.395 5.161 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.434 ' CD2' ' HB3' ' A' ' 5' ' ' LEU . 88.8 m-70 -144.93 156.92 44.24 Favored 'General case' 0 N--CA 1.451 -0.387 0 O-C-N 121.695 -0.628 . . . . 0.0 111.093 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 56.6 p30 -158.18 175.52 13.66 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 103.966 -2.605 . . . . 0.0 103.966 175.287 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 42.0 t -137.98 121.08 20.12 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.36 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 -179.027 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 95.9 t -117.33 131.9 68.69 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.621 0 N-CA-C 105.83 -1.915 . . . . 0.0 105.83 178.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -96.91 131.2 43.92 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 107.24 -1.393 . . . . 0.0 107.24 179.425 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 35.6 t0 -67.21 108.74 2.81 Favored 'General case' 0 N--CA 1.451 -0.393 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 -179.131 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -47.82 -31.33 4.84 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.028 0.931 . . . . 0.0 113.45 178.865 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 34.4 t70 -75.74 -22.38 56.57 Favored 'General case' 0 CA--C 1.536 0.426 0 N-CA-C 112.741 0.645 . . . . 0.0 112.741 179.563 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -128.39 68.07 1.37 Allowed 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 124.453 1.101 . . . . 0.0 111.791 -177.042 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 31.8 pt -153.67 157.34 32.66 Favored Pre-proline 0 CA--C 1.535 0.371 0 C-N-CA 127.884 2.474 . . . . 0.0 105.79 175.825 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_exo -56.33 115.62 2.6 Favored 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.559 2.173 . . . . 0.0 111.07 178.391 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.34 107.33 0.27 Allowed 'General case' 0 N--CA 1.455 -0.178 0 C-N-CA 123.608 0.763 . . . . 0.0 109.676 179.569 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 137.79 -32.29 2.39 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 -177.805 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 57.3 t -76.84 107.37 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.262 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 179.354 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 45.0 t0 -57.99 108.15 0.56 Allowed 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 123.252 0.621 . . . . 0.0 110.777 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.63 -38.6 32.77 Favored 'General case' 0 C--O 1.223 -0.295 0 C-N-CA 123.73 0.812 . . . . 0.0 111.228 178.883 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 46.7 t -58.67 -27.22 33.76 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 CA-C-N 118.071 0.396 . . . . 0.0 111.863 -179.44 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 44.0 mmtm -82.55 -41.93 18.98 Favored 'General case' 0 CA--C 1.529 0.172 0 CA-C-N 118.611 0.641 . . . . 0.0 110.839 -179.392 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 24.6 pt -78.03 -46.9 25.83 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.29 0 N-CA-C 112.005 0.372 . . . . 0.0 112.005 -179.29 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 60.7 m -73.22 128.41 35.4 Favored 'General case' 0 N--CA 1.451 -0.422 0 C-N-CA 124.224 1.01 . . . . 0.0 113.01 -176.018 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 88.4 mmm . . . . . 0 N--CA 1.451 -0.422 0 N-CA-C 105.401 -2.074 . . . . 0.0 105.401 174.661 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.448 -0.555 0 CA-C-O 121.713 0.768 . . . . 0.0 112.292 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 63.0 mt -79.02 106.03 10.77 Favored 'General case' 0 N--CA 1.444 -0.749 0 N-CA-C 104.862 -2.273 . . . . 0.0 104.862 178.151 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 65.6 t30 -112.29 42.14 1.86 Allowed 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 124.259 1.024 . . . . 0.0 112.747 -177.732 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -158.0 158.26 29.97 Favored Pre-proline 0 C--O 1.233 0.186 0 N-CA-C 107.045 -1.465 . . . . 0.0 107.045 178.366 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 96.8 Cg_endo -73.92 167.78 26.39 Favored 'Trans proline' 0 N--CA 1.451 -0.999 0 C-N-CA 121.542 1.495 . . . . 0.0 109.313 178.242 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 78.63 -42.65 2.26 Favored Glycine 0 CA--C 1.527 0.84 0 CA-C-O 118.74 -1.033 . . . . 0.0 114.411 175.756 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 47.7 mt-10 -42.4 131.57 3.69 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 118.494 1.147 . . . . 0.0 112.442 -179.609 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 20.8 p -118.33 127.4 53.66 Favored 'General case' 0 N--CA 1.457 -0.122 0 N-CA-C 113.675 0.991 . . . . 0.0 113.675 -178.554 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 2.4 t80 -100.15 107.16 18.97 Favored 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 103.682 -2.71 . . . . 0.0 103.682 172.367 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 38.8 t -100.08 140.11 19.99 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.162 0 C-N-CA 123.415 0.686 . . . . 0.0 109.674 -178.026 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.2 p -150.31 135.03 9.69 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.254 0 C-N-CA 122.766 0.426 . . . . 0.0 110.319 177.847 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 19.7 m -103.57 100.4 10.24 Favored 'General case' 0 CA--C 1.53 0.207 0 C-N-CA 124.59 1.156 . . . . 0.0 109.0 -179.595 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 59.5 mt -90.19 99.73 12.69 Favored 'General case' 0 CA--C 1.53 0.192 0 CA-C-O 121.074 0.464 . . . . 0.0 109.82 -179.555 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -79.13 -55.34 5.18 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 123.216 0.606 . . . . 0.0 111.27 178.863 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.5 m -64.58 119.48 10.56 Favored 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 123.386 0.674 . . . . 0.0 110.388 -176.119 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.86 161.5 20.98 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 123.449 0.7 . . . . 0.0 112.373 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 133.87 178.77 15.83 Favored Glycine 0 CA--C 1.525 0.718 0 C-N-CA 125.565 1.555 . . . . 0.0 110.74 178.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 7.4 m -96.29 114.55 26.24 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 124.417 1.087 . . . . 0.0 109.336 -178.531 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 29.8 m-85 -105.09 111.05 23.67 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 124.684 1.193 . . . . 0.0 109.217 179.73 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 18.3 m -88.01 137.58 32.21 Favored 'General case' 0 C--O 1.232 0.172 0 N-CA-C 107.517 -1.29 . . . . 0.0 107.517 177.379 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 28.5 p90 -140.95 167.24 22.67 Favored 'General case' 0 C--N 1.339 0.124 0 CA-C-N 119.06 0.845 . . . . 0.0 113.266 -178.177 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 53.7 p90 -154.31 160.49 41.77 Favored 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 114.924 -1.034 . . . . 0.0 112.202 -179.658 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.6 t -104.24 99.31 9.03 Favored 'General case' 0 CA--C 1.519 -0.241 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 177.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -33.79 -62.99 0.33 Allowed Pre-proline 0 CA--C 1.537 0.45 0 N-CA-C 115.927 1.825 . . . . 0.0 115.927 -176.296 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -60.4 -7.04 6.19 Favored 'Trans proline' 0 C--N 1.348 0.546 0 C-N-CA 122.307 2.005 . . . . 0.0 114.92 -177.558 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 36.3 m80 -135.62 14.65 3.42 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 119.416 1.007 . . . . 0.0 111.124 178.505 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 14.6 pt20 -61.04 -41.24 96.2 Favored 'General case' 0 N--CA 1.454 -0.262 0 O-C-N 121.442 -0.786 . . . . 0.0 109.489 179.531 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -58.46 -29.45 63.59 Favored Glycine 0 CA--C 1.532 1.119 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 177.039 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.91 11.86 19.13 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 123.804 0.842 . . . . 0.0 110.864 178.798 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 74.47 21.87 78.18 Favored Glycine 0 CA--C 1.527 0.8 0 CA-C-O 119.112 -0.826 . . . . 0.0 113.171 178.877 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -78.86 80.55 5.2 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 119.255 1.528 . . . . 0.0 107.464 178.156 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 12.4 m -123.49 171.76 11.94 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 C-N-CA 125.579 1.552 . . . . 0.0 111.691 -178.851 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -167.12 178.79 41.15 Favored Glycine 0 CA--C 1.529 0.948 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 178.18 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 39.1 ttpt -158.48 130.57 6.82 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 -178.518 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.7 p -119.25 128.27 75.83 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 CA-C-O 121.391 0.615 . . . . 0.0 110.346 -178.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.4 m -94.37 98.78 11.13 Favored 'General case' 0 N--CA 1.452 -0.336 0 N-CA-C 107.514 -1.291 . . . . 0.0 107.514 179.151 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 45.2 t -80.31 114.28 20.97 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.587 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 -178.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 77.7 m-20 . . . . . 0 C--O 1.233 0.212 0 C-N-CA 123.664 0.785 . . . . 0.0 109.085 -178.112 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 36.4 mt-10 . . . . . 0 N--CA 1.451 -0.378 0 N-CA-C 105.612 -1.996 . . . . 0.0 105.612 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 28.3 t -87.22 119.29 34.69 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.454 0 CA-C-N 114.968 -1.015 . . . . 0.0 108.923 -176.757 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 58.1 mt -88.27 121.47 30.7 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 179.189 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.414 ' HB3' ' CD2' ' A' ' 37' ' ' HIS . 1.4 mm? -78.01 103.18 7.78 Favored 'General case' 0 N--CA 1.445 -0.685 0 N-CA-C 105.815 -1.92 . . . . 0.0 105.815 173.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 97.1 152.31 28.6 Favored Glycine 0 N--CA 1.446 -0.675 0 C-N-CA 123.91 0.766 . . . . 0.0 111.331 179.083 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 78.9 p -85.59 173.46 10.15 Favored 'General case' 0 N--CA 1.44 -0.938 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 177.783 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -52.51 -43.94 58.97 Favored Glycine 0 CA--C 1.531 1.07 0 N-CA-C 111.265 -0.734 . . . . 0.0 111.265 178.679 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -79.81 11.78 3.05 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 123.362 0.665 . . . . 0.0 112.316 178.76 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 69.44 27.46 73.51 Favored Glycine 0 CA--C 1.524 0.639 0 CA-C-O 119.07 -0.85 . . . . 0.0 114.009 178.712 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 27.1 t -73.42 145.21 45.98 Favored 'General case' 0 C--N 1.34 0.155 0 N-CA-C 106.084 -1.821 . . . . 0.0 106.084 176.899 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 76.1 mt -76.12 64.75 2.01 Favored 'General case' 0 N--CA 1.449 -0.482 0 C-N-CA 124.363 1.065 . . . . 0.0 111.798 -176.102 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.2 m -132.89 139.45 49.6 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.215 0 C-N-CA 124.069 0.948 . . . . 0.0 111.268 -179.124 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 36.2 m-85 -82.83 129.52 35.01 Favored 'General case' 0 C--O 1.232 0.171 0 N-CA-C 104.314 -2.476 . . . . 0.0 104.314 175.201 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 25.2 t -117.84 105.2 47.93 Favored Pre-proline 0 CA--C 1.535 0.368 0 CA-C-O 118.168 -0.92 . . . . 0.0 108.963 179.561 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -75.13 164.81 87.47 Favored 'Cis proline' 0 C--N 1.348 0.518 0 CA-C-N 120.482 1.208 . . . . 0.0 111.505 -1.332 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 7.0 p -90.4 -62.29 1.49 Allowed 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 125.352 1.461 . . . . 0.0 108.655 179.207 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -106.42 137.48 44.32 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 126.313 1.845 . . . . 0.0 106.366 177.174 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 18.0 p90 -163.63 -174.73 3.82 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 118.38 0.536 . . . . 0.0 110.871 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 24.2 m -140.1 149.19 42.77 Favored 'General case' 0 N--CA 1.455 -0.212 0 C-N-CA 124.783 1.233 . . . . 0.0 108.813 -178.636 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 29.0 m -148.88 151.68 35.45 Favored Pre-proline 0 N--CA 1.463 0.2 0 C-N-CA 123.585 0.754 . . . . 0.0 110.332 -179.695 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -70.94 150.19 60.63 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 C-N-CA 121.778 1.652 . . . . 0.0 110.135 176.309 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 60.0 m -55.04 118.84 4.66 Favored 'General case' 0 CA--C 1.53 0.187 0 C-N-CA 123.308 0.643 . . . . 0.0 109.329 177.754 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 106.01 -5.6 39.51 Favored Glycine 0 CA--C 1.528 0.894 0 CA-C-O 118.877 -0.957 . . . . 0.0 112.802 -179.159 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -59.58 136.3 57.94 Favored 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 119.41 1.605 . . . . 0.0 110.623 179.374 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -90.98 93.15 9.07 Favored 'General case' 0 N--CA 1.445 -0.7 0 N-CA-C 106.013 -1.847 . . . . 0.0 106.013 177.457 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 63.4 mt -75.2 137.84 22.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 -178.616 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 67.9 t -115.75 102.41 13.67 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.296 0 C-N-CA 124.659 1.184 . . . . 0.0 108.479 -178.239 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -90.16 101.62 14.33 Favored 'General case' 0 CA--C 1.53 0.177 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 177.805 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 26.7 ttpp -99.99 129.54 46.07 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 124.774 1.229 . . . . 0.0 112.633 -176.596 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 39.6 t30 -66.82 115.35 6.5 Favored 'General case' 0 CA--C 1.528 0.098 0 CA-C-O 118.805 -0.617 . . . . 0.0 110.342 177.856 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 43.6 t30 -97.04 -73.82 0.59 Allowed 'General case' 0 N--CA 1.457 -0.114 0 CA-C-O 121.111 0.481 . . . . 0.0 110.664 179.835 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -157.95 170.97 21.12 Favored 'General case' 0 C--N 1.332 -0.183 0 C-N-CA 124.783 1.233 . . . . 0.0 108.16 -177.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 71.59 17.57 76.54 Favored Glycine 0 CA--C 1.534 1.263 0 O-C-N 121.487 -0.758 . . . . 0.0 112.252 -178.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.519 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 7.4 p90 -72.09 170.49 12.39 Favored Pre-proline 0 CA--C 1.54 0.559 0 C-N-CA 125.946 1.698 . . . . 0.0 107.77 178.59 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.519 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 26.9 Cg_exo -64.99 152.07 76.22 Favored 'Cis proline' 0 N--CA 1.451 -0.982 0 N-CA-C 115.581 1.339 . . . . 0.0 115.581 2.19 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.414 ' CD2' ' HB3' ' A' ' 5' ' ' LEU . 87.6 m-70 -141.74 170.11 16.34 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 123.311 0.645 . . . . 0.0 109.485 179.235 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 46.7 p30 -168.71 177.4 5.14 Favored 'General case' 0 N--CA 1.451 -0.423 0 N-CA-C 104.109 -2.552 . . . . 0.0 104.109 175.706 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 39.6 t -135.95 112.43 13.09 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.274 0 N-CA-C 107.262 -1.384 . . . . 0.0 107.262 -179.063 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 48.4 t -116.96 133.35 63.96 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 N-CA-C 105.98 -1.859 . . . . 0.0 105.98 -179.141 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.436 ' CG ' HD12 ' A' ' 55' ' ' ILE . 55.0 m-85 -93.69 142.69 27.07 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -179.138 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -74.62 97.95 3.29 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.749 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -39.89 -35.97 0.41 Allowed 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 125.842 1.657 . . . . 0.0 115.324 -179.234 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -82.77 -27.64 30.88 Favored 'General case' 0 CA--C 1.535 0.375 0 N-CA-C 112.607 0.595 . . . . 0.0 112.607 -179.715 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 47.5 tt0 -112.22 61.28 0.63 Allowed 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 124.62 1.168 . . . . 0.0 111.438 -176.475 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 36.8 pt -157.01 158.3 31.12 Favored Pre-proline 0 CA--C 1.535 0.374 0 C-N-CA 128.468 2.707 . . . . 0.0 105.721 176.817 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -55.4 111.94 0.9 Allowed 'Trans proline' 0 N--CA 1.456 -0.717 0 C-N-CA 122.498 2.132 . . . . 0.0 109.59 175.537 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -33.08 -48.47 0.22 Allowed 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 126.855 2.062 . . . . 0.0 115.619 -177.517 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -58.87 -29.12 64.28 Favored Glycine 0 CA--C 1.533 1.182 0 O-C-N 122.131 -0.356 . . . . 0.0 113.78 -178.457 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 43.1 t -82.19 96.28 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 CA-C-N 118.154 0.977 . . . . 0.0 109.759 -178.193 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 6.7 t0 -52.77 116.71 2.46 Favored 'General case' 0 CA--C 1.535 0.392 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 176.706 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -46.77 -38.51 10.18 Favored 'General case' 0 N--CA 1.456 -0.17 0 C-N-CA 126.085 1.754 . . . . 0.0 112.552 -178.734 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 59.9 t -59.54 -28.17 39.31 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 C-N-CA 123.006 0.522 . . . . 0.0 111.443 -179.276 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 41.7 mtmt -74.28 -45.57 46.86 Favored 'General case' 0 CA--C 1.528 0.125 0 O-C-N 121.666 -0.646 . . . . 0.0 110.602 -179.111 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.436 HD12 ' CG ' ' A' ' 41' ' ' PHE . 25.6 pt -79.59 -32.81 14.72 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 N-CA-C 113.008 0.744 . . . . 0.0 113.008 -177.766 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 47.1 m -77.39 130.54 37.23 Favored 'General case' 0 N--CA 1.452 -0.327 0 C-N-CA 123.148 0.579 . . . . 0.0 112.035 -178.034 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.5 tmt? . . . . . 0 N--CA 1.449 -0.508 0 N-CA-C 104.869 -2.271 . . . . 0.0 104.869 175.738 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 5.1 mp . . . . . 0 N--CA 1.451 -0.397 0 CA-C-O 121.378 0.609 . . . . 0.0 110.745 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 59.9 mt -80.67 93.42 6.15 Favored 'General case' 0 N--CA 1.444 -0.735 0 N-CA-C 103.046 -2.946 . . . . 0.0 103.046 174.01 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -109.65 -42.2 4.36 Favored 'General case' 0 C--N 1.333 -0.116 0 C-N-CA 124.273 1.029 . . . . 0.0 111.22 -176.736 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.27 134.61 73.63 Favored Pre-proline 0 C--O 1.236 0.356 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 -178.694 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_exo -50.7 132.51 36.56 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 C-N-CA 122.571 2.181 . . . . 0.0 110.903 179.776 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 92.73 -15.09 63.42 Favored Glycine 0 CA--C 1.527 0.821 0 CA-C-O 117.325 -1.82 . . . . 0.0 115.782 176.918 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -52.76 125.54 17.12 Favored 'General case' 0 CA--C 1.537 0.457 0 CA-C-N 121.045 2.423 . . . . 0.0 110.923 179.302 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 12.1 p -105.26 122.46 45.98 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 125.827 1.651 . . . . 0.0 112.395 -178.725 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 54.3 t80 -103.85 108.35 19.64 Favored 'General case' 0 N--CA 1.454 -0.235 0 N-CA-C 105.984 -1.858 . . . . 0.0 105.984 174.301 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 15.8 t -96.65 136.93 25.84 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 -178.609 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.5 p -145.51 127.06 8.29 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.404 0 CA-C-N 118.428 0.558 . . . . 0.0 110.97 178.628 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 7.9 m -88.73 101.97 14.53 Favored 'General case' 0 CA--C 1.53 0.174 0 C-N-CA 125.45 1.5 . . . . 0.0 110.239 -179.489 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 22.4 mt -87.33 87.45 7.43 Favored 'General case' 0 N--CA 1.462 0.151 0 CA-C-N 118.585 0.63 . . . . 0.0 109.357 179.394 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -69.5 -46.74 65.86 Favored 'General case' 0 CA--C 1.532 0.281 0 N-CA-C 113.399 0.889 . . . . 0.0 113.399 -179.703 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 2.0 m -78.83 127.47 32.09 Favored 'General case' 0 N--CA 1.454 -0.268 0 O-C-N 121.866 -0.521 . . . . 0.0 112.113 -175.23 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.1 155.38 37.0 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 122.987 0.515 . . . . 0.0 110.599 176.784 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 138.91 175.35 13.95 Favored Glycine 0 CA--C 1.525 0.67 0 C-N-CA 125.137 1.351 . . . . 0.0 109.984 179.445 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -100.0 116.04 31.12 Favored 'General case' 0 N--CA 1.451 -0.396 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 17.9 m-85 -107.83 131.33 54.59 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 124.379 1.071 . . . . 0.0 109.806 -178.101 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 18.2 m -102.31 139.27 38.14 Favored 'General case' 0 C--O 1.233 0.233 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 176.099 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 26.1 p90 -140.81 169.52 17.48 Favored 'General case' 0 CA--C 1.521 -0.151 0 CA-C-O 121.586 0.708 . . . . 0.0 111.204 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 43.4 p90 -157.57 160.61 38.32 Favored 'General case' 0 N--CA 1.45 -0.462 0 CA-C-N 115.601 -0.727 . . . . 0.0 112.016 -178.81 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 t -97.63 99.88 11.26 Favored 'General case' 0 CA--C 1.512 -0.485 0 N-CA-C 105.68 -1.97 . . . . 0.0 105.68 177.334 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.371 4.9 p -43.43 -56.5 6.77 Favored Pre-proline 0 CA--C 1.54 0.572 0 N-CA-C 114.323 1.231 . . . . 0.0 114.323 -175.175 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_exo -47.27 -20.04 1.26 Allowed 'Trans proline' 0 CA--C 1.534 0.518 0 C-N-CA 123.6 2.867 . . . . 0.0 116.103 177.248 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 38.5 m80 -136.13 18.37 3.2 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-N 119.15 0.887 . . . . 0.0 111.806 -178.298 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 16.8 pt20 -60.88 -41.97 97.04 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-N 119.047 0.84 . . . . 0.0 109.539 179.533 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -58.39 -29.48 63.41 Favored Glycine 0 CA--C 1.532 1.155 0 N-CA-C 111.209 -0.756 . . . . 0.0 111.209 177.145 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.34 10.6 21.81 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 123.718 0.807 . . . . 0.0 111.084 178.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 79.33 17.1 76.98 Favored Glycine 0 CA--C 1.526 0.772 0 CA-C-O 118.758 -1.023 . . . . 0.0 113.801 178.484 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 22.9 ttt -79.26 77.35 5.79 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 119.703 1.751 . . . . 0.0 108.265 178.213 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 14.3 m -117.87 170.58 7.11 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.319 0 C-N-CA 125.909 1.684 . . . . 0.0 110.198 179.809 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -164.86 176.54 40.64 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 178.092 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 53.8 tttp -154.68 154.48 32.99 Favored 'General case' 0 N--CA 1.454 -0.253 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 -176.074 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.4 p -145.53 134.2 17.0 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.159 0 O-C-N 121.987 -0.445 . . . . 0.0 110.988 -178.773 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.7 m -100.15 94.51 6.27 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 125.65 1.58 . . . . 0.0 110.852 -178.002 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 21.4 t -80.17 120.28 31.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 105.459 -2.052 . . . . 0.0 105.459 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 5.8 p30 . . . . . 0 C--N 1.332 -0.157 0 C-N-CA 123.483 0.713 . . . . 0.0 111.652 -174.914 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 . . . . . 0 N--CA 1.453 -0.308 0 CA-C-O 120.171 0.034 . . . . 0.0 110.997 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 39.0 t -113.23 118.24 57.55 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.332 0 N-CA-C 107.364 -1.347 . . . . 0.0 107.364 178.386 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 64.3 mt -89.1 120.86 30.88 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 -179.77 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -78.76 111.22 14.65 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 106.799 -1.556 . . . . 0.0 106.799 175.158 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 93.61 138.75 9.12 Favored Glycine 0 N--CA 1.446 -0.649 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.168 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 68.4 p -81.8 158.34 24.14 Favored 'General case' 0 N--CA 1.437 -1.11 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 178.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.0 -33.87 57.58 Favored Glycine 0 CA--C 1.53 1.025 0 CA-C-N 115.252 -0.885 . . . . 0.0 111.512 178.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -75.8 -3.71 36.57 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 123.597 0.759 . . . . 0.0 112.292 178.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 99.51 -20.85 47.98 Favored Glycine 0 CA--C 1.527 0.794 0 CA-C-O 118.892 -0.949 . . . . 0.0 113.486 178.782 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 22.7 t -57.31 131.63 50.62 Favored 'General case' 0 C--O 1.239 0.516 0 CA-C-N 119.336 1.568 . . . . 0.0 110.682 -179.228 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 56.8 mt -73.03 65.63 0.77 Allowed 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 127.085 2.154 . . . . 0.0 112.412 -176.222 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 2.4 t -123.2 151.36 27.55 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.442 0 C-N-CA 124.247 1.019 . . . . 0.0 108.785 178.859 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 33.2 m-85 -86.17 129.74 34.75 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 104.125 -2.546 . . . . 0.0 104.125 175.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 48.8 t -118.44 104.62 47.49 Favored Pre-proline 0 CA--C 1.537 0.445 0 CA-C-O 118.324 -0.846 . . . . 0.0 108.877 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -75.05 161.78 94.14 Favored 'Cis proline' 0 C--N 1.347 0.499 0 CA-C-N 120.338 1.157 . . . . 0.0 111.597 -1.073 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 6.2 p -91.89 -60.47 1.85 Allowed 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 125.502 1.521 . . . . 0.0 108.609 179.212 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -105.4 127.01 52.75 Favored 'General case' 0 N--CA 1.453 -0.282 0 C-N-CA 126.238 1.815 . . . . 0.0 106.616 177.69 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 14.6 p90 -160.03 -175.36 5.05 Favored 'General case' 0 C--O 1.232 0.18 0 CA-C-O 121.08 0.467 . . . . 0.0 110.792 179.867 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 66.1 p -147.02 156.84 43.35 Favored 'General case' 0 N--CA 1.451 -0.403 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 18.1 m -152.75 151.28 26.35 Favored Pre-proline 0 CA--C 1.531 0.245 0 C-N-CA 123.61 0.764 . . . . 0.0 109.539 -178.901 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -73.17 148.52 44.4 Favored 'Trans proline' 0 N--CA 1.451 -1.0 0 C-N-CA 121.781 1.654 . . . . 0.0 110.761 177.812 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 64.7 m -48.93 121.24 4.52 Favored 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 122.996 0.518 . . . . 0.0 110.55 176.048 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 106.39 -9.72 42.14 Favored Glycine 0 CA--C 1.529 0.961 0 C-N-CA 124.165 0.888 . . . . 0.0 112.642 179.431 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -63.3 135.81 57.28 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-N 118.813 1.307 . . . . 0.0 109.979 179.242 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 52.9 mtpt -91.54 106.03 18.19 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 125.409 1.483 . . . . 0.0 108.659 179.386 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 40.4 mt -85.21 135.12 25.53 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 -179.672 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 64.7 t -119.73 100.3 9.27 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.34 0 C-N-CA 126.134 1.774 . . . . 0.0 108.152 -178.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -87.06 107.18 18.32 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 178.025 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 62.9 tttp -105.91 131.97 52.58 Favored 'General case' 0 CA--C 1.531 0.243 0 C-N-CA 125.266 1.426 . . . . 0.0 112.78 -176.408 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 8.1 m-20 -68.56 112.53 5.41 Favored 'General case' 0 C--O 1.232 0.132 0 C-N-CA 123.149 0.579 . . . . 0.0 110.021 177.538 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 24.5 t30 -97.46 -72.22 0.65 Allowed 'General case' 0 N--CA 1.456 -0.171 0 CA-C-O 121.052 0.453 . . . . 0.0 109.851 178.727 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -143.2 167.41 22.18 Favored 'General case' 0 C--N 1.331 -0.219 0 C-N-CA 123.972 0.909 . . . . 0.0 109.521 -178.028 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 62.65 23.78 65.5 Favored Glycine 0 CA--C 1.535 1.295 0 O-C-N 121.839 -0.538 . . . . 0.0 113.774 179.407 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.438 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 10.5 p90 -74.74 167.54 35.42 Favored Pre-proline 0 CA--C 1.537 0.463 0 N-CA-C 106.671 -1.603 . . . . 0.0 106.671 176.756 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.438 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 50.8 Cg_exo -62.66 159.91 58.31 Favored 'Cis proline' 0 N--CA 1.456 -0.698 0 N-CA-C 116.99 1.881 . . . . 0.0 116.99 1.072 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 93.3 m-70 -149.67 170.14 19.39 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.809 -179.464 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 37.3 p-10 -163.98 177.04 8.83 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 104.32 -2.474 . . . . 0.0 104.32 176.298 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 39.3 t -138.25 112.17 8.07 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.389 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 179.291 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 64.8 t -116.83 133.69 62.72 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.604 0 N-CA-C 106.052 -1.833 . . . . 0.0 106.052 179.525 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 64.6 m-85 -93.33 140.65 29.32 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 -179.306 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 53.1 t0 -70.76 104.48 2.89 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 179.42 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -48.02 -32.29 6.43 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 124.168 0.987 . . . . 0.0 113.293 178.211 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -92.04 6.39 46.6 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 123.494 0.717 . . . . 0.0 112.871 -178.839 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 20.7 tt0 -150.44 63.36 0.95 Allowed 'General case' 0 CA--C 1.538 0.506 0 CA-C-O 122.108 0.956 . . . . 0.0 110.71 -179.283 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 28.0 pt -155.59 158.2 31.77 Favored Pre-proline 0 CA--C 1.532 0.263 0 C-N-CA 128.573 2.749 . . . . 0.0 105.771 177.459 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_exo -55.93 109.5 0.44 Allowed 'Trans proline' 0 CA--C 1.538 0.692 0 C-N-CA 122.306 2.004 . . . . 0.0 108.585 174.127 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -33.65 -44.21 0.15 Allowed 'General case' 0 N--CA 1.465 0.322 0 C-N-CA 126.789 2.036 . . . . 0.0 115.77 -177.195 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -58.34 -29.84 63.77 Favored Glycine 0 CA--C 1.534 1.221 0 CA-C-O 119.856 -0.413 . . . . 0.0 113.766 -178.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 37.4 t -84.69 107.54 15.86 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.316 0 CA-C-N 118.179 0.99 . . . . 0.0 110.318 -177.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 19.7 t0 -59.29 116.15 3.71 Favored 'General case' 0 CA--C 1.534 0.364 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 177.333 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -46.79 -40.33 13.45 Favored 'General case' 0 N--CA 1.457 -0.113 0 C-N-CA 125.223 1.409 . . . . 0.0 112.012 179.671 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 53.1 t -60.23 -28.88 42.77 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 C-N-CA 122.994 0.518 . . . . 0.0 111.784 -178.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -76.56 -42.11 44.01 Favored 'General case' 0 N--CA 1.462 0.128 0 CA-C-N 118.617 0.644 . . . . 0.0 110.594 -179.006 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.411 HG21 HD13 ' A' ' 55' ' ' ILE . 22.7 pt -79.09 -32.84 15.45 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 N-CA-C 112.582 0.586 . . . . 0.0 112.582 -178.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 49.1 m -78.05 141.65 38.71 Favored 'General case' 0 N--CA 1.454 -0.255 0 N-CA-C 112.531 0.567 . . . . 0.0 112.531 -178.261 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 12.8 tpt . . . . . 0 CA--C 1.535 0.401 0 N-CA-C 105.583 -2.006 . . . . 0.0 105.583 174.914 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 4.8 mp . . . . . 0 N--CA 1.452 -0.332 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 71.9 mt -79.33 96.34 5.96 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 104.391 -2.448 . . . . 0.0 104.391 177.275 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 36.9 p-10 -80.32 -58.2 3.25 Favored 'General case' 0 CA--C 1.529 0.162 0 C-N-CA 124.156 0.982 . . . . 0.0 113.303 -177.17 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -79.75 160.45 69.32 Favored Pre-proline 0 CA--C 1.535 0.403 0 C-N-CA 124.318 1.047 . . . . 0.0 111.902 -176.75 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -64.59 161.89 33.49 Favored 'Trans proline' 0 N--CA 1.458 -0.614 0 C-N-CA 122.29 1.993 . . . . 0.0 109.172 175.081 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 78.74 -39.57 1.99 Allowed Glycine 0 CA--C 1.528 0.853 0 CA-C-O 118.656 -1.08 . . . . 0.0 113.829 177.293 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 79.5 mm-40 -42.03 130.32 3.54 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 124.476 1.111 . . . . 0.0 111.669 179.827 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 6.7 p -110.88 150.4 29.24 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 125.412 1.485 . . . . 0.0 112.424 -177.856 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 30.5 t80 -126.43 113.14 16.46 Favored 'General case' 0 N--CA 1.455 -0.177 0 N-CA-C 105.082 -2.192 . . . . 0.0 105.082 172.466 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 19.6 t -100.41 136.89 29.84 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.398 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 -178.543 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.2 p -150.07 140.88 16.66 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.121 0 N-CA-C 108.275 -1.009 . . . . 0.0 108.275 178.253 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 25.1 m -112.07 127.44 55.91 Favored 'General case' 0 N--CA 1.456 -0.126 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 -178.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 55.5 mt -110.67 124.63 52.29 Favored 'General case' 0 CA--C 1.529 0.137 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 179.713 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -108.48 -47.96 3.41 Favored 'General case' 0 CA--C 1.528 0.126 0 C-N-CA 124.286 1.034 . . . . 0.0 112.096 -178.296 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 5.0 m -66.4 128.69 37.16 Favored 'General case' 0 N--CA 1.454 -0.25 0 O-C-N 121.707 -0.621 . . . . 0.0 109.661 -177.51 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 61.8 mtpt -69.04 155.46 40.33 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 123.02 0.528 . . . . 0.0 110.441 -179.155 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 128.37 175.44 14.07 Favored Glycine 0 CA--C 1.527 0.832 0 C-N-CA 124.389 0.995 . . . . 0.0 111.409 179.023 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 89.3 m -95.25 127.22 41.12 Favored 'General case' 0 N--CA 1.451 -0.405 0 C-N-CA 124.871 1.269 . . . . 0.0 109.288 -179.828 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 25.2 m-85 -115.75 120.69 40.15 Favored 'General case' 0 N--CA 1.447 -0.601 0 C-N-CA 126.051 1.74 . . . . 0.0 108.615 179.398 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 64.1 m -92.37 140.16 29.87 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 177.023 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 22.8 p90 -139.39 165.48 27.1 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-O 121.555 0.693 . . . . 0.0 112.307 -179.52 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -152.66 157.31 40.76 Favored 'General case' 0 N--CA 1.452 -0.342 0 C-N-CA 124.205 1.002 . . . . 0.0 112.64 -178.334 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.4 t -99.68 102.04 13.41 Favored 'General case' 0 CA--C 1.519 -0.234 0 N-CA-C 105.483 -2.043 . . . . 0.0 105.483 176.84 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.28 0.8 OUTLIER -43.12 -57.69 4.92 Favored Pre-proline 0 CA--C 1.535 0.384 0 N-CA-C 114.446 1.276 . . . . 0.0 114.446 -173.692 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -52.17 -20.12 10.31 Favored 'Trans proline' 0 C--N 1.347 0.494 0 C-N-CA 123.146 2.564 . . . . 0.0 115.183 178.833 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 37.1 m80 -130.61 19.01 5.19 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-N 118.697 0.68 . . . . 0.0 111.446 -178.44 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -60.01 -51.17 70.81 Favored 'General case' 0 C--N 1.339 0.128 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 179.707 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.12 -30.26 57.35 Favored Glycine 0 CA--C 1.533 1.177 0 N-CA-C 111.717 -0.553 . . . . 0.0 111.717 177.863 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -84.04 5.83 24.38 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 123.51 0.724 . . . . 0.0 111.72 179.187 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 83.56 15.35 71.25 Favored Glycine 0 CA--C 1.527 0.827 0 CA-C-O 118.991 -0.894 . . . . 0.0 113.71 178.347 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 19.2 ttt -78.44 79.65 4.86 Favored 'General case' 0 C--O 1.236 0.377 0 CA-C-N 119.527 1.664 . . . . 0.0 108.595 178.657 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 10.7 m -126.56 169.46 17.96 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.207 0 C-N-CA 125.917 1.687 . . . . 0.0 110.813 179.842 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -169.03 179.45 41.74 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 109.276 -1.53 . . . . 0.0 109.276 178.343 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 58.7 mttm -149.64 149.46 30.67 Favored 'General case' 0 N--CA 1.455 -0.203 0 CA-C-N 117.66 0.73 . . . . 0.0 109.588 -179.014 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 6.6 p -135.72 127.29 45.04 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.3 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 178.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 71.6 m -102.09 106.46 17.34 Favored 'General case' 0 C--N 1.333 -0.143 0 C-N-CA 123.772 0.829 . . . . 0.0 110.436 179.487 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 44.6 t -79.69 122.99 35.97 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.633 0 N-CA-C 106.643 -1.614 . . . . 0.0 106.643 179.021 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 48.7 p30 . . . . . 0 C--N 1.333 -0.122 0 C-N-CA 124.895 1.278 . . . . 0.0 111.034 -177.605 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 78.4 tt0 . . . . . 0 N--CA 1.452 -0.348 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 48.1 t -106.05 122.48 59.75 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 -179.361 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 40.8 mt -86.03 120.82 27.83 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 177.886 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.447 HD12 ' HA ' ' A' ' 5' ' ' LEU . 5.1 tp -78.19 98.53 5.88 Favored 'General case' 0 N--CA 1.429 -1.489 0 C-N-CA 125.424 1.49 . . . . 0.0 107.525 179.863 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 91.72 145.34 15.07 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 108.7 -1.76 . . . . 0.0 108.7 -178.393 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 78.0 p -78.86 154.94 29.37 Favored 'General case' 0 N--CA 1.44 -0.948 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 179.574 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -53.16 -35.39 49.41 Favored Glycine 0 CA--C 1.529 0.942 0 CA-C-N 114.979 -1.01 . . . . 0.0 111.697 178.808 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -74.82 -4.42 37.66 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 123.53 0.732 . . . . 0.0 112.506 179.404 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 101.08 -20.75 46.25 Favored Glycine 0 CA--C 1.527 0.782 0 CA-C-O 118.763 -1.021 . . . . 0.0 113.292 178.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 28.6 t -56.81 132.13 51.4 Favored 'General case' 0 C--O 1.239 0.536 0 CA-C-N 119.391 1.595 . . . . 0.0 110.603 -179.332 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.444 ' H ' HD22 ' A' ' 12' ' ' LEU . 1.9 mm? -71.55 69.28 0.61 Allowed 'General case' 0 N--CA 1.44 -0.935 0 C-N-CA 126.806 2.042 . . . . 0.0 111.676 -177.457 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.5 m -135.06 141.74 42.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 C-N-CA 123.708 0.803 . . . . 0.0 109.403 178.383 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 88.2 m-85 -79.16 135.2 36.75 Favored 'General case' 0 N--CA 1.455 -0.186 0 N-CA-C 105.291 -2.115 . . . . 0.0 105.291 176.81 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.8 t -120.09 104.35 43.92 Favored Pre-proline 0 CA--C 1.534 0.339 0 CA-C-O 118.25 -0.881 . . . . 0.0 109.094 179.567 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -73.85 164.16 88.15 Favored 'Cis proline' 0 C--N 1.348 0.524 0 CA-C-N 120.301 1.143 . . . . 0.0 112.179 -1.412 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 10.5 p -97.59 -62.28 1.27 Allowed 'General case' 0 N--CA 1.452 -0.331 0 C-N-CA 125.681 1.592 . . . . 0.0 109.236 179.32 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 -103.54 123.96 47.89 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 126.106 1.763 . . . . 0.0 106.857 178.345 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -158.06 174.3 15.43 Favored 'General case' 0 CA--C 1.528 0.118 0 CA-C-N 118.9 0.773 . . . . 0.0 112.013 179.486 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.4 p -116.67 147.83 41.59 Favored 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 125.478 1.511 . . . . 0.0 107.555 178.461 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.8 p -141.79 136.25 15.18 Favored Pre-proline 0 CA--C 1.536 0.428 0 CA-C-O 118.443 -0.789 . . . . 0.0 109.036 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_exo -63.03 142.73 88.86 Favored 'Trans proline' 0 N--CA 1.456 -0.693 0 C-N-CA 122.043 1.828 . . . . 0.0 111.363 177.091 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.8 m -45.8 121.61 3.25 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 124.265 1.026 . . . . 0.0 111.778 177.919 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 84.96 -5.79 81.39 Favored Glycine 0 CA--C 1.525 0.69 0 CA-C-O 118.502 -1.166 . . . . 0.0 114.411 177.407 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -74.97 147.77 40.55 Favored 'General case' 0 CA--C 1.537 0.444 0 CA-C-N 119.954 1.877 . . . . 0.0 108.084 177.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 2.7 ptpp? -92.79 138.88 31.11 Favored 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 124.007 0.923 . . . . 0.0 112.499 -177.844 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 48.8 mt -105.05 136.76 37.42 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 C-N-CA 126.292 1.837 . . . . 0.0 106.06 179.166 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 58.4 t -117.92 100.29 9.81 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 C-N-CA 125.355 1.462 . . . . 0.0 108.832 -178.7 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -84.5 100.06 11.11 Favored 'General case' 0 C--N 1.334 -0.073 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 178.418 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 64.4 tttm -92.07 125.0 36.58 Favored 'General case' 0 C--O 1.231 0.127 0 C-N-CA 123.73 0.812 . . . . 0.0 110.621 -178.622 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 49.3 t30 -63.19 111.11 2.09 Favored 'General case' 0 CA--C 1.528 0.119 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 177.367 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 36.2 t30 -99.65 -76.45 0.55 Allowed 'General case' 0 N--CA 1.457 -0.079 0 C-N-CA 122.94 0.496 . . . . 0.0 112.256 -177.036 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -151.08 174.92 12.62 Favored 'General case' 0 C--O 1.224 -0.26 0 C-N-CA 124.012 0.925 . . . . 0.0 109.383 -176.807 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 62.3 17.96 57.22 Favored Glycine 0 CA--C 1.535 1.294 0 O-C-N 121.679 -0.638 . . . . 0.0 112.519 -179.119 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.494 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.9 p90 -78.25 169.5 20.56 Favored Pre-proline 0 CA--C 1.538 0.509 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 179.153 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.494 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 37.2 Cg_exo -64.45 160.25 68.42 Favored 'Cis proline' 0 N--CA 1.449 -1.098 0 N-CA-C 116.07 1.527 . . . . 0.0 116.07 1.605 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 90.7 m-70 -152.29 177.69 10.29 Favored 'General case' 0 N--CA 1.45 -0.467 0 CA-C-N 115.118 -0.946 . . . . 0.0 109.769 179.578 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 53.4 p30 -162.94 169.78 19.14 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 105.064 -2.198 . . . . 0.0 105.064 173.556 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 44.3 t -123.93 104.55 14.22 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.333 0 N-CA-C 106.62 -1.622 . . . . 0.0 106.62 -177.522 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 38.8 t -116.33 135.26 57.13 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.366 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 -179.316 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.421 ' CG ' HG13 ' A' ' 55' ' ' ILE . 55.7 m-85 -100.65 138.19 38.04 Favored 'General case' 0 N--CA 1.454 -0.272 0 C-N-CA 123.267 0.627 . . . . 0.0 109.68 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -70.14 114.1 7.97 Favored 'General case' 0 N--CA 1.454 -0.26 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 -179.81 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -47.85 -30.57 4.17 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 115.825 1.787 . . . . 0.0 115.825 -178.471 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 23.5 t70 -88.61 -50.15 6.45 Favored 'General case' 0 CA--C 1.53 0.204 0 CA-C-N 118.52 0.6 . . . . 0.0 110.649 179.88 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -80.22 57.07 2.63 Favored 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 124.087 0.955 . . . . 0.0 112.413 -176.397 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 20.2 pt -150.14 149.0 26.11 Favored Pre-proline 0 CA--C 1.534 0.36 0 C-N-CA 127.376 2.27 . . . . 0.0 106.537 176.805 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -65.6 124.63 13.08 Favored 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 122.096 1.864 . . . . 0.0 110.504 179.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -52.0 109.95 0.43 Allowed 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 124.802 1.241 . . . . 0.0 111.228 -179.456 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 153.09 -56.77 0.43 Allowed Glycine 0 CA--C 1.522 0.517 0 N-CA-C 108.249 -1.94 . . . . 0.0 108.249 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 41.8 t -83.21 93.09 2.87 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.429 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 179.285 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -58.96 134.33 56.86 Favored 'General case' 0 CA--C 1.532 0.251 0 N-CA-C 109.319 -0.622 . . . . 0.0 109.319 177.807 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -39.56 -43.82 1.36 Allowed 'General case' 0 C--N 1.331 -0.196 0 C-N-CA 127.389 2.275 . . . . 0.0 113.963 179.52 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 98.9 t -55.62 -30.41 26.68 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.333 0 CA-C-N 118.119 0.418 . . . . 0.0 110.918 -179.378 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 33.1 mtmm -75.85 -18.83 59.3 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-O 118.451 -0.785 . . . . 0.0 112.868 -179.278 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.421 HG13 ' CG ' ' A' ' 41' ' ' PHE . 0.1 OUTLIER -115.32 -20.91 5.59 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-N 119.196 0.907 . . . . 0.0 113.065 179.642 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 35.6 m -84.13 127.46 33.93 Favored 'General case' 0 N--CA 1.451 -0.386 0 C-N-CA 123.869 0.868 . . . . 0.0 112.038 -178.577 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 7.2 tmm? . . . . . 0 CA--C 1.536 0.432 0 N-CA-C 103.801 -2.666 . . . . 0.0 103.801 175.071 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 4.8 mp . . . . . 0 N--CA 1.45 -0.469 0 CA-C-O 121.036 0.446 . . . . 0.0 110.503 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 44.1 mt -78.1 105.68 9.49 Favored 'General case' 0 N--CA 1.445 -0.68 0 N-CA-C 103.778 -2.675 . . . . 0.0 103.778 175.295 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 34.3 p-10 -101.25 -52.98 3.12 Favored 'General case' 0 N--CA 1.455 -0.183 0 C-N-CA 124.796 1.238 . . . . 0.0 111.733 -177.151 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -71.85 136.65 82.65 Favored Pre-proline 0 CA--C 1.531 0.245 0 CA-C-N 118.723 0.692 . . . . 0.0 110.069 -177.477 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -63.61 149.73 90.22 Favored 'Trans proline' 0 N--CA 1.451 -1.009 0 C-N-CA 122.142 1.895 . . . . 0.0 109.659 179.704 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 97.54 -34.98 4.76 Favored Glycine 0 CA--C 1.523 0.591 0 CA-C-O 118.623 -1.098 . . . . 0.0 112.777 177.855 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 76.9 mt-10 -45.28 118.72 1.81 Allowed 'General case' 0 CA--C 1.536 0.419 0 CA-C-N 118.537 1.169 . . . . 0.0 111.665 -179.696 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 11.0 p -101.88 120.46 40.42 Favored 'General case' 0 N--CA 1.452 -0.356 0 C-N-CA 124.992 1.317 . . . . 0.0 111.551 -179.485 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 38.4 t80 -101.34 108.06 19.58 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 106.422 -1.695 . . . . 0.0 106.422 175.124 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 14.6 t -93.91 139.86 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.301 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 -179.263 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 9.9 p -148.61 142.64 18.79 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.153 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 177.778 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 7.8 m -117.21 124.44 49.09 Favored 'General case' 0 CA--C 1.527 0.072 0 C-N-CA 124.318 1.047 . . . . 0.0 109.495 -177.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 44.3 mt -105.55 98.51 8.19 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 123.156 0.583 . . . . 0.0 109.777 -179.394 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -74.67 -58.36 3.34 Favored 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 123.782 0.833 . . . . 0.0 112.709 -179.38 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 4.1 m -70.42 128.87 37.68 Favored 'General case' 0 N--CA 1.453 -0.325 0 C-N-CA 123.495 0.718 . . . . 0.0 111.465 -175.116 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 57.5 mtmt -65.35 156.04 33.43 Favored 'General case' 0 N--CA 1.455 -0.194 0 C-N-CA 123.438 0.695 . . . . 0.0 110.8 179.115 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 142.44 -166.46 26.45 Favored Glycine 0 CA--C 1.521 0.446 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 179.33 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 88.5 m -117.44 123.83 47.35 Favored 'General case' 0 N--CA 1.454 -0.245 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 179.612 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -114.81 124.3 51.39 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 124.348 1.059 . . . . 0.0 108.58 -178.553 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 13.2 m -99.81 134.29 42.92 Favored 'General case' 0 C--O 1.233 0.205 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 177.868 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 40.3 p90 -133.67 166.96 21.39 Favored 'General case' 0 CA--C 1.521 -0.161 0 CA-C-O 121.588 0.708 . . . . 0.0 111.625 -179.552 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 46.6 p90 -159.01 165.09 34.82 Favored 'General case' 0 N--CA 1.45 -0.43 0 CA-C-N 115.453 -0.794 . . . . 0.0 112.322 -177.76 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.5 t -106.09 97.18 7.03 Favored 'General case' 0 CA--C 1.519 -0.243 0 N-CA-C 106.638 -1.615 . . . . 0.0 106.638 177.377 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.304 16.1 p -31.1 -64.56 0.21 Allowed Pre-proline 0 CA--C 1.544 0.721 0 N-CA-C 117.138 2.273 . . . . 0.0 117.138 -174.474 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -61.89 -16.49 49.76 Favored 'Trans proline' 0 C--N 1.347 0.468 0 C-N-CA 122.576 2.184 . . . . 0.0 114.294 -177.338 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 34.7 m170 -119.08 9.26 11.76 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 123.322 0.649 . . . . 0.0 110.747 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 66.4 tt0 -58.34 -49.69 76.28 Favored 'General case' 0 CA--C 1.529 0.144 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 179.228 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -57.45 -30.32 61.67 Favored Glycine 0 CA--C 1.531 1.067 0 N-CA-C 111.475 -0.65 . . . . 0.0 111.475 177.45 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -84.8 5.45 28.54 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 123.774 0.83 . . . . 0.0 111.577 179.091 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 87.37 11.39 69.21 Favored Glycine 0 CA--C 1.527 0.823 0 CA-C-O 118.608 -1.107 . . . . 0.0 113.833 178.263 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 22.2 ttt -78.9 77.26 5.38 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 119.812 1.806 . . . . 0.0 108.614 178.334 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 10.8 m -122.94 169.13 14.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 C-N-CA 126.042 1.737 . . . . 0.0 108.96 178.568 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -162.42 172.34 38.49 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 108.491 -1.843 . . . . 0.0 108.491 178.51 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 6.9 ttpm? -151.4 141.33 22.02 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 -176.765 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 6.0 p -132.97 126.43 53.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 CA-C-O 121.057 0.456 . . . . 0.0 110.697 -179.025 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 21.0 m -97.17 105.84 18.06 Favored 'General case' 0 C--O 1.235 0.324 0 C-N-CA 124.724 1.21 . . . . 0.0 109.222 179.775 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 40.8 t -79.91 103.02 6.36 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.621 0 N-CA-C 106.484 -1.673 . . . . 0.0 106.484 -179.743 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 . . . . . 0 C--O 1.235 0.313 0 C-N-CA 125.205 1.402 . . . . 0.0 109.487 -177.206 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 . . . . . 0 N--CA 1.453 -0.32 0 CA-C-O 120.267 0.08 . . . . 0.0 110.895 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 44.2 t -120.55 123.94 71.45 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 N-CA-C 106.112 -1.81 . . . . 0.0 106.112 177.492 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 32.5 mt -96.65 122.91 40.09 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 118.383 0.538 . . . . 0.0 110.206 -179.478 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.507 ' HB3' ' CD2' ' A' ' 37' ' ' HIS . 1.2 mm? -79.68 101.9 8.65 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 106.316 -1.735 . . . . 0.0 106.316 174.111 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 108.84 127.69 5.58 Favored Glycine 0 CA--C 1.522 0.522 0 C-N-CA 124.788 1.185 . . . . 0.0 111.576 179.688 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 14.9 p -84.34 46.84 1.26 Allowed 'General case' 0 N--CA 1.457 -0.092 0 O-C-N 121.434 -1.039 . . . . 0.0 111.314 179.279 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 72.07 -55.73 1.45 Allowed Glycine 0 CA--C 1.527 0.83 0 C-N-CA 126.071 1.796 . . . . 0.0 111.991 -179.26 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -73.17 33.69 0.07 Allowed 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 126.038 1.735 . . . . 0.0 113.743 -177.519 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 57.33 8.42 3.56 Favored Glycine 0 CA--C 1.531 1.069 0 C-N-CA 124.875 1.226 . . . . 0.0 115.848 179.207 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 22.8 t -68.63 141.43 55.39 Favored 'General case' 0 N--CA 1.457 -0.107 0 CA-C-N 119.532 1.666 . . . . 0.0 109.502 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 68.9 mt -78.1 66.57 3.74 Favored 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 124.411 1.084 . . . . 0.0 111.781 -176.048 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.6 p -138.44 150.08 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.217 0 CA-C-O 121.788 0.804 . . . . 0.0 111.715 -179.494 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 58.7 m-85 -92.38 126.33 37.42 Favored 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 105.185 -2.154 . . . . 0.0 105.185 177.78 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 48.8 t -115.39 107.47 49.17 Favored Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 119.629 1.104 . . . . 0.0 109.448 179.609 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -77.27 155.84 96.66 Favored 'Cis proline' 0 CA--C 1.536 0.613 0 CA-C-N 120.706 1.288 . . . . 0.0 111.729 -1.3 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.5 m -84.83 -55.1 4.26 Favored 'General case' 0 CA--C 1.527 0.096 0 C-N-CA 123.357 0.663 . . . . 0.0 110.302 179.232 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 58.9 mt-10 -114.0 131.87 56.19 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 -179.471 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 53.0 p90 -161.13 -178.41 6.73 Favored 'General case' 0 C--O 1.234 0.255 0 CA-C-O 121.372 0.606 . . . . 0.0 112.081 -178.114 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 35.2 p -140.02 140.26 36.18 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 124.948 1.299 . . . . 0.0 109.257 -179.249 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.4 m -145.47 152.19 49.05 Favored Pre-proline 0 CA--C 1.532 0.257 0 C-N-CA 124.553 1.141 . . . . 0.0 108.136 178.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo -71.67 151.44 58.03 Favored 'Trans proline' 0 N--CA 1.451 -0.998 0 C-N-CA 121.78 1.653 . . . . 0.0 111.16 179.842 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 56.7 m -49.31 127.15 14.42 Favored 'General case' 0 C--N 1.332 -0.18 0 C-N-CA 124.343 1.057 . . . . 0.0 111.508 178.479 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 92.9 -10.74 73.44 Favored Glycine 0 CA--C 1.527 0.817 0 CA-C-O 118.911 -0.938 . . . . 0.0 112.829 178.88 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -70.47 141.96 51.98 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 119.392 1.596 . . . . 0.0 108.43 178.601 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 20.4 pttp -82.01 160.45 23.27 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 123.928 0.891 . . . . 0.0 111.131 -179.018 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 15.8 mt -131.44 129.05 61.84 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 N-CA-C 105.355 -2.091 . . . . 0.0 105.355 177.775 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 75.3 t -116.37 98.06 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.202 0 C-N-CA 125.851 1.66 . . . . 0.0 107.928 -177.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -86.5 96.57 10.1 Favored 'General case' 0 CA--C 1.529 0.17 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.773 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -90.52 128.98 36.72 Favored 'General case' 0 CA--C 1.531 0.212 0 C-N-CA 125.027 1.331 . . . . 0.0 112.046 -177.6 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 45.6 t30 -69.15 116.66 9.85 Favored 'General case' 0 N--CA 1.457 -0.119 0 CA-C-O 118.393 -0.813 . . . . 0.0 109.947 177.938 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 50.2 t30 -103.4 -66.23 0.96 Allowed 'General case' 0 C--N 1.339 0.135 0 CA-C-N 118.702 0.683 . . . . 0.0 110.551 179.474 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -160.17 169.25 23.67 Favored 'General case' 0 C--O 1.225 -0.196 0 C-N-CA 123.254 0.622 . . . . 0.0 110.452 -177.684 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 71.66 18.91 77.61 Favored Glycine 0 CA--C 1.532 1.094 0 O-C-N 121.823 -0.548 . . . . 0.0 111.878 -179.512 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.557 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 10.4 p90 -71.37 168.92 17.64 Favored Pre-proline 0 CA--C 1.54 0.568 0 C-N-CA 126.001 1.72 . . . . 0.0 108.598 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.557 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 75.8 Cg_endo -70.93 158.44 94.52 Favored 'Cis proline' 0 N--CA 1.449 -1.104 0 N-CA-C 115.042 1.131 . . . . 0.0 115.042 3.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.507 ' CD2' ' HB3' ' A' ' 5' ' ' LEU . 90.3 m-70 -146.8 160.83 41.78 Favored 'General case' 0 C--O 1.222 -0.391 0 O-C-N 121.59 -0.694 . . . . 0.0 112.72 -177.808 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 52.1 p30 -157.53 177.69 11.13 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 106.39 -1.707 . . . . 0.0 106.39 176.437 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 23.4 t -132.55 113.95 21.91 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 -179.27 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 25.5 t -118.98 132.11 69.82 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 N-CA-C 105.601 -2.0 . . . . 0.0 105.601 178.522 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -93.99 136.78 33.91 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -71.02 104.75 3.08 Favored 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 -178.66 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -35.26 -37.34 0.08 Allowed 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 127.416 2.287 . . . . 0.0 115.401 178.275 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 24.9 m-20 -85.47 -53.24 5.32 Favored 'General case' 0 CA--C 1.53 0.188 0 CA-C-N 118.545 0.611 . . . . 0.0 110.301 179.43 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 38.3 mm-40 -80.91 58.28 3.34 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 124.031 0.933 . . . . 0.0 112.906 -176.706 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 36.1 pt -152.31 159.15 33.16 Favored Pre-proline 0 CA--C 1.534 0.336 0 C-N-CA 128.452 2.701 . . . . 0.0 105.633 175.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -53.12 110.84 0.53 Allowed 'Trans proline' 0 N--CA 1.456 -0.684 0 C-N-CA 122.365 2.044 . . . . 0.0 111.162 177.22 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -51.77 108.23 0.26 Allowed 'General case' 0 CA--C 1.529 0.156 0 C-N-CA 124.119 0.968 . . . . 0.0 110.284 -179.507 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 133.83 -29.42 3.1 Favored Glycine 0 CA--C 1.527 0.795 0 N-CA-C 109.958 -1.257 . . . . 0.0 109.958 -178.133 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 88.5 t -74.94 117.91 19.91 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.279 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 179.763 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -63.13 102.81 0.41 Allowed 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 122.953 0.501 . . . . 0.0 110.335 179.454 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.71 -40.5 20.38 Favored 'General case' 0 N--CA 1.456 -0.168 0 C-N-CA 124.424 1.09 . . . . 0.0 111.381 179.094 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 44.6 t -58.94 -28.62 38.9 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 C-N-CA 123.03 0.532 . . . . 0.0 111.844 -179.132 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 33.3 pttt -75.7 -31.96 59.9 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 119.497 1.044 . . . . 0.0 111.571 -178.622 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.437 HD13 HG21 ' A' ' 55' ' ' ILE . 26.4 pt -91.78 -31.45 4.89 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.36 0 C-N-CA 123.728 0.811 . . . . 0.0 111.925 -178.79 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 35.5 m -87.74 142.95 27.42 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 124.73 1.212 . . . . 0.0 114.196 -176.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 87.2 mtp . . . . . 0 N--CA 1.45 -0.428 0 N-CA-C 104.656 -2.35 . . . . 0.0 104.656 171.213 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.449 -0.475 0 N-CA-C 113.339 0.866 . . . . 0.0 113.339 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 63.9 mt -82.32 127.65 33.43 Favored 'General case' 0 N--CA 1.446 -0.644 0 N-CA-C 106.041 -1.837 . . . . 0.0 106.041 176.353 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 23.8 t30 -118.21 -47.89 2.55 Favored 'General case' 0 C--O 1.225 -0.189 0 C-N-CA 123.267 0.627 . . . . 0.0 110.469 178.617 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -67.07 136.9 94.25 Favored Pre-proline 0 CA--C 1.533 0.322 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -178.666 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -64.68 145.04 86.06 Favored 'Trans proline' 0 N--CA 1.452 -0.954 0 C-N-CA 122.462 2.108 . . . . 0.0 109.949 -178.511 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.23 -30.21 8.98 Favored Glycine 0 CA--C 1.523 0.563 0 CA-C-O 118.729 -1.04 . . . . 0.0 113.678 177.042 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 65.9 mm-40 -52.97 135.68 36.3 Favored 'General case' 0 CA--C 1.535 0.381 0 CA-C-N 118.859 1.329 . . . . 0.0 110.655 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 17.3 p -114.31 123.91 50.69 Favored 'General case' 0 N--CA 1.454 -0.251 0 C-N-CA 124.863 1.265 . . . . 0.0 113.515 -177.235 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 43.0 t80 -94.7 108.89 20.87 Favored 'General case' 0 C--O 1.233 0.194 0 N-CA-C 105.069 -2.197 . . . . 0.0 105.069 172.88 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.8 t -96.28 137.99 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.356 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 -179.21 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 13.5 p -147.55 168.5 4.54 Favored 'Isoleucine or valine' 0 C--O 1.232 0.142 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 177.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 40.9 m -149.51 136.72 19.85 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 67.5 mt -118.52 112.87 20.46 Favored 'General case' 0 CA--C 1.53 0.202 0 C-N-CA 123.681 0.792 . . . . 0.0 109.786 -177.752 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -88.23 -42.84 12.02 Favored 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 123.68 0.792 . . . . 0.0 111.473 179.692 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -71.52 127.97 34.3 Favored 'General case' 0 N--CA 1.453 -0.324 0 C-N-CA 124.095 0.958 . . . . 0.0 109.878 -177.432 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.7 mttp -66.84 160.18 26.58 Favored 'General case' 0 CA--C 1.53 0.175 0 C-N-CA 123.386 0.674 . . . . 0.0 111.683 178.87 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 129.64 177.39 14.85 Favored Glycine 0 CA--C 1.525 0.716 0 C-N-CA 124.33 0.967 . . . . 0.0 112.591 176.756 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 14.7 m -95.32 112.46 24.17 Favored 'General case' 0 N--CA 1.453 -0.277 0 C-N-CA 124.769 1.227 . . . . 0.0 108.192 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 26.2 m-85 -104.04 111.72 24.41 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 124.01 0.924 . . . . 0.0 109.47 -179.626 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 20.1 m -86.14 138.38 31.96 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 107.985 -1.116 . . . . 0.0 107.985 177.163 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 34.3 p90 -135.83 164.66 27.41 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 123.099 0.56 . . . . 0.0 111.241 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 56.0 p90 -155.31 164.22 39.06 Favored 'General case' 0 N--CA 1.45 -0.462 0 CA-C-N 114.934 -1.03 . . . . 0.0 112.089 -177.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 6.3 t -105.11 106.97 17.71 Favored 'General case' 0 CA--C 1.523 -0.064 0 N-CA-C 106.212 -1.774 . . . . 0.0 106.212 177.229 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.304 52.3 p -43.42 -60.25 2.67 Favored Pre-proline 0 CA--C 1.539 0.554 0 N-CA-C 115.776 1.769 . . . . 0.0 115.776 -173.124 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -61.38 -7.56 8.82 Favored 'Trans proline' 0 C--N 1.348 0.52 0 C-N-CA 122.21 1.94 . . . . 0.0 114.365 -178.526 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 34.7 m80 -131.34 16.84 4.96 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 119.504 1.047 . . . . 0.0 111.039 179.644 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 65.6 tt0 -60.22 -49.54 77.22 Favored 'General case' 0 C--N 1.34 0.164 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 179.048 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.77 -32.12 61.54 Favored Glycine 0 CA--C 1.53 0.976 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 177.832 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -81.49 3.89 23.12 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 123.326 0.65 . . . . 0.0 111.711 179.117 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 81.92 17.82 69.11 Favored Glycine 0 CA--C 1.526 0.775 0 CA-C-O 118.944 -0.92 . . . . 0.0 113.259 178.836 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 21.5 ttt -78.58 80.03 4.98 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-N 119.369 1.584 . . . . 0.0 107.997 178.317 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 6.8 m -127.39 170.61 16.99 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.249 0 C-N-CA 126.196 1.798 . . . . 0.0 110.949 -179.853 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -166.65 175.11 42.06 Favored Glycine 0 CA--C 1.528 0.855 0 N-CA-C 109.134 -1.587 . . . . 0.0 109.134 178.251 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 58.9 mttm -147.27 126.35 12.88 Favored 'General case' 0 N--CA 1.461 0.095 0 CA-C-N 118.037 0.919 . . . . 0.0 110.947 -178.627 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 6.8 p -113.17 124.77 70.13 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.167 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 178.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.7 m -94.14 104.23 16.25 Favored 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 124.111 0.965 . . . . 0.0 109.06 -179.648 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 21.9 t -81.89 98.6 4.47 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 N-CA-C 103.98 -2.6 . . . . 0.0 103.98 178.651 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 37.2 t-20 . . . . . 0 N--CA 1.454 -0.256 0 C-N-CA 124.898 1.279 . . . . 0.0 112.925 -175.008 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 8.9 tt . . . . . 0 CA--C 1.532 0.255 0 N-CA-C 110.26 -0.274 . . . . 0.0 110.26 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.4 tm-20 -94.7 119.43 33.31 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 123.84 0.856 . . . . 0.0 109.374 -179.3 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 25.8 t -109.72 128.92 65.43 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.293 0 C-N-CA 125.891 1.676 . . . . 0.0 109.193 179.63 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 62.4 mt -94.6 126.69 40.05 Favored 'General case' 0 C--O 1.233 0.222 0 N-CA-C 108.307 -0.998 . . . . 0.0 108.307 177.455 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 55.2 mt -86.55 99.03 11.4 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 105.942 -1.873 . . . . 0.0 105.942 177.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 101.17 134.0 8.34 Favored Glycine 0 CA--C 1.525 0.706 0 C-N-CA 125.539 1.542 . . . . 0.0 109.583 -178.495 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 22.3 p -82.87 42.86 0.81 Allowed 'General case' 0 N--CA 1.462 0.157 0 O-C-N 120.944 -1.327 . . . . 0.0 112.875 -178.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.24 -53.46 1.08 Allowed Glycine 0 CA--C 1.527 0.784 0 C-N-CA 126.18 1.848 . . . . 0.0 112.691 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -73.1 36.27 0.08 Allowed 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 125.837 1.655 . . . . 0.0 113.675 -177.539 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 70.39 -19.83 0.63 Allowed Glycine 0 CA--C 1.53 1.003 0 C-N-CA 124.808 1.194 . . . . 0.0 115.08 177.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 32.9 t -56.66 129.21 40.08 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-N 118.515 1.157 . . . . 0.0 110.916 -178.146 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 55.5 mt -77.31 65.87 2.97 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 126.378 1.871 . . . . 0.0 112.071 -175.492 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 29.6 m -130.32 144.24 38.58 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.213 0 C-N-CA 123.174 0.59 . . . . 0.0 111.475 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 37.7 m-85 -84.76 129.21 34.86 Favored 'General case' 0 N--CA 1.456 -0.138 0 N-CA-C 104.764 -2.31 . . . . 0.0 104.764 175.723 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.9 t -117.56 102.8 51.61 Favored Pre-proline 0 CA--C 1.534 0.334 0 CA-C-O 117.986 -1.007 . . . . 0.0 108.992 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -76.89 166.83 81.62 Favored 'Cis proline' 0 CA--C 1.535 0.554 0 CA-C-N 120.373 1.169 . . . . 0.0 111.23 -1.375 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 29.2 t -103.14 -60.42 1.55 Allowed 'General case' 0 CA--C 1.531 0.216 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 178.023 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 4.3 tm-20 -102.3 125.78 49.11 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 106.11 -1.811 . . . . 0.0 106.11 178.457 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.1 p90 -161.65 -176.69 5.44 Favored 'General case' 0 CA--C 1.535 0.372 0 CA-C-N 119.118 0.872 . . . . 0.0 112.757 -179.362 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.0 m -130.14 147.03 51.83 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 126.284 1.834 . . . . 0.0 108.605 179.686 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.0 m -145.25 152.17 49.85 Favored Pre-proline 0 CA--C 1.528 0.134 0 C-N-CA 125.086 1.354 . . . . 0.0 108.28 178.465 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -73.7 158.02 47.52 Favored 'Trans proline' 0 N--CA 1.453 -0.905 0 C-N-CA 121.931 1.754 . . . . 0.0 110.514 176.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 50.2 m -56.3 126.13 24.91 Favored 'General case' 0 CA--C 1.529 0.149 0 C-N-CA 123.221 0.608 . . . . 0.0 109.98 177.441 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 89.82 6.5 69.79 Favored Glycine 0 CA--C 1.526 0.73 0 CA-C-O 118.887 -0.952 . . . . 0.0 112.598 -179.621 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -61.8 138.14 58.31 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 119.315 1.557 . . . . 0.0 110.854 178.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 15.3 ptpt -93.49 95.85 9.52 Favored 'General case' 0 N--CA 1.444 -0.736 0 C-N-CA 126.394 1.878 . . . . 0.0 106.534 177.384 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 39.6 mt -83.04 136.14 23.41 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 -179.716 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 90.8 t -118.92 132.95 67.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 105.032 -2.21 . . . . 0.0 105.032 179.012 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 94.9 m-85 -121.44 123.57 42.38 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 106.33 -1.73 . . . . 0.0 106.33 178.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 7.7 ttpm? -120.15 136.57 54.57 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 118.812 0.733 . . . . 0.0 112.875 -178.369 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 6.6 m-20 -67.72 99.6 0.82 Allowed 'General case' 0 C--O 1.232 0.161 0 C-N-CA 124.108 0.963 . . . . 0.0 109.279 177.095 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 57.8 t30 -87.17 -59.75 2.17 Favored 'General case' 0 N--CA 1.455 -0.192 0 N-CA-C 109.443 -0.576 . . . . 0.0 109.443 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -161.08 167.51 26.17 Favored 'General case' 0 C--O 1.226 -0.179 0 C-N-CA 123.617 0.767 . . . . 0.0 109.841 -179.293 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 68.89 20.37 74.4 Favored Glycine 0 CA--C 1.533 1.177 0 O-C-N 121.834 -0.541 . . . . 0.0 113.181 179.308 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.454 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 18.6 p90 -68.61 166.66 24.43 Favored Pre-proline 0 CA--C 1.546 0.797 0 N-CA-C 106.53 -1.656 . . . . 0.0 106.53 177.043 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.454 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 73.7 Cg_endo -69.97 156.34 93.41 Favored 'Cis proline' 0 N--CA 1.449 -1.136 0 CA-C-N 120.446 1.195 . . . . 0.0 114.488 4.215 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 87.9 m-70 -147.61 168.95 20.69 Favored 'General case' 0 N--CA 1.449 -0.498 0 O-C-N 121.638 -0.664 . . . . 0.0 111.49 -179.197 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 51.6 p30 -163.82 174.01 12.07 Favored 'General case' 0 N--CA 1.451 -0.416 0 N-CA-C 104.948 -2.242 . . . . 0.0 104.948 176.48 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 22.9 t -133.81 103.92 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.323 0 N-CA-C 107.062 -1.459 . . . . 0.0 107.062 -179.507 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.2 t -110.92 135.86 48.74 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 N-CA-C 105.896 -1.89 . . . . 0.0 105.896 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.411 ' CG ' HG13 ' A' ' 55' ' ' ILE . 53.5 m-85 -95.81 139.42 32.06 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 -179.833 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -72.02 111.09 6.97 Favored 'General case' 0 N--CA 1.45 -0.444 0 N-CA-C 107.7 -1.222 . . . . 0.0 107.7 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -46.16 -31.3 2.33 Favored 'General case' 0 CA--C 1.532 0.274 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -178.218 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -81.99 -50.92 8.58 Favored 'General case' 0 CA--C 1.531 0.25 0 CA-C-N 118.392 0.542 . . . . 0.0 109.662 178.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 40.3 mt-10 -80.45 56.65 2.61 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 124.143 0.977 . . . . 0.0 112.713 -177.066 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 26.4 pt -151.53 149.71 24.89 Favored Pre-proline 0 CA--C 1.534 0.329 0 C-N-CA 126.06 1.744 . . . . 0.0 107.715 175.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -69.11 116.26 4.4 Favored 'Trans proline' 0 N--CA 1.45 -1.068 0 C-N-CA 121.692 1.595 . . . . 0.0 108.706 176.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -33.65 -40.61 0.08 Allowed 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 127.741 2.416 . . . . 0.0 115.192 -177.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -50.98 -35.58 32.81 Favored Glycine 0 CA--C 1.533 1.16 0 C-N-CA 123.532 0.587 . . . . 0.0 112.805 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 48.2 t -103.53 103.77 15.65 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.209 0 CA-C-N 117.862 0.831 . . . . 0.0 108.945 -179.577 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -63.39 135.23 56.82 Favored 'General case' 0 CA--C 1.535 0.402 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 177.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -43.24 -41.26 3.79 Favored 'General case' 0 C--O 1.231 0.104 0 C-N-CA 126.182 1.793 . . . . 0.0 114.212 -179.504 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 85.8 t -56.88 -27.99 27.53 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 C-N-CA 123.03 0.532 . . . . 0.0 110.767 -179.459 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 34.5 mmtp -76.27 -19.11 58.62 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-O 118.438 -0.791 . . . . 0.0 112.539 -179.198 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.411 HG13 ' CG ' ' A' ' 41' ' ' PHE . 0.1 OUTLIER -117.11 -23.37 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 N-CA-C 113.491 0.923 . . . . 0.0 113.491 -179.761 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 31.3 m -84.09 129.82 34.89 Favored 'General case' 0 N--CA 1.453 -0.308 0 N-CA-C 113.892 1.071 . . . . 0.0 113.892 -177.207 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 15.0 tpt -66.18 121.57 77.08 Favored Pre-proline 0 CA--C 1.54 0.559 0 N-CA-C 104.824 -2.287 . . . . 0.0 104.824 173.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 90.5 Cg_exo -47.99 121.58 6.12 Favored 'Trans proline' 0 N--CA 1.457 -0.636 0 C-N-CA 123.0 2.467 . . . . 0.0 112.902 -178.094 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 21.2 mm-40 -42.51 -38.23 1.88 Allowed 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 126.009 1.724 . . . . 0.0 113.372 179.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 43.0 tt0 -54.63 -36.01 64.06 Favored 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 124.821 1.248 . . . . 0.0 111.562 179.54 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 49.9 mt-10 -105.02 157.1 17.46 Favored 'General case' 0 N--CA 1.445 -0.693 0 C-N-CA 125.736 1.615 . . . . 0.0 110.734 -177.621 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -161.17 151.81 18.08 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-O 121.79 0.805 . . . . 0.0 111.247 177.558 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 50.9 mt -76.81 96.27 4.24 Favored 'General case' 0 N--CA 1.444 -0.743 0 N-CA-C 103.278 -2.86 . . . . 0.0 103.278 177.783 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 4.0 p30 -88.0 -40.42 13.89 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 126.228 1.811 . . . . 0.0 113.515 -175.207 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -95.63 156.44 37.44 Favored Pre-proline 0 CA--C 1.535 0.374 0 C-N-CA 123.823 0.849 . . . . 0.0 110.142 -178.448 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -64.69 161.42 35.82 Favored 'Trans proline' 0 N--CA 1.457 -0.664 0 C-N-CA 122.245 1.964 . . . . 0.0 109.545 176.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 78.54 -34.5 1.81 Allowed Glycine 0 CA--C 1.529 0.931 0 CA-C-O 118.59 -1.117 . . . . 0.0 114.182 177.205 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 50.6 mt-10 -48.46 140.98 7.26 Favored 'General case' 0 CA--C 1.533 0.324 0 CA-C-N 119.062 1.431 . . . . 0.0 111.056 179.17 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 2.5 p -120.14 161.44 21.02 Favored 'General case' 0 N--CA 1.453 -0.316 0 C-N-CA 124.732 1.213 . . . . 0.0 111.84 -177.028 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 47.4 t80 -137.1 147.83 46.32 Favored 'General case' 0 N--CA 1.456 -0.13 0 N-CA-C 104.608 -2.367 . . . . 0.0 104.608 173.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 25.9 t -136.21 145.03 31.49 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.097 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 -178.46 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.8 p -152.62 138.13 11.17 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 178.739 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 33.8 m -105.6 112.25 25.26 Favored 'General case' 0 CA--C 1.528 0.129 0 C-N-CA 123.927 0.891 . . . . 0.0 108.801 -179.183 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 27.6 mt -93.19 88.5 6.07 Favored 'General case' 0 CA--C 1.529 0.167 0 CA-C-O 121.247 0.546 . . . . 0.0 110.84 -178.541 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -60.9 -69.12 0.25 Allowed 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 124.747 1.219 . . . . 0.0 114.052 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 2.8 m -73.2 138.82 45.88 Favored 'General case' 0 N--CA 1.452 -0.354 0 C-N-CA 124.098 0.959 . . . . 0.0 113.459 -172.174 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -62.72 154.17 30.37 Favored 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 123.711 0.804 . . . . 0.0 110.189 177.839 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 145.31 -170.3 26.71 Favored Glycine 0 C--N 1.334 0.456 0 N-CA-C 111.194 -0.763 . . . . 0.0 111.194 178.333 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 24.0 m -112.24 120.44 41.76 Favored 'General case' 0 N--CA 1.453 -0.304 0 N-CA-C 106.451 -1.685 . . . . 0.0 106.451 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 34.7 m-85 -117.28 107.32 14.26 Favored 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 124.046 0.938 . . . . 0.0 109.327 -178.232 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -92.5 139.58 30.44 Favored 'General case' 0 C--O 1.232 0.171 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 177.601 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 32.9 p90 -137.27 167.45 21.56 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 121.387 0.613 . . . . 0.0 111.613 -178.389 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 44.8 p90 -155.84 161.03 40.68 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 114.933 -1.03 . . . . 0.0 112.379 -178.461 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.4 t -101.72 103.77 14.55 Favored 'General case' 0 CA--C 1.519 -0.241 0 N-CA-C 105.308 -2.108 . . . . 0.0 105.308 176.674 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.344 77.7 p -45.48 -58.25 6.26 Favored Pre-proline 0 CA--C 1.537 0.452 0 N-CA-C 115.723 1.749 . . . . 0.0 115.723 -173.258 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -60.3 -7.79 7.38 Favored 'Trans proline' 0 N--CA 1.458 -0.57 0 C-N-CA 121.994 1.796 . . . . 0.0 114.527 -179.414 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 35.1 m80 -132.78 18.96 4.2 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 119.843 1.201 . . . . 0.0 111.427 179.064 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 31.8 tt0 -58.07 -49.86 75.45 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 178.133 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -55.96 -32.04 59.06 Favored Glycine 0 CA--C 1.531 1.046 0 C-N-CA 123.798 0.713 . . . . 0.0 112.005 178.61 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -82.32 4.12 25.05 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 117.497 0.648 . . . . 0.0 111.56 179.277 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 83.11 16.01 70.7 Favored Glycine 0 CA--C 1.526 0.727 0 CA-C-O 119.019 -0.878 . . . . 0.0 112.967 178.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 20.5 ttt -78.76 77.96 5.22 Favored 'General case' 0 C--O 1.237 0.398 0 CA-C-N 119.322 1.561 . . . . 0.0 108.569 178.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 8.1 m -128.0 174.65 11.16 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 C-N-CA 125.984 1.714 . . . . 0.0 110.993 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -166.66 174.08 42.06 Favored Glycine 0 CA--C 1.526 0.766 0 N-CA-C 111.053 -0.819 . . . . 0.0 111.053 177.461 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 23.6 ttmm -149.01 110.88 4.57 Favored 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 124.389 1.076 . . . . 0.0 110.057 -177.128 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.1 p -106.53 128.87 60.78 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.356 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 179.799 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.0 m -100.99 110.2 22.2 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 124.73 1.212 . . . . 0.0 110.354 -177.36 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 24.0 t -83.92 101.32 8.35 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.768 0 N-CA-C 105.799 -1.926 . . . . 0.0 105.799 179.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 2.7 m-80 . . . . . 0 N--CA 1.451 -0.402 0 C-N-CA 125.749 1.62 . . . . 0.0 108.922 -177.892 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 4.0 mm? . . . . . 0 N--CA 1.455 -0.208 0 CA-C-O 121.396 0.617 . . . . 0.0 111.705 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 14.6 tp10 -113.77 118.48 34.4 Favored 'General case' 0 N--CA 1.452 -0.367 0 N-CA-C 104.756 -2.313 . . . . 0.0 104.756 177.101 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 41.6 t -118.14 130.9 72.32 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 -178.827 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 68.8 mt -94.54 126.24 39.7 Favored 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 178.838 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 82.3 mt -90.13 98.94 12.06 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 105.835 -1.913 . . . . 0.0 105.835 177.046 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 110.57 -161.27 12.93 Favored Glycine 0 N--CA 1.447 -0.606 0 N-CA-C 109.095 -1.602 . . . . 0.0 109.095 -178.563 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 19.9 p -155.9 158.35 37.84 Favored 'General case' 0 N--CA 1.447 -0.591 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 -179.551 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.55 -39.99 31.16 Favored Glycine 0 CA--C 1.53 1.015 0 C-N-CA 123.538 0.59 . . . . 0.0 112.27 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -79.21 11.38 2.89 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 124.124 0.97 . . . . 0.0 112.642 179.218 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 70.12 14.02 70.62 Favored Glycine 0 CA--C 1.527 0.832 0 C-N-CA 124.605 1.098 . . . . 0.0 114.35 178.037 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 47.3 t -77.39 135.22 38.31 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 119.417 1.609 . . . . 0.0 108.82 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.497 ' H ' HD22 ' A' ' 12' ' ' LEU . 1.7 mm? -73.57 67.98 1.14 Allowed 'General case' 0 N--CA 1.443 -0.793 0 C-N-CA 126.011 1.724 . . . . 0.0 111.179 -178.249 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 20.9 m -129.76 153.16 38.41 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 C-N-CA 123.477 0.711 . . . . 0.0 110.4 179.498 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 39.5 m-85 -93.33 131.44 38.48 Favored 'General case' 0 C--N 1.332 -0.169 0 N-CA-C 104.132 -2.544 . . . . 0.0 104.132 175.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.3 t -125.03 109.66 27.43 Favored Pre-proline 0 CA--C 1.534 0.362 0 CA-C-N 119.161 0.891 . . . . 0.0 108.906 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_endo -72.04 150.77 95.08 Favored 'Cis proline' 0 N--CA 1.459 -0.533 0 CA-C-N 120.209 1.11 . . . . 0.0 110.987 -1.478 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.2 m -77.17 -48.08 18.62 Favored 'General case' 0 N--CA 1.456 -0.133 0 C-N-CA 123.036 0.534 . . . . 0.0 110.258 179.444 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -124.68 134.28 52.92 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 179.475 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 39.0 p90 -158.67 -176.83 6.11 Favored 'General case' 0 C--O 1.233 0.215 0 O-C-N 123.181 0.301 . . . . 0.0 110.7 -178.701 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 16.0 m -133.95 149.77 51.27 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 125.036 1.334 . . . . 0.0 107.925 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.7 p -144.98 138.99 14.73 Favored Pre-proline 0 CA--C 1.537 0.445 0 C-N-CA 123.796 0.839 . . . . 0.0 109.962 -177.843 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_exo -65.3 140.54 64.64 Favored 'Trans proline' 0 N--CA 1.455 -0.743 0 CA-C-N 120.746 1.302 . . . . 0.0 110.241 176.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 52.2 m -52.42 122.35 8.64 Favored 'General case' 0 N--CA 1.455 -0.193 0 C-N-CA 124.161 0.984 . . . . 0.0 110.857 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 102.56 -19.13 48.86 Favored Glycine 0 CA--C 1.528 0.877 0 CA-C-O 118.82 -0.989 . . . . 0.0 113.051 179.446 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -73.19 143.78 47.07 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-N 119.658 1.729 . . . . 0.0 110.25 179.312 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 18.3 ptmt -81.16 144.2 31.83 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 124.424 1.09 . . . . 0.0 111.58 -178.852 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 35.9 mt -113.2 130.48 67.04 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 178.424 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 59.7 t -114.25 102.63 14.15 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.245 0 C-N-CA 125.135 1.374 . . . . 0.0 108.017 -179.258 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -90.92 98.5 11.82 Favored 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 178.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 27.0 ttpp -91.75 132.38 36.44 Favored 'General case' 0 CA--C 1.528 0.132 0 C-N-CA 123.581 0.752 . . . . 0.0 112.724 -177.608 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 54.5 t-20 -66.21 110.25 2.95 Favored 'General case' 0 CA--C 1.53 0.21 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 176.395 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 -87.34 -72.96 0.49 Allowed 'General case' 0 C--N 1.338 0.078 0 CA-C-N 118.31 0.504 . . . . 0.0 110.843 -179.11 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -163.46 175.43 10.76 Favored 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 125.131 1.372 . . . . 0.0 107.732 -177.747 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 65.36 24.11 70.53 Favored Glycine 0 CA--C 1.534 1.272 0 CA-C-N 118.694 0.679 . . . . 0.0 111.594 -178.8 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.529 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 17.1 p90 -74.72 169.05 21.7 Favored Pre-proline 0 CA--C 1.542 0.668 0 N-CA-C 107.108 -1.442 . . . . 0.0 107.108 178.411 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.529 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 88.3 Cg_endo -69.53 158.3 90.45 Favored 'Cis proline' 0 N--CA 1.448 -1.201 0 CA-C-O 123.115 1.215 . . . . 0.0 114.994 3.731 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 88.2 m-70 -149.55 172.94 14.2 Favored 'General case' 0 N--CA 1.445 -0.711 0 CA-C-N 114.693 -1.14 . . . . 0.0 109.356 179.542 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 48.0 p30 -169.77 173.11 6.38 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 104.435 -2.432 . . . . 0.0 104.435 176.514 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 37.6 t -130.14 110.51 19.4 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.222 0 N-CA-C 107.767 -1.197 . . . . 0.0 107.767 -178.54 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.9 t -113.03 129.12 69.27 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.606 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 -179.737 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 62.2 m-85 -91.04 133.17 35.52 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 178.658 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -68.61 110.57 4.3 Favored 'General case' 0 N--CA 1.452 -0.352 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 -179.751 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -41.75 -35.0 0.7 Allowed 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 126.154 1.782 . . . . 0.0 115.747 -177.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -85.14 -50.01 7.77 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 118.5 0.591 . . . . 0.0 110.879 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -79.67 56.56 2.27 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 124.271 1.028 . . . . 0.0 112.412 -176.362 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 31.8 pt -153.35 156.57 32.57 Favored Pre-proline 0 CA--C 1.533 0.304 0 C-N-CA 126.689 1.996 . . . . 0.0 107.473 176.673 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_exo -53.62 109.5 0.38 Allowed 'Trans proline' 0 N--CA 1.456 -0.681 0 C-N-CA 122.819 2.346 . . . . 0.0 111.141 177.001 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -52.28 106.42 0.15 Allowed 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 124.203 1.001 . . . . 0.0 110.107 -179.772 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 142.29 -35.57 1.73 Allowed Glycine 0 CA--C 1.526 0.756 0 N-CA-C 109.005 -1.638 . . . . 0.0 109.005 -177.699 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 47.2 t -77.08 108.19 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 179.285 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 45.2 t0 -59.11 109.11 0.78 Allowed 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 123.039 0.535 . . . . 0.0 110.566 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.34 -40.42 17.21 Favored 'General case' 0 N--CA 1.453 -0.313 0 C-N-CA 125.079 1.351 . . . . 0.0 111.531 179.274 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 54.4 t -58.33 -28.77 36.3 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 C-N-CA 123.491 0.717 . . . . 0.0 111.925 -179.088 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 2.6 mmmp? -82.34 -40.66 21.1 Favored 'General case' 0 N--CA 1.461 0.122 0 CA-C-N 118.709 0.686 . . . . 0.0 110.909 -178.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.427 HD13 HG21 ' A' ' 55' ' ' ILE . 33.1 pt -78.14 -30.26 15.84 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.209 0 N-CA-C 112.191 0.441 . . . . 0.0 112.191 -179.842 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 35.5 m -90.7 146.74 23.76 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 114.667 1.358 . . . . 0.0 114.667 -176.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 48.2 mmm -74.67 128.05 86.18 Favored Pre-proline 0 N--CA 1.448 -0.556 0 N-CA-C 102.066 -3.309 . . . . 0.0 102.066 169.005 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -61.33 133.44 46.33 Favored 'Trans proline' 0 N--CA 1.453 -0.878 0 N-CA-C 107.213 -1.88 . . . . 0.0 107.213 178.609 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -43.32 -35.18 1.41 Allowed 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 124.506 1.122 . . . . 0.0 113.812 -176.757 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -55.0 -41.64 71.49 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 124.999 1.319 . . . . 0.0 111.414 178.399 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 74.9 mm-40 -85.3 144.41 28.1 Favored 'General case' 0 N--CA 1.444 -0.737 0 C-N-CA 124.186 0.994 . . . . 0.0 111.122 -177.904 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 92.3 mt -143.49 145.25 32.43 Favored 'General case' 0 N--CA 1.45 -0.442 0 C-N-CA 124.729 1.212 . . . . 0.0 110.446 -177.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 84.4 mt -86.23 99.85 11.83 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 104.421 -2.437 . . . . 0.0 104.421 175.245 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 33.0 p-10 -86.57 -51.4 6.19 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 124.189 0.996 . . . . 0.0 111.736 -177.556 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.91 143.49 66.51 Favored Pre-proline 0 CA--C 1.533 0.322 0 O-C-N 121.932 -0.48 . . . . 0.0 110.468 -177.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -64.91 152.4 82.4 Favored 'Trans proline' 0 N--CA 1.453 -0.872 0 C-N-CA 122.522 2.148 . . . . 0.0 109.513 178.322 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 86.14 -24.52 7.97 Favored Glycine 0 CA--C 1.527 0.822 0 CA-C-O 118.41 -1.217 . . . . 0.0 114.09 177.125 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 66.1 mt-10 -51.8 127.43 20.83 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-N 119.465 1.633 . . . . 0.0 110.522 179.11 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 11.8 p -105.63 120.7 42.32 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 124.772 1.229 . . . . 0.0 112.334 -178.713 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 25.1 t80 -95.01 107.54 19.58 Favored 'General case' 0 N--CA 1.452 -0.372 0 N-CA-C 104.743 -2.317 . . . . 0.0 104.743 173.576 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 22.6 t -95.63 138.13 22.0 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 -178.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 10.9 p -145.85 168.81 7.06 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.17 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 177.548 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 29.1 m -147.02 130.39 16.66 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 64.6 mt -114.31 116.85 29.62 Favored 'General case' 0 CA--C 1.531 0.224 0 C-N-CA 123.636 0.774 . . . . 0.0 109.766 -177.601 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -91.3 -46.37 8.08 Favored 'General case' 0 CA--C 1.531 0.239 0 C-N-CA 124.195 0.998 . . . . 0.0 111.716 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.7 m -73.22 121.03 19.66 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 122.792 0.437 . . . . 0.0 110.712 -177.069 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 23.4 pttm -64.77 153.17 40.69 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 122.918 0.487 . . . . 0.0 111.462 178.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 139.18 174.28 13.45 Favored Glycine 0 CA--C 1.529 0.911 0 C-N-CA 125.552 1.548 . . . . 0.0 110.467 179.426 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 99.0 m -99.01 116.95 32.42 Favored 'General case' 0 N--CA 1.456 -0.128 0 C-N-CA 124.296 1.038 . . . . 0.0 108.646 179.457 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 10.7 m-85 -103.82 134.31 47.34 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 125.368 1.467 . . . . 0.0 108.05 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 20.2 m -104.3 139.51 39.19 Favored 'General case' 0 C--O 1.232 0.173 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 176.333 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 15.6 p90 -138.13 166.37 24.3 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-O 121.474 0.654 . . . . 0.0 111.946 -179.421 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 43.7 p90 -152.22 162.45 41.11 Favored 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 124.393 1.077 . . . . 0.0 112.294 -178.697 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.6 t -101.57 106.68 17.79 Favored 'General case' 0 CA--C 1.52 -0.174 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 176.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 4.9 t -38.82 -64.21 0.51 Allowed Pre-proline 0 CA--C 1.542 0.645 0 N-CA-C 115.349 1.611 . . . . 0.0 115.349 -175.413 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -64.09 -4.31 7.44 Favored 'Trans proline' 0 C--N 1.348 0.537 0 C-N-CA 122.467 2.111 . . . . 0.0 114.533 -177.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 37.0 m80 -130.42 20.81 5.2 Favored 'General case' 0 N--CA 1.455 -0.216 0 CA-C-N 119.461 1.028 . . . . 0.0 110.698 179.041 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 4.6 tp60 -58.43 -51.97 67.58 Favored 'General case' 0 CA--C 1.533 0.296 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 177.093 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.13 -33.55 61.19 Favored Glycine 0 CA--C 1.532 1.129 0 C-N-CA 123.526 0.584 . . . . 0.0 111.866 178.276 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -81.54 1.57 33.01 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 123.284 0.634 . . . . 0.0 111.953 179.265 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 77.14 23.82 67.74 Favored Glycine 0 CA--C 1.526 0.757 0 CA-C-O 119.231 -0.76 . . . . 0.0 113.512 178.711 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 26.1 ttt -79.27 80.47 5.63 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-N 119.207 1.504 . . . . 0.0 107.406 177.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 16.5 m -121.65 169.49 12.91 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.191 0 C-N-CA 125.943 1.697 . . . . 0.0 110.878 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -170.93 179.47 42.81 Favored Glycine 0 CA--C 1.526 0.733 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 178.139 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 49.6 mttp -148.17 161.4 41.53 Favored 'General case' 0 CA--C 1.528 0.132 0 CA-C-N 117.985 0.893 . . . . 0.0 110.581 -179.474 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 3.8 p -145.04 124.01 5.84 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 C-N-CA 123.488 0.715 . . . . 0.0 110.201 178.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 99.1 m -98.32 98.22 9.49 Favored 'General case' 0 C--O 1.236 0.359 0 C-N-CA 124.641 1.176 . . . . 0.0 111.214 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 30.2 t -75.88 120.35 25.6 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.631 0 N-CA-C 104.617 -2.364 . . . . 0.0 104.617 179.184 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 5.5 p30 . . . . . 0 N--CA 1.464 0.238 0 N-CA-C 112.634 0.605 . . . . 0.0 112.634 -174.034 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 6.0 tp . . . . . 0 CA--C 1.533 0.298 0 CA-C-O 121.024 0.44 . . . . 0.0 111.274 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 -93.08 95.76 9.63 Favored 'General case' 0 N--CA 1.456 -0.172 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 177.228 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 33.5 t -91.97 138.27 20.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 C-N-CA 125.39 1.476 . . . . 0.0 109.076 -179.503 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 72.3 mt -99.76 125.44 45.67 Favored 'General case' 0 N--CA 1.45 -0.43 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 177.816 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 59.0 mt -86.46 101.93 13.61 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 105.855 -1.906 . . . . 0.0 105.855 178.196 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 95.87 157.88 32.01 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 108.347 -1.901 . . . . 0.0 108.347 -178.196 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 53.9 p -107.57 159.71 16.23 Favored 'General case' 0 N--CA 1.445 -0.718 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 -179.833 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.91 -34.62 61.81 Favored Glycine 0 CA--C 1.529 0.937 0 C-N-CA 124.183 0.897 . . . . 0.0 111.262 178.689 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -75.66 -2.9 31.64 Favored 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 123.519 0.728 . . . . 0.0 112.243 178.902 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 96.36 -17.86 58.51 Favored Glycine 0 CA--C 1.526 0.764 0 CA-C-O 118.903 -0.943 . . . . 0.0 113.556 178.671 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 32.8 t -57.27 132.35 52.76 Favored 'General case' 0 C--O 1.238 0.487 0 CA-C-N 119.4 1.6 . . . . 0.0 110.487 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 47.8 mt -77.59 67.39 3.49 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 126.818 2.047 . . . . 0.0 110.384 -177.087 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.6 m -128.2 153.76 38.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 C-N-CA 123.264 0.626 . . . . 0.0 110.611 179.862 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -87.43 130.64 34.6 Favored 'General case' 0 N--CA 1.453 -0.311 0 N-CA-C 104.153 -2.536 . . . . 0.0 104.153 175.259 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 35.3 t -120.45 108.96 37.06 Favored Pre-proline 0 CA--C 1.535 0.385 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_endo -73.3 157.2 99.31 Favored 'Cis proline' 0 N--CA 1.459 -0.552 0 CA-C-N 120.332 1.154 . . . . 0.0 110.48 -1.566 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.5 m -79.16 -43.33 24.19 Favored 'General case' 0 C--N 1.332 -0.153 0 C-N-CA 123.054 0.542 . . . . 0.0 110.884 -179.598 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -129.08 145.18 51.34 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 106.669 -1.604 . . . . 0.0 106.669 178.192 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 19.2 p90 -166.52 -179.62 5.01 Favored 'General case' 0 C--O 1.235 0.342 0 C-N-CA 123.213 0.605 . . . . 0.0 110.186 -177.665 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 37.1 p -139.71 136.29 34.06 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 124.422 1.089 . . . . 0.0 108.684 -178.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 33.7 m -130.09 146.27 60.76 Favored Pre-proline 0 CA--C 1.533 0.298 0 C-N-CA 124.177 0.991 . . . . 0.0 110.185 179.606 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_exo -57.67 144.34 93.09 Favored 'Trans proline' 0 N--CA 1.455 -0.742 0 C-N-CA 122.591 2.194 . . . . 0.0 110.845 174.785 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 16.3 m -51.26 119.58 4.19 Favored 'General case' 0 CA--C 1.529 0.149 0 C-N-CA 122.608 0.363 . . . . 0.0 110.955 177.846 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 96.72 -7.48 65.44 Favored Glycine 0 CA--C 1.525 0.68 0 CA-C-O 118.426 -1.208 . . . . 0.0 113.618 178.526 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -69.18 152.96 44.46 Favored 'General case' 0 CA--C 1.531 0.224 0 CA-C-N 119.953 1.877 . . . . 0.0 110.494 178.28 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 64.4 mttp -83.36 142.0 31.35 Favored 'General case' 0 N--CA 1.446 -0.666 0 C-N-CA 124.172 0.989 . . . . 0.0 109.882 -178.502 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 37.8 mt -120.56 130.08 74.89 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 105.963 -1.866 . . . . 0.0 105.963 178.386 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 84.9 t -121.88 131.42 73.16 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.428 0 N-CA-C 106.459 -1.682 . . . . 0.0 106.459 -179.242 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -118.19 103.47 9.88 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 178.799 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 38.0 ttpt -100.76 131.3 46.72 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 123.886 0.874 . . . . 0.0 113.296 -175.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 6.2 m-20 -64.96 107.81 1.61 Allowed 'General case' 0 C--O 1.232 0.137 0 C-N-CA 124.124 0.969 . . . . 0.0 109.975 177.708 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 7.0 t30 -87.67 -64.42 1.15 Allowed 'General case' 0 N--CA 1.456 -0.148 0 CA-C-O 121.496 0.665 . . . . 0.0 110.089 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -163.1 172.8 14.36 Favored 'General case' 0 C--N 1.331 -0.213 0 C-N-CA 125.54 1.536 . . . . 0.0 107.191 -178.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 66.2 20.28 69.05 Favored Glycine 0 CA--C 1.534 1.219 0 CA-C-N 118.291 0.496 . . . . 0.0 112.839 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.505 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 23.4 p90 -69.96 166.94 27.89 Favored Pre-proline 0 CA--C 1.549 0.905 0 N-CA-C 106.444 -1.688 . . . . 0.0 106.444 177.177 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.505 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 88.3 Cg_endo -69.94 156.43 93.27 Favored 'Cis proline' 0 N--CA 1.444 -1.386 0 N-CA-C 115.712 1.389 . . . . 0.0 115.712 4.719 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 86.9 m-70 -147.81 164.86 32.34 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.83 -179.773 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 56.0 p30 -162.36 177.62 9.39 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 104.986 -2.228 . . . . 0.0 104.986 177.259 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 33.6 t -135.66 111.01 11.88 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 -179.547 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 93.9 t -115.19 130.47 69.68 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.586 0 N-CA-C 106.394 -1.706 . . . . 0.0 106.394 179.568 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 54.4 m-85 -87.59 136.31 33.0 Favored 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 123.4 0.68 . . . . 0.0 109.755 -179.394 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 43.7 t0 -73.11 103.89 4.01 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -47.54 -32.46 5.37 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 124.139 0.976 . . . . 0.0 113.555 179.207 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -77.3 -17.19 58.53 Favored 'General case' 0 CA--C 1.535 0.386 0 N-CA-C 112.983 0.734 . . . . 0.0 112.983 -179.78 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 81.5 mm-40 -132.91 65.9 1.58 Allowed 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.112 0.965 . . . . 0.0 111.801 -177.17 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 29.3 pt -153.3 153.49 29.44 Favored Pre-proline 0 CA--C 1.533 0.326 0 C-N-CA 127.542 2.337 . . . . 0.0 105.851 175.784 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -60.47 113.47 1.7 Allowed 'Trans proline' 0 N--CA 1.452 -0.964 0 C-N-CA 121.972 1.781 . . . . 0.0 110.556 178.293 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -51.5 108.37 0.26 Allowed 'General case' 0 N--CA 1.453 -0.276 0 C-N-CA 125.111 1.364 . . . . 0.0 110.397 -179.248 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 143.61 -37.51 1.45 Allowed Glycine 0 CA--C 1.524 0.617 0 N-CA-C 109.019 -1.632 . . . . 0.0 109.019 -178.428 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 45.8 t -77.58 113.82 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.239 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 41.9 t0 -60.94 111.65 1.75 Allowed 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 122.769 0.428 . . . . 0.0 110.114 179.543 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.4 -41.47 20.0 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 124.685 1.194 . . . . 0.0 111.149 178.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 48.6 t -59.7 -29.16 42.19 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.395 0 C-N-CA 123.283 0.633 . . . . 0.0 112.048 -179.053 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 64.3 mttp -78.71 -40.93 32.31 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-N 119.055 0.843 . . . . 0.0 110.772 -179.173 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.416 HD13 HG21 ' A' ' 55' ' ' ILE . 23.1 pt -77.6 -33.36 19.12 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 N-CA-C 111.917 0.34 . . . . 0.0 111.917 -179.767 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 49.1 m -82.55 138.97 34.11 Favored 'General case' 0 N--CA 1.452 -0.341 0 N-CA-C 113.935 1.087 . . . . 0.0 113.935 -177.602 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 15.7 tpt -70.85 126.16 92.11 Favored Pre-proline 0 N--CA 1.449 -0.498 0 N-CA-C 101.956 -3.35 . . . . 0.0 101.956 170.813 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 76.2 Cg_exo -43.91 119.27 1.88 Allowed 'Trans proline' 0 N--CA 1.457 -0.66 0 C-N-CA 122.929 2.419 . . . . 0.0 111.51 -178.457 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -47.0 -34.97 6.08 Favored 'General case' 0 CA--C 1.532 0.255 0 C-N-CA 125.162 1.385 . . . . 0.0 113.708 -177.465 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 31.0 tp10 -61.61 -34.51 75.77 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.325 1.05 . . . . 0.0 110.729 179.009 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 63.0 mt-10 -91.68 154.61 18.88 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 124.911 1.284 . . . . 0.0 110.508 -178.61 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -160.97 139.75 10.09 Favored 'General case' 0 N--CA 1.445 -0.68 0 CA-C-N 115.015 -0.993 . . . . 0.0 110.971 179.867 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 73.8 mt -77.86 112.39 14.68 Favored 'General case' 0 N--CA 1.448 -0.575 0 N-CA-C 105.059 -2.2 . . . . 0.0 105.059 178.199 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 63.7 t30 -115.54 46.69 1.45 Allowed 'General case' 0 N--CA 1.464 0.247 0 C-N-CA 124.2 1.0 . . . . 0.0 112.491 -177.03 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -160.5 155.39 20.74 Favored Pre-proline 0 CA--C 1.531 0.22 0 N-CA-C 107.08 -1.452 . . . . 0.0 107.08 178.204 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -73.02 162.64 40.42 Favored 'Trans proline' 0 N--CA 1.454 -0.833 0 C-N-CA 122.013 1.808 . . . . 0.0 109.332 178.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 77.42 -35.94 1.56 Allowed Glycine 0 CA--C 1.529 0.938 0 CA-C-O 118.798 -1.001 . . . . 0.0 114.709 176.256 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 74.5 mm-40 -47.0 134.45 10.39 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 118.783 1.291 . . . . 0.0 111.387 179.165 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 21.8 p -119.53 132.56 55.78 Favored 'General case' 0 N--CA 1.456 -0.134 0 N-CA-C 113.83 1.048 . . . . 0.0 113.83 -177.436 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 31.9 t80 -100.91 140.38 35.28 Favored 'General case' 0 CA--C 1.529 0.166 0 N-CA-C 103.801 -2.666 . . . . 0.0 103.801 170.746 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 22.0 t -128.89 145.45 35.71 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.109 0 CA-C-N 119.007 0.821 . . . . 0.0 109.74 -177.647 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 12.5 p -152.23 169.23 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.197 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 178.367 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 83.6 m -149.06 133.62 17.68 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 106.264 -1.754 . . . . 0.0 106.264 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 79.2 mt -121.25 112.14 18.25 Favored 'General case' 0 CA--C 1.53 0.189 0 C-N-CA 123.234 0.614 . . . . 0.0 110.52 -177.305 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -93.86 -39.86 10.48 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 124.427 1.091 . . . . 0.0 110.543 178.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 6.4 m -70.19 122.11 18.85 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 123.594 0.758 . . . . 0.0 110.091 -178.162 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 20.8 mmtm -59.24 160.29 6.66 Favored 'General case' 0 CA--C 1.529 0.14 0 C-N-CA 124.186 0.995 . . . . 0.0 110.988 -179.692 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 134.96 -170.29 22.91 Favored Glycine 0 CA--C 1.524 0.6 0 C-N-CA 123.604 0.621 . . . . 0.0 111.822 177.703 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 25.3 m -121.26 130.34 53.62 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 105.503 -2.036 . . . . 0.0 105.503 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 16.5 m-85 -124.05 135.01 53.29 Favored 'General case' 0 N--CA 1.448 -0.525 0 C-N-CA 124.106 0.962 . . . . 0.0 109.818 -176.595 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 19.2 m -108.81 143.6 37.77 Favored 'General case' 0 C--O 1.233 0.199 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 175.644 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 11.8 p90 -143.89 171.31 14.41 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-O 121.15 0.5 . . . . 0.0 111.167 -179.308 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 34.4 p90 -157.76 167.38 30.21 Favored 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 123.805 0.842 . . . . 0.0 111.917 -179.176 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.3 t -102.99 109.31 20.8 Favored 'General case' 0 N--CA 1.463 0.181 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 177.494 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -40.92 -61.09 1.37 Allowed Pre-proline 0 CA--C 1.535 0.395 0 N-CA-C 115.659 1.725 . . . . 0.0 115.659 -173.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 63.6 Cg_endo -65.96 -4.2 9.71 Favored 'Trans proline' 0 N--CA 1.457 -0.638 0 C-N-CA 121.885 1.723 . . . . 0.0 114.87 -177.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 34.9 m80 -135.21 4.78 3.22 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-N 120.183 1.356 . . . . 0.0 113.185 -179.395 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 16.2 pt20 -55.7 -44.38 77.33 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 119.652 1.115 . . . . 0.0 109.975 178.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -59.17 -28.15 63.71 Favored Glycine 0 CA--C 1.531 1.037 0 N-CA-C 111.454 -0.659 . . . . 0.0 111.454 177.598 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.83 10.09 24.96 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 123.875 0.87 . . . . 0.0 110.843 178.771 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 87.31 10.22 71.47 Favored Glycine 0 CA--C 1.527 0.819 0 CA-C-O 118.558 -1.135 . . . . 0.0 113.789 178.29 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 18.4 ttt -78.96 76.54 5.45 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 119.791 1.796 . . . . 0.0 109.17 179.006 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 9.5 m -123.36 169.72 14.42 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 C-N-CA 126.388 1.875 . . . . 0.0 109.664 179.172 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -170.02 -179.8 41.85 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 110.211 -1.156 . . . . 0.0 110.211 178.156 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 54.1 mtmt -145.44 163.18 35.45 Favored 'General case' 0 N--CA 1.455 -0.224 0 C-N-CA 124.218 1.007 . . . . 0.0 110.29 -178.294 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.4 p -152.93 136.14 7.54 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 C-N-CA 123.898 0.879 . . . . 0.0 108.975 177.34 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -107.26 130.43 54.75 Favored 'General case' 0 C--N 1.332 -0.167 0 C-N-CA 124.441 1.096 . . . . 0.0 109.167 -179.633 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 43.4 t -99.8 97.81 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 N-CA-C 106.078 -1.823 . . . . 0.0 106.078 179.252 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 17.4 m-20 . . . . . 0 C--O 1.236 0.377 0 C-N-CA 123.604 0.762 . . . . 0.0 109.551 -176.728 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . 0.527 ' H1 ' HD13 ' A' ' 1' ' ' LEU . 0.1 OUTLIER . . . . . 0 N--CA 1.451 -0.416 0 N-CA-C 105.976 -1.861 . . . . 0.0 105.976 . . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 69.2 tt0 -83.12 85.24 7.23 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 105.142 -2.17 . . . . 0.0 105.142 174.744 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 38.4 t -78.56 111.31 15.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 -176.713 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 57.8 mt -79.59 123.53 27.69 Favored 'General case' 0 N--CA 1.451 -0.416 0 N-CA-C 108.377 -0.971 . . . . 0.0 108.377 179.814 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 79.4 mt -84.23 107.41 16.52 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 178.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 86.56 130.48 2.79 Favored Glycine 0 C--N 1.337 0.599 0 N-CA-C 108.536 -1.826 . . . . 0.0 108.536 -179.014 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 5.0 p -78.99 157.46 28.13 Favored 'General case' 0 N--CA 1.441 -0.883 0 CA-C-N 118.461 1.131 . . . . 0.0 108.623 -178.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -43.94 -37.85 4.35 Favored Glycine 0 CA--C 1.531 1.06 0 C-N-CA 125.871 1.701 . . . . 0.0 113.76 -179.292 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -75.67 2.26 12.44 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 123.952 0.901 . . . . 0.0 113.253 -179.473 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 91.19 -10.33 75.22 Favored Glycine 0 CA--C 1.528 0.862 0 CA-C-O 118.828 -0.985 . . . . 0.0 113.188 -179.563 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.2 t -61.35 134.3 56.78 Favored 'General case' 0 C--N 1.343 0.293 0 CA-C-N 119.447 1.623 . . . . 0.0 110.518 -179.046 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 56.2 mt -76.63 66.06 2.53 Favored 'General case' 0 N--CA 1.447 -0.59 0 C-N-CA 126.079 1.751 . . . . 0.0 111.292 -176.312 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 29.4 m -131.13 148.65 32.94 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 C-N-CA 123.767 0.827 . . . . 0.0 110.361 179.437 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 49.9 m-85 -82.0 138.74 34.84 Favored 'General case' 0 N--CA 1.455 -0.204 0 N-CA-C 104.485 -2.413 . . . . 0.0 104.485 175.525 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.4 t -123.78 107.09 31.46 Favored Pre-proline 0 CA--C 1.533 0.302 0 CA-C-O 118.33 -0.843 . . . . 0.0 108.755 179.422 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_exo -70.45 154.69 95.22 Favored 'Cis proline' 0 C--N 1.346 0.429 0 CA-C-N 119.877 0.992 . . . . 0.0 112.015 -0.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.6 m -80.24 -45.44 17.97 Favored 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 177.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -126.98 142.5 51.54 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 105.84 -1.911 . . . . 0.0 105.84 177.642 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 33.8 p90 -166.88 175.62 7.59 Favored 'General case' 0 N--CA 1.455 -0.202 0 C-N-CA 123.637 0.775 . . . . 0.0 109.319 -178.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 16.4 m -134.8 143.16 46.92 Favored 'General case' 0 N--CA 1.45 -0.439 0 C-N-CA 124.499 1.12 . . . . 0.0 108.187 -179.652 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 32.7 m -137.73 149.51 64.9 Favored Pre-proline 0 CA--C 1.53 0.192 0 C-N-CA 124.632 1.173 . . . . 0.0 108.675 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -71.66 148.66 53.51 Favored 'Trans proline' 0 N--CA 1.448 -1.163 0 C-N-CA 121.76 1.64 . . . . 0.0 108.902 176.426 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 52.3 m -49.01 121.75 5.11 Favored 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 123.434 0.694 . . . . 0.0 110.961 178.572 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 99.51 -10.42 61.12 Favored Glycine 0 CA--C 1.526 0.766 0 CA-C-O 118.452 -1.193 . . . . 0.0 113.513 178.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -65.6 144.54 56.9 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 119.982 1.891 . . . . 0.0 108.969 178.394 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.2 ptmt -89.36 140.85 29.09 Favored 'General case' 0 N--CA 1.443 -0.825 0 N-CA-C 108.606 -0.886 . . . . 0.0 108.606 178.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 35.8 mt -112.61 131.94 62.74 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.386 0 N-CA-C 105.305 -2.109 . . . . 0.0 105.305 179.066 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 95.2 t -119.01 101.07 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.351 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 -179.071 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -86.27 132.66 33.94 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 106.228 -1.768 . . . . 0.0 106.228 177.357 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 61.1 tttp -131.27 130.54 42.96 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 119.237 0.926 . . . . 0.0 112.629 -176.699 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 4.1 m-20 -64.18 105.95 0.99 Allowed 'General case' 0 C--O 1.232 0.153 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 176.796 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 36.0 t30 -97.44 -69.72 0.75 Allowed 'General case' 0 N--CA 1.456 -0.162 0 CA-C-O 121.121 0.486 . . . . 0.0 110.521 -179.58 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -143.46 170.42 15.84 Favored 'General case' 0 C--O 1.224 -0.271 0 C-N-CA 124.102 0.961 . . . . 0.0 109.15 -178.56 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 57.75 19.68 36.81 Favored Glycine 0 CA--C 1.536 1.393 0 CA-C-N 118.748 0.703 . . . . 0.0 114.094 179.56 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.497 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 27.0 p90 -71.25 167.02 33.12 Favored Pre-proline 0 CA--C 1.542 0.662 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 178.026 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.497 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 94.6 Cg_endo -70.49 160.42 90.25 Favored 'Cis proline' 0 N--CA 1.448 -1.153 0 N-CA-C 115.571 1.335 . . . . 0.0 115.571 4.336 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 86.7 m-70 -151.87 173.16 15.12 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.672 -178.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 57.2 p30 -163.14 178.25 8.41 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 105.035 -2.209 . . . . 0.0 105.035 176.397 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 24.0 t -135.39 110.23 11.51 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.307 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 -179.207 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 53.7 t -112.93 131.02 65.69 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 N-CA-C 106.552 -1.647 . . . . 0.0 106.552 179.545 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -92.02 132.64 36.4 Favored 'General case' 0 N--CA 1.45 -0.43 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 178.411 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -71.74 101.2 2.52 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 -178.881 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -37.61 -36.68 0.18 Allowed 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 126.676 1.99 . . . . 0.0 115.681 179.48 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 72.6 m-20 -77.94 -43.71 29.04 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-N 118.747 0.703 . . . . 0.0 110.343 179.755 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -93.32 57.58 2.68 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 124.487 1.115 . . . . 0.0 113.028 -176.502 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 37.5 pt -154.98 157.86 32.0 Favored Pre-proline 0 CA--C 1.533 0.306 0 C-N-CA 126.392 1.877 . . . . 0.0 106.879 176.238 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -57.85 108.15 0.36 Allowed 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 122.09 1.86 . . . . 0.0 108.245 173.812 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -35.08 -43.4 0.2 Allowed 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 126.829 2.052 . . . . 0.0 115.433 -177.084 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -57.68 -31.59 64.09 Favored Glycine 0 CA--C 1.533 1.218 0 C-N-CA 123.114 0.387 . . . . 0.0 113.341 -179.208 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 41.8 t -83.54 99.94 6.61 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 CA-C-N 117.945 0.873 . . . . 0.0 109.186 -178.595 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 17.4 t0 -53.6 113.29 1.12 Allowed 'General case' 0 CA--C 1.536 0.405 0 C-N-CA 123.321 0.648 . . . . 0.0 110.306 178.149 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -46.67 -39.91 12.23 Favored 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 125.778 1.631 . . . . 0.0 112.295 -179.874 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 54.0 t -59.11 -27.72 36.92 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 C-N-CA 123.101 0.561 . . . . 0.0 111.706 -178.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 2.9 mmmp? -77.91 -42.94 31.5 Favored 'General case' 0 CA--C 1.529 0.16 0 CA-C-N 118.675 0.671 . . . . 0.0 110.837 -179.096 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.407 HG21 HD13 ' A' ' 55' ' ' ILE . 26.4 pt -78.78 -33.44 16.49 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.339 0 N-CA-C 112.284 0.475 . . . . 0.0 112.284 -179.037 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 44.4 m -80.52 141.69 34.9 Favored 'General case' 0 C--N 1.333 -0.112 0 N-CA-C 114.96 1.467 . . . . 0.0 114.96 -176.599 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -73.69 137.85 77.1 Favored Pre-proline 0 CA--C 1.539 0.528 0 N-CA-C 103.031 -2.951 . . . . 0.0 103.031 172.008 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_endo -48.97 107.31 0.14 Allowed 'Trans proline' 0 CA--C 1.535 0.568 0 C-N-CA 122.768 2.312 . . . . 0.0 112.173 -178.565 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -35.91 -43.55 0.32 Allowed 'General case' 0 C--O 1.233 0.204 0 C-N-CA 128.283 2.633 . . . . 0.0 116.598 -176.334 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 13.8 tm-20 -73.81 -32.39 63.71 Favored 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 124.576 1.15 . . . . 0.0 111.637 -178.363 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 51.8 mt-10 -84.93 165.45 17.62 Favored 'General case' 0 N--CA 1.446 -0.647 0 C-N-CA 124.118 0.967 . . . . 0.0 109.426 -177.435 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 2.2 pp -157.65 160.72 38.31 Favored 'General case' 0 N--CA 1.448 -0.547 0 CA-C-O 121.419 0.628 . . . . 0.0 112.072 -178.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 72.9 mt -86.82 109.12 19.06 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 104.166 -2.531 . . . . 0.0 104.166 177.075 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 34.6 p-10 -81.14 -55.45 4.74 Favored 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 123.936 0.895 . . . . 0.0 113.282 -176.658 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.32 156.76 78.59 Favored Pre-proline 0 CA--C 1.535 0.373 0 C-N-CA 123.918 0.887 . . . . 0.0 112.302 -176.426 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -67.04 163.39 34.14 Favored 'Trans proline' 0 N--CA 1.455 -0.74 0 C-N-CA 122.364 2.043 . . . . 0.0 108.967 175.109 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 79.1 -36.48 1.94 Allowed Glycine 0 CA--C 1.528 0.897 0 CA-C-O 119.041 -0.866 . . . . 0.0 113.62 177.336 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 50.7 mm-40 -42.26 129.14 3.81 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 124.606 1.162 . . . . 0.0 110.683 178.564 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -111.83 159.76 18.01 Favored 'General case' 0 N--CA 1.452 -0.354 0 C-N-CA 124.665 1.186 . . . . 0.0 112.393 -177.07 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 75.8 t80 -138.24 111.58 8.03 Favored 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 105.136 -2.172 . . . . 0.0 105.136 174.623 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 37.4 t -101.71 142.2 16.69 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 C-N-CA 123.686 0.794 . . . . 0.0 109.657 -177.635 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 12.1 p -149.51 168.0 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 177.648 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 28.7 m -147.46 129.61 15.54 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 107.367 -1.346 . . . . 0.0 107.367 -179.858 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 62.3 mt -113.26 107.45 15.91 Favored 'General case' 0 CA--C 1.53 0.183 0 C-N-CA 123.461 0.704 . . . . 0.0 110.319 -177.394 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -86.99 -45.03 11.15 Favored 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 123.65 0.78 . . . . 0.0 111.347 179.397 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.7 m -71.88 122.34 20.61 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 123.05 0.54 . . . . 0.0 110.742 -177.063 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 55.6 mttp -59.9 160.85 7.2 Favored 'General case' 0 N--CA 1.456 -0.17 0 C-N-CA 124.835 1.254 . . . . 0.0 112.342 179.482 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 136.94 -142.82 13.98 Favored Glycine 0 C--N 1.334 0.469 0 N-CA-C 110.209 -1.156 . . . . 0.0 110.209 177.285 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 85.2 m -146.14 135.2 22.65 Favored 'General case' 0 N--CA 1.444 -0.75 0 N-CA-C 105.221 -2.14 . . . . 0.0 105.221 178.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 10.6 m-85 -124.7 130.08 51.74 Favored 'General case' 0 N--CA 1.446 -0.672 0 C-N-CA 123.937 0.895 . . . . 0.0 108.669 -176.456 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 17.7 m -100.32 141.52 33.05 Favored 'General case' 0 C--O 1.233 0.191 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 176.425 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 20.3 p90 -140.0 168.98 18.56 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-O 121.293 0.568 . . . . 0.0 111.275 -179.443 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 52.2 p90 -158.34 166.53 32.08 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 115.52 -0.764 . . . . 0.0 111.788 -179.264 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.3 t -105.49 107.63 18.72 Favored 'General case' 0 CA--C 1.519 -0.247 0 N-CA-C 105.817 -1.92 . . . . 0.0 105.817 177.346 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.305 0.3 OUTLIER -49.37 -56.15 17.93 Favored Pre-proline 0 CA--C 1.532 0.273 0 CA-C-N 119.119 0.872 . . . . 0.0 113.057 -174.667 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_exo -46.29 -19.49 0.65 Allowed 'Trans proline' 0 N--CA 1.457 -0.654 0 C-N-CA 123.741 2.961 . . . . 0.0 115.883 177.422 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 38.0 m80 -136.63 18.27 3.09 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 119.829 1.195 . . . . 0.0 112.16 179.764 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 15.2 pt20 -60.57 -41.69 95.14 Favored 'General case' 0 N--CA 1.455 -0.204 0 CA-C-N 119.16 0.891 . . . . 0.0 109.58 179.491 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -58.33 -28.99 62.57 Favored Glycine 0 CA--C 1.532 1.136 0 N-CA-C 111.334 -0.707 . . . . 0.0 111.334 177.203 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -90.44 11.42 21.67 Favored 'General case' 0 CA--C 1.534 0.327 0 C-N-CA 123.781 0.832 . . . . 0.0 110.954 178.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 78.64 19.11 74.22 Favored Glycine 0 CA--C 1.527 0.819 0 CA-C-O 118.604 -1.109 . . . . 0.0 113.575 178.657 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 22.5 ttt -78.69 76.58 5.18 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-N 119.775 1.788 . . . . 0.0 108.756 178.147 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 10.2 m -120.86 172.54 7.76 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 C-N-CA 126.191 1.796 . . . . 0.0 109.787 179.566 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -170.52 177.34 43.73 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 177.672 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 58.6 mttp -146.63 157.26 43.68 Favored 'General case' 0 CA--C 1.526 0.047 0 CA-C-N 117.53 0.665 . . . . 0.0 110.623 -178.855 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 5.5 p -143.82 126.14 11.47 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.289 0 C-N-CA 123.152 0.581 . . . . 0.0 110.48 177.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.28 124.06 34.06 Favored 'General case' 0 CA--C 1.53 0.179 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 177.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 40.7 t -100.28 95.04 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.209 0 N-CA-C 103.161 -2.903 . . . . 0.0 103.161 177.302 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 . . . . . 0 N--CA 1.453 -0.297 0 C-N-CA 125.019 1.328 . . . . 0.0 113.108 -173.945 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 8.2 mp . . . . . 0 N--CA 1.451 -0.387 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -98.79 97.61 8.81 Favored 'General case' 0 N--CA 1.453 -0.298 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 178.24 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 40.6 t -87.77 121.52 38.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 C-N-CA 124.51 1.124 . . . . 0.0 108.527 -179.463 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 70.0 mt -85.07 122.48 29.34 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 108.588 -0.894 . . . . 0.0 108.588 179.065 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 72.2 mt -86.84 99.88 12.14 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 106.103 -1.814 . . . . 0.0 106.103 177.783 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 100.9 151.29 25.04 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 108.713 -1.755 . . . . 0.0 108.713 -178.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 96.5 p -86.73 172.94 9.79 Favored 'General case' 0 N--CA 1.445 -0.711 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 177.378 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -54.08 -43.25 73.03 Favored Glycine 0 CA--C 1.53 0.971 0 N-CA-C 110.4 -1.08 . . . . 0.0 110.4 178.219 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -81.29 13.78 2.74 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 123.313 0.645 . . . . 0.0 112.221 178.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 74.48 16.98 79.8 Favored Glycine 0 CA--C 1.526 0.737 0 CA-C-O 118.849 -0.973 . . . . 0.0 114.156 178.2 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 22.8 t -71.33 140.13 50.13 Favored 'General case' 0 C--N 1.34 0.161 0 CA-C-N 119.443 1.622 . . . . 0.0 107.119 178.293 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 67.6 mt -76.52 67.65 2.71 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 125.136 1.374 . . . . 0.0 111.954 -175.411 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 26.0 m -135.17 150.17 29.4 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.21 0 C-N-CA 123.593 0.757 . . . . 0.0 110.498 179.654 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 45.3 m-85 -89.58 129.44 36.04 Favored 'General case' 0 N--CA 1.457 -0.099 0 N-CA-C 104.809 -2.293 . . . . 0.0 104.809 175.757 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 37.0 t -122.5 107.74 34.07 Favored Pre-proline 0 CA--C 1.537 0.467 0 CA-C-O 118.496 -0.764 . . . . 0.0 109.162 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -71.69 161.5 91.04 Favored 'Cis proline' 0 N--CA 1.457 -0.635 0 CA-C-N 120.227 1.117 . . . . 0.0 111.044 -1.355 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 6.2 p -86.21 -64.71 1.11 Allowed 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 178.345 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 64.9 tt0 -102.6 127.15 49.82 Favored 'General case' 0 N--CA 1.454 -0.275 0 C-N-CA 125.819 1.648 . . . . 0.0 107.577 178.47 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 33.9 p90 -150.34 -171.51 3.93 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-O 121.578 0.704 . . . . 0.0 111.998 178.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 7.0 m -141.63 146.8 36.63 Favored 'General case' 0 N--CA 1.45 -0.431 0 C-N-CA 124.655 1.182 . . . . 0.0 108.229 -178.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.0 p -148.85 137.89 12.21 Favored Pre-proline 0 CA--C 1.539 0.552 0 C-N-CA 123.28 0.632 . . . . 0.0 110.501 -177.911 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_exo -66.59 139.7 54.25 Favored 'Trans proline' 0 N--CA 1.455 -0.736 0 C-N-CA 121.424 1.416 . . . . 0.0 111.013 176.585 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 63.1 m -46.7 127.63 9.82 Favored 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 123.708 0.803 . . . . 0.0 110.978 177.125 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 94.96 -23.82 31.37 Favored Glycine 0 CA--C 1.529 0.946 0 CA-C-O 119.188 -0.784 . . . . 0.0 113.338 178.673 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 74.9 mm-40 -74.15 96.1 2.69 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 119.469 1.634 . . . . 0.0 109.318 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -41.42 126.5 2.84 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 125.734 1.614 . . . . 0.0 114.119 179.499 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 60.3 mt -90.06 136.77 22.98 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.314 0 N-CA-C 105.943 -1.873 . . . . 0.0 105.943 178.036 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 66.6 t -117.76 119.39 61.46 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.33 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 179.532 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 95.3 m-85 -106.16 109.38 21.3 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 178.338 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 62.5 tttp -105.16 129.31 53.58 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 124.489 1.115 . . . . 0.0 113.322 -175.159 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 3.6 m-20 -65.58 110.54 2.77 Favored 'General case' 0 C--O 1.23 0.07 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 176.834 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 51.1 t-20 -84.33 -72.08 0.48 Allowed 'General case' 0 N--CA 1.456 -0.166 0 N-CA-C 111.738 0.273 . . . . 0.0 111.738 -178.653 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -146.24 -53.54 0.25 Allowed 'General case' 0 C--O 1.225 -0.199 0 N-CA-C 114.359 1.244 . . . . 0.0 114.359 -175.82 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -69.69 33.88 0.37 Allowed Glycine 0 CA--C 1.538 1.494 0 N-CA-C 116.24 1.256 . . . . 0.0 116.24 -176.762 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.435 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 18.9 p90 -73.34 165.71 50.45 Favored Pre-proline 0 CA--C 1.543 0.705 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 179.783 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.435 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 34.0 Cg_exo -62.27 149.38 60.03 Favored 'Cis proline' 0 N--CA 1.451 -0.992 0 N-CA-C 116.425 1.663 . . . . 0.0 116.425 2.446 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 91.8 m-70 -145.95 172.6 13.13 Favored 'General case' 0 N--CA 1.447 -0.59 0 O-C-N 121.715 -0.616 . . . . 0.0 110.157 179.19 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 22.9 p-10 -169.42 175.85 5.33 Favored 'General case' 0 N--CA 1.447 -0.583 0 N-CA-C 104.048 -2.575 . . . . 0.0 104.048 176.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 46.5 t -137.99 114.67 11.4 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.332 0 N-CA-C 107.225 -1.398 . . . . 0.0 107.225 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 62.0 t -119.46 135.97 58.12 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 106.335 -1.728 . . . . 0.0 106.335 179.427 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 57.2 m-85 -89.23 135.5 33.54 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 123.219 0.608 . . . . 0.0 109.682 -178.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 7.3 t0 -74.85 99.46 3.79 Favored 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 124.315 1.046 . . . . 0.0 109.721 -179.06 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -44.21 -34.33 1.84 Allowed 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 124.687 1.195 . . . . 0.0 113.59 178.714 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -66.96 -25.58 66.41 Favored 'General case' 0 CA--C 1.536 0.419 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 179.831 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -135.36 76.23 1.61 Allowed 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 123.683 0.793 . . . . 0.0 111.136 -177.312 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 25.8 pt -153.66 149.94 22.16 Favored Pre-proline 0 CA--C 1.535 0.382 0 C-N-CA 127.372 2.269 . . . . 0.0 105.354 175.228 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -64.56 131.68 30.49 Favored 'Trans proline' 0 N--CA 1.453 -0.886 0 C-N-CA 121.746 1.631 . . . . 0.0 109.773 178.886 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -51.72 143.23 13.2 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 124.027 0.931 . . . . 0.0 112.061 -178.532 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 105.13 -41.35 2.18 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 110.365 -1.094 . . . . 0.0 110.365 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 19.7 t -79.25 93.23 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 CA-C-N 117.45 0.625 . . . . 0.0 109.337 -179.286 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 18.3 t0 -55.85 118.57 4.71 Favored 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 123.09 0.556 . . . . 0.0 110.494 178.606 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -44.31 -46.25 9.12 Favored 'General case' 0 CA--C 1.529 0.135 0 C-N-CA 125.662 1.585 . . . . 0.0 111.532 179.02 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 48.4 t -56.68 -31.03 33.77 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.471 0 C-N-CA 122.786 0.434 . . . . 0.0 111.926 -178.633 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 65.6 mttp -75.71 -39.46 57.31 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-N 118.678 0.672 . . . . 0.0 111.008 -178.834 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.418 HD13 HG21 ' A' ' 55' ' ' ILE . 20.6 pt -81.15 -28.27 10.85 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.271 0 N-CA-C 112.428 0.529 . . . . 0.0 112.428 -179.521 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 63.2 m -74.95 144.86 43.03 Favored 'General case' 0 N--CA 1.455 -0.224 0 O-C-N 121.778 -0.576 . . . . 0.0 112.534 -178.313 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 7.7 tmm? -65.7 126.87 92.48 Favored Pre-proline 0 CA--C 1.537 0.463 0 N-CA-C 106.185 -1.783 . . . . 0.0 106.185 177.239 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_exo -33.54 99.28 0.02 OUTLIER 'Trans proline' 0 N--CA 1.459 -0.541 0 C-N-CA 125.195 3.93 . . . . 0.0 114.16 179.519 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 59.0 mp0 -50.58 -27.19 6.3 Favored 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 126.918 2.087 . . . . 0.0 113.894 -177.081 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.7 tm-20 -63.22 -30.75 71.83 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 122.702 0.401 . . . . 0.0 110.208 178.871 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 48.1 mt-10 -104.49 172.06 7.0 Favored 'General case' 0 N--CA 1.446 -0.655 0 C-N-CA 125.579 1.551 . . . . 0.0 109.896 -178.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 88.4 mt -151.4 145.83 25.53 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 106.407 -1.701 . . . . 0.0 106.407 177.385 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 67.8 mt -83.91 96.68 8.89 Favored 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 104.722 -2.325 . . . . 0.0 104.722 176.492 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -105.59 34.08 3.44 Favored 'General case' 0 CA--C 1.536 0.434 0 C-N-CA 124.499 1.12 . . . . 0.0 113.878 -177.45 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -151.43 156.49 34.86 Favored Pre-proline 0 CA--C 1.531 0.22 0 N-CA-C 108.106 -1.072 . . . . 0.0 108.106 179.639 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -72.79 163.54 38.13 Favored 'Trans proline' 0 N--CA 1.455 -0.782 0 C-N-CA 121.885 1.724 . . . . 0.0 109.816 179.324 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 78.07 -44.71 2.41 Favored Glycine 0 CA--C 1.526 0.771 0 CA-C-O 118.557 -1.135 . . . . 0.0 114.523 175.687 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 55.2 mm-40 -38.33 122.82 1.11 Allowed 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 124.82 1.248 . . . . 0.0 113.058 -178.809 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 17.9 p -109.13 134.03 52.24 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 125.316 1.446 . . . . 0.0 112.95 -178.104 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 17.5 t80 -107.55 143.27 36.2 Favored 'General case' 0 CA--C 1.528 0.097 0 N-CA-C 104.591 -2.374 . . . . 0.0 104.591 171.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 20.4 t -128.57 140.13 50.05 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.16 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 -179.057 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 12.8 p -146.01 144.9 20.55 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.134 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 178.301 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 7.6 m -115.25 106.65 14.29 Favored 'General case' 0 N--CA 1.454 -0.23 0 C-N-CA 124.356 1.062 . . . . 0.0 109.849 -178.6 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 50.5 mt -95.06 129.18 42.25 Favored 'General case' 0 CA--C 1.531 0.217 0 N-CA-C 107.52 -1.289 . . . . 0.0 107.52 177.913 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 13.9 m-20 -113.85 -46.53 3.02 Favored 'General case' 0 CA--C 1.527 0.08 0 C-N-CA 123.988 0.915 . . . . 0.0 111.24 -178.638 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 4.5 m -66.22 118.98 10.71 Favored 'General case' 0 N--CA 1.452 -0.362 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 -178.67 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 64.4 mttm -63.79 152.64 38.9 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 123.337 0.655 . . . . 0.0 110.306 -179.282 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 145.41 -157.81 27.46 Favored Glycine 0 CA--C 1.522 0.469 0 N-CA-C 109.328 -1.509 . . . . 0.0 109.328 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 15.3 m -123.59 132.33 53.85 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 106.535 -1.654 . . . . 0.0 106.535 -179.627 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 19.6 m-85 -125.02 119.93 30.1 Favored 'General case' 0 N--CA 1.447 -0.624 0 C-N-CA 123.681 0.793 . . . . 0.0 108.906 -178.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 70.2 m -91.51 144.88 25.1 Favored 'General case' 0 C--O 1.233 0.213 0 N-CA-C 107.699 -1.223 . . . . 0.0 107.699 175.612 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 17.4 p90 -141.22 164.14 31.07 Favored 'General case' 0 N--CA 1.455 -0.222 0 CA-C-O 121.237 0.541 . . . . 0.0 110.771 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 53.3 p90 -150.7 160.16 44.03 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-N 115.061 -0.972 . . . . 0.0 112.713 -177.424 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 11.6 t -99.41 106.16 18.19 Favored 'General case' 0 CA--C 1.522 -0.104 0 N-CA-C 105.877 -1.898 . . . . 0.0 105.877 176.453 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 4.5 m -38.83 -60.03 1.23 Allowed Pre-proline 0 CA--C 1.536 0.44 0 N-CA-C 115.976 1.843 . . . . 0.0 115.976 -174.474 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 89.3 Cg_endo -72.06 -2.53 11.7 Favored 'Trans proline' 0 N--CA 1.458 -0.612 0 C-N-CA 122.056 1.837 . . . . 0.0 114.602 -178.576 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 32.9 m170 -132.96 3.86 3.77 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 120.35 1.432 . . . . 0.0 113.723 -178.152 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 15.1 pt20 -52.72 -42.81 65.2 Favored 'General case' 0 CA--C 1.534 0.355 0 CA-C-N 119.009 0.822 . . . . 0.0 110.196 178.002 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -58.52 -28.77 62.8 Favored Glycine 0 CA--C 1.53 1.021 0 C-N-CA 123.951 0.786 . . . . 0.0 111.763 178.167 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -90.74 11.94 20.74 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 123.83 0.852 . . . . 0.0 110.505 178.661 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 82.97 13.0 78.64 Favored Glycine 0 CA--C 1.527 0.825 0 CA-C-O 118.632 -1.094 . . . . 0.0 113.227 178.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 20.5 ttt -77.66 79.82 4.14 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 119.708 1.754 . . . . 0.0 109.473 178.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 11.0 m -131.36 169.66 21.29 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.199 0 C-N-CA 126.158 1.783 . . . . 0.0 110.298 179.1 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -168.02 179.73 41.07 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 109.321 -1.511 . . . . 0.0 109.321 178.017 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 33.8 mtmm -148.32 150.5 33.73 Favored 'General case' 0 N--CA 1.456 -0.159 0 C-N-CA 123.944 0.898 . . . . 0.0 110.439 -178.429 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.0 p -135.33 131.17 51.62 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.252 0 C-N-CA 122.973 0.509 . . . . 0.0 109.948 178.76 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.0 m -98.27 100.87 12.2 Favored 'General case' 0 CA--C 1.534 0.361 0 C-N-CA 125.212 1.405 . . . . 0.0 109.396 -179.64 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 43.6 t -79.92 114.9 21.46 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.388 0 N-CA-C 105.277 -2.119 . . . . 0.0 105.277 -179.553 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 6.6 p30 . . . . . 0 C--N 1.333 -0.133 0 C-N-CA 123.426 0.691 . . . . 0.0 111.946 -174.673 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 62.6 tp . . . . . 0 N--CA 1.45 -0.433 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -150.39 163.38 38.52 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 123.791 0.836 . . . . 0.0 109.652 -178.8 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 58.6 t -132.99 117.56 29.8 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.683 0 N-CA-C 106.217 -1.772 . . . . 0.0 106.217 178.585 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 38.7 mt -84.89 119.22 25.1 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 179.427 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 49.0 mt -82.52 83.07 7.68 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 104.372 -2.455 . . . . 0.0 104.372 176.534 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 121.38 152.1 8.68 Favored Glycine 0 CA--C 1.527 0.812 0 C-N-CA 125.708 1.623 . . . . 0.0 109.616 -176.675 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 50.5 p -114.8 44.65 1.73 Allowed 'General case' 0 CA--C 1.522 -0.121 0 C-N-CA 124.28 1.032 . . . . 0.0 111.799 -179.394 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 74.87 -56.81 2.65 Favored Glycine 0 CA--C 1.523 0.542 0 C-N-CA 126.023 1.773 . . . . 0.0 111.401 179.294 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -73.72 34.37 0.08 Allowed 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 125.406 1.482 . . . . 0.0 113.625 -177.697 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 58.94 4.39 2.24 Favored Glycine 0 CA--C 1.532 1.102 0 C-N-CA 124.828 1.204 . . . . 0.0 115.837 178.743 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.3 t -64.97 138.6 58.46 Favored 'General case' 0 N--CA 1.456 -0.146 0 CA-C-N 119.528 1.664 . . . . 0.0 110.12 -179.009 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 71.0 mt -79.98 64.69 4.9 Favored 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 124.807 1.243 . . . . 0.0 110.604 -177.098 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 28.0 m -133.68 145.13 34.02 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.223 0 C-N-CA 123.253 0.621 . . . . 0.0 112.421 -178.467 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 68.8 m-85 -89.21 125.96 35.29 Favored 'General case' 0 N--CA 1.455 -0.224 0 N-CA-C 104.037 -2.579 . . . . 0.0 104.037 175.536 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 22.4 t -118.02 110.17 40.17 Favored Pre-proline 0 CA--C 1.532 0.267 0 CA-C-N 119.529 1.059 . . . . 0.0 109.218 179.25 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -74.81 153.64 99.27 Favored 'Cis proline' 0 CA--C 1.535 0.57 0 CA-C-N 120.392 1.176 . . . . 0.0 111.164 -1.375 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.2 m -80.87 -45.55 16.66 Favored 'General case' 0 CA--C 1.528 0.127 0 C-N-CA 123.324 0.65 . . . . 0.0 110.805 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -123.58 130.96 53.45 Favored 'General case' 0 N--CA 1.451 -0.396 0 N-CA-C 104.657 -2.349 . . . . 0.0 104.657 178.46 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 42.1 p90 -157.96 -177.54 6.64 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 118.435 0.562 . . . . 0.0 111.175 -177.765 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.9 p -126.09 151.26 47.44 Favored 'General case' 0 N--CA 1.448 -0.569 0 C-N-CA 125.809 1.644 . . . . 0.0 108.758 178.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.8 p -145.53 134.36 11.05 Favored Pre-proline 0 CA--C 1.539 0.52 0 C-N-CA 123.893 0.877 . . . . 0.0 109.136 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -64.64 136.88 51.9 Favored 'Trans proline' 0 N--CA 1.455 -0.782 0 C-N-CA 121.536 1.491 . . . . 0.0 110.096 175.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 48.6 m -49.69 122.1 6.0 Favored 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 123.796 0.838 . . . . 0.0 111.131 179.325 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.46 -17.25 58.74 Favored Glycine 0 CA--C 1.529 0.938 0 CA-C-O 118.816 -0.991 . . . . 0.0 113.554 179.006 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 71.1 mm-40 -70.25 167.05 18.78 Favored 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 119.623 1.712 . . . . 0.0 111.428 179.679 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -92.95 146.88 23.29 Favored 'General case' 0 N--CA 1.45 -0.434 0 C-N-CA 125.029 1.331 . . . . 0.0 111.017 -179.213 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 32.1 mt -125.23 126.41 70.8 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.424 0 N-CA-C 103.682 -2.71 . . . . 0.0 103.682 176.349 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 57.2 t -112.39 96.61 4.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 C-N-CA 125.081 1.352 . . . . 0.0 108.896 -178.259 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -81.69 97.13 7.77 Favored 'General case' 0 CA--C 1.531 0.239 0 N-CA-C 106.862 -1.533 . . . . 0.0 106.862 178.305 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 63.5 tttp -93.98 127.81 39.97 Favored 'General case' 0 CA--C 1.53 0.187 0 C-N-CA 124.884 1.274 . . . . 0.0 113.557 -174.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -67.7 93.51 0.38 Allowed 'General case' 0 CA--C 1.533 0.324 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 176.78 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 14.0 t-20 -80.69 -67.25 0.79 Allowed 'General case' 0 N--CA 1.455 -0.221 0 C-N-CA 123.342 0.657 . . . . 0.0 110.654 -179.354 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -161.05 167.93 25.43 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.258 -176.848 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 68.87 17.5 71.51 Favored Glycine 0 CA--C 1.533 1.199 0 O-C-N 121.587 -0.695 . . . . 0.0 112.144 -179.236 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.45 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 32.8 p90 -70.12 165.95 38.38 Favored Pre-proline 0 CA--C 1.545 0.771 0 N-CA-C 106.325 -1.732 . . . . 0.0 106.325 177.351 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.45 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 92.3 Cg_endo -68.97 155.53 91.03 Favored 'Cis proline' 0 N--CA 1.446 -1.274 0 N-CA-C 115.525 1.317 . . . . 0.0 115.525 4.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 90.1 m-70 -147.72 170.32 17.82 Favored 'General case' 0 N--CA 1.449 -0.478 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.464 -179.683 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 40.4 p-10 -160.55 175.37 12.79 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 104.423 -2.436 . . . . 0.0 104.423 176.639 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 21.9 t -136.15 106.52 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.314 0 N-CA-C 106.787 -1.56 . . . . 0.0 106.787 -179.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 55.5 t -113.17 133.95 57.4 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 106.422 -1.696 . . . . 0.0 106.422 179.229 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 56.9 m-85 -96.18 140.82 30.33 Favored 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 123.544 0.738 . . . . 0.0 109.647 -179.711 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -74.08 108.13 6.7 Favored 'General case' 0 N--CA 1.453 -0.308 0 N-CA-C 107.078 -1.453 . . . . 0.0 107.078 178.204 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -44.25 -30.61 0.83 Allowed 'General case' 0 CA--C 1.535 0.386 0 N-CA-C 115.916 1.821 . . . . 0.0 115.916 -177.765 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -86.17 -49.19 7.93 Favored 'General case' 0 CA--C 1.53 0.196 0 CA-C-N 118.703 0.683 . . . . 0.0 110.48 179.153 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -80.66 57.48 2.96 Favored 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 124.109 0.964 . . . . 0.0 112.257 -176.609 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 36.2 pt -153.35 156.63 32.61 Favored Pre-proline 0 CA--C 1.534 0.348 0 C-N-CA 127.634 2.374 . . . . 0.0 106.217 176.649 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -53.07 115.53 2.34 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 C-N-CA 122.51 2.14 . . . . 0.0 111.384 178.065 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -52.88 107.88 0.26 Allowed 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 123.992 0.917 . . . . 0.0 110.083 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 136.46 -30.42 2.7 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 109.835 -1.306 . . . . 0.0 109.835 -178.069 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 69.9 t -75.62 121.89 28.35 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 CA-C-N 117.861 0.831 . . . . 0.0 109.059 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 14.8 t0 -66.35 105.46 1.45 Allowed 'General case' 0 N--CA 1.453 -0.3 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 178.752 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.49 -39.03 21.73 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 124.168 0.987 . . . . 0.0 111.463 178.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 41.4 t -61.68 -29.3 45.9 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.429 0 C-N-CA 122.821 0.448 . . . . 0.0 111.574 -179.359 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.53 -34.03 58.57 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 119.224 0.92 . . . . 0.0 110.979 -178.593 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.4 HD13 HG21 ' A' ' 55' ' ' ILE . 25.0 pt -85.74 -32.35 7.0 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.21 0 C-N-CA 123.266 0.626 . . . . 0.0 111.899 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 39.7 m -85.87 136.43 33.3 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 114.273 1.212 . . . . 0.0 114.273 -177.208 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 69.2 mmm -69.01 133.56 89.95 Favored Pre-proline 0 N--CA 1.452 -0.348 0 N-CA-C 103.822 -2.659 . . . . 0.0 103.822 170.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_exo -49.5 114.87 1.49 Allowed 'Trans proline' 0 N--CA 1.456 -0.698 0 C-N-CA 122.201 1.934 . . . . 0.0 109.557 178.197 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -35.44 -44.37 0.29 Allowed 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 126.164 1.786 . . . . 0.0 115.487 -177.244 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 19.9 tp10 -61.0 -37.53 82.83 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 124.566 1.147 . . . . 0.0 111.961 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 64.4 mm-40 -83.09 153.92 24.63 Favored 'General case' 0 N--CA 1.444 -0.751 0 C-N-CA 124.703 1.201 . . . . 0.0 110.181 -178.525 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -156.53 145.8 20.53 Favored 'General case' 0 N--CA 1.446 -0.634 0 CA-C-N 115.393 -0.821 . . . . 0.0 111.833 -178.528 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 43.5 mt -76.85 99.94 5.35 Favored 'General case' 0 N--CA 1.446 -0.631 0 N-CA-C 104.176 -2.527 . . . . 0.0 104.176 177.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -96.47 -22.33 17.19 Favored 'General case' 0 N--CA 1.462 0.171 0 N-CA-C 113.993 1.108 . . . . 0.0 113.993 -176.623 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -93.97 152.94 40.89 Favored Pre-proline 0 CA--C 1.533 0.305 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -66.43 161.99 38.5 Favored 'Trans proline' 0 N--CA 1.453 -0.908 0 C-N-CA 121.773 1.649 . . . . 0.0 110.195 178.207 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 80.14 -53.93 4.45 Favored Glycine 0 CA--C 1.523 0.568 0 CA-C-O 118.228 -1.318 . . . . 0.0 113.404 176.4 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -18.53 111.07 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.399 0 C-N-CA 126.444 1.898 . . . . 0.0 114.388 -177.011 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 14.5 p -100.71 119.07 38.05 Favored 'General case' 0 N--CA 1.446 -0.633 0 C-N-CA 124.619 1.168 . . . . 0.0 112.225 -178.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 10.8 t80 -97.13 105.61 17.79 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 105.06 -2.2 . . . . 0.0 105.06 174.624 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.9 t -94.98 134.46 32.29 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.283 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 -178.686 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.1 p -151.16 161.22 3.52 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 178.485 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.1 m -133.62 142.29 48.03 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 125.501 1.52 . . . . 0.0 107.9 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 62.4 mt -118.82 120.52 37.59 Favored 'General case' 0 N--CA 1.453 -0.31 0 N-CA-C 107.567 -1.272 . . . . 0.0 107.567 179.288 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 9.0 p-10 -95.02 -41.07 9.32 Favored 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 124.178 0.991 . . . . 0.0 112.395 -178.43 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 25.0 m -77.14 125.77 29.86 Favored 'General case' 0 N--CA 1.452 -0.328 0 C-N-CA 123.428 0.691 . . . . 0.0 109.933 -176.564 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 66.3 mttm -65.47 156.02 33.75 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 124.017 0.927 . . . . 0.0 111.477 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 127.23 177.33 14.82 Favored Glycine 0 CA--C 1.526 0.743 0 C-N-CA 123.92 0.771 . . . . 0.0 112.201 177.445 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 7.3 m -94.57 127.73 40.71 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 125.15 1.38 . . . . 0.0 108.914 -179.063 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 15.6 m-85 -115.95 135.81 53.63 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 125.755 1.622 . . . . 0.0 108.643 179.066 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 16.9 m -108.81 136.23 48.71 Favored 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 123.362 0.665 . . . . 0.0 109.419 176.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 20.3 p90 -137.83 168.53 19.5 Favored 'General case' 0 C--O 1.232 0.142 0 CA-C-O 121.77 0.795 . . . . 0.0 111.818 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -156.37 160.62 39.83 Favored 'General case' 0 N--CA 1.453 -0.278 0 CA-C-N 115.322 -0.854 . . . . 0.0 112.532 -178.756 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.4 t -99.74 102.37 13.81 Favored 'General case' 0 CA--C 1.519 -0.226 0 N-CA-C 106.396 -1.705 . . . . 0.0 106.396 176.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -48.24 -55.07 20.19 Favored Pre-proline 0 CA--C 1.532 0.263 0 CA-C-O 118.593 -0.717 . . . . 0.0 112.51 -175.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_exo -50.59 -15.7 1.78 Allowed 'Trans proline' 0 N--CA 1.458 -0.572 0 C-N-CA 123.387 2.725 . . . . 0.0 115.566 178.259 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 39.3 m80 -137.69 31.5 2.52 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 119.757 1.162 . . . . 0.0 110.999 -179.765 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 1.5 pm0 -60.73 -45.64 93.48 Favored 'General case' 0 CA--C 1.534 0.333 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 178.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.99 -35.06 67.09 Favored Glycine 0 CA--C 1.527 0.816 0 C-N-CA 124.272 0.939 . . . . 0.0 111.661 179.1 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -80.96 4.97 17.71 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-N 117.209 0.504 . . . . 0.0 111.465 179.006 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 73.94 25.2 72.15 Favored Glycine 0 CA--C 1.524 0.651 0 CA-C-O 119.147 -0.807 . . . . 0.0 112.573 179.229 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 24.5 ttt -78.96 78.24 5.41 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 119.092 1.446 . . . . 0.0 107.831 177.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 13.5 m -121.25 169.09 12.99 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.245 0 C-N-CA 126.181 1.792 . . . . 0.0 109.915 179.56 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -168.87 177.97 42.43 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.108 -1.197 . . . . 0.0 110.108 178.489 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 58.6 mttm -147.57 161.22 41.57 Favored 'General case' 0 N--CA 1.455 -0.21 0 C-N-CA 123.772 0.829 . . . . 0.0 109.621 -179.48 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 4.2 p -144.88 132.63 16.59 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.246 0 C-N-CA 123.62 0.768 . . . . 0.0 109.1 178.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.3 m -103.41 106.88 17.51 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.965 1.306 . . . . 0.0 109.665 -178.44 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 32.6 t -82.55 106.97 13.95 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.574 0 N-CA-C 105.905 -1.887 . . . . 0.0 105.905 178.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 25.6 m120 . . . . . 0 C--O 1.231 0.127 0 C-N-CA 124.279 1.032 . . . . 0.0 111.042 -176.637 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 21.1 mt . . . . . 0 N--CA 1.451 -0.379 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 45.9 tt0 -87.86 107.48 18.7 Favored 'General case' 0 N--CA 1.452 -0.343 0 N-CA-C 105.546 -2.02 . . . . 0.0 105.546 175.516 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 38.7 t -99.35 118.66 46.28 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.455 0 C-N-CA 123.813 0.845 . . . . 0.0 108.833 -177.645 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 59.1 mt -81.98 122.05 27.3 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 179.297 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 70.4 mt -87.39 89.93 8.18 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 105.321 -2.103 . . . . 0.0 105.321 177.128 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 118.25 166.36 13.7 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 109.098 -1.601 . . . . 0.0 109.098 -177.408 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 5.4 p -136.26 48.56 2.15 Favored 'General case' 0 N--CA 1.461 0.102 0 CA-C-O 122.798 1.285 . . . . 0.0 113.259 -178.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.44 -62.13 0.62 Allowed Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 128.238 2.828 . . . . 0.0 113.364 176.636 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -78.31 42.97 0.44 Allowed 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 123.981 0.913 . . . . 0.0 112.268 -175.578 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 75.55 -31.22 1.21 Allowed Glycine 0 CA--C 1.528 0.891 0 C-N-CA 124.934 1.254 . . . . 0.0 113.388 178.305 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 7.4 t -40.44 106.27 0.05 Allowed 'General case' 0 C--O 1.237 0.443 0 C-N-CA 126.178 1.791 . . . . 0.0 112.141 -178.522 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 48.9 mt -75.2 69.96 2.11 Favored 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 128.196 2.598 . . . . 0.0 111.551 -176.399 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.6 m -136.49 153.38 30.78 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 C-N-CA 122.86 0.464 . . . . 0.0 110.233 179.034 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 61.5 m-85 -88.57 127.27 35.55 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 105.096 -2.187 . . . . 0.0 105.096 176.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 38.8 t -120.79 114.42 32.61 Favored Pre-proline 0 CA--C 1.533 0.313 0 CA-C-O 118.175 -0.916 . . . . 0.0 108.688 178.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -73.06 147.91 90.88 Favored 'Cis proline' 0 CA--C 1.535 0.574 0 CA-C-N 120.49 1.211 . . . . 0.0 111.423 -0.455 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.4 m -78.77 -33.02 46.76 Favored 'General case' 0 CA--C 1.529 0.148 0 C-N-CA 123.715 0.806 . . . . 0.0 111.809 179.826 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -138.75 141.25 38.85 Favored 'General case' 0 N--CA 1.454 -0.241 0 N-CA-C 105.288 -2.115 . . . . 0.0 105.288 178.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 13.3 p90 -168.1 172.44 8.74 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 123.904 0.882 . . . . 0.0 108.739 -178.486 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 14.9 m -133.26 137.7 46.16 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 123.918 0.887 . . . . 0.0 108.685 -179.09 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.3 m -139.9 155.02 71.2 Favored Pre-proline 0 CA--C 1.531 0.234 0 C-N-CA 124.26 1.024 . . . . 0.0 110.145 -178.61 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -77.11 151.21 30.22 Favored 'Trans proline' 0 N--CA 1.451 -0.992 0 C-N-CA 121.845 1.697 . . . . 0.0 110.64 177.638 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 14.7 m -49.79 126.55 14.19 Favored 'General case' 0 N--CA 1.457 -0.112 0 C-N-CA 123.328 0.651 . . . . 0.0 109.993 175.579 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 103.21 -6.64 50.81 Favored Glycine 0 CA--C 1.526 0.752 0 CA-C-O 119.082 -0.844 . . . . 0.0 111.678 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -61.65 136.87 58.17 Favored 'General case' 0 CA--C 1.534 0.329 0 CA-C-N 119.117 1.458 . . . . 0.0 110.43 178.567 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 61.0 mttp -94.93 98.56 10.79 Favored 'General case' 0 N--CA 1.446 -0.657 0 C-N-CA 127.244 2.218 . . . . 0.0 107.436 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 56.3 mt -81.45 137.4 21.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 -179.247 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 60.4 t -120.53 102.51 12.54 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.187 0 C-N-CA 125.017 1.327 . . . . 0.0 108.703 -178.767 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -88.46 107.03 18.65 Favored 'General case' 0 CA--C 1.53 0.183 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 178.669 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 64.6 tttm -103.35 128.45 50.43 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 124.49 1.116 . . . . 0.0 113.379 -175.556 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -62.27 108.69 1.14 Allowed 'General case' 0 N--CA 1.464 0.26 0 N-CA-C 109.155 -0.684 . . . . 0.0 109.155 176.654 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 20.2 t-20 -94.05 -69.93 0.73 Allowed 'General case' 0 C--N 1.339 0.152 0 C-N-CA 123.434 0.693 . . . . 0.0 110.71 -179.403 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -154.89 166.0 34.9 Favored 'General case' 0 C--N 1.331 -0.213 0 C-N-CA 123.899 0.88 . . . . 0.0 109.586 -177.722 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 64.51 23.04 68.31 Favored Glycine 0 CA--C 1.534 1.234 0 N-CA-C 111.938 -0.465 . . . . 0.0 111.938 -178.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.491 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 15.3 p90 -71.94 166.84 36.72 Favored Pre-proline 0 CA--C 1.543 0.697 0 N-CA-C 106.177 -1.786 . . . . 0.0 106.177 177.231 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.491 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 86.6 Cg_endo -70.38 161.31 88.25 Favored 'Cis proline' 0 N--CA 1.448 -1.201 0 CA-C-N 120.227 1.117 . . . . 0.0 114.928 3.708 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 -150.69 168.28 24.84 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.207 -178.606 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -159.19 177.48 11.01 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 104.029 -2.582 . . . . 0.0 104.029 175.243 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 41.6 t -132.19 119.35 39.8 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 -179.625 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 25.6 t -114.57 122.24 68.29 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.679 0 N-CA-C 105.602 -1.999 . . . . 0.0 105.602 177.501 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 59.5 m-85 -86.32 125.56 33.7 Favored 'General case' 0 N--CA 1.446 -0.668 0 N-CA-C 105.868 -1.901 . . . . 0.0 105.868 177.046 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 12.1 t0 -64.28 103.48 0.64 Allowed 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 123.059 0.543 . . . . 0.0 110.612 -177.616 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.7 pm0 -45.02 -35.47 2.97 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 125.235 1.414 . . . . 0.0 112.994 177.703 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -70.34 -20.73 62.96 Favored 'General case' 0 CA--C 1.536 0.438 0 N-CA-C 113.277 0.843 . . . . 0.0 113.277 -179.545 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -139.81 74.76 1.48 Allowed 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 123.68 0.792 . . . . 0.0 111.659 -177.732 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 30.5 pt -157.25 157.35 30.32 Favored Pre-proline 0 CA--C 1.532 0.253 0 C-N-CA 128.562 2.745 . . . . 0.0 105.67 175.845 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -58.67 108.98 0.45 Allowed 'Trans proline' 0 N--CA 1.455 -0.738 0 C-N-CA 122.02 1.813 . . . . 0.0 107.996 173.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -35.08 -43.03 0.19 Allowed 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 126.676 1.99 . . . . 0.0 115.605 -177.01 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -58.21 -29.33 62.69 Favored Glycine 0 CA--C 1.533 1.19 0 CA-C-O 119.893 -0.393 . . . . 0.0 113.538 -179.122 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 42.6 t -84.72 108.11 16.45 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.295 0 CA-C-N 118.21 1.005 . . . . 0.0 109.751 -178.451 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -58.27 114.11 2.26 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 122.955 0.502 . . . . 0.0 109.784 177.716 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.76 -40.82 21.76 Favored 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 124.205 1.002 . . . . 0.0 111.499 179.183 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 48.4 t -60.65 -30.06 46.15 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.398 0 C-N-CA 123.123 0.569 . . . . 0.0 111.768 -179.133 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 37.7 mmtm -76.56 -40.98 48.15 Favored 'General case' 0 CA--C 1.528 0.112 0 CA-C-N 118.715 0.688 . . . . 0.0 110.414 -179.084 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.408 HD13 HG21 ' A' ' 55' ' ' ILE . 23.1 pt -78.84 -33.65 16.52 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 N-CA-C 112.223 0.453 . . . . 0.0 112.223 -179.76 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 41.1 m -79.47 162.35 25.51 Favored 'General case' 0 C--N 1.331 -0.203 0 N-CA-C 113.454 0.909 . . . . 0.0 113.454 -178.089 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 2.7 tmm? -104.94 107.92 59.89 Favored Pre-proline 0 CA--C 1.54 0.576 0 N-CA-C 104.522 -2.399 . . . . 0.0 104.522 175.368 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_exo -38.47 107.37 0.06 OUTLIER 'Trans proline' 0 C--N 1.35 0.606 1 C-N-CA 125.487 4.124 . . . . 0.0 114.966 -176.689 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -50.0 -22.77 1.7 Allowed 'General case' 0 CA--C 1.53 0.195 0 C-N-CA 126.475 1.91 . . . . 0.0 115.413 -178.749 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 30.8 tt0 -58.99 -32.99 70.17 Favored 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 176.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 57.9 mt-10 -110.87 163.25 13.98 Favored 'General case' 0 N--CA 1.444 -0.775 0 C-N-CA 126.494 1.918 . . . . 0.0 107.959 178.546 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.426 ' N ' HD13 ' A' ' 62' ' ' LEU . 0.0 OUTLIER -150.22 161.8 41.72 Favored 'General case' 0 N--CA 1.443 -0.81 0 O-C-N 121.53 -0.731 . . . . 0.0 110.426 178.599 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 81.7 mt -78.5 106.06 10.2 Favored 'General case' 0 N--CA 1.446 -0.629 0 N-CA-C 104.488 -2.412 . . . . 0.0 104.488 177.121 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 13.2 t30 -77.0 -62.2 1.73 Allowed 'General case' 0 CA--C 1.528 0.133 0 N-CA-C 114.932 1.456 . . . . 0.0 114.932 -175.034 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.88 157.02 76.95 Favored Pre-proline 0 CA--C 1.533 0.295 0 C-N-CA 123.056 0.542 . . . . 0.0 111.601 -175.534 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -63.66 164.16 22.09 Favored 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 122.2 1.933 . . . . 0.0 109.433 175.335 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 80.92 -37.61 2.34 Favored Glycine 0 CA--C 1.527 0.783 0 CA-C-O 118.231 -1.316 . . . . 0.0 114.305 176.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 66.7 mt-10 -41.69 126.03 2.91 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 119.079 1.44 . . . . 0.0 112.144 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 16.9 p -109.22 127.61 54.38 Favored 'General case' 0 N--CA 1.455 -0.219 0 C-N-CA 125.481 1.512 . . . . 0.0 112.693 -178.552 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 35.5 t80 -106.45 114.02 27.89 Favored 'General case' 0 N--CA 1.456 -0.159 0 N-CA-C 106.05 -1.833 . . . . 0.0 106.05 174.034 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 15.4 t -100.52 141.23 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.236 0 C-N-CA 123.189 0.596 . . . . 0.0 110.464 -177.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 10.7 p -150.45 141.52 16.6 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.208 0 N-CA-C 108.774 -0.825 . . . . 0.0 108.774 177.308 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 23.7 m -108.46 123.57 49.08 Favored 'General case' 0 CA--C 1.528 0.113 0 C-N-CA 123.752 0.821 . . . . 0.0 108.966 -178.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 36.9 mt -104.56 104.15 13.94 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-N 118.33 0.514 . . . . 0.0 109.798 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -87.19 -53.52 4.81 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 123.974 0.909 . . . . 0.0 111.602 -179.443 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 4.7 m -66.2 128.41 36.0 Favored 'General case' 0 N--CA 1.455 -0.223 0 O-C-N 121.822 -0.549 . . . . 0.0 111.402 -175.571 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 24.9 mtpp -65.89 161.52 21.01 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 124.787 1.235 . . . . 0.0 110.871 179.648 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 132.66 -137.33 9.32 Favored Glycine 0 C--N 1.335 0.503 0 N-CA-C 110.039 -1.225 . . . . 0.0 110.039 177.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 58.8 m -147.79 141.81 25.95 Favored 'General case' 0 N--CA 1.443 -0.824 0 N-CA-C 105.717 -1.957 . . . . 0.0 105.717 179.65 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 12.1 m-85 -129.61 126.43 38.43 Favored 'General case' 0 N--CA 1.446 -0.675 0 C-N-CA 124.302 1.041 . . . . 0.0 108.821 -177.054 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 74.5 m -95.4 145.67 24.97 Favored 'General case' 0 C--N 1.331 -0.201 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 175.668 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 11.7 p90 -143.49 164.5 30.16 Favored 'General case' 0 N--CA 1.455 -0.191 0 CA-C-O 121.435 0.636 . . . . 0.0 112.369 -179.538 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 53.1 p90 -155.32 160.33 40.66 Favored 'General case' 0 N--CA 1.454 -0.256 0 CA-C-N 115.228 -0.896 . . . . 0.0 112.678 -179.714 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 4.3 t -102.44 100.92 11.08 Favored 'General case' 0 CA--C 1.516 -0.341 0 N-CA-C 105.991 -1.855 . . . . 0.0 105.991 176.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.252 0.0 OUTLIER -38.7 -63.07 0.63 Allowed Pre-proline 0 CA--C 1.538 0.511 0 N-CA-C 114.346 1.239 . . . . 0.0 114.346 -175.019 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_exo -50.53 -18.27 3.67 Favored 'Trans proline' 0 CA--C 1.534 0.501 0 C-N-CA 123.635 2.89 . . . . 0.0 115.748 179.111 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 36.6 m80 -131.63 20.19 4.68 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 119.132 0.878 . . . . 0.0 111.293 -179.044 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 66.2 tt0 -60.07 -49.06 79.13 Favored 'General case' 0 CA--C 1.528 0.13 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.226 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.8 -32.22 61.74 Favored Glycine 0 CA--C 1.531 1.073 0 N-CA-C 111.475 -0.65 . . . . 0.0 111.475 178.066 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -81.79 4.12 23.29 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 123.334 0.654 . . . . 0.0 111.718 179.105 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 84.66 16.01 66.9 Favored Glycine 0 CA--C 1.527 0.798 0 CA-C-O 118.851 -0.972 . . . . 0.0 113.509 178.384 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 19.6 ttt -78.48 78.22 4.95 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 119.509 1.655 . . . . 0.0 108.332 178.491 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 5.9 m -128.43 171.71 16.08 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 C-N-CA 125.802 1.641 . . . . 0.0 110.607 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -175.99 -174.7 42.75 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 109.155 -1.578 . . . . 0.0 109.155 177.618 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 52.2 mttp -151.63 169.77 21.33 Favored 'General case' 0 N--CA 1.453 -0.323 0 C-N-CA 124.064 0.946 . . . . 0.0 109.343 179.8 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.3 p -150.37 139.5 15.27 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.382 0 C-N-CA 123.744 0.818 . . . . 0.0 108.972 177.267 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -100.44 133.51 44.76 Favored 'General case' 0 CA--C 1.529 0.168 0 C-N-CA 124.615 1.166 . . . . 0.0 107.89 179.792 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 31.7 t -115.33 109.72 29.35 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.18 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 178.784 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 48.0 p30 . . . . . 0 C--O 1.231 0.117 0 C-N-CA 124.385 1.074 . . . . 0.0 111.878 -177.0 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 20.5 mt . . . . . 0 N--CA 1.452 -0.37 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -88.6 101.94 14.46 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 105.687 -1.968 . . . . 0.0 105.687 175.238 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 41.0 t -99.88 125.28 53.59 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.374 0 C-N-CA 124.251 1.02 . . . . 0.0 109.368 -177.273 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 74.8 mt -88.54 119.05 28.63 Favored 'General case' 0 N--CA 1.446 -0.658 0 N-CA-C 108.015 -1.105 . . . . 0.0 108.015 178.264 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 19.8 mt -83.75 101.98 11.96 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 104.841 -2.281 . . . . 0.0 104.841 176.26 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 101.83 -161.34 17.68 Favored Glycine 0 N--CA 1.447 -0.573 0 N-CA-C 108.043 -2.023 . . . . 0.0 108.043 -178.016 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 54.8 p -153.32 150.34 28.81 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 106.665 -1.606 . . . . 0.0 106.665 179.545 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -50.63 -34.79 28.82 Favored Glycine 0 CA--C 1.531 1.069 0 C-N-CA 123.293 0.473 . . . . 0.0 113.09 -179.809 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -74.29 -4.99 39.48 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 123.668 0.787 . . . . 0.0 112.75 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 97.29 -17.3 59.34 Favored Glycine 0 CA--C 1.527 0.839 0 C-N-CA 124.181 0.896 . . . . 0.0 114.091 178.597 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 33.0 t -56.94 135.03 56.06 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 119.217 1.509 . . . . 0.0 111.739 -178.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 91.6 mt -80.09 78.24 6.75 Favored 'General case' 0 N--CA 1.446 -0.655 0 C-N-CA 125.713 1.605 . . . . 0.0 109.819 -178.824 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.7 p -138.6 159.1 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.303 0 C-N-CA 123.616 0.767 . . . . 0.0 109.524 178.713 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 30.7 m-85 -97.98 124.49 42.48 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 103.521 -2.77 . . . . 0.0 103.521 175.893 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 43.4 t -120.21 109.32 37.18 Favored Pre-proline 0 CA--C 1.537 0.456 0 CA-C-N 119.337 0.972 . . . . 0.0 109.717 -179.34 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -71.01 157.39 95.59 Favored 'Cis proline' 0 N--CA 1.456 -0.679 0 CA-C-N 120.325 1.152 . . . . 0.0 110.732 -1.448 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.4 p -84.11 -62.67 1.51 Allowed 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 107.577 -1.268 . . . . 0.0 107.577 179.253 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 51.1 mt-10 -107.31 127.98 54.04 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 125.367 1.467 . . . . 0.0 107.925 178.345 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 39.1 p90 -151.5 -177.21 5.95 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.875 0.369 . . . . 0.0 111.607 179.749 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 15.1 m -139.54 145.92 39.26 Favored 'General case' 0 N--CA 1.452 -0.362 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 -179.481 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.6 p -156.34 139.61 11.01 Favored Pre-proline 0 CA--C 1.54 0.576 0 CA-C-N 118.914 0.779 . . . . 0.0 109.977 -178.163 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -55.96 146.85 66.44 Favored 'Trans proline' 0 N--CA 1.458 -0.612 0 C-N-CA 122.558 2.172 . . . . 0.0 113.597 177.432 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 21.6 m -56.87 139.76 50.44 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 123.244 0.618 . . . . 0.0 110.464 177.057 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 89.41 -13.91 62.52 Favored Glycine 0 CA--C 1.529 0.922 0 CA-C-O 119.099 -0.834 . . . . 0.0 113.928 177.46 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 72.7 mm-40 -71.56 149.66 45.48 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 119.218 1.509 . . . . 0.0 110.356 178.716 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 1.7 mptm? -90.26 114.89 27.01 Favored 'General case' 0 N--CA 1.453 -0.323 0 C-N-CA 124.3 1.04 . . . . 0.0 109.274 -179.036 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 69.2 mt -86.54 137.13 21.45 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.267 0 N-CA-C 105.403 -2.073 . . . . 0.0 105.403 177.017 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 62.5 t -120.81 107.14 19.88 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.136 0 C-N-CA 124.515 1.126 . . . . 0.0 108.986 -178.021 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -94.31 101.64 13.6 Favored 'General case' 0 CA--C 1.532 0.279 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 178.441 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -97.85 125.81 42.91 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 125.597 1.559 . . . . 0.0 113.11 -176.134 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 8.0 m-20 -63.3 102.61 0.41 Allowed 'General case' 0 N--CA 1.466 0.36 0 C-N-CA 123.306 0.642 . . . . 0.0 110.092 176.55 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -80.01 -57.44 3.64 Favored 'General case' 0 CA--C 1.519 -0.216 0 C-N-CA 123.075 0.55 . . . . 0.0 110.921 -179.364 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -174.44 178.25 2.02 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 126.561 1.944 . . . . 0.0 106.275 -177.414 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 64.38 19.0 63.91 Favored Glycine 0 CA--C 1.536 1.35 0 CA-C-N 119.098 0.863 . . . . 0.0 112.597 -179.555 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.48 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 9.0 p90 -74.07 168.8 22.86 Favored Pre-proline 0 CA--C 1.538 0.517 0 N-CA-C 106.233 -1.765 . . . . 0.0 106.233 177.353 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.48 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 41.0 Cg_exo -63.94 156.82 71.53 Favored 'Cis proline' 0 N--CA 1.454 -0.838 0 N-CA-C 116.507 1.695 . . . . 0.0 116.507 1.568 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -148.97 171.91 15.58 Favored 'General case' 0 C--O 1.221 -0.445 0 O-C-N 121.691 -0.63 . . . . 0.0 111.166 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 31.1 p-10 -166.47 -179.91 5.19 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 104.704 -2.332 . . . . 0.0 104.704 176.452 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 60.9 t -138.7 115.6 10.99 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.229 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 178.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 67.5 t -119.8 132.02 70.69 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.658 0 N-CA-C 105.618 -1.993 . . . . 0.0 105.618 178.326 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 52.9 m-85 -88.01 130.86 34.84 Favored 'General case' 0 N--CA 1.446 -0.633 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 -179.261 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -73.34 100.86 3.28 Favored 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 122.774 0.429 . . . . 0.0 109.861 -178.302 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -40.71 -38.7 0.95 Allowed 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 125.801 1.64 . . . . 0.0 113.639 178.225 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 36.8 t70 -68.26 -26.11 65.51 Favored 'General case' 0 CA--C 1.535 0.398 0 N-CA-C 113.487 0.921 . . . . 0.0 113.487 -179.055 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 40.2 mt-10 -129.49 61.64 1.55 Allowed 'General case' 0 CA--C 1.535 0.38 0 C-N-CA 124.018 0.927 . . . . 0.0 112.384 -176.812 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 40.5 pt -153.27 157.31 32.9 Favored Pre-proline 0 CA--C 1.531 0.24 0 C-N-CA 127.603 2.361 . . . . 0.0 105.509 174.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_exo -58.88 104.81 0.2 Allowed 'Trans proline' 0 N--CA 1.455 -0.788 0 C-N-CA 121.828 1.685 . . . . 0.0 108.334 173.703 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -35.15 -43.94 0.23 Allowed 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 126.993 2.117 . . . . 0.0 115.368 -176.752 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -55.21 -33.38 57.88 Favored Glycine 0 CA--C 1.533 1.175 0 C-N-CA 123.178 0.418 . . . . 0.0 112.97 -179.619 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 40.4 t -82.12 95.73 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.386 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 -179.244 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 25.2 t0 -49.03 112.48 0.63 Allowed 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 124.24 1.016 . . . . 0.0 110.679 178.819 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -44.73 -44.71 9.42 Favored 'General case' 0 N--CA 1.454 -0.228 0 C-N-CA 125.748 1.619 . . . . 0.0 111.496 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 59.4 t -54.64 -30.56 22.36 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 C-N-CA 123.544 0.738 . . . . 0.0 112.144 -179.085 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -77.53 -34.95 53.77 Favored 'General case' 0 CA--C 1.531 0.22 0 CA-C-N 118.732 0.696 . . . . 0.0 111.788 -178.464 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.426 HD13 HG21 ' A' ' 55' ' ' ILE . 25.1 pt -89.02 -26.14 5.57 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 C-N-CA 123.33 0.652 . . . . 0.0 112.375 -179.083 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 49.4 m -88.16 146.59 25.32 Favored 'General case' 0 N--CA 1.454 -0.232 0 N-CA-C 114.132 1.16 . . . . 0.0 114.132 -177.1 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 42.6 mmm -68.55 127.76 93.14 Favored Pre-proline 0 N--CA 1.451 -0.425 0 N-CA-C 103.713 -2.699 . . . . 0.0 103.713 170.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_exo -50.99 118.57 4.37 Favored 'Trans proline' 0 N--CA 1.456 -0.727 0 C-N-CA 121.905 1.736 . . . . 0.0 108.563 177.6 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -38.86 -37.05 0.32 Allowed 'General case' 0 CA--C 1.537 0.463 0 N-CA-C 115.569 1.692 . . . . 0.0 115.569 -176.532 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -61.77 -38.11 86.81 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 124.019 0.928 . . . . 0.0 111.076 179.278 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 55.4 mm-40 -90.19 151.71 21.43 Favored 'General case' 0 N--CA 1.443 -0.783 0 C-N-CA 125.475 1.51 . . . . 0.0 110.374 -178.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -162.43 154.92 19.32 Favored 'General case' 0 N--CA 1.451 -0.399 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.879 -178.112 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 42.7 mt -82.53 96.12 7.95 Favored 'General case' 0 N--CA 1.447 -0.617 0 C-N-CA 126.548 1.939 . . . . 0.0 106.065 178.242 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 11.9 t30 -79.01 -51.87 9.0 Favored 'General case' 0 C--O 1.225 -0.221 0 N-CA-C 113.204 0.816 . . . . 0.0 113.204 -178.457 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.96 157.73 78.53 Favored Pre-proline 0 CA--C 1.536 0.436 0 C-N-CA 123.475 0.71 . . . . 0.0 112.252 -175.809 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -65.54 165.73 21.92 Favored 'Trans proline' 0 N--CA 1.457 -0.656 0 C-N-CA 122.518 2.145 . . . . 0.0 109.954 175.663 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 79.31 -50.6 3.78 Favored Glycine 0 CA--C 1.526 0.742 0 CA-C-O 118.871 -0.961 . . . . 0.0 113.016 177.076 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 43.3 mm-40 -26.24 118.41 0.07 Allowed 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 126.79 2.036 . . . . 0.0 113.403 -179.424 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 13.3 p -106.54 123.49 48.18 Favored 'General case' 0 N--CA 1.453 -0.292 0 C-N-CA 125.605 1.562 . . . . 0.0 112.827 -178.239 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 19.8 t80 -101.81 115.32 30.29 Favored 'General case' 0 C--O 1.232 0.169 0 N-CA-C 105.835 -1.913 . . . . 0.0 105.835 173.477 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.8 t -100.81 136.88 30.34 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.295 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 -179.606 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.6 p -147.35 150.92 14.19 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.078 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 178.705 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 25.5 m -121.06 130.3 53.71 Favored 'General case' 0 N--CA 1.457 -0.081 0 C-N-CA 124.316 1.046 . . . . 0.0 108.408 -178.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 74.7 mt -113.11 121.32 44.21 Favored 'General case' 0 CA--C 1.53 0.21 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 179.418 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -92.35 -63.22 1.26 Allowed 'General case' 0 CA--C 1.529 0.149 0 C-N-CA 124.152 0.981 . . . . 0.0 112.458 -178.038 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.1 m -65.21 135.1 55.02 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 122.986 0.515 . . . . 0.0 110.318 -174.879 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 61.1 mttp -71.52 156.59 39.25 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 122.998 0.519 . . . . 0.0 111.259 -178.368 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 139.55 175.76 14.41 Favored Glycine 0 CA--C 1.525 0.696 0 C-N-CA 123.558 0.599 . . . . 0.0 111.662 177.825 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 18.3 m -94.47 112.18 23.95 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 107.51 -1.292 . . . . 0.0 107.51 179.072 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 18.8 m-85 -104.93 125.43 50.93 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 123.686 0.795 . . . . 0.0 109.263 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 7.3 m -98.39 142.12 30.41 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 177.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 12.0 p90 -139.55 163.6 32.13 Favored 'General case' 0 N--CA 1.455 -0.198 0 CA-C-O 121.502 0.668 . . . . 0.0 111.719 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 49.5 p90 -148.99 161.66 41.46 Favored 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 124.855 1.262 . . . . 0.0 111.784 -178.195 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.8 t -105.32 107.48 18.49 Favored 'General case' 0 CA--C 1.522 -0.126 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 177.279 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 1.3 m -41.51 -61.55 1.38 Allowed Pre-proline 0 CA--C 1.535 0.378 0 N-CA-C 115.06 1.504 . . . . 0.0 115.06 -175.812 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -60.19 -4.84 3.35 Favored 'Trans proline' 0 CA--C 1.536 0.624 0 C-N-CA 121.859 1.706 . . . . 0.0 114.792 -179.042 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 38.7 m80 -134.34 19.67 3.67 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-N 119.73 1.15 . . . . 0.0 110.556 177.443 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 19.6 pt20 -63.35 -42.46 98.9 Favored 'General case' 0 N--CA 1.452 -0.33 0 O-C-N 121.693 -0.629 . . . . 0.0 109.531 179.192 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -61.13 -40.98 99.3 Favored Glycine 0 CA--C 1.529 0.964 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 177.557 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -66.32 -34.14 77.32 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 122.713 0.405 . . . . 0.0 110.117 178.536 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 108.33 31.19 3.59 Favored Glycine 0 CA--C 1.525 0.715 0 C-N-CA 124.287 0.946 . . . . 0.0 112.513 178.072 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -80.18 91.08 5.52 Favored 'General case' 0 C--O 1.237 0.41 0 N-CA-C 106.609 -1.626 . . . . 0.0 106.609 178.122 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 20.1 m -131.12 171.6 17.64 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.246 0 C-N-CA 125.128 1.371 . . . . 0.0 112.15 -177.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -171.27 -179.89 42.66 Favored Glycine 0 CA--C 1.529 0.956 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 177.507 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 81.3 mttt -147.75 155.09 41.33 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-N 117.77 0.785 . . . . 0.0 110.435 -179.657 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 4.3 p -137.75 127.96 36.73 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 C-N-CA 123.938 0.895 . . . . 0.0 109.637 179.197 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -91.99 103.92 16.39 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 107.135 -1.431 . . . . 0.0 107.135 178.736 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 40.0 t -81.37 112.28 19.11 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 N-CA-C 105.386 -2.079 . . . . 0.0 105.386 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 31.1 m120 . . . . . 0 N--CA 1.456 -0.173 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 -178.596 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 8.6 tt . . . . . 0 N--CA 1.453 -0.324 0 CA-C-O 121.142 0.496 . . . . 0.0 111.055 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -94.34 127.81 40.45 Favored 'General case' 0 N--CA 1.455 -0.199 0 C-N-CA 124.263 1.025 . . . . 0.0 109.885 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 43.8 t -118.22 121.83 68.14 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.355 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 179.478 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 36.9 mt -89.62 127.88 35.97 Favored 'General case' 0 N--CA 1.454 -0.262 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 179.247 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 44.1 mt -86.64 96.87 10.26 Favored 'General case' 0 N--CA 1.452 -0.326 0 N-CA-C 106.656 -1.609 . . . . 0.0 106.656 177.822 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 105.39 132.41 7.31 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 -178.679 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 23.9 p -83.0 43.88 0.89 Allowed 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 119.07 1.435 . . . . 0.0 112.802 -178.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 71.58 -55.14 1.25 Allowed Glycine 0 CA--C 1.527 0.815 0 C-N-CA 126.197 1.856 . . . . 0.0 112.278 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -72.85 34.47 0.07 Allowed 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 126.163 1.785 . . . . 0.0 113.633 -177.554 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 68.08 -13.27 0.74 Allowed Glycine 0 CA--C 1.53 0.996 0 C-N-CA 124.505 1.05 . . . . 0.0 115.035 178.428 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 20.3 t -61.55 129.15 39.72 Favored 'General case' 0 C--N 1.339 0.126 0 CA-C-N 119.328 1.564 . . . . 0.0 109.768 -178.464 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 59.4 mt -75.11 66.76 1.69 Allowed 'General case' 0 N--CA 1.448 -0.534 0 C-N-CA 126.113 1.765 . . . . 0.0 111.857 -175.538 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.8 m -135.06 149.55 29.15 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.182 0 C-N-CA 123.446 0.698 . . . . 0.0 110.856 179.368 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 74.7 m-85 -88.09 135.46 33.41 Favored 'General case' 0 N--CA 1.456 -0.144 0 N-CA-C 105.477 -2.046 . . . . 0.0 105.477 176.549 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 48.4 t -122.67 110.73 31.69 Favored Pre-proline 0 CA--C 1.533 0.305 0 CA-C-O 118.026 -0.987 . . . . 0.0 108.851 178.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -72.87 151.62 97.13 Favored 'Cis proline' 0 N--CA 1.458 -0.565 0 CA-C-N 120.408 1.181 . . . . 0.0 111.175 -0.773 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.2 m -80.66 -48.92 11.92 Favored 'General case' 0 CA--C 1.529 0.161 0 C-N-CA 123.351 0.661 . . . . 0.0 110.799 179.811 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -119.97 129.47 54.32 Favored 'General case' 0 N--CA 1.454 -0.251 0 N-CA-C 105.904 -1.887 . . . . 0.0 105.904 179.821 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 38.2 p90 -157.4 -175.78 5.59 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-N 118.828 0.74 . . . . 0.0 111.963 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 32.9 m -133.97 147.9 51.09 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 125.601 1.561 . . . . 0.0 107.092 178.37 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.4 p -145.71 139.01 14.36 Favored Pre-proline 0 N--CA 1.449 -0.509 0 C-N-CA 123.568 0.747 . . . . 0.0 109.308 -178.156 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 70.7 Cg_exo -53.66 137.26 66.57 Favored 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 122.359 2.039 . . . . 0.0 111.436 177.327 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.6 m -60.13 117.23 4.88 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 179.476 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 109.35 -17.21 31.54 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-O 118.729 -1.039 . . . . 0.0 112.181 -178.119 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -72.17 157.45 37.73 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 119.534 1.667 . . . . 0.0 110.698 179.226 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 57.1 pttt -93.76 135.09 35.42 Favored 'General case' 0 N--CA 1.444 -0.76 0 C-N-CA 124.764 1.226 . . . . 0.0 110.826 -179.695 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 45.6 mt -102.36 130.71 51.81 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.358 0 N-CA-C 104.804 -2.295 . . . . 0.0 104.804 177.055 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 80.6 t -115.27 99.54 8.71 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 C-N-CA 124.819 1.247 . . . . 0.0 108.705 -178.104 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -86.13 103.0 14.37 Favored 'General case' 0 N--CA 1.456 -0.169 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 178.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 60.9 tttp -98.39 128.8 44.95 Favored 'General case' 0 CA--C 1.528 0.131 0 C-N-CA 124.315 1.046 . . . . 0.0 112.27 -177.216 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 38.8 t30 -64.43 110.36 2.25 Favored 'General case' 0 N--CA 1.456 -0.15 0 C-N-CA 123.608 0.763 . . . . 0.0 109.86 177.57 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 59.9 t30 -102.59 -64.74 1.04 Allowed 'General case' 0 C--N 1.339 0.134 0 CA-C-N 118.495 0.589 . . . . 0.0 111.312 -179.207 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -157.17 168.4 27.55 Favored 'General case' 0 C--O 1.226 -0.18 0 C-N-CA 122.869 0.468 . . . . 0.0 111.284 -177.762 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 66.23 24.86 72.19 Favored Glycine 0 CA--C 1.532 1.144 0 O-C-N 121.868 -0.52 . . . . 0.0 112.269 -179.896 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.541 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 10.3 p90 -74.68 169.53 19.42 Favored Pre-proline 0 CA--C 1.543 0.7 0 C-N-CA 125.457 1.503 . . . . 0.0 107.768 179.023 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.541 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 95.7 Cg_endo -70.32 162.21 86.17 Favored 'Cis proline' 0 N--CA 1.448 -1.19 0 CA-C-N 120.189 1.103 . . . . 0.0 114.314 2.878 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 89.9 m-70 -148.9 174.86 11.8 Favored 'General case' 0 C--O 1.22 -0.476 0 O-C-N 121.545 -0.722 . . . . 0.0 111.276 -178.634 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 25.4 p-10 -163.87 179.08 7.3 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 103.858 -2.645 . . . . 0.0 103.858 175.707 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 45.1 t -138.52 117.44 13.81 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.377 0 N-CA-C 107.358 -1.349 . . . . 0.0 107.358 178.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 91.8 t -121.55 138.18 52.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 106.737 -1.579 . . . . 0.0 106.737 178.409 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 76.2 m-85 -97.09 131.82 43.49 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -63.19 116.26 5.26 Favored 'General case' 0 N--CA 1.454 -0.242 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 -178.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.1 pm0 -48.45 -29.57 4.22 Favored 'General case' 0 CA--C 1.533 0.299 0 N-CA-C 115.682 1.734 . . . . 0.0 115.682 -177.719 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 18.0 m-20 -90.07 -52.18 5.08 Favored 'General case' 0 CA--C 1.53 0.178 0 CA-C-N 118.752 0.706 . . . . 0.0 110.101 -179.593 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 80.0 mt-10 -79.92 58.82 3.0 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 124.402 1.081 . . . . 0.0 112.169 -176.721 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 19.2 pt -150.58 151.29 30.45 Favored Pre-proline 0 CA--C 1.532 0.261 0 C-N-CA 127.025 2.13 . . . . 0.0 107.1 176.199 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 21.0 Cg_endo -61.89 117.58 4.43 Favored 'Trans proline' 0 N--CA 1.452 -0.948 0 C-N-CA 121.925 1.75 . . . . 0.0 110.466 178.746 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -46.98 120.91 3.3 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 125.02 1.328 . . . . 0.0 110.963 -179.398 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 126.31 -39.51 1.99 Allowed Glycine 0 CA--C 1.525 0.676 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -178.853 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 21.7 t -78.28 95.06 1.65 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 53.5 t0 -54.47 114.82 1.81 Allowed 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 123.213 0.605 . . . . 0.0 110.535 179.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -45.44 -43.67 11.59 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 125.554 1.541 . . . . 0.0 111.887 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 55.0 t -57.61 -28.85 32.92 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.344 0 C-N-CA 123.274 0.63 . . . . 0.0 111.805 -178.258 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 28.8 mtpp -79.05 -36.01 41.68 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 118.556 0.616 . . . . 0.0 111.229 -178.723 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.403 HD13 HG21 ' A' ' 55' ' ' ILE . 26.2 pt -86.78 -26.11 6.12 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.408 0 C-N-CA 123.201 0.6 . . . . 0.0 112.482 -179.564 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 46.0 m -90.25 148.6 22.8 Favored 'General case' 0 C--N 1.331 -0.2 0 N-CA-C 114.455 1.28 . . . . 0.0 114.455 -176.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 69.5 mmm -80.56 120.74 80.1 Favored Pre-proline 0 CA--C 1.534 0.358 0 N-CA-C 105.749 -1.945 . . . . 0.0 105.749 173.583 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 81.4 Cg_exo -47.02 132.37 17.78 Favored 'Trans proline' 0 N--CA 1.457 -0.625 0 C-N-CA 123.07 2.513 . . . . 0.0 112.073 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 81.9 mt-10 -69.06 68.86 0.18 Allowed 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 125.347 1.459 . . . . 0.0 110.578 -179.8 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -167.08 -47.96 0.02 OUTLIER 'General case' 0 N--CA 1.451 -0.411 0 C-N-CA 129.204 3.002 . . . . 0.0 105.947 -178.585 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 79.5 mt-10 -78.45 148.74 33.44 Favored 'General case' 0 N--CA 1.446 -0.636 0 C-N-CA 124.484 1.114 . . . . 0.0 108.181 178.637 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 2.5 pp -160.27 162.76 33.72 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-O 121.198 0.523 . . . . 0.0 111.279 -179.097 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 37.4 mt -102.51 134.13 46.35 Favored 'General case' 0 N--CA 1.446 -0.662 0 C-N-CA 128.049 2.54 . . . . 0.0 104.598 177.53 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 30.0 t30 -138.77 -46.12 0.49 Allowed 'General case' 0 C--O 1.227 -0.111 0 C-N-CA 122.812 0.445 . . . . 0.0 111.833 -178.029 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -69.95 131.18 89.29 Favored Pre-proline 0 C--O 1.237 0.424 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 -178.575 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -48.56 130.22 21.56 Favored 'Trans proline' 0 N--CA 1.454 -0.823 0 C-N-CA 123.047 2.498 . . . . 0.0 111.538 -179.392 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 99.31 -23.3 36.83 Favored Glycine 0 CA--C 1.525 0.693 0 CA-C-O 117.662 -1.632 . . . . 0.0 114.462 177.627 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 52.4 mt-10 -50.86 125.41 13.36 Favored 'General case' 0 CA--C 1.536 0.438 0 CA-C-N 120.116 1.958 . . . . 0.0 110.849 179.719 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 2.3 p -104.27 140.73 37.44 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 125.514 1.526 . . . . 0.0 112.184 -178.163 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 20.8 t80 -117.79 115.22 24.57 Favored 'General case' 0 C--O 1.232 0.176 0 N-CA-C 104.789 -2.3 . . . . 0.0 104.789 172.259 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.4 t -103.56 139.41 24.57 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.388 0 C-N-CA 123.183 0.593 . . . . 0.0 109.526 -178.497 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.5 p -143.48 156.11 16.61 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 N-CA-C 106.6 -1.63 . . . . 0.0 106.6 176.854 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 12.5 m -132.29 123.66 27.33 Favored 'General case' 0 C--N 1.333 -0.139 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 -179.286 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 68.1 mt -111.56 102.09 10.45 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 123.254 0.622 . . . . 0.0 109.698 -177.531 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -82.46 -42.73 18.14 Favored 'General case' 0 CA--C 1.529 0.165 0 C-N-CA 124.069 0.947 . . . . 0.0 110.676 178.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 4.4 m -73.21 112.42 9.25 Favored 'General case' 0 N--CA 1.45 -0.458 0 C-N-CA 123.083 0.553 . . . . 0.0 109.87 -177.745 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 25.8 pttm -60.21 152.17 25.35 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 123.077 0.551 . . . . 0.0 111.299 178.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 150.96 -167.94 30.61 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.106 -1.198 . . . . 0.0 110.106 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 23.3 m -113.97 124.71 52.82 Favored 'General case' 0 N--CA 1.454 -0.271 0 N-CA-C 106.435 -1.691 . . . . 0.0 106.435 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -121.01 114.9 22.18 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 124.059 0.944 . . . . 0.0 110.045 -178.164 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 48.7 m -90.51 139.62 30.52 Favored 'General case' 0 C--O 1.233 0.197 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 175.788 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 22.5 p90 -136.41 165.44 25.81 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-O 121.419 0.628 . . . . 0.0 112.071 -179.312 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 49.4 p90 -153.33 161.12 42.69 Favored 'General case' 0 N--CA 1.453 -0.323 0 C-N-CA 124.277 1.031 . . . . 0.0 112.179 -178.498 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 3.7 t -103.1 102.62 12.64 Favored 'General case' 0 CA--C 1.519 -0.239 0 N-CA-C 106.254 -1.758 . . . . 0.0 106.254 176.638 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.263 0.7 OUTLIER -44.67 -56.36 8.67 Favored Pre-proline 0 CA--C 1.535 0.402 0 N-CA-C 113.985 1.106 . . . . 0.0 113.985 -175.131 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_exo -50.93 -18.16 4.07 Favored 'Trans proline' 0 CA--C 1.534 0.514 0 C-N-CA 123.187 2.591 . . . . 0.0 115.042 177.772 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 38.2 m80 -133.85 25.73 3.98 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 123.783 0.833 . . . . 0.0 110.862 -179.599 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 65.7 tt0 -61.61 -50.27 73.27 Favored 'General case' 0 N--CA 1.457 -0.093 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 179.214 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.56 -33.3 62.27 Favored Glycine 0 CA--C 1.532 1.098 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 177.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -79.92 2.17 24.44 Favored 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 123.403 0.681 . . . . 0.0 112.037 179.082 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 79.9 21.84 64.99 Favored Glycine 0 CA--C 1.527 0.832 0 CA-C-O 118.978 -0.901 . . . . 0.0 113.706 178.42 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 22.1 ttt -78.65 80.78 5.0 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 119.321 1.56 . . . . 0.0 107.928 177.874 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 12.6 m -124.2 170.3 14.54 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.188 0 C-N-CA 125.975 1.71 . . . . 0.0 111.07 -179.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -170.02 178.56 42.8 Favored Glycine 0 CA--C 1.527 0.84 0 N-CA-C 108.848 -1.701 . . . . 0.0 108.848 177.611 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 33.8 mtmm -148.42 149.75 32.28 Favored 'General case' 0 N--CA 1.455 -0.199 0 CA-C-N 118.091 0.946 . . . . 0.0 110.463 -178.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.2 p -135.26 132.17 52.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 C-N-CA 123.121 0.569 . . . . 0.0 109.813 178.132 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.2 m -98.87 103.49 15.45 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 125.05 1.34 . . . . 0.0 107.848 179.341 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 47.0 t -82.59 102.24 8.31 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.753 0 N-CA-C 105.026 -2.213 . . . . 0.0 105.026 -179.189 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 45.5 p-10 . . . . . 0 C--N 1.332 -0.167 0 C-N-CA 124.984 1.314 . . . . 0.0 109.599 -178.059 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 9.9 mp . . . . . 0 CA--C 1.53 0.183 0 CA-C-O 121.275 0.559 . . . . 0.0 111.215 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -80.74 138.91 36.33 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 106.869 -1.53 . . . . 0.0 106.869 175.486 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 60.2 t -129.34 126.59 63.98 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 39.7 mt -87.98 122.53 31.7 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 178.763 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 88.9 mt -81.11 100.01 8.81 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 106.248 -1.76 . . . . 0.0 106.248 177.35 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 95.84 137.96 9.5 Favored Glycine 0 C--N 1.336 0.532 0 N-CA-C 107.402 -2.279 . . . . 0.0 107.402 -177.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 80.8 p -78.97 157.97 28.06 Favored 'General case' 0 N--CA 1.438 -1.037 0 CA-C-O 121.985 0.898 . . . . 0.0 109.21 -179.212 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.4 -34.55 59.69 Favored Glycine 0 CA--C 1.531 1.04 0 CA-C-N 114.608 -1.178 . . . . 0.0 111.085 178.162 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -76.03 -3.77 37.65 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 123.573 0.749 . . . . 0.0 112.256 179.074 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 99.76 -21.14 46.39 Favored Glycine 0 CA--C 1.528 0.847 0 CA-C-O 119.007 -0.885 . . . . 0.0 113.451 178.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 33.4 t -56.81 131.99 51.0 Favored 'General case' 0 C--O 1.237 0.442 0 CA-C-N 119.249 1.524 . . . . 0.0 110.426 -179.641 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 56.4 mt -74.06 68.3 1.38 Allowed 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 126.489 1.916 . . . . 0.0 111.114 -176.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.5 m -134.38 152.94 34.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 C-N-CA 123.739 0.816 . . . . 0.0 109.533 178.534 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 -82.45 135.95 35.02 Favored 'General case' 0 N--CA 1.454 -0.245 0 N-CA-C 105.529 -2.026 . . . . 0.0 105.529 176.625 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 48.0 t -123.92 110.46 29.44 Favored Pre-proline 0 CA--C 1.535 0.397 0 CA-C-O 118.158 -0.925 . . . . 0.0 108.79 179.296 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -70.43 152.28 93.89 Favored 'Cis proline' 0 N--CA 1.459 -0.524 0 CA-C-N 120.361 1.164 . . . . 0.0 111.543 -0.79 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.4 m -82.3 -44.09 16.67 Favored 'General case' 0 CA--C 1.529 0.145 0 C-N-CA 123.784 0.833 . . . . 0.0 111.019 179.721 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 37.8 tt0 -129.68 133.98 47.4 Favored 'General case' 0 N--CA 1.452 -0.33 0 N-CA-C 106.354 -1.721 . . . . 0.0 106.354 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 30.2 p90 -163.23 -179.26 6.49 Favored 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 122.944 0.498 . . . . 0.0 110.251 -179.177 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 17.7 m -128.69 148.43 50.83 Favored 'General case' 0 N--CA 1.455 -0.191 0 N-CA-C 106.932 -1.507 . . . . 0.0 106.932 177.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.8 p -141.61 127.73 11.13 Favored Pre-proline 0 CA--C 1.538 0.496 0 C-N-CA 123.16 0.584 . . . . 0.0 111.35 -177.211 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -55.57 132.21 50.79 Favored 'Trans proline' 0 N--CA 1.452 -0.921 0 C-N-CA 122.327 2.018 . . . . 0.0 110.55 175.336 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 38.2 m -47.73 127.19 11.34 Favored 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 123.118 0.567 . . . . 0.0 110.042 178.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 99.03 -25.98 26.1 Favored Glycine 0 CA--C 1.531 1.054 0 CA-C-O 118.809 -0.995 . . . . 0.0 113.011 -179.591 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 75.4 mt-10 -74.73 100.91 4.13 Favored 'General case' 0 N--CA 1.454 -0.253 0 CA-C-N 119.742 1.771 . . . . 0.0 108.586 178.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 21.5 pttp -51.66 139.56 20.64 Favored 'General case' 0 N--CA 1.45 -0.44 0 C-N-CA 124.795 1.238 . . . . 0.0 113.926 -178.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 38.1 mt -93.54 133.39 34.82 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.405 0 N-CA-C 105.199 -2.149 . . . . 0.0 105.199 176.784 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 60.7 t -119.21 94.76 3.22 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.202 0 C-N-CA 124.453 1.101 . . . . 0.0 108.49 -178.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -83.27 98.94 9.68 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 122.857 0.463 . . . . 0.0 109.948 -179.384 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 24.3 ttmm -88.35 128.47 35.5 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 125.055 1.342 . . . . 0.0 112.114 -177.653 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 4.8 t30 -67.01 93.82 0.3 Allowed 'General case' 0 CA--C 1.534 0.363 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 177.019 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 42.5 t30 -85.39 -75.77 0.35 Allowed 'General case' 0 C--O 1.228 -0.074 0 N-CA-C 113.162 0.801 . . . . 0.0 113.162 -175.871 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -143.98 163.67 32.82 Favored 'General case' 0 C--O 1.224 -0.277 0 C-N-CA 123.67 0.788 . . . . 0.0 109.79 -176.456 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 63.65 19.59 62.91 Favored Glycine 0 CA--C 1.535 1.297 0 O-C-N 121.906 -0.496 . . . . 0.0 112.697 -179.591 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.468 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 16.2 p90 -72.24 166.53 40.53 Favored Pre-proline 0 CA--C 1.546 0.799 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 177.483 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.468 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 95.4 Cg_endo -68.31 158.06 86.79 Favored 'Cis proline' 0 N--CA 1.447 -1.222 0 N-CA-C 115.754 1.405 . . . . 0.0 115.754 4.246 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 88.9 m-70 -150.74 171.32 17.37 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 114.643 -1.162 . . . . 0.0 109.459 -179.422 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 34.9 p-10 -159.61 173.2 16.46 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 104.663 -2.347 . . . . 0.0 104.663 175.423 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 36.8 t -129.19 111.55 23.03 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.245 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 -178.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.9 t -113.36 131.46 65.03 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.579 0 N-CA-C 106.547 -1.649 . . . . 0.0 106.547 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.41 ' CG ' HD12 ' A' ' 55' ' ' ILE . 67.8 m-85 -97.01 131.56 43.7 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 179.243 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -71.76 109.17 5.47 Favored 'General case' 0 N--CA 1.454 -0.26 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 -179.677 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -46.27 -31.97 2.82 Favored 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 115.279 1.585 . . . . 0.0 115.279 -178.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 20.0 m-20 -84.31 -17.96 37.85 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-N 118.518 0.599 . . . . 0.0 111.839 -179.356 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -118.91 59.36 0.83 Allowed 'General case' 0 CA--C 1.532 0.259 0 C-N-CA 124.657 1.183 . . . . 0.0 111.087 -177.078 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 25.0 pt -152.68 151.4 26.71 Favored Pre-proline 0 CA--C 1.531 0.24 0 C-N-CA 126.165 1.786 . . . . 0.0 106.224 176.746 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_endo -57.7 118.2 5.03 Favored 'Trans proline' 0 N--CA 1.453 -0.873 0 C-N-CA 122.316 2.01 . . . . 0.0 111.125 179.43 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -47.85 117.72 2.0 Allowed 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 124.996 1.318 . . . . 0.0 110.695 -179.611 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 128.54 -35.98 2.55 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 -178.504 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 34.7 t -77.4 109.27 11.77 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 46.2 t0 -64.29 112.09 2.91 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 122.676 0.39 . . . . 0.0 110.512 179.634 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.1 -40.05 14.54 Favored 'General case' 0 CA--C 1.528 0.106 0 C-N-CA 125.057 1.343 . . . . 0.0 111.626 178.644 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 55.4 t -61.3 -31.13 49.43 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.349 0 C-N-CA 123.348 0.659 . . . . 0.0 111.641 -179.027 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -78.62 -40.72 33.56 Favored 'General case' 0 C--O 1.227 -0.113 0 CA-C-N 118.515 0.598 . . . . 0.0 110.469 -178.7 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.41 HD12 ' CG ' ' A' ' 41' ' ' PHE . 35.4 pt -78.02 -33.74 18.55 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.252 0 N-CA-C 112.566 0.58 . . . . 0.0 112.566 -178.804 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 50.7 m -78.17 139.92 38.98 Favored 'General case' 0 N--CA 1.455 -0.201 0 N-CA-C 112.774 0.657 . . . . 0.0 112.774 -177.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.2 tmt? -67.34 124.59 89.43 Favored Pre-proline 0 CA--C 1.538 0.513 0 N-CA-C 105.559 -2.015 . . . . 0.0 105.559 176.017 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 81.3 Cg_exo -44.59 110.51 0.22 Allowed 'Trans proline' 0 N--CA 1.458 -0.56 0 C-N-CA 123.885 3.057 . . . . 0.0 113.43 -178.272 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -45.1 -33.94 2.39 Favored 'General case' 0 CA--C 1.531 0.226 0 C-N-CA 125.869 1.668 . . . . 0.0 114.17 -179.281 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -57.65 -33.82 68.71 Favored 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 123.666 0.786 . . . . 0.0 110.972 179.132 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -104.9 159.96 15.39 Favored 'General case' 0 N--CA 1.445 -0.719 0 C-N-CA 125.853 1.661 . . . . 0.0 110.14 -178.672 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 96.1 mt -145.41 151.77 38.78 Favored 'General case' 0 N--CA 1.454 -0.253 0 N-CA-C 106.588 -1.634 . . . . 0.0 106.588 178.38 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 74.8 mt -78.59 102.05 7.75 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 106.114 -1.81 . . . . 0.0 106.114 177.373 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 31.8 p-10 -83.26 -55.46 4.32 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 124.291 1.037 . . . . 0.0 112.311 -177.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.94 149.57 77.1 Favored Pre-proline 0 CA--C 1.533 0.289 0 C-N-CA 123.203 0.601 . . . . 0.0 111.185 -177.59 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -66.87 164.02 31.25 Favored 'Trans proline' 0 N--CA 1.454 -0.799 0 C-N-CA 122.406 2.071 . . . . 0.0 109.804 177.513 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 79.42 -38.77 2.08 Favored Glycine 0 CA--C 1.528 0.862 0 CA-C-O 118.55 -1.139 . . . . 0.0 113.947 176.295 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -39.86 123.91 1.67 Allowed 'General case' 0 CA--C 1.536 0.437 0 CA-C-N 118.495 1.147 . . . . 0.0 111.696 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 18.0 p -105.03 121.04 42.95 Favored 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 124.662 1.185 . . . . 0.0 112.647 -177.701 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 62.3 t80 -95.13 111.4 23.24 Favored 'General case' 0 N--CA 1.454 -0.239 0 N-CA-C 105.367 -2.086 . . . . 0.0 105.367 174.081 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -100.11 139.92 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 C-N-CA 123.219 0.608 . . . . 0.0 110.54 -177.448 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 11.6 p -146.67 139.28 19.64 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.174 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 176.626 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 14.2 m -126.61 99.01 5.62 Favored 'General case' 0 C--N 1.34 0.187 0 C-N-CA 122.918 0.487 . . . . 0.0 112.286 -176.067 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.423 ' H ' HD22 ' A' ' 74' ' ' LEU . 1.6 mm? -87.05 130.54 34.44 Favored 'General case' 0 N--CA 1.439 -0.984 0 C-N-CA 123.057 0.543 . . . . 0.0 111.666 178.329 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -100.9 -45.1 5.54 Favored 'General case' 0 N--CA 1.454 -0.227 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 174.549 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 4.6 m -65.52 115.64 5.96 Favored 'General case' 0 N--CA 1.446 -0.652 0 C-N-CA 124.808 1.243 . . . . 0.0 110.192 -178.231 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 25.9 pttm -63.93 153.59 36.53 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-N 115.159 -0.928 . . . . 0.0 110.896 178.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 147.08 -177.51 25.33 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.401 -1.08 . . . . 0.0 110.401 178.392 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 28.7 m -106.49 121.94 45.29 Favored 'General case' 0 N--CA 1.452 -0.327 0 N-CA-C 106.941 -1.503 . . . . 0.0 106.941 -179.024 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 16.4 m-85 -115.07 122.44 46.16 Favored 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 124.594 1.158 . . . . 0.0 109.735 -178.358 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 41.4 m -98.3 132.86 43.44 Favored 'General case' 0 C--O 1.234 0.248 0 N-CA-C 107.635 -1.246 . . . . 0.0 107.635 175.366 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 21.0 p90 -132.62 165.68 23.88 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-O 121.638 0.732 . . . . 0.0 111.842 -179.438 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 52.4 p90 -156.56 161.92 39.94 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 115.226 -0.897 . . . . 0.0 112.561 -178.601 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.7 t -103.36 99.97 9.83 Favored 'General case' 0 CA--C 1.516 -0.333 0 N-CA-C 106.454 -1.684 . . . . 0.0 106.454 177.177 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.281 13.1 p -35.84 -64.31 0.35 Allowed Pre-proline 0 CA--C 1.541 0.63 0 N-CA-C 115.861 1.8 . . . . 0.0 115.861 -175.654 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -60.68 -7.25 6.99 Favored 'Trans proline' 0 C--N 1.348 0.506 0 C-N-CA 122.663 2.242 . . . . 0.0 115.221 -177.82 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 36.2 m80 -132.09 15.83 4.65 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 119.674 1.125 . . . . 0.0 110.814 178.22 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 65.6 tt0 -59.5 -46.57 88.45 Favored 'General case' 0 CA--C 1.529 0.163 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 178.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -57.07 -30.45 60.63 Favored Glycine 0 CA--C 1.531 1.082 0 C-N-CA 123.588 0.613 . . . . 0.0 111.579 177.613 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -86.08 8.15 21.91 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 123.599 0.759 . . . . 0.0 111.347 178.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 81.67 16.33 73.44 Favored Glycine 0 CA--C 1.527 0.839 0 CA-C-O 118.762 -1.021 . . . . 0.0 113.371 178.722 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 20.0 ttt -78.25 77.12 4.75 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 119.525 1.663 . . . . 0.0 108.925 178.754 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.7 m -125.8 170.81 15.33 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.314 0 C-N-CA 125.901 1.68 . . . . 0.0 110.052 179.43 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -170.07 177.27 43.5 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 109.262 -1.535 . . . . 0.0 109.262 177.804 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 59.4 mttp -145.98 157.53 43.88 Favored 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 123.401 0.68 . . . . 0.0 109.677 -178.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.2 p -147.25 130.6 8.77 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 C-N-CA 122.689 0.396 . . . . 0.0 110.417 178.007 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 99.1 m -98.49 102.65 14.46 Favored 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 124.171 0.988 . . . . 0.0 108.85 178.579 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 48.8 t -83.2 132.29 31.75 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.444 0 N-CA-C 105.797 -1.927 . . . . 0.0 105.797 178.686 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.334 -0.106 0 CA-C-N 118.395 0.543 . . . . 0.0 111.416 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . 0.507 ' H1 ' HD12 ' A' ' 1' ' ' LEU . 9.8 mp . . . . . 0 CA--C 1.534 0.329 0 CA-C-O 121.41 0.624 . . . . 0.0 111.6 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 -89.12 117.1 27.87 Favored 'General case' 0 N--CA 1.452 -0.326 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 175.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 28.1 t -110.88 112.25 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.238 0 C-N-CA 123.695 0.798 . . . . 0.0 110.305 -177.505 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 53.6 mt -80.29 123.78 28.27 Favored 'General case' 0 N--CA 1.451 -0.403 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 178.427 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 64.9 mt -87.08 110.73 20.3 Favored 'General case' 0 N--CA 1.447 -0.575 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 178.566 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 84.61 126.37 1.45 Allowed Glycine 0 C--N 1.337 0.594 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.709 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 6.1 p -77.64 161.43 27.81 Favored 'General case' 0 N--CA 1.442 -0.827 0 O-C-N 121.48 -1.012 . . . . 0.0 108.689 -179.099 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -44.32 -38.66 5.18 Favored Glycine 0 CA--C 1.531 1.085 0 C-N-CA 125.777 1.656 . . . . 0.0 113.822 -178.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -76.31 4.08 9.6 Favored 'General case' 0 CA--C 1.537 0.48 0 N-CA-C 113.267 0.84 . . . . 0.0 113.267 -179.647 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 86.73 -6.16 83.33 Favored Glycine 0 CA--C 1.529 0.965 0 CA-C-O 118.92 -0.933 . . . . 0.0 113.105 -179.626 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 20.7 t -61.67 135.81 57.76 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-N 119.233 1.517 . . . . 0.0 110.457 -179.108 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 58.1 mt -75.94 65.93 2.09 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 126.064 1.746 . . . . 0.0 111.465 -176.556 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 28.7 m -130.94 152.5 37.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 C-N-CA 123.772 0.829 . . . . 0.0 110.436 179.547 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 73.3 m-85 -89.34 138.07 31.77 Favored 'General case' 0 N--CA 1.455 -0.222 0 N-CA-C 104.973 -2.232 . . . . 0.0 104.973 176.102 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 52.5 t -125.65 105.64 26.91 Favored Pre-proline 0 CA--C 1.537 0.457 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 179.009 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -68.23 158.44 86.05 Favored 'Cis proline' 0 C--N 1.347 0.466 0 CA-C-N 120.031 1.047 . . . . 0.0 111.799 -1.023 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.7 p -84.77 -63.65 1.3 Allowed 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 125.039 1.336 . . . . 0.0 108.907 179.672 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -117.8 135.66 53.92 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 125.102 1.361 . . . . 0.0 107.435 178.541 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 43.4 p90 -158.59 175.34 13.78 Favored 'General case' 0 C--N 1.333 -0.127 0 CA-C-O 121.22 0.533 . . . . 0.0 111.724 -178.455 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 24.0 p -128.33 147.18 50.61 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 107.19 -1.411 . . . . 0.0 107.19 178.358 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.0 p -149.93 140.46 14.06 Favored Pre-proline 0 CA--C 1.537 0.456 0 CA-C-N 118.843 0.747 . . . . 0.0 110.662 -178.08 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -52.87 138.79 60.76 Favored 'Trans proline' 0 CA--C 1.538 0.706 0 C-N-CA 122.609 2.206 . . . . 0.0 112.44 176.378 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 23.5 m -57.96 131.85 51.66 Favored 'General case' 0 CA--C 1.53 0.191 0 C-N-CA 122.875 0.47 . . . . 0.0 111.125 179.601 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 101.52 -18.1 54.0 Favored Glycine 0 CA--C 1.526 0.774 0 CA-C-O 119.156 -0.802 . . . . 0.0 112.92 179.57 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 81.5 mm-40 -68.7 156.5 38.12 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-N 119.075 1.438 . . . . 0.0 112.823 -179.198 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 24.0 ttmm -91.49 142.05 28.08 Favored 'General case' 0 N--CA 1.452 -0.372 0 C-N-CA 125.965 1.706 . . . . 0.0 110.14 -179.786 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 40.6 mt -120.88 134.42 64.35 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.343 0 N-CA-C 105.929 -1.878 . . . . 0.0 105.929 178.307 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 97.6 t -124.15 101.53 9.25 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 C-N-CA 125.236 1.414 . . . . 0.0 108.571 -177.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -86.25 136.19 33.26 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 106.115 -1.809 . . . . 0.0 106.115 176.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 12.1 tmtt? -135.27 132.46 37.81 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 118.986 0.812 . . . . 0.0 112.4 -177.369 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 6.2 m-20 -66.47 101.4 0.76 Allowed 'General case' 0 C--N 1.341 0.203 0 C-N-CA 123.69 0.796 . . . . 0.0 108.886 177.77 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 38.7 t30 -92.38 -61.84 1.53 Allowed 'General case' 0 N--CA 1.455 -0.224 0 CA-C-O 121.34 0.59 . . . . 0.0 109.951 -179.663 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -150.77 -179.47 7.29 Favored 'General case' 0 C--O 1.223 -0.299 0 C-N-CA 124.065 0.946 . . . . 0.0 108.898 -179.029 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 52.72 17.12 4.41 Favored Glycine 0 CA--C 1.538 1.503 0 N-CA-C 115.534 0.973 . . . . 0.0 115.534 178.574 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.449 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 14.5 p90 -73.85 167.62 33.61 Favored Pre-proline 0 CA--C 1.539 0.531 0 N-CA-C 106.921 -1.511 . . . . 0.0 106.921 178.535 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.449 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 33.0 Cg_exo -63.4 157.87 67.55 Favored 'Cis proline' 0 N--CA 1.454 -0.82 0 N-CA-C 117.407 2.041 . . . . 0.0 117.407 2.638 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 90.8 m-70 -152.47 169.0 23.67 Favored 'General case' 0 N--CA 1.453 -0.3 0 O-C-N 121.598 -0.689 . . . . 0.0 111.638 179.843 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 51.4 p30 -162.15 178.64 8.59 Favored 'General case' 0 N--CA 1.452 -0.332 0 N-CA-C 104.606 -2.368 . . . . 0.0 104.606 174.707 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 34.8 t -135.46 123.4 37.7 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 71.1 t -123.07 139.27 50.35 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.58 0 N-CA-C 105.558 -2.016 . . . . 0.0 105.558 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.406 ' CG ' HD12 ' A' ' 55' ' ' ILE . 80.5 m-85 -103.99 135.37 45.63 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 108.165 -1.05 . . . . 0.0 108.165 -179.918 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -66.44 122.08 16.73 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 -179.482 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -74.43 50.2 0.4 Allowed 'General case' 0 CA--C 1.538 0.511 0 N-CA-C 113.956 1.095 . . . . 0.0 113.956 -178.509 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -161.7 -64.79 0.05 Allowed 'General case' 0 N--CA 1.456 -0.129 0 C-N-CA 125.19 1.396 . . . . 0.0 108.987 177.3 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -83.0 63.81 7.28 Favored 'General case' 0 CA--C 1.538 0.496 0 CA-C-O 122.069 0.938 . . . . 0.0 110.274 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 26.8 pt -145.3 153.63 52.54 Favored Pre-proline 0 CA--C 1.536 0.408 0 C-N-CA 129.763 3.225 . . . . 0.0 105.523 177.019 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo -57.92 114.81 2.12 Favored 'Trans proline' 0 N--CA 1.455 -0.79 0 C-N-CA 121.628 1.552 . . . . 0.0 111.699 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -48.11 112.07 0.53 Allowed 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 125.384 1.474 . . . . 0.0 110.735 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 131.12 -34.08 2.69 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 109.721 -1.351 . . . . 0.0 109.721 -178.822 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 42.8 t -77.32 111.48 14.17 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.23 0 CA-C-N 117.565 0.683 . . . . 0.0 109.214 -179.863 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 40.7 t0 -64.23 109.86 2.01 Favored 'General case' 0 CA--C 1.532 0.277 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 178.734 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.51 -38.79 14.68 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 125.131 1.372 . . . . 0.0 111.97 179.508 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 60.0 t -60.63 -28.9 43.73 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.311 0 C-N-CA 123.331 0.653 . . . . 0.0 111.789 -179.109 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 47.1 mmtm -75.84 -40.99 53.73 Favored 'General case' 0 CA--C 1.53 0.197 0 CA-C-N 118.571 0.623 . . . . 0.0 110.688 -178.408 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.406 HD12 ' CG ' ' A' ' 41' ' ' PHE . 21.5 pt -80.68 -38.75 17.67 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.289 0 N-CA-C 112.576 0.584 . . . . 0.0 112.576 -179.463 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 31.5 m -76.9 135.5 38.81 Favored 'General case' 0 N--CA 1.454 -0.252 0 N-CA-C 114.0 1.111 . . . . 0.0 114.0 -176.085 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 84.7 mtp -73.43 139.27 78.16 Favored Pre-proline 0 N--CA 1.449 -0.524 0 N-CA-C 104.721 -2.326 . . . . 0.0 104.721 173.218 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -64.98 126.4 16.46 Favored 'Trans proline' 0 N--CA 1.45 -1.051 0 N-CA-C 107.799 -1.654 . . . . 0.0 107.799 178.439 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -44.79 -34.87 2.46 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 125.053 1.341 . . . . 0.0 114.148 -177.322 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 11.2 tm-20 -56.26 -37.07 69.3 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 124.346 1.058 . . . . 0.0 110.713 178.865 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 52.2 mt-10 -92.93 148.2 22.21 Favored 'General case' 0 N--CA 1.444 -0.742 0 C-N-CA 124.478 1.111 . . . . 0.0 110.207 -178.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -160.22 151.3 19.16 Favored 'General case' 0 N--CA 1.444 -0.725 0 CA-C-N 115.661 -0.7 . . . . 0.0 110.934 178.551 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 47.3 mt -80.69 106.12 12.45 Favored 'General case' 0 N--CA 1.441 -0.885 0 N-CA-C 103.561 -2.755 . . . . 0.0 103.561 177.671 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 29.0 p-10 -89.19 -38.19 14.46 Favored 'General case' 0 C--N 1.332 -0.16 0 C-N-CA 124.803 1.241 . . . . 0.0 113.153 -176.732 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.68 155.89 45.38 Favored Pre-proline 0 CA--C 1.534 0.344 0 C-N-CA 123.895 0.878 . . . . 0.0 110.882 -178.054 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -66.11 164.68 26.78 Favored 'Trans proline' 0 N--CA 1.456 -0.702 0 C-N-CA 122.419 2.079 . . . . 0.0 109.753 176.629 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 79.73 -44.03 2.69 Favored Glycine 0 CA--C 1.528 0.86 0 CA-C-O 118.78 -1.011 . . . . 0.0 113.59 176.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 53.7 mt-10 -41.19 134.03 2.2 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 124.959 1.304 . . . . 0.0 111.686 -179.399 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 69.0 p -114.18 167.71 10.45 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 123.826 0.85 . . . . 0.0 113.268 -177.147 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 3.7 t80 -140.65 114.41 8.9 Favored 'General case' 0 N--CA 1.455 -0.213 0 N-CA-C 103.849 -2.649 . . . . 0.0 103.849 174.717 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 41.3 t -106.82 144.78 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.296 0 C-N-CA 123.703 0.801 . . . . 0.0 109.638 -177.4 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 13.7 p -152.02 167.25 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.204 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 177.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 57.2 m -145.88 122.72 11.28 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 105.765 -1.939 . . . . 0.0 105.765 179.49 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 66.3 mt -107.08 99.56 9.1 Favored 'General case' 0 N--CA 1.455 -0.192 0 CA-C-O 121.303 0.573 . . . . 0.0 111.389 -175.168 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -77.14 -47.14 21.2 Favored 'General case' 0 N--CA 1.455 -0.217 0 C-N-CA 123.835 0.854 . . . . 0.0 110.539 178.143 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.7 m -72.48 122.82 21.93 Favored 'General case' 0 N--CA 1.451 -0.382 0 C-N-CA 123.012 0.525 . . . . 0.0 110.599 -177.664 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 50.6 tttm -67.02 155.18 39.32 Favored 'General case' 0 N--CA 1.436 -1.168 0 C-N-CA 126.906 2.082 . . . . 0.0 110.316 179.177 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 132.8 178.24 15.42 Favored Glycine 0 CA--C 1.526 0.761 0 C-N-CA 124.798 1.19 . . . . 0.0 111.378 178.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 74.7 m -102.13 119.83 39.44 Favored 'General case' 0 CA--C 1.52 -0.201 0 C-N-CA 124.119 0.968 . . . . 0.0 108.756 -179.283 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 37.2 m-85 -105.92 112.65 25.79 Favored 'General case' 0 N--CA 1.445 -0.681 0 C-N-CA 125.794 1.638 . . . . 0.0 109.833 -179.035 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 4.1 m -85.87 128.7 34.88 Favored 'General case' 0 C--O 1.234 0.28 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 177.368 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 35.4 p90 -132.19 167.65 19.42 Favored 'General case' 0 N--CA 1.457 -0.1 0 CA-C-O 121.822 0.82 . . . . 0.0 112.562 -179.142 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 50.5 p90 -159.96 162.48 34.41 Favored 'General case' 0 N--CA 1.452 -0.372 0 CA-C-N 114.977 -1.01 . . . . 0.0 111.569 -179.37 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.2 t -99.6 102.9 14.55 Favored 'General case' 0 CA--C 1.518 -0.279 0 N-CA-C 106.575 -1.639 . . . . 0.0 106.575 177.52 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.312 16.9 p -40.44 -61.2 1.25 Allowed Pre-proline 0 CA--C 1.538 0.518 0 N-CA-C 115.795 1.776 . . . . 0.0 115.795 -174.489 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -60.12 -6.09 4.66 Favored 'Trans proline' 0 CA--C 1.537 0.638 0 C-N-CA 122.208 1.939 . . . . 0.0 114.924 -178.751 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 35.8 m80 -134.43 14.24 3.78 Favored 'General case' 0 CA--C 1.532 0.254 0 CA-C-N 119.694 1.134 . . . . 0.0 111.355 178.671 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 16.6 pt20 -60.66 -42.83 97.82 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 119.147 0.885 . . . . 0.0 109.217 179.259 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -58.48 -31.39 66.61 Favored Glycine 0 CA--C 1.531 1.071 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 177.18 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -85.12 5.25 30.61 Favored 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 123.556 0.743 . . . . 0.0 111.333 178.91 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 83.89 17.24 65.89 Favored Glycine 0 CA--C 1.528 0.849 0 CA-C-O 118.795 -1.003 . . . . 0.0 113.591 178.726 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 21.8 ttt -78.72 77.16 5.21 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 119.593 1.696 . . . . 0.0 108.494 178.144 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 11.6 m -120.24 169.95 10.69 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 C-N-CA 125.984 1.714 . . . . 0.0 110.404 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -169.45 174.19 43.79 Favored Glycine 0 CA--C 1.527 0.83 0 N-CA-C 109.108 -1.597 . . . . 0.0 109.108 178.112 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 54.2 mttp -149.4 139.04 21.71 Favored 'General case' 0 C--O 1.231 0.083 0 CA-C-N 118.173 0.986 . . . . 0.0 109.756 -178.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 6.0 p -125.66 120.17 56.83 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.139 0 CA-C-O 120.921 0.391 . . . . 0.0 110.519 178.798 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 48.6 m -94.22 100.58 12.63 Favored 'General case' 0 N--CA 1.455 -0.203 0 C-N-CA 124.68 1.192 . . . . 0.0 109.342 178.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 44.7 t -79.69 107.09 11.73 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.012 0 N-CA-C 104.397 -2.445 . . . . 0.0 104.397 179.536 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 51.1 p-10 . . . . . 0 N--CA 1.456 -0.16 0 C-N-CA 125.157 1.383 . . . . 0.0 110.291 -177.034 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 8.5 tt . . . . . 0 N--CA 1.454 -0.275 0 CA-C-O 121.065 0.46 . . . . 0.0 110.935 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -84.08 119.49 25.02 Favored 'General case' 0 N--CA 1.453 -0.294 0 C-N-CA 123.224 0.61 . . . . 0.0 110.093 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 47.1 t -112.24 111.0 34.28 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 105.855 -1.906 . . . . 0.0 105.855 178.517 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 31.7 mt -90.46 120.4 31.54 Favored 'General case' 0 N--CA 1.45 -0.462 0 O-C-N 121.822 -0.549 . . . . 0.0 109.706 -178.68 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.434 ' HB3' ' CD2' ' A' ' 37' ' ' HIS . 1.9 mm? -79.47 106.88 11.82 Favored 'General case' 0 N--CA 1.444 -0.738 0 N-CA-C 105.909 -1.886 . . . . 0.0 105.909 174.378 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 97.03 132.8 7.54 Favored Glycine 0 CA--C 1.523 0.586 0 C-N-CA 125.871 1.701 . . . . 0.0 112.329 178.666 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.6 p -82.78 47.87 1.26 Allowed 'General case' 0 N--CA 1.456 -0.135 0 C-N-CA 124.43 1.092 . . . . 0.0 111.197 179.325 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 70.74 -52.2 0.91 Allowed Glycine 0 CA--C 1.527 0.781 0 C-N-CA 126.598 2.047 . . . . 0.0 113.078 -179.668 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -72.1 38.07 0.07 Allowed 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 126.05 1.74 . . . . 0.0 113.851 -177.298 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 59.17 3.04 1.62 Allowed Glycine 0 CA--C 1.531 1.075 0 N-CA-C 115.911 1.124 . . . . 0.0 115.911 178.569 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 27.7 t -64.31 145.45 56.0 Favored 'General case' 0 N--CA 1.455 -0.181 0 CA-C-N 119.131 1.465 . . . . 0.0 110.87 -178.661 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 93.0 mt -86.43 73.26 10.16 Favored 'General case' 0 N--CA 1.447 -0.58 0 C-N-CA 124.044 0.938 . . . . 0.0 109.482 -178.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.9 m -137.01 143.97 33.4 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.217 0 C-N-CA 123.05 0.54 . . . . 0.0 111.204 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -90.27 122.84 33.55 Favored 'General case' 0 N--CA 1.46 0.051 0 N-CA-C 103.695 -2.706 . . . . 0.0 103.695 174.865 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.8 t -113.94 100.56 52.62 Favored Pre-proline 0 CA--C 1.536 0.422 0 CA-C-O 118.237 -0.887 . . . . 0.0 109.984 -179.271 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -81.01 164.24 78.26 Favored 'Cis proline' 0 N--CA 1.46 -0.463 0 CA-C-N 120.605 1.252 . . . . 0.0 111.257 -1.618 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 15.7 p -92.61 -62.86 1.31 Allowed 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 107.576 -1.268 . . . . 0.0 107.576 177.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 10.8 mp0 -98.21 126.85 43.85 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 125.835 1.654 . . . . 0.0 107.532 178.428 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.9 p90 -160.55 -175.57 5.08 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-O 121.541 0.686 . . . . 0.0 111.847 179.631 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 35.3 m -135.97 146.07 46.85 Favored 'General case' 0 N--CA 1.45 -0.426 0 N-CA-C 106.204 -1.776 . . . . 0.0 106.204 178.245 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 1.4 p -147.21 140.56 15.02 Favored Pre-proline 0 N--CA 1.449 -0.496 0 CA-C-O 118.367 -0.825 . . . . 0.0 109.631 -178.343 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_exo -60.71 144.13 99.5 Favored 'Trans proline' 0 N--CA 1.456 -0.689 0 C-N-CA 121.671 1.58 . . . . 0.0 112.678 179.411 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.2 m -56.35 128.0 33.7 Favored 'General case' 0 N--CA 1.454 -0.233 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 176.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.76 -3.57 78.1 Favored Glycine 0 CA--C 1.526 0.719 0 CA-C-O 119.012 -0.882 . . . . 0.0 112.198 179.35 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -70.64 149.3 47.17 Favored 'General case' 0 CA--C 1.534 0.361 0 CA-C-N 119.033 1.417 . . . . 0.0 109.124 178.025 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -90.44 105.09 17.58 Favored 'General case' 0 N--CA 1.447 -0.582 0 C-N-CA 124.868 1.267 . . . . 0.0 108.585 -178.563 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 34.6 mt -81.09 130.7 35.43 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.343 0 N-CA-C 105.381 -2.081 . . . . 0.0 105.381 177.364 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 67.9 t -117.69 97.58 5.58 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 C-N-CA 124.904 1.281 . . . . 0.0 108.665 -178.439 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -84.47 97.16 9.38 Favored 'General case' 0 N--CA 1.456 -0.158 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 178.011 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 28.4 ttpp -99.3 129.29 45.5 Favored 'General case' 0 CA--C 1.528 0.126 0 C-N-CA 123.746 0.818 . . . . 0.0 112.691 -176.444 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 5.2 m-20 -69.63 105.3 2.64 Favored 'General case' 0 N--CA 1.455 -0.2 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 177.456 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 51.5 t30 -89.17 -57.42 2.9 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 178.466 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -164.37 175.28 10.14 Favored 'General case' 0 CA--C 1.529 0.167 0 C-N-CA 124.095 0.958 . . . . 0.0 109.328 179.802 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 71.09 16.07 74.78 Favored Glycine 0 CA--C 1.531 1.084 0 O-C-N 121.753 -0.592 . . . . 0.0 113.095 179.19 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.508 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 21.5 p90 -67.77 166.4 23.24 Favored Pre-proline 0 CA--C 1.545 0.785 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 178.178 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.508 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 83.5 Cg_endo -69.7 151.4 91.26 Favored 'Cis proline' 0 N--CA 1.447 -1.23 0 N-CA-C 116.395 1.652 . . . . 0.0 116.395 5.161 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.434 ' CD2' ' HB3' ' A' ' 5' ' ' LEU . 88.8 m-70 -144.93 156.92 44.24 Favored 'General case' 0 N--CA 1.451 -0.387 0 O-C-N 121.695 -0.628 . . . . 0.0 111.093 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 56.6 p30 -158.18 175.52 13.66 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 103.966 -2.605 . . . . 0.0 103.966 175.287 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 42.0 t -137.98 121.08 20.12 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.36 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 -179.027 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 95.9 t -117.33 131.9 68.69 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.621 0 N-CA-C 105.83 -1.915 . . . . 0.0 105.83 178.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -96.91 131.2 43.92 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 107.24 -1.393 . . . . 0.0 107.24 179.425 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 35.6 t0 -67.21 108.74 2.81 Favored 'General case' 0 N--CA 1.451 -0.393 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 -179.131 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -47.82 -31.33 4.84 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.028 0.931 . . . . 0.0 113.45 178.865 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 34.4 t70 -75.74 -22.38 56.57 Favored 'General case' 0 CA--C 1.536 0.426 0 N-CA-C 112.741 0.645 . . . . 0.0 112.741 179.563 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -128.39 68.07 1.37 Allowed 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 124.453 1.101 . . . . 0.0 111.791 -177.042 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 31.8 pt -153.67 157.34 32.66 Favored Pre-proline 0 CA--C 1.535 0.371 0 C-N-CA 127.884 2.474 . . . . 0.0 105.79 175.825 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_exo -56.33 115.62 2.6 Favored 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.559 2.173 . . . . 0.0 111.07 178.391 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.34 107.33 0.27 Allowed 'General case' 0 N--CA 1.455 -0.178 0 C-N-CA 123.608 0.763 . . . . 0.0 109.676 179.569 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 137.79 -32.29 2.39 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 -177.805 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 57.3 t -76.84 107.37 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.262 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 179.354 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 45.0 t0 -57.99 108.15 0.56 Allowed 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 123.252 0.621 . . . . 0.0 110.777 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.63 -38.6 32.77 Favored 'General case' 0 C--O 1.223 -0.295 0 C-N-CA 123.73 0.812 . . . . 0.0 111.228 178.883 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 46.7 t -58.67 -27.22 33.76 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 CA-C-N 118.071 0.396 . . . . 0.0 111.863 -179.44 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 44.0 mmtm -82.55 -41.93 18.98 Favored 'General case' 0 CA--C 1.529 0.172 0 CA-C-N 118.611 0.641 . . . . 0.0 110.839 -179.392 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 24.6 pt -78.03 -46.9 25.83 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.29 0 N-CA-C 112.005 0.372 . . . . 0.0 112.005 -179.29 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 60.7 m -73.22 128.41 35.4 Favored 'General case' 0 N--CA 1.451 -0.422 0 C-N-CA 124.224 1.01 . . . . 0.0 113.01 -176.018 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 88.4 mmm -66.08 133.73 94.78 Favored Pre-proline 0 N--CA 1.451 -0.422 0 N-CA-C 105.401 -2.074 . . . . 0.0 105.401 174.661 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 21.0 Cg_endo -59.59 116.52 3.34 Favored 'Trans proline' 0 N--CA 1.453 -0.894 0 C-N-CA 121.495 1.463 . . . . 0.0 108.829 179.798 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -28.76 -48.89 0.07 Allowed 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 128.174 2.59 . . . . 0.0 116.062 -176.467 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 14.2 tm-20 -61.19 -37.71 83.93 Favored 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 124.579 1.152 . . . . 0.0 112.182 -178.374 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 53.5 mt-10 -84.04 143.44 29.75 Favored 'General case' 0 N--CA 1.446 -0.64 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 -178.266 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -159.45 149.61 18.97 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-O 121.713 0.768 . . . . 0.0 112.292 -178.043 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 63.0 mt -79.02 106.03 10.77 Favored 'General case' 0 N--CA 1.444 -0.749 0 N-CA-C 104.862 -2.273 . . . . 0.0 104.862 178.151 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 65.6 t30 -112.29 42.14 1.86 Allowed 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 124.259 1.024 . . . . 0.0 112.747 -177.732 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -158.0 158.26 29.97 Favored Pre-proline 0 C--O 1.233 0.186 0 N-CA-C 107.045 -1.465 . . . . 0.0 107.045 178.366 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 96.8 Cg_endo -73.92 167.78 26.39 Favored 'Trans proline' 0 N--CA 1.451 -0.999 0 C-N-CA 121.542 1.495 . . . . 0.0 109.313 178.242 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 78.63 -42.65 2.26 Favored Glycine 0 CA--C 1.527 0.84 0 CA-C-O 118.74 -1.033 . . . . 0.0 114.411 175.756 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 47.7 mt-10 -42.4 131.57 3.69 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 118.494 1.147 . . . . 0.0 112.442 -179.609 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 20.8 p -118.33 127.4 53.66 Favored 'General case' 0 N--CA 1.457 -0.122 0 N-CA-C 113.675 0.991 . . . . 0.0 113.675 -178.554 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 2.4 t80 -100.15 107.16 18.97 Favored 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 103.682 -2.71 . . . . 0.0 103.682 172.367 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 38.8 t -100.08 140.11 19.99 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.162 0 C-N-CA 123.415 0.686 . . . . 0.0 109.674 -178.026 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.2 p -150.31 135.03 9.69 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.254 0 C-N-CA 122.766 0.426 . . . . 0.0 110.319 177.847 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 19.7 m -103.57 100.4 10.24 Favored 'General case' 0 CA--C 1.53 0.207 0 C-N-CA 124.59 1.156 . . . . 0.0 109.0 -179.595 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 59.5 mt -90.19 99.73 12.69 Favored 'General case' 0 CA--C 1.53 0.192 0 CA-C-O 121.074 0.464 . . . . 0.0 109.82 -179.555 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -79.13 -55.34 5.18 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 123.216 0.606 . . . . 0.0 111.27 178.863 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.5 m -64.58 119.48 10.56 Favored 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 123.386 0.674 . . . . 0.0 110.388 -176.119 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.86 161.5 20.98 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 123.449 0.7 . . . . 0.0 112.373 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 133.87 178.77 15.83 Favored Glycine 0 CA--C 1.525 0.718 0 C-N-CA 125.565 1.555 . . . . 0.0 110.74 178.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 7.4 m -96.29 114.55 26.24 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 124.417 1.087 . . . . 0.0 109.336 -178.531 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 29.8 m-85 -105.09 111.05 23.67 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 124.684 1.193 . . . . 0.0 109.217 179.73 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 18.3 m -88.01 137.58 32.21 Favored 'General case' 0 C--O 1.232 0.172 0 N-CA-C 107.517 -1.29 . . . . 0.0 107.517 177.379 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 28.5 p90 -140.95 167.24 22.67 Favored 'General case' 0 C--N 1.339 0.124 0 CA-C-N 119.06 0.845 . . . . 0.0 113.266 -178.177 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 53.7 p90 -154.31 160.49 41.77 Favored 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 114.924 -1.034 . . . . 0.0 112.202 -179.658 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.6 t -104.24 99.31 9.03 Favored 'General case' 0 CA--C 1.519 -0.241 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 177.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -33.79 -62.99 0.33 Allowed Pre-proline 0 CA--C 1.537 0.45 0 N-CA-C 115.927 1.825 . . . . 0.0 115.927 -176.296 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -60.4 -7.04 6.19 Favored 'Trans proline' 0 C--N 1.348 0.546 0 C-N-CA 122.307 2.005 . . . . 0.0 114.92 -177.558 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 36.3 m80 -135.62 14.65 3.42 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 119.416 1.007 . . . . 0.0 111.124 178.505 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 14.6 pt20 -61.04 -41.24 96.2 Favored 'General case' 0 N--CA 1.454 -0.262 0 O-C-N 121.442 -0.786 . . . . 0.0 109.489 179.531 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -58.46 -29.45 63.59 Favored Glycine 0 CA--C 1.532 1.119 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 177.039 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.91 11.86 19.13 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 123.804 0.842 . . . . 0.0 110.864 178.798 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 74.47 21.87 78.18 Favored Glycine 0 CA--C 1.527 0.8 0 CA-C-O 119.112 -0.826 . . . . 0.0 113.171 178.877 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -78.86 80.55 5.2 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 119.255 1.528 . . . . 0.0 107.464 178.156 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 12.4 m -123.49 171.76 11.94 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 C-N-CA 125.579 1.552 . . . . 0.0 111.691 -178.851 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -167.12 178.79 41.15 Favored Glycine 0 CA--C 1.529 0.948 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 178.18 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 39.1 ttpt -158.48 130.57 6.82 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 -178.518 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.7 p -119.25 128.27 75.83 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 CA-C-O 121.391 0.615 . . . . 0.0 110.346 -178.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.4 m -94.37 98.78 11.13 Favored 'General case' 0 N--CA 1.452 -0.336 0 N-CA-C 107.514 -1.291 . . . . 0.0 107.514 179.151 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 45.2 t -80.31 114.28 20.97 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.587 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 -178.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 77.7 m-20 . . . . . 0 C--O 1.233 0.212 0 C-N-CA 123.664 0.785 . . . . 0.0 109.085 -178.112 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 9.3 mp . . . . . 0 CA--C 1.534 0.364 0 CA-C-O 121.702 0.763 . . . . 0.0 111.524 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 36.4 mt-10 -87.76 90.9 8.56 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 105.612 -1.996 . . . . 0.0 105.612 175.116 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 28.3 t -87.22 119.29 34.69 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.454 0 CA-C-N 114.968 -1.015 . . . . 0.0 108.923 -176.757 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 58.1 mt -88.27 121.47 30.7 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 179.189 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.414 ' HB3' ' CD2' ' A' ' 37' ' ' HIS . 1.4 mm? -78.01 103.18 7.78 Favored 'General case' 0 N--CA 1.445 -0.685 0 N-CA-C 105.815 -1.92 . . . . 0.0 105.815 173.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 97.1 152.31 28.6 Favored Glycine 0 N--CA 1.446 -0.675 0 C-N-CA 123.91 0.766 . . . . 0.0 111.331 179.083 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 78.9 p -85.59 173.46 10.15 Favored 'General case' 0 N--CA 1.44 -0.938 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 177.783 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -52.51 -43.94 58.97 Favored Glycine 0 CA--C 1.531 1.07 0 N-CA-C 111.265 -0.734 . . . . 0.0 111.265 178.679 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -79.81 11.78 3.05 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 123.362 0.665 . . . . 0.0 112.316 178.76 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 69.44 27.46 73.51 Favored Glycine 0 CA--C 1.524 0.639 0 CA-C-O 119.07 -0.85 . . . . 0.0 114.009 178.712 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 27.1 t -73.42 145.21 45.98 Favored 'General case' 0 C--N 1.34 0.155 0 N-CA-C 106.084 -1.821 . . . . 0.0 106.084 176.899 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 76.1 mt -76.12 64.75 2.01 Favored 'General case' 0 N--CA 1.449 -0.482 0 C-N-CA 124.363 1.065 . . . . 0.0 111.798 -176.102 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.2 m -132.89 139.45 49.6 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.215 0 C-N-CA 124.069 0.948 . . . . 0.0 111.268 -179.124 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 36.2 m-85 -82.83 129.52 35.01 Favored 'General case' 0 C--O 1.232 0.171 0 N-CA-C 104.314 -2.476 . . . . 0.0 104.314 175.201 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 25.2 t -117.84 105.2 47.93 Favored Pre-proline 0 CA--C 1.535 0.368 0 CA-C-O 118.168 -0.92 . . . . 0.0 108.963 179.561 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -75.13 164.81 87.47 Favored 'Cis proline' 0 C--N 1.348 0.518 0 CA-C-N 120.482 1.208 . . . . 0.0 111.505 -1.332 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 7.0 p -90.4 -62.29 1.49 Allowed 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 125.352 1.461 . . . . 0.0 108.655 179.207 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -106.42 137.48 44.32 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 126.313 1.845 . . . . 0.0 106.366 177.174 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 18.0 p90 -163.63 -174.73 3.82 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 118.38 0.536 . . . . 0.0 110.871 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 24.2 m -140.1 149.19 42.77 Favored 'General case' 0 N--CA 1.455 -0.212 0 C-N-CA 124.783 1.233 . . . . 0.0 108.813 -178.636 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 29.0 m -148.88 151.68 35.45 Favored Pre-proline 0 N--CA 1.463 0.2 0 C-N-CA 123.585 0.754 . . . . 0.0 110.332 -179.695 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -70.94 150.19 60.63 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 C-N-CA 121.778 1.652 . . . . 0.0 110.135 176.309 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 60.0 m -55.04 118.84 4.66 Favored 'General case' 0 CA--C 1.53 0.187 0 C-N-CA 123.308 0.643 . . . . 0.0 109.329 177.754 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 106.01 -5.6 39.51 Favored Glycine 0 CA--C 1.528 0.894 0 CA-C-O 118.877 -0.957 . . . . 0.0 112.802 -179.159 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -59.58 136.3 57.94 Favored 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 119.41 1.605 . . . . 0.0 110.623 179.374 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -90.98 93.15 9.07 Favored 'General case' 0 N--CA 1.445 -0.7 0 N-CA-C 106.013 -1.847 . . . . 0.0 106.013 177.457 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 63.4 mt -75.2 137.84 22.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 -178.616 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 67.9 t -115.75 102.41 13.67 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.296 0 C-N-CA 124.659 1.184 . . . . 0.0 108.479 -178.239 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -90.16 101.62 14.33 Favored 'General case' 0 CA--C 1.53 0.177 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 177.805 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 26.7 ttpp -99.99 129.54 46.07 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 124.774 1.229 . . . . 0.0 112.633 -176.596 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 39.6 t30 -66.82 115.35 6.5 Favored 'General case' 0 CA--C 1.528 0.098 0 CA-C-O 118.805 -0.617 . . . . 0.0 110.342 177.856 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 43.6 t30 -97.04 -73.82 0.59 Allowed 'General case' 0 N--CA 1.457 -0.114 0 CA-C-O 121.111 0.481 . . . . 0.0 110.664 179.835 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -157.95 170.97 21.12 Favored 'General case' 0 C--N 1.332 -0.183 0 C-N-CA 124.783 1.233 . . . . 0.0 108.16 -177.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 71.59 17.57 76.54 Favored Glycine 0 CA--C 1.534 1.263 0 O-C-N 121.487 -0.758 . . . . 0.0 112.252 -178.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.519 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 7.4 p90 -72.09 170.49 12.39 Favored Pre-proline 0 CA--C 1.54 0.559 0 C-N-CA 125.946 1.698 . . . . 0.0 107.77 178.59 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.519 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 26.9 Cg_exo -64.99 152.07 76.22 Favored 'Cis proline' 0 N--CA 1.451 -0.982 0 N-CA-C 115.581 1.339 . . . . 0.0 115.581 2.19 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.414 ' CD2' ' HB3' ' A' ' 5' ' ' LEU . 87.6 m-70 -141.74 170.11 16.34 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 123.311 0.645 . . . . 0.0 109.485 179.235 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 46.7 p30 -168.71 177.4 5.14 Favored 'General case' 0 N--CA 1.451 -0.423 0 N-CA-C 104.109 -2.552 . . . . 0.0 104.109 175.706 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 39.6 t -135.95 112.43 13.09 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.274 0 N-CA-C 107.262 -1.384 . . . . 0.0 107.262 -179.063 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 48.4 t -116.96 133.35 63.96 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 N-CA-C 105.98 -1.859 . . . . 0.0 105.98 -179.141 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.436 ' CG ' HD12 ' A' ' 55' ' ' ILE . 55.0 m-85 -93.69 142.69 27.07 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -179.138 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -74.62 97.95 3.29 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.749 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -39.89 -35.97 0.41 Allowed 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 125.842 1.657 . . . . 0.0 115.324 -179.234 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -82.77 -27.64 30.88 Favored 'General case' 0 CA--C 1.535 0.375 0 N-CA-C 112.607 0.595 . . . . 0.0 112.607 -179.715 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 47.5 tt0 -112.22 61.28 0.63 Allowed 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 124.62 1.168 . . . . 0.0 111.438 -176.475 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 36.8 pt -157.01 158.3 31.12 Favored Pre-proline 0 CA--C 1.535 0.374 0 C-N-CA 128.468 2.707 . . . . 0.0 105.721 176.817 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -55.4 111.94 0.9 Allowed 'Trans proline' 0 N--CA 1.456 -0.717 0 C-N-CA 122.498 2.132 . . . . 0.0 109.59 175.537 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -33.08 -48.47 0.22 Allowed 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 126.855 2.062 . . . . 0.0 115.619 -177.517 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -58.87 -29.12 64.28 Favored Glycine 0 CA--C 1.533 1.182 0 O-C-N 122.131 -0.356 . . . . 0.0 113.78 -178.457 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 43.1 t -82.19 96.28 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 CA-C-N 118.154 0.977 . . . . 0.0 109.759 -178.193 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 6.7 t0 -52.77 116.71 2.46 Favored 'General case' 0 CA--C 1.535 0.392 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 176.706 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -46.77 -38.51 10.18 Favored 'General case' 0 N--CA 1.456 -0.17 0 C-N-CA 126.085 1.754 . . . . 0.0 112.552 -178.734 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 59.9 t -59.54 -28.17 39.31 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 C-N-CA 123.006 0.522 . . . . 0.0 111.443 -179.276 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 41.7 mtmt -74.28 -45.57 46.86 Favored 'General case' 0 CA--C 1.528 0.125 0 O-C-N 121.666 -0.646 . . . . 0.0 110.602 -179.111 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.436 HD12 ' CG ' ' A' ' 41' ' ' PHE . 25.6 pt -79.59 -32.81 14.72 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 N-CA-C 113.008 0.744 . . . . 0.0 113.008 -177.766 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 47.1 m -77.39 130.54 37.23 Favored 'General case' 0 N--CA 1.452 -0.327 0 C-N-CA 123.148 0.579 . . . . 0.0 112.035 -178.034 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.5 tmt? -63.83 124.05 83.67 Favored Pre-proline 0 N--CA 1.449 -0.508 0 N-CA-C 104.869 -2.271 . . . . 0.0 104.869 175.738 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_exo -42.64 107.18 0.08 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.565 0 C-N-CA 123.985 3.123 . . . . 0.0 112.567 -178.121 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -41.1 -39.6 1.3 Allowed 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 126.397 1.879 . . . . 0.0 114.323 -177.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -58.74 -34.47 71.43 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 124.314 1.046 . . . . 0.0 110.752 -179.677 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 88.5 mt-10 -94.46 154.51 17.39 Favored 'General case' 0 N--CA 1.445 -0.713 0 C-N-CA 125.825 1.65 . . . . 0.0 108.501 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 5.1 mp -143.72 144.67 31.95 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-O 121.378 0.609 . . . . 0.0 110.745 -178.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 59.9 mt -80.67 93.42 6.15 Favored 'General case' 0 N--CA 1.444 -0.735 0 N-CA-C 103.046 -2.946 . . . . 0.0 103.046 174.01 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -109.65 -42.2 4.36 Favored 'General case' 0 C--N 1.333 -0.116 0 C-N-CA 124.273 1.029 . . . . 0.0 111.22 -176.736 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.27 134.61 73.63 Favored Pre-proline 0 C--O 1.236 0.356 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 -178.694 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_exo -50.7 132.51 36.56 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 C-N-CA 122.571 2.181 . . . . 0.0 110.903 179.776 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 92.73 -15.09 63.42 Favored Glycine 0 CA--C 1.527 0.821 0 CA-C-O 117.325 -1.82 . . . . 0.0 115.782 176.918 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -52.76 125.54 17.12 Favored 'General case' 0 CA--C 1.537 0.457 0 CA-C-N 121.045 2.423 . . . . 0.0 110.923 179.302 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 12.1 p -105.26 122.46 45.98 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 125.827 1.651 . . . . 0.0 112.395 -178.725 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 54.3 t80 -103.85 108.35 19.64 Favored 'General case' 0 N--CA 1.454 -0.235 0 N-CA-C 105.984 -1.858 . . . . 0.0 105.984 174.301 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 15.8 t -96.65 136.93 25.84 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 -178.609 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.5 p -145.51 127.06 8.29 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.404 0 CA-C-N 118.428 0.558 . . . . 0.0 110.97 178.628 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 7.9 m -88.73 101.97 14.53 Favored 'General case' 0 CA--C 1.53 0.174 0 C-N-CA 125.45 1.5 . . . . 0.0 110.239 -179.489 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 22.4 mt -87.33 87.45 7.43 Favored 'General case' 0 N--CA 1.462 0.151 0 CA-C-N 118.585 0.63 . . . . 0.0 109.357 179.394 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -69.5 -46.74 65.86 Favored 'General case' 0 CA--C 1.532 0.281 0 N-CA-C 113.399 0.889 . . . . 0.0 113.399 -179.703 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 2.0 m -78.83 127.47 32.09 Favored 'General case' 0 N--CA 1.454 -0.268 0 O-C-N 121.866 -0.521 . . . . 0.0 112.113 -175.23 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.1 155.38 37.0 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 122.987 0.515 . . . . 0.0 110.599 176.784 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 138.91 175.35 13.95 Favored Glycine 0 CA--C 1.525 0.67 0 C-N-CA 125.137 1.351 . . . . 0.0 109.984 179.445 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -100.0 116.04 31.12 Favored 'General case' 0 N--CA 1.451 -0.396 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 17.9 m-85 -107.83 131.33 54.59 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 124.379 1.071 . . . . 0.0 109.806 -178.101 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 18.2 m -102.31 139.27 38.14 Favored 'General case' 0 C--O 1.233 0.233 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 176.099 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 26.1 p90 -140.81 169.52 17.48 Favored 'General case' 0 CA--C 1.521 -0.151 0 CA-C-O 121.586 0.708 . . . . 0.0 111.204 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 43.4 p90 -157.57 160.61 38.32 Favored 'General case' 0 N--CA 1.45 -0.462 0 CA-C-N 115.601 -0.727 . . . . 0.0 112.016 -178.81 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 t -97.63 99.88 11.26 Favored 'General case' 0 CA--C 1.512 -0.485 0 N-CA-C 105.68 -1.97 . . . . 0.0 105.68 177.334 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.371 4.9 p -43.43 -56.5 6.77 Favored Pre-proline 0 CA--C 1.54 0.572 0 N-CA-C 114.323 1.231 . . . . 0.0 114.323 -175.175 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_exo -47.27 -20.04 1.26 Allowed 'Trans proline' 0 CA--C 1.534 0.518 0 C-N-CA 123.6 2.867 . . . . 0.0 116.103 177.248 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 38.5 m80 -136.13 18.37 3.2 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-N 119.15 0.887 . . . . 0.0 111.806 -178.298 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 16.8 pt20 -60.88 -41.97 97.04 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-N 119.047 0.84 . . . . 0.0 109.539 179.533 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -58.39 -29.48 63.41 Favored Glycine 0 CA--C 1.532 1.155 0 N-CA-C 111.209 -0.756 . . . . 0.0 111.209 177.145 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.34 10.6 21.81 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 123.718 0.807 . . . . 0.0 111.084 178.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 79.33 17.1 76.98 Favored Glycine 0 CA--C 1.526 0.772 0 CA-C-O 118.758 -1.023 . . . . 0.0 113.801 178.484 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 22.9 ttt -79.26 77.35 5.79 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 119.703 1.751 . . . . 0.0 108.265 178.213 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 14.3 m -117.87 170.58 7.11 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.319 0 C-N-CA 125.909 1.684 . . . . 0.0 110.198 179.809 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -164.86 176.54 40.64 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 178.092 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 53.8 tttp -154.68 154.48 32.99 Favored 'General case' 0 N--CA 1.454 -0.253 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 -176.074 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.4 p -145.53 134.2 17.0 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.159 0 O-C-N 121.987 -0.445 . . . . 0.0 110.988 -178.773 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.7 m -100.15 94.51 6.27 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 125.65 1.58 . . . . 0.0 110.852 -178.002 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 21.4 t -80.17 120.28 31.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 105.459 -2.052 . . . . 0.0 105.459 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 5.8 p30 . . . . . 0 C--N 1.332 -0.157 0 C-N-CA 123.483 0.713 . . . . 0.0 111.652 -174.914 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 3.0 tm? . . . . . 0 N--CA 1.454 -0.268 0 N-CA-C 108.663 -0.865 . . . . 0.0 108.663 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -91.29 119.74 31.59 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 114.337 -1.301 . . . . 0.0 110.997 -177.38 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 39.0 t -113.23 118.24 57.55 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.332 0 N-CA-C 107.364 -1.347 . . . . 0.0 107.364 178.386 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 64.3 mt -89.1 120.86 30.88 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 -179.77 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -78.76 111.22 14.65 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 106.799 -1.556 . . . . 0.0 106.799 175.158 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 93.61 138.75 9.12 Favored Glycine 0 N--CA 1.446 -0.649 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.168 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 68.4 p -81.8 158.34 24.14 Favored 'General case' 0 N--CA 1.437 -1.11 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 178.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.0 -33.87 57.58 Favored Glycine 0 CA--C 1.53 1.025 0 CA-C-N 115.252 -0.885 . . . . 0.0 111.512 178.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -75.8 -3.71 36.57 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 123.597 0.759 . . . . 0.0 112.292 178.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 99.51 -20.85 47.98 Favored Glycine 0 CA--C 1.527 0.794 0 CA-C-O 118.892 -0.949 . . . . 0.0 113.486 178.782 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 22.7 t -57.31 131.63 50.62 Favored 'General case' 0 C--O 1.239 0.516 0 CA-C-N 119.336 1.568 . . . . 0.0 110.682 -179.228 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 56.8 mt -73.03 65.63 0.77 Allowed 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 127.085 2.154 . . . . 0.0 112.412 -176.222 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 2.4 t -123.2 151.36 27.55 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.442 0 C-N-CA 124.247 1.019 . . . . 0.0 108.785 178.859 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 33.2 m-85 -86.17 129.74 34.75 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 104.125 -2.546 . . . . 0.0 104.125 175.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 48.8 t -118.44 104.62 47.49 Favored Pre-proline 0 CA--C 1.537 0.445 0 CA-C-O 118.324 -0.846 . . . . 0.0 108.877 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -75.05 161.78 94.14 Favored 'Cis proline' 0 C--N 1.347 0.499 0 CA-C-N 120.338 1.157 . . . . 0.0 111.597 -1.073 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 6.2 p -91.89 -60.47 1.85 Allowed 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 125.502 1.521 . . . . 0.0 108.609 179.212 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -105.4 127.01 52.75 Favored 'General case' 0 N--CA 1.453 -0.282 0 C-N-CA 126.238 1.815 . . . . 0.0 106.616 177.69 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 14.6 p90 -160.03 -175.36 5.05 Favored 'General case' 0 C--O 1.232 0.18 0 CA-C-O 121.08 0.467 . . . . 0.0 110.792 179.867 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 66.1 p -147.02 156.84 43.35 Favored 'General case' 0 N--CA 1.451 -0.403 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 18.1 m -152.75 151.28 26.35 Favored Pre-proline 0 CA--C 1.531 0.245 0 C-N-CA 123.61 0.764 . . . . 0.0 109.539 -178.901 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -73.17 148.52 44.4 Favored 'Trans proline' 0 N--CA 1.451 -1.0 0 C-N-CA 121.781 1.654 . . . . 0.0 110.761 177.812 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 64.7 m -48.93 121.24 4.52 Favored 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 122.996 0.518 . . . . 0.0 110.55 176.048 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 106.39 -9.72 42.14 Favored Glycine 0 CA--C 1.529 0.961 0 C-N-CA 124.165 0.888 . . . . 0.0 112.642 179.431 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -63.3 135.81 57.28 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-N 118.813 1.307 . . . . 0.0 109.979 179.242 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 52.9 mtpt -91.54 106.03 18.19 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 125.409 1.483 . . . . 0.0 108.659 179.386 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 40.4 mt -85.21 135.12 25.53 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 -179.672 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 64.7 t -119.73 100.3 9.27 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.34 0 C-N-CA 126.134 1.774 . . . . 0.0 108.152 -178.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -87.06 107.18 18.32 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 178.025 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 62.9 tttp -105.91 131.97 52.58 Favored 'General case' 0 CA--C 1.531 0.243 0 C-N-CA 125.266 1.426 . . . . 0.0 112.78 -176.408 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 8.1 m-20 -68.56 112.53 5.41 Favored 'General case' 0 C--O 1.232 0.132 0 C-N-CA 123.149 0.579 . . . . 0.0 110.021 177.538 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 24.5 t30 -97.46 -72.22 0.65 Allowed 'General case' 0 N--CA 1.456 -0.171 0 CA-C-O 121.052 0.453 . . . . 0.0 109.851 178.727 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -143.2 167.41 22.18 Favored 'General case' 0 C--N 1.331 -0.219 0 C-N-CA 123.972 0.909 . . . . 0.0 109.521 -178.028 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 62.65 23.78 65.5 Favored Glycine 0 CA--C 1.535 1.295 0 O-C-N 121.839 -0.538 . . . . 0.0 113.774 179.407 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.438 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 10.5 p90 -74.74 167.54 35.42 Favored Pre-proline 0 CA--C 1.537 0.463 0 N-CA-C 106.671 -1.603 . . . . 0.0 106.671 176.756 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.438 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 50.8 Cg_exo -62.66 159.91 58.31 Favored 'Cis proline' 0 N--CA 1.456 -0.698 0 N-CA-C 116.99 1.881 . . . . 0.0 116.99 1.072 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 93.3 m-70 -149.67 170.14 19.39 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.809 -179.464 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 37.3 p-10 -163.98 177.04 8.83 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 104.32 -2.474 . . . . 0.0 104.32 176.298 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 39.3 t -138.25 112.17 8.07 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.389 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 179.291 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 64.8 t -116.83 133.69 62.72 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.604 0 N-CA-C 106.052 -1.833 . . . . 0.0 106.052 179.525 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 64.6 m-85 -93.33 140.65 29.32 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 -179.306 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 53.1 t0 -70.76 104.48 2.89 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 179.42 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -48.02 -32.29 6.43 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 124.168 0.987 . . . . 0.0 113.293 178.211 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -92.04 6.39 46.6 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 123.494 0.717 . . . . 0.0 112.871 -178.839 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 20.7 tt0 -150.44 63.36 0.95 Allowed 'General case' 0 CA--C 1.538 0.506 0 CA-C-O 122.108 0.956 . . . . 0.0 110.71 -179.283 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 28.0 pt -155.59 158.2 31.77 Favored Pre-proline 0 CA--C 1.532 0.263 0 C-N-CA 128.573 2.749 . . . . 0.0 105.771 177.459 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_exo -55.93 109.5 0.44 Allowed 'Trans proline' 0 CA--C 1.538 0.692 0 C-N-CA 122.306 2.004 . . . . 0.0 108.585 174.127 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -33.65 -44.21 0.15 Allowed 'General case' 0 N--CA 1.465 0.322 0 C-N-CA 126.789 2.036 . . . . 0.0 115.77 -177.195 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -58.34 -29.84 63.77 Favored Glycine 0 CA--C 1.534 1.221 0 CA-C-O 119.856 -0.413 . . . . 0.0 113.766 -178.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 37.4 t -84.69 107.54 15.86 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.316 0 CA-C-N 118.179 0.99 . . . . 0.0 110.318 -177.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 19.7 t0 -59.29 116.15 3.71 Favored 'General case' 0 CA--C 1.534 0.364 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 177.333 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -46.79 -40.33 13.45 Favored 'General case' 0 N--CA 1.457 -0.113 0 C-N-CA 125.223 1.409 . . . . 0.0 112.012 179.671 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 53.1 t -60.23 -28.88 42.77 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 C-N-CA 122.994 0.518 . . . . 0.0 111.784 -178.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -76.56 -42.11 44.01 Favored 'General case' 0 N--CA 1.462 0.128 0 CA-C-N 118.617 0.644 . . . . 0.0 110.594 -179.006 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.411 HG21 HD13 ' A' ' 55' ' ' ILE . 22.7 pt -79.09 -32.84 15.45 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 N-CA-C 112.582 0.586 . . . . 0.0 112.582 -178.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 49.1 m -78.05 141.65 38.71 Favored 'General case' 0 N--CA 1.454 -0.255 0 N-CA-C 112.531 0.567 . . . . 0.0 112.531 -178.261 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 12.8 tpt -58.77 121.39 53.75 Favored Pre-proline 0 CA--C 1.535 0.401 0 N-CA-C 105.583 -2.006 . . . . 0.0 105.583 174.914 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_exo -46.88 103.98 0.06 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.615 0 C-N-CA 123.649 2.9 . . . . 0.0 110.927 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 57.0 mp0 -43.3 -27.86 0.28 Allowed 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 127.056 2.143 . . . . 0.0 114.984 -175.385 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -57.81 -35.51 70.95 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 123.193 0.597 . . . . 0.0 110.843 178.392 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -117.44 158.41 24.53 Favored 'General case' 0 N--CA 1.446 -0.639 0 C-N-CA 125.76 1.624 . . . . 0.0 109.412 -179.894 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 4.8 mp -145.48 159.56 42.9 Favored 'General case' 0 N--CA 1.452 -0.332 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 -179.444 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 71.9 mt -79.33 96.34 5.96 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 104.391 -2.448 . . . . 0.0 104.391 177.275 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 36.9 p-10 -80.32 -58.2 3.25 Favored 'General case' 0 CA--C 1.529 0.162 0 C-N-CA 124.156 0.982 . . . . 0.0 113.303 -177.17 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -79.75 160.45 69.32 Favored Pre-proline 0 CA--C 1.535 0.403 0 C-N-CA 124.318 1.047 . . . . 0.0 111.902 -176.75 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -64.59 161.89 33.49 Favored 'Trans proline' 0 N--CA 1.458 -0.614 0 C-N-CA 122.29 1.993 . . . . 0.0 109.172 175.081 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 78.74 -39.57 1.99 Allowed Glycine 0 CA--C 1.528 0.853 0 CA-C-O 118.656 -1.08 . . . . 0.0 113.829 177.293 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 79.5 mm-40 -42.03 130.32 3.54 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 124.476 1.111 . . . . 0.0 111.669 179.827 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 6.7 p -110.88 150.4 29.24 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 125.412 1.485 . . . . 0.0 112.424 -177.856 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 30.5 t80 -126.43 113.14 16.46 Favored 'General case' 0 N--CA 1.455 -0.177 0 N-CA-C 105.082 -2.192 . . . . 0.0 105.082 172.466 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 19.6 t -100.41 136.89 29.84 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.398 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 -178.543 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.2 p -150.07 140.88 16.66 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.121 0 N-CA-C 108.275 -1.009 . . . . 0.0 108.275 178.253 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 25.1 m -112.07 127.44 55.91 Favored 'General case' 0 N--CA 1.456 -0.126 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 -178.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 55.5 mt -110.67 124.63 52.29 Favored 'General case' 0 CA--C 1.529 0.137 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 179.713 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -108.48 -47.96 3.41 Favored 'General case' 0 CA--C 1.528 0.126 0 C-N-CA 124.286 1.034 . . . . 0.0 112.096 -178.296 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 5.0 m -66.4 128.69 37.16 Favored 'General case' 0 N--CA 1.454 -0.25 0 O-C-N 121.707 -0.621 . . . . 0.0 109.661 -177.51 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 61.8 mtpt -69.04 155.46 40.33 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 123.02 0.528 . . . . 0.0 110.441 -179.155 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 128.37 175.44 14.07 Favored Glycine 0 CA--C 1.527 0.832 0 C-N-CA 124.389 0.995 . . . . 0.0 111.409 179.023 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 89.3 m -95.25 127.22 41.12 Favored 'General case' 0 N--CA 1.451 -0.405 0 C-N-CA 124.871 1.269 . . . . 0.0 109.288 -179.828 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 25.2 m-85 -115.75 120.69 40.15 Favored 'General case' 0 N--CA 1.447 -0.601 0 C-N-CA 126.051 1.74 . . . . 0.0 108.615 179.398 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 64.1 m -92.37 140.16 29.87 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 177.023 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 22.8 p90 -139.39 165.48 27.1 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-O 121.555 0.693 . . . . 0.0 112.307 -179.52 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -152.66 157.31 40.76 Favored 'General case' 0 N--CA 1.452 -0.342 0 C-N-CA 124.205 1.002 . . . . 0.0 112.64 -178.334 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.4 t -99.68 102.04 13.41 Favored 'General case' 0 CA--C 1.519 -0.234 0 N-CA-C 105.483 -2.043 . . . . 0.0 105.483 176.84 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.28 0.8 OUTLIER -43.12 -57.69 4.92 Favored Pre-proline 0 CA--C 1.535 0.384 0 N-CA-C 114.446 1.276 . . . . 0.0 114.446 -173.692 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -52.17 -20.12 10.31 Favored 'Trans proline' 0 C--N 1.347 0.494 0 C-N-CA 123.146 2.564 . . . . 0.0 115.183 178.833 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 37.1 m80 -130.61 19.01 5.19 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-N 118.697 0.68 . . . . 0.0 111.446 -178.44 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -60.01 -51.17 70.81 Favored 'General case' 0 C--N 1.339 0.128 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 179.707 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.12 -30.26 57.35 Favored Glycine 0 CA--C 1.533 1.177 0 N-CA-C 111.717 -0.553 . . . . 0.0 111.717 177.863 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -84.04 5.83 24.38 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 123.51 0.724 . . . . 0.0 111.72 179.187 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 83.56 15.35 71.25 Favored Glycine 0 CA--C 1.527 0.827 0 CA-C-O 118.991 -0.894 . . . . 0.0 113.71 178.347 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 19.2 ttt -78.44 79.65 4.86 Favored 'General case' 0 C--O 1.236 0.377 0 CA-C-N 119.527 1.664 . . . . 0.0 108.595 178.657 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 10.7 m -126.56 169.46 17.96 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.207 0 C-N-CA 125.917 1.687 . . . . 0.0 110.813 179.842 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -169.03 179.45 41.74 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 109.276 -1.53 . . . . 0.0 109.276 178.343 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 58.7 mttm -149.64 149.46 30.67 Favored 'General case' 0 N--CA 1.455 -0.203 0 CA-C-N 117.66 0.73 . . . . 0.0 109.588 -179.014 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 6.6 p -135.72 127.29 45.04 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.3 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 178.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 71.6 m -102.09 106.46 17.34 Favored 'General case' 0 C--N 1.333 -0.143 0 C-N-CA 123.772 0.829 . . . . 0.0 110.436 179.487 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 44.6 t -79.69 122.99 35.97 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.633 0 N-CA-C 106.643 -1.614 . . . . 0.0 106.643 179.021 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 48.7 p30 . . . . . 0 C--N 1.333 -0.122 0 C-N-CA 124.895 1.278 . . . . 0.0 111.034 -177.605 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 8.5 mp . . . . . 0 CA--C 1.531 0.233 0 CA-C-O 120.663 0.268 . . . . 0.0 110.688 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 78.4 tt0 -90.98 116.28 28.65 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 176.767 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 48.1 t -106.05 122.48 59.75 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 -179.361 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 40.8 mt -86.03 120.82 27.83 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 177.886 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.447 HD12 ' HA ' ' A' ' 5' ' ' LEU . 5.1 tp -78.19 98.53 5.88 Favored 'General case' 0 N--CA 1.429 -1.489 0 C-N-CA 125.424 1.49 . . . . 0.0 107.525 179.863 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 91.72 145.34 15.07 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 108.7 -1.76 . . . . 0.0 108.7 -178.393 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 78.0 p -78.86 154.94 29.37 Favored 'General case' 0 N--CA 1.44 -0.948 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 179.574 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -53.16 -35.39 49.41 Favored Glycine 0 CA--C 1.529 0.942 0 CA-C-N 114.979 -1.01 . . . . 0.0 111.697 178.808 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -74.82 -4.42 37.66 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 123.53 0.732 . . . . 0.0 112.506 179.404 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 101.08 -20.75 46.25 Favored Glycine 0 CA--C 1.527 0.782 0 CA-C-O 118.763 -1.021 . . . . 0.0 113.292 178.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 28.6 t -56.81 132.13 51.4 Favored 'General case' 0 C--O 1.239 0.536 0 CA-C-N 119.391 1.595 . . . . 0.0 110.603 -179.332 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.444 ' H ' HD22 ' A' ' 12' ' ' LEU . 1.9 mm? -71.55 69.28 0.61 Allowed 'General case' 0 N--CA 1.44 -0.935 0 C-N-CA 126.806 2.042 . . . . 0.0 111.676 -177.457 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.5 m -135.06 141.74 42.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 C-N-CA 123.708 0.803 . . . . 0.0 109.403 178.383 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 88.2 m-85 -79.16 135.2 36.75 Favored 'General case' 0 N--CA 1.455 -0.186 0 N-CA-C 105.291 -2.115 . . . . 0.0 105.291 176.81 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.8 t -120.09 104.35 43.92 Favored Pre-proline 0 CA--C 1.534 0.339 0 CA-C-O 118.25 -0.881 . . . . 0.0 109.094 179.567 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -73.85 164.16 88.15 Favored 'Cis proline' 0 C--N 1.348 0.524 0 CA-C-N 120.301 1.143 . . . . 0.0 112.179 -1.412 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 10.5 p -97.59 -62.28 1.27 Allowed 'General case' 0 N--CA 1.452 -0.331 0 C-N-CA 125.681 1.592 . . . . 0.0 109.236 179.32 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 -103.54 123.96 47.89 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 126.106 1.763 . . . . 0.0 106.857 178.345 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -158.06 174.3 15.43 Favored 'General case' 0 CA--C 1.528 0.118 0 CA-C-N 118.9 0.773 . . . . 0.0 112.013 179.486 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.4 p -116.67 147.83 41.59 Favored 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 125.478 1.511 . . . . 0.0 107.555 178.461 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.8 p -141.79 136.25 15.18 Favored Pre-proline 0 CA--C 1.536 0.428 0 CA-C-O 118.443 -0.789 . . . . 0.0 109.036 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_exo -63.03 142.73 88.86 Favored 'Trans proline' 0 N--CA 1.456 -0.693 0 C-N-CA 122.043 1.828 . . . . 0.0 111.363 177.091 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.8 m -45.8 121.61 3.25 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 124.265 1.026 . . . . 0.0 111.778 177.919 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 84.96 -5.79 81.39 Favored Glycine 0 CA--C 1.525 0.69 0 CA-C-O 118.502 -1.166 . . . . 0.0 114.411 177.407 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -74.97 147.77 40.55 Favored 'General case' 0 CA--C 1.537 0.444 0 CA-C-N 119.954 1.877 . . . . 0.0 108.084 177.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 2.7 ptpp? -92.79 138.88 31.11 Favored 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 124.007 0.923 . . . . 0.0 112.499 -177.844 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 48.8 mt -105.05 136.76 37.42 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 C-N-CA 126.292 1.837 . . . . 0.0 106.06 179.166 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 58.4 t -117.92 100.29 9.81 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 C-N-CA 125.355 1.462 . . . . 0.0 108.832 -178.7 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -84.5 100.06 11.11 Favored 'General case' 0 C--N 1.334 -0.073 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 178.418 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 64.4 tttm -92.07 125.0 36.58 Favored 'General case' 0 C--O 1.231 0.127 0 C-N-CA 123.73 0.812 . . . . 0.0 110.621 -178.622 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 49.3 t30 -63.19 111.11 2.09 Favored 'General case' 0 CA--C 1.528 0.119 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 177.367 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 36.2 t30 -99.65 -76.45 0.55 Allowed 'General case' 0 N--CA 1.457 -0.079 0 C-N-CA 122.94 0.496 . . . . 0.0 112.256 -177.036 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -151.08 174.92 12.62 Favored 'General case' 0 C--O 1.224 -0.26 0 C-N-CA 124.012 0.925 . . . . 0.0 109.383 -176.807 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 62.3 17.96 57.22 Favored Glycine 0 CA--C 1.535 1.294 0 O-C-N 121.679 -0.638 . . . . 0.0 112.519 -179.119 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.494 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.9 p90 -78.25 169.5 20.56 Favored Pre-proline 0 CA--C 1.538 0.509 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 179.153 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.494 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 37.2 Cg_exo -64.45 160.25 68.42 Favored 'Cis proline' 0 N--CA 1.449 -1.098 0 N-CA-C 116.07 1.527 . . . . 0.0 116.07 1.605 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 90.7 m-70 -152.29 177.69 10.29 Favored 'General case' 0 N--CA 1.45 -0.467 0 CA-C-N 115.118 -0.946 . . . . 0.0 109.769 179.578 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 53.4 p30 -162.94 169.78 19.14 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 105.064 -2.198 . . . . 0.0 105.064 173.556 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 44.3 t -123.93 104.55 14.22 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.333 0 N-CA-C 106.62 -1.622 . . . . 0.0 106.62 -177.522 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 38.8 t -116.33 135.26 57.13 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.366 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 -179.316 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.421 ' CG ' HG13 ' A' ' 55' ' ' ILE . 55.7 m-85 -100.65 138.19 38.04 Favored 'General case' 0 N--CA 1.454 -0.272 0 C-N-CA 123.267 0.627 . . . . 0.0 109.68 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -70.14 114.1 7.97 Favored 'General case' 0 N--CA 1.454 -0.26 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 -179.81 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -47.85 -30.57 4.17 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 115.825 1.787 . . . . 0.0 115.825 -178.471 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 23.5 t70 -88.61 -50.15 6.45 Favored 'General case' 0 CA--C 1.53 0.204 0 CA-C-N 118.52 0.6 . . . . 0.0 110.649 179.88 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -80.22 57.07 2.63 Favored 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 124.087 0.955 . . . . 0.0 112.413 -176.397 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 20.2 pt -150.14 149.0 26.11 Favored Pre-proline 0 CA--C 1.534 0.36 0 C-N-CA 127.376 2.27 . . . . 0.0 106.537 176.805 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -65.6 124.63 13.08 Favored 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 122.096 1.864 . . . . 0.0 110.504 179.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -52.0 109.95 0.43 Allowed 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 124.802 1.241 . . . . 0.0 111.228 -179.456 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 153.09 -56.77 0.43 Allowed Glycine 0 CA--C 1.522 0.517 0 N-CA-C 108.249 -1.94 . . . . 0.0 108.249 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 41.8 t -83.21 93.09 2.87 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.429 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 179.285 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -58.96 134.33 56.86 Favored 'General case' 0 CA--C 1.532 0.251 0 N-CA-C 109.319 -0.622 . . . . 0.0 109.319 177.807 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -39.56 -43.82 1.36 Allowed 'General case' 0 C--N 1.331 -0.196 0 C-N-CA 127.389 2.275 . . . . 0.0 113.963 179.52 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 98.9 t -55.62 -30.41 26.68 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.333 0 CA-C-N 118.119 0.418 . . . . 0.0 110.918 -179.378 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 33.1 mtmm -75.85 -18.83 59.3 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-O 118.451 -0.785 . . . . 0.0 112.868 -179.278 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.421 HG13 ' CG ' ' A' ' 41' ' ' PHE . 0.1 OUTLIER -115.32 -20.91 5.59 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-N 119.196 0.907 . . . . 0.0 113.065 179.642 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 35.6 m -84.13 127.46 33.93 Favored 'General case' 0 N--CA 1.451 -0.386 0 C-N-CA 123.869 0.868 . . . . 0.0 112.038 -178.577 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 7.2 tmm? -69.39 124.91 91.48 Favored Pre-proline 0 CA--C 1.536 0.432 0 N-CA-C 103.801 -2.666 . . . . 0.0 103.801 175.071 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 1.6 Cg_exo -29.2 99.02 0.02 OUTLIER 'Trans proline' 0 C--N 1.349 0.582 1 C-N-CA 125.462 4.108 . . . . 0.0 115.006 -177.875 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -37.9 -44.18 0.75 Allowed 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 127.851 2.46 . . . . 0.0 114.793 -177.838 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -59.87 -33.18 71.47 Favored 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 123.501 0.72 . . . . 0.0 111.246 -178.697 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 47.4 mm-40 -93.18 163.38 13.65 Favored 'General case' 0 N--CA 1.442 -0.87 0 C-N-CA 124.942 1.297 . . . . 0.0 110.254 -178.908 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 4.8 mp -144.99 143.23 30.4 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-N 115.219 -0.901 . . . . 0.0 110.503 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 44.1 mt -78.1 105.68 9.49 Favored 'General case' 0 N--CA 1.445 -0.68 0 N-CA-C 103.778 -2.675 . . . . 0.0 103.778 175.295 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 34.3 p-10 -101.25 -52.98 3.12 Favored 'General case' 0 N--CA 1.455 -0.183 0 C-N-CA 124.796 1.238 . . . . 0.0 111.733 -177.151 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -71.85 136.65 82.65 Favored Pre-proline 0 CA--C 1.531 0.245 0 CA-C-N 118.723 0.692 . . . . 0.0 110.069 -177.477 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -63.61 149.73 90.22 Favored 'Trans proline' 0 N--CA 1.451 -1.009 0 C-N-CA 122.142 1.895 . . . . 0.0 109.659 179.704 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 97.54 -34.98 4.76 Favored Glycine 0 CA--C 1.523 0.591 0 CA-C-O 118.623 -1.098 . . . . 0.0 112.777 177.855 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 76.9 mt-10 -45.28 118.72 1.81 Allowed 'General case' 0 CA--C 1.536 0.419 0 CA-C-N 118.537 1.169 . . . . 0.0 111.665 -179.696 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 11.0 p -101.88 120.46 40.42 Favored 'General case' 0 N--CA 1.452 -0.356 0 C-N-CA 124.992 1.317 . . . . 0.0 111.551 -179.485 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 38.4 t80 -101.34 108.06 19.58 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 106.422 -1.695 . . . . 0.0 106.422 175.124 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 14.6 t -93.91 139.86 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.301 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 -179.263 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 9.9 p -148.61 142.64 18.79 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.153 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 177.778 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 7.8 m -117.21 124.44 49.09 Favored 'General case' 0 CA--C 1.527 0.072 0 C-N-CA 124.318 1.047 . . . . 0.0 109.495 -177.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 44.3 mt -105.55 98.51 8.19 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 123.156 0.583 . . . . 0.0 109.777 -179.394 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -74.67 -58.36 3.34 Favored 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 123.782 0.833 . . . . 0.0 112.709 -179.38 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 4.1 m -70.42 128.87 37.68 Favored 'General case' 0 N--CA 1.453 -0.325 0 C-N-CA 123.495 0.718 . . . . 0.0 111.465 -175.116 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 57.5 mtmt -65.35 156.04 33.43 Favored 'General case' 0 N--CA 1.455 -0.194 0 C-N-CA 123.438 0.695 . . . . 0.0 110.8 179.115 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 142.44 -166.46 26.45 Favored Glycine 0 CA--C 1.521 0.446 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 179.33 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 88.5 m -117.44 123.83 47.35 Favored 'General case' 0 N--CA 1.454 -0.245 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 179.612 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -114.81 124.3 51.39 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 124.348 1.059 . . . . 0.0 108.58 -178.553 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 13.2 m -99.81 134.29 42.92 Favored 'General case' 0 C--O 1.233 0.205 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 177.868 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 40.3 p90 -133.67 166.96 21.39 Favored 'General case' 0 CA--C 1.521 -0.161 0 CA-C-O 121.588 0.708 . . . . 0.0 111.625 -179.552 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 46.6 p90 -159.01 165.09 34.82 Favored 'General case' 0 N--CA 1.45 -0.43 0 CA-C-N 115.453 -0.794 . . . . 0.0 112.322 -177.76 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 5.5 t -106.09 97.18 7.03 Favored 'General case' 0 CA--C 1.519 -0.243 0 N-CA-C 106.638 -1.615 . . . . 0.0 106.638 177.377 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.304 16.1 p -31.1 -64.56 0.21 Allowed Pre-proline 0 CA--C 1.544 0.721 0 N-CA-C 117.138 2.273 . . . . 0.0 117.138 -174.474 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -61.89 -16.49 49.76 Favored 'Trans proline' 0 C--N 1.347 0.468 0 C-N-CA 122.576 2.184 . . . . 0.0 114.294 -177.338 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 34.7 m170 -119.08 9.26 11.76 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 123.322 0.649 . . . . 0.0 110.747 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 66.4 tt0 -58.34 -49.69 76.28 Favored 'General case' 0 CA--C 1.529 0.144 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 179.228 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -57.45 -30.32 61.67 Favored Glycine 0 CA--C 1.531 1.067 0 N-CA-C 111.475 -0.65 . . . . 0.0 111.475 177.45 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -84.8 5.45 28.54 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 123.774 0.83 . . . . 0.0 111.577 179.091 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 87.37 11.39 69.21 Favored Glycine 0 CA--C 1.527 0.823 0 CA-C-O 118.608 -1.107 . . . . 0.0 113.833 178.263 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 22.2 ttt -78.9 77.26 5.38 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 119.812 1.806 . . . . 0.0 108.614 178.334 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 10.8 m -122.94 169.13 14.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 C-N-CA 126.042 1.737 . . . . 0.0 108.96 178.568 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -162.42 172.34 38.49 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 108.491 -1.843 . . . . 0.0 108.491 178.51 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 6.9 ttpm? -151.4 141.33 22.02 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 -176.765 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 6.0 p -132.97 126.43 53.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 CA-C-O 121.057 0.456 . . . . 0.0 110.697 -179.025 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 21.0 m -97.17 105.84 18.06 Favored 'General case' 0 C--O 1.235 0.324 0 C-N-CA 124.724 1.21 . . . . 0.0 109.222 179.775 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 40.8 t -79.91 103.02 6.36 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.621 0 N-CA-C 106.484 -1.673 . . . . 0.0 106.484 -179.743 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 . . . . . 0 C--O 1.235 0.313 0 C-N-CA 125.205 1.402 . . . . 0.0 109.487 -177.206 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 9.3 tt . . . . . 0 N--CA 1.454 -0.269 0 CA-C-O 121.451 0.644 . . . . 0.0 110.274 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -90.71 128.54 36.69 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 123.685 0.794 . . . . 0.0 110.895 -178.699 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 44.2 t -120.55 123.94 71.45 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 N-CA-C 106.112 -1.81 . . . . 0.0 106.112 177.492 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 32.5 mt -96.65 122.91 40.09 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 118.383 0.538 . . . . 0.0 110.206 -179.478 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.507 ' HB3' ' CD2' ' A' ' 37' ' ' HIS . 1.2 mm? -79.68 101.9 8.65 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 106.316 -1.735 . . . . 0.0 106.316 174.111 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 108.84 127.69 5.58 Favored Glycine 0 CA--C 1.522 0.522 0 C-N-CA 124.788 1.185 . . . . 0.0 111.576 179.688 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 14.9 p -84.34 46.84 1.26 Allowed 'General case' 0 N--CA 1.457 -0.092 0 O-C-N 121.434 -1.039 . . . . 0.0 111.314 179.279 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 72.07 -55.73 1.45 Allowed Glycine 0 CA--C 1.527 0.83 0 C-N-CA 126.071 1.796 . . . . 0.0 111.991 -179.26 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -73.17 33.69 0.07 Allowed 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 126.038 1.735 . . . . 0.0 113.743 -177.519 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 57.33 8.42 3.56 Favored Glycine 0 CA--C 1.531 1.069 0 C-N-CA 124.875 1.226 . . . . 0.0 115.848 179.207 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 22.8 t -68.63 141.43 55.39 Favored 'General case' 0 N--CA 1.457 -0.107 0 CA-C-N 119.532 1.666 . . . . 0.0 109.502 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 68.9 mt -78.1 66.57 3.74 Favored 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 124.411 1.084 . . . . 0.0 111.781 -176.048 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.6 p -138.44 150.08 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.217 0 CA-C-O 121.788 0.804 . . . . 0.0 111.715 -179.494 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 58.7 m-85 -92.38 126.33 37.42 Favored 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 105.185 -2.154 . . . . 0.0 105.185 177.78 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 48.8 t -115.39 107.47 49.17 Favored Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 119.629 1.104 . . . . 0.0 109.448 179.609 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -77.27 155.84 96.66 Favored 'Cis proline' 0 CA--C 1.536 0.613 0 CA-C-N 120.706 1.288 . . . . 0.0 111.729 -1.3 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.5 m -84.83 -55.1 4.26 Favored 'General case' 0 CA--C 1.527 0.096 0 C-N-CA 123.357 0.663 . . . . 0.0 110.302 179.232 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 58.9 mt-10 -114.0 131.87 56.19 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 -179.471 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 53.0 p90 -161.13 -178.41 6.73 Favored 'General case' 0 C--O 1.234 0.255 0 CA-C-O 121.372 0.606 . . . . 0.0 112.081 -178.114 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 35.2 p -140.02 140.26 36.18 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 124.948 1.299 . . . . 0.0 109.257 -179.249 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.4 m -145.47 152.19 49.05 Favored Pre-proline 0 CA--C 1.532 0.257 0 C-N-CA 124.553 1.141 . . . . 0.0 108.136 178.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo -71.67 151.44 58.03 Favored 'Trans proline' 0 N--CA 1.451 -0.998 0 C-N-CA 121.78 1.653 . . . . 0.0 111.16 179.842 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 56.7 m -49.31 127.15 14.42 Favored 'General case' 0 C--N 1.332 -0.18 0 C-N-CA 124.343 1.057 . . . . 0.0 111.508 178.479 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 92.9 -10.74 73.44 Favored Glycine 0 CA--C 1.527 0.817 0 CA-C-O 118.911 -0.938 . . . . 0.0 112.829 178.88 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -70.47 141.96 51.98 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 119.392 1.596 . . . . 0.0 108.43 178.601 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 20.4 pttp -82.01 160.45 23.27 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 123.928 0.891 . . . . 0.0 111.131 -179.018 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 15.8 mt -131.44 129.05 61.84 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 N-CA-C 105.355 -2.091 . . . . 0.0 105.355 177.775 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 75.3 t -116.37 98.06 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.202 0 C-N-CA 125.851 1.66 . . . . 0.0 107.928 -177.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -86.5 96.57 10.1 Favored 'General case' 0 CA--C 1.529 0.17 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.773 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -90.52 128.98 36.72 Favored 'General case' 0 CA--C 1.531 0.212 0 C-N-CA 125.027 1.331 . . . . 0.0 112.046 -177.6 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 45.6 t30 -69.15 116.66 9.85 Favored 'General case' 0 N--CA 1.457 -0.119 0 CA-C-O 118.393 -0.813 . . . . 0.0 109.947 177.938 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 50.2 t30 -103.4 -66.23 0.96 Allowed 'General case' 0 C--N 1.339 0.135 0 CA-C-N 118.702 0.683 . . . . 0.0 110.551 179.474 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -160.17 169.25 23.67 Favored 'General case' 0 C--O 1.225 -0.196 0 C-N-CA 123.254 0.622 . . . . 0.0 110.452 -177.684 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 71.66 18.91 77.61 Favored Glycine 0 CA--C 1.532 1.094 0 O-C-N 121.823 -0.548 . . . . 0.0 111.878 -179.512 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.557 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 10.4 p90 -71.37 168.92 17.64 Favored Pre-proline 0 CA--C 1.54 0.568 0 C-N-CA 126.001 1.72 . . . . 0.0 108.598 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.557 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 75.8 Cg_endo -70.93 158.44 94.52 Favored 'Cis proline' 0 N--CA 1.449 -1.104 0 N-CA-C 115.042 1.131 . . . . 0.0 115.042 3.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.507 ' CD2' ' HB3' ' A' ' 5' ' ' LEU . 90.3 m-70 -146.8 160.83 41.78 Favored 'General case' 0 C--O 1.222 -0.391 0 O-C-N 121.59 -0.694 . . . . 0.0 112.72 -177.808 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 52.1 p30 -157.53 177.69 11.13 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 106.39 -1.707 . . . . 0.0 106.39 176.437 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 23.4 t -132.55 113.95 21.91 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 -179.27 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 25.5 t -118.98 132.11 69.82 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 N-CA-C 105.601 -2.0 . . . . 0.0 105.601 178.522 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -93.99 136.78 33.91 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -71.02 104.75 3.08 Favored 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 -178.66 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -35.26 -37.34 0.08 Allowed 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 127.416 2.287 . . . . 0.0 115.401 178.275 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 24.9 m-20 -85.47 -53.24 5.32 Favored 'General case' 0 CA--C 1.53 0.188 0 CA-C-N 118.545 0.611 . . . . 0.0 110.301 179.43 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 38.3 mm-40 -80.91 58.28 3.34 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 124.031 0.933 . . . . 0.0 112.906 -176.706 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 36.1 pt -152.31 159.15 33.16 Favored Pre-proline 0 CA--C 1.534 0.336 0 C-N-CA 128.452 2.701 . . . . 0.0 105.633 175.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -53.12 110.84 0.53 Allowed 'Trans proline' 0 N--CA 1.456 -0.684 0 C-N-CA 122.365 2.044 . . . . 0.0 111.162 177.22 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -51.77 108.23 0.26 Allowed 'General case' 0 CA--C 1.529 0.156 0 C-N-CA 124.119 0.968 . . . . 0.0 110.284 -179.507 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 133.83 -29.42 3.1 Favored Glycine 0 CA--C 1.527 0.795 0 N-CA-C 109.958 -1.257 . . . . 0.0 109.958 -178.133 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 88.5 t -74.94 117.91 19.91 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.279 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 179.763 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -63.13 102.81 0.41 Allowed 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 122.953 0.501 . . . . 0.0 110.335 179.454 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.71 -40.5 20.38 Favored 'General case' 0 N--CA 1.456 -0.168 0 C-N-CA 124.424 1.09 . . . . 0.0 111.381 179.094 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 44.6 t -58.94 -28.62 38.9 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 C-N-CA 123.03 0.532 . . . . 0.0 111.844 -179.132 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 33.3 pttt -75.7 -31.96 59.9 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 119.497 1.044 . . . . 0.0 111.571 -178.622 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.437 HD13 HG21 ' A' ' 55' ' ' ILE . 26.4 pt -91.78 -31.45 4.89 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.36 0 C-N-CA 123.728 0.811 . . . . 0.0 111.925 -178.79 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 35.5 m -87.74 142.95 27.42 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 124.73 1.212 . . . . 0.0 114.196 -176.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 87.2 mtp -75.26 144.6 78.74 Favored Pre-proline 0 N--CA 1.45 -0.428 0 N-CA-C 104.656 -2.35 . . . . 0.0 104.656 171.213 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -61.19 122.16 10.72 Favored 'Trans proline' 0 N--CA 1.452 -0.945 0 N-CA-C 107.322 -1.838 . . . . 0.0 107.322 176.504 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -34.57 -36.38 0.05 OUTLIER 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 127.79 2.436 . . . . 0.0 116.831 -175.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -77.35 -30.08 53.68 Favored 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 123.645 0.778 . . . . 0.0 112.14 -177.905 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 76.3 mm-40 -82.1 148.61 28.46 Favored 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 123.191 0.596 . . . . 0.0 109.549 -179.053 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -162.79 152.4 15.63 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 113.339 0.866 . . . . 0.0 113.339 -176.882 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 63.9 mt -82.32 127.65 33.43 Favored 'General case' 0 N--CA 1.446 -0.644 0 N-CA-C 106.041 -1.837 . . . . 0.0 106.041 176.353 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 23.8 t30 -118.21 -47.89 2.55 Favored 'General case' 0 C--O 1.225 -0.189 0 C-N-CA 123.267 0.627 . . . . 0.0 110.469 178.617 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -67.07 136.9 94.25 Favored Pre-proline 0 CA--C 1.533 0.322 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -178.666 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -64.68 145.04 86.06 Favored 'Trans proline' 0 N--CA 1.452 -0.954 0 C-N-CA 122.462 2.108 . . . . 0.0 109.949 -178.511 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.23 -30.21 8.98 Favored Glycine 0 CA--C 1.523 0.563 0 CA-C-O 118.729 -1.04 . . . . 0.0 113.678 177.042 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 65.9 mm-40 -52.97 135.68 36.3 Favored 'General case' 0 CA--C 1.535 0.381 0 CA-C-N 118.859 1.329 . . . . 0.0 110.655 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 17.3 p -114.31 123.91 50.69 Favored 'General case' 0 N--CA 1.454 -0.251 0 C-N-CA 124.863 1.265 . . . . 0.0 113.515 -177.235 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 43.0 t80 -94.7 108.89 20.87 Favored 'General case' 0 C--O 1.233 0.194 0 N-CA-C 105.069 -2.197 . . . . 0.0 105.069 172.88 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.8 t -96.28 137.99 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.356 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 -179.21 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 13.5 p -147.55 168.5 4.54 Favored 'Isoleucine or valine' 0 C--O 1.232 0.142 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 177.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 40.9 m -149.51 136.72 19.85 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 67.5 mt -118.52 112.87 20.46 Favored 'General case' 0 CA--C 1.53 0.202 0 C-N-CA 123.681 0.792 . . . . 0.0 109.786 -177.752 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -88.23 -42.84 12.02 Favored 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 123.68 0.792 . . . . 0.0 111.473 179.692 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -71.52 127.97 34.3 Favored 'General case' 0 N--CA 1.453 -0.324 0 C-N-CA 124.095 0.958 . . . . 0.0 109.878 -177.432 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.7 mttp -66.84 160.18 26.58 Favored 'General case' 0 CA--C 1.53 0.175 0 C-N-CA 123.386 0.674 . . . . 0.0 111.683 178.87 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 129.64 177.39 14.85 Favored Glycine 0 CA--C 1.525 0.716 0 C-N-CA 124.33 0.967 . . . . 0.0 112.591 176.756 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 14.7 m -95.32 112.46 24.17 Favored 'General case' 0 N--CA 1.453 -0.277 0 C-N-CA 124.769 1.227 . . . . 0.0 108.192 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 26.2 m-85 -104.04 111.72 24.41 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 124.01 0.924 . . . . 0.0 109.47 -179.626 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 20.1 m -86.14 138.38 31.96 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 107.985 -1.116 . . . . 0.0 107.985 177.163 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 34.3 p90 -135.83 164.66 27.41 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 123.099 0.56 . . . . 0.0 111.241 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 56.0 p90 -155.31 164.22 39.06 Favored 'General case' 0 N--CA 1.45 -0.462 0 CA-C-N 114.934 -1.03 . . . . 0.0 112.089 -177.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 6.3 t -105.11 106.97 17.71 Favored 'General case' 0 CA--C 1.523 -0.064 0 N-CA-C 106.212 -1.774 . . . . 0.0 106.212 177.229 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . 0.304 52.3 p -43.42 -60.25 2.67 Favored Pre-proline 0 CA--C 1.539 0.554 0 N-CA-C 115.776 1.769 . . . . 0.0 115.776 -173.124 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -61.38 -7.56 8.82 Favored 'Trans proline' 0 C--N 1.348 0.52 0 C-N-CA 122.21 1.94 . . . . 0.0 114.365 -178.526 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 34.7 m80 -131.34 16.84 4.96 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 119.504 1.047 . . . . 0.0 111.039 179.644 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 65.6 tt0 -60.22 -49.54 77.22 Favored 'General case' 0 C--N 1.34 0.164 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 179.048 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.77 -32.12 61.54 Favored Glycine 0 CA--C 1.53 0.976 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 177.832 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -81.49 3.89 23.12 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 123.326 0.65 . . . . 0.0 111.711 179.117 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 81.92 17.82 69.11 Favored Glycine 0 CA--C 1.526 0.775 0 CA-C-O 118.944 -0.92 . . . . 0.0 113.259 178.836 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 21.5 ttt -78.58 80.03 4.98 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-N 119.369 1.584 . . . . 0.0 107.997 178.317 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 6.8 m -127.39 170.61 16.99 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.249 0 C-N-CA 126.196 1.798 . . . . 0.0 110.949 -179.853 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -166.65 175.11 42.06 Favored Glycine 0 CA--C 1.528 0.855 0 N-CA-C 109.134 -1.587 . . . . 0.0 109.134 178.251 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 58.9 mttm -147.27 126.35 12.88 Favored 'General case' 0 N--CA 1.461 0.095 0 CA-C-N 118.037 0.919 . . . . 0.0 110.947 -178.627 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 6.8 p -113.17 124.77 70.13 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.167 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 178.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.7 m -94.14 104.23 16.25 Favored 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 124.111 0.965 . . . . 0.0 109.06 -179.648 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 21.9 t -81.89 98.6 4.47 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 N-CA-C 103.98 -2.6 . . . . 0.0 103.98 178.651 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 37.2 t-20 . . . . . 0 N--CA 1.454 -0.256 0 C-N-CA 124.898 1.279 . . . . 0.0 112.925 -175.008 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 stop_ save_